<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>MM microarray data processing 20220414</title>

<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="data:text/css,html%7Bfont%2Dfamily%3Asans%2Dserif%3B%2Dwebkit%2Dtext%2Dsize%2Dadjust%3A100%25%3B%2Dms%2Dtext%2Dsize%2Dadjust%3A100%25%7Dbody%7Bmargin%3A0%7Darticle%2Caside%2Cdetails%2Cfigcaption%2Cfigure%2Cfooter%2Cheader%2Chgroup%2Cmain%2Cmenu%2Cnav%2Csection%2Csummary%7Bdisplay%3Ablock%7Daudio%2Ccanvas%2Cprogress%2Cvideo%7Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Abaseline%7Daudio%3Anot%28%5Bcontrols%5D%29%7Bdisplay%3Anone%3Bheight%3A0%7D%5Bhidden%5D%2Ctemplate%7Bdisplay%3Anone%7Da%7Bbackground%2Dcolor%3Atransparent%7Da%3Aactive%2Ca%3Ahover%7Boutline%3A0%7Dabbr%5Btitle%5D%7Bborder%2Dbottom%3A1px%20dotted%7Db%2Cstrong%7Bfont%2Dweight%3A700%7Ddfn%7Bfont%2Dstyle%3Aitalic%7Dh1%7Bmargin%3A%2E67em%200%3Bfont%2Dsize%3A2em%7Dmark%7Bcolor%3A%23000%3Bbackground%3A%23ff0%7Dsmall%7Bfont%2Dsize%3A80%25%7Dsub%2Csup%7Bposition%3Arelative%3Bfont%2Dsize%3A75%25%3Bline%2Dheight%3A0%3Bvertical%2Dalign%3Abaseline%7Dsup%7Btop%3A%2D%2E5em%7Dsub%7Bbottom%3A%2D%2E25em%7Dimg%7Bborder%3A0%7Dsvg%3Anot%28%3Aroot%29%7Boverflow%3Ahidden%7Dfigure%7Bmargin%3A1em%2040px%7Dhr%7Bheight%3A0%3B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%7Dpre%7Boverflow%3Aauto%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%2Cmonospace%3Bfont%2Dsize%3A1em%7Dbutton%2Cinput%2Coptgroup%2Cselect%2Ctextarea%7Bmargin%3A0%3Bfont%3Ainherit%3Bcolor%3Ainherit%7Dbutton%7Boverflow%3Avisible%7Dbutton%2Cselect%7Btext%2Dtransform%3Anone%7Dbutton%2Chtml%20input%5Btype%3Dbutton%5D%2Cinput%5Btype%3Dreset%5D%2Cinput%5Btype%3Dsubmit%5D%7B%2Dwebkit%2Dappearance%3Abutton%3Bcursor%3Apointer%7Dbutton%5Bdisabled%5D%2Chtml%20input%5Bdisabled%5D%7Bcursor%3Adefault%7Dbutton%3A%3A%2Dmoz%2Dfocus%2Dinner%2Cinput%3A%3A%2Dmoz%2Dfocus%2Dinner%7Bpadding%3A0%3Bborder%3A0%7Dinput%7Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%3Bpadding%3A0%7Dinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Dinner%2Dspin%2Dbutton%2Cinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Douter%2Dspin%2Dbutton%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%3B%2Dwebkit%2Dappearance%3Atextfield%7Dinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Dcancel%2Dbutton%2Cinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Ddecoration%7B%2Dwebkit%2Dappearance%3Anone%7Dfieldset%7Bpadding%3A%2E35em%20%2E625em%20%2E75em%3Bmargin%3A0%202px%3Bborder%3A1px%20solid%20silver%7Dlegend%7Bpadding%3A0%3Bborder%3A0%7Dtextarea%7Boverflow%3Aauto%7Doptgroup%7Bfont%2Dweight%3A700%7Dtable%7Bborder%2Dspacing%3A0%3Bborder%2Dcollapse%3Acollapse%7Dtd%2Cth%7Bpadding%3A0%7D%40media%20print%7B%2A%2C%3Aafter%2C%3Abefore%7Bcolor%3A%23000%21important%3Btext%2Dshadow%3Anone%21important%3Bbackground%3A0%200%21important%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%21important%3Bbox%2Dshadow%3Anone%21important%7Da%2Ca%3Avisited%7Btext%2Ddecoration%3Aunderline%7Da%5Bhref%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28href%29%20%22%29%22%7Dabbr%5Btitle%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28title%29%20%22%29%22%7Da%5Bhref%5E%3D%22javascript%3A%22%5D%3Aafter%2Ca%5Bhref%5E%3D%22%23%22%5D%3Aafter%7Bcontent%3A%22%22%7Dblockquote%2Cpre%7Bborder%3A1px%20solid%20%23999%3Bpage%2Dbreak%2Dinside%3Aavoid%7Dthead%7Bdisplay%3Atable%2Dheader%2Dgroup%7Dimg%2Ctr%7Bpage%2Dbreak%2Dinside%3Aavoid%7Dimg%7Bmax%2Dwidth%3A100%25%21important%7Dh2%2Ch3%2Cp%7Borphans%3A3%3Bwidows%3A3%7Dh2%2Ch3%7Bpage%2Dbreak%2Dafter%3Aavoid%7D%2Enavbar%7Bdisplay%3Anone%7D%2Ebtn%3E%2Ecaret%2C%2Edropup%3E%2Ebtn%3E%2Ecaret%7Bborder%2Dtop%2Dcolor%3A%23000%21important%7D%2Elabel%7Bborder%3A1px%20solid%20%23000%7D%2Etable%7Bborder%2Dcollapse%3Acollapse%21important%7D%2Etable%20td%2C%2Etable%20th%7Bbackground%2Dcolor%3A%23fff%21important%7D%2Etable%2Dbordered%20td%2C%2Etable%2Dbordered%20th%7Bborder%3A1px%20solid%20%23ddd%21important%7D%7D%40font%2Dface%7Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%20format%28%27embedded%2Dopentype%27%29%2Curl%28data%3Aapplication%2Ffont%2Dwoff%3Bbase64%2Cd09GRgABAAAAAFuAAA8AAAAAsVwAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABWAAAABwAAAAcbSqX3EdERUYAAAF0AAAAHwAAACABRAAET1MvMgAAAZQAAABFAAAAYGe5a4ljbWFwAAAB3AAAAsAAAAZy2q3jgWN2dCAAAAScAAAABAAAAAQAKAL4Z2FzcAAABKAAAAAIAAAACP%2F%2FAANnbHlmAAAEqAAATRcAAJSkfV3Cb2hlYWQAAFHAAAAANAAAADYFTS%2FYaGhlYQAAUfQAAAAcAAAAJApEBBFobXR4AABSEAAAAU8AAAN00scgYGxvY2EAAFNgAAACJwAAAjBv%2B5XObWF4cAAAVYgAAAAgAAAAIAFqANhuYW1lAABVqAAAAZ4AAAOisyygm3Bvc3QAAFdIAAAELQAACtG6o%2BU1d2ViZgAAW3gAAAAGAAAABsMYVFAAAAABAAAAAMw9os8AAAAA0HaBdQAAAADQdnOXeNpjYGRgYOADYgkGEGBiYGRgZBQDkixgHgMABUgASgB42mNgZulmnMDAysDCzMN0gYGBIQpCMy5hMGLaAeQDpRCACYkd6h3ux%2BDAoPD%2FP%2FOB%2FwJAdSIM1UBhRiQlCgyMADGWCwwAAAB42u2UP2hTQRzHf5ekaVPExv6JjW3fvTQ0sa3QLA5xylBLgyBx0gzSWEUaXbIoBBQyCQGHLqXUqYNdtIIgIg5FHJxEtwqtpbnfaV1E1KFaSvX5vVwGEbW6OPngk8%2FvvXfv7pt3v4SImojIDw6BViKxRgIVBaZwVdSv%2BxvXA%2BIuzqcog2cOkkvDNE8Lbqs74k64i%2B5Sf3u8Z2AnIRLbyVCyTflVSEXVoEqrrMqrgiqqsqqqWQ5xlAc5zWOc5TwXucxVnuE5HdQhHdFRHdNJndZZndeFLc%2FzsKJLQ%2FWV6BcrCdWkwspVKZVROaw0qUqqoqZZcJhdTnGGxznHBS5xhad5VhNWCuturBTXKZ3RObuS98pb9c57k6ql9rp2v1as5deb1r6s9q1GV2IrHSt73T631424YXzjgPwqt%2BRn%2BVG%2BlRvyirwsS%2FKCPCfPytPypDwhj8mjctRZd9acF86y89x55jxxHjkPnXstXfbt%2FpNjj%2FnwXW%2BcHa6%2FSYvZ7yEwbDYazDcIgoUGzY3h2HtqgUcs1AFPWKgTXrRQF7xkoQhRf7uF9hPFeyzUTTSwY6EoUUJY6AC8bSGMS4Ys1Au3WaiPSGGsMtkdGH2rzJgYHAaYjxIwQqtB1CnYkEZ9BM6ALOpROAfyqI%2FDBQudgidBETXuqRIooz4DV0AV9UV4GsyivkTEyMMmw1UYGdhkuAYjA5sMGMvIwCbDDRgZeAz1TXgcmDy3YeRhk%2BcOjCxsMjyAkYFNhscwMrDJ8BQ2886gXoaRhedQvyTSkDZ7uA6HLLQBI5vGntAbGHugTc53cMxC7%2BE4SKL%2BACOzNpk3YWTWJid%2BiRo5NXIKM3fBItAPW55FdJLY3FeHBDr90606JCIU9Jk%2BMs3%2FY%2F8L8jUq3y79bJ%2F0%2F%2BROoP4v9v%2F4%2Fmj%2Bi7HBXUd0%2FelU6IHfHt8Aj9EPGAAoAvgAAAAB%2F%2F8AAnjaxb0JfBvVtTA%2BdxaN1hltI1m2ZVuSJVneLVlSHCdy9oTEWchqtrBEJRAgCYEsQNhC2EsbWmpI2dqkQBoSYgKlpaQthVL0yusrpW77aEubfq%2Fly%2BujvJampSTW5Dvnzmi1E%2Bjr%2F%2F3%2BXmbu3Llz77nnbuece865DMu0MAy5jGtiOEZkOp8lTNeUwyLP%2FDH%2BrEH41ZTDHAtB5lkOowWMPiwayNiUwwTjE46AI5xwhFrINPXYn%2F7ENY0dbWHfZAiTZbL8ID%2FInAd5xz2NpIH4STpDGonHIJNE3OP1KG4ISaSNeBuITAyRLgIxoiEUhFAnmUpEiXSRSGqAQEw0kuyFUIb0k2gnGSApyBFi0il2SI5YLGb5MdFjXCey4mNHzQ7WwLGEdZiPPgYR64we8THZHAt%2BwnT84D%2Fx8YTpGPgheKH4CMEDVF9xBOIeP3EbQgGH29BGgpGkIxCMTCW9qUTA0Zsir%2BQUP1mt%2BP2KusevwIO6Bx%2FIaj8%2FOD5O0VNrZW2EsqZBWbO1skRiEKE0DdlKKaSVO5VAuRpqk8VQJAqY7ydxaK44YJvrO2EWjOoDBoFYzQbDNkON%2BUbiKoRkywMWWf1j4bEY2iIY1AeMgvmEz%2FkVo9v4FSc%2FaMZMrFbjl4zWLL0%2BY5FlyzNlEVYDudJohg8gPUP7kcB%2Fmn%2BG6cd%2B5PV4Q72dXCgocWJADBgUuDTwiXiGSyZo14HOEQ2lE6k0XDIEusexDzZOMXwt1Dutz%2BtqmxTvlskNWXXUQIbhaurum9GrePqm9Yaeabjkiqf%2BbUvzDOvb2Y1E%2BEX2DnemcTP%2FzLcuu7xjQXdAtjR0Lo5n4%2FHs%2FGtntMlysHt%2B29NXbH6se%2F%2FWbFcyu%2Br28H0MwzI30DYeYTLMXIA2EG8QlHpAsyS0EfEToR0a3utIxFPJ3kiIHCCrZ66b0e2xEmL1dM9YN%2FMwS5p01N5jMX%2FBLKt%2F1R83l0LyC29M6%2BiYxo%2FUNg%2FEF7c2WyyW5tYl8WnhWg2%2FhyySbD5UhnDyS7OcU0dnrFw%2BDfGdI7v4QfYIIzOMq9hFtY55gmvC7jZ2FK7sEdrn6IXBuucYhjsGdQ8z0yEbWkkczjjsE5hNAIZrPx2zOLZDmKNXcXtg7EMqidAEEWg%2BSJCBBNwxvxJfc%2FbZa%2BKKf%2BxoKZybnq5vaqpPTye7CiF%2BZFjxZ8%2F7Qij0hfOG%2FcowPA1rT1l4ymWnrKmxxqfErTVrpgwPlz1kC%2BOy8NMDz6c%2BIO38K%2Fx0xkPnLW8Kx6qGAoQdL%2BTD9V9rb%2B%2Fctn%2F%2Ftrxz8dUrZrD%2Fzk%2FferF0cNt1BzctmX2FZPXt%2FjnFCQNz4Ah%2FiKllGiCMs1w5Lkg0kiEwj6VTXCDKsX9rMpnvIj9pcDecXAIXMnqn2dTUbN6w0XQ9ue6FV%2FnnXCH7S3lPWGltVcLsH75ub3ab7A8M28caNrIeOr3o5Q0yFsYL80xaa0EY%2FUEczV7icUMY5pnelAkmUAXmHYjvFWFGxuqlSaow3OM%2B%2FiYY7%2Fl%2FhVELF4EjRqNR%2FbvRbOY%2BDUGzGR%2FOh3EqmE%2FugIQQguGt%2FeMYz%2F%2BL0cimjeZfQDI3phXMbMQsqH%2BCjwVz%2Fhf4idHovgVmB8gLvjbicDcC%2FNypP536E%2F9N%2FpuMibExdohBmNwyiaZdJGoigos7GpF222xrfnZhML%2F7Z%2BylaqP63Hr%2Bm7bdUkQ6%2F2cXqdfmvwixY%2Bs2ksXFeXcE%2BiX0Z%2BIow76DBNgjJ7TOdUK18iPsPflfQD%2BDPsZG2Aj9VmKMMJ4fYRrhIaxhTDR0Elh2vA6h%2FAE6xUb29mj3sjmL72petXjejPy%2Boel60M99tFduCI59N3221xe7apOvxs6aHs7vab1IqY2tv7q2xsHeHGml%2FcV06u%2F8S%2FxTjJ%2BJYc0bWEX0ukW6YmIbGkJRMdjJ9mYIH5QIdJF4hvRGyK7cC7ctImQRcUET99fGXOoft35GYLMQu%2Bg2smnkgZUrH8AL%2F9Si217IssJ916nv14ZrJrvdxLkQvrvtBcjgPC0NXOicO8Qf4mcxPqh3hgUw3DDfdvLJXngg7N3dN2zbPJSaed3OfZnMU7dvmznp3C3bruO%2BNmue0LFsy7S%2B6265%2BfCKFYdvvuW6vmlblnUI8xCXp37CrOZv4B9gauDBlYp7adcUXB5DNCwYImlXOJJKkAdvExXxVvKEYnCo%2B3eIskP9qrrfIYs71CccBjfXRC52udTHHdaP1A1ui%2FVvH1otbrLrpNXBsGX5B89QghDyimlvNB2KfkxZ5C9%2Fem3%2Bd1%2Bd%2F%2FIfFp2%2B2Oxn%2Fs%2B9n%2F79p39S3s8idN6g0yZObwJOgKUpNB3GyU0Ls0PbRzIRq4lcarLKOJBkLRzJQD4j2090XrbA7DW8K3jNF5hlGS5e4V2D17zgss4T20egOJte5iD0bReM9yjTxnQxCRj3c5kFzGJmGbNKmwGw39IJDJcXJZGMkaAB4jyJAKw0jt5IAuIE%2BA%2BU3cVAZZrq9zhDyBrU8oosuxcGNTzCKJfla7JjNVmuSb%2F%2BtuzN2H%2BX4vlB%2BPpdfMXXmuVsNiub1T34SFbjYw5itEvVi0K0Nt9pNJUMI7SLGRhf2xipfCYf8z5OdlGKayOucFeVPeS%2Fdbo3lBrbSMmwUiQN5%2Fed7g0Ds1s17IuZC5kNzM3MZ6EWCa0DtekdJfAxz%2BR%2FOX28sND7yRMTBcf%2B%2Bs8mQCQWHya4qBv%2FufeMoWyslPA9DtMxUknxkH%2FyfTnm2CMYzs%2BCq3r7PxY%2FMXomrvTEsRpfEGHa%2BWN8E1AHjElb7d06ddA7oK%2F%2B5Mdsv9EtPms0jv0Z5kf1FqPxWdFtfFr0kHfgDX0Y%2B5PRSG7RUj0tQr7rmfX8DH4G5W28kKeJLtmQsQkuwMP1pk16EV4sl7vrMJATfyUWo%2FGwEco4rh4XFQgaiUX9qxZHrMQqKnz%2Fc2d8b9TysYrAuXpP%2FRf%2FGr8b1qwwc5a%2BeuLa6S6sneNXToG2XrEJi4R5SGs8Sq2S3d97bsfCRaTdaLwKClRHt37mkudvXbjwVrLhuYeGhh56bvfQkHpk2CwvwClqgWwuBfndC3c8dwmstj81KkagcUgbfPY8Zje0W%2F82VPWJHmSq6pP8hPWpotc%2FEexDOK3qU%2BwngPhOCiO9MJRm8TJefjelrzoKnG2Bn%2B1NCUmPE4gHFmBN9jrTigRIpsACrc9Gstg58ULkp9467%2BGf%2FeFnD5%2F31lNrt2967dhrm7bzI%2BVT5m%2BfzKhvf2MzpICEm79Bopkn07lt1762adNr127LwVqQLdJ5%2BlpQDcvHPQtVY5knhYrK6q8%2FJsiP6EuhGZdFdaNszjvpqvc%2BPI0CdjN0AXsFOC3ZfALDJwr4q2Xq%2BGF%2BGNbsxUg5NLLIEXi8otcDQcUts0D8eQ1iVDRAMBTsYiNdRIxE09EIBJO9A2xqgERTaW86BUFn0OD2xFO97FAgFhF6OoQ7prYt4XwSeUgQHiJyDbeke9IdQntciLQ1FlJMaYcUNvZBg%2BFB1ubjlnRNvl3o6IEU2w7fdNPhm%2Fhh%2BFLysUu6%2B%2BDLHkOkrSHYEjH0tEPe7WdD3uyDgvAgK%2Fm4szFFR7ch0toUgBTdWHr7EpaWru6%2B6dmbbnqWEbV2EtxAsXiZAPTtGPSbHsotI2leoM8TePEqgSQprs7AGFf8kuOkPdZPXGb55POAW1d%2FjLST9v5YflasP6v%2FCO7%2BGNAPC2BMZWmsOjp2NNbfHwMCJD%2BLPVL%2BD%2FOYlWEEI%2F9jpPddOFkB5d1GSuKZYggmCCd7JUxD7EXAzxyirYnNDLdDZoFdx14kivkvGc3579Jm36reTTvDgBnaO6vzyQ6chQmlsMoIkIQ2%2BbBDWBud1Va4pcCn8CPqxlh%2FfgtG8IPaPH8C5wk6%2FnZDv69jurV5QhtwE0x2iqOsj9Mx8B9%2F0EaUdiPfOYYDCi%2Fq9jhWRuupMDEU0%2BCtX0sDFxv07T%2FK5niBPqN9%2BtQjgEc31NGCXFeMcCEuQBIc%2FBK4CO78u7EPYvl3yaEfK3vcb6qP1R2tI7vUjVDDUdKubsSrNjYKY1qBEa2P50SJoaXiksIoLiCwnxS6EBuBde87botNfdEWwYvF%2FR0%2Fu5yCqhGeEOR2ynSeyXjt6ka7neyye8kryBSWE52y%2BRBgogrXPZ8E1yIHoHIFUM%2BAbJhE7lbMtt8ApL%2BxmZW7PwbjAO0fAVoXQOuiSP%2FksIVdFZ0aulsamKUzwPZ%2FNYDMJRBPCxsBqLzqHyneXF6Ej9HlIFo7%2Bpg%2BjUb3unRmGpstGkm6etOuDBGA5wCMefp1gTHcdZlvPBXlOslvYTp1cd8UjYLVd%2FJ5awNrIOKLnIt9MD9qdrKrWCvA6ALm3QV9VrsPm60Q7%2BRHJHP%2B2hqfugo%2FMvI2H%2Fmqr4b9tFnKSRY1Y5Ek80Nm%2FWIhr1ikKnxGz9TWXrokf9xwujfvcOTtNTWnxd0F37Y2W79tteBqZ4G5qLCuomw%2BnSr28QESCRVLTyYKILGJOPfcnaIFOsewhRdvv%2BrWa%2FWih0vlbX6Zb75T5C0qNKVFvH1QL%2FvazSWgC2s6oWXXIuUxQelKiJbowuJDQViatLmLijg9CQBMg8WiPgiw3LEeYRmm5f%2BXdnvkDnxLLjMLxtvX74C3OlwPQqx4xwIdpPx38LrlDphiyWUWHWKAzzxurS%2FxTo%2BP5wGFak62ap1PVFFN4v%2Fy%2BxuR39WnIO7lsWfwgVsK17wxrs9K8ltIKuhkw7f%2F6dhK6gQokFKhWX3urrjk%2FrnI0pgfpGMeuQIUaEM7%2BGF5q2iMkCaMQwxxOzcvU0eXbsnS9XknXvP7Gtw5dwPXlFu2ecvSHEZgNDsU6x%2FGdXBYXyOQjzZReSedeEPY6nEv9gJR4oBQJtFO6Kd0fwC6BO4LNHDeBujB6dSNcUQC9zIv2LnAzGk99bUDrdFY%2B9yGFQtEo0GQPNv6vS2drj4%2B1jHbv3aJSMUWP%2BQTZrmbNTjU8wyG%2FiXNNpskybLcJ3CiTF5Ir%2BJYzmJwE0mSVhlxbtbmvweB3ulB6Til5UuUZydpgiFVeobhU0WaBqpJ198d%2B%2FXeNRTZ9%2F1OPfG7%2B2hwzd5W3D%2BhmyjsRcUg%2F%2BCavb%2B%2BVh2ls3L7zT%2FetOnHNxeerv313vzLVqPai4nJv%2BK1FC6040%2F4udw7sAb3laSg0XCkAAs0npBO6VJabS4Elk%2FU%2BD4gTXW%2Bj0wnrMlqNamq4tMIYB87tE10i0FR3LZNhJsb7%2FR561btmes8YBCRkhYNByRtKd55mqTas9FYhJnbRGHuOh3M4QTdgQSqmgRxuzGdSvZGcbMxNQGk5C3ebLjoXIOFM4l%2BWKHmLTJwRv9E8GWJ6dYvf%2FFmEyEGr%2Bgyrr1p5zrgkz0Cw2j94Hv8Jdx7dIVegBSNtgsqGsRQEYiIBoXwD0LNvQ5d7s5Z00QzwNhqZA0b%2BtMG1tQq5nd84uq8R0zPvX35G8uRaze4jcOHzz0w1%2BQ2BIRvf6J6Kgatnrbiem%2BCFvAxfkrndzD9MFPP1GWTUHclpASUkCNAQkpCCcCgDSUDAhDZ%2BCuEkgn8J7i9nMA7pA4lISappxILKfAeSAbIcSDuN2bJcfZILqeO5rLs0MnngSHYRdrHjmaz7JEsEPw51ZqDJDmUIOZIe34WaQeegNsJn1qz8AIpT3yCjyEih%2FxELkuJ0lEMYTLVCiWpo5oYMleMH6USyYJcD%2BuOe%2BkWKpn1Qns34iyYDjkSLvgnZXcgVQNeqINXr48m3iS7cjm8tedyY0f1QvTnHHdsrKby%2F%2BSSbPY8%2FNH6vpl%2FEsq3Ae4ZU1HC44KFiI9o7CEgab%2FRqHbj7s5KAg06s39ZP%2FzxI%2FmVuF%2FTbTSy%2B3Fb8If9%2Fcv7%2Bwt91yy8RfP1QXtW5RzQn7qIiZyuFM5QfJ5E9uVnqT85TanFx0lkP3ukBAMprvsRyi%2FC8NAJL1xbIIirSvnSj4O5netb4JxmNANHPssHAcHMHsFRgEug816gDBeMbdfiuRcghqYcm0%2BXxx%2F5IAEtN3fqFF3LzAXqwoT0PN0OVTNqxo8sxMkd5Ig6k79Zk7VxxX6gMLOZFQgvpW2RrMW1D0BDihaXQ9wVRoBxPLfpknmkeMtoB%2FqM9cRc9IqmMD2XUmdZ7GSRKPUZvChf8BoykriM2MnKYbOHX8R7cLdNCxSFFVQqoYswnlWtlFS2mNkhswVpZiQW1J%2FUKFfipHGlUkM6UKBhMz1istELIHJLMSctu3ugzfaVSOjKvUgc%2FTHK4Sdg2Wscz69leKIkkrwuuWiOe9yGYKQXRumkC3qbRcMwrvhjNXgdZk3RxAUEhuSPvn3nnd%2B%2BU%2F3vlVOmrJzCD8JLxV1OHRjrZifbcFDOuRNTGqdgQm1tSNJ2OcQ04YiEXuxtII1ECSQRoQGYioEsgCfchB4ghAtw7FfJre4WZ9hkVi9MtjuWqtdNDlpMrfEG9fOT6q21okg%2Be4As38MfGquNt7oUws6Ysarj1%2FefE%2Byst86YUVNvDdts3Pv5c8m%2FaP0C%2Bf8%2FQb%2BIMnGq09BgwN01oIOAnAdagI8mBSrqk1gxTDUBOtk2ousEtBH2z4Ir2d3f6k8PXXVlt2qN9RODxRuoJT%2Fv27wm09jRYVc%2Fe%2B%2Biyx2tyzJb%2Fn3J0htXP87eSsQaf2Ly0s6Zmxela88REy1cf4273mI3iXNJ7KxrZibOm9xm6rl4fqy%2Ft27smU8tOfdW2ucBzg2UfmOIVyLIl3kpYlwphDISTXJXsctmiDtN7fNV6zelgxwnWxsVr83Aj%2FS5ki1jL%2Fa0GC6%2B2L6Um%2BaoddlNFuj%2BbJ8mH%2FiaLh8I0%2FU51NspIEfq0dohwyFXKgm4NggwQ4rRhCOUFtxxo8XnitT4cnGfT93IS8FaT85XE3H5LMY4zIEPL1hw443wz%2B1UmhTJyJGxZzw%2BwsKkKZgUiVtKOKMEb2AKHTv61FNc01PQFwKnvsZ%2F9pPA4RKTASWahmh%2B8MxwzHxKy74IRn5LGRjsPUUwTu64UYNY38caqd7HKucZ%2FtHnODtENw%2F2UfHRMaq1UUPDJQ0OKkWCeet5fYOhII1VRz8%2B%2FElg5j4Gxur3J8o2PJ4rg%2B2d08T%2FfwEzSVbyZ9XPro95T477lRKqUSRXQnauHNsISAl27oWi6Fv9z48JMv8r%2FaMMj8onCP%2FDuDZOuN%2BGPPr%2F%2Bp7bx%2B7JlbYdppcNhzKU%2F1Px5aiaGDn%2Fs1iGMaBcleKUo%2Fv9rcxkZj7DBEKOfrayytXNLYiUdBY%2BpleQXdnscKlQcpzuWluxsieeyuXIK6SdxozitWyGOV3vOHHjguyCQ6fpIYy2JwvrQEF%2FQa9Pdf%2FQqOSqCiE%2FEE1%2FXIVKTc2tzWbHnimrEd%2BVyz311Ml3P0GVTj7PD5aDnsvCvH36alEaPMePcMegXs7x8igTu4B9v7G9vTHvhCu%2FkzIdx%2BBxC0ay9zRSvoS0F2lIxI%2BX7klU63I40gLQ3w5ep5na%2BSFnba3z5D64zv%2BQtM4n4ffG3tq4aNHGRfxgrXPMim%2B5487abL7xhdseIRn1KDl%2B7aINixdv0OD%2BJSPwKf5%2BxoP6aiTeQIDVlIhMcL1H5R9PYXvprs3fv2bO7MOplCmweuiq2JRZ1zz%2B9a%2Fv2PH1Hfz9236w%2BZrPXvWfAxlj4NLLHpq3c%2FPQ3uvmvbrjG7fe%2Bo2y%2FcLdtE6VUlXi0ASb1VLUBVSUWSU4HdvAraTyS8xzM8NxvxFkXV6pUVRiJwcgC5zEeht4rwcp7ki0k41G0qlQhG1Vzlq8alEmnFi58caB5Q9vn988MLhqyVlHvLEWjtQFeupdiocF%2FtkkOGPW2ibWaBTkeZ%2FdvPWazXfOnnvL6jkRXpi85sFzZt%2B55ZptW3bl1cCCHZPD06MhySha7UFzjcjbp8fOecFCirzAG%2FyVjBX6OFIaadSjQq1nNhyIe8tVbaaSdHlXIWKacMeuZA1uxS95zILhyrxAdsXTL6m7kNQlx2P9uZf2qhufePFFbpI6%2FOU0WcP99RrCsrwseVot5mtytpf6Y0gm9sdeyKnPQ7onyK4nXlR%2Frg7H95M1upzu89DH6pgUcikoiihJ6NJKmRxV1x%2BMJiOA3YwhDRQrWU0u%2F0rvq0VYXnyCwsLeTJYBq3dAtJDavuzyoVpzZ99Z0%2Ba0uoiFH%2FxcqgDR7rUFeOrUn6Cywb8ZeNMbhLV5ugP9l0zv9UN5b5mFkjzxUcpPJCn3V402pRxtJd2GrnLdhtVk9ZSZh9W91fCSH5B7ofxPiWL%2Bj3D%2FuwhBRdyAyozeZwvQzs79soi%2BBKSnafLviZCcfrpBpLyimfLfTyJtbyruIQKD01tUwJyKEo%2FybaxkSNFUMdMkhQoJyRBQFhnUkDQSXhTM%2B3NmY0EDM7ffLIjqWEGt8lCO6mLia3PukFnghosJD5p5SIho%2FVDkzQfLE%2BIrYoJXkD19pdP7OwG%2FvoIUtagiWiZ4PAFTHHlTVhRZ7dYmPar%2BNJ%2B8JhmR6DFK5DV1foHoLNO%2FpHrvZfmWZ15RQlwvoVDKhCWNK3CCch9lfFBuAqUgpFSShmNaPj%2Bi5%2B%2BWZfKeViJfW5HnUakVL4UCNVkA4%2BETfIqx4B5xSaP2L1yn0zn2ltPn4%2BOqZGmwwEVCaCSqG53ldtL1oLGAhdMLd09MpCCF6tD6ZnAZBY9hDaYsP0jzZ0j5ZjKsF4i1UmLuhbJMCnYJPt5VwFNvmZawXjEvLJqIH8STonZjq7BZ8gKgR20C9MDFqJAX1H64QW2NEup6qgzLP8cvppL%2FNNTOBTCJABOHeWoXzLhw4Wuy7gaBtjKr9kgKq8ZlRYBS32Lpxc8vIhpNDTfyNXWybMJbn2RyQ5EmWc2QF9wmSZ0KYCE%2BcPuYO6b15Uotj2Kd4MItLS7gtFbkTdrFND6pvEZqv5Yv7jXAus7Pg7avo7KDot50NX3CPkP%2BKps8J9%2F3mGQIteY%2FLGPC%2BL7872SPR2br5fy8MtKBMHedGuM28%2FMZmPJMrGgi3Gb1S%2BSi1%2FL%2FzrZwO9XH1ce%2Fz7ZQ1WSoY%2F%2BpMb5FT4ua0Wm%2BJf%2F298nFmChEQ%2BTi71est4mq9VYI6RsymoRJKYidElT2FGnDTZvqtfhGAFTbeqEw68GqtfmbVa%2F1IFO1%2FjdWr%2F8BDRRtQh9XNjubEm4aWVpVonpTGR7PVGc%2BKJNoBIWF7kYi4gUV3r1U6723i6TxUl3n3%2FtM27aZfKb7THiHW9VzFSwHJ05VfK6Ar7kaB0XgPPE0BSkSFKsBUpaLihEWoA9wBt8qirh2VSOkZwXEwyrxZ5jyt2rJmSo9gX7cg6jsEUGJU9z9xJPOEM3uQQxKgkh35DNATnVyrmJ3mbCNyIB%2Fyox4wH1bg2DwN7q9kov4pFqny8oSm3RQbGgJ1QQTs6ZMLilOVYJ9v6Wha3HcJ9jddsXp9YhGUXLXt%2FqMDnvLpPNTXfNa60z5%2FyjXQOMq%2BlNmwh5egpYrdfZQZV9rI47xlRkuyTjpzsmCBSWNkAXVoK8sgYWqQJWbo1RLo6QH0YW6pxqfCnRgkd%2BRiFjUQUQ7poIaYoakgXxwFd9BuuI38H1xBxXSFb%2FpBDIKQFn7YB3dB36l7sG1FLaKiBdp1KxLvfswap%2F30lnVESgNnvjbUoT6w9N%2BXoio0qcYOIM%2Bheg940YimsucQVvli9NEcft2UZwGQwLuilj1fFr1i3NP94X%2BPE7Hpvtj6lBJfJ4R6NvWiaL6MgzWHxiN66DExa%2BdAdAbMYX6HVF8A%2B7rjEZIXAVbDe7PVI9rmN69JOLV1DOSvRPxWNPZBZf%2FNf%2BNy65BhYxxxV%2B77XJ2wfQ389%2FIQPgajXbwMsuAz%2F0IaQcXJavKbRqR2IqyZruXjVC2%2Bhdee%2F5vdnYOedpmVtR3NGXldxSzDSIiBVpkGb9by89UpEPKrSLZmyFDzMab%2FwXl2CNe7s%2FqCtTvWgG5kpBmCBlSzDS%2Fr8N4uwBwohRW63JTS1y32f0TQsPfXVGEHQrV8%2FNCfiOUVirYcBbIeA2%2BiF68rQIo3B%2FS628vYESr79ehzS7Q9LEL9UXmik9XVHb1yBO3Ngvt5935%2Bk1efkV51mzzrM0LL3%2F20avnwMeKuWyOUZg2TasSqZ%2BKcZQiOn1Iu2Vh497ALUVZiCKt%2Fgh6IvTIj1ZLRjWAkpHKOKovNwp00eqPROiAbiNEKieXwMLcXhVJ1%2FuzmLP4tfxaHR59cBdJVG1kTAgl9ze9QKUEQ946Hkb%2BokJ5JRDyf54Axur1D%2BWS49cLr0tTPEu7UmXrxcSr3XNvumv4yXzInXKH4F7Tc7p17Zt%2Bt%2FqW2%2B93k063X7VW6lALxTY7i1nBXMxcxmzQbabxz%2BtJo%2BwijYaIGMNS8AoSMgAPt84DdHOoMPfjXhF%2BkuH1tZvuFQrRCN07xGcXRX9MYxYchDe5BcHj%2BZ4i%2B42WyPc8Xofi7bbZJN5nJLJ5qr6IqRtzqNlM17SpFsnkEyTWoABEjz4JXOQvzWYuwdnV5LNGOwTM5v9r4RpQ8ZXsYodks3o31JBlzbYtNotisnm22MxiwGFXam5oN1n0TA%2FhRvshvTSDwHff4nNzRo9Dum6PaJbMXzDz%2Bx%2BFkj4L4bFNBb1asqsgH7Dyh4DvbkPtf5yMDKzEwyoaESMSNS9P9gJVA3%2FRTlwoMwZvxECFWxIPNw9gi01nOHjP32esZTtmXHnxvZd8ZtakqQ7ekajbXetpNa6ocTVxJtY%2BuSe69OLz77zh5bDR3xjZMzUz6fxrz1nqrZGcHQHfPVefN%2BfiK86LeXj%2BSc5lPKy%2Bk%2FvCUI%2FDaLFYCWHr6nbXuILTIsb5imNKY%2FrCm28fSMxPhkN1XbNMNZGuqwOBhtTSxWuTk6bw0ZaG86b1hKddePOKuBvmiguYBn4T%2FyOqOyGRBt7bKUI1GjioBC8aUKwF7Q319UgcmtFGIzCJGBqwQij0ynDsfdFGc3TS3BlNfJ25xmzniMkpXXTPvCaD3ZaZvyzjmZdudBostmhb0ORZNN2sJBeed1HXkrUsywueQH%2BL0eCPxmsa5ZpgRJSDZ11yDv%2Bjmbd86vxZfc1WcZJ3UkMq1BOOOVtvu%2F%2BpB%2Ben186d3GTwWAw2jheaJs09%2F%2BLNfZft37DALyrNj1wABMuUKbODyTVnT%2FKYbJ3Tpq8IrNh92dkxOj5P%2FYpZx4%2FycyiVcDYdn4JbEoKdQi9054iBKsygLW46FRGxAb0NPNCm8BSNCPjoKcj6EAus4SuP3rB%2BcV99%2FeTF6294dA8%2BTK6v74MHVpYNRt%2FI30e8QGTOOdfGWzzxcy%2B87a7bLjw37rHw1nPzp0KyyRSeZO%2BQQhInt3dYgvycjrPOv%2BT8s1rptaP84VeywdWX2T4ysr0%2F7TLIs6%2Bx9zib56ye1dM9e%2FXsZmePY3NDs9zlnNVt4%2BWgHJbbz3Livg4P9WWgviOMm4kCRT6I8vw0NbUUEnFvOuFKoxQW1gTsvFirsF5pb7qTUCx4i7VmtToveaDxvK9uOaedVvPRpVOnNz0Q6bry7uiSdQ8t7Vy4JQKVS%2BXPplV2ts4bvCwZu%2BKzgITtxepaPRzWdpv74muvv6RO0SorX6cu%2FdqKn%2FXWnrtp%2FZragz13DUCl5myiFW2Ycvb0PtsXnU%2Btx8pvLFbUspLX68mdegwmOif%2FNPDONajTGoUh6tU56HBJCTBASVvNUB5VIiKpc9kd7kludodSFz7xQbiOmMk5dOYk56gzL6uaf7N8a6MQOHm0ae6snZpFDfuT3%2FjdYzjzwkXXIVHoXNuCfQslQZqBZjTsoHMqrkE4jaYdgkGz2ATOgB3cPkSukD01DnV3ttb1wx%2B6arPqbkcNAHoFPzKUUQ%2BqL0k97pjbZv1I%2FegC9zTFbrrlFpNdmea%2BgIgfWW3wqkcis8ky5FAcRd1If5nNZrl2FFpungc8wpoCl1BpQV%2FScS%2BzjlASyUTVv%2FAJ46gkJI4bHX4lTnloctxPZE1ckS3%2BjG2fKIjkQFyzuo8jvYQG1OrGvJPSTu%2FnSp9PHNTl4z5hK%2F8gtXVKF6gEKiglgcKiRlCESsQCV5QIlKWKpr34lt%2FwkSx%2FJCmP5%2FcBKQfl%2F5gd%2BrOS%2F%2Bp91%2F%2BYCg5CXK2W4M9fu%2B%2F6xxX%2BvnelVuldIDCG0VQTpU9Dw4pRfei%2B6zWx0MLie0gPbyrkmRU7OwT16JGeyXLHqOLqAfVN1GPlBzWtFNzj0TRTCjogtP1NjIvu5habN5Aoa1k66wGpqriVetJgiGdwDZtKhnN0y4n9sXYnsqGmZfDSR15%2B5NLBlhoDaedEm7sxmpqRija6ZEEg2EAnTiAC8IrmFbGz1q08P9PSkjl%2F5bqzYqT9hMmptEXDgTqP3Wiye%2BsD4Wir4jCeoHbbp5hRfpB7BakUIppIlPCD30dR1GtslDz8OsqbXmejFC%2Fv8wu5X2myq7SJ8Avzv9DFUJySf5uNvq4%2BTi7W9D%2FOZrLChdwxmPNiBRqVjnpK%2FaGxRCDspVYKAW9AN1JANoo8wP4BJUlGqdgw6m1qPQ2QW3%2BOfU5%2FieLS%2FNuKpDU3uf8bcAXyBal5jMR2NEAbPAZt0K3hvxHBEDlUxfIGcD%2BN2gNSNx36nfqlAYow0puatNpRz0e4W2oahKzQHsjf2c16ad%2F3t2KTtPobnX6D8C8pd0MDP%2BKx7wnXqGGlLQcvikMErm6TmfsuxJXbSAxqNjOogJLQBLiKEHAE%2BJGTS3JoEhTrz8%2FCB%2B5YlupJ58aOat8Kv4JvregxwcU5Cp8GFAFm1FyOfto6GS2m1NGTS6CPNKkbsTdCBlnN9onMho55BX8IJZtEQ35lk%2BhtwN5A0V3RCPoD%2FyXAcv6pAtbZczRUA64JmcUf4q7Q89ZHLeJVZ5D1Ps%2Ft%2B0iCT3AHVtZC7JDCXfR7OSb%2FXja5H3zQbZL1B%2BULX1BMTEk3AseSpmnKEK4T9ekMIidUCRQFfcbj7z8gNLvzF7mbhQN8h6ZbRset%2BnQWdS%2FZX3k7WpS8P9sfo0iGS64wV516pOhjI6TZ2dApgI5%2BLhxywYoWxKUrykKJsIoDsR4mSrCTg0egMPnLW%2F3Q5Nn8BZEuzqEI7HK3n0%2BzFmuO3TtWQ5WJoG9YqCD6Gc32SxnbnVPfsxvrFXK2dILl7bLthDp6glhcsfp4bYvbSmj%2FmQ94uBTw0E73x2jbNRCvC6VL6GCFDwU7eWQDcC5FY5s0slieRDwtAbRsbLXbaXAuu14e2OJw1dc6jQ3ZdY8v7rv2%2FBWZLqvFWVvvcmwZkK9f5jS4muO9yR5res4kfkRxhV03L1RfPOiPtYi8pd7jNEsOpyTwxpaY%2FyCZu%2FAmd5Or9uS3DYaeqVOhH7gZN%2F8I%2Fwi1fEuLXvyNivibjuKvN%2B1Nc01HF%2F3h%2Bef%2FsOhox8MPd5SFucPjorQwXT%2BytA8EmA5mamHNFDVhBI5pjZbQpugBNkO8MvRub8KVDKST1Wag7D3xlin1ZF7LFP%2F79nbvCXFOY%2BPUjrT7%2FotsPXXZ4exdPzuhZuL5LUXVAn7k7PbhG89uz3b41X01gbjP1xwlu5rrvvf9%2Bpbs6E%2FVu7Nk642%2FPYRaAiUBdrmO6CDTBLPQFA1ur0uXoBR1INDMkypKpoTqnSMx5GiEdTEaSHLs0Alvu%2F19%2F5QW9Rv1U1ridT22i%2B53pzumbs%2BXFFXYC%2B%2BCGsTj5JUT%2FGCgRt3n78i2n71FHG4%2Fu6X%2B%2B9%2Braya7os3ZbDmgWfXun44e%2Bu2NZKuGZ0HiF8M4TlMPR%2BEU6rPKRJ8wOU2RFUFLex3egEsz3YqEAq0cqhAAW19dBZIlVzR61tuIdTnpXH7l%2BuXrbjPUyep%2B8cl6aXKWhPHpDcXl9KiTWDNr4mBQc8Tq%2BNzK%2FOKSbsfl79o9G20R%2BbrBXYvUg0rLHhtrc4TN81TTOWSZ0gL1ZVlOYH2ery%2F7XVUjFMbzYpg7UswcqJPQwBd0LKLabJ8IaCr2otcjSkIrGwootKECaUd4XH1%2BSdazRrfddkBU98t1htvWrbjqSqjaCguxrffM%2F5zDCpBALUycmajhd%2BR6ww4SWafuZ5eU%2BtPid4lgd3gt%2Bb%2FY9rQoZNmiXYPXyRHbRs8zX%2Ff4WIFjWZJtUdSD55AP3xtXH%2BZipC0EqdBGDA4CoYEU6gRLGPU11QhkLTBiEYPiqOeQgwTCl9aok1Qr5pFf71qEeNxjy%2F8F0GoqYPv75Yh9j3x4DuJ%2BuEzHRpAq2lMqb%2BqfTdiq6kGtzfOWsv0c7lSeMXDHBDe1MT%2BLUgx0Pg%2Fp87u2UicdIvqQi8DkxhcUwUXCedMpb4NQjwY3npTmgsURJavLwCRyEcN2HfWsDVGfv%2Fu9ZUWUx%2BPYFueUKwaNvbtu%2BXps3eVWbN1GcgVrdMnWJ7WmJz9SD66EBidag0NF1Ukep0t5A7sFCWdhzvYwHv6L%2FBehXuHqfaBwBEU7hfVLcXvS4VQv%2BT%2FvaSIl7cbeMc7ekv9i8S3e1L5xxpvMGcu1EYPbKyCiijjGXcDKckm43PqU2qNWlXusZMiqF82cuVzolUHN9NNR0HZPxFPV9V0wLtvq%2Bk4DqOwVWDlzuQLVdqFiP08cRX7aRlBVfR8cb55bWe5LExnlcsDp1vAP8Q9BucPMk1Ulh4GnN0SAdxcNHv3q9ohx1Ati4S%2FtkWjIDe3hQdkUGrGRaFBiUdiTSkI41UkMuuQHP%2BEaSQYlPQTFWJF03BNPpTu5KFAdkWgDukzsZKMG0Q1TAQQglScOaP%2FdsZ8%2BfP75D%2F9Uu5Gs3FY%2F2SxPld0DHOciXI9gqjcEidXjE%2B3BLosy0OcX3T7O5g65ROGyzQ2BZs7WbZVnO5ydLe32hMwTQ4wnnKXW6XW5LAa7oaXOIHoUl0FgLQLH2by8wSTWeAx2Y5PDazK3BqZbeJZwXGPaYhX87ZNszoDdaRxotXO1nNlpdvAPFWHDm8PqEE0sZxDEqGzxisFNnuCWetPcGrObN0p23tTZwMuRVodSV8%2BLTrOV3eRvzjQZiSjaLYS1WEJe0kNsJlZu9LFun7%2B%2BwW4gRDRbaxw2nrOGm%2BxOj9cmtbp9ZqeTM1m8UXfQQCSTVSQox6pvtjot%2FFpHvIUjJovFEoYvHYV9C5Y%2FxN9OfcalvII37UEhTbTg%2FAQIaPb4Vz6j5u8%2FaViycMod%2FfkDcpu8QZbZoeBi%2FvbzP3XPsZvOubMtaPHkD9jt6%2BU2O7vqU%2F9C9SMvgrXpQNG%2FE0oJxun%2BCiElUa0IKQSUwERxOntKSV7ekcuh9VBZBBo3VUcB58ofKBHCwLyf9qFosz9Ibf8dGqwaBMjRig4SGOZ2UkWI7UiO9OfUPdxOYFApUZyfpY7mgEc5rtNGGk2H1lPhAk1Hp%2FVAMqQEHEUfEYkkUQq1JMdzsX7kklRrTrUi1wMcDjmu1YYfATj7Y%2BpGpPEBXuoQIj8rR9mgCl4C9yqmF7xnVWxGVniNqtpVmXBvQ6iwni5YQ8a1jYrXtc2J13HvgkvqWxuva1sbr%2BP2S5ceKGyBwDv2DbrToe1u6BkAJV7xnVLUaq0sJB8pFqcUIPi3yuwxi4JuLr%2BP30f3OkPQ72aO0xYo3%2FEsmO3QO5qEF8S0qQH0UsKXv0brnl9%2B8M7jF174%2BDsfvPOl1au%2FRL5%2F9DsbNnwHL2pHR1NTRxMZhJtHktOOxLxErPF6YlLvpC9YP73x%2B4ofw%2B3xVdrHcDE0dQQCmCRgvt9b35xINDf1CDcRSfJ%2BpYl%2BSf8YcurfmXP5F%2Fkj6J82jNsrkWiEuhVlgFfyNkB3S5MUzLhoNiwSCYcxQ7Ui4J0Xh7fmqRbaPa1tzujxkBRlsEHy0%2FOM4pYLPb7g9O6BQJN6l9zQ0OGyCaZz0vMTbHOzXfQ7a2tsterTcqxeInODoemdktw%2B1SbVhKwtW9ffe8VKadK0OVuC3bWzyKm5LeddsWTeorWyY9IMtUFutdu5g%2BRn533qkocdvLs2HmhU75br%2FMmWtD8zA3OP2t1ea636jEzqYxJZGAwFiDEd61oTsrRuW3%2F3pYNi3bS%2BRd%2BGjOfVpAPNd6y64Gsz1GaZleWIPoYL%2Fv9mTeQBENVEguiF1aC4YeXxFETw6QyPfn0m9g8IrMFAvKM1EI11DARnbqibHk%2FIojy5rSdgCyZi06y8sS024PeuO4MfwQ5Y9yKRZCqyYaF30vzeHlmUprR21tR0t0yz8KZY66zWuGvxVQB%2F36kP%2BK38t2Hu6NQ9SFJfw0AdpqPEK2qTMpf2VCqJwqPoJezTL824b8akoL%2Bx03nhh%2BoNo5e77psxg9Q5LzebIKD%2BfsY34f2MtB9fk9v5b8PT6tYrgv4kRPwd0q9z3gdJSJ0653KjCYPwCaR5aUY63eW48O%2Fkdo33yxX9wCiMv2QTrk8eGSI6Ag6moG9t2P%2FF7GRNlDjl0gw7pJ5aOXXqyqn8SENnXBmbSwUYLyqJjv3UmY1nKr4t80no0faXsaIEiF%2FBRaIBnItSce4OUif7W6Vm9T9H1X9Vj71BEm%2BRdmIJQST%2FZfVdudUvh9S%2FqqNvqT98g9SQ3lHibZY0mRVHooyDN%2FFHmTgzjdozKw28NwQ0hwN6BCoPKaEk3YtKwNhwRLXuk076CGoZNXDQcRwZvreTZY9EZi%2Bd0s4%2Bztv8iei04JQl6ZbDD2eHV7X4uHuFVfPrOmcs6m6Kr7hssr%2B1VZFcEZ%2FPdJkn1hOs8SXS%2FNFFgqt94PIZzZ3tdaL6Q5vo6piSzdy737pwsX1VyxUrF15iJ4uNkq%2Brbyg1Z%2BO8VsNC1UmcvORPRfxtPrfRwL2p%2FoA1eZp6Z%2FaGffoewaXcA%2FxBlKlQLfhQL%2FoPgBGP3qsA7IQS8qDVNswHKRSheDUvA3Q7MZoRcJMxlEygujn1QdyzfPfq3dEp%2FbXh5e5YXW2Ngfvza0ZF6UgFL%2FE0fTq4LBlvTE2qb%2FKuuzYSXVnjTfM1osvqMHVbm9950quIZlbqaL6YP7jk3kUtA0GnX2nvq53f3WoSsvEdDRnULgo2fN7lNZJgI8%2FVWi33c3bBZnGY05%2Bdm%2B3qc7fNmj4YGKLj2nfqFP%2Bg7jdDlxEV5XsJQZP6hYrS1l0VQr4c69Xueixp90gnZPmE5OF22j%2BSYEWHlZ0K%2FHgsh%2FZtsbh6h2DNRlvv6jJh9XaJaHCZDiUDKNTMkvb8vsqCyf3ZNdSmO0fa0Y4baJTtpbKzuVzeeSI7fCKr2Z0WypapnXJ4gnoWy3PoUIlIQ1TXdqhQJIXp9Wx5fYdpeWh2TY5D%2BYVyKd0jw3iumwi%2FBC3cEy4o83QlZnW79MrCgCjbhWXBlRZVVZZv4rIKpXC01HFlHdHLoeWVl6UVc%2FJ5uGm6CViW5mulYMk%2BHqNYr0AyUPivLg2oMs2MPqtuhHyRyiwvNJej1Br%2BfcLyoAyu8D9B7bgmzUqfFobF5nKnK4%2Bt8MPJkI%2FxHUNWk117jugWF%2BxazTAALQn6%2BUE9lhoI5ApGA%2FiuJOsrlNP28SVVuBVajXmircLel46w2bJS1Q0Ft0KDuikDFL%2F3pYrid1Q4FvofwRIo4R9h2ftSwc6jHAMqLcCql8YPHtlzGoByNXYN6v8hXnRaOhUvx0sVLCexwupGDR4NOYC7PePa5keIPACnuAdD7dEadRuTIiS6Lb7uskb381My5yjzF8lGCjBRqdwrWJCagfB3yCy7XT1i92hbcZ5Ci1FJkgYMDf6n%2BjspIsHFjJrTOdzSMuOa9DbDcj%2FnH9N9bIoGVgzHPWIQuFuYtaMRaq8eCKI0gEF6lPOZjBz3EEvaaxwSUT9U%2F8JbJZPJJLBLolH1La%2FRbF9AbC8JJjv%2FmMnssKjLRBJyqj9QXxNko0Ux%2FX79epfiXkm6fmKwF%2Fen1HLc6LxloXWKvGa5rVCVL83VuiPcDEX%2FK5pTXOxHfx6HHB0t2FI0qI2rCZFTrvPWU67zVuS%2FkTsLnc7IKhFg30e4FOkqNSfH5PtkmUy6Cpiv%2F36k2sbqCeCFNa%2BURpoY0sZoYmCgCr3qgZz6s8I0gP1bYiR%2BD79H56NOz0EVWCTy2%2FfffvSCCx59W7uRV9995eqrX8GLesOXNm360iZ%2BT%2FEl3uZqL%2BFyzSZ8XxpTiI%2FG0nkT4zznFZ0t4ipMz5v4q9ssqbdKUZt6u82knPCrt6PZwsnn0XySVnyPR1ZXAn72yx48bWJsu7apnI3Hy8bygUK5Js32qcytapqgmn95uexccj205vGgJ%2BeuOeG2SORmKZr%2FqKzcx9SFctMJdwMUFZDJITs7dnOp1EKZCxg304Cevyfya%2BvlKqv6aXK1qIj3imL%2BL6hL%2ByvUlFfE0VKZ7E8gBY3M%2F8VoJCFgizH1W6VyC76nH6b7jiibYVxUmVIEspry%2FLgZIlCeP11Z4zs%2FAwvVwtGFEut5S1JY4lfyT0N%2FevOLo%2BrUEgjcqc9IkGpQbv3iW7Co5b%2BKgjvpzYdH85PLcc4X21ouwEGl%2FS4qnUAvoSlXUUhR1eKr2VWFTB%2BGMl6FsiQsVD1R3urlAAIoSn7JQkmiVVCHSpCwDH%2FqPepXQ0Db77CJOAImohB%2BRPWr31ev5g%2FkE%2BzTa4lbvZo8xdWPffQu9yJTPCNB66s%2BzXoJt%2F0L6hSoCuBIoK8fnBGG87OoRckJpLqyWe4YbpGi50g0%2B3I3UD85Oa0fzubfoXxPLbW3FDWzigmyJeM0tQkax7PqTy80%2BUxfUHPlBZIRVNQ%2Bv0xRm8REKPoLmNr0%2BUo48v9GFbXPKylqQ2IKm00QddgyWGMROCTxdLB9nCY8P7j2DjlsV%2F%2Bmfr0C0r%2FNkeXbbpPlOTBBwT0mVz1zx9S%2FwJecBF9Wgv3p032iP2v4VSgfgW2G%2BHUEdEXU6iq4CtpLJfIN9XQG8dwa1VoO8XC2SrPDDyCOQptXgbcPvlAgBfxBoGwftQKeKFrNTASPt3pGGqDt%2FQRasn2kri%2BH6L80MJRsmVYJrAKyDItpJUy3%2F15WYIJqcJ9Q5N%2FLFJ4c3dc1URpWl9hW6mu50MUIelg4ucTPf15zs5DFo1c0VSp1tKB9jkwIyuM45kb%2BIP8gHed%2B6jO3v0KbIknzLy636E8KPTdCuUpB0wLo9JKnAO6pv0vS31EtBha%2FfJemkgLVVnd8KCk4qBTpQ5m7FbifBKrPJcq0pZAFVG%2FXbOFz%2BTcq2MLrcmV28Nmi%2FOHskh82bau0k8eWCaPijQPWQ5lUvslwVCfHkXBMIehqUgtDNLeauH1huvZTbYmw%2BluPjyWoNGEuxRLR7LK5fSyXFUyK7PURQv2v8D3XOt2NJ6liBbmPGOsakw1kbeOs%2B31Wm5qpH%2BiJWSzqdPr2O7zc2TmtnrzCig6bBd%2FvgQmzOlz0STWIlmZEQfupogOZFHUZ7EkUnMn0RrpIMqAgHRJAOjIJ3yGw1I%2FMAp9q9S3Q%2FclADNm1wEeO%2Bxbwg5OIYHZLY3ehG5lJk2xhco%2B6JWybpEVz2wrR6hZyD0QXZbeDVB%2BonmlimpkWprdAs4WEZDSQppsDlcdCBJJESIYFuAtUnC4GIF2C3Uu2Kv7L1bdz6FxtqxpG4TqQOqOUNAJ2HLvPWA2GgDy4O4vaDrtyl6P%2B1fAll%2BSyFcQ28GHqh7fvvf37udylf0fNwhzgz87Y%2Bcf5x9GnF6ygHu18sAbipWeF0YPBgp2GaKeQduxxdEr3SgbH1kvH7tvqSLhedomOvZyts2dw8acu3dY%2Ff%2BucuMtCuP%2Fe4zC4XnH3OLZ8ZuxTWxy8dJfU5dhDeKPSlJy5pn%2F%2B7u3XrJhmr9C5CuleGflGQocKnlAUaRKp0BAHV0ZwUt9VCqk6zYOgRIuMfePJzdmBdpPJ7%2F6B23%2Bf%2Bsp9NMDZevovvfYHG5dGPISQq1DojqNckchVrCcCYz%2FQ0hI0m3NKDRfkgsrnamo%2Bp0CAq1FyvC3a3Nak%2Fs5VX282x9Ufy3E39VAx6o7LpCvO2wK%2Bch9jNqpJCutcIOooKnYWtDK8gTRVYygRQfwgzKM5%2BjP2jOZdx3r32Py7rQUPOzAnoRs95NvRAR0qLGU11Taqu1bUYSzMcWjMEir067JQQHfIrLBHsrgv00%2FWavd8HRLMEEYFSW3HCSNQehnrHztKqHcDyo4VfZ6gPKCR%2BgufwA8GegxUEo4A%2Bgd0BASHiH6jYMLIsUdQJTs%2FC641KN4oCHWolCMLlMfIdtWKScjx7SM5LD9HnfmhrGI0S139UWfUnxgOXdJFW%2BAMcGjKr6eHAttHF5sUoeArYKDcxMSYcKA%2FxUDhPiEOEAPafSIUFArN0r24ynI91EPARDXvIDYyvqZaWeroBOUABQA%2FE%2BDXC7PWafDLQY2oiwpUEyj4RQtVlUp1GrM7In2p2A7VuiOW6otMiGOo5Mrp05ejVuTy6dNX%2Fk%2F7mybZQ0nUmfrbx3U4KueDnlHm5wdh8FFeKnoaKKh%2FTK18StOPhwG9Xo5mqXAxvw%2F79YQwwDR%2BnAKQQ4izVXioB84qcppWB7IqjU45z4CE17OvF1Dw%2BoTFqxtz8dxwtogBnF9MjIl%2Fin%2BK8s3hM9laIn0TiCbTAXL0T798bPXqx36p3chrv0O%2BGC9Xaj48Ecv8U8UEeBvUEsDlTepiU5OvlpeNGvpnKF0RvUooWhIjnx6GeBapXCQYTw9DNg6%2FOC3gZjp76oNTj9Kz6Jqobxb9NDqc08vcKReOpcsQV2K8InXFaXW3aI6Ofr1k48rp7CX7rx%2Bv1UKPsfvzQU0Kc83i2VdILmd2%2FyX55zT9luN2%2BCu4nKfwPcK%2FCvDVU%2BpHh8%2BLaldIf1fA5h3ndT6Fln9%2FW%2F9Ce1vndfvJtnPVO2xhm3qbafHVCN1X363UXHq9xuVD8OSD29Z8pZ5cZrern9cAdGW%2Fuib%2Fud%2BVK0L9a42r6C90kL8KzxwLQw9NkIQJL0ASU8M%2BVG0KsUdgdvpgP%2F6NqqP0%2FgHZFUfGEijZLHpiIgvV5%2FBltrj8Qd7XQd5p4P%2B7tJo30NMO6VGBwahSPMYiaaBYoLY6uEnciyhhh1Z%2FvvacG%2Frjpsvnpzs0B1Id6fmX8119l88XnOxe%2FuGrzzHcdu7UtY3%2B2vmXN5zUyj3ZcPl8p1sZSs6%2FnGXtwrV7Ka0XZdz83fwjjINpZWYw85lL8BRK4nGyIir2RiOsEyipuEcIakpGjWgBjLiHWOgj0Yi34gW1kKPxHt2Na5q%2Blwg1RdRSpFDNzosb44YJXnAfoEOpZW%2F%2F6u1lhYA6leevezbI26zNHO811M2dc5HFxpk4i1jPC0s21%2FBWW5DnPQbn2X1WK43%2FaM2n18DfSoybbNHijFpamzXI31eRibGUOxSu%2FlT96YZlq1Yt20DaSBuG6knw2eusHs5EPBfNmVvHKdaQzcDfz9ZsXmLDWGXy2U5OsYSsIn8CS12jQIyD12KKqZrLPy7mSPdICmd6WGHG8NDZkkHuE4h9TU8FpmUO%2FVjC%2FEinToFyoNDz2p9XD6g78WgQdPG7Z3R0T%2FZ5dTM9lsL8Ktek7szl2L%2BgQwGgwkZHc2g5Su7NvVqwGy2Ua4KSXUwt1X4PaM5paaEu6jQ5zVFyNabxvUksVt2T%2F4VeamYPlLtffdQsk%2B2sUTY%2FzDXl%2F05W53%2FBz9UK3p7LjapZ2ZxOm%2BUlZXrL3HHGqO8%2BwVroDaCTTnTxitMxmiAAYQzVJQH%2Bnj3oIHnPaN6Zq6sNSLjBl8tKgVr2mj%2F9CWi9dnKca8rBQBsd5R1tzVlgrl5pbnPw6kZclCr2CHxMnHohLz%2B3KRQokzALyeIKFU1TNCiayJdoHvDYe7K6mZLm8S3uJ9dojuaJ62%2FqN%2FtjQxnSnhnKPw%2BLNrLi8ZKyJ3x1YhiI1aNAtP6NzCGzYv3DmaGh%2FLvQZnt0evgIhTFV0kE%2FPYxAnOHhCQUZdCWY5JWJwMzlAGl1mpNbDU7yyGnhRMILsYhH3VRAijrPcBU8%2FCj1Y9NY6cnGVW0CjTLaz7E3epvaT%2FLtTV72Rs%2B0WVVmd0dz%2FMGTI5F0OsIviaqDlbbO5X6xT3PeXbXHRtf%2Fz%2Bfdka%2BeKPr8KF7IF4vBsT9MFPuPJMBTBMq9hQxXelQ%2Bbewnf18ap4Ib%2BmSMrtDU5zqlD8QANa5MBGh%2FOwOvSDfcV2d66mfEWsbGWmIz6nsyZDWQSmqmxDneYyvjHPmRXHZxeueyRGLZzvRioKnGto9nIPkibAJA16adcOZRQr1iAP3bUyBR7T4RgAWTKxhkCYFwshq%2B7iV9r0whk50cmRcTg4fy5x4OmmNkHndIA2%2BYuMbmE9dwGYB4KFTsvnDE6Ah47r%2FfE3AYI%2BoXADpkdlENcZ8OZEEf8FFGZNxMs6ZLpG3SUFLL7Q2kcFU%2FA%2FJsw%2BvWDa%2F7emewLaoeibaF1B9qUNnuqWK3%2BUfXYVL1v%2FomD15xxeDkPnXTOKSVcCbDGtOu0YQNpGAP7U1HU58UrqGu8xIbHtkQ3LVhb7Dx46ET3Ffcm1q0YcOizNmf3bC3VjWfAcpSv3MyTlgJ23FHQgmgvk%2Bgk8pL0mcCDOn08MDAQlf%2B%2FSlTZ1z12fnqntOhbOTL9%2FZdevbAPN%2Byby1f%2FuUtC%2Fixm8ZBo59LTXEW060hGrTDplNprWd58fwB%2Fb%2FE27BdS%2Fs7U%2BrGVCeQ46nzaw9QccnmZerGZZs3Yw9aVHt%2BKh6HN4ti6lxIhT%2FwahnZtWwzlY9QHQ2c79C%2BdxzvVDKy8GqKWQERO9YAKbpsDUTLdWV5dE8PVPjvj9pqw7ah%2FPFVtkit7aj6G5xY9mfJrCz1j1e0BcnPol4UjtrCdbahIVtd2HaURujnFJR8CuOuUUfhrGhgKKgjCYNSvCc1WKlEp8wHUaAYynFNyzZn%2B2MnYv36dbMDBTonl%2FT%2Fma5IKAyEGz%2B4eRnVtaX6tss2o34u8mWorFtuFgm4A6qK%2Fyp%2FgLEBVat5WnPDdKA574ubuFJ%2FIUfZ%2FY2Nt6mN%2BZNNTSTaeI56gKwkXerTe9DDHUw8%2FH35FY3nNN7GGuBKWhrV9ep%2B0k1WjNWVaHkW1yA%2BQHWNu8rtBw2a5YXuE40rs7%2FGA%2Bj09V3hA98yRnFPOGr8ltGlsFdD%2F7tRce3LH6Trcneuiy7K7J3khKu%2B3qUaXPWaX7T6%2FKfj9BX2eZq2XAcZT79u1ClJzUtHUqfqSMWBcZS43Ena0cUGLgpkKxB1QM%2B0Fxz10wgg6r5rltnFpH05pepUq3Y2HfYqeKRntmUFNz%2BXmcOs1H31U6cC6RTVLfCg7RNBF1UF2%2FwBgu0fFQtPEU1sSg3VcNsR7dWq3af87tUFn1l3ltXpaJxpNvtcZkH2WmMst3JqRpxUH%2BWC0E1qOGtP66s1MYv%2BVLu8%2FXFXvV%2FZbunYYBeVN64ls0ur6NzpV9xzlmQwB5qC4Tq70WC0tk8dWJXeHvkD0h9zJOM0vD86%2F1NJMaIAolctvlByferCsqOKDKceOfUu1PsmoFCamV5mCrMUOCi6V6FJosMF22AcrKJgQDVhfYh6tepp%2FlYgvnCEAbJQ1L0rOpajEmRcasMiPfxhgGoVo4rwreQpV6fUJHH2e8fa1s2c13Apl1b89a58ozdoap2sjgLN9uISl7P1DrulyeIkt0zr6JjWocoPOZsaXPb6jtqBblsgsaRre2xHi4nELm0MhG1%2Bx1SXwLpFi53b%2BaHRYo%2FIrbZtuWAKu5cSEXfybnnmUCaXGTpQr0xK2O2WWY76f%2BnAjNVf7nCZHU5XqIkTnpt6VtvsFlPXg1031g%2FVRdpkkyVpD7jnmax88QwDvg%2F66NnMRdRXTcGTmQc3cuINwN5IQqi0yzb%2BYFVHuVqI5s4ADfg5oE4ybDLd28mFSFmYvRoomsWXEdLU2Wl3GJy93ZNb%2Fd5gqmNaqJZSO1l6PVRy0nZIj%2F45EetjLguh1rLqR%2BSK0hO6NrsqcNX8zoUdjQYDJ7tb4os6%2Bi%2BY0qpY2AWlnLRDWdGFTfGY1gV0zNAtJ7pdo24se0D88AwLY%2FgZmE9iuP4V5v7CSR%2FRThaHLh%2BUeBkXwU6BC7lGOevK65udTv%2BtS%2FPfW7qj3ljTcj3b9OkbV85t8xsMj7Ddj7DGpthZKwKPvso%2Fc%2F1K9aLE12fMWLV1y1D9ua8lyJdWXr%2FbG%2BnoCFutf%2FmLILe39ITUV4igr3876fpX5g2zeB52sWnIL4fXHlgeUzOx5QfIvJQyrKQE9wHUqVq%2BPEaOrz0wVvNbJZVSfsuMzxN4l9PkedFzw9V5Dj%2BnzpgoT4ZxCxJfC5RWLc74YVHxKlExCYt0JAOMatREhHBSCAtSfod6x6Ls8HCWECLwXZ9nd5Dz1T24JUdWs6fU3%2B%2BfcnT49Qe%2BkBs%2BwdsMZgPXMp3U5S958snPP%2FEE7bvkOPCuTUDTUQ%2FUzirLhML9yPahoe1D5Fj5jWsaoveyP00PehdUAHk%2FseDVWsvDWXXXsyn%2F4wfpXc2V3%2FQxli3jl%2F5hj%2F83avSCfpTNxOEKLmTjxOEKuxgNlsQn0xgct724mhynupNW1Ph6o3RYS3%2F%2B2TJrzLlkFz%2Bip3qCHKf6eqW02QJLjBYuuj4sobhCWqa%2FYHGEHpcnumuWSOhxeaL7sOakNR6vvmo%2BYcfFA8UFXEPZf9UjyudIOyNwx%2Fi90DdsujS%2FFX2UAwvWSVK4NxaMhAGw3oowp%2Fuc8CTi7D2rBgZWwb%2F60faR7SPsEbjkXy4G0XaqhXPwe2cePjxjxuHD6ssQuR1fq6PF0E%2Bo2t1nePTn8TUmxz%2FA3crMoCc7egESuoTHYc7mYdg6etORoOhR7BBGD%2BqJopELrl4S6cJNRtEAsLP%2FOdvnJq0Wo0GolY2Et9VFB2Kf%2B4bZvVyxfOMz3WdFfSIryj6DwWghre7aQbdiDrkTL3A3vNDuDpk93HqXwam%2BbWmUJZfNn5ozKV5Pmmq8PF%2FjVY%2B2Tlk2M2RzSXKjmbQ4RZcQavEYrN%2F9rlXwtIQqzxQNMzPPfHYLvuPoO9TbT8bpGw5CQPGd%2BSyX%2FCyf0Vxjd2R9NmsunnXYa8xGHzn%2BsSfM5J0y0DZEXWWxkXjcR75KBLNLHi7XvX2G8VOrf4Ykg0AMdBESIpo7MgAfyakA6rkqpI6UjNs0px7cMV%2BD5BF49Tez1VGnYmq0WIijp985m4Sn2gJR9b07riPPFo97OYbUZbxJCpot7H%2FlpZBicglCPN7WOfJkcHqc3ElWqvvz%2F1E6bIQrG%2Btz6WkM1SM9FBTR7FSs8KyBBytSmNEoquJNFN5EQyTiCrnKDx1h58yxCepPHU5nxGoxEQeeOZi2m80DxNxncVhr6BmEfUarxejw%2BWSiHhWk19bSY7aKR5MsteblJpfTLtjimBouXsm3d3djjYM%2BwEW0El9dM%2FueVRWIsXwe43R7SgbVZqrnqoJ1X%2FkuF7pcgf8duv4q6vayV5U9zMV91GxO59UUjW8rHV6u799WzKMT7umRCXbYUKM%2BfoaCcwgaoqZUtmodV3p%2BX7akb4dnU9B9La38RPFUG2SCC90tVA4XwEFhyOpZZrUCsgWYHsczLFBBVGNtstoN1bw0Z%2BO4fYIbvZVt4EUcJEKOhHeincWqONw%2Bq6w5Go%2BWGOSR7LhKV%2BKBqbBPpfUvOf9QqkpDyVhBeyyZQGMsdA5FBUqvFMtUyGq9vjnsAJU4UcrxldP1CCaofyDkSAifoP5QwWx%2BSyUGxp75BzGAvtG7uQ38LehlyEQMeh0TeE6Bm7tYdXqdkt0uOb3kfYlNwmOdDyacOq%2FqlFo1v%2BPTmTi3E%2FglC9W11b34A22zmLzvb231Q0L2Bgg60OTW4YdstO%2BYOJnO38TtpH7zy9ymokWyA79qlVSn38HtpFlImFnhu3b4boNWXklOXV0Iwo7lQ1hrZyPFcwtjwFP7iEKSHSSJw509kh8kj6pr%2BH1jR7km9vcvqN9657vffefkv%2BfKxge1X%2B7RdjYUPIESN7gTvRkB%2FRMYtEkaVkdHApmdBPpnKmz0n1xSWFOyVIuLrinZwpoCRe6kyiVZoHX088F%2BUX4%2BWKS4iBTP0IWxGtZgOdMaV4KTayqHQF%2FVihBwTbgDXTCmKoOBJeNhwJMzEVjtjIFLuU38fPR7hqNG1JS7g%2FqRCuy3vmQ3W9Vu8qbVbP%2BSzazGRJH83MzP90Ck2m31mMjP8TiLn5uwD2Ugr2PFvPQjB5BnSJvQxGQZZEB%2BLopqzGzDbMmbkAPkZVJjeO5FzOSBKCgJze2ZS4Gemc9twrwY6u9H61iUQTcRvtdT9RW3tRxAWwFs2tcuJRnI6xjmBdWjbgFNRHMHiF1uHYBfUR%2Fut5Ug2jXAaT96%2B9RH%2FFToRwIzGbKmVJ1AZQnoabSB1yyIg7ByAridHApPMjyw0OiV6RjSbCuzwLAvFizBliWJua1tsuAgvNPbmljYbpt8lkWam7b3XZiOiKJskMOtmfScnsbPW208knwjuXrXK4Q1iKIgNyYXXDVT9C2Ye%2F78GQ5BEEXfFdde2RwauOysdJNL5AzCy84ard%2FnGAVN8alecnFdgu5Gbd5DJTL%2BhHZK0vApVy3OfU8XTSJg1TlssivsPYUlIqvn66PzrVTymCc4wgF6SDNR0pDf%2B9Gp%2BVnsUH5WtpHYsuhOaey8zdwLN47V8MTbm78g687%2BP3cx6tcAeNpjYGRgYGBk8s0%2FzBIfz2%2FzlUGeZQNQhOFCWfF0GP0%2F8P8c1jusIkAuBwMTSBQAYwQM6HjaY2BkYGAV%2Bd8KJgP%2FXWG9wwAUQQGLAYqPBl942n1TvUoDQRCe1VM8kWARjNrZGIurBAsRBIuA2vkAFsJiKTYW4guIjT5ARMgTxCLoA1hcb5OgDyGHrY7f7M65e8fpLF%2B%2B2W%2FnZ2eTmGfaIJi5I0qGDlZZcD51QzTTJirZPAI9JIwVA%2BwT8L5nOdMaV0AuMJ%2BicRHq8of6LSD18fzq8ds7xjpwBnQiSI9V5QVl6NwPvgM15NXn%2FAtWZyj3W0HjEXitOc%2FdIdbetPdFTZ%2BP6t%2BX7xU0%2Fk6GJtOe1%2FB3arN0%2Fpmz1J4UZc%2BD6ExwjD7vioeGd5HvhvU%2BR%2BDZcGZ6YBPNfAi0G97iBPwFXqph2cW8%2BD7kjMfwtinHb6kLb6Wygk3cZytSEoptGrlScdHtLPeri1JKueACMZfU1ViJG1Sq5E43dIt7SZZFl1zuRhb%2FGOs44xFVDbrJzB5tYs35OmaXTrEmkv0DajnMWQB42mNgYNCCwk0MLxheMPrhgUuY2JiUmOqY2pjWMD1hdmPOY%2B5hPsLCwWLEksSyiOUOawzrLrYiti%2FsCuxJ7Kc45DiSOPZxmnG2cG7jvMelweXDNYXrEbcBdxf3KR4OngheLd443g18fHwZfFv4NfiX8T8TEBIIEZggsEpQS7BMcJsQl5CFUI3QAWEp4RLhCyJaIldEbURXiJ4RYxEzE0sQ2yD2TzxIfJkEk4SeRJbENIkNEg8k%2FklqSGZITpE8InlL8p2UmVSG1A6pb9Jx0ltkjGSmyDySlZF1kc2RnSK7R%2FaZnJ5cmdwB%2BST5SwpuCvsUjRTLFHcoOShNU9qhzKespGyhXKV8SPmBCpOKgUqcyjSVR6omqgmqe9RE1OrUnqkHqO9R%2F6FholGgsUZzgeYZLTUtL60WbS7tKh0OnQydXTpvdGV0O3S%2F6Gnopekt0ruhz6fvpl%2Bnv0n%2Fh4GdQYvBJUMhwwTDdYYvjFSM4oxmGd0zVjK2M84w3mYiYZJgssLkkqmO6TzTF2Z2ZjVmd8ylzP3MJ5lfsRCwcLJoszhhyWXpZdlhecZKxirHapbVPesF1ndsJGwCbBbZ%2FLA1sn1jZ2XXY3fFXsM%2Bz36V%2FS8HD4cGh2OOTI51ThJOK5zeOUs4OzmXOS9wPuUi4JLgss7lm2uU6zY3NrcSty1u39zN3Mvct7l%2F8xDzMPLw88jyaPM44ynkaeEZ59niucqLyUvPKwgAn3OqOQAAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAHjarZK9TgJBEMf%2Fd6CRaAyRhMLqCgsbL4ciglTGRPEjSiSKlnLycXJ86CEniU%2FhM9jYWPgIFkYfwd6nsDD%2Bd1mBIIUx3mZnfzs3MzszuwDCeIYG8UUwQxmAFgxxPeeuyxrmcaNYxzTuFAewi0fFQSTxqXgM11pC8TgS2oPiCUS1d8Uh8ofiSczpYcVT5LjiCPlY8Qui%2BncOr7D02y6%2FBTCrP%2Fm%2Bb5bdTrPi2I26Z9qNGtbRQBMdXMJBGRW0YOCecxEWYoiTCvxrYBunqHPdoX2bLOyrMKlZg8thDETw5K7Itci1TXlGy0124QRZZLDFU%2FexhxztMozlosTpMH6ZPge0L%2BOKGnFKjJ4WRwppHPL0PP3SI2P9jLQwFOu3GRhDfkeyDo%2F%2FG7IHgzllZQxLdquvrdCyBVvat3seJlYo06gxapUxhU2JWnFygR03sSxnEkvcpf5Y5eibGq315TDp7fKWm8zbUVl71Aqq%2FZtNnlkWmLnQtno9ycvXYbA6W2pF3aKfCayyC0Ja7Fr%2FPW70%2FHO4YM0OKxFvzf0C1MyPjwAAeNpt1VWUU2cYRuHsgxenQt1d8%2F3JOUnqAyR1d%2FcCLQVKO22pu7tQd3d3d3d3d3cXmGzumrWy3pWLs%2FNdPDMpZaWu1783l1Lpf14MnfzO6FbqVupfGkD30iR60JNe9KYP09CXfvRnAAMZxGCGMG3pW6ZjemZgKDMyEzMzC7MyG7MzB3MyF3MzD%2FMyH%2FOzAAuyEAuzCIuyGIuzBGWCRIUqOQU16jRYkqVYmmVYluVYng6GMZwRNGmxAiuyEiuzCquyGquzBmuyFmuzDuuyHuuzARuyERuzCZuyGZuzBVuyFVuzDduyHdszklGMZgd2ZAw7MZZxjGdnJrALu9LJbuzOHkxkT%2FZib%2FZhX%2FZjfw7gQA7iYA7hUA7jcI7gSI7iaI7hWI7jeE7gRE7iZE5hEqdyGqdzBmdyFmdzDudyHudzARdyERdzCZdyGZdzBVdyFVdzDddyHddzAzdyEzdzC7dyG7dzB3dyF3dzD%2FdyH%2FfzAA%2FyEA%2FzCI%2FyGI%2FzBE%2FyFE%2FzDM%2FyHM%2FzAi%2FyEi%2FzCq%2FyGq%2FzBm%2FyFm%2FzDu%2FyHu%2FzAR%2FyER%2FzCZ%2FyGZ%2FzBV%2FyFV%2FzDd%2FyHd%2FzAz%2FyEz%2FzC7%2FyG7%2FzB3%2FyF3%2FzD%2F9mpYwsy7pl3bMeWc%2BsV9Y765NNk%2FXN%2BmX9swHZwGxQNjgb0nPkmInjR0V7Uq%2FOsaPL5Y7ylE3l8tQNN7kVt%2BrmbuHW3LrbcDvam1rtzVvdm50TxrU%2FDBvRtZUY1rV5a3jXFn550Wo%2FXDNWK3dFmh7X9LimxzU9qulRTY9qelTTo5rlKLt2wk7YiaprL%2ByFvbAX9pK9ZC%2FZS%2FaSvWQv2Uv2kr1kr2KvYq9ir2KvYq9ir2KvYq9ir2Kvaq9qr2qvaq9qr2qvaq9qr2qvai%2B3l9vL7eX2cnu5vdxebi%2B3l9sr7BV2CjuFncJOYaewU9gp7NTs1LyrZq9mr2avZq9mr2avZq9mr26vbq9ur26vbq9ur26vbq9ur26vYa9hr2GvYa9hr2GvYa%2FR7oXuQ%2Feh%2B2j%2FUU7e3C3cqc%2FV3fYdof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D92H7kP3ofvQfeg%2BdB%2B6D92H7kP3ofvQfRT29B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6j6nuG3Ya7U5q%2F0hN3nCTW3Grbu4Wrs%2FrP%2Bk%2F6T%2FpP%2Bk%2F6T%2FpP%2Bk%2B6T7pPek86TzpPOk86TzpOuk66TrpOuk66TrpOlWmPu%2F36zrpOuk66TrpOuk66TrpOvl%2FPek76TvpO%2Bk76TvpO%2Bk76TvpO%2Bk76TvpO7V9t%2BqtVs%2FOaOURU6bo6PgPt6rZbwAAAAABVFDDFwAA%29%20format%28%27woff%27%29%2Curl%28data%3Aapplication%2Ffont%2Dsfnt%3Bbase64%2CAAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw%2F%2F8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS%2FYAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv%2B5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o%2BU1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg%2F%2F8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl%2FCYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4%2F%2F%2F%2FAAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD%2BAB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl%2BIA4gniEOIY4iHiI%2BIw4kDiUOJg%2BP%2F%2F%2F%2F%2Fj%2F9r%2FZv9i4Ajf5N%2B132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH%2F4f%2BB%2F3H%2FEf6x%2FlH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl%2FAAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm%2BgAAJvoAAAAbAAAnCQAAJwkAAAAcAAAnDwAAJw8AAAAdAADgAQAA4AMAAAAeAADgBQAA4AkAAAAhAADgEAAA4BkAAAAmAADgIAAA4CkAAAAwAADgMAAA4DkAAAA6AADgQAAA4EkAAABEAADgUAAA4FkAAABOAADgYAAA4GAAAABYAADgYgAA4GkAAABZAADgcAAA4HkAAABhAADggAAA4IkAAABrAADgkAAA4JcAAAB1AADhAQAA4QkAAAB9AADhEAAA4RkAAACGAADhIAAA4SkAAACQAADhMAAA4TkAAACaAADhQAAA4UYAAACkAADhSAAA4UkAAACrAADhUAAA4VkAAACtAADhYAAA4WkAAAC3AADhcAAA4XkAAADBAADhgAAA4YkAAADLAADhkAAA4ZUAAADVAADhlwAA4ZkAAADbAADiAAAA4gYAAADeAADiCQAA4gkAAADlAADiEAAA4hYAAADmAADiGAAA4hkAAADtAADiIQAA4iEAAADvAADiIwAA4icAAADwAADiMAAA4jkAAAD1AADiQAAA4kkAAAD%2FAADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4%2FwAA%2BP8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf%2F%2FAAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA%2Fujw8AMg%2FOAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc%2BAR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg%2BeBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg%2BeBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX%2Boh0VyBUd%2FqIVHR0VAV4dBEwdFf6iHRXIFR3%2BohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5%2BgoFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP%2Fu0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK%2BhkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI%2BAzUzBgcGIyInLgEnIzczNjcjNzM%2BATc2AujycDwGtSM0QDkXEys4MjAPAXtk%2FtQGAZZk%2FtQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ%2BH3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP%2FvUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j%2B1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2%2BgMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc%2BAT0BA%2BgdFTJjUVFjMhUd%2FOAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB%2F%2FIBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY%2BARYfATc2AyEnAwL2IAkKiAHTHhQe%2B1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7%2FRYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI%2FcwIBQMBCAgI%2FvgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI%2FvgIBQoCJgoF%2FvABCAgFCv3aCgUIAQgIFID%2BlAgKCggBbAgIpAgIpAgAAAAD%2F%2FD%2F8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA%2BAmDpkNDWPWXyL9mdYCZv4f%2FrNuBLoNmQ4mDlzWYP50%2FZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V%2Bv4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm%2F2iKmAVGilucRoYEQJ%2FJioAAAACAAn%2F%2BAS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI%2BATQmAZDItoNOAQFOARMXARY7GikT%2Fu13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15%2Fu4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE%2BAh4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4%2Bp4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ%2FgHk5QHZTLQVIAAAAAf%2FTAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAyABYRMT%2Fp8RDPn%2BbxQLDPb3DAsUAZD7DBEAAv%2FTAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP%2BnxEM%2Bf5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU%2BAT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR%2BCg8PCvuCCg8PVWQCo%2F3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh%2FdoKDw8KAiYKDw%2F872QDIGT8GGQDIGQETA8K%2B%2BYKDw8KBBoKD2RkZA8K%2FqIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHQRMHRX%2BcBUdHRUBkBUdHRX%2BcBUdHRUBkBUd%2FagdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA%2FAE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3%2BcB0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH%2FoAICLEHFAirBxYB3QI7CAixBxQI%2FPAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI%2FvUBCwgIsggVB%2F70%2FvQHFQiyCAgBC%2F71CAiyCBUHAQwBDAcVBDuzCBUH%2FvT%2B9AcVCLIICAEL%2FvUICLIIFQcBDAEMBxUIsggI%2FvUBDAcAAwAX%2F%2BsExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj%2B1HeOYrSBTU2BAW%2BzmFhYmLOZWFj%2BvJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15%2FtUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF%2F%2FrBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI%2BATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K%2FqIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V%2FnAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P%2Ft6WCg8PCpYKDw%2F%2B3pYKDw8KlgoPD%2F7elgoPDwqWCg8PBLAPCvuCCg8PCgR%2BCg%2F%2BcA8K%2FRIKDw8KAu4KD%2F7UDwr%2BPgoPDwoBwgoPyA8K%2BgoPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ%2FAjY%2FASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ%2BfrJ%2BBJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF%2BfrEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD%2Fu0DwoBEzspASwBLDsp%2FUQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT%2B1PzgKTs7KQMgZP1EArz9RAK8%2FUQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg%2F%2B1A8K%2BgoPrwoFAmoCYAcH%2FaAICv3BCg8PCgF3%2FokKDw8KAj8KAAIAZAAAA%2BgEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V%2FOAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd%2FnAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnL%2BfDIKD68KDw8K%2BgoPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr%2B7Q8KMgoPDwoBXgoPAAAAAAL%2FnAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp%2FeYBr9EVohTQ%2Fp4b4BsBkP5wBLD%2B1AEs%2FnD%2B1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN%2FrkNCxS%2FHQJUMgoPDwr75goPDwoyCg8DhA8EsB0V%2Fj4XEP5wEBABkBAXAcIVHfzgDwr%2BogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K%2Fu0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf%2B7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY%2FAT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX%2FdQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K%2FXQYGf5XDB4CBggEDRkBqRkYAowKDsgOC%2F4%2BCw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJy%2Fov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2%2BDCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ%2BAjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL%2FpYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ%2BAjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L%2FpcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv%2BlwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB%2FAI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA%2FK4KDw8KA1IKDw%2F9CDIKDw8KMgoPD9IBwgoPDwr%2BPgoPD74yCg8PCjIKDw%2FSAcIKDw8K%2Fj4KDw%2B%2BMgoPDwoyCg8P0gHCCg8PCv4%2BCg8PvjIKDw8KMgoPD9IBwgoPDwr%2BPgoPDwSwDwr7ggoPDwoEfgoPyA8K%2FK4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT%2FtRSdmQpOzspA4QpOzsp%2FageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE%2BATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH%2BWwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT%2B%2BuSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF%2F%2FtQKDw8KASx03qP9wAwI%2FjQIDAwIAcwIDAwI%2FjQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ%2FAScmND8BNjIXAUEBAgkMDAn%2B%2FhUZ%2BgoPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg%2BEeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY%2FATYBQQECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK%2FRIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd%2BhGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk%2FnBkAfQCvMjI%2FtTIZAJY%2B7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs%2FUQBLGRkZAOEZGT%2BDGRkAfT%2B1AEsA4RkZGQCWP4MZMgBLAEsyGT%2B1AEs%2FtQBLMhkZGT%2BDP4MAfRk%2FtRkZGRkyGTI%2FtQBLMhkZGT%2B1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI%2FOD%2B1AEsyGRkyGRkASzIyMgD6PwYA%2Bj8GAPo%2FBgD6PwYA%2Bj7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI%2FjAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAwYCqggI%2FjAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg%2F9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj%2F%2FwRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4%2B%2Fj4dBLAdFfuCAbz%2BQwR%2FFR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY%2FATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2%2FkQLEAFOBw45BhcKAcIKFwY%2BDgdTARABVpYKFgROBBYK%2FdoKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw%2F%2Bsf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg%2F%2BcA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP%2FagOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE%2BBAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT%2Bz76Hh76H%2Fu9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K%2F7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE%2FAQEDIQMCqQGBFCgSJQkK%2Fl81LBFS%2Fnk6IgsJKjIe%2FpM4HAwaBwcBj6wBVKIEr%2FwaMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu%2FVoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU%2BATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD%2BDCk7AQYLFyEaAdc5dWM%2BHy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb%2FK5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK%2Fgy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL%2FtQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI%2BAzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI%2FOCnpwMgpwACACH%2FtQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ%2FnAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V%2FagVHR0VA%2BgVHR0V%2FBgVHR0VAyAVHR0V%2FOAVHR0VBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR3dArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V%2FagVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V%2FOAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3%2B6WQVHR0VZBUdHf7pZBUdHRVkFR0d%2FulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA%2FAAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA%2FAE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG%2F5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V%2FgwVHR3%2B%2BqfIyAHCASwVHR0V%2FtQVHR0VAlgVHR0V%2FagVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V%2FgwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd%2B7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH%2F0SHywsBIT%2B1AEsA%2BgsH%2F12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs%2FNJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7%2B4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4%2BrWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab%2FG8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ%2BBQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ%2Ff4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA%2BhsAgYUFR0OFgoFBmz9BQGQMje7%2FpApOzspAfQpO8i7o%2F5wpbm5Azj%2BlqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp%2FgwpOzsptsj%2BtKW5uaUBkKW5%2Ftf%2BljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml%2FnClubkCfwFTCAj%2BrAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn%2BDCk7OymZZ6W5uaUBkKW5G%2F7TBxUH%2Fs4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX%2BcKW5uQHKAYsHFQdlBwf97QcVB%2FgHB2UHFQdvCBQETBexOyn%2BDCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH%2BAcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE%2BAQgIFAgBBAcFCqrICggBCAgI%2FvgICsiqCgUH%2FvwIFAj%2B%2BAgFCq%2FICgj%2B%2BAgIAQgICsivCgUDlgEICAj%2B%2BAgKyK0KBAf%2B%2FAcVB%2F73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ%2F%2BMB0VZBUdHQRMHRX%2BSgHFDggV%2FBgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ%2F%2BMBUP%2FjAdFWQVHR0ETB0V%2FkoBxQ4IFf5KAcUOCBX8GBUIDgHF%2FkoVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ%2F%2BMBUP%2FhQPDwHsDxUB0A8VBBr8GBUIDgHF%2FkoVCA4B4A4qDgHgDggV%2FkoBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS%2FNISGRkEMv4OCx4L%2Fg4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2%2BsgVHR0VyBUdHQGlyBUdHRXIFR0dA%2BgdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw%2F%2BFA8V%2FjAPFRUPAmQBthUIDv4gDioO%2FiAOCBUBtv47DggVA%2BgVCA4AAAH%2F%2FgACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL%2BMQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX%2BOQ4JFAPoFQkP%2Fj4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA%2BgVCA7%2BOwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW%2B%2B4WCQ8B9Q8q%2FfcD6BUdHRX8GBUdHQQ5%2FeQPFhYPAhwP%2FUgdFWQVHR0VZBUdAAEAiP%2F8A3UESgAFAAAJAgcJAQN1%2FqABYMX92AIoA4T%2Bn%2F6fxgIoAiYAAAAAAQE7%2F%2FwEKARKAAUAAAkBJwkBNwQo%2FdnGAWH%2Bn8YCI%2F3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4%2BrWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX%2BDBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm%2F5%2BHRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI%2FARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ%2BAQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB%2FIHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm%2F4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ%2BAQUiDgMVFDsBFjc%2BATMyFhUUBgciDgUHBhY7ATI%2BAzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ%2FeMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD%2F7UDwoyCg%2FIDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw%2B5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP%2Fs2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA%2FAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJyg2oHB%2F7ACBQIyggIagcVB0%2FFBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf%2BvwcHywcVB2oICE%2FFBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ%2BAQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV%2Ft0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA%2FkAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ%2FAgoQEP32EBf92hUdHRUCJhcD8f5VDSYN%2FlUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3%2B3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN%2FlUNJg3%2BVQ0KFQEjHQSwHRX92hcQ%2FfYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ%2FAgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN%2FlUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I%2FiH%2B1BUdFQ5e%2BQgUCGoHB%2FleDggEsB0V%2FtQVCA5e%2BQcHaggUCPleDhX7UB0VASwVCA5e%2BQcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ%2FAScmNgP2agcH%2BV4OCBX%2B1BUdFQ5e%2BQgU%2FQwBLBUdFQ5e%2BQgUCGoHB%2FleDggEYGoIFAj5Xg4VHRUBLBUIDl75B%2F3xHRX%2B1BUIDl75BwdqCBQI%2BV4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3%2BDA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc%2BBAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP%2FnDI%2FnAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe%2FokKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf%2BiQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc%2BATc%2BAScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy%2Ft3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U%2FM0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc%2BATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY%2BBDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA%2F%2FcAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl%2BDiINfWjIWCwQMWv3%2FIw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP%2FcAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ%2BBTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2%2FVFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP%2FngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U%2FBQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR%2FplkGhPNzRMaZP6ZERgWDwFrBLBYPv6t%2FrsOMRQpFA0M%2Bf75XRRAFRAJgIAJEBVAFF0BB%2FkMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA%2FAEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk%2FHxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd%2FnD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb%2FkPD%2FkOFZ%2F9qP7dFR0dFdECWPEV%2FamNetEVHR0VASMDGvkPD%2FkOFfG1jXqfFQSN5g4qDuYOCBWW%2FagdFWQVHQJYlhUI%2FpiNeh0VZBUd%2Fk3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7%2FtQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3%2B1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6%2BhUdHRX6%2BhUd%2FnD%2B1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB%2F%2F8A1ARMA8IABQAAAQcJAScBBEzG%2Fp%2F%2Bn8UCJwGbxwFh%2Fp%2FHAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH%2Fp8BYQAAAAAC%2F1EAZAVfA%2BgAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW%2FoP%2BHOYOCBWWAYHX%2FRIVHZYVCA7mDioD6B0V%2FdkVDvkPD%2FkOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3%2B1B0qHR8SHQYFyTYUHh4EsBYQoiUY%2FiUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw%2B1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz%2B1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY%2FATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO%2BQ8P%2BQ4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ%2F5Dg75DxUCWBUDYOUPKQ%2FlDwkUl5cUCQ%2FlDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt%2FBgpOzspA%2BgpOzv%2Bq2RkZAGQAtwXLSgV%2FR1kOylkKTs7KWQpO8hkZGRkAAAAA%2F%2BcAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k%2FV0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj%2B7BAIHBUBUQ76AgQQDw36%2FtT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM%2BATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU%2BLwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N%2FrmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI%2BARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW%2Bv4%2BMv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3%2BqBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv%2FtQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo%2FrgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl%2BIZJZkMjIBwvoETCEY%2FqgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX%2BDBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP%2FqoHphwOOmQBJYMGGw%2FLFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7%2BrRUoog0CDRElCkj%2BCVkBUxUoMjIBAgIDBQIZFrdT5B0V%2FgwVHR0VAfQVHQAAAAP%2FnABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf%2Bqg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH%2BJd0PHAaCASZq%2FqoCUGQVHR0VZBUdHQRP5gEFEBEXC%2F3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE%2BAR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN%2FfMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V%2FgwVHR0FDm5UaoMGGw%2F%2BqgemHA4OAWsfFm4NAQxUAS5U1ssVExIW%2FjgCCgIJAwcDBQMBDBGSVv6tZAElgwYb%2FQsdFWQVHR0VZBUdAAP%2F%2FQAGA%2BgFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM%2BBDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX%2BDBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf%2Bqg8bBgHP%2Fq1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob%2B7RAX%2Fu0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm%2F453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX%2B7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm%2BjfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm%2F5AARMQEP7tEBf%2B7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg%2BJFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD%2B7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ%2BASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY%2BATc%2BAzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU%2FOR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg%2FKhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh%2BWYcrIgsW%2FawQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA%2BgpOzsp%2FBgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH%2B1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E%2FtTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv%2BDMj%2BDDspASw7KcgB9Dsp%2FBgpOwSwOylkOyn%2BcGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj%2BL2oHB8deDggV%2FtQVHRUOXscIFALLXg4VHRX%2B1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX%2B1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX%2B1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5%2Fd8t2gXl6gAcbgv29vv%2BC%2Fb2%2F%2BLS0gIC0gAUwtICAWDg83ETNIMykfegEJ%2FoctICAtIAIdLSAgLSAEqF%2Bf3fLdoF5eoN3y3Z9Xb7%2Fgv29vv%2BC%2FBiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf%2FYAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr%2Bqw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB%2F0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH%2F6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6%2BRAH%2FSBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg%2BPqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB%2FslVVsn%2BAeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn%2F8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ%2FARYfAQcXAQKru0KNQjgiHR8uEl%2F3%2FnvUaRONQkIBGxJpCgmNQkL%2B5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl%2F4%2FnvUahKNQrpCARv%2BRmkICY1CukL%2B5UJCjUK7Qjc3LxFf%2BAGFAAAAAAMAyAAAA%2BgEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7%2FVj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8%2FRY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT%2B6dT%2BzP7oywEz0gEsAQsjDx0qBKH%2B5g8qHQ8j%2FvX%2B1NL%2BzcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH%2Fs0NBxMtPGQ%2Bi6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ%2FsoCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc%2BATM2FjMyNxcOAyMiLgEHDgEPASc%2BBTc%2BAScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig%2FIhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn%2F%2FwSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF%2BYOCBWWyJYVCA7mDioBLBYO%2Bg8P%2Bg4WA4QQ%2BQ4V%2FHwDhBUO%2BQ8AAAQAGf%2F%2FA%2BgEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI%2FtTIyAEsArxkZAH0%2FHwWDvoPD%2FoOFgOEZMjI%2FRL6ZJb6ZAAAAAAEABn%2F%2FwPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO%2Bg8P%2Bg4WA4SW%2BmSW%2BmT7UGRkAfRkyMgAAAAEABn%2F%2FwRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD%2FoOFgOE%2FgwBkGT7UGQBkGTIyAAAAAAEABn%2F%2FwRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD%2FoOFgOE%2FgxkAZBkyMj7tAGQZAAAAAAFABn%2F%2FwSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk%2FnABkGT%2BDAH0ASwWDvoPD%2FoOFgOEyMj%2BDMj%2BDMj%2BDMgABQAZ%2F%2F8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD%2BDAH0ZP5wAZBk%2FtQBLGTIyAEsFg76Dw%2F6DhYDhMjI%2FgzI%2FgzI%2FgzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P%2BcKW5uQJn%2FgwpOzspAfQpOzsETLuj%2FnClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml%2FnCju7wCZP4MKTs7KQH0KTs7%2Fm%2F9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn%2BDCk7OykB9Ck7gr4MJAy%2BDAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX%2BcKW5uQJn%2FgwpOzspAfQpOzv%2BFQGQFQsMvgwkDL4MCwRMvKL%2BcKW5uaUBkKO7yDsp%2FgwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf%2BDCk7OykB9Ck7O%2F77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn%2BDCk7OykB9Ck7z%2F0QGBgQ%2FREAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX%2BcBUdHRUBwik7Oyn%2BPhUdHb8BRBAQ%2FrwQFvoVHR0V%2BhYETLml%2FnCluR0VZBUdOykB9Ck7HRVkFR3p%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B%2Fvf%2B8wQMDgkJCQUCUCcn%2FtIXCAoQSwENuwUJEASeCQoRC%2F5TBwEjEv7K%2FsUFDwgLFQnlbm4TFRRWAS%2FTBhAAAAACAAAAAAT%2BBEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4%2BKTs7KQHCFR0dFf5wpbm5AvEBRBAQ%2FrwQFvoVHR0V%2BhYETB0VZBUdOyn%2BDCk7HRVkFR25pQGQpbnp%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj%2B75wpOzspAfQpO8i7o%2F5wpbm5pQEsBLAdFf5wFQgObf7IDw%2BNDykPAThtDhX%2B1Dsp%2FgwpOzsplMj%2B1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx%2FnugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO%2FoEOJw3%2BhQ0JFfod%2FoUD6BUd%2B7QdA2dkBLAdFf6iFg%2F%2BVg8PAaoPFgFeFR38fB0V%2BvoVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE%2BAQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n%2FfkD6BUd%2B7QdA2dkBJ7%2BTQ8g%2BhQeHRX6IQ8BrxAC%2FH8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB%2F7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH%2FfMICAEjCBQIiwcH%2FdIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY%2FASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A%2BgVHfu0HQNnZAP%2Fjg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V%2BvoVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ%2FAQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A%2BgVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3%2BWB0V%2BvoVHWQyMgACAAT%2F7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d%2Fsb%2BcQSs%2FTMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V%2BgH0ZMhkZAPo%2FK4VHQGQ%2FnAdFQPoFB7%2B1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC%2FtVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf%2BXAgUCMoICGoHFQdPASkHFQPolf7VXwkJk%2F5wHRUD6BQe%2FtQBLMjI%2Fc5qBxUH%2FlsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72%2FreWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykD6P7zZ4YPAw7%2B9v5wHRUD6BQe%2FtQBLMjI%2FYxGDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM%2FqIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA%2Bj%2B1B0Vlv5wHRUD6BQe%2FtQBLMjI%2FagdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75%2Fm6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P%2Fvf%2BcB0VA%2BgUHv7UASzIyP2F5Q8V%2BhQeHhT6FQ%2FlDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd%2B1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U%2FdoVHR0VAib%2B1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX%2BcAGQFf0vMhUdHRUyyGRk%2FoL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI%2FoUdFWQVHcjI%2FcvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ%2BAzMyFh8BETMRPAE%2BAjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX%2B4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH%2FuuFR0dFQGNAQgbHzUeAWcfRJEZDA3%2BPhw%2FMSkLC%2F5BFR0dFQG%2FBA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn%2BDBlL%2FnAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr%2BdiUNODgBBQoUDgN4FhkBAjg4DSX%2BdgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn%2B2cj%2BcGQBd%2F4lASwpOzsp%2FtQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn%2BDCk7OykB9Ck7ZMjI%2FveFo4XGyMhm%2BBUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE%2BBRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB%2FLimdWQ%2FLAkJHRTKFB2N%2FsKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V%2B7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy%2FtEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI%2FOAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7%2FRv%2B1DspZCk7BEw7KfwYA%2BgpO%2F7UOyn9RAK8KTv84AGQKTs7KQAAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkyMhkZARMsHz%2BDHywsHwB9HywyP1EArzIZP7UZGQBLGT%2B1GQB9GT%2B1AEsAAAABf%2BcAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE%2FgxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI%2FUQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP%2BcAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj%2B1AEsAZDIyP7UASwETLB8%2Fgx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP%2BcAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE%2Fgz%2B1AEsAZD%2B1ARMsHz%2BDHywsHwB9HywyP1EArz%2BDJaWlpYBLAAAAAX%2FnAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8%2Fgx8sLB8AfR8sMj9RAK8%2FagB9GRWQUFUASz%2B1FRBQVYAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkZMjIZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yGT%2B1GRkASz%2BDAGQZP4MZAAG%2F5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8%2FUR8sLAYA4T9RMj%2B1GQCWGRkyP2oZAEsZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yP5wAfT%2BDAGQZMjIyP7UZAAF%2F5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI%2FUQCvP5wyDLIlmT%2BDAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz%2B1AEs%2FtRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv%2Fy%2F50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V%2FtQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi%2FbMPCv7tFxD0EBD0EBcBEwoPAAAAAAL%2F8v%2BcBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr%2Bhg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ%2BteGOkHAFoEBD%2Bk3NPRWsOExNkqWP9kuQQF%2F7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD%2B8qr%2B8qr%2B1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3%2Bs%2F7U%2FtRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd%2FtQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd%2Bx5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc%2BATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ%2Fj0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb%2F7V%2FtVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s%2FoQPCgI%2FASzIZKLU1KJktP51Cg8DhA8KwwMg%2FoTIyALzCg%2F%2B1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz%2Bov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9%2BAFe%2FdoERwoP%2FtTI%2FHzIyNT%2BZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT%2BogHCJCsRBP5w%2FnAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX%2B1BUdHRUyHQFzKTs7Kf2oARP2%2Fro7KVg%2BASw%2BWP201MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7KfzgKTsE9gFGAUQpO5Y%2BWFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG%2F2oKTs7KVg%2BASw%2BWAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7Kf4M%2FtQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP%2FogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs%2BwQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf%2BTB0U%2FtIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K%2BgoPDwr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPDwRMDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg%2F%2B1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko%2FPwoKUIcMT4BXmRkyP4%2BArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3%2B1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq%2F9WrIiCikBSAOvArwVHR0VlgET%2FEoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb%2BlR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf%2BvCcrI%2F7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW%2Fus5Okxra0w6Of5yHSodZGQdKh3%2B1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ%2F68Jysj%2Fs0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2%2BjGv4KOTpMa2tMOjn%2Bch0qHWRkHSod%2FtQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ%2BAjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz%2B1CU%2FP00T%2Fe48PUJtj0r%2BogK8FR0dFQ2K%2FEqJDBUdHbMETBUd%2B1AdBLChizlmUT9IGVO9VFShdksE%2FH4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA%2BgFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U%2F5wU3V1BRQ7KU4aXDYyMjZcGk4p%2Fkc2LmRkZGRkU3V1UwGQU3UAAAMAZP%2F%2FBEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr%2B5eANGiUNWP30Vw0mGg3g%2Ft8KDw8BqmQBRGQETB0V%2FgwVHR0VAfQVHf1EDwoyCg%2FgDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn%2B1AEsKTv%2BDDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg%2F4f%2FfsgIAEnH1n%2BrAFWAS%2F%2Bq6IDIBUd%2FHwdBI39VR9ZH4MCBh9ZHwEoH%2F5u%2FqoBMAFV%2FBsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV%2FnAVJwi9CBMVAnEdKh19FROo%2Fa0dFTIdFTDILxUdMhUdAocB%2BhMcHBP%2BBhMclhUdHRWWHP2MMhUdMhUdASz%2B1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr%2Bif7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD%2F7UyP4M%2FcEKDw8KA7YKD%2F7UyAAC%2F5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc%2BARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF%2BgoPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb%2FnP%2FmBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL%2FCtqQ0geZgM3FR0cE%2F0fFyIJKjr%2B1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g%2ByD5YrBwVODMQEAtEERzJLUAtLUD%2B24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz%2B%2BQFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg%2F%2B1MgVHR0LCgQOIhoW%2FnDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb%2BYDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj%2FsIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn%2BPilUrAFINhWWFTYFFKxn%2FgwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn%2BPilUrAFINhWWFTYFFJaz%2FkIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO%2FYL%2Bhk5klpZkAQEBBQQvkwKCAVz%2Bov6iAV4BXgL%2F%2FuWqPOCWx5SVyJb6BA0GCgYDKEEBG%2F1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz%2ByFh8WFh8%2FshYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o%2F4Mpbm5Asv9qCk7OykCWCk7O%2F2xAfQVHR0V%2FgwVHR1HAZAEsLuj%2FgylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX%2B1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA%2BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0V%2FBgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA%2BgEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8%2FV1c%2FP%2F75fLB8sAK8sHyw%2FcB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy%2FsCwfLB8fLB8sP7UsHywfHywfLD%2B05AVHR0VjgQAAAH%2FtQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc%2FKZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS%2FtkLHw8OEw0dNkY4MhwBIBgXBAQYF%2F7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH%2BVwsNATIyGQGpAQUKEw%2BWAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE%2Ft9F%2FtQSFQkfCwsBETE7EkUBJT0NISf%2B7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr%2FQ4jFQkTBQUyMisusKYiQTIBhwFW%2Fqr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F%2FtUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B%2FuAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM%2FgUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k%2FtQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR1HASzI%2B1AEsASwHRX8fBUdHRUDhBUd%2FgwdFf5wFR0dFQGQFR1k%2FtQBLP2oZAAAAAACAAAAZASwA%2BgAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX%2BcBUdZB0V%2FnAVHR0CnwEsA%2BgdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3%2B1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs%2FqIDhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX%2BcBUdZB0V%2FnAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs%2FK4DhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H%2BEhcSDhAQDhIXAe4OAjX%2BEhcbGQPoGRsX%2FhIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3%2BEg4CewHuHREp%2FBgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA%2BgpER3%2BEg4qDv4SHREDhCod%2FhIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8%2FUwBnf5jBKj84AMgAuW2%2Fr3dwcHd%2B9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI%2FtTIyAEs%2B1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy%2FOADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ%2FnAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr%2BKQcHAdcKBEoWDP4w%2FjAMFgkB1wgUCAHXCQAAAQE%2BAGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf%2BKQoNoBAKDAHQ%2FjAMCgRKCf4pCBQI%2FikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI%2FikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA%2BgAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz%2BMP4wDBYJAdcIFAPh%2FikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ%2F%2FkEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc%2BAh4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A%2BiwfLD%2BVmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR%2BTDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V%2FnAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9%2FUQCWP1EZB8BDWQEsFEs%2FFt1A7Z9%2FBgEARc0%2FV1kFGQAAQAAAAECTW%2FDBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f%2FUf%2BcBdwFFAAAAAgAAgAAAAAAAAABAAAFFP%2BFAAAFFP9R%2FtQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD%2F8gSwAAAEsAAABLD%2F8ASwAAAEsAAOBLAACQSwAGQEsP%2FTBLD%2F0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP%2BcBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw%2F7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP%2BcBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP%2F%2BBLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw%2F9wEsP%2FcBLD%2FnwSwAGQEsAAABLAAAASwAAAEsABkBLD%2F%2FwSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD%2FnASwAEoEsAAUBLAAAASwAAAEsAAABLD%2FnASwAGEEsP%2F9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD%2F2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP%2Bc%2F5z%2FnP%2Bc%2F5z%2FnP%2Bc%2F5wACQAJ%2F%2FL%2F8gBkAHkAJwBkAGQAAAAAAGT%2FogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP%2Bc%2F5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs%2F7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi%2BCTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA%2BmD%2BYQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh%2FSIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ%2BJuYnUCe8J%2FgoNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi%2F4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8%2BD0yPew%2BOj6MPtQ%2FKD9uP6o%2F%2BkBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA%2FgADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB%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%2FtQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE%2BAT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG%2FAcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB%2BgH7AfwB%2FQH%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%3D%29%20format%28%27truetype%27%29%2Curl%28data%3Aimage%2Fsvg%2Bxml%3Bbase64%2CPD94bWwgdmVyc2lvbj0iMS4wIiBzdGFuZGFsb25lPSJubyI%2FPgo8IURPQ1RZUEUgc3ZnIFBVQkxJQyAiLS8vVzNDLy9EVEQgU1ZHIDEuMS8vRU4iICJodHRwOi8vd3d3LnczLm9yZy9HcmFwaGljcy9TVkcvMS4xL0RURC9zdmcxMS5kdGQiID4KPHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPgo8bWV0YWRhdGE%2BPC9tZXRhZGF0YT4KPGRlZnM%2BCjxmb250IGlkPSJnbHlwaGljb25zX2hhbGZsaW5nc3JlZ3VsYXIiIGhvcml6LWFkdi14PSIxMjAwIiA%2BCjxmb250LWZhY2UgdW5pdHMtcGVyLWVtPSIxMjAwIiBhc2NlbnQ9Ijk2MCIgZGVzY2VudD0iLTI0MCIgLz4KPG1pc3NpbmctZ2x5cGggaG9yaXotYWR2LXg9IjUwMCIgLz4KPGdseXBoIGhvcml6LWFkdi14PSIwIiAvPgo8Z2x5cGggaG9yaXotYWR2LXg9IjQwMCIgLz4KPGdseXBoIHVuaWNvZGU9IiAiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDAzOyIgaG9yaXotYWR2LXg9IjEzMDAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA0OyIgaG9yaXotYWR2LXg9IjQzMyIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDU7IiBob3Jpei1hZHYteD0iMzI1IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwNjsiIGhvcml6LWFkdi14PSIyMTYiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA3OyIgaG9yaXotYWR2LXg9IjIxNiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDg7IiBob3Jpei1hZHYteD0iMTYyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwOTsiIGhvcml6LWFkdi14PSIyNjAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDBhOyIgaG9yaXotYWR2LXg9IjcyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAyZjsiIGhvcml6LWFkdi14PSIyNjAiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyNmZhOyIgZD0iTTc3NCAxMTkzLjVxMTYgLTkuNSAyMC41IC0yN3QtNS41IC0zMy41bC0xMzYgLTE4N2w0NjcgLTc0NmgzMHEyMCAwIDM1IC0xOC41dDE1IC0zOS41di00MmgtMTIwMHY0MnEwIDIxIDE1IDM5LjV0MzUgMTguNWgzMGw0NjggNzQ2bC0xMzUgMTgzcS0xMCAxNiAtNS41IDM0dDIwLjUgMjh0MzQgNS41dDI4IC0yMC41bDExMSAtMTQ4bDExMiAxNTBxOSAxNiAyNyAyMC41dDM0IC01ek02MDAgMjAwaDM3N2wtMTgyIDExMmwtMTk1IDUzNHYtNjQ2eiAiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI0OyIgZD0iTTEzMDAgMGgtNTM4bC00MSA0MDBoLTI0MmwtNDEgLTQwMGgtNTM4bDQzMSAxMjAwaDIwOWwtMjEgLTMwMGgxNjJsLTIwIDMwMGgyMDh6TTUxNSA4MDBsLTI3IC0zMDBoMjI0bC0yNyAzMDBoLTE3MHoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI5OyIgZD0iTTYwMCAxMTc3cTExNyAwIDIyNCAtNDUuNXQxODQuNSAtMTIzdDEyMyAtMTg0LjV0NDUuNSAtMjI0dC00NS41IC0yMjR0LTEyMyAtMTg0LjV0LTE4NC41IC0xMjN0LTIyNCAtNDUuNXQtMjI0IDQ1LjV0LTE4NC41IDEyM3QtMTIzIDE4NC41dC00NS41IDIyNHQ0NS41IDIyNHQxMjMgMTg0LjV0MTg0LjUgMTIzdDIyNCA0NS41ek02MDAgMTAyN3EtMTE2IDAgLTIxNC41IC01N3QtMTU1LjUgLTE1NS41dC01NyAtMjE0LjV0NTcgLTIxNC41IHQxNTUuNSAtMTU1LjV0MjE0LjUgLTU3dDIxNC41IDU3dDE1NS41IDE1NS41dDU3IDIxNC41dC01NyAyMTQuNXQtMTU1LjUgMTU1LjV0LTIxNC41IDU3ek01NDAgODIwbDI1MyAtMTkwcTE3IC0xMiAxNyAtMzB0LTE3IC0zMGwtMjUzIC0xOTBxLTE2IC0xMiAtMjggLTYuNXQtMTIgMjYuNXY0MDBxMCAyMSAxMiAyNi41dDI4IC02LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTAzMDsiIGQ9Ik05NDcgMTA2MGwxMzUgMTM1cTcgNyAxMi41IDV0NS41IC0xM3YtMzYycTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtMzYycS0xMSAwIC0xMyA1LjV0NSAxMi41bDEzMyAxMzNxLTEwOSA3NiAtMjM4IDc2cS0xMTYgMCAtMjE0LjUgLTU3dC0xNTUuNSAtMTU1LjV0LTU3IC0yMTQuNXQ1NyAtMjE0LjV0MTU1LjUgLTE1NS41dDIxNC41IC01N3QyMTQuNSA1N3QxNTUuNSAxNTUuNXQ1NyAyMTQuNWgxNTBxMCAtMTE3IC00NS41IC0yMjQgdC0xMjMgLTE4NC41dC0xODQuNSAtMTIzdC0yMjQgLTQ1LjV0LTIyNCA0NS41dC0xODQuNSAxMjN0LTEyMyAxODQuNXQtNDUuNSAyMjR0NDUuNSAyMjR0MTIzIDE4NC41dDE4NC41IDEyM3QyMjQgNDUuNXExOTIgMCAzNDcgLTExN3oiIC8%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQwOyIgZD0iTTEwMCAyMDBoLTEwMHYxMDAwaDEwMHYtMTAwMHpNMzAwIDIwMGgtMTAwdjEwMDBoMTAwdi0xMDAwek03MDAgMjAwaC0yMDB2MTAwMGgyMDB2LTEwMDB6TTkwMCAyMDBoLTEwMHYxMDAwaDEwMHYtMTAwMHpNMTIwMCAyMDBoLTIwMHYxMDAwaDIwMHYtMTAwMHpNNDAwIDBoLTMwMHYxMDBoMzAwdi0xMDB6TTYwMCAwaC0xMDB2OTFoMTAwdi05MXpNODAwIDBoLTEwMHY5MWgxMDB2LTkxek0xMTAwIDBoLTIwMHY5MWgyMDB2LTkxeiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwNDE7IiBkPSJNNTAwIDEyMDBsNjgyIC02ODJxOCAtOCA4IC0xOHQtOCAtMThsLTQ2NCAtNDY0cS04IC04IC0xOCAtOHQtMTggOGwtNjgyIDY4MmwxIDQ3NXEwIDEwIDcuNSAxNy41dDE3LjUgNy41aDQ3NHpNMzE5LjUgMTAyNC41cS0yOS41IDI5LjUgLTcxIDI5LjV0LTcxIC0yOS41dC0yOS41IC03MS41dDI5LjUgLTcxLjV0NzEgLTI5LjV0NzEgMjkuNXQyOS41IDcxLjV0LTI5LjUgNzEuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQyOyIgZD0iTTUwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTY4MiA2ODJsMSA0NzVxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWg0NzR6TTgwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTU2IDU2bDQyNCA0MjZsLTcwMCA3MDBoMTUwek0zMTkuNSAxMDI0LjVxLTI5LjUgMjkuNSAtNzEgMjkuNXQtNzEgLTI5LjUgdC0yOS41IC03MS41dDI5LjUgLTcxLjV0NzEgLTI5LjV0NzEgMjkuNXQyOS41IDcxLjV0LTI5LjUgNzEuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQzOyIgZD0iTTMwMCAxMjAwaDgyNXE3NSAwIDc1IC03NXYtOTAwcTAgLTI1IC0xOCAtNDNsLTY0IC02NHEtOCAtOCAtMTMgLTUuNXQtNSAxMi41djk1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjVoLTcwMHEtMjUgMCAtNDMgLTE4bC02NCAtNjRxLTggLTggLTUuNSAtMTN0MTIuNSAtNWg3MDBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di05NTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC04NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY5NzUgcTAgMjUgMTggNDNsMTM5IDEzOXExOCAxOCA0MyAxOHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQ5OyIgZD0iTTg3NyAxMjAwbDIgLTU3cS04MyAtMTkgLTExNiAtNDUuNXQtNDAgLTY2LjVsLTEzMiAtODM5cS05IC00OSAxMyAtNjl0OTYgLTI2di05N2gtNTAwdjk3cTE4NiAxNiAyMDAgOThsMTczIDgzMnEzIDE3IDMgMzB0LTEuNSAyMi41dC05IDE3LjV0LTEzLjUgMTIuNXQtMjEuNSAxMHQtMjYgOC41dC0zMy41IDEwcS0xMyAzIC0xOSA1djU3aDQyNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDU0OyIgZD0iTTUwMCA5NTB2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWg2MDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtNjAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXpNMTAwIDY1MHYxMDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDEwMDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwMCBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41ek0zMDAgMzUwdjEwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjVoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTgwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV6TTAgNTB2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWgxMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDAgcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY5OyIgZD0iTTI1MCAxMTAwaDEwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNDM4bDQ2NCA0NTNxMTUgMTQgMjUuNSAxMHQxMC41IC0yNXYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcwOyIgZD0iTTUwIDExMDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di0xMDAwcTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcxOyIgZD0iTTEyMDAgMTA1MHYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ5MiA0ODBxLTE1IDE0IC0xNSAzNXQxNSAzNWw0OTIgNDgwcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV2LTQzOGw0NjQgNDUzcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA3MjsiIGQ9Ik0yNDMgMTA3NGw4MTQgLTQ5OHExOCAtMTEgMTggLTI2dC0xOCAtMjZsLTgxNCAtNDk4cS0xOCAtMTEgLTMwLjUgLTR0LTEyLjUgMjh2MTAwMHEwIDIxIDEyLjUgMjh0MzAuNSAtNHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDczOyIgZD0iTTI1MCAxMDAwaDIwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtODAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0yMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djgwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6TTY1MCAxMDAwaDIwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtODAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0yMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djgwMCBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwNzQ7IiBkPSJNMTEwMCA5NTB2LTgwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtODAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXY4MDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDgwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDc5OyIgZD0iTTg4NSA5MDBsLTM1MiAtMzUzbDM1MiAtMzUzbC0xOTcgLTE5OGwtNTUyIDU1Mmw1NTIgNTUweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwODA7IiBkPSJNMTA2NCA1NDdsLTU1MSAtNTUxbC0xOTggMTk4bDM1MyAzNTNsLTM1MyAzNTNsMTk4IDE5OHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDg2OyIgZD0iTTYwMCAxMTc3cTExNyAwIDIyNCAtNDUuNXQxODQuNSAtMTIzdDEyMyAtMTg0LjV0NDUuNSAtMjI0dC00NS41IC0yMjR0LTEyMyAtMTg0LjV0LTE4NC41IC0xMjN0LTIyNCAtNDUuNXQtMjI0IDQ1LjV0LTE4NC41IDEyM3QtMTIzIDE4NC41dC00NS41IDIyNHQ0NS41IDIyNHQxMjMgMTg0LjV0MTg0LjUgMTIzdDIyNCA0NS41ek02NzUgMTAwMGgtMTUwcS0xMCAwIC0xNy41IC03LjV0LTcuNSAtMTcuNXYtMTUwcTAgLTEwIDcuNSAtMTcuNSB0MTcuNSAtNy41aDE1MHExMCAwIDE3LjUgNy41dDcuNSAxNy41djE1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjV6TTY3NSA3MDBoLTI1MHEtMTAgMCAtMTcuNSAtNy41dC03LjUgLTE3LjV2LTUwcTAgLTEwIDcuNSAtMTcuNXQxNy41IC03LjVoNzV2LTIwMGgtNzVxLTEwIDAgLTE3LjUgLTcuNXQtNy41IC0xNy41di01MHEwIC0xMCA3LjUgLTE3LjV0MTcuNSAtNy41aDM1MHExMCAwIDE3LjUgNy41dDcuNSAxNy41djUwcTAgMTAgLTcuNSAxNy41IHQtMTcuNSA3LjVoLTc1djI3NXEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA4NzsiIGQ9Ik01MjUgMTIwMGgxNTBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di0xOTRxMTAzIC0yNyAxNzguNSAtMTAyLjV0MTAyLjUgLTE3OC41aDE5NHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTE1MHEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTE5NHEtMjcgLTEwMyAtMTAyLjUgLTE3OC41dC0xNzguNSAtMTAyLjV2LTE5NHEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTE1MHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djE5NCBxLTEwMyAyNyAtMTc4LjUgMTAyLjV0LTEwMi41IDE3OC41aC0xOTRxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXYxNTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWgxOTRxMjcgMTAzIDEwMi41IDE3OC41dDE3OC41IDEwMi41djE5NHEwIDEwIDcuNSAxNy41dDE3LjUgNy41ek03MDAgODkzdi0xNjhxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC0xNTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXYxNjhxLTY4IC0yMyAtMTE5IC03NCB0LTc0IC0xMTloMTY4cTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtMTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtMTY4cTIzIC02OCA3NCAtMTE5dDExOSAtNzR2MTY4cTAgMTAgNy41IDE3LjV0MTcuNSA3LjVoMTUwcTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtMTY4cTY4IDIzIDExOSA3NHQ3NCAxMTloLTE2OHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djE1MHEwIDEwIDcuNSAxNy41dDE3LjUgNy41aDE2OCBxLTIzIDY4IC03NCAxMTl0LTExOSA3NHoiIC8%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk2OyIgZD0iTTg1MCAxMjAwaDMwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMzAwcTAgLTIxIC0xMC41IC0yNXQtMjQuNSAxMGwtOTQgOTRsLTI0OSAtMjQ5cS04IC03IC0xOCAtN3QtMTggN2wtMTA2IDEwNnEtNyA4IC03IDE4dDcgMThsMjQ5IDI0OWwtOTQgOTRxLTE0IDE0IC0xMCAyNC41dDI1IDEwLjV6TTM1MCAwaC0zMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djMwMHEwIDIxIDEwLjUgMjV0MjQuNSAtMTBsOTQgLTk0bDI0OSAyNDkgcTggNyAxOCA3dDE4IC03bDEwNiAtMTA2cTcgLTggNyAtMTh0LTcgLTE4bC0yNDkgLTI0OWw5NCAtOTRxMTQgLTE0IDEwIC0yNC41dC0yNSAtMTAuNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTAxOyIgZD0iTTYwMCAxMTc3cTExNyAwIDIyNCAtNDUuNXQxODQuNSAtMTIzdDEyMyAtMTg0LjV0NDUuNSAtMjI0dC00NS41IC0yMjR0LTEyMyAtMTg0LjV0LTE4NC41IC0xMjN0LTIyNCAtNDUuNXQtMjI0IDQ1LjV0LTE4NC41IDEyM3QtMTIzIDE4NC41dC00NS41IDIyNHQ0NS41IDIyNHQxMjMgMTg0LjV0MTg0LjUgMTIzdDIyNCA0NS41ek03MDQgOTAwaC0yMDhxLTIwIDAgLTMyIC0xNC41dC04IC0zNC41bDU4IC0zMDJxNCAtMjAgMjEuNSAtMzQuNSB0MzcuNSAtMTQuNWg1NHEyMCAwIDM3LjUgMTQuNXQyMS41IDM0LjVsNTggMzAycTQgMjAgLTggMzQuNXQtMzIgMTQuNXpNNjc1IDQwMGgtMTUwcS0xMCAwIC0xNy41IC03LjV0LTcuNSAtMTcuNXYtMTUwcTAgLTEwIDcuNSAtMTcuNXQxNy41IC03LjVoMTUwcTEwIDAgMTcuNSA3LjV0Ny41IDE3LjV2MTUwcTAgMTAgLTcuNSAxNy41dC0xNy41IDcuNXoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTA3OyIgZD0iTS05MCAxMDBsNjQyIDEwNjZxMjAgMzEgNDggMjguNXQ0OCAtMzUuNWw2NDIgLTEwNTZxMjEgLTMyIDcuNSAtNjcuNXQtNTAuNSAtMzUuNWgtMTI5NHEtMzcgMCAtNTAuNSAzNHQ3LjUgNjZ6TTE1NSAyMDBoMzQ1djc1cTAgMTAgNy41IDE3LjV0MTcuNSA3LjVoMTUwcTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtNzVoMzQ1bC00NDUgNzIzek00OTYgNzAwaDIwOHEyMCAwIDMyIC0xNC41dDggLTM0LjVsLTU4IC0yNTIgcS00IC0yMCAtMjEuNSAtMzQuNXQtMzcuNSAtMTQuNWgtNTRxLTIwIDAgLTM3LjUgMTQuNXQtMjEuNSAzNC41bC01OCAyNTJxLTQgMjAgOCAzNC41dDMyIDE0LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEwODsiIGQ9Ik02NTAgMTIwMHE2MiAwIDEwNiAtNDR0NDQgLTEwNnYtMzM5bDM2MyAtMzI1cTE1IC0xNCAyNiAtMzguNXQxMSAtNDQuNXYtNDFxMCAtMjAgLTEyIC0yNi41dC0yOSA1LjVsLTM1OSAyNDl2LTI2M3ExMDAgLTkzIDEwMCAtMTEzdi02NHEwIC0yMSAtMTMgLTI5dC0zMiAxbC0yMDUgMTI4bC0yMDUgLTEyOHEtMTkgLTkgLTMyIC0xdC0xMyAyOXY2NHEwIDIwIDEwMCAxMTN2MjYzbC0zNTkgLTI0OXEtMTcgLTEyIC0yOSAtNS41dC0xMiAyNi41djQxIHEwIDIwIDExIDQ0LjV0MjYgMzguNWwzNjMgMzI1djMzOXEwIDYyIDQ0IDEwNnQxMDYgNDR6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEwOTsiIGQ9Ik04NTAgMTIwMGgxMDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTUwaDUwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xNTBoLTExMDB2MTUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWg1MHY1MHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjVoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MGg1MDB2NTBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41ek0xMTAwIDgwMHYtNzUwcTAgLTIxIC0xNC41IC0zNS41IHQtMzUuNSAtMTQuNWgtMTAwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2NzUwaDExMDB6TTEwMCA2MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTMwMCA2MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTUwMCA2MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTcwMCA2MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTkwMCA2MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTEwMCA0MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTMwMCA0MDB2LTEwMGgxMDB2MTAwaC0xMDB6TTUwMCA0MDAgdi0xMDBoMTAwdjEwMGgtMTAwek03MDAgNDAwdi0xMDBoMTAwdjEwMGgtMTAwek05MDAgNDAwdi0xMDBoMTAwdjEwMGgtMTAwek0xMDAgMjAwdi0xMDBoMTAwdjEwMGgtMTAwek0zMDAgMjAwdi0xMDBoMTAwdjEwMGgtMTAwek01MDAgMjAwdi0xMDBoMTAwdjEwMGgtMTAwek03MDAgMjAwdi0xMDBoMTAwdjEwMGgtMTAwek05MDAgMjAwdi0xMDBoMTAwdjEwMGgtMTAweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTA7IiBkPSJNMTEzNSAxMTY1bDI0OSAtMjMwcTE1IC0xNCAxNSAtMzV0LTE1IC0zNWwtMjQ5IC0yMzBxLTE0IC0xNCAtMjQuNSAtMTB0LTEwLjUgMjV2MTUwaC0xNTlsLTYwMCAtNjAwaC0yOTFxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djEwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjVoMjA5bDYwMCA2MDBoMjQxdjE1MHEwIDIxIDEwLjUgMjV0MjQuNSAtMTB6TTUyMiA4MTlsLTE0MSAtMTQxbC0xMjIgMTIyaC0yMDlxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXYxMDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDI5MXpNMTEzNSA1NjVsMjQ5IC0yMzBxMTUgLTE0IDE1IC0zNXQtMTUgLTM1bC0yNDkgLTIzMHEtMTQgLTE0IC0yNC41IC0xMHQtMTAuNSAyNXYxNTBoLTI0MWwtMTgxIDE4MWwxNDEgMTQxbDEyMiAtMTIyaDE1OXYxNTBxMCAyMSAxMC41IDI1dDI0LjUgLTEweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTE7IiBkPSJNMTAwIDExMDBoMTAwMHE0MSAwIDcwLjUgLTI5LjV0MjkuNSAtNzAuNXYtNjAwcTAgLTQxIC0yOS41IC03MC41dC03MC41IC0yOS41aC01OTZsLTMwNCAtMzAwdjMwMGgtMTAwcS00MSAwIC03MC41IDI5LjV0LTI5LjUgNzAuNXY2MDBxMCA0MSAyOS41IDcwLjV0NzAuNSAyOS41eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTI7IiBkPSJNMTUwIDEyMDBoMjAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0yNTBoLTMwMHYyNTBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41ek04NTAgMTIwMGgyMDBxMjEgMCAzNS41IC0xNC41dDE0LjUgLTM1LjV2LTI1MGgtMzAwdjI1MHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6TTExMDAgODAwdi0zMDBxMCAtNDEgLTMgLTc3LjV0LTE1IC04OS41dC0zMiAtOTZ0LTU4IC04OXQtODkgLTc3dC0xMjkgLTUxdC0xNzQgLTIwdC0xNzQgMjAgdC0xMjkgNTF0LTg5IDc3dC01OCA4OXQtMzIgOTZ0LTE1IDg5LjV0LTMgNzcuNXYzMDBoMzAwdi0yNTB2LTI3di00Mi41dDEuNSAtNDF0NSAtMzh0MTAgLTM1dDE2LjUgLTMwdDI1LjUgLTI0LjV0MzUgLTE5dDQ2LjUgLTEydDYwIC00dDYwIDQuNXQ0Ni41IDEyLjV0MzUgMTkuNXQyNSAyNS41dDE3IDMwLjV0MTAgMzV0NSAzOHQyIDQwLjV0LTAuNSA0MnYyNXYyNTBoMzAweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTM7IiBkPSJNMTEwMCA0MTFsLTE5OCAtMTk5bC0zNTMgMzUzbC0zNTMgLTM1M2wtMTk3IDE5OWw1NTEgNTUxeiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMTQ7IiBkPSJNMTEwMSA3ODlsLTU1MCAtNTUxbC01NTEgNTUxbDE5OCAxOTlsMzUzIC0zNTNsMzUzIDM1M3oiIC8%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTM2OyIgZD0iTTc1NiAxMTU3cTE2NCA5MiAzMDYgLTlsLTI1OSAtMTM4bDE0NSAtMjMybDI1MSAxMjZxNiAtODkgLTM0IC0xNTYuNXQtMTE3IC0xMTAuNXEtNjAgLTM0IC0xMjcgLTM5LjV0LTEyNiAxNi41bC01OTYgLTU5NnEtMTUgLTE2IC0zNi41IC0xNnQtMzYuNSAxNmwtMTExIDExMHEtMTUgMTUgLTE1IDM2LjV0MTUgMzcuNWw2MDAgNTk5cS0zNCAxMDEgNS41IDIwMS41dDEzNS41IDE1NC41eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMzc7IiBob3Jpei1hZHYteD0iMTIyMCIgZD0iTTEwMCAxMTk2aDEwMDBxNDEgMCA3MC41IC0yOS41dDI5LjUgLTcwLjV2LTEwMHEwIC00MSAtMjkuNSAtNzAuNXQtNzAuNSAtMjkuNWgtMTAwMHEtNDEgMCAtNzAuNSAyOS41dC0yOS41IDcwLjV2MTAwcTAgNDEgMjkuNSA3MC41dDcwLjUgMjkuNXpNMTEwMCAxMDk2aC0yMDB2LTEwMGgyMDB2MTAwek0xMDAgNzk2aDEwMDBxNDEgMCA3MC41IC0yOS41dDI5LjUgLTcwLjV2LTEwMHEwIC00MSAtMjkuNSAtNzAuNXQtNzAuNSAtMjkuNWgtMTAwMCBxLTQxIDAgLTcwLjUgMjkuNXQtMjkuNSA3MC41djEwMHEwIDQxIDI5LjUgNzAuNXQ3MC41IDI5LjV6TTExMDAgNjk2aC01MDB2LTEwMGg1MDB2MTAwek0xMDAgMzk2aDEwMDBxNDEgMCA3MC41IC0yOS41dDI5LjUgLTcwLjV2LTEwMHEwIC00MSAtMjkuNSAtNzAuNXQtNzAuNSAtMjkuNWgtMTAwMHEtNDEgMCAtNzAuNSAyOS41dC0yOS41IDcwLjV2MTAwcTAgNDEgMjkuNSA3MC41dDcwLjUgMjkuNXpNMTEwMCAyOTZoLTMwMHYtMTAwaDMwMHYxMDB6ICIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMzg7IiBkPSJNMTUwIDEyMDBoOTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41dC0xNC41IC0zNS41dC0zNS41IC0xNC41aC05MDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41dDE0LjUgMzUuNXQzNS41IDE0LjV6TTcwMCA1MDB2LTMwMGwtMjAwIC0yMDB2NTAwbC0zNTAgNTAwaDkwMHoiIC8%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYwOyIgZD0iTTM1MCAxMTAwaDQwMHExNjUgMCAyNTcuNSAtOTIuNXQ5Mi41IC0yNTcuNXYtNDAwcTAgLTE2MyAtOTIuNSAtMjU2LjV0LTI1Ny41IC05My41aC00MDBxLTE2MyAwIC0yNTYuNSA5NHQtOTMuNSAyNTZ2NDAwcTAgMTY1IDkyLjUgMjU3LjV0MjU3LjUgOTIuNXpNODAwIDkwMGgtNTAwcS00MSAwIC03MC41IC0yOS41dC0yOS41IC03MC41di01MDBxMCAtNDEgMjkuNSAtNzAuNXQ3MC41IC0yOS41aDUwMHE0MSAwIDcwLjUgMjkuNXQyOS41IDcwLjUgdjUwMHEwIDQxIC0yOS41IDcwLjV0LTcwLjUgMjkuNXpNNTgwIDY5M2wxOTAgLTI1M3ExMiAtMTYgNi41IC0yOHQtMjYuNSAtMTJoLTQwMHEtMjEgMCAtMjYuNSAxMnQ2LjUgMjhsMTkwIDI1M3ExMiAxNyAzMCAxN3QzMCAtMTd6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTE2MTsiIGQ9Ik01NTAgMTEwMGg0MDBxMTY1IDAgMjU3LjUgLTkyLjV0OTIuNSAtMjU3LjV2LTQwMHEwIC0xNjUgLTkyLjUgLTI1Ny41dC0yNTcuNSAtOTIuNWgtNDAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDQ1MHE0MSAwIDcwLjUgMjkuNXQyOS41IDcwLjV2NTAwcTAgNDEgLTI5LjUgNzAuNXQtNzAuNSAyOS41aC00NTBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djEwMCBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41ek0zMzggODY3bDMyNCAtMjg0cTE2IC0xNCAxNiAtMzN0LTE2IC0zM2wtMzI0IC0yODRxLTE2IC0xNCAtMjcgLTl0LTExIDI2djE1MGgtMjUwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYyMDBxMCAyMSAxNC41IDM1LjV0MzUuNSAxNC41aDI1MHYxNTBxMCAyMSAxMSAyNnQyNyAtOXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYyOyIgZD0iTTc5MyAxMTgybDkgLTlxOCAtMTAgNSAtMjdxLTMgLTExIC03OSAtMjI1LjV0LTc4IC0yMjEuNWwzMDAgMXEyNCAwIDMyLjUgLTE3LjV0LTUuNSAtMzUuNXEtMSAwIC0xMzMuNSAtMTU1dC0yNjcgLTMxMi41dC0xMzguNSAtMTYyLjVxLTEyIC0xNSAtMjYgLTE1aC05bC05IDhxLTkgMTEgLTQgMzJxMiA5IDQyIDEyMy41dDc5IDIyNC41bDM5IDExMGgtMzAycS0yMyAwIC0zMSAxOXEtMTAgMjEgNiA0MXE3NSA4NiAyMDkuNSAyMzcuNSB0MjI4IDI1N3Q5OC41IDExMS41cTkgMTYgMjUgMTZoOXoiIC8%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%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%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%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%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjIxOyIgZD0iTTQ4MCAxMTY1bDY4MiAtNjgzcTMxIC0zMSAzMSAtNzUuNXQtMzEgLTc1LjVsLTEzMSAtMTMxaC00ODFsLTUxNyA1MThxLTMyIDMxIC0zMiA3NS41dDMyIDc1LjVsMjk1IDI5NnEzMSAzMSA3NS41IDMxdDc2LjUgLTMxek0xMDggNzk0bDM0MiAtMzQybDMwMyAzMDRsLTM0MSAzNDF6TTI1MCAxMDBoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MGgtOTAwdjUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUwOyIgZD0iTTg2NSA1NjVsLTQ5NCAtNDk0cS0yMyAtMjMgLTQxIC0yM3EtMTQgMCAtMjIgMTMuNXQtOCAzOC41djEwMDBxMCAyNSA4IDM4LjV0MjIgMTMuNXExOCAwIDQxIC0yM2w0OTQgLTQ5NHExNCAtMTQgMTQgLTM1dC0xNCAtMzV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTI1MTsiIGQ9Ik0zMzUgNjM1bDQ5NCA0OTRxMjkgMjkgNTAgMjAuNXQyMSAtNDkuNXYtMTAwMHEwIC00MSAtMjEgLTQ5LjV0LTUwIDIwLjVsLTQ5NCA0OTRxLTE0IDE0IC0xNCAzNXQxNCAzNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUyOyIgZD0iTTEwMCA5MDBoMTAwMHE0MSAwIDQ5LjUgLTIxdC0yMC41IC01MGwtNDk0IC00OTRxLTE0IC0xNCAtMzUgLTE0dC0zNSAxNGwtNDk0IDQ5NHEtMjkgMjkgLTIwLjUgNTB0NDkuNSAyMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUzOyIgZD0iTTYzNSA4NjVsNDk0IC00OTRxMjkgLTI5IDIwLjUgLTUwdC00OS41IC0yMWgtMTAwMHEtNDEgMCAtNDkuNSAyMXQyMC41IDUwbDQ5NCA0OTRxMTQgMTQgMzUgMTR0MzUgLTE0eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTQ7IiBkPSJNNzAwIDc0MXYtMTgybC02OTIgLTMyM3YyMjFsNDEzIDE5M2wtNDEzIDE5M3YyMjF6TTEyMDAgMGgtODAwdjIwMGg4MDB2LTIwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU1OyIgZD0iTTEyMDAgOTAwaC0yMDB2LTEwMGgyMDB2LTEwMGgtMzAwdjMwMGgyMDB2MTAwaC0yMDB2MTAwaDMwMHYtMzAwek0wIDcwMGg1MHEwIDIxIDQgMzd0OS41IDI2LjV0MTggMTcuNXQyMiAxMXQyOC41IDUuNXQzMSAydDM3IDAuNWgxMDB2LTU1MHEwIC0yMiAtMjUgLTM0LjV0LTUwIC0xMy41bC0yNSAtMnYtMTAwaDQwMHYxMDBxLTQgMCAtMTEgMC41dC0yNCAzdC0zMCA3dC0yNCAxNXQtMTEgMjQuNXY1NTBoMTAwcTI1IDAgMzcgLTAuNXQzMSAtMiB0MjguNSAtNS41dDIyIC0xMXQxOCAtMTcuNXQ5LjUgLTI2LjV0NCAtMzdoNTB2MzAwaC04MDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU2OyIgZD0iTTgwMCA3MDBoLTUwcTAgMjEgLTQgMzd0LTkuNSAyNi41dC0xOCAxNy41dC0yMiAxMXQtMjguNSA1LjV0LTMxIDJ0LTM3IDAuNWgtMTAwdi01NTBxMCAtMjIgMjUgLTM0LjV0NTAgLTE0LjVsMjUgLTF2LTEwMGgtNDAwdjEwMHE0IDAgMTEgMC41dDI0IDN0MzAgN3QyNCAxNXQxMSAyNC41djU1MGgtMTAwcS0yNSAwIC0zNyAtMC41dC0zMSAtMnQtMjguNSAtNS41dC0yMiAtMTF0LTE4IC0xNy41dC05LjUgLTI2LjV0LTQgLTM3aC01MHYzMDAgaDgwMHYtMzAwek0xMTAwIDIwMGgtMjAwdi0xMDBoMjAwdi0xMDBoLTMwMHYzMDBoMjAwdjEwMGgtMjAwdjEwMGgzMDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU3OyIgZD0iTTcwMSAxMDk4aDE2MHExNiAwIDIxIC0xMXQtNyAtMjNsLTQ2NCAtNDY0bDQ2NCAtNDY0cTEyIC0xMiA3IC0yM3QtMjEgLTExaC0xNjBxLTEzIDAgLTIzIDlsLTQ3MSA0NzFxLTcgOCAtNyAxOHQ3IDE4bDQ3MSA0NzFxMTAgOSAyMyA5eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTg7IiBkPSJNMzM5IDEwOThoMTYwcTEzIDAgMjMgLTlsNDcxIC00NzFxNyAtOCA3IC0xOHQtNyAtMThsLTQ3MSAtNDcxcS0xMCAtOSAtMjMgLTloLTE2MHEtMTYgMCAtMjEgMTF0NyAyM2w0NjQgNDY0bC00NjQgNDY0cS0xMiAxMiAtNyAyM3QyMSAxMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU5OyIgZD0iTTEwODcgODgycTExIC01IDExIC0yMXYtMTYwcTAgLTEzIC05IC0yM2wtNDcxIC00NzFxLTggLTcgLTE4IC03dC0xOCA3bC00NzEgNDcxcS05IDEwIC05IDIzdjE2MHEwIDE2IDExIDIxdDIzIC03bDQ2NCAtNDY0bDQ2NCA0NjRxMTIgMTIgMjMgN3oiIC8%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%2BCjwvZGVmcz48L3N2Zz4g%29%20format%28%27svg%27%29%7D%2Eglyphicon%7Bposition%3Arelative%3Btop%3A1px%3Bdisplay%3Ainline%2Dblock%3Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3B%2Dwebkit%2Dfont%2Dsmoothing%3Aantialiased%3B%2Dmoz%2Dosx%2Dfont%2Dsmoothing%3Agrayscale%7D%2Eglyphicon%2Dasterisk%3Abefore%7Bcontent%3A%22%5C2a%22%7D%2Eglyphicon%2Dplus%3Abefore%7Bcontent%3A%22%5C2b%22%7D%2Eglyphicon%2Deur%3Abefore%2C%2Eglyphicon%2Deuro%3Abefore%7Bcontent%3A%22%5C20ac%22%7D%2Eglyphicon%2Dminus%3Abefore%7Bcontent%3A%22%5C2212%22%7D%2Eglyphicon%2Dcloud%3Abefore%7Bcontent%3A%22%5C2601%22%7D%2Eglyphicon%2Denvelope%3Abefore%7Bcontent%3A%22%5C2709%22%7D%2Eglyphicon%2Dpencil%3Abefore%7Bcontent%3A%22%5C270f%22%7D%2Eglyphicon%2Dglass%3Abefore%7Bcontent%3A%22%5Ce001%22%7D%2Eglyphicon%2Dmusic%3Abefore%7Bcontent%3A%22%5Ce002%22%7D%2Eglyphicon%2Dsearch%3Abefore%7Bcontent%3A%22%5Ce003%22%7D%2Eglyphicon%2Dheart%3Abefore%7Bcontent%3A%22%5Ce005%22%7D%2Eglyphicon%2Dstar%3Abefore%7Bcontent%3A%22%5Ce006%22%7D%2Eglyphicon%2Dstar%2Dempty%3Abefore%7Bcontent%3A%22%5Ce007%22%7D%2Eglyphicon%2Duser%3Abefore%7Bcontent%3A%22%5Ce008%22%7D%2Eglyphicon%2Dfilm%3Abefore%7Bcontent%3A%22%5Ce009%22%7D%2Eglyphicon%2Dth%2Dlarge%3Abefore%7Bcontent%3A%22%5Ce010%22%7D%2Eglyphicon%2Dth%3Abefore%7Bcontent%3A%22%5Ce011%22%7D%2Eglyphicon%2Dth%2Dlist%3Abefore%7Bcontent%3A%22%5Ce012%22%7D%2Eglyphicon%2Dok%3Abefore%7Bcontent%3A%22%5Ce013%22%7D%2Eglyphicon%2Dremove%3Abefore%7Bcontent%3A%22%5Ce014%22%7D%2Eglyphicon%2Dzoom%2Din%3Abefore%7Bcontent%3A%22%5Ce015%22%7D%2Eglyphicon%2Dzoom%2Dout%3Abefore%7Bcontent%3A%22%5Ce016%22%7D%2Eglyphicon%2Doff%3Abefore%7Bcontent%3A%22%5Ce017%22%7D%2Eglyphicon%2Dsignal%3Abefore%7Bcontent%3A%22%5Ce018%22%7D%2Eglyphicon%2Dcog%3Abefore%7Bcontent%3A%22%5Ce019%22%7D%2Eglyphicon%2Dtrash%3Abefore%7Bcontent%3A%22%5Ce020%22%7D%2Eglyphicon%2Dhome%3Abefore%7Bcontent%3A%22%5Ce021%22%7D%2Eglyphicon%2Dfile%3Abefore%7Bcontent%3A%22%5Ce022%22%7D%2Eglyphicon%2Dtime%3Abefore%7Bcontent%3A%22%5Ce023%22%7D%2Eglyphicon%2Droad%3Abefore%7Bcontent%3A%22%5Ce024%22%7D%2Eglyphicon%2Ddownload%2Dalt%3Abefore%7Bcontent%3A%22%5Ce025%22%7D%2Eglyphicon%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce026%22%7D%2Eglyphicon%2Dupload%3Abefore%7Bcontent%3A%22%5Ce027%22%7D%2Eglyphicon%2Dinbox%3Abefore%7Bcontent%3A%22%5Ce028%22%7D%2Eglyphicon%2Dplay%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce029%22%7D%2Eglyphicon%2Drepeat%3Abefore%7Bcontent%3A%22%5Ce030%22%7D%2Eglyphicon%2Drefresh%3Abefore%7Bcontent%3A%22%5Ce031%22%7D%2Eglyphicon%2Dlist%2Dalt%3Abefore%7Bcontent%3A%22%5Ce032%22%7D%2Eglyphicon%2Dlock%3Abefore%7Bcontent%3A%22%5Ce033%22%7D%2Eglyphicon%2Dflag%3Abefore%7Bcontent%3A%22%5Ce034%22%7D%2Eglyphicon%2Dheadphones%3Abefore%7Bcontent%3A%22%5Ce035%22%7D%2Eglyphicon%2Dvolume%2Doff%3Abefore%7Bcontent%3A%22%5Ce036%22%7D%2Eglyphicon%2Dvolume%2Ddown%3Abefore%7Bcontent%3A%22%5Ce037%22%7D%2Eglyphicon%2Dvolume%2Dup%3Abefore%7Bcontent%3A%22%5Ce038%22%7D%2Eglyphicon%2Dqrcode%3Abefore%7Bcontent%3A%22%5Ce039%22%7D%2Eglyphicon%2Dbarcode%3Abefore%7Bcontent%3A%22%5Ce040%22%7D%2Eglyphicon%2Dtag%3Abefore%7Bcontent%3A%22%5Ce041%22%7D%2Eglyphicon%2Dtags%3Abefore%7Bcontent%3A%22%5Ce042%22%7D%2Eglyphicon%2Dbook%3Abefore%7Bcontent%3A%22%5Ce043%22%7D%2Eglyphicon%2Dbookmark%3Abefore%7Bcontent%3A%22%5Ce044%22%7D%2Eglyphicon%2Dprint%3Abefore%7Bcontent%3A%22%5Ce045%22%7D%2Eglyphicon%2Dcamera%3Abefore%7Bcontent%3A%22%5Ce046%22%7D%2Eglyphicon%2Dfont%3Abefore%7Bcontent%3A%22%5Ce047%22%7D%2Eglyphicon%2Dbold%3Abefore%7Bcontent%3A%22%5Ce048%22%7D%2Eglyphicon%2Ditalic%3Abefore%7Bcontent%3A%22%5Ce049%22%7D%2Eglyphicon%2Dtext%2Dheight%3Abefore%7Bcontent%3A%22%5Ce050%22%7D%2Eglyphicon%2Dtext%2Dwidth%3Abefore%7Bcontent%3A%22%5Ce051%22%7D%2Eglyphicon%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce052%22%7D%2Eglyphicon%2Dalign%2Dcenter%3Abefore%7Bcontent%3A%22%5Ce053%22%7D%2Eglyphicon%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce054%22%7D%2Eglyphicon%2Dalign%2Djustify%3Abefore%7Bcontent%3A%22%5Ce055%22%7D%2Eglyphicon%2Dlist%3Abefore%7Bcontent%3A%22%5Ce056%22%7D%2Eglyphicon%2Dindent%2Dleft%3Abefore%7Bcontent%3A%22%5Ce057%22%7D%2Eglyphicon%2Dindent%2Dright%3Abefore%7Bcontent%3A%22%5Ce058%22%7D%2Eglyphicon%2Dfacetime%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce059%22%7D%2Eglyphicon%2Dpicture%3Abefore%7Bcontent%3A%22%5Ce060%22%7D%2Eglyphicon%2Dmap%2Dmarker%3Abefore%7Bcontent%3A%22%5Ce062%22%7D%2Eglyphicon%2Dadjust%3Abefore%7Bcontent%3A%22%5Ce063%22%7D%2Eglyphicon%2Dtint%3Abefore%7Bcontent%3A%22%5Ce064%22%7D%2Eglyphicon%2Dedit%3Abefore%7Bcontent%3A%22%5Ce065%22%7D%2Eglyphicon%2Dshare%3Abefore%7Bcontent%3A%22%5Ce066%22%7D%2Eglyphicon%2Dcheck%3Abefore%7Bcontent%3A%22%5Ce067%22%7D%2Eglyphicon%2Dmove%3Abefore%7Bcontent%3A%22%5Ce068%22%7D%2Eglyphicon%2Dstep%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce069%22%7D%2Eglyphicon%2Dfast%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce070%22%7D%2Eglyphicon%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce071%22%7D%2Eglyphicon%2Dplay%3Abefore%7Bcontent%3A%22%5Ce072%22%7D%2Eglyphicon%2Dpause%3Abefore%7Bcontent%3A%22%5Ce073%22%7D%2Eglyphicon%2Dstop%3Abefore%7Bcontent%3A%22%5Ce074%22%7D%2Eglyphicon%2Dforward%3Abefore%7Bcontent%3A%22%5Ce075%22%7D%2Eglyphicon%2Dfast%2Dforward%3Abefore%7Bcontent%3A%22%5Ce076%22%7D%2Eglyphicon%2Dstep%2Dforward%3Abefore%7Bcontent%3A%22%5Ce077%22%7D%2Eglyphicon%2Deject%3Abefore%7Bcontent%3A%22%5Ce078%22%7D%2Eglyphicon%2Dchevron%2Dleft%3Abefore%7Bcontent%3A%22%5Ce079%22%7D%2Eglyphicon%2Dchevron%2Dright%3Abefore%7Bcontent%3A%22%5Ce080%22%7D%2Eglyphicon%2Dplus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce081%22%7D%2Eglyphicon%2Dminus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce082%22%7D%2Eglyphicon%2Dremove%2Dsign%3Abefore%7Bcontent%3A%22%5Ce083%22%7D%2Eglyphicon%2Dok%2Dsign%3Abefore%7Bcontent%3A%22%5Ce084%22%7D%2Eglyphicon%2Dquestion%2Dsign%3Abefore%7Bcontent%3A%22%5Ce085%22%7D%2Eglyphicon%2Dinfo%2Dsign%3Abefore%7Bcontent%3A%22%5Ce086%22%7D%2Eglyphicon%2Dscreenshot%3Abefore%7Bcontent%3A%22%5Ce087%22%7D%2Eglyphicon%2Dremove%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce088%22%7D%2Eglyphicon%2Dok%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce089%22%7D%2Eglyphicon%2Dban%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce090%22%7D%2Eglyphicon%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce091%22%7D%2Eglyphicon%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce092%22%7D%2Eglyphicon%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce093%22%7D%2Eglyphicon%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce094%22%7D%2Eglyphicon%2Dshare%2Dalt%3Abefore%7Bcontent%3A%22%5Ce095%22%7D%2Eglyphicon%2Dresize%2Dfull%3Abefore%7Bcontent%3A%22%5Ce096%22%7D%2Eglyphicon%2Dresize%2Dsmall%3Abefore%7Bcontent%3A%22%5Ce097%22%7D%2Eglyphicon%2Dexclamation%2Dsign%3Abefore%7Bcontent%3A%22%5Ce101%22%7D%2Eglyphicon%2Dgift%3Abefore%7Bcontent%3A%22%5Ce102%22%7D%2Eglyphicon%2Dleaf%3Abefore%7Bcontent%3A%22%5Ce103%22%7D%2Eglyphicon%2Dfire%3Abefore%7Bcontent%3A%22%5Ce104%22%7D%2Eglyphicon%2Deye%2Dopen%3Abefore%7Bcontent%3A%22%5Ce105%22%7D%2Eglyphicon%2Deye%2Dclose%3Abefore%7Bcontent%3A%22%5Ce106%22%7D%2Eglyphicon%2Dwarning%2Dsign%3Abefore%7Bcontent%3A%22%5Ce107%22%7D%2Eglyphicon%2Dplane%3Abefore%7Bcontent%3A%22%5Ce108%22%7D%2Eglyphicon%2Dcalendar%3Abefore%7Bcontent%3A%22%5Ce109%22%7D%2Eglyphicon%2Drandom%3Abefore%7Bcontent%3A%22%5Ce110%22%7D%2Eglyphicon%2Dcomment%3Abefore%7Bcontent%3A%22%5Ce111%22%7D%2Eglyphicon%2Dmagnet%3Abefore%7Bcontent%3A%22%5Ce112%22%7D%2Eglyphicon%2Dchevron%2Dup%3Abefore%7Bcontent%3A%22%5Ce113%22%7D%2Eglyphicon%2Dchevron%2Ddown%3Abefore%7Bcontent%3A%22%5Ce114%22%7D%2Eglyphicon%2Dretweet%3Abefore%7Bcontent%3A%22%5Ce115%22%7D%2Eglyphicon%2Dshopping%2Dcart%3Abefore%7Bcontent%3A%22%5Ce116%22%7D%2Eglyphicon%2Dfolder%2Dclose%3Abefore%7Bcontent%3A%22%5Ce117%22%7D%2Eglyphicon%2Dfolder%2Dopen%3Abefore%7Bcontent%3A%22%5Ce118%22%7D%2Eglyphicon%2Dresize%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce119%22%7D%2Eglyphicon%2Dresize%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce120%22%7D%2Eglyphicon%2Dhdd%3Abefore%7Bcontent%3A%22%5Ce121%22%7D%2Eglyphicon%2Dbullhorn%3Abefore%7Bcontent%3A%22%5Ce122%22%7D%2Eglyphicon%2Dbell%3Abefore%7Bcontent%3A%22%5Ce123%22%7D%2Eglyphicon%2Dcertificate%3Abefore%7Bcontent%3A%22%5Ce124%22%7D%2Eglyphicon%2Dthumbs%2Dup%3Abefore%7Bcontent%3A%22%5Ce125%22%7D%2Eglyphicon%2Dthumbs%2Ddown%3Abefore%7Bcontent%3A%22%5Ce126%22%7D%2Eglyphicon%2Dhand%2Dright%3Abefore%7Bcontent%3A%22%5Ce127%22%7D%2Eglyphicon%2Dhand%2Dleft%3Abefore%7Bcontent%3A%22%5Ce128%22%7D%2Eglyphicon%2Dhand%2Dup%3Abefore%7Bcontent%3A%22%5Ce129%22%7D%2Eglyphicon%2Dhand%2Ddown%3Abefore%7Bcontent%3A%22%5Ce130%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce131%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce132%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce133%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce134%22%7D%2Eglyphicon%2Dglobe%3Abefore%7Bcontent%3A%22%5Ce135%22%7D%2Eglyphicon%2Dwrench%3Abefore%7Bcontent%3A%22%5Ce136%22%7D%2Eglyphicon%2Dtasks%3Abefore%7Bcontent%3A%22%5Ce137%22%7D%2Eglyphicon%2Dfilter%3Abefore%7Bcontent%3A%22%5Ce138%22%7D%2Eglyphicon%2Dbriefcase%3Abefore%7Bcontent%3A%22%5Ce139%22%7D%2Eglyphicon%2Dfullscreen%3Abefore%7Bcontent%3A%22%5Ce140%22%7D%2Eglyphicon%2Ddashboard%3Abefore%7Bcontent%3A%22%5Ce141%22%7D%2Eglyphicon%2Dpaperclip%3Abefore%7Bcontent%3A%22%5Ce142%22%7D%2Eglyphicon%2Dheart%2Dempty%3Abefore%7Bcontent%3A%22%5Ce143%22%7D%2Eglyphicon%2Dlink%3Abefore%7Bcontent%3A%22%5Ce144%22%7D%2Eglyphicon%2Dphone%3Abefore%7Bcontent%3A%22%5Ce145%22%7D%2Eglyphicon%2Dpushpin%3Abefore%7Bcontent%3A%22%5Ce146%22%7D%2Eglyphicon%2Dusd%3Abefore%7Bcontent%3A%22%5Ce148%22%7D%2Eglyphicon%2Dgbp%3Abefore%7Bcontent%3A%22%5Ce149%22%7D%2Eglyphicon%2Dsort%3Abefore%7Bcontent%3A%22%5Ce150%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%3Abefore%7Bcontent%3A%22%5Ce151%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%2Dalt%3Abefore%7Bcontent%3A%22%5Ce152%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%3Abefore%7Bcontent%3A%22%5Ce153%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%2Dalt%3Abefore%7Bcontent%3A%22%5Ce154%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%3Abefore%7Bcontent%3A%22%5Ce155%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%2Dalt%3Abefore%7Bcontent%3A%22%5Ce156%22%7D%2Eglyphicon%2Dunchecked%3Abefore%7Bcontent%3A%22%5Ce157%22%7D%2Eglyphicon%2Dexpand%3Abefore%7Bcontent%3A%22%5Ce158%22%7D%2Eglyphicon%2Dcollapse%2Ddown%3Abefore%7Bcontent%3A%22%5Ce159%22%7D%2Eglyphicon%2Dcollapse%2Dup%3Abefore%7Bcontent%3A%22%5Ce160%22%7D%2Eglyphicon%2Dlog%2Din%3Abefore%7Bcontent%3A%22%5Ce161%22%7D%2Eglyphicon%2Dflash%3Abefore%7Bcontent%3A%22%5Ce162%22%7D%2Eglyphicon%2Dlog%2Dout%3Abefore%7Bcontent%3A%22%5Ce163%22%7D%2Eglyphicon%2Dnew%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce164%22%7D%2Eglyphicon%2Drecord%3Abefore%7Bcontent%3A%22%5Ce165%22%7D%2Eglyphicon%2Dsave%3Abefore%7Bcontent%3A%22%5Ce166%22%7D%2Eglyphicon%2Dopen%3Abefore%7Bcontent%3A%22%5Ce167%22%7D%2Eglyphicon%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce168%22%7D%2Eglyphicon%2Dimport%3Abefore%7Bcontent%3A%22%5Ce169%22%7D%2Eglyphicon%2Dexport%3Abefore%7Bcontent%3A%22%5Ce170%22%7D%2Eglyphicon%2Dsend%3Abefore%7Bcontent%3A%22%5Ce171%22%7D%2Eglyphicon%2Dfloppy%2Ddisk%3Abefore%7Bcontent%3A%22%5Ce172%22%7D%2Eglyphicon%2Dfloppy%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce173%22%7D%2Eglyphicon%2Dfloppy%2Dremove%3Abefore%7Bcontent%3A%22%5Ce174%22%7D%2Eglyphicon%2Dfloppy%2Dsave%3Abefore%7Bcontent%3A%22%5Ce175%22%7D%2Eglyphicon%2Dfloppy%2Dopen%3Abefore%7Bcontent%3A%22%5Ce176%22%7D%2Eglyphicon%2Dcredit%2Dcard%3Abefore%7Bcontent%3A%22%5Ce177%22%7D%2Eglyphicon%2Dtransfer%3Abefore%7Bcontent%3A%22%5Ce178%22%7D%2Eglyphicon%2Dcutlery%3Abefore%7Bcontent%3A%22%5Ce179%22%7D%2Eglyphicon%2Dheader%3Abefore%7Bcontent%3A%22%5Ce180%22%7D%2Eglyphicon%2Dcompressed%3Abefore%7Bcontent%3A%22%5Ce181%22%7D%2Eglyphicon%2Dearphone%3Abefore%7Bcontent%3A%22%5Ce182%22%7D%2Eglyphicon%2Dphone%2Dalt%3Abefore%7Bcontent%3A%22%5Ce183%22%7D%2Eglyphicon%2Dtower%3Abefore%7Bcontent%3A%22%5Ce184%22%7D%2Eglyphicon%2Dstats%3Abefore%7Bcontent%3A%22%5Ce185%22%7D%2Eglyphicon%2Dsd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce186%22%7D%2Eglyphicon%2Dhd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce187%22%7D%2Eglyphicon%2Dsubtitles%3Abefore%7Bcontent%3A%22%5Ce188%22%7D%2Eglyphicon%2Dsound%2Dstereo%3Abefore%7Bcontent%3A%22%5Ce189%22%7D%2Eglyphicon%2Dsound%2Ddolby%3Abefore%7Bcontent%3A%22%5Ce190%22%7D%2Eglyphicon%2Dsound%2D5%2D1%3Abefore%7Bcontent%3A%22%5Ce191%22%7D%2Eglyphicon%2Dsound%2D6%2D1%3Abefore%7Bcontent%3A%22%5Ce192%22%7D%2Eglyphicon%2Dsound%2D7%2D1%3Abefore%7Bcontent%3A%22%5Ce193%22%7D%2Eglyphicon%2Dcopyright%2Dmark%3Abefore%7Bcontent%3A%22%5Ce194%22%7D%2Eglyphicon%2Dregistration%2Dmark%3Abefore%7Bcontent%3A%22%5Ce195%22%7D%2Eglyphicon%2Dcloud%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce197%22%7D%2Eglyphicon%2Dcloud%2Dupload%3Abefore%7Bcontent%3A%22%5Ce198%22%7D%2Eglyphicon%2Dtree%2Dconifer%3Abefore%7Bcontent%3A%22%5Ce199%22%7D%2Eglyphicon%2Dtree%2Ddeciduous%3Abefore%7Bcontent%3A%22%5Ce200%22%7D%2Eglyphicon%2Dcd%3Abefore%7Bcontent%3A%22%5Ce201%22%7D%2Eglyphicon%2Dsave%2Dfile%3Abefore%7Bcontent%3A%22%5Ce202%22%7D%2Eglyphicon%2Dopen%2Dfile%3Abefore%7Bcontent%3A%22%5Ce203%22%7D%2Eglyphicon%2Dlevel%2Dup%3Abefore%7Bcontent%3A%22%5Ce204%22%7D%2Eglyphicon%2Dcopy%3Abefore%7Bcontent%3A%22%5Ce205%22%7D%2Eglyphicon%2Dpaste%3Abefore%7Bcontent%3A%22%5Ce206%22%7D%2Eglyphicon%2Dalert%3Abefore%7Bcontent%3A%22%5Ce209%22%7D%2Eglyphicon%2Dequalizer%3Abefore%7Bcontent%3A%22%5Ce210%22%7D%2Eglyphicon%2Dking%3Abefore%7Bcontent%3A%22%5Ce211%22%7D%2Eglyphicon%2Dqueen%3Abefore%7Bcontent%3A%22%5Ce212%22%7D%2Eglyphicon%2Dpawn%3Abefore%7Bcontent%3A%22%5Ce213%22%7D%2Eglyphicon%2Dbishop%3Abefore%7Bcontent%3A%22%5Ce214%22%7D%2Eglyphicon%2Dknight%3Abefore%7Bcontent%3A%22%5Ce215%22%7D%2Eglyphicon%2Dbaby%2Dformula%3Abefore%7Bcontent%3A%22%5Ce216%22%7D%2Eglyphicon%2Dtent%3Abefore%7Bcontent%3A%22%5C26fa%22%7D%2Eglyphicon%2Dblackboard%3Abefore%7Bcontent%3A%22%5Ce218%22%7D%2Eglyphicon%2Dbed%3Abefore%7Bcontent%3A%22%5Ce219%22%7D%2Eglyphicon%2Dapple%3Abefore%7Bcontent%3A%22%5Cf8ff%22%7D%2Eglyphicon%2Derase%3Abefore%7Bcontent%3A%22%5Ce221%22%7D%2Eglyphicon%2Dhourglass%3Abefore%7Bcontent%3A%22%5C231b%22%7D%2Eglyphicon%2Dlamp%3Abefore%7Bcontent%3A%22%5Ce223%22%7D%2Eglyphicon%2Dduplicate%3Abefore%7Bcontent%3A%22%5Ce224%22%7D%2Eglyphicon%2Dpiggy%2Dbank%3Abefore%7Bcontent%3A%22%5Ce225%22%7D%2Eglyphicon%2Dscissors%3Abefore%7Bcontent%3A%22%5Ce226%22%7D%2Eglyphicon%2Dbitcoin%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dbtc%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dxbt%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dyen%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Djpy%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Druble%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Drub%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Dscale%3Abefore%7Bcontent%3A%22%5Ce230%22%7D%2Eglyphicon%2Dice%2Dlolly%3Abefore%7Bcontent%3A%22%5Ce231%22%7D%2Eglyphicon%2Dice%2Dlolly%2Dtasted%3Abefore%7Bcontent%3A%22%5Ce232%22%7D%2Eglyphicon%2Deducation%3Abefore%7Bcontent%3A%22%5Ce233%22%7D%2Eglyphicon%2Doption%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce234%22%7D%2Eglyphicon%2Doption%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce235%22%7D%2Eglyphicon%2Dmenu%2Dhamburger%3Abefore%7Bcontent%3A%22%5Ce236%22%7D%2Eglyphicon%2Dmodal%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce237%22%7D%2Eglyphicon%2Doil%3Abefore%7Bcontent%3A%22%5Ce238%22%7D%2Eglyphicon%2Dgrain%3Abefore%7Bcontent%3A%22%5Ce239%22%7D%2Eglyphicon%2Dsunglasses%3Abefore%7Bcontent%3A%22%5Ce240%22%7D%2Eglyphicon%2Dtext%2Dsize%3Abefore%7Bcontent%3A%22%5Ce241%22%7D%2Eglyphicon%2Dtext%2Dcolor%3Abefore%7Bcontent%3A%22%5Ce242%22%7D%2Eglyphicon%2Dtext%2Dbackground%3Abefore%7Bcontent%3A%22%5Ce243%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dtop%3Abefore%7Bcontent%3A%22%5Ce244%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce245%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce246%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce247%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce248%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce249%22%7D%2Eglyphicon%2Dtriangle%2Dright%3Abefore%7Bcontent%3A%22%5Ce250%22%7D%2Eglyphicon%2Dtriangle%2Dleft%3Abefore%7Bcontent%3A%22%5Ce251%22%7D%2Eglyphicon%2Dtriangle%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce252%22%7D%2Eglyphicon%2Dtriangle%2Dtop%3Abefore%7Bcontent%3A%22%5Ce253%22%7D%2Eglyphicon%2Dconsole%3Abefore%7Bcontent%3A%22%5Ce254%22%7D%2Eglyphicon%2Dsuperscript%3Abefore%7Bcontent%3A%22%5Ce255%22%7D%2Eglyphicon%2Dsubscript%3Abefore%7Bcontent%3A%22%5Ce256%22%7D%2Eglyphicon%2Dmenu%2Dleft%3Abefore%7Bcontent%3A%22%5Ce257%22%7D%2Eglyphicon%2Dmenu%2Dright%3Abefore%7Bcontent%3A%22%5Ce258%22%7D%2Eglyphicon%2Dmenu%2Ddown%3Abefore%7Bcontent%3A%22%5Ce259%22%7D%2Eglyphicon%2Dmenu%2Dup%3Abefore%7Bcontent%3A%22%5Ce260%22%7D%2A%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7D%3Aafter%2C%3Abefore%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dhtml%7Bfont%2Dsize%3A10px%3B%2Dwebkit%2Dtap%2Dhighlight%2Dcolor%3Argba%280%2C0%2C0%2C0%29%7Dbody%7Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%7Dbutton%2Cinput%2Cselect%2Ctextarea%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bline%2Dheight%3Ainherit%7Da%7Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%7Da%3Afocus%2Ca%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%7Da%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Dfigure%7Bmargin%3A0%7Dimg%7Bvertical%2Dalign%3Amiddle%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%2C%2Eimg%2Dresponsive%2C%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bdisplay%3Ablock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%7D%2Eimg%2Drounded%7Bborder%2Dradius%3A6px%7D%2Eimg%2Dthumbnail%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%3Bpadding%3A4px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aall%20%2E2s%20ease%2Din%2Dout%7D%2Eimg%2Dcircle%7Bborder%2Dradius%3A50%25%7Dhr%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A20px%3Bborder%3A0%3Bborder%2Dtop%3A1px%20solid%20%23eee%7D%2Esr%2Donly%7Bposition%3Aabsolute%3Bwidth%3A1px%3Bheight%3A1px%3Bpadding%3A0%3Bmargin%3A%2D1px%3Boverflow%3Ahidden%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bborder%3A0%7D%2Esr%2Donly%2Dfocusable%3Aactive%2C%2Esr%2Donly%2Dfocusable%3Afocus%7Bposition%3Astatic%3Bwidth%3Aauto%3Bheight%3Aauto%3Bmargin%3A0%3Boverflow%3Avisible%3Bclip%3Aauto%7D%5Brole%3Dbutton%5D%7Bcursor%3Apointer%7D%2Eh1%2C%2Eh2%2C%2Eh3%2C%2Eh4%2C%2Eh5%2C%2Eh6%2Ch1%2Ch2%2Ch3%2Ch4%2Ch5%2Ch6%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dweight%3A500%3Bline%2Dheight%3A1%2E1%3Bcolor%3Ainherit%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2C%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23777%7D%2Eh1%2C%2Eh2%2C%2Eh3%2Ch1%2Ch2%2Ch3%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A10px%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%7Bfont%2Dsize%3A65%25%7D%2Eh4%2C%2Eh5%2C%2Eh6%2Ch4%2Ch5%2Ch6%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dsize%3A75%25%7D%2Eh1%2Ch1%7Bfont%2Dsize%3A36px%7D%2Eh2%2Ch2%7Bfont%2Dsize%3A30px%7D%2Eh3%2Ch3%7Bfont%2Dsize%3A24px%7D%2Eh4%2Ch4%7Bfont%2Dsize%3A18px%7D%2Eh5%2Ch5%7Bfont%2Dsize%3A14px%7D%2Eh6%2Ch6%7Bfont%2Dsize%3A12px%7Dp%7Bmargin%3A0%200%2010px%7D%2Elead%7Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A16px%3Bfont%2Dweight%3A300%3Bline%2Dheight%3A1%2E4%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Elead%7Bfont%2Dsize%3A21px%7D%7D%2Esmall%2Csmall%7Bfont%2Dsize%3A85%25%7D%2Emark%2Cmark%7Bpadding%3A%2E2em%3Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etext%2Dleft%7Btext%2Dalign%3Aleft%7D%2Etext%2Dright%7Btext%2Dalign%3Aright%7D%2Etext%2Dcenter%7Btext%2Dalign%3Acenter%7D%2Etext%2Djustify%7Btext%2Dalign%3Ajustify%7D%2Etext%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7D%2Etext%2Dlowercase%7Btext%2Dtransform%3Alowercase%7D%2Etext%2Duppercase%7Btext%2Dtransform%3Auppercase%7D%2Etext%2Dcapitalize%7Btext%2Dtransform%3Acapitalize%7D%2Etext%2Dmuted%7Bcolor%3A%23777%7D%2Etext%2Dprimary%7Bcolor%3A%23337ab7%7Da%2Etext%2Dprimary%3Afocus%2Ca%2Etext%2Dprimary%3Ahover%7Bcolor%3A%23286090%7D%2Etext%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Etext%2Dsuccess%3Afocus%2Ca%2Etext%2Dsuccess%3Ahover%7Bcolor%3A%232b542c%7D%2Etext%2Dinfo%7Bcolor%3A%2331708f%7Da%2Etext%2Dinfo%3Afocus%2Ca%2Etext%2Dinfo%3Ahover%7Bcolor%3A%23245269%7D%2Etext%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Etext%2Dwarning%3Afocus%2Ca%2Etext%2Dwarning%3Ahover%7Bcolor%3A%2366512c%7D%2Etext%2Ddanger%7Bcolor%3A%23a94442%7Da%2Etext%2Ddanger%3Afocus%2Ca%2Etext%2Ddanger%3Ahover%7Bcolor%3A%23843534%7D%2Ebg%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7Da%2Ebg%2Dprimary%3Afocus%2Ca%2Ebg%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Ebg%2Dsuccess%7Bbackground%2Dcolor%3A%23dff0d8%7Da%2Ebg%2Dsuccess%3Afocus%2Ca%2Ebg%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%23c1e2b3%7D%2Ebg%2Dinfo%7Bbackground%2Dcolor%3A%23d9edf7%7Da%2Ebg%2Dinfo%3Afocus%2Ca%2Ebg%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%23afd9ee%7D%2Ebg%2Dwarning%7Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Ebg%2Dwarning%3Afocus%2Ca%2Ebg%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f7ecb5%7D%2Ebg%2Ddanger%7Bbackground%2Dcolor%3A%23f2dede%7Da%2Ebg%2Ddanger%3Afocus%2Ca%2Ebg%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23e4b9b9%7D%2Epage%2Dheader%7Bpadding%2Dbottom%3A9px%3Bmargin%3A40px%200%2020px%3Bborder%2Dbottom%3A1px%20solid%20%23eee%7Dol%2Cul%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A10px%7Dol%20ol%2Col%20ul%2Cul%20ol%2Cul%20ul%7Bmargin%2Dbottom%3A0%7D%2Elist%2Dunstyled%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%7Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D5px%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%3Eli%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dright%3A5px%3Bpadding%2Dleft%3A5px%7Ddl%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A20px%7Ddd%2Cdt%7Bline%2Dheight%3A1%2E42857143%7Ddt%7Bfont%2Dweight%3A700%7Ddd%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Edl%2Dhorizontal%20dt%7Bfloat%3Aleft%3Bwidth%3A160px%3Boverflow%3Ahidden%3Bclear%3Aleft%3Btext%2Dalign%3Aright%3Btext%2Doverflow%3Aellipsis%3Bwhite%2Dspace%3Anowrap%7D%2Edl%2Dhorizontal%20dd%7Bmargin%2Dleft%3A180px%7D%7Dabbr%5Bdata%2Doriginal%2Dtitle%5D%2Cabbr%5Btitle%5D%7Bcursor%3Ahelp%3Bborder%2Dbottom%3A1px%20dotted%20%23777%7D%2Einitialism%7Bfont%2Dsize%3A90%25%3Btext%2Dtransform%3Auppercase%7Dblockquote%7Bpadding%3A10px%2020px%3Bmargin%3A0%200%2020px%3Bfont%2Dsize%3A17%2E5px%3Bborder%2Dleft%3A5px%20solid%20%23eee%7Dblockquote%20ol%3Alast%2Dchild%2Cblockquote%20p%3Alast%2Dchild%2Cblockquote%20ul%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7Dblockquote%20%2Esmall%2Cblockquote%20footer%2Cblockquote%20small%7Bdisplay%3Ablock%3Bfont%2Dsize%3A80%25%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%7Dblockquote%20%2Esmall%3Abefore%2Cblockquote%20footer%3Abefore%2Cblockquote%20small%3Abefore%7Bcontent%3A%27%5C2014%20%5C00A0%27%7D%2Eblockquote%2Dreverse%2Cblockquote%2Epull%2Dright%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A0%3Btext%2Dalign%3Aright%3Bborder%2Dright%3A5px%20solid%20%23eee%3Bborder%2Dleft%3A0%7D%2Eblockquote%2Dreverse%20%2Esmall%3Abefore%2C%2Eblockquote%2Dreverse%20footer%3Abefore%2C%2Eblockquote%2Dreverse%20small%3Abefore%2Cblockquote%2Epull%2Dright%20%2Esmall%3Abefore%2Cblockquote%2Epull%2Dright%20footer%3Abefore%2Cblockquote%2Epull%2Dright%20small%3Abefore%7Bcontent%3A%27%27%7D%2Eblockquote%2Dreverse%20%2Esmall%3Aafter%2C%2Eblockquote%2Dreverse%20footer%3Aafter%2C%2Eblockquote%2Dreverse%20small%3Aafter%2Cblockquote%2Epull%2Dright%20%2Esmall%3Aafter%2Cblockquote%2Epull%2Dright%20footer%3Aafter%2Cblockquote%2Epull%2Dright%20small%3Aafter%7Bcontent%3A%27%5C00A0%20%5C2014%27%7Daddress%7Bmargin%2Dbottom%3A20px%3Bfont%2Dstyle%3Anormal%3Bline%2Dheight%3A1%2E42857143%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%7Dcode%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23c7254e%3Bbackground%2Dcolor%3A%23f9f2f4%3Bborder%2Dradius%3A4px%7Dkbd%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%3Bborder%2Dradius%3A3px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%7Dkbd%20kbd%7Bpadding%3A0%3Bfont%2Dsize%3A100%25%3Bfont%2Dweight%3A700%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7Dpre%7Bdisplay%3Ablock%3Bpadding%3A9%2E5px%3Bmargin%3A0%200%2010px%3Bfont%2Dsize%3A13px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bword%2Dbreak%3Abreak%2Dall%3Bword%2Dwrap%3Abreak%2Dword%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7Dpre%20code%7Bpadding%3A0%3Bfont%2Dsize%3Ainherit%3Bcolor%3Ainherit%3Bwhite%2Dspace%3Apre%2Dwrap%3Bbackground%2Dcolor%3Atransparent%3Bborder%2Dradius%3A0%7D%2Epre%2Dscrollable%7Bmax%2Dheight%3A340px%3Boverflow%2Dy%3Ascroll%7D%2Econtainer%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%7Bwidth%3A750px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Econtainer%7Bwidth%3A970px%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Econtainer%7Bwidth%3A1170px%7D%7D%2Econtainer%2Dfluid%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Erow%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%2C%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%2C%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%2C%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bposition%3Arelative%3Bmin%2Dheight%3A1px%3Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dxs%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dxs%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dxs%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dxs%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dxs%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dxs%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dxs%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dxs%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dxs%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dxs%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dxs%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dxs%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dxs%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dxs%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dxs%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dxs%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dxs%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dxs%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dxs%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dxs%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dxs%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dxs%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dxs%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dxs%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dxs%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dxs%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dsm%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dsm%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dsm%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dsm%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dsm%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dsm%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dsm%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dsm%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dsm%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dsm%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dsm%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dsm%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dsm%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dsm%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dsm%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dsm%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dsm%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dsm%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dsm%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dsm%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dsm%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dsm%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dsm%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dsm%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dsm%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dsm%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dmd%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dmd%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dmd%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dmd%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dmd%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dmd%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dmd%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dmd%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dmd%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dmd%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dmd%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dmd%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dmd%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dmd%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dmd%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dmd%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dmd%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dmd%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dmd%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dmd%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dmd%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dmd%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dmd%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dmd%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dmd%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dmd%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dlg%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dlg%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dlg%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dlg%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dlg%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dlg%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dlg%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dlg%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dlg%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dlg%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dlg%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dlg%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dlg%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dlg%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dlg%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dlg%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dlg%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dlg%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dlg%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dlg%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dlg%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dlg%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dlg%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dlg%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dlg%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dlg%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7Dtable%7Bbackground%2Dcolor%3Atransparent%7Dcaption%7Bpadding%2Dtop%3A8px%3Bpadding%2Dbottom%3A8px%3Bcolor%3A%23777%3Btext%2Dalign%3Aleft%7Dth%7B%7D%2Etable%7Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A20px%7D%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%3Ethead%3Etr%3Eth%7Bpadding%3A8px%3Bline%2Dheight%3A1%2E42857143%3Bvertical%2Dalign%3Atop%3Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Etable%3Ethead%3Etr%3Eth%7Bvertical%2Dalign%3Abottom%3Bborder%2Dbottom%3A2px%20solid%20%23ddd%7D%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dtop%3A0%7D%2Etable%3Etbody%2Btbody%7Bborder%2Dtop%3A2px%20solid%20%23ddd%7D%2Etable%20%2Etable%7Bbackground%2Dcolor%3A%23fff%7D%2Etable%2Dcondensed%3Etbody%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etbody%3Etr%3Eth%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Eth%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Etd%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Eth%7Bpadding%3A5px%7D%2Etable%2Dbordered%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Etbody%3Etr%3Etd%2C%2Etable%2Dbordered%3Etbody%3Etr%3Eth%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%2C%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%2Dbottom%2Dwidth%3A2px%7D%2Etable%2Dstriped%3Etbody%3Etr%3Anth%2Dof%2Dtype%28odd%29%7Bbackground%2Dcolor%3A%23f9f9f9%7D%2Etable%2Dhover%3Etbody%3Etr%3Ahover%7Bbackground%2Dcolor%3A%23f5f5f5%7Dtable%20col%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcolumn%3Bfloat%3Anone%7Dtable%20td%5Bclass%2A%3Dcol%2D%5D%2Ctable%20th%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%7D%2Etable%3Etbody%3Etr%2Eactive%3Etd%2C%2Etable%3Etbody%3Etr%2Eactive%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Eactive%2C%2Etable%3Etbody%3Etr%3Eth%2Eactive%2C%2Etable%3Etfoot%3Etr%2Eactive%3Etd%2C%2Etable%3Etfoot%3Etr%2Eactive%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Eactive%2C%2Etable%3Etfoot%3Etr%3Eth%2Eactive%2C%2Etable%3Ethead%3Etr%2Eactive%3Etd%2C%2Etable%3Ethead%3Etr%2Eactive%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Eactive%2C%2Etable%3Ethead%3Etr%3Eth%2Eactive%7Bbackground%2Dcolor%3A%23f5f5f5%7D%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Eactive%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Eactive%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Eactive%3Ahover%7Bbackground%2Dcolor%3A%23e8e8e8%7D%2Etable%3Etbody%3Etr%2Esuccess%3Etd%2C%2Etable%3Etbody%3Etr%2Esuccess%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Esuccess%2C%2Etable%3Etbody%3Etr%3Eth%2Esuccess%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Etd%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Esuccess%2C%2Etable%3Etfoot%3Etr%3Eth%2Esuccess%2C%2Etable%3Ethead%3Etr%2Esuccess%3Etd%2C%2Etable%3Ethead%3Etr%2Esuccess%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Esuccess%2C%2Etable%3Ethead%3Etr%3Eth%2Esuccess%7Bbackground%2Dcolor%3A%23dff0d8%7D%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Esuccess%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Esuccess%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Esuccess%3Ahover%7Bbackground%2Dcolor%3A%23d0e9c6%7D%2Etable%3Etbody%3Etr%2Einfo%3Etd%2C%2Etable%3Etbody%3Etr%2Einfo%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Einfo%2C%2Etable%3Etbody%3Etr%3Eth%2Einfo%2C%2Etable%3Etfoot%3Etr%2Einfo%3Etd%2C%2Etable%3Etfoot%3Etr%2Einfo%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Einfo%2C%2Etable%3Etfoot%3Etr%3Eth%2Einfo%2C%2Etable%3Ethead%3Etr%2Einfo%3Etd%2C%2Etable%3Ethead%3Etr%2Einfo%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Einfo%2C%2Etable%3Ethead%3Etr%3Eth%2Einfo%7Bbackground%2Dcolor%3A%23d9edf7%7D%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Einfo%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Einfo%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Einfo%3Ahover%7Bbackground%2Dcolor%3A%23c4e3f3%7D%2Etable%3Etbody%3Etr%2Ewarning%3Etd%2C%2Etable%3Etbody%3Etr%2Ewarning%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Ewarning%2C%2Etable%3Etbody%3Etr%3Eth%2Ewarning%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Etd%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Ewarning%2C%2Etable%3Etfoot%3Etr%3Eth%2Ewarning%2C%2Etable%3Ethead%3Etr%2Ewarning%3Etd%2C%2Etable%3Ethead%3Etr%2Ewarning%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Ewarning%2C%2Etable%3Ethead%3Etr%3Eth%2Ewarning%7Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Ewarning%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Ewarning%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Ewarning%3Ahover%7Bbackground%2Dcolor%3A%23faf2cc%7D%2Etable%3Etbody%3Etr%2Edanger%3Etd%2C%2Etable%3Etbody%3Etr%2Edanger%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Edanger%2C%2Etable%3Etbody%3Etr%3Eth%2Edanger%2C%2Etable%3Etfoot%3Etr%2Edanger%3Etd%2C%2Etable%3Etfoot%3Etr%2Edanger%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Edanger%2C%2Etable%3Etfoot%3Etr%3Eth%2Edanger%2C%2Etable%3Ethead%3Etr%2Edanger%3Etd%2C%2Etable%3Ethead%3Etr%2Edanger%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Edanger%2C%2Etable%3Ethead%3Etr%3Eth%2Edanger%7Bbackground%2Dcolor%3A%23f2dede%7D%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Edanger%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Edanger%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Edanger%3Ahover%7Bbackground%2Dcolor%3A%23ebcccc%7D%2Etable%2Dresponsive%7Bmin%2Dheight%3A%2E01%25%3Boverflow%2Dx%3Aauto%7D%40media%20screen%20and%20%28max%2Dwidth%3A767px%29%7B%2Etable%2Dresponsive%7Bwidth%3A100%25%3Bmargin%2Dbottom%3A15px%3Boverflow%2Dy%3Ahidden%3B%2Dms%2Doverflow%2Dstyle%3A%2Dms%2Dautohiding%2Dscrollbar%3Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Eth%7Bwhite%2Dspace%3Anowrap%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%7Dfieldset%7Bmin%2Dwidth%3A0%3Bpadding%3A0%3Bmargin%3A0%3Bborder%3A0%7Dlegend%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bpadding%3A0%3Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A21px%3Bline%2Dheight%3Ainherit%3Bcolor%3A%23333%3Bborder%3A0%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7Dlabel%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A5px%3Bfont%2Dweight%3A700%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7Bmargin%3A4px%200%200%3Bmargin%2Dtop%3A1px%5C9%3Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dfile%5D%7Bdisplay%3Ablock%7Dinput%5Btype%3Drange%5D%7Bdisplay%3Ablock%3Bwidth%3A100%25%7Dselect%5Bmultiple%5D%2Cselect%5Bsize%5D%7Bheight%3Aauto%7Dinput%5Btype%3Dfile%5D%3Afocus%2Cinput%5Btype%3Dcheckbox%5D%3Afocus%2Cinput%5Btype%3Dradio%5D%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Doutput%7Bdisplay%3Ablock%3Bpadding%2Dtop%3A7px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%7D%2Eform%2Dcontrol%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bheight%3A34px%3Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23fff%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3B%2Dwebkit%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2C%2Dwebkit%2Dbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3B%2Do%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3Btransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%7D%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366afe9%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%7D%2Eform%2Dcontrol%3A%3A%2Dmoz%2Dplaceholder%7Bcolor%3A%23999%3Bopacity%3A1%7D%2Eform%2Dcontrol%3A%2Dms%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%3A%3A%2Dwebkit%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%5Bdisabled%5D%2C%2Eform%2Dcontrol%5Breadonly%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bbackground%2Dcolor%3A%23eee%3Bopacity%3A1%7D%2Eform%2Dcontrol%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bcursor%3Anot%2Dallowed%7Dtextarea%2Eform%2Dcontrol%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dappearance%3Anone%7D%40media%20screen%20and%20%28%2Dwebkit%2Dmin%2Ddevice%2Dpixel%2Dratio%3A0%29%7Binput%5Btype%3Ddate%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dtime%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dmonth%5D%2Eform%2Dcontrol%7Bline%2Dheight%3A34px%7D%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dsm%2Cinput%5Btype%3Dtime%5D%2Einput%2Dsm%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dsm%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dsm%7Bline%2Dheight%3A30px%7D%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dlg%2Cinput%5Btype%3Dtime%5D%2Einput%2Dlg%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dlg%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dlg%7Bline%2Dheight%3A46px%7D%7D%2Eform%2Dgroup%7Bmargin%2Dbottom%3A15px%7D%2Echeckbox%2C%2Eradio%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Echeckbox%20label%2C%2Eradio%20label%7Bmin%2Dheight%3A20px%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bcursor%3Apointer%7D%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Echeckbox%2Dinline%20input%5Btype%3Dcheckbox%5D%2C%2Eradio%20input%5Btype%3Dradio%5D%2C%2Eradio%2Dinline%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bmargin%2Dtop%3A4px%5C9%3Bmargin%2Dleft%3A%2D20px%7D%2Echeckbox%2B%2Echeckbox%2C%2Eradio%2B%2Eradio%7Bmargin%2Dtop%3A%2D5px%7D%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bvertical%2Dalign%3Amiddle%3Bcursor%3Apointer%7D%2Echeckbox%2Dinline%2B%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%2B%2Eradio%2Dinline%7Bmargin%2Dtop%3A0%3Bmargin%2Dleft%3A10px%7Dfieldset%5Bdisabled%5D%20input%5Btype%3Dcheckbox%5D%2Cfieldset%5Bdisabled%5D%20input%5Btype%3Dradio%5D%2Cinput%5Btype%3Dcheckbox%5D%2Edisabled%2Cinput%5Btype%3Dcheckbox%5D%5Bdisabled%5D%2Cinput%5Btype%3Dradio%5D%2Edisabled%2Cinput%5Btype%3Dradio%5D%5Bdisabled%5D%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Dinline%2Edisabled%2C%2Eradio%2Dinline%2Edisabled%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%2Dinline%2Cfieldset%5Bdisabled%5D%20%2Eradio%2Dinline%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Edisabled%20label%2C%2Eradio%2Edisabled%20label%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%20label%2Cfieldset%5Bdisabled%5D%20%2Eradio%20label%7Bcursor%3Anot%2Dallowed%7D%2Eform%2Dcontrol%2Dstatic%7Bmin%2Dheight%3A34px%3Bpadding%2Dtop%3A7px%3Bpadding%2Dbottom%3A7px%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dcontrol%2Dstatic%2Einput%2Dlg%2C%2Eform%2Dcontrol%2Dstatic%2Einput%2Dsm%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dsm%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dsm%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dsm%2Ctextarea%2Einput%2Dsm%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Eform%2Dgroup%2Dsm%20select%2Eform%2Dcontrol%7Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Eform%2Dgroup%2Dsm%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dsm%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A30px%3Bmin%2Dheight%3A32px%3Bpadding%3A6px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Einput%2Dlg%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dlg%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dlg%2Ctextarea%2Einput%2Dlg%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Eform%2Dgroup%2Dlg%20select%2Eform%2Dcontrol%7Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dlg%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dlg%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A46px%3Bmin%2Dheight%3A38px%3Bpadding%3A11px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Ehas%2Dfeedback%7Bposition%3Arelative%7D%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%7Bpadding%2Dright%3A42%2E5px%7D%2Eform%2Dcontrol%2Dfeedback%7Bposition%3Aabsolute%3Btop%3A0%3Bright%3A0%3Bz%2Dindex%3A2%3Bdisplay%3Ablock%3Bwidth%3A34px%3Bheight%3A34px%3Bline%2Dheight%3A34px%3Btext%2Dalign%3Acenter%3Bpointer%2Devents%3Anone%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A46px%3Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A30px%3Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Ehas%2Dsuccess%20%2Echeckbox%2C%2Ehas%2Dsuccess%20%2Echeckbox%2Dinline%2C%2Ehas%2Dsuccess%20%2Econtrol%2Dlabel%2C%2Ehas%2Dsuccess%20%2Ehelp%2Dblock%2C%2Ehas%2Dsuccess%20%2Eradio%2C%2Ehas%2Dsuccess%20%2Eradio%2Dinline%2C%2Ehas%2Dsuccess%2Echeckbox%20label%2C%2Ehas%2Dsuccess%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dsuccess%2Eradio%20label%2C%2Ehas%2Dsuccess%2Eradio%2Dinline%20label%7Bcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%233c763d%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%232b542c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%7D%2Ehas%2Dsuccess%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%233c763d%7D%2Ehas%2Dwarning%20%2Echeckbox%2C%2Ehas%2Dwarning%20%2Echeckbox%2Dinline%2C%2Ehas%2Dwarning%20%2Econtrol%2Dlabel%2C%2Ehas%2Dwarning%20%2Ehelp%2Dblock%2C%2Ehas%2Dwarning%20%2Eradio%2C%2Ehas%2Dwarning%20%2Eradio%2Dinline%2C%2Ehas%2Dwarning%2Echeckbox%20label%2C%2Ehas%2Dwarning%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dwarning%2Eradio%20label%2C%2Ehas%2Dwarning%2Eradio%2Dinline%20label%7Bcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%238a6d3b%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366512c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%7D%2Ehas%2Dwarning%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%238a6d3b%7D%2Ehas%2Derror%20%2Echeckbox%2C%2Ehas%2Derror%20%2Echeckbox%2Dinline%2C%2Ehas%2Derror%20%2Econtrol%2Dlabel%2C%2Ehas%2Derror%20%2Ehelp%2Dblock%2C%2Ehas%2Derror%20%2Eradio%2C%2Ehas%2Derror%20%2Eradio%2Dinline%2C%2Ehas%2Derror%2Echeckbox%20label%2C%2Ehas%2Derror%2Echeckbox%2Dinline%20label%2C%2Ehas%2Derror%2Eradio%20label%2C%2Ehas%2Derror%2Eradio%2Dinline%20label%7Bcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%23a94442%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%23843534%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%7D%2Ehas%2Derror%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%23a94442%7D%2Ehas%2Dfeedback%20label%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A25px%7D%2Ehas%2Dfeedback%20label%2Esr%2Donly%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%2Ehelp%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dtop%3A5px%3Bmargin%2Dbottom%3A10px%3Bcolor%3A%23737373%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dinline%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Eform%2Dinline%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Eform%2Dinline%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Eform%2Dinline%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%2C%2Eform%2Dinline%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%20label%2C%2Eform%2Dinline%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Eform%2Dinline%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Eform%2Dinline%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Eform%2Dinline%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Echeckbox%2Dinline%2C%2Eform%2Dhorizontal%20%2Eradio%2C%2Eform%2Dhorizontal%20%2Eradio%2Dinline%7Bpadding%2Dtop%3A7px%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Eradio%7Bmin%2Dheight%3A27px%7D%2Eform%2Dhorizontal%20%2Eform%2Dgroup%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A7px%3Bmargin%2Dbottom%3A0%3Btext%2Dalign%3Aright%7D%7D%2Eform%2Dhorizontal%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Bright%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dlg%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A14%2E33px%3Bfont%2Dsize%3A18px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dsm%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A6px%3Bfont%2Dsize%3A12px%7D%7D%2Ebtn%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A6px%2012px%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3B%2Dms%2Dtouch%2Daction%3Amanipulation%3Btouch%2Daction%3Amanipulation%3Bcursor%3Apointer%3B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ebtn%2Eactive%2Efocus%2C%2Ebtn%2Eactive%3Afocus%2C%2Ebtn%2Efocus%2C%2Ebtn%3Aactive%2Efocus%2C%2Ebtn%3Aactive%3Afocus%2C%2Ebtn%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7D%2Ebtn%2Efocus%2C%2Ebtn%3Afocus%2C%2Ebtn%3Ahover%7Bcolor%3A%23333%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Eactive%2C%2Ebtn%3Aactive%7Bbackground%2Dimage%3Anone%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Edisabled%2C%2Ebtn%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%7Bcursor%3Anot%2Dallowed%3Bfilter%3Aalpha%28opacity%3D65%29%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%3Bopacity%3A%2E65%7Da%2Ebtn%2Edisabled%2Cfieldset%5Bdisabled%5D%20a%2Ebtn%7Bpointer%2Devents%3Anone%7D%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%2Efocus%2C%2Ebtn%2Ddefault%3Afocus%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2Efocus%2C%2Ebtn%2Ddefault%2Eactive%3Afocus%2C%2Ebtn%2Ddefault%2Eactive%3Ahover%2C%2Ebtn%2Ddefault%3Aactive%2Efocus%2C%2Ebtn%2Ddefault%3Aactive%3Afocus%2C%2Ebtn%2Ddefault%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23d4d4d4%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddefault%2Edisabled%2C%2Ebtn%2Ddefault%2Edisabled%2Eactive%2C%2Ebtn%2Ddefault%2Edisabled%2Efocus%2C%2Ebtn%2Ddefault%2Edisabled%3Aactive%2C%2Ebtn%2Ddefault%2Edisabled%3Afocus%2C%2Ebtn%2Ddefault%2Edisabled%3Ahover%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Ahover%7Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%20%2Ebadge%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%7D%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%2Efocus%2C%2Ebtn%2Dprimary%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2Efocus%2C%2Ebtn%2Dprimary%2Eactive%3Afocus%2C%2Ebtn%2Dprimary%2Eactive%3Ahover%2C%2Ebtn%2Dprimary%3Aactive%2Efocus%2C%2Ebtn%2Dprimary%3Aactive%3Afocus%2C%2Ebtn%2Dprimary%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23204d74%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dprimary%2Edisabled%2C%2Ebtn%2Dprimary%2Edisabled%2Eactive%2C%2Ebtn%2Dprimary%2Edisabled%2Efocus%2C%2Ebtn%2Dprimary%2Edisabled%3Aactive%2C%2Ebtn%2Dprimary%2Edisabled%3Afocus%2C%2Ebtn%2Dprimary%2Edisabled%3Ahover%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%2Efocus%2C%2Ebtn%2Dsuccess%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2Efocus%2C%2Ebtn%2Dsuccess%2Eactive%3Afocus%2C%2Ebtn%2Dsuccess%2Eactive%3Ahover%2C%2Ebtn%2Dsuccess%3Aactive%2Efocus%2C%2Ebtn%2Dsuccess%3Aactive%3Afocus%2C%2Ebtn%2Dsuccess%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23398439%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dsuccess%2Edisabled%2C%2Ebtn%2Dsuccess%2Edisabled%2Eactive%2C%2Ebtn%2Dsuccess%2Edisabled%2Efocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Aactive%2C%2Ebtn%2Dsuccess%2Edisabled%3Afocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Ahover%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%20%2Ebadge%7Bcolor%3A%235cb85c%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%2Efocus%2C%2Ebtn%2Dinfo%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2Efocus%2C%2Ebtn%2Dinfo%2Eactive%3Afocus%2C%2Ebtn%2Dinfo%2Eactive%3Ahover%2C%2Ebtn%2Dinfo%3Aactive%2Efocus%2C%2Ebtn%2Dinfo%3Aactive%3Afocus%2C%2Ebtn%2Dinfo%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23269abc%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dinfo%2Edisabled%2C%2Ebtn%2Dinfo%2Edisabled%2Eactive%2C%2Ebtn%2Dinfo%2Edisabled%2Efocus%2C%2Ebtn%2Dinfo%2Edisabled%3Aactive%2C%2Ebtn%2Dinfo%2Edisabled%3Afocus%2C%2Ebtn%2Dinfo%2Edisabled%3Ahover%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%20%2Ebadge%7Bcolor%3A%235bc0de%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%2Efocus%2C%2Ebtn%2Dwarning%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2Efocus%2C%2Ebtn%2Dwarning%2Eactive%3Afocus%2C%2Ebtn%2Dwarning%2Eactive%3Ahover%2C%2Ebtn%2Dwarning%3Aactive%2Efocus%2C%2Ebtn%2Dwarning%3Aactive%3Afocus%2C%2Ebtn%2Dwarning%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d58512%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dwarning%2Edisabled%2C%2Ebtn%2Dwarning%2Edisabled%2Eactive%2C%2Ebtn%2Dwarning%2Edisabled%2Efocus%2C%2Ebtn%2Dwarning%2Edisabled%3Aactive%2C%2Ebtn%2Dwarning%2Edisabled%3Afocus%2C%2Ebtn%2Dwarning%2Edisabled%3Ahover%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%20%2Ebadge%7Bcolor%3A%23f0ad4e%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%2Efocus%2C%2Ebtn%2Ddanger%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2Efocus%2C%2Ebtn%2Ddanger%2Eactive%3Afocus%2C%2Ebtn%2Ddanger%2Eactive%3Ahover%2C%2Ebtn%2Ddanger%3Aactive%2Efocus%2C%2Ebtn%2Ddanger%3Aactive%3Afocus%2C%2Ebtn%2Ddanger%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ac2925%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddanger%2Edisabled%2C%2Ebtn%2Ddanger%2Edisabled%2Eactive%2C%2Ebtn%2Ddanger%2Edisabled%2Efocus%2C%2Ebtn%2Ddanger%2Edisabled%3Aactive%2C%2Ebtn%2Ddanger%2Edisabled%3Afocus%2C%2Ebtn%2Ddanger%2Edisabled%3Ahover%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%20%2Ebadge%7Bcolor%3A%23d9534f%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dlink%7Bfont%2Dweight%3A400%3Bcolor%3A%23337ab7%3Bborder%2Dradius%3A0%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%2Eactive%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%7Bbackground%2Dcolor%3Atransparent%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bborder%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%3Bbackground%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Dgroup%2Dlg%3E%2Ebtn%2C%2Ebtn%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Ebtn%2Dgroup%2Dsm%3E%2Ebtn%2C%2Ebtn%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%2C%2Ebtn%2Dxs%7Bpadding%3A1px%205px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dblock%7Bdisplay%3Ablock%3Bwidth%3A100%25%7D%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dtop%3A5px%7Dinput%5Btype%3Dbutton%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dreset%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dsubmit%5D%2Ebtn%2Dblock%7Bwidth%3A100%25%7D%2Efade%7Bopacity%3A0%3B%2Dwebkit%2Dtransition%3Aopacity%20%2E15s%20linear%3B%2Do%2Dtransition%3Aopacity%20%2E15s%20linear%3Btransition%3Aopacity%20%2E15s%20linear%7D%2Efade%2Ein%7Bopacity%3A1%7D%2Ecollapse%7Bdisplay%3Anone%7D%2Ecollapse%2Ein%7Bdisplay%3Ablock%7Dtr%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%7Dtbody%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%2Dgroup%7D%2Ecollapsing%7Bposition%3Arelative%3Bheight%3A0%3Boverflow%3Ahidden%3B%2Dwebkit%2Dtransition%2Dtiming%2Dfunction%3Aease%3B%2Do%2Dtransition%2Dtiming%2Dfunction%3Aease%3Btransition%2Dtiming%2Dfunction%3Aease%3B%2Dwebkit%2Dtransition%2Dduration%3A%2E35s%3B%2Do%2Dtransition%2Dduration%3A%2E35s%3Btransition%2Dduration%3A%2E35s%3B%2Dwebkit%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3B%2Do%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3Btransition%2Dproperty%3Aheight%2Cvisibility%7D%2Ecaret%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A0%3Bheight%3A0%3Bmargin%2Dleft%3A2px%3Bvertical%2Dalign%3Amiddle%3Bborder%2Dtop%3A4px%20dashed%3Bborder%2Dtop%3A4px%20solid%5C9%3Bborder%2Dright%3A4px%20solid%20transparent%3Bborder%2Dleft%3A4px%20solid%20transparent%7D%2Edropdown%2C%2Edropup%7Bposition%3Arelative%7D%2Edropdown%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Edropdown%2Dmenu%7Bposition%3Aabsolute%3Btop%3A100%25%3Bleft%3A0%3Bz%2Dindex%3A1000%3Bdisplay%3Anone%3Bfloat%3Aleft%3Bmin%2Dwidth%3A160px%3Bpadding%3A5px%200%3Bmargin%3A2px%200%200%3Bfont%2Dsize%3A14px%3Btext%2Dalign%3Aleft%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E15%29%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%3Bbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%7D%2Edropdown%2Dmenu%2Epull%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%20%2Edivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Edropdown%2Dmenu%3Eli%3Ea%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bclear%3Aboth%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23262626%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7D%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23337ab7%3Boutline%3A0%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28enabled%3Dfalse%29%7D%2Eopen%3E%2Edropdown%2Dmenu%7Bdisplay%3Ablock%7D%2Eopen%3Ea%7Boutline%3A0%7D%2Edropdown%2Dmenu%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%2Edropdown%2Dheader%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A990%7D%2Epull%2Dright%3E%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Edropup%20%2Ecaret%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Ecaret%7Bcontent%3A%22%22%3Bborder%2Dtop%3A0%3Bborder%2Dbottom%3A4px%20dashed%3Bborder%2Dbottom%3A4px%20solid%5C9%7D%2Edropup%20%2Edropdown%2Dmenu%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bbottom%3A100%25%3Bmargin%2Dbottom%3A2px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dright%20%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Enavbar%2Dright%20%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%7D%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Amiddle%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%3E%2Ebtn%7Bposition%3Arelative%3Bfloat%3Aleft%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Ahover%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dleft%3A%2D1px%7D%2Ebtn%2Dtoolbar%7Bmargin%2Dleft%3A%2D5px%7D%2Ebtn%2Dtoolbar%20%2Ebtn%2C%2Ebtn%2Dtoolbar%20%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%20%2Einput%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dtoolbar%3E%2Ebtn%2C%2Ebtn%2Dtoolbar%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%3E%2Einput%2Dgroup%7Bmargin%2Dleft%3A5px%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%2C%2Ebtn%2Dgroup%3E%2Edropdown%2Dtoggle%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%20%2Edropdown%2Dtoggle%3Aactive%2C%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7Boutline%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A8px%3Bpadding%2Dleft%3A8px%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dlg%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A12px%3Bpadding%2Dleft%3A12px%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%2Ebtn%2Dlink%7B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%20%2Ecaret%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Edropup%20%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A0%205px%205px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bdisplay%3Ablock%3Bfloat%3Anone%3Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bfloat%3Anone%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dtop%3A%2D1px%3Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Djustified%7Bdisplay%3Atable%3Bwidth%3A100%25%3Btable%2Dlayout%3Afixed%3Bborder%2Dcollapse%3Aseparate%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%7Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%3Bwidth%3A1%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Ebtn%7Bwidth%3A100%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Edropdown%2Dmenu%7Bleft%3Aauto%7D%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dradio%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bpointer%2Devents%3Anone%7D%2Einput%2Dgroup%7Bposition%3Arelative%3Bdisplay%3Atable%3Bborder%2Dcollapse%3Aseparate%7D%2Einput%2Dgroup%5Bclass%2A%3Dcol%2D%5D%7Bfloat%3Anone%3Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%7Bposition%3Arelative%3Bz%2Dindex%3A2%3Bfloat%3Aleft%3Bwidth%3A100%25%3Bmargin%2Dbottom%3A0%7D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bdisplay%3Atable%2Dcell%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Daddon%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bwidth%3A1%25%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%7D%2Einput%2Dgroup%2Daddon%7Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23555%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23eee%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bborder%2Dradius%3A3px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bborder%2Dradius%3A6px%7D%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dcheckbox%5D%2C%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dradio%5D%7Bmargin%2Dtop%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Edropdown%2Dtoggle%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%7Bborder%2Dright%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Alast%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%7Bborder%2Dleft%3A0%7D%2Einput%2Dgroup%2Dbtn%7Bposition%3Arelative%3Bfont%2Dsize%3A0%3Bwhite%2Dspace%3Anowrap%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bposition%3Arelative%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Aactive%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Afocus%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%7Bmargin%2Dright%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%7Bz%2Dindex%3A2%3Bmargin%2Dleft%3A%2D1px%7D%2Enav%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A0%3Blist%2Dstyle%3Anone%7D%2Enav%3Eli%7Bposition%3Arelative%3Bdisplay%3Ablock%7D%2Enav%3Eli%3Ea%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%7D%2Enav%3Eli%3Ea%3Afocus%2C%2Enav%3Eli%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Enav%3Eli%2Edisabled%3Ea%7Bcolor%3A%23777%7D%2Enav%3Eli%2Edisabled%3Ea%3Afocus%2C%2Enav%3Eli%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%7D%2Enav%20%2Eopen%3Ea%2C%2Enav%20%2Eopen%3Ea%3Afocus%2C%2Enav%20%2Eopen%3Ea%3Ahover%7Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23337ab7%7D%2Enav%20%2Enav%2Ddivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Enav%3Eli%3Ea%3Eimg%7Bmax%2Dwidth%3Anone%7D%2Enav%2Dtabs%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Enav%2Dtabs%3Eli%7Bfloat%3Aleft%3Bmargin%2Dbottom%3A%2D1px%7D%2Enav%2Dtabs%3Eli%3Ea%7Bmargin%2Dright%3A2px%3Bline%2Dheight%3A1%2E42857143%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%3Eli%3Ea%3Ahover%7Bborder%2Dcolor%3A%23eee%20%23eee%20%23ddd%7D%2Enav%2Dtabs%3Eli%2Eactive%3Ea%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dcolor%3Atransparent%7D%2Enav%2Dtabs%2Enav%2Djustified%7Bwidth%3A100%25%3Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Enav%2Dpills%3Eli%7Bfloat%3Aleft%7D%2Enav%2Dpills%3Eli%3Ea%7Bborder%2Dradius%3A4px%7D%2Enav%2Dpills%3Eli%2Bli%7Bmargin%2Dleft%3A2px%7D%2Enav%2Dpills%3Eli%2Eactive%3Ea%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7D%2Enav%2Dstacked%3Eli%7Bfloat%3Anone%7D%2Enav%2Dstacked%3Eli%2Bli%7Bmargin%2Dtop%3A2px%3Bmargin%2Dleft%3A0%7D%2Enav%2Djustified%7Bwidth%3A100%25%7D%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Djustified%7Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Etab%2Dcontent%3E%2Etab%2Dpane%7Bdisplay%3Anone%7D%2Etab%2Dcontent%3E%2Eactive%7Bdisplay%3Ablock%7D%2Enav%2Dtabs%20%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A%2D1px%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%7Bposition%3Arelative%3Bmin%2Dheight%3A50px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%7Bborder%2Dradius%3A4px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dheader%7Bfloat%3Aleft%7D%7D%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Boverflow%2Dx%3Avisible%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Bborder%2Dtop%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dcollapse%7Bwidth%3Aauto%3Bborder%2Dtop%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dcollapse%2Ecollapse%7Bdisplay%3Ablock%21important%3Bheight%3Aauto%21important%3Bpadding%2Dbottom%3A0%3Boverflow%3Avisible%21important%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Avisible%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dstatic%2Dtop%20%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A340px%7D%40media%20%28max%2Ddevice%2Dwidth%3A480px%29%20and%20%28orientation%3Alandscape%29%7B%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A200px%7D%7D%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%7D%7D%2Enavbar%2Dstatic%2Dtop%7Bz%2Dindex%3A1000%3Bborder%2Dwidth%3A0%200%201px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dstatic%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bposition%3Afixed%3Bright%3A0%3Bleft%3A0%3Bz%2Dindex%3A1030%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dtop%7Btop%3A0%3Bborder%2Dwidth%3A0%200%201px%7D%2Enavbar%2Dfixed%2Dbottom%7Bbottom%3A0%3Bmargin%2Dbottom%3A0%3Bborder%2Dwidth%3A1px%200%200%7D%2Enavbar%2Dbrand%7Bfloat%3Aleft%3Bheight%3A50px%3Bpadding%3A15px%2015px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A20px%7D%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dbrand%3Ahover%7Btext%2Ddecoration%3Anone%7D%2Enavbar%2Dbrand%3Eimg%7Bdisplay%3Ablock%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%3E%2Econtainer%20%2Enavbar%2Dbrand%2C%2Enavbar%3E%2Econtainer%2Dfluid%20%2Enavbar%2Dbrand%7Bmargin%2Dleft%3A%2D15px%7D%7D%2Enavbar%2Dtoggle%7Bposition%3Arelative%3Bfloat%3Aright%3Bpadding%3A9px%2010px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A15px%3Bmargin%2Dbottom%3A8px%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Enavbar%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bdisplay%3Ablock%3Bwidth%3A22px%3Bheight%3A2px%3Bborder%2Dradius%3A1px%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%2B%2Eicon%2Dbar%7Bmargin%2Dtop%3A4px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtoggle%7Bdisplay%3Anone%7D%7D%2Enavbar%2Dnav%7Bmargin%3A7%2E5px%20%2D15px%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A10px%3Bpadding%2Dbottom%3A10px%3Bline%2Dheight%3A20px%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%7Bposition%3Astatic%3Bfloat%3Anone%3Bwidth%3Aauto%3Bmargin%2Dtop%3A0%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edropdown%2Dheader%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bpadding%3A5px%2015px%205px%2025px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bline%2Dheight%3A20px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bbackground%2Dimage%3Anone%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dnav%7Bfloat%3Aleft%3Bmargin%3A0%7D%2Enavbar%2Dnav%3Eli%7Bfloat%3Aleft%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A15px%3Bpadding%2Dbottom%3A15px%7D%7D%2Enavbar%2Dform%7Bpadding%3A10px%2015px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A%2D15px%3Bmargin%2Dbottom%3A8px%3Bmargin%2Dleft%3A%2D15px%3Bborder%2Dtop%3A1px%20solid%20transparent%3Bborder%2Dbottom%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Enavbar%2Dform%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%2C%2Enavbar%2Dform%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%20label%2C%2Enavbar%2Dform%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Enavbar%2Dform%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bmargin%2Dbottom%3A5px%7D%2Enavbar%2Dform%20%2Eform%2Dgroup%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%7Bwidth%3Aauto%3Bpadding%2Dtop%3A0%3Bpadding%2Dbottom%3A0%3Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%7D%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dbottom%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Enavbar%2Dbtn%7Bmargin%2Dtop%3A8px%3Bmargin%2Dbottom%3A8px%7D%2Enavbar%2Dbtn%2Ebtn%2Dsm%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Enavbar%2Dbtn%2Ebtn%2Dxs%7Bmargin%2Dtop%3A14px%3Bmargin%2Dbottom%3A14px%7D%2Enavbar%2Dtext%7Bmargin%2Dtop%3A15px%3Bmargin%2Dbottom%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtext%7Bfloat%3Aleft%3Bmargin%2Dright%3A15px%3Bmargin%2Dleft%3A15px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dleft%7Bfloat%3Aleft%21important%7D%2Enavbar%2Dright%7Bfloat%3Aright%21important%3Bmargin%2Dright%3A%2D15px%7D%2Enavbar%2Dright%7E%2Enavbar%2Dright%7Bmargin%2Dright%3A0%7D%7D%2Enavbar%2Ddefault%7Bbackground%2Dcolor%3A%23f8f8f8%3Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%235e5e5e%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtext%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23888%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23ccc%7D%2Enavbar%2Dinverse%7Bbackground%2Dcolor%3A%23222%3Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtext%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23101010%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edropdown%2Dheader%7Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edivider%7Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23444%7D%2Ebreadcrumb%7Bpadding%3A8px%2015px%3Bmargin%2Dbottom%3A20px%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%7D%2Ebreadcrumb%3Eli%7Bdisplay%3Ainline%2Dblock%7D%2Ebreadcrumb%3Eli%2Bli%3Abefore%7Bpadding%3A0%205px%3Bcolor%3A%23ccc%3Bcontent%3A%22%2F%5C00a0%22%7D%2Ebreadcrumb%3E%2Eactive%7Bcolor%3A%23777%7D%2Epagination%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Bborder%2Dradius%3A4px%7D%2Epagination%3Eli%7Bdisplay%3Ainline%7D%2Epagination%3Eli%3Ea%2C%2Epagination%3Eli%3Espan%7Bposition%3Arelative%3Bfloat%3Aleft%3Bpadding%3A6px%2012px%3Bmargin%2Dleft%3A%2D1px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Epagination%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%3Eli%3Afirst%2Dchild%3Espan%7Bmargin%2Dleft%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Epagination%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%7D%2Epagination%3Eli%3Ea%3Afocus%2C%2Epagination%3Eli%3Ea%3Ahover%2C%2Epagination%3Eli%3Espan%3Afocus%2C%2Epagination%3Eli%3Espan%3Ahover%7Bz%2Dindex%3A3%3Bcolor%3A%2323527c%3Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%3E%2Eactive%3Ea%2C%2Epagination%3E%2Eactive%3Ea%3Afocus%2C%2Epagination%3E%2Eactive%3Ea%3Ahover%2C%2Epagination%3E%2Eactive%3Espan%2C%2Epagination%3E%2Eactive%3Espan%3Afocus%2C%2Epagination%3E%2Eactive%3Espan%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epagination%3E%2Edisabled%3Ea%2C%2Epagination%3E%2Edisabled%3Ea%3Afocus%2C%2Epagination%3E%2Edisabled%3Ea%3Ahover%2C%2Epagination%3E%2Edisabled%3Espan%2C%2Epagination%3E%2Edisabled%3Espan%3Afocus%2C%2Epagination%3E%2Edisabled%3Espan%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%2Dlg%3Eli%3Ea%2C%2Epagination%2Dlg%3Eli%3Espan%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A6px%3Bborder%2Dbottom%2Dleft%2Dradius%3A6px%7D%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A6px%3Bborder%2Dbottom%2Dright%2Dradius%3A6px%7D%2Epagination%2Dsm%3Eli%3Ea%2C%2Epagination%2Dsm%3Eli%3Espan%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epager%7Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Epager%20li%7Bdisplay%3Ainline%7D%2Epager%20li%3Ea%2C%2Epager%20li%3Espan%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A5px%2014px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A15px%7D%2Epager%20li%3Ea%3Afocus%2C%2Epager%20li%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Epager%20%2Enext%3Ea%2C%2Epager%20%2Enext%3Espan%7Bfloat%3Aright%7D%2Epager%20%2Eprevious%3Ea%2C%2Epager%20%2Eprevious%3Espan%7Bfloat%3Aleft%7D%2Epager%20%2Edisabled%3Ea%2C%2Epager%20%2Edisabled%3Ea%3Afocus%2C%2Epager%20%2Edisabled%3Ea%3Ahover%2C%2Epager%20%2Edisabled%3Espan%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%7D%2Elabel%7Bdisplay%3Ainline%3Bpadding%3A%2E2em%20%2E6em%20%2E3em%3Bfont%2Dsize%3A75%25%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Abaseline%3Bborder%2Dradius%3A%2E25em%7Da%2Elabel%3Afocus%2Ca%2Elabel%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elabel%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Elabel%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Elabel%2Ddefault%7Bbackground%2Dcolor%3A%23777%7D%2Elabel%2Ddefault%5Bhref%5D%3Afocus%2C%2Elabel%2Ddefault%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%235e5e5e%7D%2Elabel%2Dprimary%7Bbackground%2Dcolor%3A%23337ab7%7D%2Elabel%2Dprimary%5Bhref%5D%3Afocus%2C%2Elabel%2Dprimary%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Elabel%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Elabel%2Dsuccess%5Bhref%5D%3Afocus%2C%2Elabel%2Dsuccess%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23449d44%7D%2Elabel%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Elabel%2Dinfo%5Bhref%5D%3Afocus%2C%2Elabel%2Dinfo%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%2331b0d5%7D%2Elabel%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Elabel%2Dwarning%5Bhref%5D%3Afocus%2C%2Elabel%2Dwarning%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23ec971f%7D%2Elabel%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Elabel%2Ddanger%5Bhref%5D%3Afocus%2C%2Elabel%2Ddanger%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23c9302c%7D%2Ebadge%7Bdisplay%3Ainline%2Dblock%3Bmin%2Dwidth%3A10px%3Bpadding%3A3px%207px%3Bfont%2Dsize%3A12px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3Bbackground%2Dcolor%3A%23777%3Bborder%2Dradius%3A10px%7D%2Ebadge%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Ebadge%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%20%2Ebadge%2C%2Ebtn%2Dxs%20%2Ebadge%7Btop%3A0%3Bpadding%3A1px%205px%7Da%2Ebadge%3Afocus%2Ca%2Ebadge%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elist%2Dgroup%2Ditem%2Eactive%3E%2Ebadge%2C%2Enav%2Dpills%3E%2Eactive%3Ea%3E%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%7Bfloat%3Aright%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%2B%2Ebadge%7Bmargin%2Dright%3A5px%7D%2Enav%2Dpills%3Eli%3Ea%3E%2Ebadge%7Bmargin%2Dleft%3A3px%7D%2Ejumbotron%7Bpadding%2Dtop%3A30px%3Bpadding%2Dbottom%3A30px%3Bmargin%2Dbottom%3A30px%3Bcolor%3Ainherit%3Bbackground%2Dcolor%3A%23eee%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bcolor%3Ainherit%7D%2Ejumbotron%20p%7Bmargin%2Dbottom%3A15px%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A200%7D%2Ejumbotron%3Ehr%7Bborder%2Dtop%2Dcolor%3A%23d5d5d5%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bborder%2Dradius%3A6px%7D%2Ejumbotron%20%2Econtainer%7Bmax%2Dwidth%3A100%25%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ejumbotron%7Bpadding%2Dtop%3A48px%3Bpadding%2Dbottom%3A48px%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bpadding%2Dright%3A60px%3Bpadding%2Dleft%3A60px%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bfont%2Dsize%3A63px%7D%7D%2Ethumbnail%7Bdisplay%3Ablock%3Bpadding%3A4px%3Bmargin%2Dbottom%3A20px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aborder%20%2E2s%20ease%2Din%2Dout%7D%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7Da%2Ethumbnail%2Eactive%2Ca%2Ethumbnail%3Afocus%2Ca%2Ethumbnail%3Ahover%7Bborder%2Dcolor%3A%23337ab7%7D%2Ethumbnail%20%2Ecaption%7Bpadding%3A9px%3Bcolor%3A%23333%7D%2Ealert%7Bpadding%3A15px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ealert%20h4%7Bmargin%2Dtop%3A0%3Bcolor%3Ainherit%7D%2Ealert%20%2Ealert%2Dlink%7Bfont%2Dweight%3A700%7D%2Ealert%3Ep%2C%2Ealert%3Eul%7Bmargin%2Dbottom%3A0%7D%2Ealert%3Ep%2Bp%7Bmargin%2Dtop%3A5px%7D%2Ealert%2Ddismissable%2C%2Ealert%2Ddismissible%7Bpadding%2Dright%3A35px%7D%2Ealert%2Ddismissable%20%2Eclose%2C%2Ealert%2Ddismissible%20%2Eclose%7Bposition%3Arelative%3Btop%3A%2D2px%3Bright%3A%2D21px%3Bcolor%3Ainherit%7D%2Ealert%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Ealert%2Dsuccess%20hr%7Bborder%2Dtop%2Dcolor%3A%23c9e2b3%7D%2Ealert%2Dsuccess%20%2Ealert%2Dlink%7Bcolor%3A%232b542c%7D%2Ealert%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Ealert%2Dinfo%20hr%7Bborder%2Dtop%2Dcolor%3A%23a6e1ec%7D%2Ealert%2Dinfo%20%2Ealert%2Dlink%7Bcolor%3A%23245269%7D%2Ealert%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Ealert%2Dwarning%20hr%7Bborder%2Dtop%2Dcolor%3A%23f7e1b5%7D%2Ealert%2Dwarning%20%2Ealert%2Dlink%7Bcolor%3A%2366512c%7D%2Ealert%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Ealert%2Ddanger%20hr%7Bborder%2Dtop%2Dcolor%3A%23e4b9c0%7D%2Ealert%2Ddanger%20%2Ealert%2Dlink%7Bcolor%3A%23843534%7D%40%2Dwebkit%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40%2Do%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40keyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%2Eprogress%7Bheight%3A20px%3Bmargin%2Dbottom%3A20px%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%7D%2Eprogress%2Dbar%7Bfloat%3Aleft%3Bwidth%3A0%3Bheight%3A100%25%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23337ab7%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3B%2Dwebkit%2Dtransition%3Awidth%20%2E6s%20ease%3B%2Do%2Dtransition%3Awidth%20%2E6s%20ease%3Btransition%3Awidth%20%2E6s%20ease%7D%2Eprogress%2Dbar%2Dstriped%2C%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3B%2Dwebkit%2Dbackground%2Dsize%3A40px%2040px%3Bbackground%2Dsize%3A40px%2040px%7D%2Eprogress%2Dbar%2Eactive%2C%2Eprogress%2Eactive%20%2Eprogress%2Dbar%7B%2Dwebkit%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3B%2Do%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3Banimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%7D%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Emedia%7Bmargin%2Dtop%3A15px%7D%2Emedia%3Afirst%2Dchild%7Bmargin%2Dtop%3A0%7D%2Emedia%2C%2Emedia%2Dbody%7Boverflow%3Ahidden%3Bzoom%3A1%7D%2Emedia%2Dbody%7Bwidth%3A10000px%7D%2Emedia%2Dobject%7Bdisplay%3Ablock%7D%2Emedia%2Dobject%2Eimg%2Dthumbnail%7Bmax%2Dwidth%3Anone%7D%2Emedia%2Dright%2C%2Emedia%3E%2Epull%2Dright%7Bpadding%2Dleft%3A10px%7D%2Emedia%2Dleft%2C%2Emedia%3E%2Epull%2Dleft%7Bpadding%2Dright%3A10px%7D%2Emedia%2Dbody%2C%2Emedia%2Dleft%2C%2Emedia%2Dright%7Bdisplay%3Atable%2Dcell%3Bvertical%2Dalign%3Atop%7D%2Emedia%2Dmiddle%7Bvertical%2Dalign%3Amiddle%7D%2Emedia%2Dbottom%7Bvertical%2Dalign%3Abottom%7D%2Emedia%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Emedia%2Dlist%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dgroup%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A20px%7D%2Elist%2Dgroup%2Ditem%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%3Bmargin%2Dbottom%3A%2D1px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%7D%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7Da%2Elist%2Dgroup%2Ditem%2Cbutton%2Elist%2Dgroup%2Ditem%7Bcolor%3A%23555%7Da%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3A%23333%7Da%2Elist%2Dgroup%2Ditem%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%3Ahover%7Bcolor%3A%23555%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7Dbutton%2Elist%2Dgroup%2Ditem%7Bwidth%3A100%25%3Btext%2Dalign%3Aleft%7D%2Elist%2Dgroup%2Ditem%2Edisabled%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23eee%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23777%7D%2Elist%2Dgroup%2Ditem%2Eactive%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23c7ddef%7D%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23d0e9c6%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%233c763d%3Bborder%2Dcolor%3A%233c763d%7D%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23c4e3f3%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331708f%3Bborder%2Dcolor%3A%2331708f%7D%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23faf2cc%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%238a6d3b%3Bborder%2Dcolor%3A%238a6d3b%7D%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23ebcccc%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23a94442%3Bborder%2Dcolor%3A%23a94442%7D%2Elist%2Dgroup%2Ditem%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Elist%2Dgroup%2Ditem%2Dtext%7Bmargin%2Dbottom%3A0%3Bline%2Dheight%3A1%2E3%7D%2Epanel%7Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Epanel%2Dbody%7Bpadding%3A15px%7D%2Epanel%2Dheading%7Bpadding%3A10px%2015px%3Bborder%2Dbottom%3A1px%20solid%20transparent%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%2Dheading%3E%2Edropdown%20%2Edropdown%2Dtoggle%7Bcolor%3Ainherit%7D%2Epanel%2Dtitle%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A16px%3Bcolor%3Ainherit%7D%2Epanel%2Dtitle%3E%2Esmall%2C%2Epanel%2Dtitle%3E%2Esmall%3Ea%2C%2Epanel%2Dtitle%3Ea%2C%2Epanel%2Dtitle%3Esmall%2C%2Epanel%2Dtitle%3Esmall%3Ea%7Bcolor%3Ainherit%7D%2Epanel%2Dfooter%7Bpadding%3A10px%2015px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dtop%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%7Bborder%2Dwidth%3A1px%200%3Bborder%2Dradius%3A0%7D%2Epanel%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bborder%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Epanel%2Dheading%2B%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dwidth%3A0%7D%2Elist%2Dgroup%2B%2Epanel%2Dfooter%7Bborder%2Dtop%2Dwidth%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%2C%2Epanel%3E%2Etable%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%20caption%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2C%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2Dresponsive%2C%2Epanel%3E%2Etable%2B%2Epanel%2Dbody%2C%2Epanel%3E%2Etable%2Dresponsive%2B%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%2C%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%7Bborder%2Dtop%3A0%7D%2Epanel%3E%2Etable%2Dbordered%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dresponsive%7Bmargin%2Dbottom%3A0%3Bborder%3A0%7D%2Epanel%2Dgroup%7Bmargin%2Dbottom%3A20px%7D%2Epanel%2Dgroup%20%2Epanel%7Bmargin%2Dbottom%3A0%3Bborder%2Dradius%3A4px%7D%2Epanel%2Dgroup%20%2Epanel%2B%2Epanel%7Bmargin%2Dtop%3A5px%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%7Bborder%2Dbottom%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%2C%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%7Bborder%2Dtop%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%20%2Epanel%2Dbody%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Epanel%2Ddefault%7Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f5f5f5%3Bbackground%2Dcolor%3A%23333%7D%2Epanel%2Ddefault%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ddd%7D%2Epanel%2Dprimary%7Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Epanel%2Dprimary%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23337ab7%7D%2Epanel%2Dsuccess%7Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23dff0d8%3Bbackground%2Dcolor%3A%233c763d%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dinfo%7Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23d9edf7%3Bbackground%2Dcolor%3A%2331708f%7D%2Epanel%2Dinfo%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dwarning%7Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23fcf8e3%3Bbackground%2Dcolor%3A%238a6d3b%7D%2Epanel%2Dwarning%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23faebcc%7D%2Epanel%2Ddanger%7Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f2dede%3Bbackground%2Dcolor%3A%23a94442%7D%2Epanel%2Ddanger%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ebccd1%7D%2Eembed%2Dresponsive%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bheight%3A0%3Bpadding%3A0%3Boverflow%3Ahidden%7D%2Eembed%2Dresponsive%20%2Eembed%2Dresponsive%2Ditem%2C%2Eembed%2Dresponsive%20embed%2C%2Eembed%2Dresponsive%20iframe%2C%2Eembed%2Dresponsive%20object%2C%2Eembed%2Dresponsive%20video%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A100%25%3Bheight%3A100%25%3Bborder%3A0%7D%2Eembed%2Dresponsive%2D16by9%7Bpadding%2Dbottom%3A56%2E25%25%7D%2Eembed%2Dresponsive%2D4by3%7Bpadding%2Dbottom%3A75%25%7D%2Ewell%7Bmin%2Dheight%3A20px%3Bpadding%3A19px%3Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23e3e3e3%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Ewell%20blockquote%7Bborder%2Dcolor%3A%23ddd%3Bborder%2Dcolor%3Argba%280%2C0%2C0%2C%2E15%29%7D%2Ewell%2Dlg%7Bpadding%3A24px%3Bborder%2Dradius%3A6px%7D%2Ewell%2Dsm%7Bpadding%3A9px%3Bborder%2Dradius%3A3px%7D%2Eclose%7Bfloat%3Aright%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23000%3Btext%2Dshadow%3A0%201px%200%20%23fff%3Bfilter%3Aalpha%28opacity%3D20%29%3Bopacity%3A%2E2%7D%2Eclose%3Afocus%2C%2Eclose%3Ahover%7Bcolor%3A%23000%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7Dbutton%2Eclose%7B%2Dwebkit%2Dappearance%3Anone%3Bpadding%3A0%3Bcursor%3Apointer%3Bbackground%3A0%200%3Bborder%3A0%7D%2Emodal%2Dopen%7Boverflow%3Ahidden%7D%2Emodal%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1050%3Bdisplay%3Anone%3Boverflow%3Ahidden%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Boutline%3A0%7D%2Emodal%2Efade%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E3s%20ease%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E3s%20ease%2Dout%3Btransition%3Atransform%20%2E3s%20ease%2Dout%3B%2Dwebkit%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Dms%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Do%2Dtransform%3Atranslate%280%2C%2D25%25%29%3Btransform%3Atranslate%280%2C%2D25%25%29%7D%2Emodal%2Ein%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransform%3Atranslate%280%2C0%29%3B%2Dms%2Dtransform%3Atranslate%280%2C0%29%3B%2Do%2Dtransform%3Atranslate%280%2C0%29%3Btransform%3Atranslate%280%2C0%29%7D%2Emodal%2Dopen%20%2Emodal%7Boverflow%2Dx%3Ahidden%3Boverflow%2Dy%3Aauto%7D%2Emodal%2Ddialog%7Bposition%3Arelative%3Bwidth%3Aauto%3Bmargin%3A10px%7D%2Emodal%2Dcontent%7Bposition%3Arelative%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23999%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1040%3Bbackground%2Dcolor%3A%23000%7D%2Emodal%2Dbackdrop%2Efade%7Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%7D%2Emodal%2Dbackdrop%2Ein%7Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Emodal%2Dheader%7Bmin%2Dheight%3A16%2E43px%3Bpadding%3A15px%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dheader%20%2Eclose%7Bmargin%2Dtop%3A%2D2px%7D%2Emodal%2Dtitle%7Bmargin%3A0%3Bline%2Dheight%3A1%2E42857143%7D%2Emodal%2Dbody%7Bposition%3Arelative%3Bpadding%3A15px%7D%2Emodal%2Dfooter%7Bpadding%3A15px%3Btext%2Dalign%3Aright%3Bborder%2Dtop%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dfooter%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dbottom%3A0%3Bmargin%2Dleft%3A5px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dleft%3A0%7D%2Emodal%2Dscrollbar%2Dmeasure%7Bposition%3Aabsolute%3Btop%3A%2D9999px%3Bwidth%3A50px%3Bheight%3A50px%3Boverflow%3Ascroll%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Emodal%2Ddialog%7Bwidth%3A600px%3Bmargin%3A30px%20auto%7D%2Emodal%2Dcontent%7B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dsm%7Bwidth%3A300px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Emodal%2Dlg%7Bwidth%3A900px%7D%7D%2Etooltip%7Bposition%3Aabsolute%3Bz%2Dindex%3A1070%3Bdisplay%3Ablock%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A12px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%3Bline%2Dbreak%3Aauto%7D%2Etooltip%2Ein%7Bfilter%3Aalpha%28opacity%3D90%29%3Bopacity%3A%2E9%7D%2Etooltip%2Etop%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A%2D3px%7D%2Etooltip%2Eright%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A3px%7D%2Etooltip%2Ebottom%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A3px%7D%2Etooltip%2Eleft%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A%2D3px%7D%2Etooltip%2Dinner%7Bmax%2Dwidth%3A200px%3Bpadding%3A3px%208px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23000%3Bborder%2Dradius%3A4px%7D%2Etooltip%2Darrow%7Bposition%3Aabsolute%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Etooltip%2Etop%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dleft%20%2Etooltip%2Darrow%7Bright%3A5px%3Bbottom%3A0%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dright%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A5px%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Eright%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bleft%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%205px%200%3Bborder%2Dright%2Dcolor%3A%23000%7D%2Etooltip%2Eleft%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bright%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%200%205px%205px%3Bborder%2Dleft%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dleft%20%2Etooltip%2Darrow%7Btop%3A0%3Bright%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dright%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Epopover%7Bposition%3Aabsolute%3Btop%3A0%3Bleft%3A0%3Bz%2Dindex%3A1060%3Bdisplay%3Anone%3Bmax%2Dwidth%3A276px%3Bpadding%3A1px%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bline%2Dbreak%3Aauto%7D%2Epopover%2Etop%7Bmargin%2Dtop%3A%2D10px%7D%2Epopover%2Eright%7Bmargin%2Dleft%3A10px%7D%2Epopover%2Ebottom%7Bmargin%2Dtop%3A10px%7D%2Epopover%2Eleft%7Bmargin%2Dleft%3A%2D10px%7D%2Epopover%2Dtitle%7Bpadding%3A8px%2014px%3Bmargin%3A0%3Bfont%2Dsize%3A14px%3Bbackground%2Dcolor%3A%23f7f7f7%3Bborder%2Dbottom%3A1px%20solid%20%23ebebeb%3Bborder%2Dradius%3A5px%205px%200%200%7D%2Epopover%2Dcontent%7Bpadding%3A9px%2014px%7D%2Epopover%3E%2Earrow%2C%2Epopover%3E%2Earrow%3Aafter%7Bposition%3Aabsolute%3Bdisplay%3Ablock%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Epopover%3E%2Earrow%7Bborder%2Dwidth%3A11px%7D%2Epopover%3E%2Earrow%3Aafter%7Bcontent%3A%22%22%3Bborder%2Dwidth%3A10px%7D%2Epopover%2Etop%3E%2Earrow%7Bbottom%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dcolor%3A%23999%3Bborder%2Dtop%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Etop%3E%2Earrow%3Aafter%7Bbottom%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dcolor%3A%23fff%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%7Btop%3A50%25%3Bleft%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dcolor%3A%23999%3Bborder%2Dright%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%3Aafter%7Bbottom%3A%2D10px%3Bleft%3A1px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dcolor%3A%23fff%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Ebottom%3E%2Earrow%7Btop%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23999%3Bborder%2Dbottom%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Ebottom%3E%2Earrow%3Aafter%7Btop%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23fff%7D%2Epopover%2Eleft%3E%2Earrow%7Btop%3A50%25%3Bright%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23999%3Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Eleft%3E%2Earrow%3Aafter%7Bright%3A1px%3Bbottom%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23fff%7D%2Ecarousel%7Bposition%3Arelative%7D%2Ecarousel%2Dinner%7Bposition%3Arelative%3Bwidth%3A100%25%3Boverflow%3Ahidden%7D%2Ecarousel%2Dinner%3E%2Eitem%7Bposition%3Arelative%3Bdisplay%3Anone%3B%2Dwebkit%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3B%2Do%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3Btransition%3A%2E6s%20ease%2Din%2Dout%20left%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%7Bline%2Dheight%3A1%7D%40media%20all%20and%20%28transform%2D3d%29%2C%28%2Dwebkit%2Dtransform%2D3d%29%7B%2Ecarousel%2Dinner%3E%2Eitem%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E6s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E6s%20ease%2Din%2Dout%3Btransition%3Atransform%20%2E6s%20ease%2Din%2Dout%3B%2Dwebkit%2Dbackface%2Dvisibility%3Ahidden%3Bbackface%2Dvisibility%3Ahidden%3B%2Dwebkit%2Dperspective%3A1000px%3Bperspective%3A1000px%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eright%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%2Eright%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%280%2C0%2C0%29%3Btransform%3Atranslate3d%280%2C0%2C0%29%7D%7D%2Ecarousel%2Dinner%3E%2Eactive%2C%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bdisplay%3Ablock%7D%2Ecarousel%2Dinner%3E%2Eactive%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bposition%3Aabsolute%3Btop%3A0%3Bwidth%3A100%25%7D%2Ecarousel%2Dinner%3E%2Enext%7Bleft%3A100%25%7D%2Ecarousel%2Dinner%3E%2Eprev%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eprev%2Eright%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eleft%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eright%7Bleft%3A100%25%7D%2Ecarousel%2Dcontrol%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A15%25%3Bfont%2Dsize%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Ecarousel%2Dcontrol%2Eleft%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E5%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E0001%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2380000000%27%2C%20endColorstr%3D%27%2300000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%2Eright%7Bright%3A0%3Bleft%3Aauto%3Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E0001%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E5%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2300000000%27%2C%20endColorstr%3D%27%2380000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%3Afocus%2C%2Ecarousel%2Dcontrol%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bfilter%3Aalpha%28opacity%3D90%29%3Boutline%3A0%3Bopacity%3A%2E9%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bposition%3Aabsolute%3Btop%3A50%25%3Bz%2Dindex%3A5%3Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bleft%3A50%25%3Bmargin%2Dleft%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bright%3A50%25%3Bmargin%2Dright%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A20px%3Bheight%3A20px%3Bfont%2Dfamily%3Aserif%3Bline%2Dheight%3A1%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%3Abefore%7Bcontent%3A%27%5C2039%27%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%3Abefore%7Bcontent%3A%27%5C203a%27%7D%2Ecarousel%2Dindicators%7Bposition%3Aabsolute%3Bbottom%3A10px%3Bleft%3A50%25%3Bz%2Dindex%3A15%3Bwidth%3A60%25%3Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D30%25%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Ecarousel%2Dindicators%20li%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A10px%3Bheight%3A10px%3Bmargin%3A1px%3Btext%2Dindent%3A%2D999px%3Bcursor%3Apointer%3Bbackground%2Dcolor%3A%23000%5C9%3Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C0%29%3Bborder%3A1px%20solid%20%23fff%3Bborder%2Dradius%3A10px%7D%2Ecarousel%2Dindicators%20%2Eactive%7Bwidth%3A12px%3Bheight%3A12px%3Bmargin%3A0%3Bbackground%2Dcolor%3A%23fff%7D%2Ecarousel%2Dcaption%7Bposition%3Aabsolute%3Bright%3A15%25%3Bbottom%3A20px%3Bleft%3A15%25%3Bz%2Dindex%3A10%3Bpadding%2Dtop%3A20px%3Bpadding%2Dbottom%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%7D%2Ecarousel%2Dcaption%20%2Ebtn%7Btext%2Dshadow%3Anone%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A30px%3Bheight%3A30px%3Bmargin%2Dtop%3A%2D15px%3Bfont%2Dsize%3A30px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bmargin%2Dleft%3A%2D15px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bmargin%2Dright%3A%2D15px%7D%2Ecarousel%2Dcaption%7Bright%3A20%25%3Bleft%3A20%25%3Bpadding%2Dbottom%3A30px%7D%2Ecarousel%2Dindicators%7Bbottom%3A20px%7D%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Abefore%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Ebtn%2Dtoolbar%3Abefore%2C%2Eclearfix%3Aafter%2C%2Eclearfix%3Abefore%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%2Dfluid%3Abefore%2C%2Econtainer%3Aafter%2C%2Econtainer%3Abefore%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Abefore%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Abefore%2C%2Emodal%2Dfooter%3Aafter%2C%2Emodal%2Dfooter%3Abefore%2C%2Enav%3Aafter%2C%2Enav%3Abefore%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dcollapse%3Abefore%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%2Dheader%3Abefore%2C%2Enavbar%3Aafter%2C%2Enavbar%3Abefore%2C%2Epager%3Aafter%2C%2Epager%3Abefore%2C%2Epanel%2Dbody%3Aafter%2C%2Epanel%2Dbody%3Abefore%2C%2Erow%3Aafter%2C%2Erow%3Abefore%7Bdisplay%3Atable%3Bcontent%3A%22%20%22%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Eclearfix%3Aafter%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Emodal%2Dfooter%3Aafter%2C%2Enav%3Aafter%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%3Aafter%2C%2Epager%3Aafter%2C%2Epanel%2Dbody%3Aafter%2C%2Erow%3Aafter%7Bclear%3Aboth%7D%2Ecenter%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Epull%2Dright%7Bfloat%3Aright%21important%7D%2Epull%2Dleft%7Bfloat%3Aleft%21important%7D%2Ehide%7Bdisplay%3Anone%21important%7D%2Eshow%7Bdisplay%3Ablock%21important%7D%2Einvisible%7Bvisibility%3Ahidden%7D%2Etext%2Dhide%7Bfont%3A0%2F0%20a%3Bcolor%3Atransparent%3Btext%2Dshadow%3Anone%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%7D%2Ehidden%7Bdisplay%3Anone%21important%7D%2Eaffix%7Bposition%3Afixed%7D%40%2Dms%2Dviewport%7Bwidth%3Adevice%2Dwidth%7D%2Evisible%2Dlg%2C%2Evisible%2Dmd%2C%2Evisible%2Dsm%2C%2Evisible%2Dxs%7Bdisplay%3Anone%21important%7D%2Evisible%2Dlg%2Dblock%2C%2Evisible%2Dlg%2Dinline%2C%2Evisible%2Dlg%2Dinline%2Dblock%2C%2Evisible%2Dmd%2Dblock%2C%2Evisible%2Dmd%2Dinline%2C%2Evisible%2Dmd%2Dinline%2Dblock%2C%2Evisible%2Dsm%2Dblock%2C%2Evisible%2Dsm%2Dinline%2C%2Evisible%2Dsm%2Dinline%2Dblock%2C%2Evisible%2Dxs%2Dblock%2C%2Evisible%2Dxs%2Dinline%2C%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dxs%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dxs%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dxs%2Cth%2Evisible%2Dxs%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dsm%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dsm%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dsm%2Cth%2Evisible%2Dsm%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dmd%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dmd%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dmd%2Cth%2Evisible%2Dmd%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dlg%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dlg%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dlg%2Cth%2Evisible%2Dlg%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Ehidden%2Dxs%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Ehidden%2Dsm%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Ehidden%2Dmd%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ehidden%2Dlg%7Bdisplay%3Anone%21important%7D%7D%2Evisible%2Dprint%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dprint%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dprint%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dprint%2Cth%2Evisible%2Dprint%7Bdisplay%3Atable%2Dcell%21important%7D%7D%2Evisible%2Dprint%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%2Evisible%2Dprint%2Dinline%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20print%7B%2Ehidden%2Dprint%7Bdisplay%3Anone%21important%7D%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);"></script>
<script src="data:application/javascript;base64,LyoqCiogQHByZXNlcnZlIEhUTUw1IFNoaXYgMy43LjIgfCBAYWZhcmthcyBAamRhbHRvbiBAam9uX25lYWwgQHJlbSB8IE1JVC9HUEwyIExpY2Vuc2VkCiovCi8vIE9ubHkgcnVuIHRoaXMgY29kZSBpbiBJRSA4CmlmICghIXdpbmRvdy5uYXZpZ2F0b3IudXNlckFnZW50Lm1hdGNoKCJNU0lFIDgiKSkgewohZnVuY3Rpb24oYSxiKXtmdW5jdGlvbiBjKGEsYil7dmFyIGM9YS5jcmVhdGVFbGVtZW50KCJwIiksZD1hLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJoZWFkIilbMF18fGEuZG9jdW1lbnRFbGVtZW50O3JldHVybiBjLmlubmVySFRNTD0ieDxzdHlsZT4iK2IrIjwvc3R5bGU+IixkLmluc2VydEJlZm9yZShjLmxhc3RDaGlsZCxkLmZpcnN0Q2hpbGQpfWZ1bmN0aW9uIGQoKXt2YXIgYT10LmVsZW1lbnRzO3JldHVybiJzdHJpbmciPT10eXBlb2YgYT9hLnNwbGl0KCIgIik6YX1mdW5jdGlvbiBlKGEsYil7dmFyIGM9dC5lbGVtZW50czsic3RyaW5nIiE9dHlwZW9mIGMmJihjPWMuam9pbigiICIpKSwic3RyaW5nIiE9dHlwZW9mIGEmJihhPWEuam9pbigiICIpKSx0LmVsZW1lbnRzPWMrIiAiK2EsaihiKX1mdW5jdGlvbiBmKGEpe3ZhciBiPXNbYVtxXV07cmV0dXJuIGJ8fChiPXt9LHIrKyxhW3FdPXIsc1tyXT1iKSxifWZ1bmN0aW9uIGcoYSxjLGQpe2lmKGN8fChjPWIpLGwpcmV0dXJuIGMuY3JlYXRlRWxlbWVudChhKTtkfHwoZD1mKGMpKTt2YXIgZTtyZXR1cm4gZT1kLmNhY2hlW2FdP2QuY2FjaGVbYV0uY2xvbmVOb2RlKCk6cC50ZXN0KGEpPyhkLmNhY2hlW2FdPWQuY3JlYXRlRWxlbShhKSkuY2xvbmVOb2RlKCk6ZC5jcmVhdGVFbGVtKGEpLCFlLmNhbkhhdmVDaGlsZHJlbnx8by50ZXN0KGEpfHxlLnRhZ1Vybj9lOmQuZnJhZy5hcHBlbmRDaGlsZChlKX1mdW5jdGlvbiBoKGEsYyl7aWYoYXx8KGE9YiksbClyZXR1cm4gYS5jcmVhdGVEb2N1bWVudEZyYWdtZW50KCk7Yz1jfHxmKGEpO2Zvcih2YXIgZT1jLmZyYWcuY2xvbmVOb2RlKCksZz0wLGg9ZCgpLGk9aC5sZW5ndGg7aT5nO2crKyllLmNyZWF0ZUVsZW1lbnQoaFtnXSk7cmV0dXJuIGV9ZnVuY3Rpb24gaShhLGIpe2IuY2FjaGV8fChiLmNhY2hlPXt9LGIuY3JlYXRlRWxlbT1hLmNyZWF0ZUVsZW1lbnQsYi5jcmVhdGVGcmFnPWEuY3JlYXRlRG9jdW1lbnRGcmFnbWVudCxiLmZyYWc9Yi5jcmVhdGVGcmFnKCkpLGEuY3JlYXRlRWxlbWVudD1mdW5jdGlvbihjKXtyZXR1cm4gdC5zaGl2TWV0aG9kcz9nKGMsYSxiKTpiLmNyZWF0ZUVsZW0oYyl9LGEuY3JlYXRlRG9jdW1lbnRGcmFnbWVudD1GdW5jdGlvbigiaCxmIiwicmV0dXJuIGZ1bmN0aW9uKCl7dmFyIG49Zi5jbG9uZU5vZGUoKSxjPW4uY3JlYXRlRWxlbWVudDtoLnNoaXZNZXRob2RzJiYoIitkKCkuam9pbigpLnJlcGxhY2UoL1tcd1wtOl0rL2csZnVuY3Rpb24oYSl7cmV0dXJuIGIuY3JlYXRlRWxlbShhKSxiLmZyYWcuY3JlYXRlRWxlbWVudChhKSwnYygiJythKyciKSd9KSsiKTtyZXR1cm4gbn0iKSh0LGIuZnJhZyl9ZnVuY3Rpb24gaihhKXthfHwoYT1iKTt2YXIgZD1mKGEpO3JldHVybiF0LnNoaXZDU1N8fGt8fGQuaGFzQ1NTfHwoZC5oYXNDU1M9ISFjKGEsImFydGljbGUsYXNpZGUsZGlhbG9nLGZpZ2NhcHRpb24sZmlndXJlLGZvb3RlcixoZWFkZXIsaGdyb3VwLG1haW4sbmF2LHNlY3Rpb257ZGlzcGxheTpibG9ja31tYXJre2JhY2tncm91bmQ6I0ZGMDtjb2xvcjojMDAwfXRlbXBsYXRle2Rpc3BsYXk6bm9uZX0iKSksbHx8aShhLGQpLGF9dmFyIGssbCxtPSIzLjcuMiIsbj1hLmh0bWw1fHx7fSxvPS9ePHxeKD86YnV0dG9ufG1hcHxzZWxlY3R8dGV4dGFyZWF8b2JqZWN0fGlmcmFtZXxvcHRpb258b3B0Z3JvdXApJC9pLHA9L14oPzphfGJ8Y29kZXxkaXZ8ZmllbGRzZXR8aDF8aDJ8aDN8aDR8aDV8aDZ8aXxsYWJlbHxsaXxvbHxwfHF8c3BhbnxzdHJvbmd8c3R5bGV8dGFibGV8dGJvZHl8dGR8dGh8dHJ8dWwpJC9pLHE9Il9odG1sNXNoaXYiLHI9MCxzPXt9OyFmdW5jdGlvbigpe3RyeXt2YXIgYT1iLmNyZWF0ZUVsZW1lbnQoImEiKTthLmlubmVySFRNTD0iPHh5ej48L3h5ej4iLGs9ImhpZGRlbiJpbiBhLGw9MT09YS5jaGlsZE5vZGVzLmxlbmd0aHx8ZnVuY3Rpb24oKXtiLmNyZWF0ZUVsZW1lbnQoImEiKTt2YXIgYT1iLmNyZWF0ZURvY3VtZW50RnJhZ21lbnQoKTtyZXR1cm4idW5kZWZpbmVkIj09dHlwZW9mIGEuY2xvbmVOb2RlfHwidW5kZWZpbmVkIj09dHlwZW9mIGEuY3JlYXRlRG9jdW1lbnRGcmFnbWVudHx8InVuZGVmaW5lZCI9PXR5cGVvZiBhLmNyZWF0ZUVsZW1lbnR9KCl9Y2F0Y2goYyl7az0hMCxsPSEwfX0oKTt2YXIgdD17ZWxlbWVudHM6bi5lbGVtZW50c3x8ImFiYnIgYXJ0aWNsZSBhc2lkZSBhdWRpbyBiZGkgY2FudmFzIGRhdGEgZGF0YWxpc3QgZGV0YWlscyBkaWFsb2cgZmlnY2FwdGlvbiBmaWd1cmUgZm9vdGVyIGhlYWRlciBoZ3JvdXAgbWFpbiBtYXJrIG1ldGVyIG5hdiBvdXRwdXQgcGljdHVyZSBwcm9ncmVzcyBzZWN0aW9uIHN1bW1hcnkgdGVtcGxhdGUgdGltZSB2aWRlbyIsdmVyc2lvbjptLHNoaXZDU1M6bi5zaGl2Q1NTIT09ITEsc3VwcG9ydHNVbmtub3duRWxlbWVudHM6bCxzaGl2TWV0aG9kczpuLnNoaXZNZXRob2RzIT09ITEsdHlwZToiZGVmYXVsdCIsc2hpdkRvY3VtZW50OmosY3JlYXRlRWxlbWVudDpnLGNyZWF0ZURvY3VtZW50RnJhZ21lbnQ6aCxhZGRFbGVtZW50czplfTthLmh0bWw1PXQsaihiKX0odGhpcyxkb2N1bWVudCk7Cn07Cg=="></script>
<script src="data:application/javascript;base64,LyohIFJlc3BvbmQuanMgdjEuNC4yOiBtaW4vbWF4LXdpZHRoIG1lZGlhIHF1ZXJ5IHBvbHlmaWxsICogQ29weXJpZ2h0IDIwMTMgU2NvdHQgSmVobAogKiBMaWNlbnNlZCB1bmRlciBodHRwczovL2dpdGh1Yi5jb20vc2NvdHRqZWhsL1Jlc3BvbmQvYmxvYi9tYXN0ZXIvTElDRU5TRS1NSVQKICogICovCgovLyBPbmx5IHJ1biB0aGlzIGNvZGUgaW4gSUUgOAppZiAoISF3aW5kb3cubmF2aWdhdG9yLnVzZXJBZ2VudC5tYXRjaCgiTVNJRSA4IikpIHsKIWZ1bmN0aW9uKGEpeyJ1c2Ugc3RyaWN0IjthLm1hdGNoTWVkaWE9YS5tYXRjaE1lZGlhfHxmdW5jdGlvbihhKXt2YXIgYixjPWEuZG9jdW1lbnRFbGVtZW50LGQ9Yy5maXJzdEVsZW1lbnRDaGlsZHx8Yy5maXJzdENoaWxkLGU9YS5jcmVhdGVFbGVtZW50KCJib2R5IiksZj1hLmNyZWF0ZUVsZW1lbnQoImRpdiIpO3JldHVybiBmLmlkPSJtcS10ZXN0LTEiLGYuc3R5bGUuY3NzVGV4dD0icG9zaXRpb246YWJzb2x1dGU7dG9wOi0xMDBlbSIsZS5zdHlsZS5iYWNrZ3JvdW5kPSJub25lIixlLmFwcGVuZENoaWxkKGYpLGZ1bmN0aW9uKGEpe3JldHVybiBmLmlubmVySFRNTD0nJnNoeTs8c3R5bGUgbWVkaWE9IicrYSsnIj4gI21xLXRlc3QtMSB7IHdpZHRoOiA0MnB4OyB9PC9zdHlsZT4nLGMuaW5zZXJ0QmVmb3JlKGUsZCksYj00Mj09PWYub2Zmc2V0V2lkdGgsYy5yZW1vdmVDaGlsZChlKSx7bWF0Y2hlczpiLG1lZGlhOmF9fX0oYS5kb2N1bWVudCl9KHRoaXMpLGZ1bmN0aW9uKGEpeyJ1c2Ugc3RyaWN0IjtmdW5jdGlvbiBiKCl7dSghMCl9dmFyIGM9e307YS5yZXNwb25kPWMsYy51cGRhdGU9ZnVuY3Rpb24oKXt9O3ZhciBkPVtdLGU9ZnVuY3Rpb24oKXt2YXIgYj0hMTt0cnl7Yj1uZXcgYS5YTUxIdHRwUmVxdWVzdH1jYXRjaChjKXtiPW5ldyBhLkFjdGl2ZVhPYmplY3QoIk1pY3Jvc29mdC5YTUxIVFRQIil9cmV0dXJuIGZ1bmN0aW9uKCl7cmV0dXJuIGJ9fSgpLGY9ZnVuY3Rpb24oYSxiKXt2YXIgYz1lKCk7YyYmKGMub3BlbigiR0VUIixhLCEwKSxjLm9ucmVhZHlzdGF0ZWNoYW5nZT1mdW5jdGlvbigpezQhPT1jLnJlYWR5U3RhdGV8fDIwMCE9PWMuc3RhdHVzJiYzMDQhPT1jLnN0YXR1c3x8YihjLnJlc3BvbnNlVGV4dCl9LDQhPT1jLnJlYWR5U3RhdGUmJmMuc2VuZChudWxsKSl9O2lmKGMuYWpheD1mLGMucXVldWU9ZCxjLnJlZ2V4PXttZWRpYTovQG1lZGlhW15ce10rXHsoW15ce1x9XSpce1teXH1ce10qXH0pKy9naSxrZXlmcmFtZXM6L0AoPzpcLSg/Om98bW96fHdlYmtpdClcLSk/a2V5ZnJhbWVzW15ce10rXHsoPzpbXlx7XH1dKlx7W15cfVx7XSpcfSkrW15cfV0qXH0vZ2ksdXJsczovKHVybFwoKVsnIl0/KFteXC9cKSciXVteOlwpJyJdKylbJyJdPyhcKSkvZyxmaW5kU3R5bGVzOi9AbWVkaWEgKihbXlx7XSspXHsoW1xTXHNdKz8pJC8sb25seTovKG9ubHlccyspPyhbYS16QS1aXSspXHM/LyxtaW53Oi9cKFtcc10qbWluXC13aWR0aFxzKjpbXHNdKihbXHNdKlswLTlcLl0rKShweHxlbSlbXHNdKlwpLyxtYXh3Oi9cKFtcc10qbWF4XC13aWR0aFxzKjpbXHNdKihbXHNdKlswLTlcLl0rKShweHxlbSlbXHNdKlwpL30sYy5tZWRpYVF1ZXJpZXNTdXBwb3J0ZWQ9YS5tYXRjaE1lZGlhJiZudWxsIT09YS5tYXRjaE1lZGlhKCJvbmx5IGFsbCIpJiZhLm1hdGNoTWVkaWEoIm9ubHkgYWxsIikubWF0Y2hlcywhYy5tZWRpYVF1ZXJpZXNTdXBwb3J0ZWQpe3ZhciBnLGgsaSxqPWEuZG9jdW1lbnQsaz1qLmRvY3VtZW50RWxlbWVudCxsPVtdLG09W10sbj1bXSxvPXt9LHA9MzAscT1qLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJoZWFkIilbMF18fGsscj1qLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJiYXNlIilbMF0scz1xLmdldEVsZW1lbnRzQnlUYWdOYW1lKCJsaW5rIiksdD1mdW5jdGlvbigpe3ZhciBhLGI9ai5jcmVhdGVFbGVtZW50KCJkaXYiKSxjPWouYm9keSxkPWsuc3R5bGUuZm9udFNpemUsZT1jJiZjLnN0eWxlLmZvbnRTaXplLGY9ITE7cmV0dXJuIGIuc3R5bGUuY3NzVGV4dD0icG9zaXRpb246YWJzb2x1dGU7Zm9udC1zaXplOjFlbTt3aWR0aDoxZW0iLGN8fChjPWY9ai5jcmVhdGVFbGVtZW50KCJib2R5IiksYy5zdHlsZS5iYWNrZ3JvdW5kPSJub25lIiksay5zdHlsZS5mb250U2l6ZT0iMTAwJSIsYy5zdHlsZS5mb250U2l6ZT0iMTAwJSIsYy5hcHBlbmRDaGlsZChiKSxmJiZrLmluc2VydEJlZm9yZShjLGsuZmlyc3RDaGlsZCksYT1iLm9mZnNldFdpZHRoLGY/ay5yZW1vdmVDaGlsZChjKTpjLnJlbW92ZUNoaWxkKGIpLGsuc3R5bGUuZm9udFNpemU9ZCxlJiYoYy5zdHlsZS5mb250U2l6ZT1lKSxhPWk9cGFyc2VGbG9hdChhKX0sdT1mdW5jdGlvbihiKXt2YXIgYz0iY2xpZW50V2lkdGgiLGQ9a1tjXSxlPSJDU1MxQ29tcGF0Ij09PWouY29tcGF0TW9kZSYmZHx8ai5ib2R5W2NdfHxkLGY9e30sbz1zW3MubGVuZ3RoLTFdLHI9KG5ldyBEYXRlKS5nZXRUaW1lKCk7aWYoYiYmZyYmcD5yLWcpcmV0dXJuIGEuY2xlYXJUaW1lb3V0KGgpLGg9YS5zZXRUaW1lb3V0KHUscCksdm9pZCAwO2c9cjtmb3IodmFyIHYgaW4gbClpZihsLmhhc093blByb3BlcnR5KHYpKXt2YXIgdz1sW3ZdLHg9dy5taW53LHk9dy5tYXh3LHo9bnVsbD09PXgsQT1udWxsPT09eSxCPSJlbSI7eCYmKHg9cGFyc2VGbG9hdCh4KSooeC5pbmRleE9mKEIpPi0xP2l8fHQoKToxKSkseSYmKHk9cGFyc2VGbG9hdCh5KSooeS5pbmRleE9mKEIpPi0xP2l8fHQoKToxKSksdy5oYXNxdWVyeSYmKHomJkF8fCEoenx8ZT49eCl8fCEoQXx8eT49ZSkpfHwoZlt3Lm1lZGlhXXx8KGZbdy5tZWRpYV09W10pLGZbdy5tZWRpYV0ucHVzaChtW3cucnVsZXNdKSl9Zm9yKHZhciBDIGluIG4pbi5oYXNPd25Qcm9wZXJ0eShDKSYmbltDXSYmbltDXS5wYXJlbnROb2RlPT09cSYmcS5yZW1vdmVDaGlsZChuW0NdKTtuLmxlbmd0aD0wO2Zvcih2YXIgRCBpbiBmKWlmKGYuaGFzT3duUHJvcGVydHkoRCkpe3ZhciBFPWouY3JlYXRlRWxlbWVudCgic3R5bGUiKSxGPWZbRF0uam9pbigiXG4iKTtFLnR5cGU9InRleHQvY3NzIixFLm1lZGlhPUQscS5pbnNlcnRCZWZvcmUoRSxvLm5leHRTaWJsaW5nKSxFLnN0eWxlU2hlZXQ/RS5zdHlsZVNoZWV0LmNzc1RleHQ9RjpFLmFwcGVuZENoaWxkKGouY3JlYXRlVGV4dE5vZGUoRikpLG4ucHVzaChFKX19LHY9ZnVuY3Rpb24oYSxiLGQpe3ZhciBlPWEucmVwbGFjZShjLnJlZ2V4LmtleWZyYW1lcywiIikubWF0Y2goYy5yZWdleC5tZWRpYSksZj1lJiZlLmxlbmd0aHx8MDtiPWIuc3Vic3RyaW5nKDAsYi5sYXN0SW5kZXhPZigiLyIpKTt2YXIgZz1mdW5jdGlvbihhKXtyZXR1cm4gYS5yZXBsYWNlKGMucmVnZXgudXJscywiJDEiK2IrIiQyJDMiKX0saD0hZiYmZDtiLmxlbmd0aCYmKGIrPSIvIiksaCYmKGY9MSk7Zm9yKHZhciBpPTA7Zj5pO2krKyl7dmFyIGosayxuLG87aD8oaj1kLG0ucHVzaChnKGEpKSk6KGo9ZVtpXS5tYXRjaChjLnJlZ2V4LmZpbmRTdHlsZXMpJiZSZWdFeHAuJDEsbS5wdXNoKFJlZ0V4cC4kMiYmZyhSZWdFeHAuJDIpKSksbj1qLnNwbGl0KCIsIiksbz1uLmxlbmd0aDtmb3IodmFyIHA9MDtvPnA7cCsrKWs9bltwXSxsLnB1c2goe21lZGlhOmsuc3BsaXQoIigiKVswXS5tYXRjaChjLnJlZ2V4Lm9ubHkpJiZSZWdFeHAuJDJ8fCJhbGwiLHJ1bGVzOm0ubGVuZ3RoLTEsaGFzcXVlcnk6ay5pbmRleE9mKCIoIik+LTEsbWludzprLm1hdGNoKGMucmVnZXgubWludykmJnBhcnNlRmxvYXQoUmVnRXhwLiQxKSsoUmVnRXhwLiQyfHwiIiksbWF4dzprLm1hdGNoKGMucmVnZXgubWF4dykmJnBhcnNlRmxvYXQoUmVnRXhwLiQxKSsoUmVnRXhwLiQyfHwiIil9KX11KCl9LHc9ZnVuY3Rpb24oKXtpZihkLmxlbmd0aCl7dmFyIGI9ZC5zaGlmdCgpO2YoYi5ocmVmLGZ1bmN0aW9uKGMpe3YoYyxiLmhyZWYsYi5tZWRpYSksb1tiLmhyZWZdPSEwLGEuc2V0VGltZW91dChmdW5jdGlvbigpe3coKX0sMCl9KX19LHg9ZnVuY3Rpb24oKXtmb3IodmFyIGI9MDtiPHMubGVuZ3RoO2IrKyl7dmFyIGM9c1tiXSxlPWMuaHJlZixmPWMubWVkaWEsZz1jLnJlbCYmInN0eWxlc2hlZXQiPT09Yy5yZWwudG9Mb3dlckNhc2UoKTtlJiZnJiYhb1tlXSYmKGMuc3R5bGVTaGVldCYmYy5zdHlsZVNoZWV0LnJhd0Nzc1RleHQ/KHYoYy5zdHlsZVNoZWV0LnJhd0Nzc1RleHQsZSxmKSxvW2VdPSEwKTooIS9eKFthLXpBLVo6XSpcL1wvKS8udGVzdChlKSYmIXJ8fGUucmVwbGFjZShSZWdFeHAuJDEsIiIpLnNwbGl0KCIvIilbMF09PT1hLmxvY2F0aW9uLmhvc3QpJiYoIi8vIj09PWUuc3Vic3RyaW5nKDAsMikmJihlPWEubG9jYXRpb24ucHJvdG9jb2wrZSksZC5wdXNoKHtocmVmOmUsbWVkaWE6Zn0pKSl9dygpfTt4KCksYy51cGRhdGU9eCxjLmdldEVtVmFsdWU9dCxhLmFkZEV2ZW50TGlzdGVuZXI/YS5hZGRFdmVudExpc3RlbmVyKCJyZXNpemUiLGIsITEpOmEuYXR0YWNoRXZlbnQmJmEuYXR0YWNoRXZlbnQoIm9ucmVzaXplIixiKX19KHRoaXMpOwp9Owo="></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<link href="data:text/css,%2Epagedtable%20%7B%0Aoverflow%3A%20auto%3B%0Apadding%2Dleft%3A%208px%3B%0Apadding%2Dright%3A%208px%3B%0A%7D%0A%2Epagedtable%2Dwrapper%20%7B%0Aborder%3A%201px%20solid%20%23ccc%3B%0Aborder%2Dradius%3A%204px%3B%0Amargin%2Dbottom%3A%2010px%3B%0A%7D%0A%2Epagedtable%20table%20%7B%0Awidth%3A%20100%25%3B%0Amax%2Dwidth%3A%20100%25%3B%0Amargin%3A%200%3B%0A%7D%0A%2Epagedtable%20th%20%7B%0Apadding%3A%200%205px%200%205px%3B%0Aborder%3A%20none%3B%0Aborder%2Dbottom%3A%202px%20solid%20%23dddddd%3B%0Amin%2Dwidth%3A%2045px%3B%0A%7D%0A%2Epagedtable%2Dempty%20th%20%7B%0Adisplay%3A%20none%3B%0A%7D%0A%2Epagedtable%20td%20%7B%0Apadding%3A%200%204px%200%204px%3B%0A%7D%0A%2Epagedtable%20%2Eeven%20%7B%0Abackground%2Dcolor%3A%20rgba%28140%2C%20140%2C%20140%2C%200%2E1%29%3B%0A%7D%0A%2Epagedtable%2Dpadding%2Dcol%20%7B%0Adisplay%3A%20none%3B%0A%7D%0A%2Epagedtable%20a%20%7B%0A%2Dwebkit%2Dtouch%2Dcallout%3A%20none%3B%0A%2Dwebkit%2Duser%2Dselect%3A%20none%3B%0A%2Dkhtml%2Duser%2Dselect%3A%20none%3B%0A%2Dmoz%2Duser%2Dselect%3A%20none%3B%0A%2Dms%2Duser%2Dselect%3A%20none%3B%0Auser%2Dselect%3A%20none%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dnav%20%7B%0Acursor%3A%20pointer%3B%0Apadding%3A%200%205px%200%205px%3B%0Afloat%3A%20right%3B%0Aborder%3A%200%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dnav%2Ddisabled%20%7B%0Acursor%3A%20default%3B%0Atext%2Ddecoration%3A%20none%3B%0Acolor%3A%20%23999%3B%0A%7D%0Aa%2Epagedtable%2Dindex%2Dnav%2Ddisabled%3Ahover%20%7B%0Atext%2Ddecoration%3A%20none%3B%0Acolor%3A%20%23999%3B%0A%7D%0A%2Epagedtable%2Dindexes%20%7B%0Acursor%3A%20pointer%3B%0Afloat%3A%20right%3B%0Aborder%3A%200%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dcurrent%20%7B%0Acursor%3A%20default%3B%0Atext%2Ddecoration%3A%20none%3B%0Afont%2Dweight%3A%20bold%3B%0Acolor%3A%20%23333%3B%0Aborder%3A%200%3B%0A%7D%0Aa%2Epagedtable%2Dindex%2Dcurrent%3Ahover%20%7B%0Atext%2Ddecoration%3A%20none%3B%0Afont%2Dweight%3A%20bold%3B%0Acolor%3A%20%23333%3B%0A%7D%0A%2Epagedtable%2Dindex%20%7B%0Awidth%3A%2030px%3B%0Adisplay%3A%20inline%2Dblock%3B%0Atext%2Dalign%3A%20center%3B%0Aborder%3A%200%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dseparator%2Dleft%20%7B%0Adisplay%3A%20inline%2Dblock%3B%0Acolor%3A%20%23333%3B%0Afont%2Dsize%3A%209px%3B%0Apadding%3A%200%200%200%200%3B%0Acursor%3A%20default%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dseparator%2Dright%20%7B%0Adisplay%3A%20inline%2Dblock%3B%0Acolor%3A%20%23333%3B%0Afont%2Dsize%3A%209px%3B%0Apadding%3A%200%204px%200%200%3B%0Acursor%3A%20default%3B%0A%7D%0A%2Epagedtable%2Dfooter%20%7B%0Apadding%2Dtop%3A%204px%3B%0Apadding%2Dbottom%3A%205px%3B%0A%7D%0A%2Epagedtable%2Dnot%2Dempty%20%2Epagedtable%2Dfooter%20%7B%0Aborder%2Dtop%3A%202px%20solid%20%23dddddd%3B%0A%7D%0A%2Epagedtable%2Dinfo%20%7B%0Aoverflow%3A%20hidden%3B%0Acolor%3A%20%23999%3B%0Awhite%2Dspace%3A%20nowrap%3B%0Atext%2Doverflow%3A%20ellipsis%3B%0A%7D%0A%2Epagedtable%2Dheader%2Dname%20%7B%0Aoverflow%3A%20hidden%3B%0Atext%2Doverflow%3A%20ellipsis%3B%0A%7D%0A%2Epagedtable%2Dheader%2Dtype%20%7B%0Acolor%3A%20%23999%3B%0Afont%2Dweight%3A%20400%3B%0A%7D%0A%2Epagedtable%2Dna%2Dcell%20%7B%0Afont%2Dstyle%3A%20italic%3B%0Aopacity%3A%200%2E3%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
"></script>
<script src="data:application/javascript;base64,/*! jQuery UI - v1.11.4 - 2016-01-05
* http://jqueryui.com
* Includes: core.js, widget.js, mouse.js, position.js, draggable.js, droppable.js, resizable.js, selectable.js, sortable.js, accordion.js, autocomplete.js, button.js, dialog.js, menu.js, progressbar.js, selectmenu.js, slider.js, spinner.js, tabs.js, tooltip.js, effect.js, effect-blind.js, effect-bounce.js, effect-clip.js, effect-drop.js, effect-explode.js, effect-fade.js, effect-fold.js, effect-highlight.js, effect-puff.js, effect-pulsate.js, effect-scale.js, effect-shake.js, effect-size.js, effect-slide.js, effect-transfer.js
* Copyright jQuery Foundation and other contributors; Licensed MIT */

(function(e){"function"==typeof define&&define.amd?define(["jquery"],e):e(jQuery)})(function(e){function t(t,s){var n,a,o,r=t.nodeName.toLowerCase();return"area"===r?(n=t.parentNode,a=n.name,t.href&&a&&"map"===n.nodeName.toLowerCase()?(o=e("img[usemap='#"+a+"']")[0],!!o&&i(o)):!1):(/^(input|select|textarea|button|object)$/.test(r)?!t.disabled:"a"===r?t.href||s:s)&&i(t)}function i(t){return e.expr.filters.visible(t)&&!e(t).parents().addBack().filter(function(){return"hidden"===e.css(this,"visibility")}).length}function s(e){return function(){var t=this.element.val();e.apply(this,arguments),this._refresh(),t!==this.element.val()&&this._trigger("change")}}e.ui=e.ui||{},e.extend(e.ui,{version:"1.11.4",keyCode:{BACKSPACE:8,COMMA:188,DELETE:46,DOWN:40,END:35,ENTER:13,ESCAPE:27,HOME:36,LEFT:37,PAGE_DOWN:34,PAGE_UP:33,PERIOD:190,RIGHT:39,SPACE:32,TAB:9,UP:38}}),e.fn.extend({scrollParent:function(t){var i=this.css("position"),s="absolute"===i,n=t?/(auto|scroll|hidden)/:/(auto|scroll)/,a=this.parents().filter(function(){var t=e(this);return s&&"static"===t.css("position")?!1:n.test(t.css("overflow")+t.css("overflow-y")+t.css("overflow-x"))}).eq(0);return"fixed"!==i&&a.length?a:e(this[0].ownerDocument||document)},uniqueId:function(){var e=0;return function(){return this.each(function(){this.id||(this.id="ui-id-"+ ++e)})}}(),removeUniqueId:function(){return this.each(function(){/^ui-id-\d+$/.test(this.id)&&e(this).removeAttr("id")})}}),e.extend(e.expr[":"],{data:e.expr.createPseudo?e.expr.createPseudo(function(t){return function(i){return!!e.data(i,t)}}):function(t,i,s){return!!e.data(t,s[3])},focusable:function(i){return t(i,!isNaN(e.attr(i,"tabindex")))},tabbable:function(i){var s=e.attr(i,"tabindex"),n=isNaN(s);return(n||s>=0)&&t(i,!n)}}),e("<a>").outerWidth(1).jquery||e.each(["Width","Height"],function(t,i){function s(t,i,s,a){return e.each(n,function(){i-=parseFloat(e.css(t,"padding"+this))||0,s&&(i-=parseFloat(e.css(t,"border"+this+"Width"))||0),a&&(i-=parseFloat(e.css(t,"margin"+this))||0)}),i}var n="Width"===i?["Left","Right"]:["Top","Bottom"],a=i.toLowerCase(),o={innerWidth:e.fn.innerWidth,innerHeight:e.fn.innerHeight,outerWidth:e.fn.outerWidth,outerHeight:e.fn.outerHeight};e.fn["inner"+i]=function(t){return void 0===t?o["inner"+i].call(this):this.each(function(){e(this).css(a,s(this,t)+"px")})},e.fn["outer"+i]=function(t,n){return"number"!=typeof t?o["outer"+i].call(this,t):this.each(function(){e(this).css(a,s(this,t,!0,n)+"px")})}}),e.fn.addBack||(e.fn.addBack=function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}),e("<a>").data("a-b","a").removeData("a-b").data("a-b")&&(e.fn.removeData=function(t){return function(i){return arguments.length?t.call(this,e.camelCase(i)):t.call(this)}}(e.fn.removeData)),e.ui.ie=!!/msie [\w.]+/.exec(navigator.userAgent.toLowerCase()),e.fn.extend({focus:function(t){return function(i,s){return"number"==typeof i?this.each(function(){var t=this;setTimeout(function(){e(t).focus(),s&&s.call(t)},i)}):t.apply(this,arguments)}}(e.fn.focus),disableSelection:function(){var e="onselectstart"in document.createElement("div")?"selectstart":"mousedown";return function(){return this.bind(e+".ui-disableSelection",function(e){e.preventDefault()})}}(),enableSelection:function(){return this.unbind(".ui-disableSelection")},zIndex:function(t){if(void 0!==t)return this.css("zIndex",t);if(this.length)for(var i,s,n=e(this[0]);n.length&&n[0]!==document;){if(i=n.css("position"),("absolute"===i||"relative"===i||"fixed"===i)&&(s=parseInt(n.css("zIndex"),10),!isNaN(s)&&0!==s))return s;n=n.parent()}return 0}}),e.ui.plugin={add:function(t,i,s){var n,a=e.ui[t].prototype;for(n in s)a.plugins[n]=a.plugins[n]||[],a.plugins[n].push([i,s[n]])},call:function(e,t,i,s){var n,a=e.plugins[t];if(a&&(s||e.element[0].parentNode&&11!==e.element[0].parentNode.nodeType))for(n=0;a.length>n;n++)e.options[a[n][0]]&&a[n][1].apply(e.element,i)}};var n=0,a=Array.prototype.slice;e.cleanData=function(t){return function(i){var s,n,a;for(a=0;null!=(n=i[a]);a++)try{s=e._data(n,"events"),s&&s.remove&&e(n).triggerHandler("remove")}catch(o){}t(i)}}(e.cleanData),e.widget=function(t,i,s){var n,a,o,r,h={},l=t.split(".")[0];return t=t.split(".")[1],n=l+"-"+t,s||(s=i,i=e.Widget),e.expr[":"][n.toLowerCase()]=function(t){return!!e.data(t,n)},e[l]=e[l]||{},a=e[l][t],o=e[l][t]=function(e,t){return this._createWidget?(arguments.length&&this._createWidget(e,t),void 0):new o(e,t)},e.extend(o,a,{version:s.version,_proto:e.extend({},s),_childConstructors:[]}),r=new i,r.options=e.widget.extend({},r.options),e.each(s,function(t,s){return e.isFunction(s)?(h[t]=function(){var e=function(){return i.prototype[t].apply(this,arguments)},n=function(e){return i.prototype[t].apply(this,e)};return function(){var t,i=this._super,a=this._superApply;return this._super=e,this._superApply=n,t=s.apply(this,arguments),this._super=i,this._superApply=a,t}}(),void 0):(h[t]=s,void 0)}),o.prototype=e.widget.extend(r,{widgetEventPrefix:a?r.widgetEventPrefix||t:t},h,{constructor:o,namespace:l,widgetName:t,widgetFullName:n}),a?(e.each(a._childConstructors,function(t,i){var s=i.prototype;e.widget(s.namespace+"."+s.widgetName,o,i._proto)}),delete a._childConstructors):i._childConstructors.push(o),e.widget.bridge(t,o),o},e.widget.extend=function(t){for(var i,s,n=a.call(arguments,1),o=0,r=n.length;r>o;o++)for(i in n[o])s=n[o][i],n[o].hasOwnProperty(i)&&void 0!==s&&(t[i]=e.isPlainObject(s)?e.isPlainObject(t[i])?e.widget.extend({},t[i],s):e.widget.extend({},s):s);return t},e.widget.bridge=function(t,i){var s=i.prototype.widgetFullName||t;e.fn[t]=function(n){var o="string"==typeof n,r=a.call(arguments,1),h=this;return o?this.each(function(){var i,a=e.data(this,s);return"instance"===n?(h=a,!1):a?e.isFunction(a[n])&&"_"!==n.charAt(0)?(i=a[n].apply(a,r),i!==a&&void 0!==i?(h=i&&i.jquery?h.pushStack(i.get()):i,!1):void 0):e.error("no such method '"+n+"' for "+t+" widget instance"):e.error("cannot call methods on "+t+" prior to initialization; "+"attempted to call method '"+n+"'")}):(r.length&&(n=e.widget.extend.apply(null,[n].concat(r))),this.each(function(){var t=e.data(this,s);t?(t.option(n||{}),t._init&&t._init()):e.data(this,s,new i(n,this))})),h}},e.Widget=function(){},e.Widget._childConstructors=[],e.Widget.prototype={widgetName:"widget",widgetEventPrefix:"",defaultElement:"<div>",options:{disabled:!1,create:null},_createWidget:function(t,i){i=e(i||this.defaultElement||this)[0],this.element=e(i),this.uuid=n++,this.eventNamespace="."+this.widgetName+this.uuid,this.bindings=e(),this.hoverable=e(),this.focusable=e(),i!==this&&(e.data(i,this.widgetFullName,this),this._on(!0,this.element,{remove:function(e){e.target===i&&this.destroy()}}),this.document=e(i.style?i.ownerDocument:i.document||i),this.window=e(this.document[0].defaultView||this.document[0].parentWindow)),this.options=e.widget.extend({},this.options,this._getCreateOptions(),t),this._create(),this._trigger("create",null,this._getCreateEventData()),this._init()},_getCreateOptions:e.noop,_getCreateEventData:e.noop,_create:e.noop,_init:e.noop,destroy:function(){this._destroy(),this.element.unbind(this.eventNamespace).removeData(this.widgetFullName).removeData(e.camelCase(this.widgetFullName)),this.widget().unbind(this.eventNamespace).removeAttr("aria-disabled").removeClass(this.widgetFullName+"-disabled "+"ui-state-disabled"),this.bindings.unbind(this.eventNamespace),this.hoverable.removeClass("ui-state-hover"),this.focusable.removeClass("ui-state-focus")},_destroy:e.noop,widget:function(){return this.element},option:function(t,i){var s,n,a,o=t;if(0===arguments.length)return e.widget.extend({},this.options);if("string"==typeof t)if(o={},s=t.split("."),t=s.shift(),s.length){for(n=o[t]=e.widget.extend({},this.options[t]),a=0;s.length-1>a;a++)n[s[a]]=n[s[a]]||{},n=n[s[a]];if(t=s.pop(),1===arguments.length)return void 0===n[t]?null:n[t];n[t]=i}else{if(1===arguments.length)return void 0===this.options[t]?null:this.options[t];o[t]=i}return this._setOptions(o),this},_setOptions:function(e){var t;for(t in e)this._setOption(t,e[t]);return this},_setOption:function(e,t){return this.options[e]=t,"disabled"===e&&(this.widget().toggleClass(this.widgetFullName+"-disabled",!!t),t&&(this.hoverable.removeClass("ui-state-hover"),this.focusable.removeClass("ui-state-focus"))),this},enable:function(){return this._setOptions({disabled:!1})},disable:function(){return this._setOptions({disabled:!0})},_on:function(t,i,s){var n,a=this;"boolean"!=typeof t&&(s=i,i=t,t=!1),s?(i=n=e(i),this.bindings=this.bindings.add(i)):(s=i,i=this.element,n=this.widget()),e.each(s,function(s,o){function r(){return t||a.options.disabled!==!0&&!e(this).hasClass("ui-state-disabled")?("string"==typeof o?a[o]:o).apply(a,arguments):void 0}"string"!=typeof o&&(r.guid=o.guid=o.guid||r.guid||e.guid++);var h=s.match(/^([\w:-]*)\s*(.*)$/),l=h[1]+a.eventNamespace,u=h[2];u?n.delegate(u,l,r):i.bind(l,r)})},_off:function(t,i){i=(i||"").split(" ").join(this.eventNamespace+" ")+this.eventNamespace,t.unbind(i).undelegate(i),this.bindings=e(this.bindings.not(t).get()),this.focusable=e(this.focusable.not(t).get()),this.hoverable=e(this.hoverable.not(t).get())},_delay:function(e,t){function i(){return("string"==typeof e?s[e]:e).apply(s,arguments)}var s=this;return setTimeout(i,t||0)},_hoverable:function(t){this.hoverable=this.hoverable.add(t),this._on(t,{mouseenter:function(t){e(t.currentTarget).addClass("ui-state-hover")},mouseleave:function(t){e(t.currentTarget).removeClass("ui-state-hover")}})},_focusable:function(t){this.focusable=this.focusable.add(t),this._on(t,{focusin:function(t){e(t.currentTarget).addClass("ui-state-focus")},focusout:function(t){e(t.currentTarget).removeClass("ui-state-focus")}})},_trigger:function(t,i,s){var n,a,o=this.options[t];if(s=s||{},i=e.Event(i),i.type=(t===this.widgetEventPrefix?t:this.widgetEventPrefix+t).toLowerCase(),i.target=this.element[0],a=i.originalEvent)for(n in a)n in i||(i[n]=a[n]);return this.element.trigger(i,s),!(e.isFunction(o)&&o.apply(this.element[0],[i].concat(s))===!1||i.isDefaultPrevented())}},e.each({show:"fadeIn",hide:"fadeOut"},function(t,i){e.Widget.prototype["_"+t]=function(s,n,a){"string"==typeof n&&(n={effect:n});var o,r=n?n===!0||"number"==typeof n?i:n.effect||i:t;n=n||{},"number"==typeof n&&(n={duration:n}),o=!e.isEmptyObject(n),n.complete=a,n.delay&&s.delay(n.delay),o&&e.effects&&e.effects.effect[r]?s[t](n):r!==t&&s[r]?s[r](n.duration,n.easing,a):s.queue(function(i){e(this)[t](),a&&a.call(s[0]),i()})}}),e.widget;var o=!1;e(document).mouseup(function(){o=!1}),e.widget("ui.mouse",{version:"1.11.4",options:{cancel:"input,textarea,button,select,option",distance:1,delay:0},_mouseInit:function(){var t=this;this.element.bind("mousedown."+this.widgetName,function(e){return t._mouseDown(e)}).bind("click."+this.widgetName,function(i){return!0===e.data(i.target,t.widgetName+".preventClickEvent")?(e.removeData(i.target,t.widgetName+".preventClickEvent"),i.stopImmediatePropagation(),!1):void 0}),this.started=!1},_mouseDestroy:function(){this.element.unbind("."+this.widgetName),this._mouseMoveDelegate&&this.document.unbind("mousemove."+this.widgetName,this._mouseMoveDelegate).unbind("mouseup."+this.widgetName,this._mouseUpDelegate)},_mouseDown:function(t){if(!o){this._mouseMoved=!1,this._mouseStarted&&this._mouseUp(t),this._mouseDownEvent=t;var i=this,s=1===t.which,n="string"==typeof this.options.cancel&&t.target.nodeName?e(t.target).closest(this.options.cancel).length:!1;return s&&!n&&this._mouseCapture(t)?(this.mouseDelayMet=!this.options.delay,this.mouseDelayMet||(this._mouseDelayTimer=setTimeout(function(){i.mouseDelayMet=!0},this.options.delay)),this._mouseDistanceMet(t)&&this._mouseDelayMet(t)&&(this._mouseStarted=this._mouseStart(t)!==!1,!this._mouseStarted)?(t.preventDefault(),!0):(!0===e.data(t.target,this.widgetName+".preventClickEvent")&&e.removeData(t.target,this.widgetName+".preventClickEvent"),this._mouseMoveDelegate=function(e){return i._mouseMove(e)},this._mouseUpDelegate=function(e){return i._mouseUp(e)},this.document.bind("mousemove."+this.widgetName,this._mouseMoveDelegate).bind("mouseup."+this.widgetName,this._mouseUpDelegate),t.preventDefault(),o=!0,!0)):!0}},_mouseMove:function(t){if(this._mouseMoved){if(e.ui.ie&&(!document.documentMode||9>document.documentMode)&&!t.button)return this._mouseUp(t);if(!t.which)return this._mouseUp(t)}return(t.which||t.button)&&(this._mouseMoved=!0),this._mouseStarted?(this._mouseDrag(t),t.preventDefault()):(this._mouseDistanceMet(t)&&this._mouseDelayMet(t)&&(this._mouseStarted=this._mouseStart(this._mouseDownEvent,t)!==!1,this._mouseStarted?this._mouseDrag(t):this._mouseUp(t)),!this._mouseStarted)},_mouseUp:function(t){return this.document.unbind("mousemove."+this.widgetName,this._mouseMoveDelegate).unbind("mouseup."+this.widgetName,this._mouseUpDelegate),this._mouseStarted&&(this._mouseStarted=!1,t.target===this._mouseDownEvent.target&&e.data(t.target,this.widgetName+".preventClickEvent",!0),this._mouseStop(t)),o=!1,!1},_mouseDistanceMet:function(e){return Math.max(Math.abs(this._mouseDownEvent.pageX-e.pageX),Math.abs(this._mouseDownEvent.pageY-e.pageY))>=this.options.distance},_mouseDelayMet:function(){return this.mouseDelayMet},_mouseStart:function(){},_mouseDrag:function(){},_mouseStop:function(){},_mouseCapture:function(){return!0}}),function(){function t(e,t,i){return[parseFloat(e[0])*(p.test(e[0])?t/100:1),parseFloat(e[1])*(p.test(e[1])?i/100:1)]}function i(t,i){return parseInt(e.css(t,i),10)||0}function s(t){var i=t[0];return 9===i.nodeType?{width:t.width(),height:t.height(),offset:{top:0,left:0}}:e.isWindow(i)?{width:t.width(),height:t.height(),offset:{top:t.scrollTop(),left:t.scrollLeft()}}:i.preventDefault?{width:0,height:0,offset:{top:i.pageY,left:i.pageX}}:{width:t.outerWidth(),height:t.outerHeight(),offset:t.offset()}}e.ui=e.ui||{};var n,a,o=Math.max,r=Math.abs,h=Math.round,l=/left|center|right/,u=/top|center|bottom/,d=/[\+\-]\d+(\.[\d]+)?%?/,c=/^\w+/,p=/%$/,f=e.fn.position;e.position={scrollbarWidth:function(){if(void 0!==n)return n;var t,i,s=e("<div style='display:block;position:absolute;width:50px;height:50px;overflow:hidden;'><div style='height:100px;width:auto;'></div></div>"),a=s.children()[0];return e("body").append(s),t=a.offsetWidth,s.css("overflow","scroll"),i=a.offsetWidth,t===i&&(i=s[0].clientWidth),s.remove(),n=t-i},getScrollInfo:function(t){var i=t.isWindow||t.isDocument?"":t.element.css("overflow-x"),s=t.isWindow||t.isDocument?"":t.element.css("overflow-y"),n="scroll"===i||"auto"===i&&t.width<t.element[0].scrollWidth,a="scroll"===s||"auto"===s&&t.height<t.element[0].scrollHeight;return{width:a?e.position.scrollbarWidth():0,height:n?e.position.scrollbarWidth():0}},getWithinInfo:function(t){var i=e(t||window),s=e.isWindow(i[0]),n=!!i[0]&&9===i[0].nodeType;return{element:i,isWindow:s,isDocument:n,offset:i.offset()||{left:0,top:0},scrollLeft:i.scrollLeft(),scrollTop:i.scrollTop(),width:s||n?i.width():i.outerWidth(),height:s||n?i.height():i.outerHeight()}}},e.fn.position=function(n){if(!n||!n.of)return f.apply(this,arguments);n=e.extend({},n);var p,m,g,v,y,b,_=e(n.of),x=e.position.getWithinInfo(n.within),w=e.position.getScrollInfo(x),k=(n.collision||"flip").split(" "),T={};return b=s(_),_[0].preventDefault&&(n.at="left top"),m=b.width,g=b.height,v=b.offset,y=e.extend({},v),e.each(["my","at"],function(){var e,t,i=(n[this]||"").split(" ");1===i.length&&(i=l.test(i[0])?i.concat(["center"]):u.test(i[0])?["center"].concat(i):["center","center"]),i[0]=l.test(i[0])?i[0]:"center",i[1]=u.test(i[1])?i[1]:"center",e=d.exec(i[0]),t=d.exec(i[1]),T[this]=[e?e[0]:0,t?t[0]:0],n[this]=[c.exec(i[0])[0],c.exec(i[1])[0]]}),1===k.length&&(k[1]=k[0]),"right"===n.at[0]?y.left+=m:"center"===n.at[0]&&(y.left+=m/2),"bottom"===n.at[1]?y.top+=g:"center"===n.at[1]&&(y.top+=g/2),p=t(T.at,m,g),y.left+=p[0],y.top+=p[1],this.each(function(){var s,l,u=e(this),d=u.outerWidth(),c=u.outerHeight(),f=i(this,"marginLeft"),b=i(this,"marginTop"),D=d+f+i(this,"marginRight")+w.width,S=c+b+i(this,"marginBottom")+w.height,N=e.extend({},y),M=t(T.my,u.outerWidth(),u.outerHeight());"right"===n.my[0]?N.left-=d:"center"===n.my[0]&&(N.left-=d/2),"bottom"===n.my[1]?N.top-=c:"center"===n.my[1]&&(N.top-=c/2),N.left+=M[0],N.top+=M[1],a||(N.left=h(N.left),N.top=h(N.top)),s={marginLeft:f,marginTop:b},e.each(["left","top"],function(t,i){e.ui.position[k[t]]&&e.ui.position[k[t]][i](N,{targetWidth:m,targetHeight:g,elemWidth:d,elemHeight:c,collisionPosition:s,collisionWidth:D,collisionHeight:S,offset:[p[0]+M[0],p[1]+M[1]],my:n.my,at:n.at,within:x,elem:u})}),n.using&&(l=function(e){var t=v.left-N.left,i=t+m-d,s=v.top-N.top,a=s+g-c,h={target:{element:_,left:v.left,top:v.top,width:m,height:g},element:{element:u,left:N.left,top:N.top,width:d,height:c},horizontal:0>i?"left":t>0?"right":"center",vertical:0>a?"top":s>0?"bottom":"middle"};d>m&&m>r(t+i)&&(h.horizontal="center"),c>g&&g>r(s+a)&&(h.vertical="middle"),h.important=o(r(t),r(i))>o(r(s),r(a))?"horizontal":"vertical",n.using.call(this,e,h)}),u.offset(e.extend(N,{using:l}))})},e.ui.position={fit:{left:function(e,t){var i,s=t.within,n=s.isWindow?s.scrollLeft:s.offset.left,a=s.width,r=e.left-t.collisionPosition.marginLeft,h=n-r,l=r+t.collisionWidth-a-n;t.collisionWidth>a?h>0&&0>=l?(i=e.left+h+t.collisionWidth-a-n,e.left+=h-i):e.left=l>0&&0>=h?n:h>l?n+a-t.collisionWidth:n:h>0?e.left+=h:l>0?e.left-=l:e.left=o(e.left-r,e.left)},top:function(e,t){var i,s=t.within,n=s.isWindow?s.scrollTop:s.offset.top,a=t.within.height,r=e.top-t.collisionPosition.marginTop,h=n-r,l=r+t.collisionHeight-a-n;t.collisionHeight>a?h>0&&0>=l?(i=e.top+h+t.collisionHeight-a-n,e.top+=h-i):e.top=l>0&&0>=h?n:h>l?n+a-t.collisionHeight:n:h>0?e.top+=h:l>0?e.top-=l:e.top=o(e.top-r,e.top)}},flip:{left:function(e,t){var i,s,n=t.within,a=n.offset.left+n.scrollLeft,o=n.width,h=n.isWindow?n.scrollLeft:n.offset.left,l=e.left-t.collisionPosition.marginLeft,u=l-h,d=l+t.collisionWidth-o-h,c="left"===t.my[0]?-t.elemWidth:"right"===t.my[0]?t.elemWidth:0,p="left"===t.at[0]?t.targetWidth:"right"===t.at[0]?-t.targetWidth:0,f=-2*t.offset[0];0>u?(i=e.left+c+p+f+t.collisionWidth-o-a,(0>i||r(u)>i)&&(e.left+=c+p+f)):d>0&&(s=e.left-t.collisionPosition.marginLeft+c+p+f-h,(s>0||d>r(s))&&(e.left+=c+p+f))},top:function(e,t){var i,s,n=t.within,a=n.offset.top+n.scrollTop,o=n.height,h=n.isWindow?n.scrollTop:n.offset.top,l=e.top-t.collisionPosition.marginTop,u=l-h,d=l+t.collisionHeight-o-h,c="top"===t.my[1],p=c?-t.elemHeight:"bottom"===t.my[1]?t.elemHeight:0,f="top"===t.at[1]?t.targetHeight:"bottom"===t.at[1]?-t.targetHeight:0,m=-2*t.offset[1];0>u?(s=e.top+p+f+m+t.collisionHeight-o-a,(0>s||r(u)>s)&&(e.top+=p+f+m)):d>0&&(i=e.top-t.collisionPosition.marginTop+p+f+m-h,(i>0||d>r(i))&&(e.top+=p+f+m))}},flipfit:{left:function(){e.ui.position.flip.left.apply(this,arguments),e.ui.position.fit.left.apply(this,arguments)},top:function(){e.ui.position.flip.top.apply(this,arguments),e.ui.position.fit.top.apply(this,arguments)}}},function(){var t,i,s,n,o,r=document.getElementsByTagName("body")[0],h=document.createElement("div");t=document.createElement(r?"div":"body"),s={visibility:"hidden",width:0,height:0,border:0,margin:0,background:"none"},r&&e.extend(s,{position:"absolute",left:"-1000px",top:"-1000px"});for(o in s)t.style[o]=s[o];t.appendChild(h),i=r||document.documentElement,i.insertBefore(t,i.firstChild),h.style.cssText="position: absolute; left: 10.7432222px;",n=e(h).offset().left,a=n>10&&11>n,t.innerHTML="",i.removeChild(t)}()}(),e.ui.position,e.widget("ui.draggable",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"drag",options:{addClasses:!0,appendTo:"parent",axis:!1,connectToSortable:!1,containment:!1,cursor:"auto",cursorAt:!1,grid:!1,handle:!1,helper:"original",iframeFix:!1,opacity:!1,refreshPositions:!1,revert:!1,revertDuration:500,scope:"default",scroll:!0,scrollSensitivity:20,scrollSpeed:20,snap:!1,snapMode:"both",snapTolerance:20,stack:!1,zIndex:!1,drag:null,start:null,stop:null},_create:function(){"original"===this.options.helper&&this._setPositionRelative(),this.options.addClasses&&this.element.addClass("ui-draggable"),this.options.disabled&&this.element.addClass("ui-draggable-disabled"),this._setHandleClassName(),this._mouseInit()},_setOption:function(e,t){this._super(e,t),"handle"===e&&(this._removeHandleClassName(),this._setHandleClassName())},_destroy:function(){return(this.helper||this.element).is(".ui-draggable-dragging")?(this.destroyOnClear=!0,void 0):(this.element.removeClass("ui-draggable ui-draggable-dragging ui-draggable-disabled"),this._removeHandleClassName(),this._mouseDestroy(),void 0)},_mouseCapture:function(t){var i=this.options;return this._blurActiveElement(t),this.helper||i.disabled||e(t.target).closest(".ui-resizable-handle").length>0?!1:(this.handle=this._getHandle(t),this.handle?(this._blockFrames(i.iframeFix===!0?"iframe":i.iframeFix),!0):!1)},_blockFrames:function(t){this.iframeBlocks=this.document.find(t).map(function(){var t=e(this);return e("<div>").css("position","absolute").appendTo(t.parent()).outerWidth(t.outerWidth()).outerHeight(t.outerHeight()).offset(t.offset())[0]})},_unblockFrames:function(){this.iframeBlocks&&(this.iframeBlocks.remove(),delete this.iframeBlocks)},_blurActiveElement:function(t){var i=this.document[0];if(this.handleElement.is(t.target))try{i.activeElement&&"body"!==i.activeElement.nodeName.toLowerCase()&&e(i.activeElement).blur()}catch(s){}},_mouseStart:function(t){var i=this.options;return this.helper=this._createHelper(t),this.helper.addClass("ui-draggable-dragging"),this._cacheHelperProportions(),e.ui.ddmanager&&(e.ui.ddmanager.current=this),this._cacheMargins(),this.cssPosition=this.helper.css("position"),this.scrollParent=this.helper.scrollParent(!0),this.offsetParent=this.helper.offsetParent(),this.hasFixedAncestor=this.helper.parents().filter(function(){return"fixed"===e(this).css("position")}).length>0,this.positionAbs=this.element.offset(),this._refreshOffsets(t),this.originalPosition=this.position=this._generatePosition(t,!1),this.originalPageX=t.pageX,this.originalPageY=t.pageY,i.cursorAt&&this._adjustOffsetFromHelper(i.cursorAt),this._setContainment(),this._trigger("start",t)===!1?(this._clear(),!1):(this._cacheHelperProportions(),e.ui.ddmanager&&!i.dropBehaviour&&e.ui.ddmanager.prepareOffsets(this,t),this._normalizeRightBottom(),this._mouseDrag(t,!0),e.ui.ddmanager&&e.ui.ddmanager.dragStart(this,t),!0)},_refreshOffsets:function(e){this.offset={top:this.positionAbs.top-this.margins.top,left:this.positionAbs.left-this.margins.left,scroll:!1,parent:this._getParentOffset(),relative:this._getRelativeOffset()},this.offset.click={left:e.pageX-this.offset.left,top:e.pageY-this.offset.top}},_mouseDrag:function(t,i){if(this.hasFixedAncestor&&(this.offset.parent=this._getParentOffset()),this.position=this._generatePosition(t,!0),this.positionAbs=this._convertPositionTo("absolute"),!i){var s=this._uiHash();if(this._trigger("drag",t,s)===!1)return this._mouseUp({}),!1;this.position=s.position}return this.helper[0].style.left=this.position.left+"px",this.helper[0].style.top=this.position.top+"px",e.ui.ddmanager&&e.ui.ddmanager.drag(this,t),!1},_mouseStop:function(t){var i=this,s=!1;return e.ui.ddmanager&&!this.options.dropBehaviour&&(s=e.ui.ddmanager.drop(this,t)),this.dropped&&(s=this.dropped,this.dropped=!1),"invalid"===this.options.revert&&!s||"valid"===this.options.revert&&s||this.options.revert===!0||e.isFunction(this.options.revert)&&this.options.revert.call(this.element,s)?e(this.helper).animate(this.originalPosition,parseInt(this.options.revertDuration,10),function(){i._trigger("stop",t)!==!1&&i._clear()}):this._trigger("stop",t)!==!1&&this._clear(),!1},_mouseUp:function(t){return this._unblockFrames(),e.ui.ddmanager&&e.ui.ddmanager.dragStop(this,t),this.handleElement.is(t.target)&&this.element.focus(),e.ui.mouse.prototype._mouseUp.call(this,t)},cancel:function(){return this.helper.is(".ui-draggable-dragging")?this._mouseUp({}):this._clear(),this},_getHandle:function(t){return this.options.handle?!!e(t.target).closest(this.element.find(this.options.handle)).length:!0},_setHandleClassName:function(){this.handleElement=this.options.handle?this.element.find(this.options.handle):this.element,this.handleElement.addClass("ui-draggable-handle")},_removeHandleClassName:function(){this.handleElement.removeClass("ui-draggable-handle")},_createHelper:function(t){var i=this.options,s=e.isFunction(i.helper),n=s?e(i.helper.apply(this.element[0],[t])):"clone"===i.helper?this.element.clone().removeAttr("id"):this.element;return n.parents("body").length||n.appendTo("parent"===i.appendTo?this.element[0].parentNode:i.appendTo),s&&n[0]===this.element[0]&&this._setPositionRelative(),n[0]===this.element[0]||/(fixed|absolute)/.test(n.css("position"))||n.css("position","absolute"),n},_setPositionRelative:function(){/^(?:r|a|f)/.test(this.element.css("position"))||(this.element[0].style.position="relative")},_adjustOffsetFromHelper:function(t){"string"==typeof t&&(t=t.split(" ")),e.isArray(t)&&(t={left:+t[0],top:+t[1]||0}),"left"in t&&(this.offset.click.left=t.left+this.margins.left),"right"in t&&(this.offset.click.left=this.helperProportions.width-t.right+this.margins.left),"top"in t&&(this.offset.click.top=t.top+this.margins.top),"bottom"in t&&(this.offset.click.top=this.helperProportions.height-t.bottom+this.margins.top)},_isRootNode:function(e){return/(html|body)/i.test(e.tagName)||e===this.document[0]},_getParentOffset:function(){var t=this.offsetParent.offset(),i=this.document[0];return"absolute"===this.cssPosition&&this.scrollParent[0]!==i&&e.contains(this.scrollParent[0],this.offsetParent[0])&&(t.left+=this.scrollParent.scrollLeft(),t.top+=this.scrollParent.scrollTop()),this._isRootNode(this.offsetParent[0])&&(t={top:0,left:0}),{top:t.top+(parseInt(this.offsetParent.css("borderTopWidth"),10)||0),left:t.left+(parseInt(this.offsetParent.css("borderLeftWidth"),10)||0)}},_getRelativeOffset:function(){if("relative"!==this.cssPosition)return{top:0,left:0};var e=this.element.position(),t=this._isRootNode(this.scrollParent[0]);return{top:e.top-(parseInt(this.helper.css("top"),10)||0)+(t?0:this.scrollParent.scrollTop()),left:e.left-(parseInt(this.helper.css("left"),10)||0)+(t?0:this.scrollParent.scrollLeft())}},_cacheMargins:function(){this.margins={left:parseInt(this.element.css("marginLeft"),10)||0,top:parseInt(this.element.css("marginTop"),10)||0,right:parseInt(this.element.css("marginRight"),10)||0,bottom:parseInt(this.element.css("marginBottom"),10)||0}},_cacheHelperProportions:function(){this.helperProportions={width:this.helper.outerWidth(),height:this.helper.outerHeight()}},_setContainment:function(){var t,i,s,n=this.options,a=this.document[0];return this.relativeContainer=null,n.containment?"window"===n.containment?(this.containment=[e(window).scrollLeft()-this.offset.relative.left-this.offset.parent.left,e(window).scrollTop()-this.offset.relative.top-this.offset.parent.top,e(window).scrollLeft()+e(window).width()-this.helperProportions.width-this.margins.left,e(window).scrollTop()+(e(window).height()||a.body.parentNode.scrollHeight)-this.helperProportions.height-this.margins.top],void 0):"document"===n.containment?(this.containment=[0,0,e(a).width()-this.helperProportions.width-this.margins.left,(e(a).height()||a.body.parentNode.scrollHeight)-this.helperProportions.height-this.margins.top],void 0):n.containment.constructor===Array?(this.containment=n.containment,void 0):("parent"===n.containment&&(n.containment=this.helper[0].parentNode),i=e(n.containment),s=i[0],s&&(t=/(scroll|auto)/.test(i.css("overflow")),this.containment=[(parseInt(i.css("borderLeftWidth"),10)||0)+(parseInt(i.css("paddingLeft"),10)||0),(parseInt(i.css("borderTopWidth"),10)||0)+(parseInt(i.css("paddingTop"),10)||0),(t?Math.max(s.scrollWidth,s.offsetWidth):s.offsetWidth)-(parseInt(i.css("borderRightWidth"),10)||0)-(parseInt(i.css("paddingRight"),10)||0)-this.helperProportions.width-this.margins.left-this.margins.right,(t?Math.max(s.scrollHeight,s.offsetHeight):s.offsetHeight)-(parseInt(i.css("borderBottomWidth"),10)||0)-(parseInt(i.css("paddingBottom"),10)||0)-this.helperProportions.height-this.margins.top-this.margins.bottom],this.relativeContainer=i),void 0):(this.containment=null,void 0)},_convertPositionTo:function(e,t){t||(t=this.position);var i="absolute"===e?1:-1,s=this._isRootNode(this.scrollParent[0]);return{top:t.top+this.offset.relative.top*i+this.offset.parent.top*i-("fixed"===this.cssPosition?-this.offset.scroll.top:s?0:this.offset.scroll.top)*i,left:t.left+this.offset.relative.left*i+this.offset.parent.left*i-("fixed"===this.cssPosition?-this.offset.scroll.left:s?0:this.offset.scroll.left)*i}},_generatePosition:function(e,t){var i,s,n,a,o=this.options,r=this._isRootNode(this.scrollParent[0]),h=e.pageX,l=e.pageY;return r&&this.offset.scroll||(this.offset.scroll={top:this.scrollParent.scrollTop(),left:this.scrollParent.scrollLeft()}),t&&(this.containment&&(this.relativeContainer?(s=this.relativeContainer.offset(),i=[this.containment[0]+s.left,this.containment[1]+s.top,this.containment[2]+s.left,this.containment[3]+s.top]):i=this.containment,e.pageX-this.offset.click.left<i[0]&&(h=i[0]+this.offset.click.left),e.pageY-this.offset.click.top<i[1]&&(l=i[1]+this.offset.click.top),e.pageX-this.offset.click.left>i[2]&&(h=i[2]+this.offset.click.left),e.pageY-this.offset.click.top>i[3]&&(l=i[3]+this.offset.click.top)),o.grid&&(n=o.grid[1]?this.originalPageY+Math.round((l-this.originalPageY)/o.grid[1])*o.grid[1]:this.originalPageY,l=i?n-this.offset.click.top>=i[1]||n-this.offset.click.top>i[3]?n:n-this.offset.click.top>=i[1]?n-o.grid[1]:n+o.grid[1]:n,a=o.grid[0]?this.originalPageX+Math.round((h-this.originalPageX)/o.grid[0])*o.grid[0]:this.originalPageX,h=i?a-this.offset.click.left>=i[0]||a-this.offset.click.left>i[2]?a:a-this.offset.click.left>=i[0]?a-o.grid[0]:a+o.grid[0]:a),"y"===o.axis&&(h=this.originalPageX),"x"===o.axis&&(l=this.originalPageY)),{top:l-this.offset.click.top-this.offset.relative.top-this.offset.parent.top+("fixed"===this.cssPosition?-this.offset.scroll.top:r?0:this.offset.scroll.top),left:h-this.offset.click.left-this.offset.relative.left-this.offset.parent.left+("fixed"===this.cssPosition?-this.offset.scroll.left:r?0:this.offset.scroll.left)}},_clear:function(){this.helper.removeClass("ui-draggable-dragging"),this.helper[0]===this.element[0]||this.cancelHelperRemoval||this.helper.remove(),this.helper=null,this.cancelHelperRemoval=!1,this.destroyOnClear&&this.destroy()},_normalizeRightBottom:function(){"y"!==this.options.axis&&"auto"!==this.helper.css("right")&&(this.helper.width(this.helper.width()),this.helper.css("right","auto")),"x"!==this.options.axis&&"auto"!==this.helper.css("bottom")&&(this.helper.height(this.helper.height()),this.helper.css("bottom","auto"))},_trigger:function(t,i,s){return s=s||this._uiHash(),e.ui.plugin.call(this,t,[i,s,this],!0),/^(drag|start|stop)/.test(t)&&(this.positionAbs=this._convertPositionTo("absolute"),s.offset=this.positionAbs),e.Widget.prototype._trigger.call(this,t,i,s)},plugins:{},_uiHash:function(){return{helper:this.helper,position:this.position,originalPosition:this.originalPosition,offset:this.positionAbs}}}),e.ui.plugin.add("draggable","connectToSortable",{start:function(t,i,s){var n=e.extend({},i,{item:s.element});s.sortables=[],e(s.options.connectToSortable).each(function(){var i=e(this).sortable("instance");i&&!i.options.disabled&&(s.sortables.push(i),i.refreshPositions(),i._trigger("activate",t,n))})},stop:function(t,i,s){var n=e.extend({},i,{item:s.element});s.cancelHelperRemoval=!1,e.each(s.sortables,function(){var e=this;e.isOver?(e.isOver=0,s.cancelHelperRemoval=!0,e.cancelHelperRemoval=!1,e._storedCSS={position:e.placeholder.css("position"),top:e.placeholder.css("top"),left:e.placeholder.css("left")},e._mouseStop(t),e.options.helper=e.options._helper):(e.cancelHelperRemoval=!0,e._trigger("deactivate",t,n))})},drag:function(t,i,s){e.each(s.sortables,function(){var n=!1,a=this;a.positionAbs=s.positionAbs,a.helperProportions=s.helperProportions,a.offset.click=s.offset.click,a._intersectsWith(a.containerCache)&&(n=!0,e.each(s.sortables,function(){return this.positionAbs=s.positionAbs,this.helperProportions=s.helperProportions,this.offset.click=s.offset.click,this!==a&&this._intersectsWith(this.containerCache)&&e.contains(a.element[0],this.element[0])&&(n=!1),n
})),n?(a.isOver||(a.isOver=1,s._parent=i.helper.parent(),a.currentItem=i.helper.appendTo(a.element).data("ui-sortable-item",!0),a.options._helper=a.options.helper,a.options.helper=function(){return i.helper[0]},t.target=a.currentItem[0],a._mouseCapture(t,!0),a._mouseStart(t,!0,!0),a.offset.click.top=s.offset.click.top,a.offset.click.left=s.offset.click.left,a.offset.parent.left-=s.offset.parent.left-a.offset.parent.left,a.offset.parent.top-=s.offset.parent.top-a.offset.parent.top,s._trigger("toSortable",t),s.dropped=a.element,e.each(s.sortables,function(){this.refreshPositions()}),s.currentItem=s.element,a.fromOutside=s),a.currentItem&&(a._mouseDrag(t),i.position=a.position)):a.isOver&&(a.isOver=0,a.cancelHelperRemoval=!0,a.options._revert=a.options.revert,a.options.revert=!1,a._trigger("out",t,a._uiHash(a)),a._mouseStop(t,!0),a.options.revert=a.options._revert,a.options.helper=a.options._helper,a.placeholder&&a.placeholder.remove(),i.helper.appendTo(s._parent),s._refreshOffsets(t),i.position=s._generatePosition(t,!0),s._trigger("fromSortable",t),s.dropped=!1,e.each(s.sortables,function(){this.refreshPositions()}))})}}),e.ui.plugin.add("draggable","cursor",{start:function(t,i,s){var n=e("body"),a=s.options;n.css("cursor")&&(a._cursor=n.css("cursor")),n.css("cursor",a.cursor)},stop:function(t,i,s){var n=s.options;n._cursor&&e("body").css("cursor",n._cursor)}}),e.ui.plugin.add("draggable","opacity",{start:function(t,i,s){var n=e(i.helper),a=s.options;n.css("opacity")&&(a._opacity=n.css("opacity")),n.css("opacity",a.opacity)},stop:function(t,i,s){var n=s.options;n._opacity&&e(i.helper).css("opacity",n._opacity)}}),e.ui.plugin.add("draggable","scroll",{start:function(e,t,i){i.scrollParentNotHidden||(i.scrollParentNotHidden=i.helper.scrollParent(!1)),i.scrollParentNotHidden[0]!==i.document[0]&&"HTML"!==i.scrollParentNotHidden[0].tagName&&(i.overflowOffset=i.scrollParentNotHidden.offset())},drag:function(t,i,s){var n=s.options,a=!1,o=s.scrollParentNotHidden[0],r=s.document[0];o!==r&&"HTML"!==o.tagName?(n.axis&&"x"===n.axis||(s.overflowOffset.top+o.offsetHeight-t.pageY<n.scrollSensitivity?o.scrollTop=a=o.scrollTop+n.scrollSpeed:t.pageY-s.overflowOffset.top<n.scrollSensitivity&&(o.scrollTop=a=o.scrollTop-n.scrollSpeed)),n.axis&&"y"===n.axis||(s.overflowOffset.left+o.offsetWidth-t.pageX<n.scrollSensitivity?o.scrollLeft=a=o.scrollLeft+n.scrollSpeed:t.pageX-s.overflowOffset.left<n.scrollSensitivity&&(o.scrollLeft=a=o.scrollLeft-n.scrollSpeed))):(n.axis&&"x"===n.axis||(t.pageY-e(r).scrollTop()<n.scrollSensitivity?a=e(r).scrollTop(e(r).scrollTop()-n.scrollSpeed):e(window).height()-(t.pageY-e(r).scrollTop())<n.scrollSensitivity&&(a=e(r).scrollTop(e(r).scrollTop()+n.scrollSpeed))),n.axis&&"y"===n.axis||(t.pageX-e(r).scrollLeft()<n.scrollSensitivity?a=e(r).scrollLeft(e(r).scrollLeft()-n.scrollSpeed):e(window).width()-(t.pageX-e(r).scrollLeft())<n.scrollSensitivity&&(a=e(r).scrollLeft(e(r).scrollLeft()+n.scrollSpeed)))),a!==!1&&e.ui.ddmanager&&!n.dropBehaviour&&e.ui.ddmanager.prepareOffsets(s,t)}}),e.ui.plugin.add("draggable","snap",{start:function(t,i,s){var n=s.options;s.snapElements=[],e(n.snap.constructor!==String?n.snap.items||":data(ui-draggable)":n.snap).each(function(){var t=e(this),i=t.offset();this!==s.element[0]&&s.snapElements.push({item:this,width:t.outerWidth(),height:t.outerHeight(),top:i.top,left:i.left})})},drag:function(t,i,s){var n,a,o,r,h,l,u,d,c,p,f=s.options,m=f.snapTolerance,g=i.offset.left,v=g+s.helperProportions.width,y=i.offset.top,b=y+s.helperProportions.height;for(c=s.snapElements.length-1;c>=0;c--)h=s.snapElements[c].left-s.margins.left,l=h+s.snapElements[c].width,u=s.snapElements[c].top-s.margins.top,d=u+s.snapElements[c].height,h-m>v||g>l+m||u-m>b||y>d+m||!e.contains(s.snapElements[c].item.ownerDocument,s.snapElements[c].item)?(s.snapElements[c].snapping&&s.options.snap.release&&s.options.snap.release.call(s.element,t,e.extend(s._uiHash(),{snapItem:s.snapElements[c].item})),s.snapElements[c].snapping=!1):("inner"!==f.snapMode&&(n=m>=Math.abs(u-b),a=m>=Math.abs(d-y),o=m>=Math.abs(h-v),r=m>=Math.abs(l-g),n&&(i.position.top=s._convertPositionTo("relative",{top:u-s.helperProportions.height,left:0}).top),a&&(i.position.top=s._convertPositionTo("relative",{top:d,left:0}).top),o&&(i.position.left=s._convertPositionTo("relative",{top:0,left:h-s.helperProportions.width}).left),r&&(i.position.left=s._convertPositionTo("relative",{top:0,left:l}).left)),p=n||a||o||r,"outer"!==f.snapMode&&(n=m>=Math.abs(u-y),a=m>=Math.abs(d-b),o=m>=Math.abs(h-g),r=m>=Math.abs(l-v),n&&(i.position.top=s._convertPositionTo("relative",{top:u,left:0}).top),a&&(i.position.top=s._convertPositionTo("relative",{top:d-s.helperProportions.height,left:0}).top),o&&(i.position.left=s._convertPositionTo("relative",{top:0,left:h}).left),r&&(i.position.left=s._convertPositionTo("relative",{top:0,left:l-s.helperProportions.width}).left)),!s.snapElements[c].snapping&&(n||a||o||r||p)&&s.options.snap.snap&&s.options.snap.snap.call(s.element,t,e.extend(s._uiHash(),{snapItem:s.snapElements[c].item})),s.snapElements[c].snapping=n||a||o||r||p)}}),e.ui.plugin.add("draggable","stack",{start:function(t,i,s){var n,a=s.options,o=e.makeArray(e(a.stack)).sort(function(t,i){return(parseInt(e(t).css("zIndex"),10)||0)-(parseInt(e(i).css("zIndex"),10)||0)});o.length&&(n=parseInt(e(o[0]).css("zIndex"),10)||0,e(o).each(function(t){e(this).css("zIndex",n+t)}),this.css("zIndex",n+o.length))}}),e.ui.plugin.add("draggable","zIndex",{start:function(t,i,s){var n=e(i.helper),a=s.options;n.css("zIndex")&&(a._zIndex=n.css("zIndex")),n.css("zIndex",a.zIndex)},stop:function(t,i,s){var n=s.options;n._zIndex&&e(i.helper).css("zIndex",n._zIndex)}}),e.ui.draggable,e.widget("ui.droppable",{version:"1.11.4",widgetEventPrefix:"drop",options:{accept:"*",activeClass:!1,addClasses:!0,greedy:!1,hoverClass:!1,scope:"default",tolerance:"intersect",activate:null,deactivate:null,drop:null,out:null,over:null},_create:function(){var t,i=this.options,s=i.accept;this.isover=!1,this.isout=!0,this.accept=e.isFunction(s)?s:function(e){return e.is(s)},this.proportions=function(){return arguments.length?(t=arguments[0],void 0):t?t:t={width:this.element[0].offsetWidth,height:this.element[0].offsetHeight}},this._addToManager(i.scope),i.addClasses&&this.element.addClass("ui-droppable")},_addToManager:function(t){e.ui.ddmanager.droppables[t]=e.ui.ddmanager.droppables[t]||[],e.ui.ddmanager.droppables[t].push(this)},_splice:function(e){for(var t=0;e.length>t;t++)e[t]===this&&e.splice(t,1)},_destroy:function(){var t=e.ui.ddmanager.droppables[this.options.scope];this._splice(t),this.element.removeClass("ui-droppable ui-droppable-disabled")},_setOption:function(t,i){if("accept"===t)this.accept=e.isFunction(i)?i:function(e){return e.is(i)};else if("scope"===t){var s=e.ui.ddmanager.droppables[this.options.scope];this._splice(s),this._addToManager(i)}this._super(t,i)},_activate:function(t){var i=e.ui.ddmanager.current;this.options.activeClass&&this.element.addClass(this.options.activeClass),i&&this._trigger("activate",t,this.ui(i))},_deactivate:function(t){var i=e.ui.ddmanager.current;this.options.activeClass&&this.element.removeClass(this.options.activeClass),i&&this._trigger("deactivate",t,this.ui(i))},_over:function(t){var i=e.ui.ddmanager.current;i&&(i.currentItem||i.element)[0]!==this.element[0]&&this.accept.call(this.element[0],i.currentItem||i.element)&&(this.options.hoverClass&&this.element.addClass(this.options.hoverClass),this._trigger("over",t,this.ui(i)))},_out:function(t){var i=e.ui.ddmanager.current;i&&(i.currentItem||i.element)[0]!==this.element[0]&&this.accept.call(this.element[0],i.currentItem||i.element)&&(this.options.hoverClass&&this.element.removeClass(this.options.hoverClass),this._trigger("out",t,this.ui(i)))},_drop:function(t,i){var s=i||e.ui.ddmanager.current,n=!1;return s&&(s.currentItem||s.element)[0]!==this.element[0]?(this.element.find(":data(ui-droppable)").not(".ui-draggable-dragging").each(function(){var i=e(this).droppable("instance");return i.options.greedy&&!i.options.disabled&&i.options.scope===s.options.scope&&i.accept.call(i.element[0],s.currentItem||s.element)&&e.ui.intersect(s,e.extend(i,{offset:i.element.offset()}),i.options.tolerance,t)?(n=!0,!1):void 0}),n?!1:this.accept.call(this.element[0],s.currentItem||s.element)?(this.options.activeClass&&this.element.removeClass(this.options.activeClass),this.options.hoverClass&&this.element.removeClass(this.options.hoverClass),this._trigger("drop",t,this.ui(s)),this.element):!1):!1},ui:function(e){return{draggable:e.currentItem||e.element,helper:e.helper,position:e.position,offset:e.positionAbs}}}),e.ui.intersect=function(){function e(e,t,i){return e>=t&&t+i>e}return function(t,i,s,n){if(!i.offset)return!1;var a=(t.positionAbs||t.position.absolute).left+t.margins.left,o=(t.positionAbs||t.position.absolute).top+t.margins.top,r=a+t.helperProportions.width,h=o+t.helperProportions.height,l=i.offset.left,u=i.offset.top,d=l+i.proportions().width,c=u+i.proportions().height;switch(s){case"fit":return a>=l&&d>=r&&o>=u&&c>=h;case"intersect":return a+t.helperProportions.width/2>l&&d>r-t.helperProportions.width/2&&o+t.helperProportions.height/2>u&&c>h-t.helperProportions.height/2;case"pointer":return e(n.pageY,u,i.proportions().height)&&e(n.pageX,l,i.proportions().width);case"touch":return(o>=u&&c>=o||h>=u&&c>=h||u>o&&h>c)&&(a>=l&&d>=a||r>=l&&d>=r||l>a&&r>d);default:return!1}}}(),e.ui.ddmanager={current:null,droppables:{"default":[]},prepareOffsets:function(t,i){var s,n,a=e.ui.ddmanager.droppables[t.options.scope]||[],o=i?i.type:null,r=(t.currentItem||t.element).find(":data(ui-droppable)").addBack();e:for(s=0;a.length>s;s++)if(!(a[s].options.disabled||t&&!a[s].accept.call(a[s].element[0],t.currentItem||t.element))){for(n=0;r.length>n;n++)if(r[n]===a[s].element[0]){a[s].proportions().height=0;continue e}a[s].visible="none"!==a[s].element.css("display"),a[s].visible&&("mousedown"===o&&a[s]._activate.call(a[s],i),a[s].offset=a[s].element.offset(),a[s].proportions({width:a[s].element[0].offsetWidth,height:a[s].element[0].offsetHeight}))}},drop:function(t,i){var s=!1;return e.each((e.ui.ddmanager.droppables[t.options.scope]||[]).slice(),function(){this.options&&(!this.options.disabled&&this.visible&&e.ui.intersect(t,this,this.options.tolerance,i)&&(s=this._drop.call(this,i)||s),!this.options.disabled&&this.visible&&this.accept.call(this.element[0],t.currentItem||t.element)&&(this.isout=!0,this.isover=!1,this._deactivate.call(this,i)))}),s},dragStart:function(t,i){t.element.parentsUntil("body").bind("scroll.droppable",function(){t.options.refreshPositions||e.ui.ddmanager.prepareOffsets(t,i)})},drag:function(t,i){t.options.refreshPositions&&e.ui.ddmanager.prepareOffsets(t,i),e.each(e.ui.ddmanager.droppables[t.options.scope]||[],function(){if(!this.options.disabled&&!this.greedyChild&&this.visible){var s,n,a,o=e.ui.intersect(t,this,this.options.tolerance,i),r=!o&&this.isover?"isout":o&&!this.isover?"isover":null;r&&(this.options.greedy&&(n=this.options.scope,a=this.element.parents(":data(ui-droppable)").filter(function(){return e(this).droppable("instance").options.scope===n}),a.length&&(s=e(a[0]).droppable("instance"),s.greedyChild="isover"===r)),s&&"isover"===r&&(s.isover=!1,s.isout=!0,s._out.call(s,i)),this[r]=!0,this["isout"===r?"isover":"isout"]=!1,this["isover"===r?"_over":"_out"].call(this,i),s&&"isout"===r&&(s.isout=!1,s.isover=!0,s._over.call(s,i)))}})},dragStop:function(t,i){t.element.parentsUntil("body").unbind("scroll.droppable"),t.options.refreshPositions||e.ui.ddmanager.prepareOffsets(t,i)}},e.ui.droppable,e.widget("ui.resizable",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"resize",options:{alsoResize:!1,animate:!1,animateDuration:"slow",animateEasing:"swing",aspectRatio:!1,autoHide:!1,containment:!1,ghost:!1,grid:!1,handles:"e,s,se",helper:!1,maxHeight:null,maxWidth:null,minHeight:10,minWidth:10,zIndex:90,resize:null,start:null,stop:null},_num:function(e){return parseInt(e,10)||0},_isNumber:function(e){return!isNaN(parseInt(e,10))},_hasScroll:function(t,i){if("hidden"===e(t).css("overflow"))return!1;var s=i&&"left"===i?"scrollLeft":"scrollTop",n=!1;return t[s]>0?!0:(t[s]=1,n=t[s]>0,t[s]=0,n)},_create:function(){var t,i,s,n,a,o=this,r=this.options;if(this.element.addClass("ui-resizable"),e.extend(this,{_aspectRatio:!!r.aspectRatio,aspectRatio:r.aspectRatio,originalElement:this.element,_proportionallyResizeElements:[],_helper:r.helper||r.ghost||r.animate?r.helper||"ui-resizable-helper":null}),this.element[0].nodeName.match(/^(canvas|textarea|input|select|button|img)$/i)&&(this.element.wrap(e("<div class='ui-wrapper' style='overflow: hidden;'></div>").css({position:this.element.css("position"),width:this.element.outerWidth(),height:this.element.outerHeight(),top:this.element.css("top"),left:this.element.css("left")})),this.element=this.element.parent().data("ui-resizable",this.element.resizable("instance")),this.elementIsWrapper=!0,this.element.css({marginLeft:this.originalElement.css("marginLeft"),marginTop:this.originalElement.css("marginTop"),marginRight:this.originalElement.css("marginRight"),marginBottom:this.originalElement.css("marginBottom")}),this.originalElement.css({marginLeft:0,marginTop:0,marginRight:0,marginBottom:0}),this.originalResizeStyle=this.originalElement.css("resize"),this.originalElement.css("resize","none"),this._proportionallyResizeElements.push(this.originalElement.css({position:"static",zoom:1,display:"block"})),this.originalElement.css({margin:this.originalElement.css("margin")}),this._proportionallyResize()),this.handles=r.handles||(e(".ui-resizable-handle",this.element).length?{n:".ui-resizable-n",e:".ui-resizable-e",s:".ui-resizable-s",w:".ui-resizable-w",se:".ui-resizable-se",sw:".ui-resizable-sw",ne:".ui-resizable-ne",nw:".ui-resizable-nw"}:"e,s,se"),this._handles=e(),this.handles.constructor===String)for("all"===this.handles&&(this.handles="n,e,s,w,se,sw,ne,nw"),t=this.handles.split(","),this.handles={},i=0;t.length>i;i++)s=e.trim(t[i]),a="ui-resizable-"+s,n=e("<div class='ui-resizable-handle "+a+"'></div>"),n.css({zIndex:r.zIndex}),"se"===s&&n.addClass("ui-icon ui-icon-gripsmall-diagonal-se"),this.handles[s]=".ui-resizable-"+s,this.element.append(n);this._renderAxis=function(t){var i,s,n,a;t=t||this.element;for(i in this.handles)this.handles[i].constructor===String?this.handles[i]=this.element.children(this.handles[i]).first().show():(this.handles[i].jquery||this.handles[i].nodeType)&&(this.handles[i]=e(this.handles[i]),this._on(this.handles[i],{mousedown:o._mouseDown})),this.elementIsWrapper&&this.originalElement[0].nodeName.match(/^(textarea|input|select|button)$/i)&&(s=e(this.handles[i],this.element),a=/sw|ne|nw|se|n|s/.test(i)?s.outerHeight():s.outerWidth(),n=["padding",/ne|nw|n/.test(i)?"Top":/se|sw|s/.test(i)?"Bottom":/^e$/.test(i)?"Right":"Left"].join(""),t.css(n,a),this._proportionallyResize()),this._handles=this._handles.add(this.handles[i])},this._renderAxis(this.element),this._handles=this._handles.add(this.element.find(".ui-resizable-handle")),this._handles.disableSelection(),this._handles.mouseover(function(){o.resizing||(this.className&&(n=this.className.match(/ui-resizable-(se|sw|ne|nw|n|e|s|w)/i)),o.axis=n&&n[1]?n[1]:"se")}),r.autoHide&&(this._handles.hide(),e(this.element).addClass("ui-resizable-autohide").mouseenter(function(){r.disabled||(e(this).removeClass("ui-resizable-autohide"),o._handles.show())}).mouseleave(function(){r.disabled||o.resizing||(e(this).addClass("ui-resizable-autohide"),o._handles.hide())})),this._mouseInit()},_destroy:function(){this._mouseDestroy();var t,i=function(t){e(t).removeClass("ui-resizable ui-resizable-disabled ui-resizable-resizing").removeData("resizable").removeData("ui-resizable").unbind(".resizable").find(".ui-resizable-handle").remove()};return this.elementIsWrapper&&(i(this.element),t=this.element,this.originalElement.css({position:t.css("position"),width:t.outerWidth(),height:t.outerHeight(),top:t.css("top"),left:t.css("left")}).insertAfter(t),t.remove()),this.originalElement.css("resize",this.originalResizeStyle),i(this.originalElement),this},_mouseCapture:function(t){var i,s,n=!1;for(i in this.handles)s=e(this.handles[i])[0],(s===t.target||e.contains(s,t.target))&&(n=!0);return!this.options.disabled&&n},_mouseStart:function(t){var i,s,n,a=this.options,o=this.element;return this.resizing=!0,this._renderProxy(),i=this._num(this.helper.css("left")),s=this._num(this.helper.css("top")),a.containment&&(i+=e(a.containment).scrollLeft()||0,s+=e(a.containment).scrollTop()||0),this.offset=this.helper.offset(),this.position={left:i,top:s},this.size=this._helper?{width:this.helper.width(),height:this.helper.height()}:{width:o.width(),height:o.height()},this.originalSize=this._helper?{width:o.outerWidth(),height:o.outerHeight()}:{width:o.width(),height:o.height()},this.sizeDiff={width:o.outerWidth()-o.width(),height:o.outerHeight()-o.height()},this.originalPosition={left:i,top:s},this.originalMousePosition={left:t.pageX,top:t.pageY},this.aspectRatio="number"==typeof a.aspectRatio?a.aspectRatio:this.originalSize.width/this.originalSize.height||1,n=e(".ui-resizable-"+this.axis).css("cursor"),e("body").css("cursor","auto"===n?this.axis+"-resize":n),o.addClass("ui-resizable-resizing"),this._propagate("start",t),!0},_mouseDrag:function(t){var i,s,n=this.originalMousePosition,a=this.axis,o=t.pageX-n.left||0,r=t.pageY-n.top||0,h=this._change[a];return this._updatePrevProperties(),h?(i=h.apply(this,[t,o,r]),this._updateVirtualBoundaries(t.shiftKey),(this._aspectRatio||t.shiftKey)&&(i=this._updateRatio(i,t)),i=this._respectSize(i,t),this._updateCache(i),this._propagate("resize",t),s=this._applyChanges(),!this._helper&&this._proportionallyResizeElements.length&&this._proportionallyResize(),e.isEmptyObject(s)||(this._updatePrevProperties(),this._trigger("resize",t,this.ui()),this._applyChanges()),!1):!1},_mouseStop:function(t){this.resizing=!1;var i,s,n,a,o,r,h,l=this.options,u=this;return this._helper&&(i=this._proportionallyResizeElements,s=i.length&&/textarea/i.test(i[0].nodeName),n=s&&this._hasScroll(i[0],"left")?0:u.sizeDiff.height,a=s?0:u.sizeDiff.width,o={width:u.helper.width()-a,height:u.helper.height()-n},r=parseInt(u.element.css("left"),10)+(u.position.left-u.originalPosition.left)||null,h=parseInt(u.element.css("top"),10)+(u.position.top-u.originalPosition.top)||null,l.animate||this.element.css(e.extend(o,{top:h,left:r})),u.helper.height(u.size.height),u.helper.width(u.size.width),this._helper&&!l.animate&&this._proportionallyResize()),e("body").css("cursor","auto"),this.element.removeClass("ui-resizable-resizing"),this._propagate("stop",t),this._helper&&this.helper.remove(),!1},_updatePrevProperties:function(){this.prevPosition={top:this.position.top,left:this.position.left},this.prevSize={width:this.size.width,height:this.size.height}},_applyChanges:function(){var e={};return this.position.top!==this.prevPosition.top&&(e.top=this.position.top+"px"),this.position.left!==this.prevPosition.left&&(e.left=this.position.left+"px"),this.size.width!==this.prevSize.width&&(e.width=this.size.width+"px"),this.size.height!==this.prevSize.height&&(e.height=this.size.height+"px"),this.helper.css(e),e},_updateVirtualBoundaries:function(e){var t,i,s,n,a,o=this.options;a={minWidth:this._isNumber(o.minWidth)?o.minWidth:0,maxWidth:this._isNumber(o.maxWidth)?o.maxWidth:1/0,minHeight:this._isNumber(o.minHeight)?o.minHeight:0,maxHeight:this._isNumber(o.maxHeight)?o.maxHeight:1/0},(this._aspectRatio||e)&&(t=a.minHeight*this.aspectRatio,s=a.minWidth/this.aspectRatio,i=a.maxHeight*this.aspectRatio,n=a.maxWidth/this.aspectRatio,t>a.minWidth&&(a.minWidth=t),s>a.minHeight&&(a.minHeight=s),a.maxWidth>i&&(a.maxWidth=i),a.maxHeight>n&&(a.maxHeight=n)),this._vBoundaries=a},_updateCache:function(e){this.offset=this.helper.offset(),this._isNumber(e.left)&&(this.position.left=e.left),this._isNumber(e.top)&&(this.position.top=e.top),this._isNumber(e.height)&&(this.size.height=e.height),this._isNumber(e.width)&&(this.size.width=e.width)},_updateRatio:function(e){var t=this.position,i=this.size,s=this.axis;return this._isNumber(e.height)?e.width=e.height*this.aspectRatio:this._isNumber(e.width)&&(e.height=e.width/this.aspectRatio),"sw"===s&&(e.left=t.left+(i.width-e.width),e.top=null),"nw"===s&&(e.top=t.top+(i.height-e.height),e.left=t.left+(i.width-e.width)),e},_respectSize:function(e){var t=this._vBoundaries,i=this.axis,s=this._isNumber(e.width)&&t.maxWidth&&t.maxWidth<e.width,n=this._isNumber(e.height)&&t.maxHeight&&t.maxHeight<e.height,a=this._isNumber(e.width)&&t.minWidth&&t.minWidth>e.width,o=this._isNumber(e.height)&&t.minHeight&&t.minHeight>e.height,r=this.originalPosition.left+this.originalSize.width,h=this.position.top+this.size.height,l=/sw|nw|w/.test(i),u=/nw|ne|n/.test(i);return a&&(e.width=t.minWidth),o&&(e.height=t.minHeight),s&&(e.width=t.maxWidth),n&&(e.height=t.maxHeight),a&&l&&(e.left=r-t.minWidth),s&&l&&(e.left=r-t.maxWidth),o&&u&&(e.top=h-t.minHeight),n&&u&&(e.top=h-t.maxHeight),e.width||e.height||e.left||!e.top?e.width||e.height||e.top||!e.left||(e.left=null):e.top=null,e},_getPaddingPlusBorderDimensions:function(e){for(var t=0,i=[],s=[e.css("borderTopWidth"),e.css("borderRightWidth"),e.css("borderBottomWidth"),e.css("borderLeftWidth")],n=[e.css("paddingTop"),e.css("paddingRight"),e.css("paddingBottom"),e.css("paddingLeft")];4>t;t++)i[t]=parseInt(s[t],10)||0,i[t]+=parseInt(n[t],10)||0;return{height:i[0]+i[2],width:i[1]+i[3]}},_proportionallyResize:function(){if(this._proportionallyResizeElements.length)for(var e,t=0,i=this.helper||this.element;this._proportionallyResizeElements.length>t;t++)e=this._proportionallyResizeElements[t],this.outerDimensions||(this.outerDimensions=this._getPaddingPlusBorderDimensions(e)),e.css({height:i.height()-this.outerDimensions.height||0,width:i.width()-this.outerDimensions.width||0})},_renderProxy:function(){var t=this.element,i=this.options;this.elementOffset=t.offset(),this._helper?(this.helper=this.helper||e("<div style='overflow:hidden;'></div>"),this.helper.addClass(this._helper).css({width:this.element.outerWidth()-1,height:this.element.outerHeight()-1,position:"absolute",left:this.elementOffset.left+"px",top:this.elementOffset.top+"px",zIndex:++i.zIndex}),this.helper.appendTo("body").disableSelection()):this.helper=this.element},_change:{e:function(e,t){return{width:this.originalSize.width+t}},w:function(e,t){var i=this.originalSize,s=this.originalPosition;return{left:s.left+t,width:i.width-t}},n:function(e,t,i){var s=this.originalSize,n=this.originalPosition;return{top:n.top+i,height:s.height-i}},s:function(e,t,i){return{height:this.originalSize.height+i}},se:function(t,i,s){return e.extend(this._change.s.apply(this,arguments),this._change.e.apply(this,[t,i,s]))},sw:function(t,i,s){return e.extend(this._change.s.apply(this,arguments),this._change.w.apply(this,[t,i,s]))},ne:function(t,i,s){return e.extend(this._change.n.apply(this,arguments),this._change.e.apply(this,[t,i,s]))},nw:function(t,i,s){return e.extend(this._change.n.apply(this,arguments),this._change.w.apply(this,[t,i,s]))}},_propagate:function(t,i){e.ui.plugin.call(this,t,[i,this.ui()]),"resize"!==t&&this._trigger(t,i,this.ui())},plugins:{},ui:function(){return{originalElement:this.originalElement,element:this.element,helper:this.helper,position:this.position,size:this.size,originalSize:this.originalSize,originalPosition:this.originalPosition}}}),e.ui.plugin.add("resizable","animate",{stop:function(t){var i=e(this).resizable("instance"),s=i.options,n=i._proportionallyResizeElements,a=n.length&&/textarea/i.test(n[0].nodeName),o=a&&i._hasScroll(n[0],"left")?0:i.sizeDiff.height,r=a?0:i.sizeDiff.width,h={width:i.size.width-r,height:i.size.height-o},l=parseInt(i.element.css("left"),10)+(i.position.left-i.originalPosition.left)||null,u=parseInt(i.element.css("top"),10)+(i.position.top-i.originalPosition.top)||null;i.element.animate(e.extend(h,u&&l?{top:u,left:l}:{}),{duration:s.animateDuration,easing:s.animateEasing,step:function(){var s={width:parseInt(i.element.css("width"),10),height:parseInt(i.element.css("height"),10),top:parseInt(i.element.css("top"),10),left:parseInt(i.element.css("left"),10)};n&&n.length&&e(n[0]).css({width:s.width,height:s.height}),i._updateCache(s),i._propagate("resize",t)}})}}),e.ui.plugin.add("resizable","containment",{start:function(){var t,i,s,n,a,o,r,h=e(this).resizable("instance"),l=h.options,u=h.element,d=l.containment,c=d instanceof e?d.get(0):/parent/.test(d)?u.parent().get(0):d;c&&(h.containerElement=e(c),/document/.test(d)||d===document?(h.containerOffset={left:0,top:0},h.containerPosition={left:0,top:0},h.parentData={element:e(document),left:0,top:0,width:e(document).width(),height:e(document).height()||document.body.parentNode.scrollHeight}):(t=e(c),i=[],e(["Top","Right","Left","Bottom"]).each(function(e,s){i[e]=h._num(t.css("padding"+s))}),h.containerOffset=t.offset(),h.containerPosition=t.position(),h.containerSize={height:t.innerHeight()-i[3],width:t.innerWidth()-i[1]},s=h.containerOffset,n=h.containerSize.height,a=h.containerSize.width,o=h._hasScroll(c,"left")?c.scrollWidth:a,r=h._hasScroll(c)?c.scrollHeight:n,h.parentData={element:c,left:s.left,top:s.top,width:o,height:r}))},resize:function(t){var i,s,n,a,o=e(this).resizable("instance"),r=o.options,h=o.containerOffset,l=o.position,u=o._aspectRatio||t.shiftKey,d={top:0,left:0},c=o.containerElement,p=!0;c[0]!==document&&/static/.test(c.css("position"))&&(d=h),l.left<(o._helper?h.left:0)&&(o.size.width=o.size.width+(o._helper?o.position.left-h.left:o.position.left-d.left),u&&(o.size.height=o.size.width/o.aspectRatio,p=!1),o.position.left=r.helper?h.left:0),l.top<(o._helper?h.top:0)&&(o.size.height=o.size.height+(o._helper?o.position.top-h.top:o.position.top),u&&(o.size.width=o.size.height*o.aspectRatio,p=!1),o.position.top=o._helper?h.top:0),n=o.containerElement.get(0)===o.element.parent().get(0),a=/relative|absolute/.test(o.containerElement.css("position")),n&&a?(o.offset.left=o.parentData.left+o.position.left,o.offset.top=o.parentData.top+o.position.top):(o.offset.left=o.element.offset().left,o.offset.top=o.element.offset().top),i=Math.abs(o.sizeDiff.width+(o._helper?o.offset.left-d.left:o.offset.left-h.left)),s=Math.abs(o.sizeDiff.height+(o._helper?o.offset.top-d.top:o.offset.top-h.top)),i+o.size.width>=o.parentData.width&&(o.size.width=o.parentData.width-i,u&&(o.size.height=o.size.width/o.aspectRatio,p=!1)),s+o.size.height>=o.parentData.height&&(o.size.height=o.parentData.height-s,u&&(o.size.width=o.size.height*o.aspectRatio,p=!1)),p||(o.position.left=o.prevPosition.left,o.position.top=o.prevPosition.top,o.size.width=o.prevSize.width,o.size.height=o.prevSize.height)},stop:function(){var t=e(this).resizable("instance"),i=t.options,s=t.containerOffset,n=t.containerPosition,a=t.containerElement,o=e(t.helper),r=o.offset(),h=o.outerWidth()-t.sizeDiff.width,l=o.outerHeight()-t.sizeDiff.height;t._helper&&!i.animate&&/relative/.test(a.css("position"))&&e(this).css({left:r.left-n.left-s.left,width:h,height:l}),t._helper&&!i.animate&&/static/.test(a.css("position"))&&e(this).css({left:r.left-n.left-s.left,width:h,height:l})}}),e.ui.plugin.add("resizable","alsoResize",{start:function(){var t=e(this).resizable("instance"),i=t.options;e(i.alsoResize).each(function(){var t=e(this);t.data("ui-resizable-alsoresize",{width:parseInt(t.width(),10),height:parseInt(t.height(),10),left:parseInt(t.css("left"),10),top:parseInt(t.css("top"),10)})})},resize:function(t,i){var s=e(this).resizable("instance"),n=s.options,a=s.originalSize,o=s.originalPosition,r={height:s.size.height-a.height||0,width:s.size.width-a.width||0,top:s.position.top-o.top||0,left:s.position.left-o.left||0};e(n.alsoResize).each(function(){var t=e(this),s=e(this).data("ui-resizable-alsoresize"),n={},a=t.parents(i.originalElement[0]).length?["width","height"]:["width","height","top","left"];e.each(a,function(e,t){var i=(s[t]||0)+(r[t]||0);i&&i>=0&&(n[t]=i||null)}),t.css(n)})},stop:function(){e(this).removeData("resizable-alsoresize")}}),e.ui.plugin.add("resizable","ghost",{start:function(){var t=e(this).resizable("instance"),i=t.options,s=t.size;t.ghost=t.originalElement.clone(),t.ghost.css({opacity:.25,display:"block",position:"relative",height:s.height,width:s.width,margin:0,left:0,top:0}).addClass("ui-resizable-ghost").addClass("string"==typeof i.ghost?i.ghost:""),t.ghost.appendTo(t.helper)},resize:function(){var t=e(this).resizable("instance");t.ghost&&t.ghost.css({position:"relative",height:t.size.height,width:t.size.width})},stop:function(){var t=e(this).resizable("instance");t.ghost&&t.helper&&t.helper.get(0).removeChild(t.ghost.get(0))}}),e.ui.plugin.add("resizable","grid",{resize:function(){var t,i=e(this).resizable("instance"),s=i.options,n=i.size,a=i.originalSize,o=i.originalPosition,r=i.axis,h="number"==typeof s.grid?[s.grid,s.grid]:s.grid,l=h[0]||1,u=h[1]||1,d=Math.round((n.width-a.width)/l)*l,c=Math.round((n.height-a.height)/u)*u,p=a.width+d,f=a.height+c,m=s.maxWidth&&p>s.maxWidth,g=s.maxHeight&&f>s.maxHeight,v=s.minWidth&&s.minWidth>p,y=s.minHeight&&s.minHeight>f;s.grid=h,v&&(p+=l),y&&(f+=u),m&&(p-=l),g&&(f-=u),/^(se|s|e)$/.test(r)?(i.size.width=p,i.size.height=f):/^(ne)$/.test(r)?(i.size.width=p,i.size.height=f,i.position.top=o.top-c):/^(sw)$/.test(r)?(i.size.width=p,i.size.height=f,i.position.left=o.left-d):((0>=f-u||0>=p-l)&&(t=i._getPaddingPlusBorderDimensions(this)),f-u>0?(i.size.height=f,i.position.top=o.top-c):(f=u-t.height,i.size.height=f,i.position.top=o.top+a.height-f),p-l>0?(i.size.width=p,i.position.left=o.left-d):(p=l-t.width,i.size.width=p,i.position.left=o.left+a.width-p))}}),e.ui.resizable,e.widget("ui.selectable",e.ui.mouse,{version:"1.11.4",options:{appendTo:"body",autoRefresh:!0,distance:0,filter:"*",tolerance:"touch",selected:null,selecting:null,start:null,stop:null,unselected:null,unselecting:null},_create:function(){var t,i=this;this.element.addClass("ui-selectable"),this.dragged=!1,this.refresh=function(){t=e(i.options.filter,i.element[0]),t.addClass("ui-selectee"),t.each(function(){var t=e(this),i=t.offset();e.data(this,"selectable-item",{element:this,$element:t,left:i.left,top:i.top,right:i.left+t.outerWidth(),bottom:i.top+t.outerHeight(),startselected:!1,selected:t.hasClass("ui-selected"),selecting:t.hasClass("ui-selecting"),unselecting:t.hasClass("ui-unselecting")})})},this.refresh(),this.selectees=t.addClass("ui-selectee"),this._mouseInit(),this.helper=e("<div class='ui-selectable-helper'></div>")},_destroy:function(){this.selectees.removeClass("ui-selectee").removeData("selectable-item"),this.element.removeClass("ui-selectable ui-selectable-disabled"),this._mouseDestroy()},_mouseStart:function(t){var i=this,s=this.options;this.opos=[t.pageX,t.pageY],this.options.disabled||(this.selectees=e(s.filter,this.element[0]),this._trigger("start",t),e(s.appendTo).append(this.helper),this.helper.css({left:t.pageX,top:t.pageY,width:0,height:0}),s.autoRefresh&&this.refresh(),this.selectees.filter(".ui-selected").each(function(){var s=e.data(this,"selectable-item");s.startselected=!0,t.metaKey||t.ctrlKey||(s.$element.removeClass("ui-selected"),s.selected=!1,s.$element.addClass("ui-unselecting"),s.unselecting=!0,i._trigger("unselecting",t,{unselecting:s.element}))}),e(t.target).parents().addBack().each(function(){var s,n=e.data(this,"selectable-item");return n?(s=!t.metaKey&&!t.ctrlKey||!n.$element.hasClass("ui-selected"),n.$element.removeClass(s?"ui-unselecting":"ui-selected").addClass(s?"ui-selecting":"ui-unselecting"),n.unselecting=!s,n.selecting=s,n.selected=s,s?i._trigger("selecting",t,{selecting:n.element}):i._trigger("unselecting",t,{unselecting:n.element}),!1):void 0}))},_mouseDrag:function(t){if(this.dragged=!0,!this.options.disabled){var i,s=this,n=this.options,a=this.opos[0],o=this.opos[1],r=t.pageX,h=t.pageY;return a>r&&(i=r,r=a,a=i),o>h&&(i=h,h=o,o=i),this.helper.css({left:a,top:o,width:r-a,height:h-o}),this.selectees.each(function(){var i=e.data(this,"selectable-item"),l=!1;
i&&i.element!==s.element[0]&&("touch"===n.tolerance?l=!(i.left>r||a>i.right||i.top>h||o>i.bottom):"fit"===n.tolerance&&(l=i.left>a&&r>i.right&&i.top>o&&h>i.bottom),l?(i.selected&&(i.$element.removeClass("ui-selected"),i.selected=!1),i.unselecting&&(i.$element.removeClass("ui-unselecting"),i.unselecting=!1),i.selecting||(i.$element.addClass("ui-selecting"),i.selecting=!0,s._trigger("selecting",t,{selecting:i.element}))):(i.selecting&&((t.metaKey||t.ctrlKey)&&i.startselected?(i.$element.removeClass("ui-selecting"),i.selecting=!1,i.$element.addClass("ui-selected"),i.selected=!0):(i.$element.removeClass("ui-selecting"),i.selecting=!1,i.startselected&&(i.$element.addClass("ui-unselecting"),i.unselecting=!0),s._trigger("unselecting",t,{unselecting:i.element}))),i.selected&&(t.metaKey||t.ctrlKey||i.startselected||(i.$element.removeClass("ui-selected"),i.selected=!1,i.$element.addClass("ui-unselecting"),i.unselecting=!0,s._trigger("unselecting",t,{unselecting:i.element})))))}),!1}},_mouseStop:function(t){var i=this;return this.dragged=!1,e(".ui-unselecting",this.element[0]).each(function(){var s=e.data(this,"selectable-item");s.$element.removeClass("ui-unselecting"),s.unselecting=!1,s.startselected=!1,i._trigger("unselected",t,{unselected:s.element})}),e(".ui-selecting",this.element[0]).each(function(){var s=e.data(this,"selectable-item");s.$element.removeClass("ui-selecting").addClass("ui-selected"),s.selecting=!1,s.selected=!0,s.startselected=!0,i._trigger("selected",t,{selected:s.element})}),this._trigger("stop",t),this.helper.remove(),!1}}),e.widget("ui.sortable",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"sort",ready:!1,options:{appendTo:"parent",axis:!1,connectWith:!1,containment:!1,cursor:"auto",cursorAt:!1,dropOnEmpty:!0,forcePlaceholderSize:!1,forceHelperSize:!1,grid:!1,handle:!1,helper:"original",items:"> *",opacity:!1,placeholder:!1,revert:!1,scroll:!0,scrollSensitivity:20,scrollSpeed:20,scope:"default",tolerance:"intersect",zIndex:1e3,activate:null,beforeStop:null,change:null,deactivate:null,out:null,over:null,receive:null,remove:null,sort:null,start:null,stop:null,update:null},_isOverAxis:function(e,t,i){return e>=t&&t+i>e},_isFloating:function(e){return/left|right/.test(e.css("float"))||/inline|table-cell/.test(e.css("display"))},_create:function(){this.containerCache={},this.element.addClass("ui-sortable"),this.refresh(),this.offset=this.element.offset(),this._mouseInit(),this._setHandleClassName(),this.ready=!0},_setOption:function(e,t){this._super(e,t),"handle"===e&&this._setHandleClassName()},_setHandleClassName:function(){this.element.find(".ui-sortable-handle").removeClass("ui-sortable-handle"),e.each(this.items,function(){(this.instance.options.handle?this.item.find(this.instance.options.handle):this.item).addClass("ui-sortable-handle")})},_destroy:function(){this.element.removeClass("ui-sortable ui-sortable-disabled").find(".ui-sortable-handle").removeClass("ui-sortable-handle"),this._mouseDestroy();for(var e=this.items.length-1;e>=0;e--)this.items[e].item.removeData(this.widgetName+"-item");return this},_mouseCapture:function(t,i){var s=null,n=!1,a=this;return this.reverting?!1:this.options.disabled||"static"===this.options.type?!1:(this._refreshItems(t),e(t.target).parents().each(function(){return e.data(this,a.widgetName+"-item")===a?(s=e(this),!1):void 0}),e.data(t.target,a.widgetName+"-item")===a&&(s=e(t.target)),s?!this.options.handle||i||(e(this.options.handle,s).find("*").addBack().each(function(){this===t.target&&(n=!0)}),n)?(this.currentItem=s,this._removeCurrentsFromItems(),!0):!1:!1)},_mouseStart:function(t,i,s){var n,a,o=this.options;if(this.currentContainer=this,this.refreshPositions(),this.helper=this._createHelper(t),this._cacheHelperProportions(),this._cacheMargins(),this.scrollParent=this.helper.scrollParent(),this.offset=this.currentItem.offset(),this.offset={top:this.offset.top-this.margins.top,left:this.offset.left-this.margins.left},e.extend(this.offset,{click:{left:t.pageX-this.offset.left,top:t.pageY-this.offset.top},parent:this._getParentOffset(),relative:this._getRelativeOffset()}),this.helper.css("position","absolute"),this.cssPosition=this.helper.css("position"),this.originalPosition=this._generatePosition(t),this.originalPageX=t.pageX,this.originalPageY=t.pageY,o.cursorAt&&this._adjustOffsetFromHelper(o.cursorAt),this.domPosition={prev:this.currentItem.prev()[0],parent:this.currentItem.parent()[0]},this.helper[0]!==this.currentItem[0]&&this.currentItem.hide(),this._createPlaceholder(),o.containment&&this._setContainment(),o.cursor&&"auto"!==o.cursor&&(a=this.document.find("body"),this.storedCursor=a.css("cursor"),a.css("cursor",o.cursor),this.storedStylesheet=e("<style>*{ cursor: "+o.cursor+" !important; }</style>").appendTo(a)),o.opacity&&(this.helper.css("opacity")&&(this._storedOpacity=this.helper.css("opacity")),this.helper.css("opacity",o.opacity)),o.zIndex&&(this.helper.css("zIndex")&&(this._storedZIndex=this.helper.css("zIndex")),this.helper.css("zIndex",o.zIndex)),this.scrollParent[0]!==this.document[0]&&"HTML"!==this.scrollParent[0].tagName&&(this.overflowOffset=this.scrollParent.offset()),this._trigger("start",t,this._uiHash()),this._preserveHelperProportions||this._cacheHelperProportions(),!s)for(n=this.containers.length-1;n>=0;n--)this.containers[n]._trigger("activate",t,this._uiHash(this));return e.ui.ddmanager&&(e.ui.ddmanager.current=this),e.ui.ddmanager&&!o.dropBehaviour&&e.ui.ddmanager.prepareOffsets(this,t),this.dragging=!0,this.helper.addClass("ui-sortable-helper"),this._mouseDrag(t),!0},_mouseDrag:function(t){var i,s,n,a,o=this.options,r=!1;for(this.position=this._generatePosition(t),this.positionAbs=this._convertPositionTo("absolute"),this.lastPositionAbs||(this.lastPositionAbs=this.positionAbs),this.options.scroll&&(this.scrollParent[0]!==this.document[0]&&"HTML"!==this.scrollParent[0].tagName?(this.overflowOffset.top+this.scrollParent[0].offsetHeight-t.pageY<o.scrollSensitivity?this.scrollParent[0].scrollTop=r=this.scrollParent[0].scrollTop+o.scrollSpeed:t.pageY-this.overflowOffset.top<o.scrollSensitivity&&(this.scrollParent[0].scrollTop=r=this.scrollParent[0].scrollTop-o.scrollSpeed),this.overflowOffset.left+this.scrollParent[0].offsetWidth-t.pageX<o.scrollSensitivity?this.scrollParent[0].scrollLeft=r=this.scrollParent[0].scrollLeft+o.scrollSpeed:t.pageX-this.overflowOffset.left<o.scrollSensitivity&&(this.scrollParent[0].scrollLeft=r=this.scrollParent[0].scrollLeft-o.scrollSpeed)):(t.pageY-this.document.scrollTop()<o.scrollSensitivity?r=this.document.scrollTop(this.document.scrollTop()-o.scrollSpeed):this.window.height()-(t.pageY-this.document.scrollTop())<o.scrollSensitivity&&(r=this.document.scrollTop(this.document.scrollTop()+o.scrollSpeed)),t.pageX-this.document.scrollLeft()<o.scrollSensitivity?r=this.document.scrollLeft(this.document.scrollLeft()-o.scrollSpeed):this.window.width()-(t.pageX-this.document.scrollLeft())<o.scrollSensitivity&&(r=this.document.scrollLeft(this.document.scrollLeft()+o.scrollSpeed))),r!==!1&&e.ui.ddmanager&&!o.dropBehaviour&&e.ui.ddmanager.prepareOffsets(this,t)),this.positionAbs=this._convertPositionTo("absolute"),this.options.axis&&"y"===this.options.axis||(this.helper[0].style.left=this.position.left+"px"),this.options.axis&&"x"===this.options.axis||(this.helper[0].style.top=this.position.top+"px"),i=this.items.length-1;i>=0;i--)if(s=this.items[i],n=s.item[0],a=this._intersectsWithPointer(s),a&&s.instance===this.currentContainer&&n!==this.currentItem[0]&&this.placeholder[1===a?"next":"prev"]()[0]!==n&&!e.contains(this.placeholder[0],n)&&("semi-dynamic"===this.options.type?!e.contains(this.element[0],n):!0)){if(this.direction=1===a?"down":"up","pointer"!==this.options.tolerance&&!this._intersectsWithSides(s))break;this._rearrange(t,s),this._trigger("change",t,this._uiHash());break}return this._contactContainers(t),e.ui.ddmanager&&e.ui.ddmanager.drag(this,t),this._trigger("sort",t,this._uiHash()),this.lastPositionAbs=this.positionAbs,!1},_mouseStop:function(t,i){if(t){if(e.ui.ddmanager&&!this.options.dropBehaviour&&e.ui.ddmanager.drop(this,t),this.options.revert){var s=this,n=this.placeholder.offset(),a=this.options.axis,o={};a&&"x"!==a||(o.left=n.left-this.offset.parent.left-this.margins.left+(this.offsetParent[0]===this.document[0].body?0:this.offsetParent[0].scrollLeft)),a&&"y"!==a||(o.top=n.top-this.offset.parent.top-this.margins.top+(this.offsetParent[0]===this.document[0].body?0:this.offsetParent[0].scrollTop)),this.reverting=!0,e(this.helper).animate(o,parseInt(this.options.revert,10)||500,function(){s._clear(t)})}else this._clear(t,i);return!1}},cancel:function(){if(this.dragging){this._mouseUp({target:null}),"original"===this.options.helper?this.currentItem.css(this._storedCSS).removeClass("ui-sortable-helper"):this.currentItem.show();for(var t=this.containers.length-1;t>=0;t--)this.containers[t]._trigger("deactivate",null,this._uiHash(this)),this.containers[t].containerCache.over&&(this.containers[t]._trigger("out",null,this._uiHash(this)),this.containers[t].containerCache.over=0)}return this.placeholder&&(this.placeholder[0].parentNode&&this.placeholder[0].parentNode.removeChild(this.placeholder[0]),"original"!==this.options.helper&&this.helper&&this.helper[0].parentNode&&this.helper.remove(),e.extend(this,{helper:null,dragging:!1,reverting:!1,_noFinalSort:null}),this.domPosition.prev?e(this.domPosition.prev).after(this.currentItem):e(this.domPosition.parent).prepend(this.currentItem)),this},serialize:function(t){var i=this._getItemsAsjQuery(t&&t.connected),s=[];return t=t||{},e(i).each(function(){var i=(e(t.item||this).attr(t.attribute||"id")||"").match(t.expression||/(.+)[\-=_](.+)/);i&&s.push((t.key||i[1]+"[]")+"="+(t.key&&t.expression?i[1]:i[2]))}),!s.length&&t.key&&s.push(t.key+"="),s.join("&")},toArray:function(t){var i=this._getItemsAsjQuery(t&&t.connected),s=[];return t=t||{},i.each(function(){s.push(e(t.item||this).attr(t.attribute||"id")||"")}),s},_intersectsWith:function(e){var t=this.positionAbs.left,i=t+this.helperProportions.width,s=this.positionAbs.top,n=s+this.helperProportions.height,a=e.left,o=a+e.width,r=e.top,h=r+e.height,l=this.offset.click.top,u=this.offset.click.left,d="x"===this.options.axis||s+l>r&&h>s+l,c="y"===this.options.axis||t+u>a&&o>t+u,p=d&&c;return"pointer"===this.options.tolerance||this.options.forcePointerForContainers||"pointer"!==this.options.tolerance&&this.helperProportions[this.floating?"width":"height"]>e[this.floating?"width":"height"]?p:t+this.helperProportions.width/2>a&&o>i-this.helperProportions.width/2&&s+this.helperProportions.height/2>r&&h>n-this.helperProportions.height/2},_intersectsWithPointer:function(e){var t="x"===this.options.axis||this._isOverAxis(this.positionAbs.top+this.offset.click.top,e.top,e.height),i="y"===this.options.axis||this._isOverAxis(this.positionAbs.left+this.offset.click.left,e.left,e.width),s=t&&i,n=this._getDragVerticalDirection(),a=this._getDragHorizontalDirection();return s?this.floating?a&&"right"===a||"down"===n?2:1:n&&("down"===n?2:1):!1},_intersectsWithSides:function(e){var t=this._isOverAxis(this.positionAbs.top+this.offset.click.top,e.top+e.height/2,e.height),i=this._isOverAxis(this.positionAbs.left+this.offset.click.left,e.left+e.width/2,e.width),s=this._getDragVerticalDirection(),n=this._getDragHorizontalDirection();return this.floating&&n?"right"===n&&i||"left"===n&&!i:s&&("down"===s&&t||"up"===s&&!t)},_getDragVerticalDirection:function(){var e=this.positionAbs.top-this.lastPositionAbs.top;return 0!==e&&(e>0?"down":"up")},_getDragHorizontalDirection:function(){var e=this.positionAbs.left-this.lastPositionAbs.left;return 0!==e&&(e>0?"right":"left")},refresh:function(e){return this._refreshItems(e),this._setHandleClassName(),this.refreshPositions(),this},_connectWith:function(){var e=this.options;return e.connectWith.constructor===String?[e.connectWith]:e.connectWith},_getItemsAsjQuery:function(t){function i(){r.push(this)}var s,n,a,o,r=[],h=[],l=this._connectWith();if(l&&t)for(s=l.length-1;s>=0;s--)for(a=e(l[s],this.document[0]),n=a.length-1;n>=0;n--)o=e.data(a[n],this.widgetFullName),o&&o!==this&&!o.options.disabled&&h.push([e.isFunction(o.options.items)?o.options.items.call(o.element):e(o.options.items,o.element).not(".ui-sortable-helper").not(".ui-sortable-placeholder"),o]);for(h.push([e.isFunction(this.options.items)?this.options.items.call(this.element,null,{options:this.options,item:this.currentItem}):e(this.options.items,this.element).not(".ui-sortable-helper").not(".ui-sortable-placeholder"),this]),s=h.length-1;s>=0;s--)h[s][0].each(i);return e(r)},_removeCurrentsFromItems:function(){var t=this.currentItem.find(":data("+this.widgetName+"-item)");this.items=e.grep(this.items,function(e){for(var i=0;t.length>i;i++)if(t[i]===e.item[0])return!1;return!0})},_refreshItems:function(t){this.items=[],this.containers=[this];var i,s,n,a,o,r,h,l,u=this.items,d=[[e.isFunction(this.options.items)?this.options.items.call(this.element[0],t,{item:this.currentItem}):e(this.options.items,this.element),this]],c=this._connectWith();if(c&&this.ready)for(i=c.length-1;i>=0;i--)for(n=e(c[i],this.document[0]),s=n.length-1;s>=0;s--)a=e.data(n[s],this.widgetFullName),a&&a!==this&&!a.options.disabled&&(d.push([e.isFunction(a.options.items)?a.options.items.call(a.element[0],t,{item:this.currentItem}):e(a.options.items,a.element),a]),this.containers.push(a));for(i=d.length-1;i>=0;i--)for(o=d[i][1],r=d[i][0],s=0,l=r.length;l>s;s++)h=e(r[s]),h.data(this.widgetName+"-item",o),u.push({item:h,instance:o,width:0,height:0,left:0,top:0})},refreshPositions:function(t){this.floating=this.items.length?"x"===this.options.axis||this._isFloating(this.items[0].item):!1,this.offsetParent&&this.helper&&(this.offset.parent=this._getParentOffset());var i,s,n,a;for(i=this.items.length-1;i>=0;i--)s=this.items[i],s.instance!==this.currentContainer&&this.currentContainer&&s.item[0]!==this.currentItem[0]||(n=this.options.toleranceElement?e(this.options.toleranceElement,s.item):s.item,t||(s.width=n.outerWidth(),s.height=n.outerHeight()),a=n.offset(),s.left=a.left,s.top=a.top);if(this.options.custom&&this.options.custom.refreshContainers)this.options.custom.refreshContainers.call(this);else for(i=this.containers.length-1;i>=0;i--)a=this.containers[i].element.offset(),this.containers[i].containerCache.left=a.left,this.containers[i].containerCache.top=a.top,this.containers[i].containerCache.width=this.containers[i].element.outerWidth(),this.containers[i].containerCache.height=this.containers[i].element.outerHeight();return this},_createPlaceholder:function(t){t=t||this;var i,s=t.options;s.placeholder&&s.placeholder.constructor!==String||(i=s.placeholder,s.placeholder={element:function(){var s=t.currentItem[0].nodeName.toLowerCase(),n=e("<"+s+">",t.document[0]).addClass(i||t.currentItem[0].className+" ui-sortable-placeholder").removeClass("ui-sortable-helper");return"tbody"===s?t._createTrPlaceholder(t.currentItem.find("tr").eq(0),e("<tr>",t.document[0]).appendTo(n)):"tr"===s?t._createTrPlaceholder(t.currentItem,n):"img"===s&&n.attr("src",t.currentItem.attr("src")),i||n.css("visibility","hidden"),n},update:function(e,n){(!i||s.forcePlaceholderSize)&&(n.height()||n.height(t.currentItem.innerHeight()-parseInt(t.currentItem.css("paddingTop")||0,10)-parseInt(t.currentItem.css("paddingBottom")||0,10)),n.width()||n.width(t.currentItem.innerWidth()-parseInt(t.currentItem.css("paddingLeft")||0,10)-parseInt(t.currentItem.css("paddingRight")||0,10)))}}),t.placeholder=e(s.placeholder.element.call(t.element,t.currentItem)),t.currentItem.after(t.placeholder),s.placeholder.update(t,t.placeholder)},_createTrPlaceholder:function(t,i){var s=this;t.children().each(function(){e("<td>&#160;</td>",s.document[0]).attr("colspan",e(this).attr("colspan")||1).appendTo(i)})},_contactContainers:function(t){var i,s,n,a,o,r,h,l,u,d,c=null,p=null;for(i=this.containers.length-1;i>=0;i--)if(!e.contains(this.currentItem[0],this.containers[i].element[0]))if(this._intersectsWith(this.containers[i].containerCache)){if(c&&e.contains(this.containers[i].element[0],c.element[0]))continue;c=this.containers[i],p=i}else this.containers[i].containerCache.over&&(this.containers[i]._trigger("out",t,this._uiHash(this)),this.containers[i].containerCache.over=0);if(c)if(1===this.containers.length)this.containers[p].containerCache.over||(this.containers[p]._trigger("over",t,this._uiHash(this)),this.containers[p].containerCache.over=1);else{for(n=1e4,a=null,u=c.floating||this._isFloating(this.currentItem),o=u?"left":"top",r=u?"width":"height",d=u?"clientX":"clientY",s=this.items.length-1;s>=0;s--)e.contains(this.containers[p].element[0],this.items[s].item[0])&&this.items[s].item[0]!==this.currentItem[0]&&(h=this.items[s].item.offset()[o],l=!1,t[d]-h>this.items[s][r]/2&&(l=!0),n>Math.abs(t[d]-h)&&(n=Math.abs(t[d]-h),a=this.items[s],this.direction=l?"up":"down"));if(!a&&!this.options.dropOnEmpty)return;if(this.currentContainer===this.containers[p])return this.currentContainer.containerCache.over||(this.containers[p]._trigger("over",t,this._uiHash()),this.currentContainer.containerCache.over=1),void 0;a?this._rearrange(t,a,null,!0):this._rearrange(t,null,this.containers[p].element,!0),this._trigger("change",t,this._uiHash()),this.containers[p]._trigger("change",t,this._uiHash(this)),this.currentContainer=this.containers[p],this.options.placeholder.update(this.currentContainer,this.placeholder),this.containers[p]._trigger("over",t,this._uiHash(this)),this.containers[p].containerCache.over=1}},_createHelper:function(t){var i=this.options,s=e.isFunction(i.helper)?e(i.helper.apply(this.element[0],[t,this.currentItem])):"clone"===i.helper?this.currentItem.clone():this.currentItem;return s.parents("body").length||e("parent"!==i.appendTo?i.appendTo:this.currentItem[0].parentNode)[0].appendChild(s[0]),s[0]===this.currentItem[0]&&(this._storedCSS={width:this.currentItem[0].style.width,height:this.currentItem[0].style.height,position:this.currentItem.css("position"),top:this.currentItem.css("top"),left:this.currentItem.css("left")}),(!s[0].style.width||i.forceHelperSize)&&s.width(this.currentItem.width()),(!s[0].style.height||i.forceHelperSize)&&s.height(this.currentItem.height()),s},_adjustOffsetFromHelper:function(t){"string"==typeof t&&(t=t.split(" ")),e.isArray(t)&&(t={left:+t[0],top:+t[1]||0}),"left"in t&&(this.offset.click.left=t.left+this.margins.left),"right"in t&&(this.offset.click.left=this.helperProportions.width-t.right+this.margins.left),"top"in t&&(this.offset.click.top=t.top+this.margins.top),"bottom"in t&&(this.offset.click.top=this.helperProportions.height-t.bottom+this.margins.top)},_getParentOffset:function(){this.offsetParent=this.helper.offsetParent();var t=this.offsetParent.offset();return"absolute"===this.cssPosition&&this.scrollParent[0]!==this.document[0]&&e.contains(this.scrollParent[0],this.offsetParent[0])&&(t.left+=this.scrollParent.scrollLeft(),t.top+=this.scrollParent.scrollTop()),(this.offsetParent[0]===this.document[0].body||this.offsetParent[0].tagName&&"html"===this.offsetParent[0].tagName.toLowerCase()&&e.ui.ie)&&(t={top:0,left:0}),{top:t.top+(parseInt(this.offsetParent.css("borderTopWidth"),10)||0),left:t.left+(parseInt(this.offsetParent.css("borderLeftWidth"),10)||0)}},_getRelativeOffset:function(){if("relative"===this.cssPosition){var e=this.currentItem.position();return{top:e.top-(parseInt(this.helper.css("top"),10)||0)+this.scrollParent.scrollTop(),left:e.left-(parseInt(this.helper.css("left"),10)||0)+this.scrollParent.scrollLeft()}}return{top:0,left:0}},_cacheMargins:function(){this.margins={left:parseInt(this.currentItem.css("marginLeft"),10)||0,top:parseInt(this.currentItem.css("marginTop"),10)||0}},_cacheHelperProportions:function(){this.helperProportions={width:this.helper.outerWidth(),height:this.helper.outerHeight()}},_setContainment:function(){var t,i,s,n=this.options;"parent"===n.containment&&(n.containment=this.helper[0].parentNode),("document"===n.containment||"window"===n.containment)&&(this.containment=[0-this.offset.relative.left-this.offset.parent.left,0-this.offset.relative.top-this.offset.parent.top,"document"===n.containment?this.document.width():this.window.width()-this.helperProportions.width-this.margins.left,("document"===n.containment?this.document.width():this.window.height()||this.document[0].body.parentNode.scrollHeight)-this.helperProportions.height-this.margins.top]),/^(document|window|parent)$/.test(n.containment)||(t=e(n.containment)[0],i=e(n.containment).offset(),s="hidden"!==e(t).css("overflow"),this.containment=[i.left+(parseInt(e(t).css("borderLeftWidth"),10)||0)+(parseInt(e(t).css("paddingLeft"),10)||0)-this.margins.left,i.top+(parseInt(e(t).css("borderTopWidth"),10)||0)+(parseInt(e(t).css("paddingTop"),10)||0)-this.margins.top,i.left+(s?Math.max(t.scrollWidth,t.offsetWidth):t.offsetWidth)-(parseInt(e(t).css("borderLeftWidth"),10)||0)-(parseInt(e(t).css("paddingRight"),10)||0)-this.helperProportions.width-this.margins.left,i.top+(s?Math.max(t.scrollHeight,t.offsetHeight):t.offsetHeight)-(parseInt(e(t).css("borderTopWidth"),10)||0)-(parseInt(e(t).css("paddingBottom"),10)||0)-this.helperProportions.height-this.margins.top])},_convertPositionTo:function(t,i){i||(i=this.position);var s="absolute"===t?1:-1,n="absolute"!==this.cssPosition||this.scrollParent[0]!==this.document[0]&&e.contains(this.scrollParent[0],this.offsetParent[0])?this.scrollParent:this.offsetParent,a=/(html|body)/i.test(n[0].tagName);return{top:i.top+this.offset.relative.top*s+this.offset.parent.top*s-("fixed"===this.cssPosition?-this.scrollParent.scrollTop():a?0:n.scrollTop())*s,left:i.left+this.offset.relative.left*s+this.offset.parent.left*s-("fixed"===this.cssPosition?-this.scrollParent.scrollLeft():a?0:n.scrollLeft())*s}},_generatePosition:function(t){var i,s,n=this.options,a=t.pageX,o=t.pageY,r="absolute"!==this.cssPosition||this.scrollParent[0]!==this.document[0]&&e.contains(this.scrollParent[0],this.offsetParent[0])?this.scrollParent:this.offsetParent,h=/(html|body)/i.test(r[0].tagName);return"relative"!==this.cssPosition||this.scrollParent[0]!==this.document[0]&&this.scrollParent[0]!==this.offsetParent[0]||(this.offset.relative=this._getRelativeOffset()),this.originalPosition&&(this.containment&&(t.pageX-this.offset.click.left<this.containment[0]&&(a=this.containment[0]+this.offset.click.left),t.pageY-this.offset.click.top<this.containment[1]&&(o=this.containment[1]+this.offset.click.top),t.pageX-this.offset.click.left>this.containment[2]&&(a=this.containment[2]+this.offset.click.left),t.pageY-this.offset.click.top>this.containment[3]&&(o=this.containment[3]+this.offset.click.top)),n.grid&&(i=this.originalPageY+Math.round((o-this.originalPageY)/n.grid[1])*n.grid[1],o=this.containment?i-this.offset.click.top>=this.containment[1]&&i-this.offset.click.top<=this.containment[3]?i:i-this.offset.click.top>=this.containment[1]?i-n.grid[1]:i+n.grid[1]:i,s=this.originalPageX+Math.round((a-this.originalPageX)/n.grid[0])*n.grid[0],a=this.containment?s-this.offset.click.left>=this.containment[0]&&s-this.offset.click.left<=this.containment[2]?s:s-this.offset.click.left>=this.containment[0]?s-n.grid[0]:s+n.grid[0]:s)),{top:o-this.offset.click.top-this.offset.relative.top-this.offset.parent.top+("fixed"===this.cssPosition?-this.scrollParent.scrollTop():h?0:r.scrollTop()),left:a-this.offset.click.left-this.offset.relative.left-this.offset.parent.left+("fixed"===this.cssPosition?-this.scrollParent.scrollLeft():h?0:r.scrollLeft())}},_rearrange:function(e,t,i,s){i?i[0].appendChild(this.placeholder[0]):t.item[0].parentNode.insertBefore(this.placeholder[0],"down"===this.direction?t.item[0]:t.item[0].nextSibling),this.counter=this.counter?++this.counter:1;var n=this.counter;this._delay(function(){n===this.counter&&this.refreshPositions(!s)})},_clear:function(e,t){function i(e,t,i){return function(s){i._trigger(e,s,t._uiHash(t))}}this.reverting=!1;var s,n=[];if(!this._noFinalSort&&this.currentItem.parent().length&&this.placeholder.before(this.currentItem),this._noFinalSort=null,this.helper[0]===this.currentItem[0]){for(s in this._storedCSS)("auto"===this._storedCSS[s]||"static"===this._storedCSS[s])&&(this._storedCSS[s]="");this.currentItem.css(this._storedCSS).removeClass("ui-sortable-helper")}else this.currentItem.show();for(this.fromOutside&&!t&&n.push(function(e){this._trigger("receive",e,this._uiHash(this.fromOutside))}),!this.fromOutside&&this.domPosition.prev===this.currentItem.prev().not(".ui-sortable-helper")[0]&&this.domPosition.parent===this.currentItem.parent()[0]||t||n.push(function(e){this._trigger("update",e,this._uiHash())}),this!==this.currentContainer&&(t||(n.push(function(e){this._trigger("remove",e,this._uiHash())}),n.push(function(e){return function(t){e._trigger("receive",t,this._uiHash(this))}}.call(this,this.currentContainer)),n.push(function(e){return function(t){e._trigger("update",t,this._uiHash(this))}}.call(this,this.currentContainer)))),s=this.containers.length-1;s>=0;s--)t||n.push(i("deactivate",this,this.containers[s])),this.containers[s].containerCache.over&&(n.push(i("out",this,this.containers[s])),this.containers[s].containerCache.over=0);if(this.storedCursor&&(this.document.find("body").css("cursor",this.storedCursor),this.storedStylesheet.remove()),this._storedOpacity&&this.helper.css("opacity",this._storedOpacity),this._storedZIndex&&this.helper.css("zIndex","auto"===this._storedZIndex?"":this._storedZIndex),this.dragging=!1,t||this._trigger("beforeStop",e,this._uiHash()),this.placeholder[0].parentNode.removeChild(this.placeholder[0]),this.cancelHelperRemoval||(this.helper[0]!==this.currentItem[0]&&this.helper.remove(),this.helper=null),!t){for(s=0;n.length>s;s++)n[s].call(this,e);this._trigger("stop",e,this._uiHash())}return this.fromOutside=!1,!this.cancelHelperRemoval},_trigger:function(){e.Widget.prototype._trigger.apply(this,arguments)===!1&&this.cancel()},_uiHash:function(t){var i=t||this;return{helper:i.helper,placeholder:i.placeholder||e([]),position:i.position,originalPosition:i.originalPosition,offset:i.positionAbs,item:i.currentItem,sender:t?t.element:null}}}),e.widget("ui.accordion",{version:"1.11.4",options:{active:0,animate:{},collapsible:!1,event:"click",header:"> li > :first-child,> :not(li):even",heightStyle:"auto",icons:{activeHeader:"ui-icon-triangle-1-s",header:"ui-icon-triangle-1-e"},activate:null,beforeActivate:null},hideProps:{borderTopWidth:"hide",borderBottomWidth:"hide",paddingTop:"hide",paddingBottom:"hide",height:"hide"},showProps:{borderTopWidth:"show",borderBottomWidth:"show",paddingTop:"show",paddingBottom:"show",height:"show"},_create:function(){var t=this.options;this.prevShow=this.prevHide=e(),this.element.addClass("ui-accordion ui-widget ui-helper-reset").attr("role","tablist"),t.collapsible||t.active!==!1&&null!=t.active||(t.active=0),this._processPanels(),0>t.active&&(t.active+=this.headers.length),this._refresh()},_getCreateEventData:function(){return{header:this.active,panel:this.active.length?this.active.next():e()}},_createIcons:function(){var t=this.options.icons;t&&(e("<span>").addClass("ui-accordion-header-icon ui-icon "+t.header).prependTo(this.headers),this.active.children(".ui-accordion-header-icon").removeClass(t.header).addClass(t.activeHeader),this.headers.addClass("ui-accordion-icons"))},_destroyIcons:function(){this.headers.removeClass("ui-accordion-icons").children(".ui-accordion-header-icon").remove()},_destroy:function(){var e;this.element.removeClass("ui-accordion ui-widget ui-helper-reset").removeAttr("role"),this.headers.removeClass("ui-accordion-header ui-accordion-header-active ui-state-default ui-corner-all ui-state-active ui-state-disabled ui-corner-top").removeAttr("role").removeAttr("aria-expanded").removeAttr("aria-selected").removeAttr("aria-controls").removeAttr("tabIndex").removeUniqueId(),this._destroyIcons(),e=this.headers.next().removeClass("ui-helper-reset ui-widget-content ui-corner-bottom ui-accordion-content ui-accordion-content-active ui-state-disabled").css("display","").removeAttr("role").removeAttr("aria-hidden").removeAttr("aria-labelledby").removeUniqueId(),"content"!==this.options.heightStyle&&e.css("height","")},_setOption:function(e,t){return"active"===e?(this._activate(t),void 0):("event"===e&&(this.options.event&&this._off(this.headers,this.options.event),this._setupEvents(t)),this._super(e,t),"collapsible"!==e||t||this.options.active!==!1||this._activate(0),"icons"===e&&(this._destroyIcons(),t&&this._createIcons()),"disabled"===e&&(this.element.toggleClass("ui-state-disabled",!!t).attr("aria-disabled",t),this.headers.add(this.headers.next()).toggleClass("ui-state-disabled",!!t)),void 0)},_keydown:function(t){if(!t.altKey&&!t.ctrlKey){var i=e.ui.keyCode,s=this.headers.length,n=this.headers.index(t.target),a=!1;switch(t.keyCode){case i.RIGHT:case i.DOWN:a=this.headers[(n+1)%s];break;case i.LEFT:case i.UP:a=this.headers[(n-1+s)%s];break;case i.SPACE:case i.ENTER:this._eventHandler(t);break;case i.HOME:a=this.headers[0];break;case i.END:a=this.headers[s-1]}a&&(e(t.target).attr("tabIndex",-1),e(a).attr("tabIndex",0),a.focus(),t.preventDefault())}},_panelKeyDown:function(t){t.keyCode===e.ui.keyCode.UP&&t.ctrlKey&&e(t.currentTarget).prev().focus()},refresh:function(){var t=this.options;this._processPanels(),t.active===!1&&t.collapsible===!0||!this.headers.length?(t.active=!1,this.active=e()):t.active===!1?this._activate(0):this.active.length&&!e.contains(this.element[0],this.active[0])?this.headers.length===this.headers.find(".ui-state-disabled").length?(t.active=!1,this.active=e()):this._activate(Math.max(0,t.active-1)):t.active=this.headers.index(this.active),this._destroyIcons(),this._refresh()},_processPanels:function(){var e=this.headers,t=this.panels;this.headers=this.element.find(this.options.header).addClass("ui-accordion-header ui-state-default ui-corner-all"),this.panels=this.headers.next().addClass("ui-accordion-content ui-helper-reset ui-widget-content ui-corner-bottom").filter(":not(.ui-accordion-content-active)").hide(),t&&(this._off(e.not(this.headers)),this._off(t.not(this.panels)))},_refresh:function(){var t,i=this.options,s=i.heightStyle,n=this.element.parent();this.active=this._findActive(i.active).addClass("ui-accordion-header-active ui-state-active ui-corner-top").removeClass("ui-corner-all"),this.active.next().addClass("ui-accordion-content-active").show(),this.headers.attr("role","tab").each(function(){var t=e(this),i=t.uniqueId().attr("id"),s=t.next(),n=s.uniqueId().attr("id");t.attr("aria-controls",n),s.attr("aria-labelledby",i)}).next().attr("role","tabpanel"),this.headers.not(this.active).attr({"aria-selected":"false","aria-expanded":"false",tabIndex:-1}).next().attr({"aria-hidden":"true"}).hide(),this.active.length?this.active.attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0}).next().attr({"aria-hidden":"false"}):this.headers.eq(0).attr("tabIndex",0),this._createIcons(),this._setupEvents(i.event),"fill"===s?(t=n.height(),this.element.siblings(":visible").each(function(){var i=e(this),s=i.css("position");"absolute"!==s&&"fixed"!==s&&(t-=i.outerHeight(!0))}),this.headers.each(function(){t-=e(this).outerHeight(!0)}),this.headers.next().each(function(){e(this).height(Math.max(0,t-e(this).innerHeight()+e(this).height()))}).css("overflow","auto")):"auto"===s&&(t=0,this.headers.next().each(function(){t=Math.max(t,e(this).css("height","").height())}).height(t))},_activate:function(t){var i=this._findActive(t)[0];i!==this.active[0]&&(i=i||this.active[0],this._eventHandler({target:i,currentTarget:i,preventDefault:e.noop}))},_findActive:function(t){return"number"==typeof t?this.headers.eq(t):e()},_setupEvents:function(t){var i={keydown:"_keydown"};t&&e.each(t.split(" "),function(e,t){i[t]="_eventHandler"}),this._off(this.headers.add(this.headers.next())),this._on(this.headers,i),this._on(this.headers.next(),{keydown:"_panelKeyDown"}),this._hoverable(this.headers),this._focusable(this.headers)},_eventHandler:function(t){var i=this.options,s=this.active,n=e(t.currentTarget),a=n[0]===s[0],o=a&&i.collapsible,r=o?e():n.next(),h=s.next(),l={oldHeader:s,oldPanel:h,newHeader:o?e():n,newPanel:r};
t.preventDefault(),a&&!i.collapsible||this._trigger("beforeActivate",t,l)===!1||(i.active=o?!1:this.headers.index(n),this.active=a?e():n,this._toggle(l),s.removeClass("ui-accordion-header-active ui-state-active"),i.icons&&s.children(".ui-accordion-header-icon").removeClass(i.icons.activeHeader).addClass(i.icons.header),a||(n.removeClass("ui-corner-all").addClass("ui-accordion-header-active ui-state-active ui-corner-top"),i.icons&&n.children(".ui-accordion-header-icon").removeClass(i.icons.header).addClass(i.icons.activeHeader),n.next().addClass("ui-accordion-content-active")))},_toggle:function(t){var i=t.newPanel,s=this.prevShow.length?this.prevShow:t.oldPanel;this.prevShow.add(this.prevHide).stop(!0,!0),this.prevShow=i,this.prevHide=s,this.options.animate?this._animate(i,s,t):(s.hide(),i.show(),this._toggleComplete(t)),s.attr({"aria-hidden":"true"}),s.prev().attr({"aria-selected":"false","aria-expanded":"false"}),i.length&&s.length?s.prev().attr({tabIndex:-1,"aria-expanded":"false"}):i.length&&this.headers.filter(function(){return 0===parseInt(e(this).attr("tabIndex"),10)}).attr("tabIndex",-1),i.attr("aria-hidden","false").prev().attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0})},_animate:function(e,t,i){var s,n,a,o=this,r=0,h=e.css("box-sizing"),l=e.length&&(!t.length||e.index()<t.index()),u=this.options.animate||{},d=l&&u.down||u,c=function(){o._toggleComplete(i)};return"number"==typeof d&&(a=d),"string"==typeof d&&(n=d),n=n||d.easing||u.easing,a=a||d.duration||u.duration,t.length?e.length?(s=e.show().outerHeight(),t.animate(this.hideProps,{duration:a,easing:n,step:function(e,t){t.now=Math.round(e)}}),e.hide().animate(this.showProps,{duration:a,easing:n,complete:c,step:function(e,i){i.now=Math.round(e),"height"!==i.prop?"content-box"===h&&(r+=i.now):"content"!==o.options.heightStyle&&(i.now=Math.round(s-t.outerHeight()-r),r=0)}}),void 0):t.animate(this.hideProps,a,n,c):e.animate(this.showProps,a,n,c)},_toggleComplete:function(e){var t=e.oldPanel;t.removeClass("ui-accordion-content-active").prev().removeClass("ui-corner-top").addClass("ui-corner-all"),t.length&&(t.parent()[0].className=t.parent()[0].className),this._trigger("activate",null,e)}}),e.widget("ui.menu",{version:"1.11.4",defaultElement:"<ul>",delay:300,options:{icons:{submenu:"ui-icon-carat-1-e"},items:"> *",menus:"ul",position:{my:"left-1 top",at:"right top"},role:"menu",blur:null,focus:null,select:null},_create:function(){this.activeMenu=this.element,this.mouseHandled=!1,this.element.uniqueId().addClass("ui-menu ui-widget ui-widget-content").toggleClass("ui-menu-icons",!!this.element.find(".ui-icon").length).attr({role:this.options.role,tabIndex:0}),this.options.disabled&&this.element.addClass("ui-state-disabled").attr("aria-disabled","true"),this._on({"mousedown .ui-menu-item":function(e){e.preventDefault()},"click .ui-menu-item":function(t){var i=e(t.target);!this.mouseHandled&&i.not(".ui-state-disabled").length&&(this.select(t),t.isPropagationStopped()||(this.mouseHandled=!0),i.has(".ui-menu").length?this.expand(t):!this.element.is(":focus")&&e(this.document[0].activeElement).closest(".ui-menu").length&&(this.element.trigger("focus",[!0]),this.active&&1===this.active.parents(".ui-menu").length&&clearTimeout(this.timer)))},"mouseenter .ui-menu-item":function(t){if(!this.previousFilter){var i=e(t.currentTarget);i.siblings(".ui-state-active").removeClass("ui-state-active"),this.focus(t,i)}},mouseleave:"collapseAll","mouseleave .ui-menu":"collapseAll",focus:function(e,t){var i=this.active||this.element.find(this.options.items).eq(0);t||this.focus(e,i)},blur:function(t){this._delay(function(){e.contains(this.element[0],this.document[0].activeElement)||this.collapseAll(t)})},keydown:"_keydown"}),this.refresh(),this._on(this.document,{click:function(e){this._closeOnDocumentClick(e)&&this.collapseAll(e),this.mouseHandled=!1}})},_destroy:function(){this.element.removeAttr("aria-activedescendant").find(".ui-menu").addBack().removeClass("ui-menu ui-widget ui-widget-content ui-menu-icons ui-front").removeAttr("role").removeAttr("tabIndex").removeAttr("aria-labelledby").removeAttr("aria-expanded").removeAttr("aria-hidden").removeAttr("aria-disabled").removeUniqueId().show(),this.element.find(".ui-menu-item").removeClass("ui-menu-item").removeAttr("role").removeAttr("aria-disabled").removeUniqueId().removeClass("ui-state-hover").removeAttr("tabIndex").removeAttr("role").removeAttr("aria-haspopup").children().each(function(){var t=e(this);t.data("ui-menu-submenu-carat")&&t.remove()}),this.element.find(".ui-menu-divider").removeClass("ui-menu-divider ui-widget-content")},_keydown:function(t){var i,s,n,a,o=!0;switch(t.keyCode){case e.ui.keyCode.PAGE_UP:this.previousPage(t);break;case e.ui.keyCode.PAGE_DOWN:this.nextPage(t);break;case e.ui.keyCode.HOME:this._move("first","first",t);break;case e.ui.keyCode.END:this._move("last","last",t);break;case e.ui.keyCode.UP:this.previous(t);break;case e.ui.keyCode.DOWN:this.next(t);break;case e.ui.keyCode.LEFT:this.collapse(t);break;case e.ui.keyCode.RIGHT:this.active&&!this.active.is(".ui-state-disabled")&&this.expand(t);break;case e.ui.keyCode.ENTER:case e.ui.keyCode.SPACE:this._activate(t);break;case e.ui.keyCode.ESCAPE:this.collapse(t);break;default:o=!1,s=this.previousFilter||"",n=String.fromCharCode(t.keyCode),a=!1,clearTimeout(this.filterTimer),n===s?a=!0:n=s+n,i=this._filterMenuItems(n),i=a&&-1!==i.index(this.active.next())?this.active.nextAll(".ui-menu-item"):i,i.length||(n=String.fromCharCode(t.keyCode),i=this._filterMenuItems(n)),i.length?(this.focus(t,i),this.previousFilter=n,this.filterTimer=this._delay(function(){delete this.previousFilter},1e3)):delete this.previousFilter}o&&t.preventDefault()},_activate:function(e){this.active.is(".ui-state-disabled")||(this.active.is("[aria-haspopup='true']")?this.expand(e):this.select(e))},refresh:function(){var t,i,s=this,n=this.options.icons.submenu,a=this.element.find(this.options.menus);this.element.toggleClass("ui-menu-icons",!!this.element.find(".ui-icon").length),a.filter(":not(.ui-menu)").addClass("ui-menu ui-widget ui-widget-content ui-front").hide().attr({role:this.options.role,"aria-hidden":"true","aria-expanded":"false"}).each(function(){var t=e(this),i=t.parent(),s=e("<span>").addClass("ui-menu-icon ui-icon "+n).data("ui-menu-submenu-carat",!0);i.attr("aria-haspopup","true").prepend(s),t.attr("aria-labelledby",i.attr("id"))}),t=a.add(this.element),i=t.find(this.options.items),i.not(".ui-menu-item").each(function(){var t=e(this);s._isDivider(t)&&t.addClass("ui-widget-content ui-menu-divider")}),i.not(".ui-menu-item, .ui-menu-divider").addClass("ui-menu-item").uniqueId().attr({tabIndex:-1,role:this._itemRole()}),i.filter(".ui-state-disabled").attr("aria-disabled","true"),this.active&&!e.contains(this.element[0],this.active[0])&&this.blur()},_itemRole:function(){return{menu:"menuitem",listbox:"option"}[this.options.role]},_setOption:function(e,t){"icons"===e&&this.element.find(".ui-menu-icon").removeClass(this.options.icons.submenu).addClass(t.submenu),"disabled"===e&&this.element.toggleClass("ui-state-disabled",!!t).attr("aria-disabled",t),this._super(e,t)},focus:function(e,t){var i,s;this.blur(e,e&&"focus"===e.type),this._scrollIntoView(t),this.active=t.first(),s=this.active.addClass("ui-state-focus").removeClass("ui-state-active"),this.options.role&&this.element.attr("aria-activedescendant",s.attr("id")),this.active.parent().closest(".ui-menu-item").addClass("ui-state-active"),e&&"keydown"===e.type?this._close():this.timer=this._delay(function(){this._close()},this.delay),i=t.children(".ui-menu"),i.length&&e&&/^mouse/.test(e.type)&&this._startOpening(i),this.activeMenu=t.parent(),this._trigger("focus",e,{item:t})},_scrollIntoView:function(t){var i,s,n,a,o,r;this._hasScroll()&&(i=parseFloat(e.css(this.activeMenu[0],"borderTopWidth"))||0,s=parseFloat(e.css(this.activeMenu[0],"paddingTop"))||0,n=t.offset().top-this.activeMenu.offset().top-i-s,a=this.activeMenu.scrollTop(),o=this.activeMenu.height(),r=t.outerHeight(),0>n?this.activeMenu.scrollTop(a+n):n+r>o&&this.activeMenu.scrollTop(a+n-o+r))},blur:function(e,t){t||clearTimeout(this.timer),this.active&&(this.active.removeClass("ui-state-focus"),this.active=null,this._trigger("blur",e,{item:this.active}))},_startOpening:function(e){clearTimeout(this.timer),"true"===e.attr("aria-hidden")&&(this.timer=this._delay(function(){this._close(),this._open(e)},this.delay))},_open:function(t){var i=e.extend({of:this.active},this.options.position);clearTimeout(this.timer),this.element.find(".ui-menu").not(t.parents(".ui-menu")).hide().attr("aria-hidden","true"),t.show().removeAttr("aria-hidden").attr("aria-expanded","true").position(i)},collapseAll:function(t,i){clearTimeout(this.timer),this.timer=this._delay(function(){var s=i?this.element:e(t&&t.target).closest(this.element.find(".ui-menu"));s.length||(s=this.element),this._close(s),this.blur(t),this.activeMenu=s},this.delay)},_close:function(e){e||(e=this.active?this.active.parent():this.element),e.find(".ui-menu").hide().attr("aria-hidden","true").attr("aria-expanded","false").end().find(".ui-state-active").not(".ui-state-focus").removeClass("ui-state-active")},_closeOnDocumentClick:function(t){return!e(t.target).closest(".ui-menu").length},_isDivider:function(e){return!/[^\-\u2014\u2013\s]/.test(e.text())},collapse:function(e){var t=this.active&&this.active.parent().closest(".ui-menu-item",this.element);t&&t.length&&(this._close(),this.focus(e,t))},expand:function(e){var t=this.active&&this.active.children(".ui-menu ").find(this.options.items).first();t&&t.length&&(this._open(t.parent()),this._delay(function(){this.focus(e,t)}))},next:function(e){this._move("next","first",e)},previous:function(e){this._move("prev","last",e)},isFirstItem:function(){return this.active&&!this.active.prevAll(".ui-menu-item").length},isLastItem:function(){return this.active&&!this.active.nextAll(".ui-menu-item").length},_move:function(e,t,i){var s;this.active&&(s="first"===e||"last"===e?this.active["first"===e?"prevAll":"nextAll"](".ui-menu-item").eq(-1):this.active[e+"All"](".ui-menu-item").eq(0)),s&&s.length&&this.active||(s=this.activeMenu.find(this.options.items)[t]()),this.focus(i,s)},nextPage:function(t){var i,s,n;return this.active?(this.isLastItem()||(this._hasScroll()?(s=this.active.offset().top,n=this.element.height(),this.active.nextAll(".ui-menu-item").each(function(){return i=e(this),0>i.offset().top-s-n}),this.focus(t,i)):this.focus(t,this.activeMenu.find(this.options.items)[this.active?"last":"first"]())),void 0):(this.next(t),void 0)},previousPage:function(t){var i,s,n;return this.active?(this.isFirstItem()||(this._hasScroll()?(s=this.active.offset().top,n=this.element.height(),this.active.prevAll(".ui-menu-item").each(function(){return i=e(this),i.offset().top-s+n>0}),this.focus(t,i)):this.focus(t,this.activeMenu.find(this.options.items).first())),void 0):(this.next(t),void 0)},_hasScroll:function(){return this.element.outerHeight()<this.element.prop("scrollHeight")},select:function(t){this.active=this.active||e(t.target).closest(".ui-menu-item");var i={item:this.active};this.active.has(".ui-menu").length||this.collapseAll(t,!0),this._trigger("select",t,i)},_filterMenuItems:function(t){var i=t.replace(/[\-\[\]{}()*+?.,\\\^$|#\s]/g,"\\$&"),s=RegExp("^"+i,"i");return this.activeMenu.find(this.options.items).filter(".ui-menu-item").filter(function(){return s.test(e.trim(e(this).text()))})}}),e.widget("ui.autocomplete",{version:"1.11.4",defaultElement:"<input>",options:{appendTo:null,autoFocus:!1,delay:300,minLength:1,position:{my:"left top",at:"left bottom",collision:"none"},source:null,change:null,close:null,focus:null,open:null,response:null,search:null,select:null},requestIndex:0,pending:0,_create:function(){var t,i,s,n=this.element[0].nodeName.toLowerCase(),a="textarea"===n,o="input"===n;this.isMultiLine=a?!0:o?!1:this.element.prop("isContentEditable"),this.valueMethod=this.element[a||o?"val":"text"],this.isNewMenu=!0,this.element.addClass("ui-autocomplete-input").attr("autocomplete","off"),this._on(this.element,{keydown:function(n){if(this.element.prop("readOnly"))return t=!0,s=!0,i=!0,void 0;t=!1,s=!1,i=!1;var a=e.ui.keyCode;switch(n.keyCode){case a.PAGE_UP:t=!0,this._move("previousPage",n);break;case a.PAGE_DOWN:t=!0,this._move("nextPage",n);break;case a.UP:t=!0,this._keyEvent("previous",n);break;case a.DOWN:t=!0,this._keyEvent("next",n);break;case a.ENTER:this.menu.active&&(t=!0,n.preventDefault(),this.menu.select(n));break;case a.TAB:this.menu.active&&this.menu.select(n);break;case a.ESCAPE:this.menu.element.is(":visible")&&(this.isMultiLine||this._value(this.term),this.close(n),n.preventDefault());break;default:i=!0,this._searchTimeout(n)}},keypress:function(s){if(t)return t=!1,(!this.isMultiLine||this.menu.element.is(":visible"))&&s.preventDefault(),void 0;if(!i){var n=e.ui.keyCode;switch(s.keyCode){case n.PAGE_UP:this._move("previousPage",s);break;case n.PAGE_DOWN:this._move("nextPage",s);break;case n.UP:this._keyEvent("previous",s);break;case n.DOWN:this._keyEvent("next",s)}}},input:function(e){return s?(s=!1,e.preventDefault(),void 0):(this._searchTimeout(e),void 0)},focus:function(){this.selectedItem=null,this.previous=this._value()},blur:function(e){return this.cancelBlur?(delete this.cancelBlur,void 0):(clearTimeout(this.searching),this.close(e),this._change(e),void 0)}}),this._initSource(),this.menu=e("<ul>").addClass("ui-autocomplete ui-front").appendTo(this._appendTo()).menu({role:null}).hide().menu("instance"),this._on(this.menu.element,{mousedown:function(t){t.preventDefault(),this.cancelBlur=!0,this._delay(function(){delete this.cancelBlur});var i=this.menu.element[0];e(t.target).closest(".ui-menu-item").length||this._delay(function(){var t=this;this.document.one("mousedown",function(s){s.target===t.element[0]||s.target===i||e.contains(i,s.target)||t.close()})})},menufocus:function(t,i){var s,n;return this.isNewMenu&&(this.isNewMenu=!1,t.originalEvent&&/^mouse/.test(t.originalEvent.type))?(this.menu.blur(),this.document.one("mousemove",function(){e(t.target).trigger(t.originalEvent)}),void 0):(n=i.item.data("ui-autocomplete-item"),!1!==this._trigger("focus",t,{item:n})&&t.originalEvent&&/^key/.test(t.originalEvent.type)&&this._value(n.value),s=i.item.attr("aria-label")||n.value,s&&e.trim(s).length&&(this.liveRegion.children().hide(),e("<div>").text(s).appendTo(this.liveRegion)),void 0)},menuselect:function(e,t){var i=t.item.data("ui-autocomplete-item"),s=this.previous;this.element[0]!==this.document[0].activeElement&&(this.element.focus(),this.previous=s,this._delay(function(){this.previous=s,this.selectedItem=i})),!1!==this._trigger("select",e,{item:i})&&this._value(i.value),this.term=this._value(),this.close(e),this.selectedItem=i}}),this.liveRegion=e("<span>",{role:"status","aria-live":"assertive","aria-relevant":"additions"}).addClass("ui-helper-hidden-accessible").appendTo(this.document[0].body),this._on(this.window,{beforeunload:function(){this.element.removeAttr("autocomplete")}})},_destroy:function(){clearTimeout(this.searching),this.element.removeClass("ui-autocomplete-input").removeAttr("autocomplete"),this.menu.element.remove(),this.liveRegion.remove()},_setOption:function(e,t){this._super(e,t),"source"===e&&this._initSource(),"appendTo"===e&&this.menu.element.appendTo(this._appendTo()),"disabled"===e&&t&&this.xhr&&this.xhr.abort()},_appendTo:function(){var t=this.options.appendTo;return t&&(t=t.jquery||t.nodeType?e(t):this.document.find(t).eq(0)),t&&t[0]||(t=this.element.closest(".ui-front")),t.length||(t=this.document[0].body),t},_initSource:function(){var t,i,s=this;e.isArray(this.options.source)?(t=this.options.source,this.source=function(i,s){s(e.ui.autocomplete.filter(t,i.term))}):"string"==typeof this.options.source?(i=this.options.source,this.source=function(t,n){s.xhr&&s.xhr.abort(),s.xhr=e.ajax({url:i,data:t,dataType:"json",success:function(e){n(e)},error:function(){n([])}})}):this.source=this.options.source},_searchTimeout:function(e){clearTimeout(this.searching),this.searching=this._delay(function(){var t=this.term===this._value(),i=this.menu.element.is(":visible"),s=e.altKey||e.ctrlKey||e.metaKey||e.shiftKey;(!t||t&&!i&&!s)&&(this.selectedItem=null,this.search(null,e))},this.options.delay)},search:function(e,t){return e=null!=e?e:this._value(),this.term=this._value(),e.length<this.options.minLength?this.close(t):this._trigger("search",t)!==!1?this._search(e):void 0},_search:function(e){this.pending++,this.element.addClass("ui-autocomplete-loading"),this.cancelSearch=!1,this.source({term:e},this._response())},_response:function(){var t=++this.requestIndex;return e.proxy(function(e){t===this.requestIndex&&this.__response(e),this.pending--,this.pending||this.element.removeClass("ui-autocomplete-loading")},this)},__response:function(e){e&&(e=this._normalize(e)),this._trigger("response",null,{content:e}),!this.options.disabled&&e&&e.length&&!this.cancelSearch?(this._suggest(e),this._trigger("open")):this._close()},close:function(e){this.cancelSearch=!0,this._close(e)},_close:function(e){this.menu.element.is(":visible")&&(this.menu.element.hide(),this.menu.blur(),this.isNewMenu=!0,this._trigger("close",e))},_change:function(e){this.previous!==this._value()&&this._trigger("change",e,{item:this.selectedItem})},_normalize:function(t){return t.length&&t[0].label&&t[0].value?t:e.map(t,function(t){return"string"==typeof t?{label:t,value:t}:e.extend({},t,{label:t.label||t.value,value:t.value||t.label})})},_suggest:function(t){var i=this.menu.element.empty();this._renderMenu(i,t),this.isNewMenu=!0,this.menu.refresh(),i.show(),this._resizeMenu(),i.position(e.extend({of:this.element},this.options.position)),this.options.autoFocus&&this.menu.next()},_resizeMenu:function(){var e=this.menu.element;e.outerWidth(Math.max(e.width("").outerWidth()+1,this.element.outerWidth()))},_renderMenu:function(t,i){var s=this;e.each(i,function(e,i){s._renderItemData(t,i)})},_renderItemData:function(e,t){return this._renderItem(e,t).data("ui-autocomplete-item",t)},_renderItem:function(t,i){return e("<li>").text(i.label).appendTo(t)},_move:function(e,t){return this.menu.element.is(":visible")?this.menu.isFirstItem()&&/^previous/.test(e)||this.menu.isLastItem()&&/^next/.test(e)?(this.isMultiLine||this._value(this.term),this.menu.blur(),void 0):(this.menu[e](t),void 0):(this.search(null,t),void 0)},widget:function(){return this.menu.element},_value:function(){return this.valueMethod.apply(this.element,arguments)},_keyEvent:function(e,t){(!this.isMultiLine||this.menu.element.is(":visible"))&&(this._move(e,t),t.preventDefault())}}),e.extend(e.ui.autocomplete,{escapeRegex:function(e){return e.replace(/[\-\[\]{}()*+?.,\\\^$|#\s]/g,"\\$&")},filter:function(t,i){var s=RegExp(e.ui.autocomplete.escapeRegex(i),"i");return e.grep(t,function(e){return s.test(e.label||e.value||e)})}}),e.widget("ui.autocomplete",e.ui.autocomplete,{options:{messages:{noResults:"No search results.",results:function(e){return e+(e>1?" results are":" result is")+" available, use up and down arrow keys to navigate."}}},__response:function(t){var i;this._superApply(arguments),this.options.disabled||this.cancelSearch||(i=t&&t.length?this.options.messages.results(t.length):this.options.messages.noResults,this.liveRegion.children().hide(),e("<div>").text(i).appendTo(this.liveRegion))}}),e.ui.autocomplete;var r,h="ui-button ui-widget ui-state-default ui-corner-all",l="ui-button-icons-only ui-button-icon-only ui-button-text-icons ui-button-text-icon-primary ui-button-text-icon-secondary ui-button-text-only",u=function(){var t=e(this);setTimeout(function(){t.find(":ui-button").button("refresh")},1)},d=function(t){var i=t.name,s=t.form,n=e([]);return i&&(i=i.replace(/'/g,"\\'"),n=s?e(s).find("[name='"+i+"'][type=radio]"):e("[name='"+i+"'][type=radio]",t.ownerDocument).filter(function(){return!this.form})),n};e.widget("ui.button",{version:"1.11.4",defaultElement:"<button>",options:{disabled:null,text:!0,label:null,icons:{primary:null,secondary:null}},_create:function(){this.element.closest("form").unbind("reset"+this.eventNamespace).bind("reset"+this.eventNamespace,u),"boolean"!=typeof this.options.disabled?this.options.disabled=!!this.element.prop("disabled"):this.element.prop("disabled",this.options.disabled),this._determineButtonType(),this.hasTitle=!!this.buttonElement.attr("title");var t=this,i=this.options,s="checkbox"===this.type||"radio"===this.type,n=s?"":"ui-state-active";null===i.label&&(i.label="input"===this.type?this.buttonElement.val():this.buttonElement.html()),this._hoverable(this.buttonElement),this.buttonElement.addClass(h).attr("role","button").bind("mouseenter"+this.eventNamespace,function(){i.disabled||this===r&&e(this).addClass("ui-state-active")}).bind("mouseleave"+this.eventNamespace,function(){i.disabled||e(this).removeClass(n)}).bind("click"+this.eventNamespace,function(e){i.disabled&&(e.preventDefault(),e.stopImmediatePropagation())}),this._on({focus:function(){this.buttonElement.addClass("ui-state-focus")},blur:function(){this.buttonElement.removeClass("ui-state-focus")}}),s&&this.element.bind("change"+this.eventNamespace,function(){t.refresh()}),"checkbox"===this.type?this.buttonElement.bind("click"+this.eventNamespace,function(){return i.disabled?!1:void 0}):"radio"===this.type?this.buttonElement.bind("click"+this.eventNamespace,function(){if(i.disabled)return!1;e(this).addClass("ui-state-active"),t.buttonElement.attr("aria-pressed","true");var s=t.element[0];d(s).not(s).map(function(){return e(this).button("widget")[0]}).removeClass("ui-state-active").attr("aria-pressed","false")}):(this.buttonElement.bind("mousedown"+this.eventNamespace,function(){return i.disabled?!1:(e(this).addClass("ui-state-active"),r=this,t.document.one("mouseup",function(){r=null}),void 0)}).bind("mouseup"+this.eventNamespace,function(){return i.disabled?!1:(e(this).removeClass("ui-state-active"),void 0)}).bind("keydown"+this.eventNamespace,function(t){return i.disabled?!1:((t.keyCode===e.ui.keyCode.SPACE||t.keyCode===e.ui.keyCode.ENTER)&&e(this).addClass("ui-state-active"),void 0)}).bind("keyup"+this.eventNamespace+" blur"+this.eventNamespace,function(){e(this).removeClass("ui-state-active")}),this.buttonElement.is("a")&&this.buttonElement.keyup(function(t){t.keyCode===e.ui.keyCode.SPACE&&e(this).click()})),this._setOption("disabled",i.disabled),this._resetButton()},_determineButtonType:function(){var e,t,i;this.type=this.element.is("[type=checkbox]")?"checkbox":this.element.is("[type=radio]")?"radio":this.element.is("input")?"input":"button","checkbox"===this.type||"radio"===this.type?(e=this.element.parents().last(),t="label[for='"+this.element.attr("id")+"']",this.buttonElement=e.find(t),this.buttonElement.length||(e=e.length?e.siblings():this.element.siblings(),this.buttonElement=e.filter(t),this.buttonElement.length||(this.buttonElement=e.find(t))),this.element.addClass("ui-helper-hidden-accessible"),i=this.element.is(":checked"),i&&this.buttonElement.addClass("ui-state-active"),this.buttonElement.prop("aria-pressed",i)):this.buttonElement=this.element},widget:function(){return this.buttonElement},_destroy:function(){this.element.removeClass("ui-helper-hidden-accessible"),this.buttonElement.removeClass(h+" ui-state-active "+l).removeAttr("role").removeAttr("aria-pressed").html(this.buttonElement.find(".ui-button-text").html()),this.hasTitle||this.buttonElement.removeAttr("title")},_setOption:function(e,t){return this._super(e,t),"disabled"===e?(this.widget().toggleClass("ui-state-disabled",!!t),this.element.prop("disabled",!!t),t&&("checkbox"===this.type||"radio"===this.type?this.buttonElement.removeClass("ui-state-focus"):this.buttonElement.removeClass("ui-state-focus ui-state-active")),void 0):(this._resetButton(),void 0)},refresh:function(){var t=this.element.is("input, button")?this.element.is(":disabled"):this.element.hasClass("ui-button-disabled");t!==this.options.disabled&&this._setOption("disabled",t),"radio"===this.type?d(this.element[0]).each(function(){e(this).is(":checked")?e(this).button("widget").addClass("ui-state-active").attr("aria-pressed","true"):e(this).button("widget").removeClass("ui-state-active").attr("aria-pressed","false")}):"checkbox"===this.type&&(this.element.is(":checked")?this.buttonElement.addClass("ui-state-active").attr("aria-pressed","true"):this.buttonElement.removeClass("ui-state-active").attr("aria-pressed","false"))},_resetButton:function(){if("input"===this.type)return this.options.label&&this.element.val(this.options.label),void 0;var t=this.buttonElement.removeClass(l),i=e("<span></span>",this.document[0]).addClass("ui-button-text").html(this.options.label).appendTo(t.empty()).text(),s=this.options.icons,n=s.primary&&s.secondary,a=[];s.primary||s.secondary?(this.options.text&&a.push("ui-button-text-icon"+(n?"s":s.primary?"-primary":"-secondary")),s.primary&&t.prepend("<span class='ui-button-icon-primary ui-icon "+s.primary+"'></span>"),s.secondary&&t.append("<span class='ui-button-icon-secondary ui-icon "+s.secondary+"'></span>"),this.options.text||(a.push(n?"ui-button-icons-only":"ui-button-icon-only"),this.hasTitle||t.attr("title",e.trim(i)))):a.push("ui-button-text-only"),t.addClass(a.join(" "))}}),e.widget("ui.buttonset",{version:"1.11.4",options:{items:"button, input[type=button], input[type=submit], input[type=reset], input[type=checkbox], input[type=radio], a, :data(ui-button)"},_create:function(){this.element.addClass("ui-buttonset")},_init:function(){this.refresh()},_setOption:function(e,t){"disabled"===e&&this.buttons.button("option",e,t),this._super(e,t)},refresh:function(){var t="rtl"===this.element.css("direction"),i=this.element.find(this.options.items),s=i.filter(":ui-button");i.not(":ui-button").button(),s.button("refresh"),this.buttons=i.map(function(){return e(this).button("widget")[0]}).removeClass("ui-corner-all ui-corner-left ui-corner-right").filter(":first").addClass(t?"ui-corner-right":"ui-corner-left").end().filter(":last").addClass(t?"ui-corner-left":"ui-corner-right").end().end()},_destroy:function(){this.element.removeClass("ui-buttonset"),this.buttons.map(function(){return e(this).button("widget")[0]}).removeClass("ui-corner-left ui-corner-right").end().button("destroy")}}),e.ui.button,e.widget("ui.dialog",{version:"1.11.4",options:{appendTo:"body",autoOpen:!0,buttons:[],closeOnEscape:!0,closeText:"Close",dialogClass:"",draggable:!0,hide:null,height:"auto",maxHeight:null,maxWidth:null,minHeight:150,minWidth:150,modal:!1,position:{my:"center",at:"center",of:window,collision:"fit",using:function(t){var i=e(this).css(t).offset().top;0>i&&e(this).css("top",t.top-i)}},resizable:!0,show:null,title:null,width:300,beforeClose:null,close:null,drag:null,dragStart:null,dragStop:null,focus:null,open:null,resize:null,resizeStart:null,resizeStop:null},sizeRelatedOptions:{buttons:!0,height:!0,maxHeight:!0,maxWidth:!0,minHeight:!0,minWidth:!0,width:!0},resizableRelatedOptions:{maxHeight:!0,maxWidth:!0,minHeight:!0,minWidth:!0},_create:function(){this.originalCss={display:this.element[0].style.display,width:this.element[0].style.width,minHeight:this.element[0].style.minHeight,maxHeight:this.element[0].style.maxHeight,height:this.element[0].style.height},this.originalPosition={parent:this.element.parent(),index:this.element.parent().children().index(this.element)},this.originalTitle=this.element.attr("title"),this.options.title=this.options.title||this.originalTitle,this._createWrapper(),this.element.show().removeAttr("title").addClass("ui-dialog-content ui-widget-content").appendTo(this.uiDialog),this._createTitlebar(),this._createButtonPane(),this.options.draggable&&e.fn.draggable&&this._makeDraggable(),this.options.resizable&&e.fn.resizable&&this._makeResizable(),this._isOpen=!1,this._trackFocus()},_init:function(){this.options.autoOpen&&this.open()},_appendTo:function(){var t=this.options.appendTo;return t&&(t.jquery||t.nodeType)?e(t):this.document.find(t||"body").eq(0)},_destroy:function(){var e,t=this.originalPosition;this._untrackInstance(),this._destroyOverlay(),this.element.removeUniqueId().removeClass("ui-dialog-content ui-widget-content").css(this.originalCss).detach(),this.uiDialog.stop(!0,!0).remove(),this.originalTitle&&this.element.attr("title",this.originalTitle),e=t.parent.children().eq(t.index),e.length&&e[0]!==this.element[0]?e.before(this.element):t.parent.append(this.element)},widget:function(){return this.uiDialog},disable:e.noop,enable:e.noop,close:function(t){var i,s=this;if(this._isOpen&&this._trigger("beforeClose",t)!==!1){if(this._isOpen=!1,this._focusedElement=null,this._destroyOverlay(),this._untrackInstance(),!this.opener.filter(":focusable").focus().length)try{i=this.document[0].activeElement,i&&"body"!==i.nodeName.toLowerCase()&&e(i).blur()}catch(n){}this._hide(this.uiDialog,this.options.hide,function(){s._trigger("close",t)})}},isOpen:function(){return this._isOpen},moveToTop:function(){this._moveToTop()},_moveToTop:function(t,i){var s=!1,n=this.uiDialog.siblings(".ui-front:visible").map(function(){return+e(this).css("z-index")}).get(),a=Math.max.apply(null,n);return a>=+this.uiDialog.css("z-index")&&(this.uiDialog.css("z-index",a+1),s=!0),s&&!i&&this._trigger("focus",t),s},open:function(){var t=this;return this._isOpen?(this._moveToTop()&&this._focusTabbable(),void 0):(this._isOpen=!0,this.opener=e(this.document[0].activeElement),this._size(),this._position(),this._createOverlay(),this._moveToTop(null,!0),this.overlay&&this.overlay.css("z-index",this.uiDialog.css("z-index")-1),this._show(this.uiDialog,this.options.show,function(){t._focusTabbable(),t._trigger("focus")}),this._makeFocusTarget(),this._trigger("open"),void 0)},_focusTabbable:function(){var e=this._focusedElement;e||(e=this.element.find("[autofocus]")),e.length||(e=this.element.find(":tabbable")),e.length||(e=this.uiDialogButtonPane.find(":tabbable")),e.length||(e=this.uiDialogTitlebarClose.filter(":tabbable")),e.length||(e=this.uiDialog),e.eq(0).focus()},_keepFocus:function(t){function i(){var t=this.document[0].activeElement,i=this.uiDialog[0]===t||e.contains(this.uiDialog[0],t);i||this._focusTabbable()}t.preventDefault(),i.call(this),this._delay(i)},_createWrapper:function(){this.uiDialog=e("<div>").addClass("ui-dialog ui-widget ui-widget-content ui-corner-all ui-front "+this.options.dialogClass).hide().attr({tabIndex:-1,role:"dialog"}).appendTo(this._appendTo()),this._on(this.uiDialog,{keydown:function(t){if(this.options.closeOnEscape&&!t.isDefaultPrevented()&&t.keyCode&&t.keyCode===e.ui.keyCode.ESCAPE)return t.preventDefault(),this.close(t),void 0;if(t.keyCode===e.ui.keyCode.TAB&&!t.isDefaultPrevented()){var i=this.uiDialog.find(":tabbable"),s=i.filter(":first"),n=i.filter(":last");t.target!==n[0]&&t.target!==this.uiDialog[0]||t.shiftKey?t.target!==s[0]&&t.target!==this.uiDialog[0]||!t.shiftKey||(this._delay(function(){n.focus()}),t.preventDefault()):(this._delay(function(){s.focus()}),t.preventDefault())}},mousedown:function(e){this._moveToTop(e)&&this._focusTabbable()}}),this.element.find("[aria-describedby]").length||this.uiDialog.attr({"aria-describedby":this.element.uniqueId().attr("id")})},_createTitlebar:function(){var t;this.uiDialogTitlebar=e("<div>").addClass("ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix").prependTo(this.uiDialog),this._on(this.uiDialogTitlebar,{mousedown:function(t){e(t.target).closest(".ui-dialog-titlebar-close")||this.uiDialog.focus()}}),this.uiDialogTitlebarClose=e("<button type='button'></button>").button({label:this.options.closeText,icons:{primary:"ui-icon-closethick"},text:!1}).addClass("ui-dialog-titlebar-close").appendTo(this.uiDialogTitlebar),this._on(this.uiDialogTitlebarClose,{click:function(e){e.preventDefault(),this.close(e)}}),t=e("<span>").uniqueId().addClass("ui-dialog-title").prependTo(this.uiDialogTitlebar),this._title(t),this.uiDialog.attr({"aria-labelledby":t.attr("id")})},_title:function(e){this.options.title||e.html("&#160;"),e.text(this.options.title)
},_createButtonPane:function(){this.uiDialogButtonPane=e("<div>").addClass("ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"),this.uiButtonSet=e("<div>").addClass("ui-dialog-buttonset").appendTo(this.uiDialogButtonPane),this._createButtons()},_createButtons:function(){var t=this,i=this.options.buttons;return this.uiDialogButtonPane.remove(),this.uiButtonSet.empty(),e.isEmptyObject(i)||e.isArray(i)&&!i.length?(this.uiDialog.removeClass("ui-dialog-buttons"),void 0):(e.each(i,function(i,s){var n,a;s=e.isFunction(s)?{click:s,text:i}:s,s=e.extend({type:"button"},s),n=s.click,s.click=function(){n.apply(t.element[0],arguments)},a={icons:s.icons,text:s.showText},delete s.icons,delete s.showText,e("<button></button>",s).button(a).appendTo(t.uiButtonSet)}),this.uiDialog.addClass("ui-dialog-buttons"),this.uiDialogButtonPane.appendTo(this.uiDialog),void 0)},_makeDraggable:function(){function t(e){return{position:e.position,offset:e.offset}}var i=this,s=this.options;this.uiDialog.draggable({cancel:".ui-dialog-content, .ui-dialog-titlebar-close",handle:".ui-dialog-titlebar",containment:"document",start:function(s,n){e(this).addClass("ui-dialog-dragging"),i._blockFrames(),i._trigger("dragStart",s,t(n))},drag:function(e,s){i._trigger("drag",e,t(s))},stop:function(n,a){var o=a.offset.left-i.document.scrollLeft(),r=a.offset.top-i.document.scrollTop();s.position={my:"left top",at:"left"+(o>=0?"+":"")+o+" "+"top"+(r>=0?"+":"")+r,of:i.window},e(this).removeClass("ui-dialog-dragging"),i._unblockFrames(),i._trigger("dragStop",n,t(a))}})},_makeResizable:function(){function t(e){return{originalPosition:e.originalPosition,originalSize:e.originalSize,position:e.position,size:e.size}}var i=this,s=this.options,n=s.resizable,a=this.uiDialog.css("position"),o="string"==typeof n?n:"n,e,s,w,se,sw,ne,nw";this.uiDialog.resizable({cancel:".ui-dialog-content",containment:"document",alsoResize:this.element,maxWidth:s.maxWidth,maxHeight:s.maxHeight,minWidth:s.minWidth,minHeight:this._minHeight(),handles:o,start:function(s,n){e(this).addClass("ui-dialog-resizing"),i._blockFrames(),i._trigger("resizeStart",s,t(n))},resize:function(e,s){i._trigger("resize",e,t(s))},stop:function(n,a){var o=i.uiDialog.offset(),r=o.left-i.document.scrollLeft(),h=o.top-i.document.scrollTop();s.height=i.uiDialog.height(),s.width=i.uiDialog.width(),s.position={my:"left top",at:"left"+(r>=0?"+":"")+r+" "+"top"+(h>=0?"+":"")+h,of:i.window},e(this).removeClass("ui-dialog-resizing"),i._unblockFrames(),i._trigger("resizeStop",n,t(a))}}).css("position",a)},_trackFocus:function(){this._on(this.widget(),{focusin:function(t){this._makeFocusTarget(),this._focusedElement=e(t.target)}})},_makeFocusTarget:function(){this._untrackInstance(),this._trackingInstances().unshift(this)},_untrackInstance:function(){var t=this._trackingInstances(),i=e.inArray(this,t);-1!==i&&t.splice(i,1)},_trackingInstances:function(){var e=this.document.data("ui-dialog-instances");return e||(e=[],this.document.data("ui-dialog-instances",e)),e},_minHeight:function(){var e=this.options;return"auto"===e.height?e.minHeight:Math.min(e.minHeight,e.height)},_position:function(){var e=this.uiDialog.is(":visible");e||this.uiDialog.show(),this.uiDialog.position(this.options.position),e||this.uiDialog.hide()},_setOptions:function(t){var i=this,s=!1,n={};e.each(t,function(e,t){i._setOption(e,t),e in i.sizeRelatedOptions&&(s=!0),e in i.resizableRelatedOptions&&(n[e]=t)}),s&&(this._size(),this._position()),this.uiDialog.is(":data(ui-resizable)")&&this.uiDialog.resizable("option",n)},_setOption:function(e,t){var i,s,n=this.uiDialog;"dialogClass"===e&&n.removeClass(this.options.dialogClass).addClass(t),"disabled"!==e&&(this._super(e,t),"appendTo"===e&&this.uiDialog.appendTo(this._appendTo()),"buttons"===e&&this._createButtons(),"closeText"===e&&this.uiDialogTitlebarClose.button({label:""+t}),"draggable"===e&&(i=n.is(":data(ui-draggable)"),i&&!t&&n.draggable("destroy"),!i&&t&&this._makeDraggable()),"position"===e&&this._position(),"resizable"===e&&(s=n.is(":data(ui-resizable)"),s&&!t&&n.resizable("destroy"),s&&"string"==typeof t&&n.resizable("option","handles",t),s||t===!1||this._makeResizable()),"title"===e&&this._title(this.uiDialogTitlebar.find(".ui-dialog-title")))},_size:function(){var e,t,i,s=this.options;this.element.show().css({width:"auto",minHeight:0,maxHeight:"none",height:0}),s.minWidth>s.width&&(s.width=s.minWidth),e=this.uiDialog.css({height:"auto",width:s.width}).outerHeight(),t=Math.max(0,s.minHeight-e),i="number"==typeof s.maxHeight?Math.max(0,s.maxHeight-e):"none","auto"===s.height?this.element.css({minHeight:t,maxHeight:i,height:"auto"}):this.element.height(Math.max(0,s.height-e)),this.uiDialog.is(":data(ui-resizable)")&&this.uiDialog.resizable("option","minHeight",this._minHeight())},_blockFrames:function(){this.iframeBlocks=this.document.find("iframe").map(function(){var t=e(this);return e("<div>").css({position:"absolute",width:t.outerWidth(),height:t.outerHeight()}).appendTo(t.parent()).offset(t.offset())[0]})},_unblockFrames:function(){this.iframeBlocks&&(this.iframeBlocks.remove(),delete this.iframeBlocks)},_allowInteraction:function(t){return e(t.target).closest(".ui-dialog").length?!0:!!e(t.target).closest(".ui-datepicker").length},_createOverlay:function(){if(this.options.modal){var t=!0;this._delay(function(){t=!1}),this.document.data("ui-dialog-overlays")||this._on(this.document,{focusin:function(e){t||this._allowInteraction(e)||(e.preventDefault(),this._trackingInstances()[0]._focusTabbable())}}),this.overlay=e("<div>").addClass("ui-widget-overlay ui-front").appendTo(this._appendTo()),this._on(this.overlay,{mousedown:"_keepFocus"}),this.document.data("ui-dialog-overlays",(this.document.data("ui-dialog-overlays")||0)+1)}},_destroyOverlay:function(){if(this.options.modal&&this.overlay){var e=this.document.data("ui-dialog-overlays")-1;e?this.document.data("ui-dialog-overlays",e):this.document.unbind("focusin").removeData("ui-dialog-overlays"),this.overlay.remove(),this.overlay=null}}}),e.widget("ui.progressbar",{version:"1.11.4",options:{max:100,value:0,change:null,complete:null},min:0,_create:function(){this.oldValue=this.options.value=this._constrainedValue(),this.element.addClass("ui-progressbar ui-widget ui-widget-content ui-corner-all").attr({role:"progressbar","aria-valuemin":this.min}),this.valueDiv=e("<div class='ui-progressbar-value ui-widget-header ui-corner-left'></div>").appendTo(this.element),this._refreshValue()},_destroy:function(){this.element.removeClass("ui-progressbar ui-widget ui-widget-content ui-corner-all").removeAttr("role").removeAttr("aria-valuemin").removeAttr("aria-valuemax").removeAttr("aria-valuenow"),this.valueDiv.remove()},value:function(e){return void 0===e?this.options.value:(this.options.value=this._constrainedValue(e),this._refreshValue(),void 0)},_constrainedValue:function(e){return void 0===e&&(e=this.options.value),this.indeterminate=e===!1,"number"!=typeof e&&(e=0),this.indeterminate?!1:Math.min(this.options.max,Math.max(this.min,e))},_setOptions:function(e){var t=e.value;delete e.value,this._super(e),this.options.value=this._constrainedValue(t),this._refreshValue()},_setOption:function(e,t){"max"===e&&(t=Math.max(this.min,t)),"disabled"===e&&this.element.toggleClass("ui-state-disabled",!!t).attr("aria-disabled",t),this._super(e,t)},_percentage:function(){return this.indeterminate?100:100*(this.options.value-this.min)/(this.options.max-this.min)},_refreshValue:function(){var t=this.options.value,i=this._percentage();this.valueDiv.toggle(this.indeterminate||t>this.min).toggleClass("ui-corner-right",t===this.options.max).width(i.toFixed(0)+"%"),this.element.toggleClass("ui-progressbar-indeterminate",this.indeterminate),this.indeterminate?(this.element.removeAttr("aria-valuenow"),this.overlayDiv||(this.overlayDiv=e("<div class='ui-progressbar-overlay'></div>").appendTo(this.valueDiv))):(this.element.attr({"aria-valuemax":this.options.max,"aria-valuenow":t}),this.overlayDiv&&(this.overlayDiv.remove(),this.overlayDiv=null)),this.oldValue!==t&&(this.oldValue=t,this._trigger("change")),t===this.options.max&&this._trigger("complete")}}),e.widget("ui.selectmenu",{version:"1.11.4",defaultElement:"<select>",options:{appendTo:null,disabled:null,icons:{button:"ui-icon-triangle-1-s"},position:{my:"left top",at:"left bottom",collision:"none"},width:null,change:null,close:null,focus:null,open:null,select:null},_create:function(){var e=this.element.uniqueId().attr("id");this.ids={element:e,button:e+"-button",menu:e+"-menu"},this._drawButton(),this._drawMenu(),this.options.disabled&&this.disable()},_drawButton:function(){var t=this;this.label=e("label[for='"+this.ids.element+"']").attr("for",this.ids.button),this._on(this.label,{click:function(e){this.button.focus(),e.preventDefault()}}),this.element.hide(),this.button=e("<span>",{"class":"ui-selectmenu-button ui-widget ui-state-default ui-corner-all",tabindex:this.options.disabled?-1:0,id:this.ids.button,role:"combobox","aria-expanded":"false","aria-autocomplete":"list","aria-owns":this.ids.menu,"aria-haspopup":"true"}).insertAfter(this.element),e("<span>",{"class":"ui-icon "+this.options.icons.button}).prependTo(this.button),this.buttonText=e("<span>",{"class":"ui-selectmenu-text"}).appendTo(this.button),this._setText(this.buttonText,this.element.find("option:selected").text()),this._resizeButton(),this._on(this.button,this._buttonEvents),this.button.one("focusin",function(){t.menuItems||t._refreshMenu()}),this._hoverable(this.button),this._focusable(this.button)},_drawMenu:function(){var t=this;this.menu=e("<ul>",{"aria-hidden":"true","aria-labelledby":this.ids.button,id:this.ids.menu}),this.menuWrap=e("<div>",{"class":"ui-selectmenu-menu ui-front"}).append(this.menu).appendTo(this._appendTo()),this.menuInstance=this.menu.menu({role:"listbox",select:function(e,i){e.preventDefault(),t._setSelection(),t._select(i.item.data("ui-selectmenu-item"),e)},focus:function(e,i){var s=i.item.data("ui-selectmenu-item");null!=t.focusIndex&&s.index!==t.focusIndex&&(t._trigger("focus",e,{item:s}),t.isOpen||t._select(s,e)),t.focusIndex=s.index,t.button.attr("aria-activedescendant",t.menuItems.eq(s.index).attr("id"))}}).menu("instance"),this.menu.addClass("ui-corner-bottom").removeClass("ui-corner-all"),this.menuInstance._off(this.menu,"mouseleave"),this.menuInstance._closeOnDocumentClick=function(){return!1},this.menuInstance._isDivider=function(){return!1}},refresh:function(){this._refreshMenu(),this._setText(this.buttonText,this._getSelectedItem().text()),this.options.width||this._resizeButton()},_refreshMenu:function(){this.menu.empty();var e,t=this.element.find("option");t.length&&(this._parseOptions(t),this._renderMenu(this.menu,this.items),this.menuInstance.refresh(),this.menuItems=this.menu.find("li").not(".ui-selectmenu-optgroup"),e=this._getSelectedItem(),this.menuInstance.focus(null,e),this._setAria(e.data("ui-selectmenu-item")),this._setOption("disabled",this.element.prop("disabled")))},open:function(e){this.options.disabled||(this.menuItems?(this.menu.find(".ui-state-focus").removeClass("ui-state-focus"),this.menuInstance.focus(null,this._getSelectedItem())):this._refreshMenu(),this.isOpen=!0,this._toggleAttr(),this._resizeMenu(),this._position(),this._on(this.document,this._documentClick),this._trigger("open",e))},_position:function(){this.menuWrap.position(e.extend({of:this.button},this.options.position))},close:function(e){this.isOpen&&(this.isOpen=!1,this._toggleAttr(),this.range=null,this._off(this.document),this._trigger("close",e))},widget:function(){return this.button},menuWidget:function(){return this.menu},_renderMenu:function(t,i){var s=this,n="";e.each(i,function(i,a){a.optgroup!==n&&(e("<li>",{"class":"ui-selectmenu-optgroup ui-menu-divider"+(a.element.parent("optgroup").prop("disabled")?" ui-state-disabled":""),text:a.optgroup}).appendTo(t),n=a.optgroup),s._renderItemData(t,a)})},_renderItemData:function(e,t){return this._renderItem(e,t).data("ui-selectmenu-item",t)},_renderItem:function(t,i){var s=e("<li>");return i.disabled&&s.addClass("ui-state-disabled"),this._setText(s,i.label),s.appendTo(t)},_setText:function(e,t){t?e.text(t):e.html("&#160;")},_move:function(e,t){var i,s,n=".ui-menu-item";this.isOpen?i=this.menuItems.eq(this.focusIndex):(i=this.menuItems.eq(this.element[0].selectedIndex),n+=":not(.ui-state-disabled)"),s="first"===e||"last"===e?i["first"===e?"prevAll":"nextAll"](n).eq(-1):i[e+"All"](n).eq(0),s.length&&this.menuInstance.focus(t,s)},_getSelectedItem:function(){return this.menuItems.eq(this.element[0].selectedIndex)},_toggle:function(e){this[this.isOpen?"close":"open"](e)},_setSelection:function(){var e;this.range&&(window.getSelection?(e=window.getSelection(),e.removeAllRanges(),e.addRange(this.range)):this.range.select(),this.button.focus())},_documentClick:{mousedown:function(t){this.isOpen&&(e(t.target).closest(".ui-selectmenu-menu, #"+this.ids.button).length||this.close(t))}},_buttonEvents:{mousedown:function(){var e;window.getSelection?(e=window.getSelection(),e.rangeCount&&(this.range=e.getRangeAt(0))):this.range=document.selection.createRange()},click:function(e){this._setSelection(),this._toggle(e)},keydown:function(t){var i=!0;switch(t.keyCode){case e.ui.keyCode.TAB:case e.ui.keyCode.ESCAPE:this.close(t),i=!1;break;case e.ui.keyCode.ENTER:this.isOpen&&this._selectFocusedItem(t);break;case e.ui.keyCode.UP:t.altKey?this._toggle(t):this._move("prev",t);break;case e.ui.keyCode.DOWN:t.altKey?this._toggle(t):this._move("next",t);break;case e.ui.keyCode.SPACE:this.isOpen?this._selectFocusedItem(t):this._toggle(t);break;case e.ui.keyCode.LEFT:this._move("prev",t);break;case e.ui.keyCode.RIGHT:this._move("next",t);break;case e.ui.keyCode.HOME:case e.ui.keyCode.PAGE_UP:this._move("first",t);break;case e.ui.keyCode.END:case e.ui.keyCode.PAGE_DOWN:this._move("last",t);break;default:this.menu.trigger(t),i=!1}i&&t.preventDefault()}},_selectFocusedItem:function(e){var t=this.menuItems.eq(this.focusIndex);t.hasClass("ui-state-disabled")||this._select(t.data("ui-selectmenu-item"),e)},_select:function(e,t){var i=this.element[0].selectedIndex;this.element[0].selectedIndex=e.index,this._setText(this.buttonText,e.label),this._setAria(e),this._trigger("select",t,{item:e}),e.index!==i&&this._trigger("change",t,{item:e}),this.close(t)},_setAria:function(e){var t=this.menuItems.eq(e.index).attr("id");this.button.attr({"aria-labelledby":t,"aria-activedescendant":t}),this.menu.attr("aria-activedescendant",t)},_setOption:function(e,t){"icons"===e&&this.button.find("span.ui-icon").removeClass(this.options.icons.button).addClass(t.button),this._super(e,t),"appendTo"===e&&this.menuWrap.appendTo(this._appendTo()),"disabled"===e&&(this.menuInstance.option("disabled",t),this.button.toggleClass("ui-state-disabled",t).attr("aria-disabled",t),this.element.prop("disabled",t),t?(this.button.attr("tabindex",-1),this.close()):this.button.attr("tabindex",0)),"width"===e&&this._resizeButton()},_appendTo:function(){var t=this.options.appendTo;return t&&(t=t.jquery||t.nodeType?e(t):this.document.find(t).eq(0)),t&&t[0]||(t=this.element.closest(".ui-front")),t.length||(t=this.document[0].body),t},_toggleAttr:function(){this.button.toggleClass("ui-corner-top",this.isOpen).toggleClass("ui-corner-all",!this.isOpen).attr("aria-expanded",this.isOpen),this.menuWrap.toggleClass("ui-selectmenu-open",this.isOpen),this.menu.attr("aria-hidden",!this.isOpen)},_resizeButton:function(){var e=this.options.width;e||(e=this.element.show().outerWidth(),this.element.hide()),this.button.outerWidth(e)},_resizeMenu:function(){this.menu.outerWidth(Math.max(this.button.outerWidth(),this.menu.width("").outerWidth()+1))},_getCreateOptions:function(){return{disabled:this.element.prop("disabled")}},_parseOptions:function(t){var i=[];t.each(function(t,s){var n=e(s),a=n.parent("optgroup");i.push({element:n,index:t,value:n.val(),label:n.text(),optgroup:a.attr("label")||"",disabled:a.prop("disabled")||n.prop("disabled")})}),this.items=i},_destroy:function(){this.menuWrap.remove(),this.button.remove(),this.element.show(),this.element.removeUniqueId(),this.label.attr("for",this.ids.element)}}),e.widget("ui.slider",e.ui.mouse,{version:"1.11.4",widgetEventPrefix:"slide",options:{animate:!1,distance:0,max:100,min:0,orientation:"horizontal",range:!1,step:1,value:0,values:null,change:null,slide:null,start:null,stop:null},numPages:5,_create:function(){this._keySliding=!1,this._mouseSliding=!1,this._animateOff=!0,this._handleIndex=null,this._detectOrientation(),this._mouseInit(),this._calculateNewMax(),this.element.addClass("ui-slider ui-slider-"+this.orientation+" ui-widget"+" ui-widget-content"+" ui-corner-all"),this._refresh(),this._setOption("disabled",this.options.disabled),this._animateOff=!1},_refresh:function(){this._createRange(),this._createHandles(),this._setupEvents(),this._refreshValue()},_createHandles:function(){var t,i,s=this.options,n=this.element.find(".ui-slider-handle").addClass("ui-state-default ui-corner-all"),a="<span class='ui-slider-handle ui-state-default ui-corner-all' tabindex='0'></span>",o=[];for(i=s.values&&s.values.length||1,n.length>i&&(n.slice(i).remove(),n=n.slice(0,i)),t=n.length;i>t;t++)o.push(a);this.handles=n.add(e(o.join("")).appendTo(this.element)),this.handle=this.handles.eq(0),this.handles.each(function(t){e(this).data("ui-slider-handle-index",t)})},_createRange:function(){var t=this.options,i="";t.range?(t.range===!0&&(t.values?t.values.length&&2!==t.values.length?t.values=[t.values[0],t.values[0]]:e.isArray(t.values)&&(t.values=t.values.slice(0)):t.values=[this._valueMin(),this._valueMin()]),this.range&&this.range.length?this.range.removeClass("ui-slider-range-min ui-slider-range-max").css({left:"",bottom:""}):(this.range=e("<div></div>").appendTo(this.element),i="ui-slider-range ui-widget-header ui-corner-all"),this.range.addClass(i+("min"===t.range||"max"===t.range?" ui-slider-range-"+t.range:""))):(this.range&&this.range.remove(),this.range=null)},_setupEvents:function(){this._off(this.handles),this._on(this.handles,this._handleEvents),this._hoverable(this.handles),this._focusable(this.handles)},_destroy:function(){this.handles.remove(),this.range&&this.range.remove(),this.element.removeClass("ui-slider ui-slider-horizontal ui-slider-vertical ui-widget ui-widget-content ui-corner-all"),this._mouseDestroy()},_mouseCapture:function(t){var i,s,n,a,o,r,h,l,u=this,d=this.options;return d.disabled?!1:(this.elementSize={width:this.element.outerWidth(),height:this.element.outerHeight()},this.elementOffset=this.element.offset(),i={x:t.pageX,y:t.pageY},s=this._normValueFromMouse(i),n=this._valueMax()-this._valueMin()+1,this.handles.each(function(t){var i=Math.abs(s-u.values(t));(n>i||n===i&&(t===u._lastChangedValue||u.values(t)===d.min))&&(n=i,a=e(this),o=t)}),r=this._start(t,o),r===!1?!1:(this._mouseSliding=!0,this._handleIndex=o,a.addClass("ui-state-active").focus(),h=a.offset(),l=!e(t.target).parents().addBack().is(".ui-slider-handle"),this._clickOffset=l?{left:0,top:0}:{left:t.pageX-h.left-a.width()/2,top:t.pageY-h.top-a.height()/2-(parseInt(a.css("borderTopWidth"),10)||0)-(parseInt(a.css("borderBottomWidth"),10)||0)+(parseInt(a.css("marginTop"),10)||0)},this.handles.hasClass("ui-state-hover")||this._slide(t,o,s),this._animateOff=!0,!0))},_mouseStart:function(){return!0},_mouseDrag:function(e){var t={x:e.pageX,y:e.pageY},i=this._normValueFromMouse(t);return this._slide(e,this._handleIndex,i),!1},_mouseStop:function(e){return this.handles.removeClass("ui-state-active"),this._mouseSliding=!1,this._stop(e,this._handleIndex),this._change(e,this._handleIndex),this._handleIndex=null,this._clickOffset=null,this._animateOff=!1,!1},_detectOrientation:function(){this.orientation="vertical"===this.options.orientation?"vertical":"horizontal"},_normValueFromMouse:function(e){var t,i,s,n,a;return"horizontal"===this.orientation?(t=this.elementSize.width,i=e.x-this.elementOffset.left-(this._clickOffset?this._clickOffset.left:0)):(t=this.elementSize.height,i=e.y-this.elementOffset.top-(this._clickOffset?this._clickOffset.top:0)),s=i/t,s>1&&(s=1),0>s&&(s=0),"vertical"===this.orientation&&(s=1-s),n=this._valueMax()-this._valueMin(),a=this._valueMin()+s*n,this._trimAlignValue(a)},_start:function(e,t){var i={handle:this.handles[t],value:this.value()};return this.options.values&&this.options.values.length&&(i.value=this.values(t),i.values=this.values()),this._trigger("start",e,i)},_slide:function(e,t,i){var s,n,a;this.options.values&&this.options.values.length?(s=this.values(t?0:1),2===this.options.values.length&&this.options.range===!0&&(0===t&&i>s||1===t&&s>i)&&(i=s),i!==this.values(t)&&(n=this.values(),n[t]=i,a=this._trigger("slide",e,{handle:this.handles[t],value:i,values:n}),s=this.values(t?0:1),a!==!1&&this.values(t,i))):i!==this.value()&&(a=this._trigger("slide",e,{handle:this.handles[t],value:i}),a!==!1&&this.value(i))},_stop:function(e,t){var i={handle:this.handles[t],value:this.value()};this.options.values&&this.options.values.length&&(i.value=this.values(t),i.values=this.values()),this._trigger("stop",e,i)},_change:function(e,t){if(!this._keySliding&&!this._mouseSliding){var i={handle:this.handles[t],value:this.value()};this.options.values&&this.options.values.length&&(i.value=this.values(t),i.values=this.values()),this._lastChangedValue=t,this._trigger("change",e,i)}},value:function(e){return arguments.length?(this.options.value=this._trimAlignValue(e),this._refreshValue(),this._change(null,0),void 0):this._value()},values:function(t,i){var s,n,a;if(arguments.length>1)return this.options.values[t]=this._trimAlignValue(i),this._refreshValue(),this._change(null,t),void 0;if(!arguments.length)return this._values();if(!e.isArray(arguments[0]))return this.options.values&&this.options.values.length?this._values(t):this.value();for(s=this.options.values,n=arguments[0],a=0;s.length>a;a+=1)s[a]=this._trimAlignValue(n[a]),this._change(null,a);this._refreshValue()},_setOption:function(t,i){var s,n=0;switch("range"===t&&this.options.range===!0&&("min"===i?(this.options.value=this._values(0),this.options.values=null):"max"===i&&(this.options.value=this._values(this.options.values.length-1),this.options.values=null)),e.isArray(this.options.values)&&(n=this.options.values.length),"disabled"===t&&this.element.toggleClass("ui-state-disabled",!!i),this._super(t,i),t){case"orientation":this._detectOrientation(),this.element.removeClass("ui-slider-horizontal ui-slider-vertical").addClass("ui-slider-"+this.orientation),this._refreshValue(),this.handles.css("horizontal"===i?"bottom":"left","");break;case"value":this._animateOff=!0,this._refreshValue(),this._change(null,0),this._animateOff=!1;break;case"values":for(this._animateOff=!0,this._refreshValue(),s=0;n>s;s+=1)this._change(null,s);this._animateOff=!1;break;case"step":case"min":case"max":this._animateOff=!0,this._calculateNewMax(),this._refreshValue(),this._animateOff=!1;break;case"range":this._animateOff=!0,this._refresh(),this._animateOff=!1}},_value:function(){var e=this.options.value;return e=this._trimAlignValue(e)},_values:function(e){var t,i,s;if(arguments.length)return t=this.options.values[e],t=this._trimAlignValue(t);if(this.options.values&&this.options.values.length){for(i=this.options.values.slice(),s=0;i.length>s;s+=1)i[s]=this._trimAlignValue(i[s]);return i}return[]},_trimAlignValue:function(e){if(this._valueMin()>=e)return this._valueMin();if(e>=this._valueMax())return this._valueMax();var t=this.options.step>0?this.options.step:1,i=(e-this._valueMin())%t,s=e-i;return 2*Math.abs(i)>=t&&(s+=i>0?t:-t),parseFloat(s.toFixed(5))},_calculateNewMax:function(){var e=this.options.max,t=this._valueMin(),i=this.options.step,s=Math.floor(+(e-t).toFixed(this._precision())/i)*i;e=s+t,this.max=parseFloat(e.toFixed(this._precision()))},_precision:function(){var e=this._precisionOf(this.options.step);return null!==this.options.min&&(e=Math.max(e,this._precisionOf(this.options.min))),e},_precisionOf:function(e){var t=""+e,i=t.indexOf(".");return-1===i?0:t.length-i-1},_valueMin:function(){return this.options.min},_valueMax:function(){return this.max},_refreshValue:function(){var t,i,s,n,a,o=this.options.range,r=this.options,h=this,l=this._animateOff?!1:r.animate,u={};this.options.values&&this.options.values.length?this.handles.each(function(s){i=100*((h.values(s)-h._valueMin())/(h._valueMax()-h._valueMin())),u["horizontal"===h.orientation?"left":"bottom"]=i+"%",e(this).stop(1,1)[l?"animate":"css"](u,r.animate),h.options.range===!0&&("horizontal"===h.orientation?(0===s&&h.range.stop(1,1)[l?"animate":"css"]({left:i+"%"},r.animate),1===s&&h.range[l?"animate":"css"]({width:i-t+"%"},{queue:!1,duration:r.animate})):(0===s&&h.range.stop(1,1)[l?"animate":"css"]({bottom:i+"%"},r.animate),1===s&&h.range[l?"animate":"css"]({height:i-t+"%"},{queue:!1,duration:r.animate}))),t=i}):(s=this.value(),n=this._valueMin(),a=this._valueMax(),i=a!==n?100*((s-n)/(a-n)):0,u["horizontal"===this.orientation?"left":"bottom"]=i+"%",this.handle.stop(1,1)[l?"animate":"css"](u,r.animate),"min"===o&&"horizontal"===this.orientation&&this.range.stop(1,1)[l?"animate":"css"]({width:i+"%"},r.animate),"max"===o&&"horizontal"===this.orientation&&this.range[l?"animate":"css"]({width:100-i+"%"},{queue:!1,duration:r.animate}),"min"===o&&"vertical"===this.orientation&&this.range.stop(1,1)[l?"animate":"css"]({height:i+"%"},r.animate),"max"===o&&"vertical"===this.orientation&&this.range[l?"animate":"css"]({height:100-i+"%"},{queue:!1,duration:r.animate}))},_handleEvents:{keydown:function(t){var i,s,n,a,o=e(t.target).data("ui-slider-handle-index");switch(t.keyCode){case e.ui.keyCode.HOME:case e.ui.keyCode.END:case e.ui.keyCode.PAGE_UP:case e.ui.keyCode.PAGE_DOWN:case e.ui.keyCode.UP:case e.ui.keyCode.RIGHT:case e.ui.keyCode.DOWN:case e.ui.keyCode.LEFT:if(t.preventDefault(),!this._keySliding&&(this._keySliding=!0,e(t.target).addClass("ui-state-active"),i=this._start(t,o),i===!1))return}switch(a=this.options.step,s=n=this.options.values&&this.options.values.length?this.values(o):this.value(),t.keyCode){case e.ui.keyCode.HOME:n=this._valueMin();break;case e.ui.keyCode.END:n=this._valueMax();break;case e.ui.keyCode.PAGE_UP:n=this._trimAlignValue(s+(this._valueMax()-this._valueMin())/this.numPages);break;case e.ui.keyCode.PAGE_DOWN:n=this._trimAlignValue(s-(this._valueMax()-this._valueMin())/this.numPages);break;case e.ui.keyCode.UP:case e.ui.keyCode.RIGHT:if(s===this._valueMax())return;n=this._trimAlignValue(s+a);break;case e.ui.keyCode.DOWN:case e.ui.keyCode.LEFT:if(s===this._valueMin())return;n=this._trimAlignValue(s-a)}this._slide(t,o,n)},keyup:function(t){var i=e(t.target).data("ui-slider-handle-index");this._keySliding&&(this._keySliding=!1,this._stop(t,i),this._change(t,i),e(t.target).removeClass("ui-state-active"))}}}),e.widget("ui.spinner",{version:"1.11.4",defaultElement:"<input>",widgetEventPrefix:"spin",options:{culture:null,icons:{down:"ui-icon-triangle-1-s",up:"ui-icon-triangle-1-n"},incremental:!0,max:null,min:null,numberFormat:null,page:10,step:1,change:null,spin:null,start:null,stop:null},_create:function(){this._setOption("max",this.options.max),this._setOption("min",this.options.min),this._setOption("step",this.options.step),""!==this.value()&&this._value(this.element.val(),!0),this._draw(),this._on(this._events),this._refresh(),this._on(this.window,{beforeunload:function(){this.element.removeAttr("autocomplete")}})},_getCreateOptions:function(){var t={},i=this.element;return e.each(["min","max","step"],function(e,s){var n=i.attr(s);void 0!==n&&n.length&&(t[s]=n)}),t},_events:{keydown:function(e){this._start(e)&&this._keydown(e)&&e.preventDefault()},keyup:"_stop",focus:function(){this.previous=this.element.val()},blur:function(e){return this.cancelBlur?(delete this.cancelBlur,void 0):(this._stop(),this._refresh(),this.previous!==this.element.val()&&this._trigger("change",e),void 0)},mousewheel:function(e,t){if(t){if(!this.spinning&&!this._start(e))return!1;this._spin((t>0?1:-1)*this.options.step,e),clearTimeout(this.mousewheelTimer),this.mousewheelTimer=this._delay(function(){this.spinning&&this._stop(e)},100),e.preventDefault()}},"mousedown .ui-spinner-button":function(t){function i(){var e=this.element[0]===this.document[0].activeElement;e||(this.element.focus(),this.previous=s,this._delay(function(){this.previous=s}))}var s;s=this.element[0]===this.document[0].activeElement?this.previous:this.element.val(),t.preventDefault(),i.call(this),this.cancelBlur=!0,this._delay(function(){delete this.cancelBlur,i.call(this)}),this._start(t)!==!1&&this._repeat(null,e(t.currentTarget).hasClass("ui-spinner-up")?1:-1,t)},"mouseup .ui-spinner-button":"_stop","mouseenter .ui-spinner-button":function(t){return e(t.currentTarget).hasClass("ui-state-active")?this._start(t)===!1?!1:(this._repeat(null,e(t.currentTarget).hasClass("ui-spinner-up")?1:-1,t),void 0):void 0},"mouseleave .ui-spinner-button":"_stop"},_draw:function(){var e=this.uiSpinner=this.element.addClass("ui-spinner-input").attr("autocomplete","off").wrap(this._uiSpinnerHtml()).parent().append(this._buttonHtml());this.element.attr("role","spinbutton"),this.buttons=e.find(".ui-spinner-button").attr("tabIndex",-1).button().removeClass("ui-corner-all"),this.buttons.height()>Math.ceil(.5*e.height())&&e.height()>0&&e.height(e.height()),this.options.disabled&&this.disable()},_keydown:function(t){var i=this.options,s=e.ui.keyCode;switch(t.keyCode){case s.UP:return this._repeat(null,1,t),!0;case s.DOWN:return this._repeat(null,-1,t),!0;case s.PAGE_UP:return this._repeat(null,i.page,t),!0;case s.PAGE_DOWN:return this._repeat(null,-i.page,t),!0}return!1},_uiSpinnerHtml:function(){return"<span class='ui-spinner ui-widget ui-widget-content ui-corner-all'></span>"},_buttonHtml:function(){return"<a class='ui-spinner-button ui-spinner-up ui-corner-tr'><span class='ui-icon "+this.options.icons.up+"'>&#9650;</span>"+"</a>"+"<a class='ui-spinner-button ui-spinner-down ui-corner-br'>"+"<span class='ui-icon "+this.options.icons.down+"'>&#9660;</span>"+"</a>"},_start:function(e){return this.spinning||this._trigger("start",e)!==!1?(this.counter||(this.counter=1),this.spinning=!0,!0):!1},_repeat:function(e,t,i){e=e||500,clearTimeout(this.timer),this.timer=this._delay(function(){this._repeat(40,t,i)},e),this._spin(t*this.options.step,i)},_spin:function(e,t){var i=this.value()||0;this.counter||(this.counter=1),i=this._adjustValue(i+e*this._increment(this.counter)),this.spinning&&this._trigger("spin",t,{value:i})===!1||(this._value(i),this.counter++)},_increment:function(t){var i=this.options.incremental;return i?e.isFunction(i)?i(t):Math.floor(t*t*t/5e4-t*t/500+17*t/200+1):1},_precision:function(){var e=this._precisionOf(this.options.step);return null!==this.options.min&&(e=Math.max(e,this._precisionOf(this.options.min))),e},_precisionOf:function(e){var t=""+e,i=t.indexOf(".");return-1===i?0:t.length-i-1},_adjustValue:function(e){var t,i,s=this.options;return t=null!==s.min?s.min:0,i=e-t,i=Math.round(i/s.step)*s.step,e=t+i,e=parseFloat(e.toFixed(this._precision())),null!==s.max&&e>s.max?s.max:null!==s.min&&s.min>e?s.min:e},_stop:function(e){this.spinning&&(clearTimeout(this.timer),clearTimeout(this.mousewheelTimer),this.counter=0,this.spinning=!1,this._trigger("stop",e))},_setOption:function(e,t){if("culture"===e||"numberFormat"===e){var i=this._parse(this.element.val());return this.options[e]=t,this.element.val(this._format(i)),void 0}("max"===e||"min"===e||"step"===e)&&"string"==typeof t&&(t=this._parse(t)),"icons"===e&&(this.buttons.first().find(".ui-icon").removeClass(this.options.icons.up).addClass(t.up),this.buttons.last().find(".ui-icon").removeClass(this.options.icons.down).addClass(t.down)),this._super(e,t),"disabled"===e&&(this.widget().toggleClass("ui-state-disabled",!!t),this.element.prop("disabled",!!t),this.buttons.button(t?"disable":"enable"))},_setOptions:s(function(e){this._super(e)}),_parse:function(e){return"string"==typeof e&&""!==e&&(e=window.Globalize&&this.options.numberFormat?Globalize.parseFloat(e,10,this.options.culture):+e),""===e||isNaN(e)?null:e
},_format:function(e){return""===e?"":window.Globalize&&this.options.numberFormat?Globalize.format(e,this.options.numberFormat,this.options.culture):e},_refresh:function(){this.element.attr({"aria-valuemin":this.options.min,"aria-valuemax":this.options.max,"aria-valuenow":this._parse(this.element.val())})},isValid:function(){var e=this.value();return null===e?!1:e===this._adjustValue(e)},_value:function(e,t){var i;""!==e&&(i=this._parse(e),null!==i&&(t||(i=this._adjustValue(i)),e=this._format(i))),this.element.val(e),this._refresh()},_destroy:function(){this.element.removeClass("ui-spinner-input").prop("disabled",!1).removeAttr("autocomplete").removeAttr("role").removeAttr("aria-valuemin").removeAttr("aria-valuemax").removeAttr("aria-valuenow"),this.uiSpinner.replaceWith(this.element)},stepUp:s(function(e){this._stepUp(e)}),_stepUp:function(e){this._start()&&(this._spin((e||1)*this.options.step),this._stop())},stepDown:s(function(e){this._stepDown(e)}),_stepDown:function(e){this._start()&&(this._spin((e||1)*-this.options.step),this._stop())},pageUp:s(function(e){this._stepUp((e||1)*this.options.page)}),pageDown:s(function(e){this._stepDown((e||1)*this.options.page)}),value:function(e){return arguments.length?(s(this._value).call(this,e),void 0):this._parse(this.element.val())},widget:function(){return this.uiSpinner}}),e.widget("ui.tabs",{version:"1.11.4",delay:300,options:{active:null,collapsible:!1,event:"click",heightStyle:"content",hide:null,show:null,activate:null,beforeActivate:null,beforeLoad:null,load:null},_isLocal:function(){var e=/#.*$/;return function(t){var i,s;t=t.cloneNode(!1),i=t.href.replace(e,""),s=location.href.replace(e,"");try{i=decodeURIComponent(i)}catch(n){}try{s=decodeURIComponent(s)}catch(n){}return t.hash.length>1&&i===s}}(),_create:function(){var t=this,i=this.options;this.running=!1,this.element.addClass("ui-tabs ui-widget ui-widget-content ui-corner-all").toggleClass("ui-tabs-collapsible",i.collapsible),this._processTabs(),i.active=this._initialActive(),e.isArray(i.disabled)&&(i.disabled=e.unique(i.disabled.concat(e.map(this.tabs.filter(".ui-state-disabled"),function(e){return t.tabs.index(e)}))).sort()),this.active=this.options.active!==!1&&this.anchors.length?this._findActive(i.active):e(),this._refresh(),this.active.length&&this.load(i.active)},_initialActive:function(){var t=this.options.active,i=this.options.collapsible,s=location.hash.substring(1);return null===t&&(s&&this.tabs.each(function(i,n){return e(n).attr("aria-controls")===s?(t=i,!1):void 0}),null===t&&(t=this.tabs.index(this.tabs.filter(".ui-tabs-active"))),(null===t||-1===t)&&(t=this.tabs.length?0:!1)),t!==!1&&(t=this.tabs.index(this.tabs.eq(t)),-1===t&&(t=i?!1:0)),!i&&t===!1&&this.anchors.length&&(t=0),t},_getCreateEventData:function(){return{tab:this.active,panel:this.active.length?this._getPanelForTab(this.active):e()}},_tabKeydown:function(t){var i=e(this.document[0].activeElement).closest("li"),s=this.tabs.index(i),n=!0;if(!this._handlePageNav(t)){switch(t.keyCode){case e.ui.keyCode.RIGHT:case e.ui.keyCode.DOWN:s++;break;case e.ui.keyCode.UP:case e.ui.keyCode.LEFT:n=!1,s--;break;case e.ui.keyCode.END:s=this.anchors.length-1;break;case e.ui.keyCode.HOME:s=0;break;case e.ui.keyCode.SPACE:return t.preventDefault(),clearTimeout(this.activating),this._activate(s),void 0;case e.ui.keyCode.ENTER:return t.preventDefault(),clearTimeout(this.activating),this._activate(s===this.options.active?!1:s),void 0;default:return}t.preventDefault(),clearTimeout(this.activating),s=this._focusNextTab(s,n),t.ctrlKey||t.metaKey||(i.attr("aria-selected","false"),this.tabs.eq(s).attr("aria-selected","true"),this.activating=this._delay(function(){this.option("active",s)},this.delay))}},_panelKeydown:function(t){this._handlePageNav(t)||t.ctrlKey&&t.keyCode===e.ui.keyCode.UP&&(t.preventDefault(),this.active.focus())},_handlePageNav:function(t){return t.altKey&&t.keyCode===e.ui.keyCode.PAGE_UP?(this._activate(this._focusNextTab(this.options.active-1,!1)),!0):t.altKey&&t.keyCode===e.ui.keyCode.PAGE_DOWN?(this._activate(this._focusNextTab(this.options.active+1,!0)),!0):void 0},_findNextTab:function(t,i){function s(){return t>n&&(t=0),0>t&&(t=n),t}for(var n=this.tabs.length-1;-1!==e.inArray(s(),this.options.disabled);)t=i?t+1:t-1;return t},_focusNextTab:function(e,t){return e=this._findNextTab(e,t),this.tabs.eq(e).focus(),e},_setOption:function(e,t){return"active"===e?(this._activate(t),void 0):"disabled"===e?(this._setupDisabled(t),void 0):(this._super(e,t),"collapsible"===e&&(this.element.toggleClass("ui-tabs-collapsible",t),t||this.options.active!==!1||this._activate(0)),"event"===e&&this._setupEvents(t),"heightStyle"===e&&this._setupHeightStyle(t),void 0)},_sanitizeSelector:function(e){return e?e.replace(/[!"$%&'()*+,.\/:;<=>?@\[\]\^`{|}~]/g,"\\$&"):""},refresh:function(){var t=this.options,i=this.tablist.children(":has(a[href])");t.disabled=e.map(i.filter(".ui-state-disabled"),function(e){return i.index(e)}),this._processTabs(),t.active!==!1&&this.anchors.length?this.active.length&&!e.contains(this.tablist[0],this.active[0])?this.tabs.length===t.disabled.length?(t.active=!1,this.active=e()):this._activate(this._findNextTab(Math.max(0,t.active-1),!1)):t.active=this.tabs.index(this.active):(t.active=!1,this.active=e()),this._refresh()},_refresh:function(){this._setupDisabled(this.options.disabled),this._setupEvents(this.options.event),this._setupHeightStyle(this.options.heightStyle),this.tabs.not(this.active).attr({"aria-selected":"false","aria-expanded":"false",tabIndex:-1}),this.panels.not(this._getPanelForTab(this.active)).hide().attr({"aria-hidden":"true"}),this.active.length?(this.active.addClass("ui-tabs-active ui-state-active").attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0}),this._getPanelForTab(this.active).show().attr({"aria-hidden":"false"})):this.tabs.eq(0).attr("tabIndex",0)},_processTabs:function(){var t=this,i=this.tabs,s=this.anchors,n=this.panels;this.tablist=this._getList().addClass("ui-tabs-nav ui-helper-reset ui-helper-clearfix ui-widget-header ui-corner-all").attr("role","tablist").delegate("> li","mousedown"+this.eventNamespace,function(t){e(this).is(".ui-state-disabled")&&t.preventDefault()}).delegate(".ui-tabs-anchor","focus"+this.eventNamespace,function(){e(this).closest("li").is(".ui-state-disabled")&&this.blur()}),this.tabs=this.tablist.find("> li:has(a[href])").addClass("ui-state-default ui-corner-top").attr({role:"tab",tabIndex:-1}),this.anchors=this.tabs.map(function(){return e("a",this)[0]}).addClass("ui-tabs-anchor").attr({role:"presentation",tabIndex:-1}),this.panels=e(),this.anchors.each(function(i,s){var n,a,o,r=e(s).uniqueId().attr("id"),h=e(s).closest("li"),l=h.attr("aria-controls");t._isLocal(s)?(n=s.hash,o=n.substring(1),a=t.element.find(t._sanitizeSelector(n))):(o=h.attr("aria-controls")||e({}).uniqueId()[0].id,n="#"+o,a=t.element.find(n),a.length||(a=t._createPanel(o),a.insertAfter(t.panels[i-1]||t.tablist)),a.attr("aria-live","polite")),a.length&&(t.panels=t.panels.add(a)),l&&h.data("ui-tabs-aria-controls",l),h.attr({"aria-controls":o,"aria-labelledby":r}),a.attr("aria-labelledby",r)}),this.panels.addClass("ui-tabs-panel ui-widget-content ui-corner-bottom").attr("role","tabpanel"),i&&(this._off(i.not(this.tabs)),this._off(s.not(this.anchors)),this._off(n.not(this.panels)))},_getList:function(){return this.tablist||this.element.find("ol,ul").eq(0)},_createPanel:function(t){return e("<div>").attr("id",t).addClass("ui-tabs-panel ui-widget-content ui-corner-bottom").data("ui-tabs-destroy",!0)},_setupDisabled:function(t){e.isArray(t)&&(t.length?t.length===this.anchors.length&&(t=!0):t=!1);for(var i,s=0;i=this.tabs[s];s++)t===!0||-1!==e.inArray(s,t)?e(i).addClass("ui-state-disabled").attr("aria-disabled","true"):e(i).removeClass("ui-state-disabled").removeAttr("aria-disabled");this.options.disabled=t},_setupEvents:function(t){var i={};t&&e.each(t.split(" "),function(e,t){i[t]="_eventHandler"}),this._off(this.anchors.add(this.tabs).add(this.panels)),this._on(!0,this.anchors,{click:function(e){e.preventDefault()}}),this._on(this.anchors,i),this._on(this.tabs,{keydown:"_tabKeydown"}),this._on(this.panels,{keydown:"_panelKeydown"}),this._focusable(this.tabs),this._hoverable(this.tabs)},_setupHeightStyle:function(t){var i,s=this.element.parent();"fill"===t?(i=s.height(),i-=this.element.outerHeight()-this.element.height(),this.element.siblings(":visible").each(function(){var t=e(this),s=t.css("position");"absolute"!==s&&"fixed"!==s&&(i-=t.outerHeight(!0))}),this.element.children().not(this.panels).each(function(){i-=e(this).outerHeight(!0)}),this.panels.each(function(){e(this).height(Math.max(0,i-e(this).innerHeight()+e(this).height()))}).css("overflow","auto")):"auto"===t&&(i=0,this.panels.each(function(){i=Math.max(i,e(this).height("").height())}).height(i))},_eventHandler:function(t){var i=this.options,s=this.active,n=e(t.currentTarget),a=n.closest("li"),o=a[0]===s[0],r=o&&i.collapsible,h=r?e():this._getPanelForTab(a),l=s.length?this._getPanelForTab(s):e(),u={oldTab:s,oldPanel:l,newTab:r?e():a,newPanel:h};t.preventDefault(),a.hasClass("ui-state-disabled")||a.hasClass("ui-tabs-loading")||this.running||o&&!i.collapsible||this._trigger("beforeActivate",t,u)===!1||(i.active=r?!1:this.tabs.index(a),this.active=o?e():a,this.xhr&&this.xhr.abort(),l.length||h.length||e.error("jQuery UI Tabs: Mismatching fragment identifier."),h.length&&this.load(this.tabs.index(a),t),this._toggle(t,u))},_toggle:function(t,i){function s(){a.running=!1,a._trigger("activate",t,i)}function n(){i.newTab.closest("li").addClass("ui-tabs-active ui-state-active"),o.length&&a.options.show?a._show(o,a.options.show,s):(o.show(),s())}var a=this,o=i.newPanel,r=i.oldPanel;this.running=!0,r.length&&this.options.hide?this._hide(r,this.options.hide,function(){i.oldTab.closest("li").removeClass("ui-tabs-active ui-state-active"),n()}):(i.oldTab.closest("li").removeClass("ui-tabs-active ui-state-active"),r.hide(),n()),r.attr("aria-hidden","true"),i.oldTab.attr({"aria-selected":"false","aria-expanded":"false"}),o.length&&r.length?i.oldTab.attr("tabIndex",-1):o.length&&this.tabs.filter(function(){return 0===e(this).attr("tabIndex")}).attr("tabIndex",-1),o.attr("aria-hidden","false"),i.newTab.attr({"aria-selected":"true","aria-expanded":"true",tabIndex:0})},_activate:function(t){var i,s=this._findActive(t);s[0]!==this.active[0]&&(s.length||(s=this.active),i=s.find(".ui-tabs-anchor")[0],this._eventHandler({target:i,currentTarget:i,preventDefault:e.noop}))},_findActive:function(t){return t===!1?e():this.tabs.eq(t)},_getIndex:function(e){return"string"==typeof e&&(e=this.anchors.index(this.anchors.filter("[href$='"+e+"']"))),e},_destroy:function(){this.xhr&&this.xhr.abort(),this.element.removeClass("ui-tabs ui-widget ui-widget-content ui-corner-all ui-tabs-collapsible"),this.tablist.removeClass("ui-tabs-nav ui-helper-reset ui-helper-clearfix ui-widget-header ui-corner-all").removeAttr("role"),this.anchors.removeClass("ui-tabs-anchor").removeAttr("role").removeAttr("tabIndex").removeUniqueId(),this.tablist.unbind(this.eventNamespace),this.tabs.add(this.panels).each(function(){e.data(this,"ui-tabs-destroy")?e(this).remove():e(this).removeClass("ui-state-default ui-state-active ui-state-disabled ui-corner-top ui-corner-bottom ui-widget-content ui-tabs-active ui-tabs-panel").removeAttr("tabIndex").removeAttr("aria-live").removeAttr("aria-busy").removeAttr("aria-selected").removeAttr("aria-labelledby").removeAttr("aria-hidden").removeAttr("aria-expanded").removeAttr("role")}),this.tabs.each(function(){var t=e(this),i=t.data("ui-tabs-aria-controls");i?t.attr("aria-controls",i).removeData("ui-tabs-aria-controls"):t.removeAttr("aria-controls")}),this.panels.show(),"content"!==this.options.heightStyle&&this.panels.css("height","")},enable:function(t){var i=this.options.disabled;i!==!1&&(void 0===t?i=!1:(t=this._getIndex(t),i=e.isArray(i)?e.map(i,function(e){return e!==t?e:null}):e.map(this.tabs,function(e,i){return i!==t?i:null})),this._setupDisabled(i))},disable:function(t){var i=this.options.disabled;if(i!==!0){if(void 0===t)i=!0;else{if(t=this._getIndex(t),-1!==e.inArray(t,i))return;i=e.isArray(i)?e.merge([t],i).sort():[t]}this._setupDisabled(i)}},load:function(t,i){t=this._getIndex(t);var s=this,n=this.tabs.eq(t),a=n.find(".ui-tabs-anchor"),o=this._getPanelForTab(n),r={tab:n,panel:o},h=function(e,t){"abort"===t&&s.panels.stop(!1,!0),n.removeClass("ui-tabs-loading"),o.removeAttr("aria-busy"),e===s.xhr&&delete s.xhr};this._isLocal(a[0])||(this.xhr=e.ajax(this._ajaxSettings(a,i,r)),this.xhr&&"canceled"!==this.xhr.statusText&&(n.addClass("ui-tabs-loading"),o.attr("aria-busy","true"),this.xhr.done(function(e,t,n){setTimeout(function(){o.html(e),s._trigger("load",i,r),h(n,t)},1)}).fail(function(e,t){setTimeout(function(){h(e,t)},1)})))},_ajaxSettings:function(t,i,s){var n=this;return{url:t.attr("href"),beforeSend:function(t,a){return n._trigger("beforeLoad",i,e.extend({jqXHR:t,ajaxSettings:a},s))}}},_getPanelForTab:function(t){var i=e(t).attr("aria-controls");return this.element.find(this._sanitizeSelector("#"+i))}}),e.widget("ui.tooltip",{version:"1.11.4",options:{content:function(){var t=e(this).attr("title")||"";return e("<a>").text(t).html()},hide:!0,items:"[title]:not([disabled])",position:{my:"left top+15",at:"left bottom",collision:"flipfit flip"},show:!0,tooltipClass:null,track:!1,close:null,open:null},_addDescribedBy:function(t,i){var s=(t.attr("aria-describedby")||"").split(/\s+/);s.push(i),t.data("ui-tooltip-id",i).attr("aria-describedby",e.trim(s.join(" ")))},_removeDescribedBy:function(t){var i=t.data("ui-tooltip-id"),s=(t.attr("aria-describedby")||"").split(/\s+/),n=e.inArray(i,s);-1!==n&&s.splice(n,1),t.removeData("ui-tooltip-id"),s=e.trim(s.join(" ")),s?t.attr("aria-describedby",s):t.removeAttr("aria-describedby")},_create:function(){this._on({mouseover:"open",focusin:"open"}),this.tooltips={},this.parents={},this.options.disabled&&this._disable(),this.liveRegion=e("<div>").attr({role:"log","aria-live":"assertive","aria-relevant":"additions"}).addClass("ui-helper-hidden-accessible").appendTo(this.document[0].body)},_setOption:function(t,i){var s=this;return"disabled"===t?(this[i?"_disable":"_enable"](),this.options[t]=i,void 0):(this._super(t,i),"content"===t&&e.each(this.tooltips,function(e,t){s._updateContent(t.element)}),void 0)},_disable:function(){var t=this;e.each(this.tooltips,function(i,s){var n=e.Event("blur");n.target=n.currentTarget=s.element[0],t.close(n,!0)}),this.element.find(this.options.items).addBack().each(function(){var t=e(this);t.is("[title]")&&t.data("ui-tooltip-title",t.attr("title")).removeAttr("title")})},_enable:function(){this.element.find(this.options.items).addBack().each(function(){var t=e(this);t.data("ui-tooltip-title")&&t.attr("title",t.data("ui-tooltip-title"))})},open:function(t){var i=this,s=e(t?t.target:this.element).closest(this.options.items);s.length&&!s.data("ui-tooltip-id")&&(s.attr("title")&&s.data("ui-tooltip-title",s.attr("title")),s.data("ui-tooltip-open",!0),t&&"mouseover"===t.type&&s.parents().each(function(){var t,s=e(this);s.data("ui-tooltip-open")&&(t=e.Event("blur"),t.target=t.currentTarget=this,i.close(t,!0)),s.attr("title")&&(s.uniqueId(),i.parents[this.id]={element:this,title:s.attr("title")},s.attr("title",""))}),this._registerCloseHandlers(t,s),this._updateContent(s,t))},_updateContent:function(e,t){var i,s=this.options.content,n=this,a=t?t.type:null;return"string"==typeof s?this._open(t,e,s):(i=s.call(e[0],function(i){n._delay(function(){e.data("ui-tooltip-open")&&(t&&(t.type=a),this._open(t,e,i))})}),i&&this._open(t,e,i),void 0)},_open:function(t,i,s){function n(e){l.of=e,o.is(":hidden")||o.position(l)}var a,o,r,h,l=e.extend({},this.options.position);if(s){if(a=this._find(i))return a.tooltip.find(".ui-tooltip-content").html(s),void 0;i.is("[title]")&&(t&&"mouseover"===t.type?i.attr("title",""):i.removeAttr("title")),a=this._tooltip(i),o=a.tooltip,this._addDescribedBy(i,o.attr("id")),o.find(".ui-tooltip-content").html(s),this.liveRegion.children().hide(),s.clone?(h=s.clone(),h.removeAttr("id").find("[id]").removeAttr("id")):h=s,e("<div>").html(h).appendTo(this.liveRegion),this.options.track&&t&&/^mouse/.test(t.type)?(this._on(this.document,{mousemove:n}),n(t)):o.position(e.extend({of:i},this.options.position)),o.hide(),this._show(o,this.options.show),this.options.show&&this.options.show.delay&&(r=this.delayedShow=setInterval(function(){o.is(":visible")&&(n(l.of),clearInterval(r))},e.fx.interval)),this._trigger("open",t,{tooltip:o})}},_registerCloseHandlers:function(t,i){var s={keyup:function(t){if(t.keyCode===e.ui.keyCode.ESCAPE){var s=e.Event(t);s.currentTarget=i[0],this.close(s,!0)}}};i[0]!==this.element[0]&&(s.remove=function(){this._removeTooltip(this._find(i).tooltip)}),t&&"mouseover"!==t.type||(s.mouseleave="close"),t&&"focusin"!==t.type||(s.focusout="close"),this._on(!0,i,s)},close:function(t){var i,s=this,n=e(t?t.currentTarget:this.element),a=this._find(n);return a?(i=a.tooltip,a.closing||(clearInterval(this.delayedShow),n.data("ui-tooltip-title")&&!n.attr("title")&&n.attr("title",n.data("ui-tooltip-title")),this._removeDescribedBy(n),a.hiding=!0,i.stop(!0),this._hide(i,this.options.hide,function(){s._removeTooltip(e(this))}),n.removeData("ui-tooltip-open"),this._off(n,"mouseleave focusout keyup"),n[0]!==this.element[0]&&this._off(n,"remove"),this._off(this.document,"mousemove"),t&&"mouseleave"===t.type&&e.each(this.parents,function(t,i){e(i.element).attr("title",i.title),delete s.parents[t]}),a.closing=!0,this._trigger("close",t,{tooltip:i}),a.hiding||(a.closing=!1)),void 0):(n.removeData("ui-tooltip-open"),void 0)},_tooltip:function(t){var i=e("<div>").attr("role","tooltip").addClass("ui-tooltip ui-widget ui-corner-all ui-widget-content "+(this.options.tooltipClass||"")),s=i.uniqueId().attr("id");return e("<div>").addClass("ui-tooltip-content").appendTo(i),i.appendTo(this.document[0].body),this.tooltips[s]={element:t,tooltip:i}},_find:function(e){var t=e.data("ui-tooltip-id");return t?this.tooltips[t]:null},_removeTooltip:function(e){e.remove(),delete this.tooltips[e.attr("id")]},_destroy:function(){var t=this;e.each(this.tooltips,function(i,s){var n=e.Event("blur"),a=s.element;n.target=n.currentTarget=a[0],t.close(n,!0),e("#"+i).remove(),a.data("ui-tooltip-title")&&(a.attr("title")||a.attr("title",a.data("ui-tooltip-title")),a.removeData("ui-tooltip-title"))}),this.liveRegion.remove()}});var c="ui-effects-",p=e;e.effects={effect:{}},function(e,t){function i(e,t,i){var s=d[t.type]||{};return null==e?i||!t.def?null:t.def:(e=s.floor?~~e:parseFloat(e),isNaN(e)?t.def:s.mod?(e+s.mod)%s.mod:0>e?0:e>s.max?s.max:e)}function s(i){var s=l(),n=s._rgba=[];return i=i.toLowerCase(),f(h,function(e,a){var o,r=a.re.exec(i),h=r&&a.parse(r),l=a.space||"rgba";return h?(o=s[l](h),s[u[l].cache]=o[u[l].cache],n=s._rgba=o._rgba,!1):t}),n.length?("0,0,0,0"===n.join()&&e.extend(n,a.transparent),s):a[i]}function n(e,t,i){return i=(i+1)%1,1>6*i?e+6*(t-e)*i:1>2*i?t:2>3*i?e+6*(t-e)*(2/3-i):e}var a,o="backgroundColor borderBottomColor borderLeftColor borderRightColor borderTopColor color columnRuleColor outlineColor textDecorationColor textEmphasisColor",r=/^([\-+])=\s*(\d+\.?\d*)/,h=[{re:/rgba?\(\s*(\d{1,3})\s*,\s*(\d{1,3})\s*,\s*(\d{1,3})\s*(?:,\s*(\d?(?:\.\d+)?)\s*)?\)/,parse:function(e){return[e[1],e[2],e[3],e[4]]}},{re:/rgba?\(\s*(\d+(?:\.\d+)?)\%\s*,\s*(\d+(?:\.\d+)?)\%\s*,\s*(\d+(?:\.\d+)?)\%\s*(?:,\s*(\d?(?:\.\d+)?)\s*)?\)/,parse:function(e){return[2.55*e[1],2.55*e[2],2.55*e[3],e[4]]}},{re:/#([a-f0-9]{2})([a-f0-9]{2})([a-f0-9]{2})/,parse:function(e){return[parseInt(e[1],16),parseInt(e[2],16),parseInt(e[3],16)]}},{re:/#([a-f0-9])([a-f0-9])([a-f0-9])/,parse:function(e){return[parseInt(e[1]+e[1],16),parseInt(e[2]+e[2],16),parseInt(e[3]+e[3],16)]}},{re:/hsla?\(\s*(\d+(?:\.\d+)?)\s*,\s*(\d+(?:\.\d+)?)\%\s*,\s*(\d+(?:\.\d+)?)\%\s*(?:,\s*(\d?(?:\.\d+)?)\s*)?\)/,space:"hsla",parse:function(e){return[e[1],e[2]/100,e[3]/100,e[4]]}}],l=e.Color=function(t,i,s,n){return new e.Color.fn.parse(t,i,s,n)},u={rgba:{props:{red:{idx:0,type:"byte"},green:{idx:1,type:"byte"},blue:{idx:2,type:"byte"}}},hsla:{props:{hue:{idx:0,type:"degrees"},saturation:{idx:1,type:"percent"},lightness:{idx:2,type:"percent"}}}},d={"byte":{floor:!0,max:255},percent:{max:1},degrees:{mod:360,floor:!0}},c=l.support={},p=e("<p>")[0],f=e.each;p.style.cssText="background-color:rgba(1,1,1,.5)",c.rgba=p.style.backgroundColor.indexOf("rgba")>-1,f(u,function(e,t){t.cache="_"+e,t.props.alpha={idx:3,type:"percent",def:1}}),l.fn=e.extend(l.prototype,{parse:function(n,o,r,h){if(n===t)return this._rgba=[null,null,null,null],this;(n.jquery||n.nodeType)&&(n=e(n).css(o),o=t);var d=this,c=e.type(n),p=this._rgba=[];return o!==t&&(n=[n,o,r,h],c="array"),"string"===c?this.parse(s(n)||a._default):"array"===c?(f(u.rgba.props,function(e,t){p[t.idx]=i(n[t.idx],t)}),this):"object"===c?(n instanceof l?f(u,function(e,t){n[t.cache]&&(d[t.cache]=n[t.cache].slice())}):f(u,function(t,s){var a=s.cache;f(s.props,function(e,t){if(!d[a]&&s.to){if("alpha"===e||null==n[e])return;d[a]=s.to(d._rgba)}d[a][t.idx]=i(n[e],t,!0)}),d[a]&&0>e.inArray(null,d[a].slice(0,3))&&(d[a][3]=1,s.from&&(d._rgba=s.from(d[a])))}),this):t},is:function(e){var i=l(e),s=!0,n=this;return f(u,function(e,a){var o,r=i[a.cache];return r&&(o=n[a.cache]||a.to&&a.to(n._rgba)||[],f(a.props,function(e,i){return null!=r[i.idx]?s=r[i.idx]===o[i.idx]:t})),s}),s},_space:function(){var e=[],t=this;return f(u,function(i,s){t[s.cache]&&e.push(i)}),e.pop()},transition:function(e,t){var s=l(e),n=s._space(),a=u[n],o=0===this.alpha()?l("transparent"):this,r=o[a.cache]||a.to(o._rgba),h=r.slice();return s=s[a.cache],f(a.props,function(e,n){var a=n.idx,o=r[a],l=s[a],u=d[n.type]||{};null!==l&&(null===o?h[a]=l:(u.mod&&(l-o>u.mod/2?o+=u.mod:o-l>u.mod/2&&(o-=u.mod)),h[a]=i((l-o)*t+o,n)))}),this[n](h)},blend:function(t){if(1===this._rgba[3])return this;var i=this._rgba.slice(),s=i.pop(),n=l(t)._rgba;return l(e.map(i,function(e,t){return(1-s)*n[t]+s*e}))},toRgbaString:function(){var t="rgba(",i=e.map(this._rgba,function(e,t){return null==e?t>2?1:0:e});return 1===i[3]&&(i.pop(),t="rgb("),t+i.join()+")"},toHslaString:function(){var t="hsla(",i=e.map(this.hsla(),function(e,t){return null==e&&(e=t>2?1:0),t&&3>t&&(e=Math.round(100*e)+"%"),e});return 1===i[3]&&(i.pop(),t="hsl("),t+i.join()+")"},toHexString:function(t){var i=this._rgba.slice(),s=i.pop();return t&&i.push(~~(255*s)),"#"+e.map(i,function(e){return e=(e||0).toString(16),1===e.length?"0"+e:e}).join("")},toString:function(){return 0===this._rgba[3]?"transparent":this.toRgbaString()}}),l.fn.parse.prototype=l.fn,u.hsla.to=function(e){if(null==e[0]||null==e[1]||null==e[2])return[null,null,null,e[3]];var t,i,s=e[0]/255,n=e[1]/255,a=e[2]/255,o=e[3],r=Math.max(s,n,a),h=Math.min(s,n,a),l=r-h,u=r+h,d=.5*u;return t=h===r?0:s===r?60*(n-a)/l+360:n===r?60*(a-s)/l+120:60*(s-n)/l+240,i=0===l?0:.5>=d?l/u:l/(2-u),[Math.round(t)%360,i,d,null==o?1:o]},u.hsla.from=function(e){if(null==e[0]||null==e[1]||null==e[2])return[null,null,null,e[3]];var t=e[0]/360,i=e[1],s=e[2],a=e[3],o=.5>=s?s*(1+i):s+i-s*i,r=2*s-o;return[Math.round(255*n(r,o,t+1/3)),Math.round(255*n(r,o,t)),Math.round(255*n(r,o,t-1/3)),a]},f(u,function(s,n){var a=n.props,o=n.cache,h=n.to,u=n.from;l.fn[s]=function(s){if(h&&!this[o]&&(this[o]=h(this._rgba)),s===t)return this[o].slice();var n,r=e.type(s),d="array"===r||"object"===r?s:arguments,c=this[o].slice();return f(a,function(e,t){var s=d["object"===r?e:t.idx];null==s&&(s=c[t.idx]),c[t.idx]=i(s,t)}),u?(n=l(u(c)),n[o]=c,n):l(c)},f(a,function(t,i){l.fn[t]||(l.fn[t]=function(n){var a,o=e.type(n),h="alpha"===t?this._hsla?"hsla":"rgba":s,l=this[h](),u=l[i.idx];return"undefined"===o?u:("function"===o&&(n=n.call(this,u),o=e.type(n)),null==n&&i.empty?this:("string"===o&&(a=r.exec(n),a&&(n=u+parseFloat(a[2])*("+"===a[1]?1:-1))),l[i.idx]=n,this[h](l)))})})}),l.hook=function(t){var i=t.split(" ");f(i,function(t,i){e.cssHooks[i]={set:function(t,n){var a,o,r="";if("transparent"!==n&&("string"!==e.type(n)||(a=s(n)))){if(n=l(a||n),!c.rgba&&1!==n._rgba[3]){for(o="backgroundColor"===i?t.parentNode:t;(""===r||"transparent"===r)&&o&&o.style;)try{r=e.css(o,"backgroundColor"),o=o.parentNode}catch(h){}n=n.blend(r&&"transparent"!==r?r:"_default")}n=n.toRgbaString()}try{t.style[i]=n}catch(h){}}},e.fx.step[i]=function(t){t.colorInit||(t.start=l(t.elem,i),t.end=l(t.end),t.colorInit=!0),e.cssHooks[i].set(t.elem,t.start.transition(t.end,t.pos))}})},l.hook(o),e.cssHooks.borderColor={expand:function(e){var t={};return f(["Top","Right","Bottom","Left"],function(i,s){t["border"+s+"Color"]=e}),t}},a=e.Color.names={aqua:"#00ffff",black:"#000000",blue:"#0000ff",fuchsia:"#ff00ff",gray:"#808080",green:"#008000",lime:"#00ff00",maroon:"#800000",navy:"#000080",olive:"#808000",purple:"#800080",red:"#ff0000",silver:"#c0c0c0",teal:"#008080",white:"#ffffff",yellow:"#ffff00",transparent:[null,null,null,0],_default:"#ffffff"}}(p),function(){function t(t){var i,s,n=t.ownerDocument.defaultView?t.ownerDocument.defaultView.getComputedStyle(t,null):t.currentStyle,a={};if(n&&n.length&&n[0]&&n[n[0]])for(s=n.length;s--;)i=n[s],"string"==typeof n[i]&&(a[e.camelCase(i)]=n[i]);else for(i in n)"string"==typeof n[i]&&(a[i]=n[i]);return a}function i(t,i){var s,a,o={};for(s in i)a=i[s],t[s]!==a&&(n[s]||(e.fx.step[s]||!isNaN(parseFloat(a)))&&(o[s]=a));return o}var s=["add","remove","toggle"],n={border:1,borderBottom:1,borderColor:1,borderLeft:1,borderRight:1,borderTop:1,borderWidth:1,margin:1,padding:1};e.each(["borderLeftStyle","borderRightStyle","borderBottomStyle","borderTopStyle"],function(t,i){e.fx.step[i]=function(e){("none"!==e.end&&!e.setAttr||1===e.pos&&!e.setAttr)&&(p.style(e.elem,i,e.end),e.setAttr=!0)}}),e.fn.addBack||(e.fn.addBack=function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}),e.effects.animateClass=function(n,a,o,r){var h=e.speed(a,o,r);return this.queue(function(){var a,o=e(this),r=o.attr("class")||"",l=h.children?o.find("*").addBack():o;l=l.map(function(){var i=e(this);return{el:i,start:t(this)}}),a=function(){e.each(s,function(e,t){n[t]&&o[t+"Class"](n[t])})},a(),l=l.map(function(){return this.end=t(this.el[0]),this.diff=i(this.start,this.end),this}),o.attr("class",r),l=l.map(function(){var t=this,i=e.Deferred(),s=e.extend({},h,{queue:!1,complete:function(){i.resolve(t)}});return this.el.animate(this.diff,s),i.promise()}),e.when.apply(e,l.get()).done(function(){a(),e.each(arguments,function(){var t=this.el;e.each(this.diff,function(e){t.css(e,"")})}),h.complete.call(o[0])})})},e.fn.extend({addClass:function(t){return function(i,s,n,a){return s?e.effects.animateClass.call(this,{add:i},s,n,a):t.apply(this,arguments)}}(e.fn.addClass),removeClass:function(t){return function(i,s,n,a){return arguments.length>1?e.effects.animateClass.call(this,{remove:i},s,n,a):t.apply(this,arguments)}}(e.fn.removeClass),toggleClass:function(t){return function(i,s,n,a,o){return"boolean"==typeof s||void 0===s?n?e.effects.animateClass.call(this,s?{add:i}:{remove:i},n,a,o):t.apply(this,arguments):e.effects.animateClass.call(this,{toggle:i},s,n,a)}}(e.fn.toggleClass),switchClass:function(t,i,s,n,a){return e.effects.animateClass.call(this,{add:i,remove:t},s,n,a)}})}(),function(){function t(t,i,s,n){return e.isPlainObject(t)&&(i=t,t=t.effect),t={effect:t},null==i&&(i={}),e.isFunction(i)&&(n=i,s=null,i={}),("number"==typeof i||e.fx.speeds[i])&&(n=s,s=i,i={}),e.isFunction(s)&&(n=s,s=null),i&&e.extend(t,i),s=s||i.duration,t.duration=e.fx.off?0:"number"==typeof s?s:s in e.fx.speeds?e.fx.speeds[s]:e.fx.speeds._default,t.complete=n||i.complete,t}function i(t){return!t||"number"==typeof t||e.fx.speeds[t]?!0:"string"!=typeof t||e.effects.effect[t]?e.isFunction(t)?!0:"object"!=typeof t||t.effect?!1:!0:!0}e.extend(e.effects,{version:"1.11.4",save:function(e,t){for(var i=0;t.length>i;i++)null!==t[i]&&e.data(c+t[i],e[0].style[t[i]])},restore:function(e,t){var i,s;for(s=0;t.length>s;s++)null!==t[s]&&(i=e.data(c+t[s]),void 0===i&&(i=""),e.css(t[s],i))},setMode:function(e,t){return"toggle"===t&&(t=e.is(":hidden")?"show":"hide"),t},getBaseline:function(e,t){var i,s;switch(e[0]){case"top":i=0;break;case"middle":i=.5;break;case"bottom":i=1;break;default:i=e[0]/t.height}switch(e[1]){case"left":s=0;break;case"center":s=.5;break;case"right":s=1;break;default:s=e[1]/t.width}return{x:s,y:i}},createWrapper:function(t){if(t.parent().is(".ui-effects-wrapper"))return t.parent();var i={width:t.outerWidth(!0),height:t.outerHeight(!0),"float":t.css("float")},s=e("<div></div>").addClass("ui-effects-wrapper").css({fontSize:"100%",background:"transparent",border:"none",margin:0,padding:0}),n={width:t.width(),height:t.height()},a=document.activeElement;try{a.id}catch(o){a=document.body}return t.wrap(s),(t[0]===a||e.contains(t[0],a))&&e(a).focus(),s=t.parent(),"static"===t.css("position")?(s.css({position:"relative"}),t.css({position:"relative"})):(e.extend(i,{position:t.css("position"),zIndex:t.css("z-index")}),e.each(["top","left","bottom","right"],function(e,s){i[s]=t.css(s),isNaN(parseInt(i[s],10))&&(i[s]="auto")}),t.css({position:"relative",top:0,left:0,right:"auto",bottom:"auto"})),t.css(n),s.css(i).show()},removeWrapper:function(t){var i=document.activeElement;return t.parent().is(".ui-effects-wrapper")&&(t.parent().replaceWith(t),(t[0]===i||e.contains(t[0],i))&&e(i).focus()),t},setTransition:function(t,i,s,n){return n=n||{},e.each(i,function(e,i){var a=t.cssUnit(i);a[0]>0&&(n[i]=a[0]*s+a[1])}),n}}),e.fn.extend({effect:function(){function i(t){function i(){e.isFunction(a)&&a.call(n[0]),e.isFunction(t)&&t()}var n=e(this),a=s.complete,r=s.mode;(n.is(":hidden")?"hide"===r:"show"===r)?(n[r](),i()):o.call(n[0],s,i)}var s=t.apply(this,arguments),n=s.mode,a=s.queue,o=e.effects.effect[s.effect];return e.fx.off||!o?n?this[n](s.duration,s.complete):this.each(function(){s.complete&&s.complete.call(this)}):a===!1?this.each(i):this.queue(a||"fx",i)},show:function(e){return function(s){if(i(s))return e.apply(this,arguments);var n=t.apply(this,arguments);return n.mode="show",this.effect.call(this,n)}}(e.fn.show),hide:function(e){return function(s){if(i(s))return e.apply(this,arguments);var n=t.apply(this,arguments);return n.mode="hide",this.effect.call(this,n)}}(e.fn.hide),toggle:function(e){return function(s){if(i(s)||"boolean"==typeof s)return e.apply(this,arguments);var n=t.apply(this,arguments);return n.mode="toggle",this.effect.call(this,n)}}(e.fn.toggle),cssUnit:function(t){var i=this.css(t),s=[];return e.each(["em","px","%","pt"],function(e,t){i.indexOf(t)>0&&(s=[parseFloat(i),t])}),s}})}(),function(){var t={};e.each(["Quad","Cubic","Quart","Quint","Expo"],function(e,i){t[i]=function(t){return Math.pow(t,e+2)}}),e.extend(t,{Sine:function(e){return 1-Math.cos(e*Math.PI/2)},Circ:function(e){return 1-Math.sqrt(1-e*e)},Elastic:function(e){return 0===e||1===e?e:-Math.pow(2,8*(e-1))*Math.sin((80*(e-1)-7.5)*Math.PI/15)},Back:function(e){return e*e*(3*e-2)},Bounce:function(e){for(var t,i=4;((t=Math.pow(2,--i))-1)/11>e;);return 1/Math.pow(4,3-i)-7.5625*Math.pow((3*t-2)/22-e,2)}}),e.each(t,function(t,i){e.easing["easeIn"+t]=i,e.easing["easeOut"+t]=function(e){return 1-i(1-e)},e.easing["easeInOut"+t]=function(e){return.5>e?i(2*e)/2:1-i(-2*e+2)/2}})}(),e.effects,e.effects.effect.blind=function(t,i){var s,n,a,o=e(this),r=/up|down|vertical/,h=/up|left|vertical|horizontal/,l=["position","top","bottom","left","right","height","width"],u=e.effects.setMode(o,t.mode||"hide"),d=t.direction||"up",c=r.test(d),p=c?"height":"width",f=c?"top":"left",m=h.test(d),g={},v="show"===u;o.parent().is(".ui-effects-wrapper")?e.effects.save(o.parent(),l):e.effects.save(o,l),o.show(),s=e.effects.createWrapper(o).css({overflow:"hidden"}),n=s[p](),a=parseFloat(s.css(f))||0,g[p]=v?n:0,m||(o.css(c?"bottom":"right",0).css(c?"top":"left","auto").css({position:"absolute"}),g[f]=v?a:n+a),v&&(s.css(p,0),m||s.css(f,a+n)),s.animate(g,{duration:t.duration,easing:t.easing,queue:!1,complete:function(){"hide"===u&&o.hide(),e.effects.restore(o,l),e.effects.removeWrapper(o),i()
}})},e.effects.effect.bounce=function(t,i){var s,n,a,o=e(this),r=["position","top","bottom","left","right","height","width"],h=e.effects.setMode(o,t.mode||"effect"),l="hide"===h,u="show"===h,d=t.direction||"up",c=t.distance,p=t.times||5,f=2*p+(u||l?1:0),m=t.duration/f,g=t.easing,v="up"===d||"down"===d?"top":"left",y="up"===d||"left"===d,b=o.queue(),_=b.length;for((u||l)&&r.push("opacity"),e.effects.save(o,r),o.show(),e.effects.createWrapper(o),c||(c=o["top"===v?"outerHeight":"outerWidth"]()/3),u&&(a={opacity:1},a[v]=0,o.css("opacity",0).css(v,y?2*-c:2*c).animate(a,m,g)),l&&(c/=Math.pow(2,p-1)),a={},a[v]=0,s=0;p>s;s++)n={},n[v]=(y?"-=":"+=")+c,o.animate(n,m,g).animate(a,m,g),c=l?2*c:c/2;l&&(n={opacity:0},n[v]=(y?"-=":"+=")+c,o.animate(n,m,g)),o.queue(function(){l&&o.hide(),e.effects.restore(o,r),e.effects.removeWrapper(o),i()}),_>1&&b.splice.apply(b,[1,0].concat(b.splice(_,f+1))),o.dequeue()},e.effects.effect.clip=function(t,i){var s,n,a,o=e(this),r=["position","top","bottom","left","right","height","width"],h=e.effects.setMode(o,t.mode||"hide"),l="show"===h,u=t.direction||"vertical",d="vertical"===u,c=d?"height":"width",p=d?"top":"left",f={};e.effects.save(o,r),o.show(),s=e.effects.createWrapper(o).css({overflow:"hidden"}),n="IMG"===o[0].tagName?s:o,a=n[c](),l&&(n.css(c,0),n.css(p,a/2)),f[c]=l?a:0,f[p]=l?0:a/2,n.animate(f,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){l||o.hide(),e.effects.restore(o,r),e.effects.removeWrapper(o),i()}})},e.effects.effect.drop=function(t,i){var s,n=e(this),a=["position","top","bottom","left","right","opacity","height","width"],o=e.effects.setMode(n,t.mode||"hide"),r="show"===o,h=t.direction||"left",l="up"===h||"down"===h?"top":"left",u="up"===h||"left"===h?"pos":"neg",d={opacity:r?1:0};e.effects.save(n,a),n.show(),e.effects.createWrapper(n),s=t.distance||n["top"===l?"outerHeight":"outerWidth"](!0)/2,r&&n.css("opacity",0).css(l,"pos"===u?-s:s),d[l]=(r?"pos"===u?"+=":"-=":"pos"===u?"-=":"+=")+s,n.animate(d,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){"hide"===o&&n.hide(),e.effects.restore(n,a),e.effects.removeWrapper(n),i()}})},e.effects.effect.explode=function(t,i){function s(){b.push(this),b.length===d*c&&n()}function n(){p.css({visibility:"visible"}),e(b).remove(),m||p.hide(),i()}var a,o,r,h,l,u,d=t.pieces?Math.round(Math.sqrt(t.pieces)):3,c=d,p=e(this),f=e.effects.setMode(p,t.mode||"hide"),m="show"===f,g=p.show().css("visibility","hidden").offset(),v=Math.ceil(p.outerWidth()/c),y=Math.ceil(p.outerHeight()/d),b=[];for(a=0;d>a;a++)for(h=g.top+a*y,u=a-(d-1)/2,o=0;c>o;o++)r=g.left+o*v,l=o-(c-1)/2,p.clone().appendTo("body").wrap("<div></div>").css({position:"absolute",visibility:"visible",left:-o*v,top:-a*y}).parent().addClass("ui-effects-explode").css({position:"absolute",overflow:"hidden",width:v,height:y,left:r+(m?l*v:0),top:h+(m?u*y:0),opacity:m?0:1}).animate({left:r+(m?0:l*v),top:h+(m?0:u*y),opacity:m?1:0},t.duration||500,t.easing,s)},e.effects.effect.fade=function(t,i){var s=e(this),n=e.effects.setMode(s,t.mode||"toggle");s.animate({opacity:n},{queue:!1,duration:t.duration,easing:t.easing,complete:i})},e.effects.effect.fold=function(t,i){var s,n,a=e(this),o=["position","top","bottom","left","right","height","width"],r=e.effects.setMode(a,t.mode||"hide"),h="show"===r,l="hide"===r,u=t.size||15,d=/([0-9]+)%/.exec(u),c=!!t.horizFirst,p=h!==c,f=p?["width","height"]:["height","width"],m=t.duration/2,g={},v={};e.effects.save(a,o),a.show(),s=e.effects.createWrapper(a).css({overflow:"hidden"}),n=p?[s.width(),s.height()]:[s.height(),s.width()],d&&(u=parseInt(d[1],10)/100*n[l?0:1]),h&&s.css(c?{height:0,width:u}:{height:u,width:0}),g[f[0]]=h?n[0]:u,v[f[1]]=h?n[1]:0,s.animate(g,m,t.easing).animate(v,m,t.easing,function(){l&&a.hide(),e.effects.restore(a,o),e.effects.removeWrapper(a),i()})},e.effects.effect.highlight=function(t,i){var s=e(this),n=["backgroundImage","backgroundColor","opacity"],a=e.effects.setMode(s,t.mode||"show"),o={backgroundColor:s.css("backgroundColor")};"hide"===a&&(o.opacity=0),e.effects.save(s,n),s.show().css({backgroundImage:"none",backgroundColor:t.color||"#ffff99"}).animate(o,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){"hide"===a&&s.hide(),e.effects.restore(s,n),i()}})},e.effects.effect.size=function(t,i){var s,n,a,o=e(this),r=["position","top","bottom","left","right","width","height","overflow","opacity"],h=["position","top","bottom","left","right","overflow","opacity"],l=["width","height","overflow"],u=["fontSize"],d=["borderTopWidth","borderBottomWidth","paddingTop","paddingBottom"],c=["borderLeftWidth","borderRightWidth","paddingLeft","paddingRight"],p=e.effects.setMode(o,t.mode||"effect"),f=t.restore||"effect"!==p,m=t.scale||"both",g=t.origin||["middle","center"],v=o.css("position"),y=f?r:h,b={height:0,width:0,outerHeight:0,outerWidth:0};"show"===p&&o.show(),s={height:o.height(),width:o.width(),outerHeight:o.outerHeight(),outerWidth:o.outerWidth()},"toggle"===t.mode&&"show"===p?(o.from=t.to||b,o.to=t.from||s):(o.from=t.from||("show"===p?b:s),o.to=t.to||("hide"===p?b:s)),a={from:{y:o.from.height/s.height,x:o.from.width/s.width},to:{y:o.to.height/s.height,x:o.to.width/s.width}},("box"===m||"both"===m)&&(a.from.y!==a.to.y&&(y=y.concat(d),o.from=e.effects.setTransition(o,d,a.from.y,o.from),o.to=e.effects.setTransition(o,d,a.to.y,o.to)),a.from.x!==a.to.x&&(y=y.concat(c),o.from=e.effects.setTransition(o,c,a.from.x,o.from),o.to=e.effects.setTransition(o,c,a.to.x,o.to))),("content"===m||"both"===m)&&a.from.y!==a.to.y&&(y=y.concat(u).concat(l),o.from=e.effects.setTransition(o,u,a.from.y,o.from),o.to=e.effects.setTransition(o,u,a.to.y,o.to)),e.effects.save(o,y),o.show(),e.effects.createWrapper(o),o.css("overflow","hidden").css(o.from),g&&(n=e.effects.getBaseline(g,s),o.from.top=(s.outerHeight-o.outerHeight())*n.y,o.from.left=(s.outerWidth-o.outerWidth())*n.x,o.to.top=(s.outerHeight-o.to.outerHeight)*n.y,o.to.left=(s.outerWidth-o.to.outerWidth)*n.x),o.css(o.from),("content"===m||"both"===m)&&(d=d.concat(["marginTop","marginBottom"]).concat(u),c=c.concat(["marginLeft","marginRight"]),l=r.concat(d).concat(c),o.find("*[width]").each(function(){var i=e(this),s={height:i.height(),width:i.width(),outerHeight:i.outerHeight(),outerWidth:i.outerWidth()};f&&e.effects.save(i,l),i.from={height:s.height*a.from.y,width:s.width*a.from.x,outerHeight:s.outerHeight*a.from.y,outerWidth:s.outerWidth*a.from.x},i.to={height:s.height*a.to.y,width:s.width*a.to.x,outerHeight:s.height*a.to.y,outerWidth:s.width*a.to.x},a.from.y!==a.to.y&&(i.from=e.effects.setTransition(i,d,a.from.y,i.from),i.to=e.effects.setTransition(i,d,a.to.y,i.to)),a.from.x!==a.to.x&&(i.from=e.effects.setTransition(i,c,a.from.x,i.from),i.to=e.effects.setTransition(i,c,a.to.x,i.to)),i.css(i.from),i.animate(i.to,t.duration,t.easing,function(){f&&e.effects.restore(i,l)})})),o.animate(o.to,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){0===o.to.opacity&&o.css("opacity",o.from.opacity),"hide"===p&&o.hide(),e.effects.restore(o,y),f||("static"===v?o.css({position:"relative",top:o.to.top,left:o.to.left}):e.each(["top","left"],function(e,t){o.css(t,function(t,i){var s=parseInt(i,10),n=e?o.to.left:o.to.top;return"auto"===i?n+"px":s+n+"px"})})),e.effects.removeWrapper(o),i()}})},e.effects.effect.scale=function(t,i){var s=e(this),n=e.extend(!0,{},t),a=e.effects.setMode(s,t.mode||"effect"),o=parseInt(t.percent,10)||(0===parseInt(t.percent,10)?0:"hide"===a?0:100),r=t.direction||"both",h=t.origin,l={height:s.height(),width:s.width(),outerHeight:s.outerHeight(),outerWidth:s.outerWidth()},u={y:"horizontal"!==r?o/100:1,x:"vertical"!==r?o/100:1};n.effect="size",n.queue=!1,n.complete=i,"effect"!==a&&(n.origin=h||["middle","center"],n.restore=!0),n.from=t.from||("show"===a?{height:0,width:0,outerHeight:0,outerWidth:0}:l),n.to={height:l.height*u.y,width:l.width*u.x,outerHeight:l.outerHeight*u.y,outerWidth:l.outerWidth*u.x},n.fade&&("show"===a&&(n.from.opacity=0,n.to.opacity=1),"hide"===a&&(n.from.opacity=1,n.to.opacity=0)),s.effect(n)},e.effects.effect.puff=function(t,i){var s=e(this),n=e.effects.setMode(s,t.mode||"hide"),a="hide"===n,o=parseInt(t.percent,10)||150,r=o/100,h={height:s.height(),width:s.width(),outerHeight:s.outerHeight(),outerWidth:s.outerWidth()};e.extend(t,{effect:"scale",queue:!1,fade:!0,mode:n,complete:i,percent:a?o:100,from:a?h:{height:h.height*r,width:h.width*r,outerHeight:h.outerHeight*r,outerWidth:h.outerWidth*r}}),s.effect(t)},e.effects.effect.pulsate=function(t,i){var s,n=e(this),a=e.effects.setMode(n,t.mode||"show"),o="show"===a,r="hide"===a,h=o||"hide"===a,l=2*(t.times||5)+(h?1:0),u=t.duration/l,d=0,c=n.queue(),p=c.length;for((o||!n.is(":visible"))&&(n.css("opacity",0).show(),d=1),s=1;l>s;s++)n.animate({opacity:d},u,t.easing),d=1-d;n.animate({opacity:d},u,t.easing),n.queue(function(){r&&n.hide(),i()}),p>1&&c.splice.apply(c,[1,0].concat(c.splice(p,l+1))),n.dequeue()},e.effects.effect.shake=function(t,i){var s,n=e(this),a=["position","top","bottom","left","right","height","width"],o=e.effects.setMode(n,t.mode||"effect"),r=t.direction||"left",h=t.distance||20,l=t.times||3,u=2*l+1,d=Math.round(t.duration/u),c="up"===r||"down"===r?"top":"left",p="up"===r||"left"===r,f={},m={},g={},v=n.queue(),y=v.length;for(e.effects.save(n,a),n.show(),e.effects.createWrapper(n),f[c]=(p?"-=":"+=")+h,m[c]=(p?"+=":"-=")+2*h,g[c]=(p?"-=":"+=")+2*h,n.animate(f,d,t.easing),s=1;l>s;s++)n.animate(m,d,t.easing).animate(g,d,t.easing);n.animate(m,d,t.easing).animate(f,d/2,t.easing).queue(function(){"hide"===o&&n.hide(),e.effects.restore(n,a),e.effects.removeWrapper(n),i()}),y>1&&v.splice.apply(v,[1,0].concat(v.splice(y,u+1))),n.dequeue()},e.effects.effect.slide=function(t,i){var s,n=e(this),a=["position","top","bottom","left","right","width","height"],o=e.effects.setMode(n,t.mode||"show"),r="show"===o,h=t.direction||"left",l="up"===h||"down"===h?"top":"left",u="up"===h||"left"===h,d={};e.effects.save(n,a),n.show(),s=t.distance||n["top"===l?"outerHeight":"outerWidth"](!0),e.effects.createWrapper(n).css({overflow:"hidden"}),r&&n.css(l,u?isNaN(s)?"-"+s:-s:s),d[l]=(r?u?"+=":"-=":u?"-=":"+=")+s,n.animate(d,{queue:!1,duration:t.duration,easing:t.easing,complete:function(){"hide"===o&&n.hide(),e.effects.restore(n,a),e.effects.removeWrapper(n),i()}})},e.effects.effect.transfer=function(t,i){var s=e(this),n=e(t.to),a="fixed"===n.css("position"),o=e("body"),r=a?o.scrollTop():0,h=a?o.scrollLeft():0,l=n.offset(),u={top:l.top-r,left:l.left-h,height:n.innerHeight(),width:n.innerWidth()},d=s.offset(),c=e("<div class='ui-effects-transfer'></div>").appendTo(document.body).addClass(t.className).css({top:d.top-r,left:d.left-h,height:s.innerHeight(),width:s.innerWidth(),position:a?"fixed":"absolute"}).animate(u,t.duration,t.easing,function(){c.remove(),i()})}});"></script>
<link href="data:text/css,%0A%0A%2Etocify%20%7B%0Awidth%3A%2020%25%3B%0Amax%2Dheight%3A%2090%25%3B%0Aoverflow%3A%20auto%3B%0Amargin%2Dleft%3A%202%25%3B%0Aposition%3A%20fixed%3B%0Aborder%3A%201px%20solid%20%23ccc%3B%0Aborder%2Dradius%3A%206px%3B%0A%7D%0A%0A%2Etocify%20ul%2C%20%2Etocify%20li%20%7B%0Alist%2Dstyle%3A%20none%3B%0Amargin%3A%200%3B%0Apadding%3A%200%3B%0Aborder%3A%20none%3B%0Aline%2Dheight%3A%2030px%3B%0A%7D%0A%0A%2Etocify%2Dheader%20%7B%0Atext%2Dindent%3A%2010px%3B%0A%7D%0A%0A%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2020px%3B%0Adisplay%3A%20none%3B%0A%7D%0A%0A%2Etocify%2Dsubheader%20li%20%7B%0Afont%2Dsize%3A%2012px%3B%0A%7D%0A%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2030px%3B%0A%7D%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2040px%3B%0A%7D%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2050px%3B%0A%7D%0A%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%2Etocify%2Dsubheader%20%7B%0Atext%2Dindent%3A%2060px%3B%0A%7D%0A%0A%2Etocify%20%2Etocify%2Ditem%20%3E%20a%2C%20%2Etocify%20%2Enav%2Dlist%20%2Enav%2Dheader%20%7B%0Amargin%3A%200px%3B%0A%7D%0A%0A%2Etocify%20%2Etocify%2Ditem%20a%2C%20%2Etocify%20%2Elist%2Dgroup%2Ditem%20%7B%0Apadding%3A%205px%3B%0A%7D%0A%2Etocify%20%2Enav%2Dpills%20%3E%20li%20%7B%0Afloat%3A%20none%3B%0A%7D%0A%0A%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/* jquery Tocify - v1.9.1 - 2013-10-22
 * http://www.gregfranko.com/jquery.tocify.js/
 * Copyright (c) 2013 Greg Franko; Licensed MIT */

// Immediately-Invoked Function Expression (IIFE) [Ben Alman Blog Post](http://benalman.com/news/2010/11/immediately-invoked-function-expression/) that calls another IIFE that contains all of the plugin logic.  I used this pattern so that anyone viewing this code would not have to scroll to the bottom of the page to view the local parameters that were passed to the main IIFE.
(function(tocify) {

    // ECMAScript 5 Strict Mode: [John Resig Blog Post](http://ejohn.org/blog/ecmascript-5-strict-mode-json-and-more/)
    "use strict";

    // Calls the second IIFE and locally passes in the global jQuery, window, and document objects
    tocify(window.jQuery, window, document);

  }

  // Locally passes in `jQuery`, the `window` object, the `document` object, and an `undefined` variable.  The `jQuery`, `window` and `document` objects are passed in locally, to improve performance, since javascript first searches for a variable match within the local variables set before searching the global variables set.  All of the global variables are also passed in locally to be minifier friendly. `undefined` can be passed in locally, because it is not a reserved word in JavaScript.
  (function($, window, document, undefined) {

    // ECMAScript 5 Strict Mode: [John Resig Blog Post](http://ejohn.org/blog/ecmascript-5-strict-mode-json-and-more/)
    "use strict";

    var tocClassName = "tocify",
      tocClass = "." + tocClassName,
      tocFocusClassName = "tocify-focus",
      tocHoverClassName = "tocify-hover",
      hideTocClassName = "tocify-hide",
      hideTocClass = "." + hideTocClassName,
      headerClassName = "tocify-header",
      headerClass = "." + headerClassName,
      subheaderClassName = "tocify-subheader",
      subheaderClass = "." + subheaderClassName,
      itemClassName = "tocify-item",
      itemClass = "." + itemClassName,
      extendPageClassName = "tocify-extend-page",
      extendPageClass = "." + extendPageClassName;

    // Calling the jQueryUI Widget Factory Method
    $.widget("toc.tocify", {

      //Plugin version
      version: "1.9.1",

      // These options will be used as defaults
      options: {

        // **context**: Accepts String: Any jQuery selector
        // The container element that holds all of the elements used to generate the table of contents
        context: "body",

        // **ignoreSelector**: Accepts String: Any jQuery selector
        // A selector to any element that would be matched by selectors that you wish to be ignored
        ignoreSelector: null,

        // **selectors**: Accepts an Array of Strings: Any jQuery selectors
        // The element's used to generate the table of contents.  The order is very important since it will determine the table of content's nesting structure
        selectors: "h1, h2, h3",

        // **showAndHide**: Accepts a boolean: true or false
        // Used to determine if elements should be shown and hidden
        showAndHide: true,

        // **showEffect**: Accepts String: "none", "fadeIn", "show", or "slideDown"
        // Used to display any of the table of contents nested items
        showEffect: "slideDown",

        // **showEffectSpeed**: Accepts Number (milliseconds) or String: "slow", "medium", or "fast"
        // The time duration of the show animation
        showEffectSpeed: "medium",

        // **hideEffect**: Accepts String: "none", "fadeOut", "hide", or "slideUp"
        // Used to hide any of the table of contents nested items
        hideEffect: "slideUp",

        // **hideEffectSpeed**: Accepts Number (milliseconds) or String: "slow", "medium", or "fast"
        // The time duration of the hide animation
        hideEffectSpeed: "medium",

        // **smoothScroll**: Accepts a boolean: true or false
        // Determines if a jQuery animation should be used to scroll to specific table of contents items on the page
        smoothScroll: true,

        // **smoothScrollSpeed**: Accepts Number (milliseconds) or String: "slow", "medium", or "fast"
        // The time duration of the smoothScroll animation
        smoothScrollSpeed: "medium",

        // **scrollTo**: Accepts Number (pixels)
        // The amount of space between the top of page and the selected table of contents item after the page has been scrolled
        scrollTo: 0,

        // **showAndHideOnScroll**: Accepts a boolean: true or false
        // Determines if table of contents nested items should be shown and hidden while scrolling
        showAndHideOnScroll: true,

        // **highlightOnScroll**: Accepts a boolean: true or false
        // Determines if table of contents nested items should be highlighted (set to a different color) while scrolling
        highlightOnScroll: true,

        // **highlightOffset**: Accepts a number
        // The offset distance in pixels to trigger the next active table of contents item
        highlightOffset: 40,

        // **theme**: Accepts a string: "bootstrap", "jqueryui", or "none"
        // Determines if Twitter Bootstrap, jQueryUI, or Tocify classes should be added to the table of contents
        theme: "bootstrap",

        // **extendPage**: Accepts a boolean: true or false
        // If a user scrolls to the bottom of the page and the page is not tall enough to scroll to the last table of contents item, then the page height is increased
        extendPage: true,

        // **extendPageOffset**: Accepts a number: pixels
        // How close to the bottom of the page a user must scroll before the page is extended
        extendPageOffset: 100,

        // **history**: Accepts a boolean: true or false
        // Adds a hash to the page url to maintain history
        history: true,

        // **scrollHistory**: Accepts a boolean: true or false
        // Adds a hash to the page url, to maintain history, when scrolling to a TOC item
        scrollHistory: false,

        // **hashGenerator**: How the hash value (the anchor segment of the URL, following the
        // # character) will be generated.
        //
        // "compact" (default) - #CompressesEverythingTogether
        // "pretty" - #looks-like-a-nice-url-and-is-easily-readable
        // function(text, element){} - Your own hash generation function that accepts the text as an
        // argument, and returns the hash value.
        hashGenerator: "compact",

        // **highlightDefault**: Accepts a boolean: true or false
        // Set's the first TOC item as active if no other TOC item is active.
        highlightDefault: true

      },

      // _Create
      // -------
      //      Constructs the plugin.  Only called once.
      _create: function() {

        var self = this;

        self.extendPageScroll = true;

        // Internal array that keeps track of all TOC items (Helps to recognize if there are duplicate TOC item strings)
        self.items = [];

        // Generates the HTML for the dynamic table of contents
        self._generateToc();

        // Adds CSS classes to the newly generated table of contents HTML
        self._addCSSClasses();

        self.webkit = (function() {

          for (var prop in window) {

            if (prop) {

              if (prop.toLowerCase().indexOf("webkit") !== -1) {

                return true;

              }

            }

          }

          return false;

        }());

        // Adds jQuery event handlers to the newly generated table of contents
        self._setEventHandlers();

        // Binding to the Window load event to make sure the correct scrollTop is calculated
        $(window).on("load", function() {

          // Sets the active TOC item
          self._setActiveElement(true);

          // Once all animations on the page are complete, this callback function will be called
          $("html, body").promise().done(function() {

            setTimeout(function() {

              self.extendPageScroll = false;

            }, 0);

          });

        });

      },

      // _generateToc
      // ------------
      //      Generates the HTML for the dynamic table of contents
      _generateToc: function() {

        // _Local variables_

        // Stores the plugin context in the self variable
        var self = this,

          // All of the HTML tags found within the context provided (i.e. body) that match the top level jQuery selector above
          firstElem,

          // Instantiated variable that will store the top level newly created unordered list DOM element
          ul,
          ignoreSelector = self.options.ignoreSelector;


        // Determine the element to start the toc with
        // get all the top level selectors
        firstElem = [];
        var selectors = this.options.selectors.replace(/ /g, "").split(",");
        // find the first set that have at least one non-ignored element
        for(var i = 0; i < selectors.length; i++) {
          var foundSelectors = $(this.options.context).find(selectors[i]);
          for (var s = 0; s < foundSelectors.length; s++) {
            if (!$(foundSelectors[s]).is(ignoreSelector)) {
              firstElem = foundSelectors;
              break;
            }
          }
          if (firstElem.length> 0)
            break;
        }

        if (!firstElem.length) {

          self.element.addClass(hideTocClassName);

          return;

        }

        self.element.addClass(tocClassName);

        // Loops through each top level selector
        firstElem.each(function(index) {

          //If the element matches the ignoreSelector then we skip it
          if ($(this).is(ignoreSelector)) {
            return;
          }

          // Creates an unordered list HTML element and adds a dynamic ID and standard class name
          ul = $("<ul/>", {
            "id": headerClassName + index,
            "class": headerClassName
          }).

          // Appends a top level list item HTML element to the previously created HTML header
          append(self._nestElements($(this), index));

          // Add the created unordered list element to the HTML element calling the plugin
          self.element.append(ul);

          // Finds all of the HTML tags between the header and subheader elements
          $(this).nextUntil(this.nodeName.toLowerCase()).each(function() {

            // If there are no nested subheader elemements
            if ($(this).find(self.options.selectors).length === 0) {

              // Loops through all of the subheader elements
              $(this).filter(self.options.selectors).each(function() {

                //If the element matches the ignoreSelector then we skip it
                if ($(this).is(ignoreSelector)) {
                  return;
                }

                self._appendSubheaders.call(this, self, ul);

              });

            }

            // If there are nested subheader elements
            else {

              // Loops through all of the subheader elements
              $(this).find(self.options.selectors).each(function() {

                //If the element matches the ignoreSelector then we skip it
                if ($(this).is(ignoreSelector)) {
                  return;
                }

                self._appendSubheaders.call(this, self, ul);

              });

            }

          });

        });

      },

      _setActiveElement: function(pageload) {

        var self = this,

          hash = window.location.hash.substring(1),

          elem = self.element.find('li[data-unique="' + hash + '"]');

        if (hash.length) {

          // Removes highlighting from all of the list item's
          self.element.find("." + self.focusClass).removeClass(self.focusClass);

          // Highlights the current list item that was clicked
          elem.addClass(self.focusClass);

          // Triggers the click event on the currently focused TOC item
          elem.click();

        } else {

          // Removes highlighting from all of the list item's
          self.element.find("." + self.focusClass).removeClass(self.focusClass);

          if (!hash.length && pageload && self.options.highlightDefault) {

            // Highlights the first TOC item if no other items are highlighted
            self.element.find(itemClass).first().addClass(self.focusClass);

          }

        }

        return self;

      },

      // _nestElements
      // -------------
      //      Helps create the table of contents list by appending nested list items
      _nestElements: function(self, index) {

        var arr, item, hashValue;

        arr = $.grep(this.items, function(item) {

          return item === self.text();

        });

        // If there is already a duplicate TOC item
        if (arr.length) {

          // Adds the current TOC item text and index (for slight randomization) to the internal array
          this.items.push(self.text() + index);

        }

        // If there not a duplicate TOC item
        else {

          // Adds the current TOC item text to the internal array
          this.items.push(self.text());

        }

        hashValue = this._generateHashValue(arr, self, index);

        // Appends a list item HTML element to the last unordered list HTML element found within the HTML element calling the plugin
        item = $("<li/>", {

          // Sets a common class name to the list item
          "class": itemClassName,

          "data-unique": hashValue

        });

        if (this.options.theme !== "bootstrap3") {

          item.append($("<a/>", {

            "html": self.html()

          }));

        } else {

          item.html(self.html());

        }

        // Adds an HTML anchor tag before the currently traversed HTML element
        self.before($("<div/>", {

          // Sets a name attribute on the anchor tag to the text of the currently traversed HTML element (also making sure that all whitespace is replaced with an underscore)
          "name": hashValue,

          "data-unique": hashValue

        }));

        return item;

      },

      // _generateHashValue
      // ------------------
      //      Generates the hash value that will be used to refer to each item.
      _generateHashValue: function(arr, self, index) {

        var hashValue = "",
          hashGeneratorOption = this.options.hashGenerator;

        if (hashGeneratorOption === "pretty") {

          // prettify the text
          hashValue = self.text().toLowerCase().replace(/\s/g, "-");

          // fix double hyphens
          while (hashValue.indexOf("--") > -1) {
            hashValue = hashValue.replace(/--/g, "-");
          }

          // fix colon-space instances
          while (hashValue.indexOf(":-") > -1) {
            hashValue = hashValue.replace(/:-/g, "-");
          }

        } else if (typeof hashGeneratorOption === "function") {

          // call the function
          hashValue = hashGeneratorOption(self.text(), self);

        } else {

          // compact - the default
          hashValue = self.text().replace(/\s/g, "");

        }

        // add the index if we need to
        if (arr.length) {
          hashValue += "" + index;
        }

        // return the value
        return hashValue;

      },

      // _appendElements
      // ---------------
      //      Helps create the table of contents list by appending subheader elements

      _appendSubheaders: function(self, ul) {

        // The current element index
        var index = $(this).index(self.options.selectors),

          // Finds the previous header DOM element
          previousHeader = $(self.options.selectors).eq(index - 1),

          currentTagName = +$(this).prop("tagName").charAt(1),

          previousTagName = +previousHeader.prop("tagName").charAt(1),

          lastSubheader;

        // If the current header DOM element is smaller than the previous header DOM element or the first subheader
        if (currentTagName < previousTagName) {

          // Selects the last unordered list HTML found within the HTML element calling the plugin
          self.element.find(subheaderClass + "[data-tag=" + currentTagName + "]").last().append(self._nestElements($(this), index));

        }

        // If the current header DOM element is the same type of header(eg. h4) as the previous header DOM element
        else if (currentTagName === previousTagName) {

          ul.find(itemClass).last().after(self._nestElements($(this), index));

        } else {

          // Selects the last unordered list HTML found within the HTML element calling the plugin
          ul.find(itemClass).last().

          // Appends an unorderedList HTML element to the dynamic `unorderedList` variable and sets a common class name
          after($("<ul/>", {

            "class": subheaderClassName,

            "data-tag": currentTagName

          })).next(subheaderClass).

          // Appends a list item HTML element to the last unordered list HTML element found within the HTML element calling the plugin
          append(self._nestElements($(this), index));
        }

      },

      // _setEventHandlers
      // ----------------
      //      Adds jQuery event handlers to the newly generated table of contents
      _setEventHandlers: function() {

        // _Local variables_

        // Stores the plugin context in the self variable
        var self = this,

          // Instantiates a new variable that will be used to hold a specific element's context
          $self,

          // Instantiates a new variable that will be used to determine the smoothScroll animation time duration
          duration;

        // Event delegation that looks for any clicks on list item elements inside of the HTML element calling the plugin
        this.element.on("click.tocify", "li", function(event) {

          if (self.options.history) {

            window.location.hash = $(this).attr("data-unique");

          }

          // Removes highlighting from all of the list item's
          self.element.find("." + self.focusClass).removeClass(self.focusClass);

          // Highlights the current list item that was clicked
          $(this).addClass(self.focusClass);

          // If the showAndHide option is true
          if (self.options.showAndHide) {

            var elem = $('li[data-unique="' + $(this).attr("data-unique") + '"]');

            self._triggerShow(elem);

          }

          self._scrollTo($(this));

        });

        // Mouseenter and Mouseleave event handlers for the list item's within the HTML element calling the plugin
        this.element.find("li").on({

          // Mouseenter event handler
          "mouseenter.tocify": function() {

            // Adds a hover CSS class to the current list item
            $(this).addClass(self.hoverClass);

            // Makes sure the cursor is set to the pointer icon
            $(this).css("cursor", "pointer");

          },

          // Mouseleave event handler
          "mouseleave.tocify": function() {

            if (self.options.theme !== "bootstrap") {

              // Removes the hover CSS class from the current list item
              $(this).removeClass(self.hoverClass);

            }

          }
        });

        // only attach handler if needed (expensive in IE)
        if (self.options.extendPage || self.options.highlightOnScroll || self.options.scrollHistory || self.options.showAndHideOnScroll) {
          // Window scroll event handler
          $(window).on("scroll.tocify", function() {

            // Once all animations on the page are complete, this callback function will be called
            $("html, body").promise().done(function() {

              // Local variables

              // Stores how far the user has scrolled
              var winScrollTop = $(window).scrollTop(),

                // Stores the height of the window
                winHeight = $(window).height(),

                // Stores the height of the document
                docHeight = $(document).height(),

                scrollHeight = $("body")[0].scrollHeight,

                // Instantiates a variable that will be used to hold a selected HTML element
                elem,

                lastElem,

                lastElemOffset,

                currentElem;

              if (self.options.extendPage) {

                // If the user has scrolled to the bottom of the page and the last toc item is not focused
                if ((self.webkit && winScrollTop >= scrollHeight - winHeight - self.options.extendPageOffset) || (!self.webkit && winHeight + winScrollTop > docHeight - self.options.extendPageOffset)) {

                  if (!$(extendPageClass).length) {

                    lastElem = $('div[data-unique="' + $(itemClass).last().attr("data-unique") + '"]');

                    if (!lastElem.length) return;

                    // Gets the top offset of the page header that is linked to the last toc item
                    lastElemOffset = lastElem.offset().top;

                    // Appends a div to the bottom of the page and sets the height to the difference of the window scrollTop and the last element's position top offset
                    $(self.options.context).append($("<div/>", {

                      "class": extendPageClassName,

                      "height": Math.abs(lastElemOffset - winScrollTop) + "px",

                      "data-unique": extendPageClassName

                    }));

                    if (self.extendPageScroll) {

                      currentElem = self.element.find('li.' + self.focusClass);

                      self._scrollTo($('div[data-unique="' + currentElem.attr("data-unique") + '"]'));

                    }

                  }

                }

              }

              // The zero timeout ensures the following code is run after the scroll events
              setTimeout(function() {

                // _Local variables_

                // Stores the distance to the closest anchor
                var closestAnchorDistance = null,

                  // Stores the index of the closest anchor
                  closestAnchorIdx = null,

                  // Keeps a reference to all anchors
                  anchors = $(self.options.context).find("div[data-unique]"),

                  anchorText;

                // Determines the index of the closest anchor
                anchors.each(function(idx) {
                  var distance = Math.abs(($(this).next().length ? $(this).next() : $(this)).offset().top - winScrollTop - self.options.highlightOffset);
                  if (closestAnchorDistance == null || distance < closestAnchorDistance) {
                    closestAnchorDistance = distance;
                    closestAnchorIdx = idx;
                  } else {
                    return false;
                  }
                });

                anchorText = $(anchors[closestAnchorIdx]).attr("data-unique");

                // Stores the list item HTML element that corresponds to the currently traversed anchor tag
                elem = $('li[data-unique="' + anchorText + '"]');

                // If the `highlightOnScroll` option is true and a next element is found
                if (self.options.highlightOnScroll && elem.length) {

                  // Removes highlighting from all of the list item's
                  self.element.find("." + self.focusClass).removeClass(self.focusClass);

                  // Highlights the corresponding list item
                  elem.addClass(self.focusClass);

                }

                if (self.options.scrollHistory) {

                  if (window.location.hash !== "#" + anchorText) {

                    window.location.replace("#" + anchorText);

                  }
                }

                // If the `showAndHideOnScroll` option is true
                if (self.options.showAndHideOnScroll && self.options.showAndHide) {

                  self._triggerShow(elem, true);

                }

              }, 0);

            });

          });
        }

      },

      // Show
      // ----
      //      Opens the current sub-header
      show: function(elem, scroll) {

        // Stores the plugin context in the `self` variable
        var self = this,
          element = elem;

        // If the sub-header is not already visible
        if (!elem.is(":visible")) {

          // If the current element does not have any nested subheaders, is not a header, and its parent is not visible
          if (!elem.find(subheaderClass).length && !elem.parent().is(headerClass) && !elem.parent().is(":visible")) {

            // Sets the current element to all of the subheaders within the current header
            elem = elem.parents(subheaderClass).add(elem);

          }

          // If the current element does not have any nested subheaders and is not a header
          else if (!elem.children(subheaderClass).length && !elem.parent().is(headerClass)) {

            // Sets the current element to the closest subheader
            elem = elem.closest(subheaderClass);

          }

          //Determines what jQuery effect to use
          switch (self.options.showEffect) {

            //Uses `no effect`
            case "none":

              elem.show();

              break;

              //Uses the jQuery `show` special effect
            case "show":

              elem.show(self.options.showEffectSpeed);

              break;

              //Uses the jQuery `slideDown` special effect
            case "slideDown":

              elem.slideDown(self.options.showEffectSpeed);

              break;

              //Uses the jQuery `fadeIn` special effect
            case "fadeIn":

              elem.fadeIn(self.options.showEffectSpeed);

              break;

              //If none of the above options were passed, then a `jQueryUI show effect` is expected
            default:

              elem.show();

              break;

          }

        }

        // If the current subheader parent element is a header
        if (elem.parent().is(headerClass)) {

          // Hides all non-active sub-headers
          self.hide($(subheaderClass).not(elem));

        }

        // If the current subheader parent element is not a header
        else {

          // Hides all non-active sub-headers
          self.hide($(subheaderClass).not(elem.closest(headerClass).find(subheaderClass).not(elem.siblings())));

        }

        // Maintains chainablity
        return self;

      },

      // Hide
      // ----
      //      Closes the current sub-header
      hide: function(elem) {

        // Stores the plugin context in the `self` variable
        var self = this;

        //Determines what jQuery effect to use
        switch (self.options.hideEffect) {

          // Uses `no effect`
          case "none":

            elem.hide();

            break;

            // Uses the jQuery `hide` special effect
          case "hide":

            elem.hide(self.options.hideEffectSpeed);

            break;

            // Uses the jQuery `slideUp` special effect
          case "slideUp":

            elem.slideUp(self.options.hideEffectSpeed);

            break;

            // Uses the jQuery `fadeOut` special effect
          case "fadeOut":

            elem.fadeOut(self.options.hideEffectSpeed);

            break;

            // If none of the above options were passed, then a `jqueryUI hide effect` is expected
          default:

            elem.hide();

            break;

        }

        // Maintains chainablity
        return self;
      },

      // _triggerShow
      // ------------
      //      Determines what elements get shown on scroll and click
      _triggerShow: function(elem, scroll) {

        var self = this;

        // If the current element's parent is a header element or the next element is a nested subheader element
        if (elem.parent().is(headerClass) || elem.next().is(subheaderClass)) {

          // Shows the next sub-header element
          self.show(elem.next(subheaderClass), scroll);

        }

        // If the current element's parent is a subheader element
        else if (elem.parent().is(subheaderClass)) {

          // Shows the parent sub-header element
          self.show(elem.parent(), scroll);

        }

        // Maintains chainability
        return self;

      },

      // _addCSSClasses
      // --------------
      //      Adds CSS classes to the newly generated table of contents HTML
      _addCSSClasses: function() {

        // If the user wants a jqueryUI theme
        if (this.options.theme === "jqueryui") {

          this.focusClass = "ui-state-default";

          this.hoverClass = "ui-state-hover";

          //Adds the default styling to the dropdown list
          this.element.addClass("ui-widget").find(".toc-title").addClass("ui-widget-header").end().find("li").addClass("ui-widget-content");

        }

        // If the user wants a twitterBootstrap theme
        else if (this.options.theme === "bootstrap") {

          this.element.find(headerClass + "," + subheaderClass).addClass("nav nav-list");

          this.focusClass = "active";

        }

        // If the user wants a twitterBootstrap theme
        else if (this.options.theme === "bootstrap3") {

          this.element.find(headerClass + "," + subheaderClass).addClass("list-group");

          this.element.find(itemClass).addClass("list-group-item");

          this.focusClass = "active";

        }

        // If a user does not want a prebuilt theme
        else {

          // Adds more neutral classes (instead of jqueryui)

          this.focusClass = tocFocusClassName;

          this.hoverClass = tocHoverClassName;

        }

        //Maintains chainability
        return this;

      },

      // setOption
      // ---------
      //      Sets a single Tocify option after the plugin is invoked
      setOption: function() {

        // Calls the jQueryUI Widget Factory setOption method
        $.Widget.prototype._setOption.apply(this, arguments);

      },

      // setOptions
      // ----------
      //      Sets a single or multiple Tocify options after the plugin is invoked
      setOptions: function() {

        // Calls the jQueryUI Widget Factory setOptions method
        $.Widget.prototype._setOptions.apply(this, arguments);

      },

      // _scrollTo
      // ---------
      //      Scrolls to a specific element
      _scrollTo: function(elem) {

        var self = this,
          duration = self.options.smoothScroll || 0,
          scrollTo = self.options.scrollTo,
          currentDiv = $('div[data-unique="' + elem.attr("data-unique") + '"]');

        if (!currentDiv.length) {

          return self;

        }

        // Once all animations on the page are complete, this callback function will be called
        $("html, body").promise().done(function() {

          // Animates the html and body element scrolltops
          $("html, body").animate({

            // Sets the jQuery `scrollTop` to the top offset of the HTML div tag that matches the current list item's `data-unique` tag
            "scrollTop": currentDiv.offset().top - ($.isFunction(scrollTo) ? scrollTo.call() : scrollTo) + "px"

          }, {

            // Sets the smoothScroll animation time duration to the smoothScrollSpeed option
            "duration": duration

          });

        });

        // Maintains chainability
        return self;

      }

    });

  })); //end of plugin
"></script>
<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,CndpbmRvdy5pbml0aWFsaXplU291cmNlRW1iZWQgPSBmdW5jdGlvbihmaWxlbmFtZSkgewogICQoIiNybWQtZG93bmxvYWQtc291cmNlIikuY2xpY2soZnVuY3Rpb24oKSB7CiAgICB2YXIgc3JjID0gJCgiI3JtZC1zb3VyY2UtY29kZSIpLmh0bWwoKTsKICAgIHZhciBhID0gZG9jdW1lbnQuY3JlYXRlRWxlbWVudCgnYScpOwogICAgYS5ocmVmID0gImRhdGE6dGV4dC94LXItbWFya2Rvd247YmFzZTY0LCIgKyBzcmM7CiAgICBhLmRvd25sb2FkID0gZmlsZW5hbWU7CiAgICBkb2N1bWVudC5ib2R5LmFwcGVuZENoaWxkKGEpOwogICAgYS5jbGljaygpOwogICAgZG9jdW1lbnQuYm9keS5yZW1vdmVDaGlsZChhKTsKICB9KTsKfTsK"></script>
<link href="data:text/css,%2Ehljs%2Dliteral%20%7B%0Acolor%3A%20rgb%2888%2C%2072%2C%20246%29%3B%0A%7D%0A%2Ehljs%2Dnumber%20%7B%0Acolor%3A%20rgb%280%2C%200%2C%20205%29%3B%0A%7D%0A%2Ehljs%2Dcomment%20%7B%0Acolor%3A%20rgb%2876%2C%20136%2C%20107%29%3B%0A%7D%0A%2Ehljs%2Dkeyword%20%7B%0Acolor%3A%20rgb%280%2C%200%2C%20255%29%3B%0A%7D%0A%2Ehljs%2Dstring%20%7B%0Acolor%3A%20rgb%283%2C%20106%2C%207%29%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>




<style type="text/css">
#rmd-source-code {
  display: none;
}
</style>





<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>

<style type="text/css">
.kable-table {
  border: 1px solid #ccc;
  border-radius: 4px;
  overflow: auto;
  padding-left: 8px;
  padding-right: 8px;
  margin-bottom: 20px;
  max-height: 350px;
}

.kable-table table {
  margin-bottom: 0px;
}

.kable-table table>thead>tr>th {
  border: none;
  border-bottom: 2px solid #dddddd;
}

.kable-table table>thead {
  background-color: #fff;
}
</style>


<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->
<style type="text/css">
.code-folding-btn { margin-bottom: 4px; }
</style>



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div id="header">

<div class="btn-group pull-right float-right">
<button type="button" class="btn btn-default btn-xs btn-secondary btn-sm dropdown-toggle" data-toggle="dropdown" data-bs-toggle="dropdown" aria-haspopup="true" aria-expanded="false"><span>Code</span> <span class="caret"></span></button>
<ul class="dropdown-menu dropdown-menu-right" style="min-width: 50px;">
<li><a id="rmd-show-all-code" href="#">Show All Code</a></li>
<li><a id="rmd-hide-all-code" href="#">Hide All Code</a></li>
<li role="separator" class="divider"></li>
<li><a id="rmd-download-source" href="#">Download Rmd</a></li>
</ul>
</div>



<h1 class="title toc-ignore">MM microarray data processing 20220414</h1>

</div>


<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShHRU9xdWVyeSlcbmBgYCJ9 -->
<pre class="r"><code>library(GEOquery)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>Loading required package: Biobase
Loading required package: BiocGenerics

Attaching package: BiocGenerics

The following objects are masked from package:stats:

    IQR, mad, sd, var, xtabs

The following objects are masked from package:base:

    anyDuplicated, append, as.data.frame, basename, cbind, colnames, dirname, do.call, duplicated,
    eval, evalq, Filter, Find, get, grep, grepl, intersect, is.unsorted, lapply, Map, mapply, match,
    mget, order, paste, pmax, pmax.int, pmin, pmin.int, Position, rank, rbind, Reduce, rownames,
    sapply, setdiff, sort, table, tapply, union, unique, unsplit, which.max, which.min

Welcome to Bioconductor

    Vignettes contain introductory material; view with &#39;browseVignettes()&#39;. To cite Bioconductor, see
    &#39;citation(&quot;Biobase&quot;)&#39;, and for packages &#39;citation(&quot;pkgname&quot;)&#39;.

Registered S3 method overwritten by &#39;data.table&#39;:
  method           from
  print.data.table     
Setting options(&#39;download.file.method.GEOquery&#39;=&#39;auto&#39;)
Setting options(&#39;GEOquery.inmemory.gpl&#39;=FALSE)</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShyZWFkcilcbmxpYnJhcnkodGlkeXIpXG5saWJyYXJ5KGRwbHlyKVxuYGBgIn0= -->
<pre class="r"><code>library(readr)
library(tidyr)
library(dplyr)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>
Attaching package: dplyr

The following object is masked from package:Biobase:

    combine

The following objects are masked from package:BiocGenerics:

    combine, intersect, setdiff, union

The following objects are masked from package:stats:

    filter, lag

The following objects are masked from package:base:

    intersect, setdiff, setequal, union</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGlicmFyeShnZ3Bsb3QyKVxubGlicmFyeShzdHJpbmdyKVxuYGBgIn0= -->
<pre class="r"><code>library(ggplot2)
library(stringr)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>not using</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBnc2UyNjU4IDwtIGdldEdFTygnR1NFMjY1OCcsIEdTRU1hdHJpeD1UUlVFKVxuIyBzaG93KGdzZTI2NTgpXG5gYGAifQ== -->
<pre class="r"><code># gse2658 &lt;- getGEO(&#39;GSE2658&#39;, GSEMatrix=TRUE)
# show(gse2658)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<div id="bring-in-data" class="section level2">
<h2>bring in data</h2>
<p>geo data from GSE2658 (Shaughnessy data from GEO)<br />
<a href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2658" class="uri">https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2658</a></p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9sYyA8LSBnZXRHRU8oXG4gIGZpbGVuYW1lPVwifi9Eb2N1bWVudHMvc3RhdHMvc3Vydml2YWwvY29tbXBhc3NfcHJvai9tbV9taWNyb2FycmF5X2RhdGFzZXRzL0dTRTI2NThfc2VyaWVzX21hdHJpeC50eHQuZ3pcIiwgXG4gIEdTRU1hdHJpeD1UUlVFKVxuc2hvdyhnc2UyNjU4X2xjKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_lc &lt;- getGEO(
  filename=&quot;~/Documents/stats/survival/commpass_proj/mm_microarray_datasets/GSE2658_series_matrix.txt.gz&quot;, 
  GSEMatrix=TRUE)
show(gse2658_lc)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>ExpressionSet (storageMode: lockedEnvironment)
assayData: 54675 features, 559 samples 
  element names: exprs 
protocolData: none
phenoData
  sampleNames: GSM50986 GSM50987 ... GSM102634 (559 total)
  varLabels: title geo_accession ... data_row_count (52 total)
  varMetadata: labelDescription
featureData
  featureNames: 1007_s_at 1053_at ... AFFX-TrpnX-M_at (54675 total)
  fvarLabels: ID GB_ACC ... Gene Ontology Molecular Function (16 total)
  fvarMetadata: Column Description labelDescription
experimentData: use &#39;experimentData(object)&#39;
  pubMedIds: 16688228
16728703
17023574
19837979
29980194
30213928
25753926
27363682
23456977
23537707
18337559
33572851 
Annotation: GPL570 </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>get out phenotype data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9wZGF0YSA8LSBwRGF0YShwaGVub0RhdGEoZ3NlMjY1OF9sYykpXG5nc2UyNjU4X3BkYXRhXG5gYGAifQ== -->
<pre class="r"><code>gse2658_pdata &lt;- pData(phenoData(gse2658_lc))
gse2658_pdata</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":559,"ncol":52,"summary":{"Description":["df [559 × 52]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["title"],"name":[1],"type":["chr"],"align":["left"]},{"label":["geo_accession"],"name":[2],"type":["chr"],"align":["left"]},{"label":["status"],"name":[3],"type":["chr"],"align":["left"]},{"label":["submission_date"],"name":[4],"type":["chr"],"align":["left"]},{"label":["last_update_date"],"name":[5],"type":["chr"],"align":["left"]},{"label":["type"],"name":[6],"type":["chr"],"align":["left"]},{"label":["channel_count"],"name":[7],"type":["chr"],"align":["left"]},{"label":["source_name_ch1"],"name":[8],"type":["chr"],"align":["left"]},{"label":["organism_ch1"],"name":[9],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1"],"name":[10],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.1"],"name":[11],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.2"],"name":[12],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.3"],"name":[13],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.4"],"name":[14],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.5"],"name":[15],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.6"],"name":[16],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.7"],"name":[17],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.8"],"name":[18],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.9"],"name":[19],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.10"],"name":[20],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.11"],"name":[21],"type":["chr"],"align":["left"]},{"label":["molecule_ch1"],"name":[22],"type":["chr"],"align":["left"]},{"label":["extract_protocol_ch1"],"name":[23],"type":["chr"],"align":["left"]},{"label":["label_ch1"],"name":[24],"type":["chr"],"align":["left"]},{"label":["label_protocol_ch1"],"name":[25],"type":["chr"],"align":["left"]},{"label":["taxid_ch1"],"name":[26],"type":["chr"],"align":["left"]},{"label":["hyb_protocol"],"name":[27],"type":["chr"],"align":["left"]},{"label":["scan_protocol"],"name":[28],"type":["chr"],"align":["left"]},{"label":["description"],"name":[29],"type":["chr"],"align":["left"]},{"label":["description.1"],"name":[30],"type":["chr"],"align":["left"]},{"label":["description.2"],"name":[31],"type":["chr"],"align":["left"]},{"label":["description.3"],"name":[32],"type":["chr"],"align":["left"]},{"label":["description.4"],"name":[33],"type":["chr"],"align":["left"]},{"label":["description.5"],"name":[34],"type":["chr"],"align":["left"]},{"label":["data_processing"],"name":[35],"type":["chr"],"align":["left"]},{"label":["data_processing.1"],"name":[36],"type":["chr"],"align":["left"]},{"label":["data_processing.2"],"name":[37],"type":["chr"],"align":["left"]},{"label":["data_processing.3"],"name":[38],"type":["chr"],"align":["left"]},{"label":["platform_id"],"name":[39],"type":["chr"],"align":["left"]},{"label":["contact_name"],"name":[40],"type":["chr"],"align":["left"]},{"label":["contact_email"],"name":[41],"type":["chr"],"align":["left"]},{"label":["contact_phone"],"name":[42],"type":["chr"],"align":["left"]},{"label":["contact_laboratory"],"name":[43],"type":["chr"],"align":["left"]},{"label":["contact_department"],"name":[44],"type":["chr"],"align":["left"]},{"label":["contact_institute"],"name":[45],"type":["chr"],"align":["left"]},{"label":["contact_address"],"name":[46],"type":["chr"],"align":["left"]},{"label":["contact_city"],"name":[47],"type":["chr"],"align":["left"]},{"label":["contact_state"],"name":[48],"type":["chr"],"align":["left"]},{"label":["contact_zip/postal_code"],"name":[49],"type":["chr"],"align":["left"]},{"label":["contact_country"],"name":[50],"type":["chr"],"align":["left"]},{"label":["supplementary_file"],"name":[51],"type":["chr"],"align":["left"]},{"label":["data_row_count"],"name":[52],"type":["chr"],"align":["left"]}],"data":[{"1":"U133Plus-P002 (TT2 pre-treatment)","2":"GSM50986","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=69.24 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/5%/91%/3% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50986"},{"1":"U133Plus-P008 (TT2 pre-treatment)","2":"GSM50987","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=66.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50987"},{"1":"U133Plus-P009 (TT2 pre-treatment)","2":"GSM50988","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=66.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50988"},{"1":"U133Plus-P010 (TT2 pre-treatment)","2":"GSM50989","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=66.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50989"},{"1":"U133Plus-P015 (TT2 pre-treatment)","2":"GSM50990","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/90%/9% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50990"},{"1":"U133Plus-P016 (TT2 pre-treatment)","2":"GSM50991","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=65 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50991"},{"1":"U133Plus-P018 (TT2 pre-treatment)","2":"GSM50992","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=65.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50992"},{"1":"U133Plus-P019 (TT2 pre-treatment)","2":"GSM50993","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=38.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/92%/8%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50993"},{"1":"U133Plus-P025 (TT2 pre-treatment)","2":"GSM50994","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=64.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50994"},{"1":"U133Plus-P029 (TT2 pre-treatment)","2":"GSM50995","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=64.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50995"},{"1":"U133Plus-P030 (TT2 pre-treatment)","2":"GSM50996","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=64.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50996"},{"1":"U133Plus-P034 (TT2 pre-treatment)","2":"GSM50997","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/12%/74%/14% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50997"},{"1":"U133Plus-P036 (TT2 pre-treatment)","2":"GSM50998","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=62.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/4%/93%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50998"},{"1":"U133Plus-P037 (TT2 pre-treatment)","2":"GSM50999","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=63.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/1%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM50999"},{"1":"U133Plus-P043 (TT2 pre-treatment)","2":"GSM51000","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.84 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/18%/64%/18% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51000"},{"1":"U133Plus-P048 (TT2 pre-treatment)","2":"GSM51001","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=36.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/0%/100% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51001"},{"1":"U133Plus-P051 (TT2 pre-treatment)","2":"GSM51002","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/19%/35%/45% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51002"},{"1":"U133Plus-P052 (TT2 pre-treatment)","2":"GSM51003","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=61.71 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/90%/7%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51003"},{"1":"U133Plus-P053 (TT2 pre-treatment)","2":"GSM51004","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51004"},{"1":"U133Plus-P054 (TT2 pre-treatment)","2":"GSM51005","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51005"},{"1":"U133Plus-P055 (TT2 pre-treatment)","2":"GSM51006","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51006"},{"1":"U133Plus-P056 (TT2 pre-treatment)","2":"GSM51007","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=61.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51007"},{"1":"U133Plus-P057 (TT2 pre-treatment)","2":"GSM51008","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/70%/25% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51008"},{"1":"U133Plus-P061 (TT2 pre-treatment)","2":"GSM51009","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=60.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51009"},{"1":"U133Plus-P063 (TT2 pre-treatment)","2":"GSM51010","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/94%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51010"},{"1":"U133Plus-P065 (TT2 pre-treatment)","2":"GSM51011","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=60.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/4%/73%/23% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51011"},{"1":"U133Plus-P066 (TT2 pre-treatment)","2":"GSM51012","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51012"},{"1":"U133Plus-P067 (TT2 pre-treatment)","2":"GSM51013","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=1.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/19%/76%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51013"},{"1":"U133Plus-P069 (TT2 pre-treatment)","2":"GSM51014","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=59.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51014"},{"1":"U133Plus-P075 (TT2 pre-treatment)","2":"GSM51015","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51015"},{"1":"U133Plus-P077 (TT2 pre-treatment)","2":"GSM51016","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=58.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51016"},{"1":"U133Plus-P079 (TT2 pre-treatment)","2":"GSM51017","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51017"},{"1":"U133Plus-P083 (TT2 pre-treatment)","2":"GSM51018","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51018"},{"1":"U133Plus-P084 (TT2 pre-treatment)","2":"GSM51019","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/75%/15%/10% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51019"},{"1":"U133Plus-P085 (TT2 pre-treatment)","2":"GSM51020","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51020"},{"1":"U133Plus-P090 (TT2 pre-treatment)","2":"GSM51021","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=50.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51021"},{"1":"U133Plus-P091 (TT2 pre-treatment)","2":"GSM51022","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=58.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51022"},{"1":"U133Plus-P092 (TT2 pre-treatment)","2":"GSM51023","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/50%/50%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51023"},{"1":"U133Plus-P095 (TT2 pre-treatment)","2":"GSM51024","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51024"},{"1":"U133Plus-P096 (TT2 pre-treatment)","2":"GSM51025","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=49.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/25%/63%/12% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51025"},{"1":"U133Plus-P098 (TT2 pre-treatment)","2":"GSM51026","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=59.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51026"},{"1":"U133Plus-P099 (TT2 pre-treatment)","2":"GSM51027","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51027"},{"1":"U133Plus-P101 (TT2 pre-treatment)","2":"GSM51028","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.84 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51028"},{"1":"U133Plus-P102 (TT2 pre-treatment)","2":"GSM51029","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/6%/36%/58% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51029"},{"1":"U133Plus-P103 (TT2 pre-treatment)","2":"GSM51030","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/21%/71%/8% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51030"},{"1":"U133Plus-P104 (TT2 pre-treatment)","2":"GSM51031","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=58.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51031"},{"1":"U133Plus-P107 (TT2 pre-treatment)","2":"GSM51032","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=57.31 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51032"},{"1":"U133Plus-P111 (TT2 pre-treatment)","2":"GSM51033","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51033"},{"1":"U133Plus-P117 (TT2 pre-treatment)","2":"GSM51034","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=56.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51034"},{"1":"U133Plus-P118 (TT2 pre-treatment)","2":"GSM51035","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/99%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51035"},{"1":"U133Plus-P119 (TT2 pre-treatment)","2":"GSM51036","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=61.51 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/95%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51036"},{"1":"U133Plus-P120 (TT2 pre-treatment)","2":"GSM51037","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.22 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51037"},{"1":"U133Plus-P121 (TT2 pre-treatment)","2":"GSM51038","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=59.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/32%/64%/4% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51038"},{"1":"U133Plus-P122 (TT2 pre-treatment)","2":"GSM51039","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=59.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51039"},{"1":"U133Plus-P124 (TT2 pre-treatment)","2":"GSM51040","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=58.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51040"},{"1":"U133Plus-P127 (TT2 pre-treatment)","2":"GSM51041","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/2%/10%/88% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51041"},{"1":"U133Plus-P131 (TT2 pre-treatment)","2":"GSM51042","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=56.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51042"},{"1":"U133Plus-P138 (TT2 pre-treatment)","2":"GSM51043","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=59.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51043"},{"1":"U133Plus-P144 (TT2 pre-treatment)","2":"GSM51044","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=54.71 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51044"},{"1":"U133Plus-P154 (TT2 pre-treatment)","2":"GSM51045","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/19%/65%/14% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51045"},{"1":"U133Plus-P155 (TT2 pre-treatment)","2":"GSM51046","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=56.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51046"},{"1":"U133Plus-P157 (TT2 pre-treatment)","2":"GSM51047","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=56.22 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51047"},{"1":"U133Plus-P158 (TT2 pre-treatment)","2":"GSM51048","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51048"},{"1":"U133Plus-P163 (TT2 pre-treatment)","2":"GSM51049","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=55.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51049"},{"1":"U133Plus-P165 (TT2 pre-treatment)","2":"GSM51050","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51050"},{"1":"U133Plus-P168 (TT2 pre-treatment)","2":"GSM51051","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=55.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51051"},{"1":"U133Plus-P170 (TT2 pre-treatment)","2":"GSM51052","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51052"},{"1":"U133Plus-P171 (TT2 pre-treatment)","2":"GSM51053","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51053"},{"1":"U133Plus-P175 (TT2 pre-treatment)","2":"GSM51054","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=0 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51054"},{"1":"U133Plus-P176 (TT2 pre-treatment)","2":"GSM51055","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=55.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51055"},{"1":"U133Plus-P187 (TT2 pre-treatment)","2":"GSM51056","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51056"},{"1":"U133Plus-P199 (TT2 pre-treatment)","2":"GSM51057","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/93%/4%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51057"},{"1":"U133Plus-P200 (TT2 pre-treatment)","2":"GSM51058","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=65.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/4%/20%/76% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51058"},{"1":"U133Plus-P202 (TT2 pre-treatment)","2":"GSM51059","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=54.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/16%/79% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51059"},{"1":"U133Plus-P208 (TT2 pre-treatment)","2":"GSM51060","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=47.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51060"},{"1":"U133Plus-P212 (TT2 pre-treatment)","2":"GSM51061","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51061"},{"1":"U133Plus-P213 (TT2 pre-treatment)","2":"GSM51062","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=54.35 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51062"},{"1":"U133Plus-P215 (TT2 pre-treatment)","2":"GSM51063","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=54 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51063"},{"1":"U133Plus-P221 (TT2 pre-treatment)","2":"GSM51064","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51064"},{"1":"U133Plus-P222 (TT2 pre-treatment)","2":"GSM51065","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=54.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51065"},{"1":"U133Plus-P226 (TT2 pre-treatment)","2":"GSM51066","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/39%/60%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51066"},{"1":"U133Plus-P232 (TT2 pre-treatment)","2":"GSM51067","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/2%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51067"},{"1":"U133Plus-P237 (TT2 pre-treatment)","2":"GSM51068","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51068"},{"1":"U133Plus-P239 (TT2 pre-treatment)","2":"GSM51069","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51069"},{"1":"U133Plus-P241 (TT2 pre-treatment)","2":"GSM51070","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/28%/70%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51070"},{"1":"U133Plus-P249 (TT2 pre-treatment)","2":"GSM51071","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51071"},{"1":"U133Plus-P250 (TT2 pre-treatment)","2":"GSM51072","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/15%/69%/16% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51072"},{"1":"U133Plus-P251 (TT2 pre-treatment)","2":"GSM51073","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51073"},{"1":"U133Plus-P254 (TT2 pre-treatment)","2":"GSM51074","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/0%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51074"},{"1":"U133Plus-P255 (TT2 pre-treatment)","2":"GSM51075","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/11%/89%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51075"},{"1":"U133Plus-P256 (TT2 pre-treatment)","2":"GSM51076","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/21%/73%/6% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51076"},{"1":"U133Plus-P259 (TT2 pre-treatment)","2":"GSM51077","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/6%/21%/70% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51077"},{"1":"U133Plus-P260 (TT2 pre-treatment)","2":"GSM51078","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51078"},{"1":"U133Plus-P265 (TT2 pre-treatment)","2":"GSM51079","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51079"},{"1":"U133Plus-P266 (TT2 pre-treatment)","2":"GSM51080","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51080"},{"1":"U133Plus-P270 (TT2 pre-treatment)","2":"GSM51081","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51081"},{"1":"U133Plus-P271 (TT2 pre-treatment)","2":"GSM51082","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=52.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51082"},{"1":"U133Plus-P272 (TT2 pre-treatment)","2":"GSM51083","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.81 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/95%/5%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51083"},{"1":"U133Plus-P274 (TT2 pre-treatment)","2":"GSM51084","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=53.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51084"},{"1":"U133Plus-P276 (TT2 pre-treatment)","2":"GSM51085","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/20%/79%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51085"},{"1":"U133Plus-P277 (TT2 pre-treatment)","2":"GSM51086","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=1.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/79%/11%/10% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51086"},{"1":"U133Plus-P278 (TT2 pre-treatment)","2":"GSM51087","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=51.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51087"},{"1":"U133Plus-P279 (TT2 pre-treatment)","2":"GSM51088","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.79 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/47%/48%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51088"},{"1":"U133Plus-P280 (TT2 pre-treatment)","2":"GSM51089","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=37.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51089"},{"1":"U133Plus-P281 (TT2 pre-treatment)","2":"GSM51090","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=36.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51090"},{"1":"U133Plus-P283 (TT2 pre-treatment)","2":"GSM51091","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51091"},{"1":"U133Plus-P285 (TT2 pre-treatment)","2":"GSM51092","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=51.65 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51092"},{"1":"U133Plus-P286 (TT2 pre-treatment)","2":"GSM51093","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51093"},{"1":"U133Plus-P288 (TT2 pre-treatment)","2":"GSM51094","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=51.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/95%/3%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51094"},{"1":"U133Plus-P291 (TT2 pre-treatment)","2":"GSM51095","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=46.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51095"},{"1":"U133Plus-P296 (TT2 pre-treatment)","2":"GSM51096","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=50.94 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/93%/6%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51096"},{"1":"U133Plus-P299 (TT2 pre-treatment)","2":"GSM51097","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=50.75 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/6%/94%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51097"},{"1":"U133Plus-P301 (TT2 pre-treatment)","2":"GSM51098","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=50.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51098"},{"1":"U133Plus-P303 (TT2 pre-treatment)","2":"GSM51099","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51099"},{"1":"U133Plus-P307 (TT2 pre-treatment)","2":"GSM51100","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=50.01 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/98%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51100"},{"1":"U133Plus-P308 (TT2 pre-treatment)","2":"GSM51101","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=49.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/35%/65%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51101"},{"1":"U133Plus-P313 (TT2 pre-treatment)","2":"GSM51102","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=49.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/96%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51102"},{"1":"U133Plus-P314 (TT2 pre-treatment)","2":"GSM51103","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=49.55 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51103"},{"1":"U133Plus-P324 (TT2 pre-treatment)","2":"GSM51104","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=49.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51104"},{"1":"U133Plus-P330 (TT2 pre-treatment)","2":"GSM51105","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=48.21 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/8%/89%/3% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51105"},{"1":"U133Plus-P332 (TT2 pre-treatment)","2":"GSM51106","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=49 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51106"},{"1":"U133Plus-P335 (TT2 pre-treatment)","2":"GSM51107","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=48.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/1%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51107"},{"1":"U133Plus-P340 (TT2 pre-treatment)","2":"GSM51108","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=48.21 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/4%/41%/55% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51108"},{"1":"U133Plus-P343 (TT2 pre-treatment)","2":"GSM51109","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=47.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/90%/10%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51109"},{"1":"U133Plus-P347 (TT2 pre-treatment)","2":"GSM51110","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=47.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/98%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51110"},{"1":"U133Plus-P349 (TT2 pre-treatment)","2":"GSM51111","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=47.21 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51111"},{"1":"U133Plus-P352 (TT2 pre-treatment)","2":"GSM51112","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=46.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51112"},{"1":"U133Plus-P354 (TT2 pre-treatment)","2":"GSM51113","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=1.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51113"},{"1":"U133Plus-P355 (TT2 pre-treatment)","2":"GSM51114","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=46.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/98%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51114"},{"1":"U133Plus-P357 (TT2 pre-treatment)","2":"GSM51115","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/15%/83%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51115"},{"1":"U133Plus-P364 (TT2 pre-treatment)","2":"GSM51116","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.04 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/95%/3%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51116"},{"1":"U133Plus-P365 (TT2 pre-treatment)","2":"GSM51117","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/19%/81% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51117"},{"1":"U133Plus-P366 (TT2 pre-treatment)","2":"GSM51118","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=46.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/55%/39%/7% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51118"},{"1":"U133Plus-P368 (TT2 pre-treatment)","2":"GSM51119","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=46.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51119"},{"1":"U133Plus-P371 (TT2 pre-treatment)","2":"GSM51120","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/10%/87%/3% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51120"},{"1":"U133Plus-P374 (TT2 pre-treatment)","2":"GSM51121","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51121"},{"1":"U133Plus-P381 (TT2 pre-treatment)","2":"GSM51122","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/3%/97% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51122"},{"1":"U133Plus-P385 (TT2 pre-treatment)","2":"GSM51123","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/0%/100% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51123"},{"1":"U133Plus-P387 (TT2 pre-treatment)","2":"GSM51124","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/9%/73%/18% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51124"},{"1":"U133Plus-P390 (TT2 pre-treatment)","2":"GSM51125","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/96%/1%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51125"},{"1":"U133Plus-P391 (TT2 pre-treatment)","2":"GSM51126","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/97%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51126"},{"1":"U133Plus-P392 (TT2 pre-treatment)","2":"GSM51127","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51127"},{"1":"U133Plus-P393 (TT2 pre-treatment)","2":"GSM51128","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=45.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51128"},{"1":"U133Plus-P397 (TT2 pre-treatment)","2":"GSM51129","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/9%/91%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51129"},{"1":"U133Plus-P399 (TT2 pre-treatment)","2":"GSM51130","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/33%/67%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51130"},{"1":"U133Plus-P401 (TT2 pre-treatment)","2":"GSM51131","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/99%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51131"},{"1":"U133Plus-P405 (TT2 pre-treatment)","2":"GSM51132","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51132"},{"1":"U133Plus-P408 (TT2 pre-treatment)","2":"GSM51133","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/96%/4%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51133"},{"1":"U133Plus-P415 (TT2 pre-treatment)","2":"GSM51134","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.55 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51134"},{"1":"U133Plus-P418 (TT2 pre-treatment)","2":"GSM51135","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/95%/4%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51135"},{"1":"U133Plus-P420 (TT2 pre-treatment)","2":"GSM51136","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=46.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/0%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51136"},{"1":"U133Plus-P421 (TT2 pre-treatment)","2":"GSM51137","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/91%/8%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51137"},{"1":"U133Plus-P426 (TT2 pre-treatment)","2":"GSM51138","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51138"},{"1":"U133Plus-P427 (TT2 pre-treatment)","2":"GSM51139","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=44.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/91%/4%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51139"},{"1":"U133Plus-P433 (TT2 pre-treatment)","2":"GSM51140","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51140"},{"1":"U133Plus-P434 (TT2 pre-treatment)","2":"GSM51141","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/1%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51141"},{"1":"U133Plus-P438 (TT2 pre-treatment)","2":"GSM51142","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.49 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/10%/90% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51142"},{"1":"U133Plus-P440 (TT2 pre-treatment)","2":"GSM51143","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.54 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/19%/77%/4%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51143"},{"1":"U133Plus-P446 (TT2 pre-treatment)","2":"GSM51144","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/5%/93%/0%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51144"},{"1":"U133Plus-P447 (TT2 pre-treatment)","2":"GSM51145","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51145"},{"1":"U133Plus-P451 (TT2 pre-treatment)","2":"GSM51146","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51146"},{"1":"U133Plus-P454 (TT2 pre-treatment)","2":"GSM51147","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51147"},{"1":"U133Plus-P457 (TT2 pre-treatment)","2":"GSM51148","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=43.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51148"},{"1":"U133Plus-P463 (TT2 pre-treatment)","2":"GSM51149","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.84 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/96%/0%/4% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51149"},{"1":"U133Plus-P465 (TT2 pre-treatment)","2":"GSM51150","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51150"},{"1":"U133Plus-P474 (TT2 pre-treatment)","2":"GSM51151","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/10%/88%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51151"},{"1":"U133Plus-P478 (TT2 pre-treatment)","2":"GSM51152","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.51 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51152"},{"1":"U133Plus-P480 (TT2 pre-treatment)","2":"GSM51153","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51153"},{"1":"U133Plus-P481 (TT2 pre-treatment)","2":"GSM51154","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/3%/92%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51154"},{"1":"U133Plus-P482 (TT2 pre-treatment)","2":"GSM51155","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51155"},{"1":"U133Plus-P487 (TT2 pre-treatment)","2":"GSM51156","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.92 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/96%/0%/4% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51156"},{"1":"U133Plus-P490 (TT2 pre-treatment)","2":"GSM51157","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.12 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/97%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51157"},{"1":"U133Plus-P492-2 (TT2 pre-treatment)","2":"GSM51158","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=42.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51158"},{"1":"U133Plus-P495 (TT2 pre-treatment)","2":"GSM51159","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51159"},{"1":"U133Plus-P501 (TT2 pre-treatment)","2":"GSM51160","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/2%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51160"},{"1":"U133Plus-P502 (TT2 pre-treatment)","2":"GSM51161","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51161"},{"1":"U133Plus-P503 (TT2 pre-treatment)","2":"GSM51162","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/27%/26%/47% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51162"},{"1":"U133Plus-P504 (TT2 pre-treatment)","2":"GSM51163","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/99%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51163"},{"1":"U133Plus-P508 (TT2 pre-treatment)","2":"GSM51164","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=41.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/19%/78%/3% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51164"},{"1":"U133Plus-P510 (TT2 pre-treatment)","2":"GSM51165","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51165"},{"1":"U133Plus-P511 (TT2 pre-treatment)","2":"GSM51166","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/8%/69%/23% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51166"},{"1":"U133Plus-P517 (TT2 pre-treatment)","2":"GSM51167","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/97%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51167"},{"1":"U133Plus-P522 (TT2 pre-treatment)","2":"GSM51168","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.54 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51168"},{"1":"U133Plus-P526 (TT2 pre-treatment)","2":"GSM51169","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51169"},{"1":"U133Plus-P535 (TT2 pre-treatment)","2":"GSM51170","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/14%/86% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51170"},{"1":"U133Plus-P536 (TT2 pre-treatment)","2":"GSM51171","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/95%/2%/3% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51171"},{"1":"U133Plus-P538 (TT2 pre-treatment)","2":"GSM51172","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=40.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/64%/36%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51172"},{"1":"U133Plus-P541 (TT2 pre-treatment)","2":"GSM51173","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51173"},{"1":"U133Plus-P549 (TT2 pre-treatment)","2":"GSM51174","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/79%/3%/18% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51174"},{"1":"U133Plus-P556 (TT2 pre-treatment)","2":"GSM51175","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51175"},{"1":"U133Plus-P559 (TT2 pre-treatment)","2":"GSM51176","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/97%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51176"},{"1":"U133Plus-P561 (TT2 pre-treatment)","2":"GSM51177","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51177"},{"1":"U133Plus-P562 (TT2 pre-treatment)","2":"GSM51178","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=36.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51178"},{"1":"U133Plus-P563 (TT2 pre-treatment)","2":"GSM51179","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=38.34 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/47%/35%/18% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51179"},{"1":"U133Plus-P564 (TT2 pre-treatment)","2":"GSM51180","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51180"},{"1":"U133Plus-P565 (TT2 pre-treatment)","2":"GSM51181","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=39.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51181"},{"1":"U133Plus-P566 (TT2 pre-treatment)","2":"GSM51182","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51182"},{"1":"U133Plus-P569 (TT2 pre-treatment)","2":"GSM51183","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=37.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51183"},{"1":"U133Plus-P575 (TT2 pre-treatment)","2":"GSM51184","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/99%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51184"},{"1":"U133Plus-P577 (TT2 pre-treatment)","2":"GSM51185","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=32.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/10%/84%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51185"},{"1":"U133Plus-P584 (TT2 pre-treatment)","2":"GSM51186","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=38.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51186"},{"1":"U133Plus-P592 (TT2 pre-treatment)","2":"GSM51187","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=37.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51187"},{"1":"U133Plus-P597 (TT2 pre-treatment)","2":"GSM51188","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51188"},{"1":"U133Plus-P598 (TT2 pre-treatment)","2":"GSM51189","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=37.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51189"},{"1":"U133Plus-P600 (TT2 pre-treatment)","2":"GSM51190","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/20%/10%/70% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51190"},{"1":"U133Plus-P604 (TT2 pre-treatment)","2":"GSM51191","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=37.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/70%/25% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51191"},{"1":"U133Plus-P610 (TT2 pre-treatment)","2":"GSM51192","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=37.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/97%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51192"},{"1":"U133Plus-P614 (TT2 pre-treatment)","2":"GSM51193","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/3%/18%/79% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51193"},{"1":"U133Plus-P625 (TT2 pre-treatment)","2":"GSM51194","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=36.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/6%/12%/82% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51194"},{"1":"U133Plus-P630 (TT2 pre-treatment)","2":"GSM51195","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=32.14 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/15%/85%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51195"},{"1":"U133Plus-P631 (TT2 pre-treatment)","2":"GSM51196","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.11 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/96%/4%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51196"},{"1":"U133Plus-P635 (TT2 pre-treatment)","2":"GSM51197","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/74%/11%/15% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51197"},{"1":"U133Plus-P636 (TT2 pre-treatment)","2":"GSM51198","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/9%/91% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51198"},{"1":"U133Plus-P640 (TT2 pre-treatment)","2":"GSM51199","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/40%/47%/12% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51199"},{"1":"U133Plus-P642 (TT2 pre-treatment)","2":"GSM51200","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/94%/6%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51200"},{"1":"U133Plus-P647 (TT2 pre-treatment)","2":"GSM51201","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/0%/100% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51201"},{"1":"U133Plus-P649 (TT2 pre-treatment)","2":"GSM51202","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/24%/74%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51202"},{"1":"U133Plus-P651 (TT2 pre-treatment)","2":"GSM51203","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/98%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51203"},{"1":"U133Plus-P653 (TT2 pre-treatment)","2":"GSM51204","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.14 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/4%/95%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51204"},{"1":"U133Plus-P655 (TT2 pre-treatment)","2":"GSM51205","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51205"},{"1":"U133Plus-P657 (TT2 pre-treatment)","2":"GSM51206","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.59 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51206"},{"1":"U133Plus-P658 (TT2 pre-treatment)","2":"GSM51207","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/6%/61%/18%/15% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51207"},{"1":"U133Plus-P659 (TT2 pre-treatment)","2":"GSM51208","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.65 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51208"},{"1":"U133Plus-P663 (TT2 pre-treatment)","2":"GSM51209","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=35.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/94%/6%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51209"},{"1":"U133Plus-P665 (TT2 pre-treatment)","2":"GSM51210","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/92%/8%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51210"},{"1":"U133Plus-P666 (TT2 pre-treatment)","2":"GSM51211","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/10%/90%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51211"},{"1":"U133Plus-P667 (TT2 pre-treatment)","2":"GSM51212","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51212"},{"1":"U133Plus-P669 (TT2 pre-treatment)","2":"GSM51213","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/10%/90%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51213"},{"1":"U133Plus-P670 (TT2 pre-treatment)","2":"GSM51214","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/91%/9% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51214"},{"1":"U133Plus-P672 (TT2 pre-treatment)","2":"GSM51215","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/50%/13%/35% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51215"},{"1":"U133Plus-P673 (TT2 pre-treatment)","2":"GSM51216","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51216"},{"1":"U133Plus-P678 (TT2 pre-treatment)","2":"GSM51217","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51217"},{"1":"U133Plus-P681 (TT2 pre-treatment)","2":"GSM51218","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/100%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51218"},{"1":"U133Plus-P684 (TT2 pre-treatment)","2":"GSM51219","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=34.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/6%/47%/47% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51219"},{"1":"U133Plus-P686 (TT2 pre-treatment)","2":"GSM51220","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51220"},{"1":"U133Plus-P689 (TT2 pre-treatment)","2":"GSM51221","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51221"},{"1":"U133Plus-P691 (TT2 pre-treatment)","2":"GSM51222","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=32.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/7%/69%/23%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51222"},{"1":"U133Plus-P692 (TT2 pre-treatment)","2":"GSM51223","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=32.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/94%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51223"},{"1":"U133Plus-P695 (TT2 pre-treatment)","2":"GSM51224","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=32.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/3%/3%/94% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51224"},{"1":"U133Plus-P698 (TT2 pre-treatment)","2":"GSM51225","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/14%/86% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51225"},{"1":"U133Plus-P702 (TT2 pre-treatment)","2":"GSM51226","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=33.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51226"},{"1":"U133Plus-P705 (TT2 pre-treatment)","2":"GSM51227","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/4%/72%/11%/12% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51227"},{"1":"U133Plus-P707 (TT2 pre-treatment)","2":"GSM51228","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/2%/10%/88% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51228"},{"1":"U133Plus-P712 (TT2 pre-treatment)","2":"GSM51229","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/90%/7%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51229"},{"1":"U133Plus-P713 (TT2 pre-treatment)","2":"GSM51230","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51230"},{"1":"U133Plus-P718 (TT2 pre-treatment)","2":"GSM51231","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=32.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51231"},{"1":"U133Plus-P722 (TT2 pre-treatment)","2":"GSM51232","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/3%/8%/88% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51232"},{"1":"U133Plus-P723 (TT2 pre-treatment)","2":"GSM51233","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/3%/0%/97% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51233"},{"1":"U133Plus-P724 (TT2 pre-treatment)","2":"GSM51234","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/12%/79%/9% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51234"},{"1":"U133Plus-P725 (TT2 pre-treatment)","2":"GSM51235","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51235"},{"1":"U133Plus-P727 (TT2 pre-treatment)","2":"GSM51236","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/75%/10%/15% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51236"},{"1":"U133Plus-P730 (TT2 pre-treatment)","2":"GSM51237","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.89 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/93%/5%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51237"},{"1":"U133Plus-P731-2 (TT2 pre-treatment)","2":"GSM51238","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.31 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/82%/16%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51238"},{"1":"U133Plus-P733 (TT2 pre-treatment)","2":"GSM51239","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51239"},{"1":"U133Plus-P734 (TT2 pre-treatment)","2":"GSM51240","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=31.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/56%/36%/8% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51240"},{"1":"U133Plus-P735 (TT2 pre-treatment)","2":"GSM51241","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.81 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/93%/7%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51241"},{"1":"U133Plus-P737 (TT2 pre-treatment)","2":"GSM51242","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51242"},{"1":"U133Plus-P739 (TT2 pre-treatment)","2":"GSM51243","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/95%/3%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51243"},{"1":"U133Plus-P740 (TT2 pre-treatment)","2":"GSM51244","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/9%/91% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51244"},{"1":"U133Plus-P741 (TT2 pre-treatment)","2":"GSM51245","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/9%/81%/10% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51245"},{"1":"U133Plus-P746 (TT2 pre-treatment)","2":"GSM51246","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/45%/50% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51246"},{"1":"U133Plus-P748 (TT2 pre-treatment)","2":"GSM51247","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51247"},{"1":"U133Plus-P749 (TT2 pre-treatment)","2":"GSM51248","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/3%/97% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51248"},{"1":"U133Plus-P750 (TT2 pre-treatment)","2":"GSM51249","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51249"},{"1":"U133Plus-P753 (TT2 pre-treatment)","2":"GSM51250","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/94%/2%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51250"},{"1":"U133Plus-P755 (TT2 pre-treatment)","2":"GSM51251","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.34 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/11%/89%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51251"},{"1":"U133Plus-P758 (TT2 pre-treatment)","2":"GSM51252","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.82 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51252"},{"1":"U133Plus-P760 (TT2 pre-treatment)","2":"GSM51253","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.72 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51253"},{"1":"U133Plus-P762 (TT2 pre-treatment)","2":"GSM51254","3":"Public on Apr 15 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51254"},{"1":"U133Plus-P766 (TT2 pre-treatment)","2":"GSM51255","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51255"},{"1":"U133Plus-P767 (TT2 pre-treatment)","2":"GSM51256","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=30.31 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/1%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51256"},{"1":"U133Plus-P768 (TT2 pre-treatment)","2":"GSM51257","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/88%/10%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51257"},{"1":"U133Plus-P769 (TT2 pre-treatment)","2":"GSM51258","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.91 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/98%/2%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51258"},{"1":"U133Plus-P770 (TT2 pre-treatment)","2":"GSM51259","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/3%/96%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51259"},{"1":"U133Plus-P772 (TT2 pre-treatment)","2":"GSM51260","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.62 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/9%/77%/14% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51260"},{"1":"U133Plus-P774 (TT2 pre-treatment)","2":"GSM51261","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.52 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51261"},{"1":"U133Plus-P775 (TT2 pre-treatment)","2":"GSM51262","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/97%/1%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51262"},{"1":"U133Plus-P777 (TT2 pre-treatment)","2":"GSM51263","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=29.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/7%/91%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51263"},{"1":"U133Plus-P778 (TT2 pre-treatment)","2":"GSM51264","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51264"},{"1":"U133Plus-P779 (TT2 pre-treatment)","2":"GSM51265","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.92 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/94%/5%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51265"},{"1":"U133Plus-P782 (TT2 pre-treatment)","2":"GSM51266","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.65 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/16%/81%/3% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51266"},{"1":"U133Plus-P783 (TT2 pre-treatment)","2":"GSM51267","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.35 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51267"},{"1":"U133Plus-P789 (TT2 pre-treatment)","2":"GSM51268","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/85%/10% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51268"},{"1":"U133Plus-P797 (TT2 pre-treatment)","2":"GSM51269","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/7%/93% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51269"},{"1":"U133Plus-P798 (TT2 pre-treatment)","2":"GSM51270","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=28.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/10%/80%/10% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51270"},{"1":"U133Plus-P804 (TT2 pre-treatment)","2":"GSM51271","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/4%/93%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51271"},{"1":"U133Plus-P806 (TT2 pre-treatment)","2":"GSM51272","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.45 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/10%/90% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51272"},{"1":"U133Plus-P807 (TT2 pre-treatment)","2":"GSM51273","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/0%/100% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51273"},{"1":"U133Plus-P821 (TT2 pre-treatment)","2":"GSM51274","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51274"},{"1":"U133Plus-P822 (TT2 pre-treatment)","2":"GSM51275","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/96%/3%/1% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51275"},{"1":"U133Plus-P830 (TT2 pre-treatment)","2":"GSM51276","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/1%/99%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51276"},{"1":"U133Plus-P834 (TT2 pre-treatment)","2":"GSM51277","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/88%/6%/6% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51277"},{"1":"U133Plus-P842 (TT2 pre-treatment)","2":"GSM51278","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/77%/19%/4% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51278"},{"1":"U133Plus-P845 (TT2 pre-treatment)","2":"GSM51279","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/10%/30%/60% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51279"},{"1":"U133Plus-P846 (TT2 pre-treatment)","2":"GSM51280","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.62 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/23%/69%/7% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51280"},{"1":"U133Plus-P854 (TT2 pre-treatment)","2":"GSM51281","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51281"},{"1":"U133Plus-P864 (TT2 pre-treatment)","2":"GSM51282","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/94%/3%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51282"},{"1":"U133Plus-P867 (TT2 pre-treatment)","2":"GSM51283","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51283"},{"1":"U133Plus-P868 (TT2 pre-treatment)","2":"GSM51284","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/11%/78%/11% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51284"},{"1":"U133Plus-P871 (TT2 pre-treatment)","2":"GSM51285","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.44 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51285"},{"1":"U133Plus-P875 (TT2 pre-treatment)","2":"GSM51286","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/6%/94%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51286"},{"1":"U133Plus-P877 (TT2 pre-treatment)","2":"GSM51287","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51287"},{"1":"U133Plus-P889 (TT2 pre-treatment)","2":"GSM51288","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/9%/65%/5%/21% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51288"},{"1":"U133Plus-P890 (TT2 pre-treatment)","2":"GSM51289","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/91%/8%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51289"},{"1":"U133Plus-P892 (TT2 pre-treatment)","2":"GSM51290","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51290"},{"1":"U133Plus-P894 (TT2 pre-treatment)","2":"GSM51291","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.42 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/92%/7% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51291"},{"1":"U133Plus-P896 (TT2 pre-treatment)","2":"GSM51292","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51292"},{"1":"U133Plus-P907 (TT2 pre-treatment)","2":"GSM51293","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/3%/71%/26% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51293"},{"1":"U133Plus-P908 (TT2 pre-treatment)","2":"GSM51294","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.45 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51294"},{"1":"U133Plus-P911 (TT2 pre-treatment)","2":"GSM51295","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.24 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51295"},{"1":"U133Plus-P912 (TT2 pre-treatment)","2":"GSM51296","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/95%/5%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51296"},{"1":"U133Plus-P913 (TT2 pre-treatment)","2":"GSM51297","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.11 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/10%/82%/8% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51297"},{"1":"U133Plus-P915 (TT2 pre-treatment)","2":"GSM51298","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/96%/2%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51298"},{"1":"U133Plus-P916 (TT2 pre-treatment)","2":"GSM51299","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51299"},{"1":"U133Plus-P917 (TT2 pre-treatment)","2":"GSM51300","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51300"},{"1":"U133Plus-P918 (TT2 pre-treatment)","2":"GSM51301","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/5%/90%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51301"},{"1":"U133Plus-P919-2 (TT2 pre-treatment)","2":"GSM51302","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=27.92 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51302"},{"1":"U133Plus-P920 (TT2 pre-treatment)","2":"GSM51303","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/21%/60%/16% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51303"},{"1":"U133Plus-P921 (TT2 pre-treatment)","2":"GSM51304","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.75 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51304"},{"1":"U133Plus-P923 (TT2 pre-treatment)","2":"GSM51305","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.01 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51305"},{"1":"U133Plus-P924 (TT2 pre-treatment)","2":"GSM51306","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.81 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51306"},{"1":"U133Plus-P927-3 (TT2 pre-treatment)","2":"GSM51307","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/29%/62%/9% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51307"},{"1":"U133Plus-P930 (TT2 pre-treatment)","2":"GSM51308","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.71 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/0%/0%/100% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51308"},{"1":"U133Plus-P931 (TT2 pre-treatment)","2":"GSM51309","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=25.35 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51309"},{"1":"U133Plus-P934 (TT2 pre-treatment)","2":"GSM51310","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51310"},{"1":"U133Plus-P935-2 (TT2 pre-treatment)","2":"GSM51311","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/80%/1%/16% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51311"},{"1":"U133Plus-P937-2 (TT2 pre-treatment)","2":"GSM51312","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51312"},{"1":"U133Plus-P939-2 (TT2 pre-treatment)","2":"GSM51313","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.59 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/99%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51313"},{"1":"U133Plus-P941-2 (TT2 pre-treatment)","2":"GSM51314","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/52%/23%/25% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51314"},{"1":"U133Plus-P954 (TT2 pre-treatment)","2":"GSM51315","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51315"},{"1":"U133Plus-P955 (TT2 pre-treatment)","2":"GSM51316","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.45 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51316"},{"1":"U133Plus-P957 (TT2 pre-treatment)","2":"GSM51317","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/58%/40%/2% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51317"},{"1":"U133Plus-P958-0 (TT2 pre-treatment)","2":"GSM51318","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/10%/89% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51318"},{"1":"U133Plus-P959-0 (TT2 pre-treatment)","2":"GSM51319","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.68 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51319"},{"1":"U133Plus-P960 (TT2 pre-treatment)","2":"GSM51320","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/26%/58%/13% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51320"},{"1":"U133Plus-P961 (TT2 pre-treatment)","2":"GSM51321","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.12 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51321"},{"1":"U133Plus-P965 (TT2 pre-treatment)","2":"GSM51322","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/15%/78%/5% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51322"},{"1":"U133Plus-P966 (TT2 pre-treatment)","2":"GSM51323","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=24.14 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51323"},{"1":"U133Plus-P967 (TT2 pre-treatment)","2":"GSM51324","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51324"},{"1":"U133Plus-P969 (TT2 pre-treatment)","2":"GSM51325","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=26.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/16%/70%/14% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51325"},{"1":"U133Plus-P971 (TT2 pre-treatment)","2":"GSM51326","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/60%/39% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51326"},{"1":"U133Plus-P972 (TT2 pre-treatment)","2":"GSM51327","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.01 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/87%/12% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51327"},{"1":"U133Plus-P973 (TT2 pre-treatment)","2":"GSM51328","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51328"},{"1":"U133Plus-P975 (TT2 pre-treatment)","2":"GSM51329","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/25%/71%/4% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51329"},{"1":"U133Plus-P976 (TT2 pre-treatment)","2":"GSM51330","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51330"},{"1":"U133Plus-P977 (TT2 pre-treatment)","2":"GSM51331","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.88 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/100%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51331"},{"1":"U133Plus-P978 (TT2 pre-treatment)","2":"GSM51332","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/5%/58%/23%/14% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=3 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51332"},{"1":"U133Plus-P979 (TT2 pre-treatment)","2":"GSM51333","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=22.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/2%/98%/0%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51333"},{"1":"U133Plus-P981 (TT2 pre-treatment)","2":"GSM51334","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=21.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51334"},{"1":"U133Plus-P984 (TT2 pre-treatment)","2":"GSM51335","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=23.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/0%/1%/0%/99% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=4+ copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51335"},{"1":"U133Plus-P986 (TT2 pre-treatment)","2":"GSM51336","3":"Public on Jun 01 2006","4":"May 13 2005","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=0%/3%/96%/1%/0% (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=2 copies (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 5, 2004","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM51336"},{"1":"U133Plus-P1003-2 (TT3 pre-treatment)","2":"GSM95646","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95646"},{"1":"U133Plus-P1010 (TT3 pre-treatment)","2":"GSM95647","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95647"},{"1":"U133Plus-P1011 (TT3 pre-treatment)","2":"GSM95648","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95648"},{"1":"U133Plus-P1013 (TT3 pre-treatment)","2":"GSM95649","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95649"},{"1":"U133Plus-P1016-04 (TT3 pre-treatment)","2":"GSM95650","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95650"},{"1":"U133Plus-P1017 (TT3 pre-treatment)","2":"GSM95651","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95651"},{"1":"U133Plus-P1023 (TT3 pre-treatment)","2":"GSM95652","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95652"},{"1":"U133Plus-P1027-2 (TT3 pre-treatment)","2":"GSM95653","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95653"},{"1":"U133Plus-P1049 (TT3 pre-treatment)","2":"GSM95654","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95654"},{"1":"U133Plus-P1052 (TT3 pre-treatment)","2":"GSM95655","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95655"},{"1":"U133Plus-P1053-2 (TT3 pre-treatment)","2":"GSM95656","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95656"},{"1":"U133Plus-P1055-3 (TT3 pre-treatment)","2":"GSM95657","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95657"},{"1":"U133Plus-P1063 (TT3 pre-treatment)","2":"GSM95658","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95658"},{"1":"U133Plus-P1064 (TT3 pre-treatment)","2":"GSM95659","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95659"},{"1":"U133Plus-P1065 (TT3 pre-treatment)","2":"GSM95660","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=1.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95660"},{"1":"U133Plus-P1066 (TT3 pre-treatment)","2":"GSM95661","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95661"},{"1":"U133Plus-P1067 (TT3 pre-treatment)","2":"GSM95662","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95662"},{"1":"U133Plus-P1068 (TT3 pre-treatment)","2":"GSM95663","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95663"},{"1":"U133Plus-P1070 (TT3 pre-treatment)","2":"GSM95664","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95664"},{"1":"U133Plus-P1077-2 (TT3 pre-treatment)","2":"GSM95665","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95665"},{"1":"U133Plus-P1079-2 (TT3 pre-treatment)","2":"GSM95666","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=13.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95666"},{"1":"U133Plus-P1080-2 (TT3 pre-treatment)","2":"GSM95667","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95667"},{"1":"U133Plus-P1081-2 (TT3 pre-treatment)","2":"GSM95668","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95668"},{"1":"U133Plus-P1086 (TT3 pre-treatment)","2":"GSM95669","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95669"},{"1":"U133Plus-P1088 (TT3 pre-treatment)","2":"GSM95670","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95670"},{"1":"U133Plus-P1092 (TT3 pre-treatment)","2":"GSM95671","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95671"},{"1":"U133Plus-P1093 (TT3 pre-treatment)","2":"GSM95672","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95672"},{"1":"U133Plus-P1094 (TT3 pre-treatment)","2":"GSM95673","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95673"},{"1":"U133Plus-P1100 (TT3 pre-treatment)","2":"GSM95674","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95674"},{"1":"U133Plus-P1101-2 (TT3 pre-treatment)","2":"GSM95675","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95675"},{"1":"U133Plus-P1112 (TT3 pre-treatment)","2":"GSM95676","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95676"},{"1":"U133Plus-P1113 (TT3 pre-treatment)","2":"GSM95677","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95677"},{"1":"U133Plus-P1114 (TT3 pre-treatment)","2":"GSM95678","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=13.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95678"},{"1":"U133Plus-P1116-0 (TT3 pre-treatment)","2":"GSM95679","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95679"},{"1":"U133Plus-P1117-0 (TT3 pre-treatment)","2":"GSM95680","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95680"},{"1":"U133Plus-P1118-0 (TT3 pre-treatment)","2":"GSM95681","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95681"},{"1":"U133Plus-P1119 (TT3 pre-treatment)","2":"GSM95682","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95682"},{"1":"U133Plus-P1120 (TT3 pre-treatment)","2":"GSM95683","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95683"},{"1":"U133Plus-P1121 (TT3 pre-treatment)","2":"GSM95684","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95684"},{"1":"U133Plus-P1122-0 (TT3 pre-treatment)","2":"GSM95685","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95685"},{"1":"U133Plus-P1130-3 (TT3 pre-treatment)","2":"GSM95686","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95686"},{"1":"U133Plus-P1132-3 (TT3 pre-treatment)","2":"GSM95687","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95687"},{"1":"U133Plus-P1138-2 (TT3 pre-treatment)","2":"GSM95688","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95688"},{"1":"U133Plus-P1139 (TT3 pre-treatment)","2":"GSM95689","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95689"},{"1":"U133Plus-P1140 (TT3 pre-treatment)","2":"GSM95690","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95690"},{"1":"U133Plus-P1141 (TT3 pre-treatment)","2":"GSM95691","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95691"},{"1":"U133Plus-P1142 (TT3 pre-treatment)","2":"GSM95692","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95692"},{"1":"U133Plus-P1143 (TT3 pre-treatment)","2":"GSM95693","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=18.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95693"},{"1":"U133Plus-P1144 (TT3 pre-treatment)","2":"GSM95694","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95694"},{"1":"U133Plus-P1145 (TT3 pre-treatment)","2":"GSM95695","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=17.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95695"},{"1":"U133Plus-P1146 (TT3 pre-treatment)","2":"GSM95696","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95696"},{"1":"U133Plus-P1164 (TT3 pre-treatment)","2":"GSM95697","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95697"},{"1":"U133Plus-P1165 (TT3 pre-treatment)","2":"GSM95698","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95698"},{"1":"U133Plus-P1166 (TT3 pre-treatment)","2":"GSM95699","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95699"},{"1":"U133Plus-P1167 (TT3 pre-treatment)","2":"GSM95700","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95700"},{"1":"U133Plus-P1169 (TT3 pre-treatment)","2":"GSM95701","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95701"},{"1":"U133Plus-P1173 (TT3 pre-treatment)","2":"GSM95702","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95702"},{"1":"U133Plus-P1176 (TT3 pre-treatment)","2":"GSM95703","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95703"},{"1":"U133Plus-P1177 (TT3 pre-treatment)","2":"GSM95704","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95704"},{"1":"U133Plus-P1178 (TT3 pre-treatment)","2":"GSM95705","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95705"},{"1":"U133Plus-P1181 (TT3 pre-treatment)","2":"GSM95706","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95706"},{"1":"U133Plus-P1182 (TT3 pre-treatment)","2":"GSM95707","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95707"},{"1":"U133Plus-P1183 (TT3 pre-treatment)","2":"GSM95708","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95708"},{"1":"U133Plus-P1184 (TT3 pre-treatment)","2":"GSM95709","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95709"},{"1":"U133Plus-P1185 (TT3 pre-treatment)","2":"GSM95710","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95710"},{"1":"U133Plus-P1186 (TT3 pre-treatment)","2":"GSM95711","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95711"},{"1":"U133Plus-P1187 (TT3 pre-treatment)","2":"GSM95712","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95712"},{"1":"U133Plus-P1188 (TT3 pre-treatment)","2":"GSM95713","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95713"},{"1":"U133Plus-P1189 (TT3 pre-treatment)","2":"GSM95714","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95714"},{"1":"U133Plus-P1190 (TT3 pre-treatment)","2":"GSM95715","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95715"},{"1":"U133Plus-P1191 (TT3 pre-treatment)","2":"GSM95716","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=13.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95716"},{"1":"U133Plus-P1195 (TT3 pre-treatment)","2":"GSM95717","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95717"},{"1":"U133Plus-P1196 (TT3 pre-treatment)","2":"GSM95718","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95718"},{"1":"U133Plus-P1201 (TT3 pre-treatment)","2":"GSM95719","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95719"},{"1":"U133Plus-P1223-02 (TT3 pre-treatment)","2":"GSM95720","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95720"},{"1":"U133Plus-P1224 (TT3 pre-treatment)","2":"GSM95721","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95721"},{"1":"U133Plus-P1225 (TT3 pre-treatment)","2":"GSM95722","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95722"},{"1":"U133Plus-P1228 (TT3 pre-treatment)","2":"GSM95723","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95723"},{"1":"U133Plus-P1231 (TT3 pre-treatment)","2":"GSM95724","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95724"},{"1":"U133Plus-P1232 (TT3 pre-treatment)","2":"GSM95725","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=15.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95725"},{"1":"U133Plus-P1235 (TT3 pre-treatment)","2":"GSM95726","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95726"},{"1":"U133Plus-P1236 (TT3 pre-treatment)","2":"GSM95727","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95727"},{"1":"U133Plus-P1239 (TT3 pre-treatment)","2":"GSM95728","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95728"},{"1":"U133Plus-P1248 (TT3 pre-treatment)","2":"GSM95729","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=14.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95729"},{"1":"U133Plus-P1259 (TT3 pre-treatment)","2":"GSM95730","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=13.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95730"},{"1":"U133Plus-P1263 (TT3 pre-treatment)","2":"GSM95731","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=13.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95731"},{"1":"U133Plus-P1271 (TT3 pre-treatment)","2":"GSM95732","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=13.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95732"},{"1":"U133Plus-P1282-01 (TT3 pre-treatment)","2":"GSM95733","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95733"},{"1":"U133Plus-P1283-01 (TT3 pre-treatment)","2":"GSM95734","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95734"},{"1":"U133Plus-P1291-02 (TT3 pre-treatment)","2":"GSM95735","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95735"},{"1":"U133Plus-P1295-01 (TT3 pre-treatment)","2":"GSM95736","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95736"},{"1":"U133Plus-P1296-00 (TT3 pre-treatment)","2":"GSM95737","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95737"},{"1":"U133Plus-P1305-01 (TT3 pre-treatment)","2":"GSM95738","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95738"},{"1":"U133Plus-P1307-01 (TT3 pre-treatment)","2":"GSM95739","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95739"},{"1":"U133Plus-P1308-01 (TT3 pre-treatment)","2":"GSM95740","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95740"},{"1":"U133Plus-P1309-01 (TT3 pre-treatment)","2":"GSM95741","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95741"},{"1":"U133Plus-P1312-02 (TT3 pre-treatment)","2":"GSM95742","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95742"},{"1":"U133Plus-P1313-02 (TT3 pre-treatment)","2":"GSM95743","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95743"},{"1":"U133Plus-P1314-00 (TT3 pre-treatment)","2":"GSM95744","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95744"},{"1":"U133Plus-P1316-00 (TT3 pre-treatment)","2":"GSM95745","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95745"},{"1":"U133Plus-P1320-01 (TT3 pre-treatment)","2":"GSM95746","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95746"},{"1":"U133Plus-P1321-00 (TT3 pre-treatment)","2":"GSM95747","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=12.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95747"},{"1":"U133Plus-P1323-01 (TT3 pre-treatment)","2":"GSM95748","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95748"},{"1":"U133Plus-P1331-02 (TT3 pre-treatment)","2":"GSM95749","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95749"},{"1":"U133Plus-P1336-02 (TT3 pre-treatment)","2":"GSM95750","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95750"},{"1":"U133Plus-P1337-01 (TT3 pre-treatment)","2":"GSM95751","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95751"},{"1":"U133Plus-P1338-01 (TT3 pre-treatment)","2":"GSM95752","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95752"},{"1":"U133Plus-P1339-01 (TT3 pre-treatment)","2":"GSM95753","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95753"},{"1":"U133Plus-P1341-01 (TT3 pre-treatment)","2":"GSM95754","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95754"},{"1":"U133Plus-P1350-01 (TT3 pre-treatment)","2":"GSM95755","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95755"},{"1":"U133Plus-P1354-01 (TT3 pre-treatment)","2":"GSM95756","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95756"},{"1":"U133Plus-P1359-01 (TT3 pre-treatment)","2":"GSM95757","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95757"},{"1":"U133Plus-P1361-01 (TT3 pre-treatment)","2":"GSM95758","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95758"},{"1":"U133Plus-P1362-01 (TT3 pre-treatment)","2":"GSM95759","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95759"},{"1":"U133Plus-P1363-01 (TT3 pre-treatment)","2":"GSM95760","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95760"},{"1":"U133Plus-P1364-01 (TT3 pre-treatment)","2":"GSM95761","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95761"},{"1":"U133Plus-P1365-01 (TT3 pre-treatment)","2":"GSM95762","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95762"},{"1":"U133Plus-P1366-01 (TT3 pre-treatment)","2":"GSM95763","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95763"},{"1":"U133Plus-P1367-01 (TT3 pre-treatment)","2":"GSM95764","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=10.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95764"},{"1":"U133Plus-P1368-01 (TT3 pre-treatment)","2":"GSM95765","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95765"},{"1":"U133Plus-P1371-01 (TT3 pre-treatment)","2":"GSM95766","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95766"},{"1":"U133Plus-P1372-01 (TT3 pre-treatment)","2":"GSM95767","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95767"},{"1":"U133Plus-P1374-01 (TT3 pre-treatment)","2":"GSM95768","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95768"},{"1":"U133Plus-P1375-01 (TT3 pre-treatment)","2":"GSM95769","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=11.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95769"},{"1":"U133Plus-P1383-01 (TT3 pre-treatment)","2":"GSM95770","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95770"},{"1":"U133Plus-P1384-01 (TT3 pre-treatment)","2":"GSM95771","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95771"},{"1":"U133Plus-P1389-00 (TT3 pre-treatment)","2":"GSM95772","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95772"},{"1":"U133Plus-P1390-00 (TT3 pre-treatment)","2":"GSM95773","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95773"},{"1":"U133Plus-P1391-00 (TT3 pre-treatment)","2":"GSM95774","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95774"},{"1":"U133Plus-P1400-01 (TT3 pre-treatment)","2":"GSM95775","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95775"},{"1":"U133Plus-P1401-01 (TT3 pre-treatment)","2":"GSM95776","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95776"},{"1":"U133Plus-P1402-01 (TT3 pre-treatment)","2":"GSM95777","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95777"},{"1":"U133Plus-P1403-01 (TT3 pre-treatment)","2":"GSM95778","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95778"},{"1":"U133Plus-P1405-01 (TT3 pre-treatment)","2":"GSM95779","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95779"},{"1":"U133Plus-P1407-01 (TT3 pre-treatment)","2":"GSM95780","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95780"},{"1":"U133Plus-P1408-01 (TT3 pre-treatment)","2":"GSM95781","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95781"},{"1":"U133Plus-P1409-01 (TT3 pre-treatment)","2":"GSM95782","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=8.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95782"},{"1":"U133Plus-P1412-01 (TT3 pre-treatment)","2":"GSM95783","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95783"},{"1":"U133Plus-P1424-02 (TT3 pre-treatment)","2":"GSM95784","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95784"},{"1":"U133Plus-P1432-01 (TT3 pre-treatment)","2":"GSM95785","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95785"},{"1":"U133Plus-P1434-01 (TT3 pre-treatment)","2":"GSM95786","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95786"},{"1":"U133Plus-P1437-01 (TT3 pre-treatment)","2":"GSM95787","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95787"},{"1":"U133Plus-P1438-01 (TT3 pre-treatment)","2":"GSM95788","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95788"},{"1":"U133Plus-P1439-01 (TT3 pre-treatment)","2":"GSM95789","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95789"},{"1":"U133Plus-P1441-01 (TT3 pre-treatment)","2":"GSM95790","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95790"},{"1":"U133Plus-P1442-01 (TT3 pre-treatment)","2":"GSM95791","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95791"},{"1":"U133Plus-P1443-01 (TT3 pre-treatment)","2":"GSM95792","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95792"},{"1":"U133Plus-P1444-01 (TT3 pre-treatment)","2":"GSM95793","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95793"},{"1":"U133Plus-P1445-01 (TT3 pre-treatment)","2":"GSM95794","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95794"},{"1":"U133Plus-P1446-01 (TT3 pre-treatment)","2":"GSM95795","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95795"},{"1":"U133Plus-P1447-01 (TT3 pre-treatment)","2":"GSM95796","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95796"},{"1":"U133Plus-P1448-01 (TT3 pre-treatment)","2":"GSM95797","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95797"},{"1":"U133Plus-P1450-01 (TT3 pre-treatment)","2":"GSM95798","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95798"},{"1":"U133Plus-P1451-01 (TT3 pre-treatment)","2":"GSM95799","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95799"},{"1":"U133Plus-P1453-01 (TT3 pre-treatment)","2":"GSM95800","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95800"},{"1":"U133Plus-P1454-01 (TT3 pre-treatment)","2":"GSM95801","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95801"},{"1":"U133Plus-P1455-01 (TT3 pre-treatment)","2":"GSM95802","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95802"},{"1":"U133Plus-P1456-01 (TT3 pre-treatment)","2":"GSM95803","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95803"},{"1":"U133Plus-P1458-01 (TT3 pre-treatment)","2":"GSM95804","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95804"},{"1":"U133Plus-P1463-01 (TT3 pre-treatment)","2":"GSM95805","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95805"},{"1":"U133Plus-P1465-01 (TT3 pre-treatment)","2":"GSM95806","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95806"},{"1":"U133Plus-P1477-01 (TT3 pre-treatment)","2":"GSM95807","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95807"},{"1":"U133Plus-P1480-01 (TT3 pre-treatment)","2":"GSM95808","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95808"},{"1":"U133Plus-P1492-01 (TT3 pre-treatment)","2":"GSM95809","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95809"},{"1":"U133Plus-P1502-01 (TT3 pre-treatment)","2":"GSM95810","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95810"},{"1":"U133Plus-P1507-01 (TT3 pre-treatment)","2":"GSM95811","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95811"},{"1":"U133Plus-P1509-01 (TT3 pre-treatment)","2":"GSM95812","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=0.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95812"},{"1":"U133Plus-P1529-01 (TT3 pre-treatment)","2":"GSM95813","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95813"},{"1":"U133Plus-P1550-01 (TT3 pre-treatment)","2":"GSM95814","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95814"},{"1":"U133Plus-P1558-02 (TT3 pre-treatment)","2":"GSM95815","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95815"},{"1":"U133Plus-P1562-01 (TT3 pre-treatment)","2":"GSM95816","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95816"},{"1":"U133Plus-P1569-01 (TT3 pre-treatment)","2":"GSM95817","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=0.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95817"},{"1":"U133Plus-P1571-01 (TT3 pre-treatment)","2":"GSM95818","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95818"},{"1":"U133Plus-P1579-01 (TT3 pre-treatment)","2":"GSM95819","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=1.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95819"},{"1":"U133Plus-P521-2 (TT3 pre-treatment)","2":"GSM95820","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95820"},{"1":"U133Plus-P675-2 (TT3 pre-treatment)","2":"GSM95821","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=16.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95821"},{"1":"U133Plus-P990-2 (TT3 pre-treatment)","2":"GSM95822","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95822"},{"1":"U133Plus-P993-0 (TT3 pre-treatment)","2":"GSM95823","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95823"},{"1":"U133Plus-P995-2 (TT3 pre-treatment)","2":"GSM95824","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95824"},{"1":"U133Plus-P996-4 (TT3 pre-treatment)","2":"GSM95825","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=20.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95825"},{"1":"U133Plus-P997-2 (TT3 pre-treatment)","2":"GSM95826","3":"Public on Jun 01 2006","4":"Feb 06 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=19.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[CONTAMIND=1 (Indicator of myeloid cell and normal plasma cell contamination; integer, 0=NO, 1=YES, na=Not Available)]","19":"","20":"[Subgrp7=MY]","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"Keywords = CKS1B in Multiple Myeloma","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54674","_rn_":"GSM95826"},{"1":"U133Plus-P1503-01 (TT3 pre-treatment)","2":"GSM102606","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=1.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102606"},{"1":"U133Plus-P1589-01 (TT3 pre-treatment)","2":"GSM102607","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=9.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD1]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102607"},{"1":"U133Plus-P1591-01 (TT3 pre-treatment)","2":"GSM102609","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=7.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102609"},{"1":"U133Plus-P1580-01 (TT3 pre-treatment)","2":"GSM102610","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102610"},{"1":"U133Plus-P1593-01 (TT3 pre-treatment)","2":"GSM102611","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102611"},{"1":"U133Plus-P1586-01 (TT3 pre-treatment)","2":"GSM102612","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102612"},{"1":"U133Plus-P1594-01 (TT3 pre-treatment)","2":"GSM102613","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102613"},{"1":"U133Plus-P1596-01 (TT3 pre-treatment)","2":"GSM102614","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102614"},{"1":"U133Plus-P1597-01 (TT3 pre-treatment)","2":"GSM102615","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=PR]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102615"},{"1":"U133Plus-P1581-01 (TT3 pre-treatment)","2":"GSM102616","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=6.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102616"},{"1":"U133Plus-P1583-01 (TT3 pre-treatment)","2":"GSM102617","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102617"},{"1":"U133Plus-P1599-01 (TT3 pre-treatment)","2":"GSM102618","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102618"},{"1":"U133Plus-P1600-01 (TT3 pre-treatment)","2":"GSM102620","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=5.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102620"},{"1":"U133Plus-P1601-01 (TT3 pre-treatment)","2":"GSM102621","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102621"},{"1":"U133Plus-P1587-01 (TT3 pre-treatment)","2":"GSM102622","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MF]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102622"},{"1":"U133Plus-P1602-01 (TT3 pre-treatment)","2":"GSM102623","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102623"},{"1":"U133Plus-P1603-01 (TT3 pre-treatment)","2":"GSM102624","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102624"},{"1":"U133Plus-P1604-01 (TT3 pre-treatment)","2":"GSM102625","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102625"},{"1":"U133Plus-P1605-01 (TT3 pre-treatment)","2":"GSM102626","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102626"},{"1":"U133Plus-P1606-01 (TT3 pre-treatment)","2":"GSM102627","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=4.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102627"},{"1":"U133Plus-P1635-01 (TT3 pre-treatment)","2":"GSM102628","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102628"},{"1":"U133Plus-P1614-01 (TT3 pre-treatment)","2":"GSM102629","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102629"},{"1":"U133Plus-P1622-01 (TT3 pre-treatment)","2":"GSM102630","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102630"},{"1":"U133Plus-P1618-01 (TT3 pre-treatment)","2":"GSM102631","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=3.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=CD2]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102631"},{"1":"U133Plus-P1646-01 (TT3 pre-treatment)","2":"GSM102632","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=MS]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102632"},{"1":"U133Plus-P1645-01 (TT3 pre-treatment)","2":"GSM102633","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=2.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=LB]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102633"},{"1":"U133Plus-P1639-01 (TT3 pre-treatment)","2":"GSM102634","3":"Public on Jun 01 2006","4":"Mar 30 2006","5":"Apr 01 2010","6":"RNA","7":"1","8":"pre-treatment bone marrow","9":"Homo sapiens","10":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","11":"","12":"[SURTIM=0.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","13":"","14":"[PCTCELLS=na/na/na/na/na (Percentage of cells with 0 copy/1 copy/2 copies/3 copies/4+ copies; percentage, na=not available)]","15":"","16":"[AMPIND=na (Indicator of FISH 1q21 Amplification; string, na=not available)]","17":"","18":"[Subgrp7=HY]","19":"","20":"","21":"","22":"total RNA","23":"Total RNA was isolated with RNeasy Mini Kit (Qiagen, Valencia, CA).","24":"biotin","25":"As recommended by manufacturer","26":"9606","27":"As recommended by manufacturer","28":"As recommended by manufacturer","29":"Following Ficoll-Hypaque gradient centrifugation, plasma cells obtained from the bone marrow were isolated from the mononuclear cell fraction by immunomagnetic bead selection using a monoclonal mouse anti-human CD138 antibody (Miltenyi-Biotec, Auburn, CA)","30":"More than 90 percent of the cells used for gene expression profiling were plasma cells, as shown by two-color flow cytometry using CD138+/CD45- and CD38+/CD45- markers, the presence of cytoplasmic immunoglobulin light chains by immunocytochemistry, and morphology by Wright-Giemsa staining","31":"The clinic survival follow-up is through November 07, 2005","32":"Disease-related survival: Deaths were coded as disease-related according to a physician chart review. Three deaths had not been coded as of the time of the analysis and these corresponding to the three missing status indicators in the data set. Non-disease related deaths are competing risks, so distribution estimates should use cumulative incidence of disease-related death as the outcome, rather than survival","33":"Censored data analysis: Analyses using the status indicator as a grouping variable directly are not recommended. Tests for censored data can be applied, gene-by-gene, as in the published analysis, or disease-related deaths can be matched to a random sample of longer survivors","34":"","35":"All data used in these analyses were derived with the Affymetrix Microarray Suite GCOS1.1 software.","36":"","37":"CEL files are available upon request via a Materials Transfer Agreement. Please contact Dr. John Shaughnessy  for details.","38":"","39":"GPL570","40":"Shaughnessy,Jr.,John","41":"shaughnessyjohn@uams.edu","42":"(501)296-1503 1410","43":"Donna D. and Donald M. Lambert Laboratory of Myeloma Genetics","44":"","45":"Myeloma Institute for Research and Therapy","46":"4301 West Markham St., Slot 776","47":"Little Rock","48":"AR","49":"72205","50":"USA","51":"NONE","52":"54675","_rn_":"GSM102634"}],"options":{"columns":{"min":{},"max":[10],"total":[52]},"rows":{"min":[10],"max":[10],"total":[559]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>get out expression matrix</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHBycyA8LSBleHBycyhnc2UyNjU4X2xjKVxuZGltKGdzZTI2NThfZXhwcnMpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs &lt;- exprs(gse2658_lc)
dim(gse2658_exprs)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDU0Njc1ICAgNTU5XG4ifQ== -->
<pre><code>[1] 54675   559</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc1sxOjEwLDE6MTBdXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs[1:10,1:10]</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>          GSM50986 GSM50987 GSM50988 GSM50989 GSM50990 GSM50991 GSM50992 GSM50993 GSM50994 GSM50995
1007_s_at    311.7    527.1    196.3    791.6   1155.0    838.1   1162.0    709.1    431.8   1473.7
1053_at      421.0    468.9    335.6    334.1    571.5    416.7    376.9    376.0    431.9    354.5
117_at       315.7    351.2    277.9    959.6    249.9    662.9    266.8    200.1    364.6    149.2
121_at      3720.2   2371.1   2097.2   4262.2   2171.6   3902.2   3203.3   2690.0   2807.0   2854.0
1255_g_at     25.8     52.1     55.8     34.8     32.4     18.9    125.4     92.6    140.7     72.7
1294_at      924.5   1198.1    771.5   1528.2    438.5    624.8   1551.9   1338.2    754.3   1595.6
1316_at      300.3    246.3    111.8    286.5    281.5    232.3     90.0    160.2    200.8    208.8
1320_at       28.7     25.0     17.0     40.1     12.3     25.5     18.0     17.3     14.7     21.7
1405_i_at    189.8     72.6    277.9     49.9    212.8     76.0     12.7     36.8     48.2     60.6
1431_at      341.7    135.8    159.6    205.5    198.7    177.9    142.6    458.4    227.7    278.1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHBycyA8LSBkYXRhLmZyYW1lKGdzZTI2NThfZXhwcnMpICU+JSB0aWJibGU6OnJvd25hbWVzX3RvX2NvbHVtbih2YXI9XCJwcm9iZVwiKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs &lt;- data.frame(gse2658_exprs) %&gt;% tibble::rownames_to_column(var=&quot;probe&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>there is one row with many NAs</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc1t3aGljaChyb3dTdW1zKGlzLm5hKGdzZTI2NThfZXhwcnMpKT4wKSxdIFxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs[which(rowSums(is.na(gse2658_exprs))&gt;0),] </code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["probe"],"name":[1],"type":["chr"],"align":["left"]},{"label":["GSM50986"],"name":[2],"type":["dbl"],"align":["right"]},{"label":["GSM50987"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["GSM50988"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["GSM50989"],"name":[5],"type":["dbl"],"align":["right"]},{"label":["GSM50990"],"name":[6],"type":["dbl"],"align":["right"]},{"label":["GSM50991"],"name":[7],"type":["dbl"],"align":["right"]},{"label":["GSM50992"],"name":[8],"type":["dbl"],"align":["right"]},{"label":["GSM50993"],"name":[9],"type":["dbl"],"align":["right"]},{"label":["GSM50994"],"name":[10],"type":["dbl"],"align":["right"]},{"label":["GSM50995"],"name":[11],"type":["dbl"],"align":["right"]},{"label":["GSM50996"],"name":[12],"type":["dbl"],"align":["right"]},{"label":["GSM50997"],"name":[13],"type":["dbl"],"align":["right"]},{"label":["GSM50998"],"name":[14],"type":["dbl"],"align":["right"]},{"label":["GSM50999"],"name":[15],"type":["dbl"],"align":["right"]},{"label":["GSM51000"],"name":[16],"type":["dbl"],"align":["right"]},{"label":["GSM51001"],"name":[17],"type":["dbl"],"align":["right"]},{"label":["GSM51002"],"name":[18],"type":["dbl"],"align":["right"]},{"label":["GSM51003"],"name":[19],"type":["dbl"],"align":["right"]},{"label":["GSM51004"],"name":[20],"type":["dbl"],"align":["right"]},{"label":["GSM51005"],"name":[21],"type":["dbl"],"align":["right"]},{"label":["GSM51006"],"name":[22],"type":["dbl"],"align":["right"]},{"label":["GSM51007"],"name":[23],"type":["dbl"],"align":["right"]},{"label":["GSM51008"],"name":[24],"type":["dbl"],"align":["right"]},{"label":["GSM51009"],"name":[25],"type":["dbl"],"align":["right"]},{"label":["GSM51010"],"name":[26],"type":["dbl"],"align":["right"]},{"label":["GSM51011"],"name":[27],"type":["dbl"],"align":["right"]},{"label":["GSM51012"],"name":[28],"type":["dbl"],"align":["right"]},{"label":["GSM51013"],"name":[29],"type":["dbl"],"align":["right"]},{"label":["GSM51014"],"name":[30],"type":["dbl"],"align":["right"]},{"label":["GSM51015"],"name":[31],"type":["dbl"],"align":["right"]},{"label":["GSM51016"],"name":[32],"type":["dbl"],"align":["right"]},{"label":["GSM51017"],"name":[33],"type":["dbl"],"align":["right"]},{"label":["GSM51018"],"name":[34],"type":["dbl"],"align":["right"]},{"label":["GSM51019"],"name":[35],"type":["dbl"],"align":["right"]},{"label":["GSM51020"],"name":[36],"type":["dbl"],"align":["right"]},{"label":["GSM51021"],"name":[37],"type":["dbl"],"align":["right"]},{"label":["GSM51022"],"name":[38],"type":["dbl"],"align":["right"]},{"label":["GSM51023"],"name":[39],"type":["dbl"],"align":["right"]},{"label":["GSM51024"],"name":[40],"type":["dbl"],"align":["right"]},{"label":["GSM51025"],"name":[41],"type":["dbl"],"align":["right"]},{"label":["GSM51026"],"name":[42],"type":["dbl"],"align":["right"]},{"label":["GSM51027"],"name":[43],"type":["dbl"],"align":["right"]},{"label":["GSM51028"],"name":[44],"type":["dbl"],"align":["right"]},{"label":["GSM51029"],"name":[45],"type":["dbl"],"align":["right"]},{"label":["GSM51030"],"name":[46],"type":["dbl"],"align":["right"]},{"label":["GSM51031"],"name":[47],"type":["dbl"],"align":["right"]},{"label":["GSM51032"],"name":[48],"type":["dbl"],"align":["right"]},{"label":["GSM51033"],"name":[49],"type":["dbl"],"align":["right"]},{"label":["GSM51034"],"name":[50],"type":["dbl"],"align":["right"]},{"label":["GSM51035"],"name":[51],"type":["dbl"],"align":["right"]},{"label":["GSM51036"],"name":[52],"type":["dbl"],"align":["right"]},{"label":["GSM51037"],"name":[53],"type":["dbl"],"align":["right"]},{"label":["GSM51038"],"name":[54],"type":["dbl"],"align":["right"]},{"label":["GSM51039"],"name":[55],"type":["dbl"],"align":["right"]},{"label":["GSM51040"],"name":[56],"type":["dbl"],"align":["right"]},{"label":["GSM51041"],"name":[57],"type":["dbl"],"align":["right"]},{"label":["GSM51042"],"name":[58],"type":["dbl"],"align":["right"]},{"label":["GSM51043"],"name":[59],"type":["dbl"],"align":["right"]},{"label":["GSM51044"],"name":[60],"type":["dbl"],"align":["right"]},{"label":["GSM51045"],"name":[61],"type":["dbl"],"align":["right"]},{"label":["GSM51046"],"name":[62],"type":["dbl"],"align":["right"]},{"label":["GSM51047"],"name":[63],"type":["dbl"],"align":["right"]},{"label":["GSM51048"],"name":[64],"type":["dbl"],"align":["right"]},{"label":["GSM51049"],"name":[65],"type":["dbl"],"align":["right"]},{"label":["GSM51050"],"name":[66],"type":["dbl"],"align":["right"]},{"label":["GSM51051"],"name":[67],"type":["dbl"],"align":["right"]},{"label":["GSM51052"],"name":[68],"type":["dbl"],"align":["right"]},{"label":["GSM51053"],"name":[69],"type":["dbl"],"align":["right"]},{"label":["GSM51054"],"name":[70],"type":["dbl"],"align":["right"]},{"label":["GSM51055"],"name":[71],"type":["dbl"],"align":["right"]},{"label":["GSM51056"],"name":[72],"type":["dbl"],"align":["right"]},{"label":["GSM51057"],"name":[73],"type":["dbl"],"align":["right"]},{"label":["GSM51058"],"name":[74],"type":["dbl"],"align":["right"]},{"label":["GSM51059"],"name":[75],"type":["dbl"],"align":["right"]},{"label":["GSM51060"],"name":[76],"type":["dbl"],"align":["right"]},{"label":["GSM51061"],"name":[77],"type":["dbl"],"align":["right"]},{"label":["GSM51062"],"name":[78],"type":["dbl"],"align":["right"]},{"label":["GSM51063"],"name":[79],"type":["dbl"],"align":["right"]},{"label":["GSM51064"],"name":[80],"type":["dbl"],"align":["right"]},{"label":["GSM51065"],"name":[81],"type":["dbl"],"align":["right"]},{"label":["GSM51066"],"name":[82],"type":["dbl"],"align":["right"]},{"label":["GSM51067"],"name":[83],"type":["dbl"],"align":["right"]},{"label":["GSM51068"],"name":[84],"type":["dbl"],"align":["right"]},{"label":["GSM51069"],"name":[85],"type":["dbl"],"align":["right"]},{"label":["GSM51070"],"name":[86],"type":["dbl"],"align":["right"]},{"label":["GSM51071"],"name":[87],"type":["dbl"],"align":["right"]},{"label":["GSM51072"],"name":[88],"type":["dbl"],"align":["right"]},{"label":["GSM51073"],"name":[89],"type":["dbl"],"align":["right"]},{"label":["GSM51074"],"name":[90],"type":["dbl"],"align":["right"]},{"label":["GSM51075"],"name":[91],"type":["dbl"],"align":["right"]},{"label":["GSM51076"],"name":[92],"type":["dbl"],"align":["right"]},{"label":["GSM51077"],"name":[93],"type":["dbl"],"align":["right"]},{"label":["GSM51078"],"name":[94],"type":["dbl"],"align":["right"]},{"label":["GSM51079"],"name":[95],"type":["dbl"],"align":["right"]},{"label":["GSM51080"],"name":[96],"type":["dbl"],"align":["right"]},{"label":["GSM51081"],"name":[97],"type":["dbl"],"align":["right"]},{"label":["GSM51082"],"name":[98],"type":["dbl"],"align":["right"]},{"label":["GSM51083"],"name":[99],"type":["dbl"],"align":["right"]},{"label":["GSM51084"],"name":[100],"type":["dbl"],"align":["right"]},{"label":["GSM51085"],"name":[101],"type":["dbl"],"align":["right"]},{"label":["GSM51086"],"name":[102],"type":["dbl"],"align":["right"]},{"label":["GSM51087"],"name":[103],"type":["dbl"],"align":["right"]},{"label":["GSM51088"],"name":[104],"type":["dbl"],"align":["right"]},{"label":["GSM51089"],"name":[105],"type":["dbl"],"align":["right"]},{"label":["GSM51090"],"name":[106],"type":["dbl"],"align":["right"]},{"label":["GSM51091"],"name":[107],"type":["dbl"],"align":["right"]},{"label":["GSM51092"],"name":[108],"type":["dbl"],"align":["right"]},{"label":["GSM51093"],"name":[109],"type":["dbl"],"align":["right"]},{"label":["GSM51094"],"name":[110],"type":["dbl"],"align":["right"]},{"label":["GSM51095"],"name":[111],"type":["dbl"],"align":["right"]},{"label":["GSM51096"],"name":[112],"type":["dbl"],"align":["right"]},{"label":["GSM51097"],"name":[113],"type":["dbl"],"align":["right"]},{"label":["GSM51098"],"name":[114],"type":["dbl"],"align":["right"]},{"label":["GSM51099"],"name":[115],"type":["dbl"],"align":["right"]},{"label":["GSM51100"],"name":[116],"type":["dbl"],"align":["right"]},{"label":["GSM51101"],"name":[117],"type":["dbl"],"align":["right"]},{"label":["GSM51102"],"name":[118],"type":["dbl"],"align":["right"]},{"label":["GSM51103"],"name":[119],"type":["dbl"],"align":["right"]},{"label":["GSM51104"],"name":[120],"type":["dbl"],"align":["right"]},{"label":["GSM51105"],"name":[121],"type":["dbl"],"align":["right"]},{"label":["GSM51106"],"name":[122],"type":["dbl"],"align":["right"]},{"label":["GSM51107"],"name":[123],"type":["dbl"],"align":["right"]},{"label":["GSM51108"],"name":[124],"type":["dbl"],"align":["right"]},{"label":["GSM51109"],"name":[125],"type":["dbl"],"align":["right"]},{"label":["GSM51110"],"name":[126],"type":["dbl"],"align":["right"]},{"label":["GSM51111"],"name":[127],"type":["dbl"],"align":["right"]},{"label":["GSM51112"],"name":[128],"type":["dbl"],"align":["right"]},{"label":["GSM51113"],"name":[129],"type":["dbl"],"align":["right"]},{"label":["GSM51114"],"name":[130],"type":["dbl"],"align":["right"]},{"label":["GSM51115"],"name":[131],"type":["dbl"],"align":["right"]},{"label":["GSM51116"],"name":[132],"type":["dbl"],"align":["right"]},{"label":["GSM51117"],"name":[133],"type":["dbl"],"align":["right"]},{"label":["GSM51118"],"name":[134],"type":["dbl"],"align":["right"]},{"label":["GSM51119"],"name":[135],"type":["dbl"],"align":["right"]},{"label":["GSM51120"],"name":[136],"type":["dbl"],"align":["right"]},{"label":["GSM51121"],"name":[137],"type":["dbl"],"align":["right"]},{"label":["GSM51122"],"name":[138],"type":["dbl"],"align":["right"]},{"label":["GSM51123"],"name":[139],"type":["dbl"],"align":["right"]},{"label":["GSM51124"],"name":[140],"type":["dbl"],"align":["right"]},{"label":["GSM51125"],"name":[141],"type":["dbl"],"align":["right"]},{"label":["GSM51126"],"name":[142],"type":["dbl"],"align":["right"]},{"label":["GSM51127"],"name":[143],"type":["dbl"],"align":["right"]},{"label":["GSM51128"],"name":[144],"type":["dbl"],"align":["right"]},{"label":["GSM51129"],"name":[145],"type":["dbl"],"align":["right"]},{"label":["GSM51130"],"name":[146],"type":["dbl"],"align":["right"]},{"label":["GSM51131"],"name":[147],"type":["dbl"],"align":["right"]},{"label":["GSM51132"],"name":[148],"type":["dbl"],"align":["right"]},{"label":["GSM51133"],"name":[149],"type":["dbl"],"align":["right"]},{"label":["GSM51134"],"name":[150],"type":["dbl"],"align":["right"]},{"label":["GSM51135"],"name":[151],"type":["dbl"],"align":["right"]},{"label":["GSM51136"],"name":[152],"type":["dbl"],"align":["right"]},{"label":["GSM51137"],"name":[153],"type":["dbl"],"align":["right"]},{"label":["GSM51138"],"name":[154],"type":["dbl"],"align":["right"]},{"label":["GSM51139"],"name":[155],"type":["dbl"],"align":["right"]},{"label":["GSM51140"],"name":[156],"type":["dbl"],"align":["right"]},{"label":["GSM51141"],"name":[157],"type":["dbl"],"align":["right"]},{"label":["GSM51142"],"name":[158],"type":["dbl"],"align":["right"]},{"label":["GSM51143"],"name":[159],"type":["dbl"],"align":["right"]},{"label":["GSM51144"],"name":[160],"type":["dbl"],"align":["right"]},{"label":["GSM51145"],"name":[161],"type":["dbl"],"align":["right"]},{"label":["GSM51146"],"name":[162],"type":["dbl"],"align":["right"]},{"label":["GSM51147"],"name":[163],"type":["dbl"],"align":["right"]},{"label":["GSM51148"],"name":[164],"type":["dbl"],"align":["right"]},{"label":["GSM51149"],"name":[165],"type":["dbl"],"align":["right"]},{"label":["GSM51150"],"name":[166],"type":["dbl"],"align":["right"]},{"label":["GSM51151"],"name":[167],"type":["dbl"],"align":["right"]},{"label":["GSM51152"],"name":[168],"type":["dbl"],"align":["right"]},{"label":["GSM51153"],"name":[169],"type":["dbl"],"align":["right"]},{"label":["GSM51154"],"name":[170],"type":["dbl"],"align":["right"]},{"label":["GSM51155"],"name":[171],"type":["dbl"],"align":["right"]},{"label":["GSM51156"],"name":[172],"type":["dbl"],"align":["right"]},{"label":["GSM51157"],"name":[173],"type":["dbl"],"align":["right"]},{"label":["GSM51158"],"name":[174],"type":["dbl"],"align":["right"]},{"label":["GSM51159"],"name":[175],"type":["dbl"],"align":["right"]},{"label":["GSM51160"],"name":[176],"type":["dbl"],"align":["right"]},{"label":["GSM51161"],"name":[177],"type":["dbl"],"align":["right"]},{"label":["GSM51162"],"name":[178],"type":["dbl"],"align":["right"]},{"label":["GSM51163"],"name":[179],"type":["dbl"],"align":["right"]},{"label":["GSM51164"],"name":[180],"type":["dbl"],"align":["right"]},{"label":["GSM51165"],"name":[181],"type":["dbl"],"align":["right"]},{"label":["GSM51166"],"name":[182],"type":["dbl"],"align":["right"]},{"label":["GSM51167"],"name":[183],"type":["dbl"],"align":["right"]},{"label":["GSM51168"],"name":[184],"type":["dbl"],"align":["right"]},{"label":["GSM51169"],"name":[185],"type":["dbl"],"align":["right"]},{"label":["GSM51170"],"name":[186],"type":["dbl"],"align":["right"]},{"label":["GSM51171"],"name":[187],"type":["dbl"],"align":["right"]},{"label":["GSM51172"],"name":[188],"type":["dbl"],"align":["right"]},{"label":["GSM51173"],"name":[189],"type":["dbl"],"align":["right"]},{"label":["GSM51174"],"name":[190],"type":["dbl"],"align":["right"]},{"label":["GSM51175"],"name":[191],"type":["dbl"],"align":["right"]},{"label":["GSM51176"],"name":[192],"type":["dbl"],"align":["right"]},{"label":["GSM51177"],"name":[193],"type":["dbl"],"align":["right"]},{"label":["GSM51178"],"name":[194],"type":["dbl"],"align":["right"]},{"label":["GSM51179"],"name":[195],"type":["dbl"],"align":["right"]},{"label":["GSM51180"],"name":[196],"type":["dbl"],"align":["right"]},{"label":["GSM51181"],"name":[197],"type":["dbl"],"align":["right"]},{"label":["GSM51182"],"name":[198],"type":["dbl"],"align":["right"]},{"label":["GSM51183"],"name":[199],"type":["dbl"],"align":["right"]},{"label":["GSM51184"],"name":[200],"type":["dbl"],"align":["right"]},{"label":["GSM51185"],"name":[201],"type":["dbl"],"align":["right"]},{"label":["GSM51186"],"name":[202],"type":["dbl"],"align":["right"]},{"label":["GSM51187"],"name":[203],"type":["dbl"],"align":["right"]},{"label":["GSM51188"],"name":[204],"type":["dbl"],"align":["right"]},{"label":["GSM51189"],"name":[205],"type":["dbl"],"align":["right"]},{"label":["GSM51190"],"name":[206],"type":["dbl"],"align":["right"]},{"label":["GSM51191"],"name":[207],"type":["dbl"],"align":["right"]},{"label":["GSM51192"],"name":[208],"type":["dbl"],"align":["right"]},{"label":["GSM51193"],"name":[209],"type":["dbl"],"align":["right"]},{"label":["GSM51194"],"name":[210],"type":["dbl"],"align":["right"]},{"label":["GSM51195"],"name":[211],"type":["dbl"],"align":["right"]},{"label":["GSM51196"],"name":[212],"type":["dbl"],"align":["right"]},{"label":["GSM51197"],"name":[213],"type":["dbl"],"align":["right"]},{"label":["GSM51198"],"name":[214],"type":["dbl"],"align":["right"]},{"label":["GSM51199"],"name":[215],"type":["dbl"],"align":["right"]},{"label":["GSM51200"],"name":[216],"type":["dbl"],"align":["right"]},{"label":["GSM51201"],"name":[217],"type":["dbl"],"align":["right"]},{"label":["GSM51202"],"name":[218],"type":["dbl"],"align":["right"]},{"label":["GSM51203"],"name":[219],"type":["dbl"],"align":["right"]},{"label":["GSM51204"],"name":[220],"type":["dbl"],"align":["right"]},{"label":["GSM51205"],"name":[221],"type":["dbl"],"align":["right"]},{"label":["GSM51206"],"name":[222],"type":["dbl"],"align":["right"]},{"label":["GSM51207"],"name":[223],"type":["dbl"],"align":["right"]},{"label":["GSM51208"],"name":[224],"type":["dbl"],"align":["right"]},{"label":["GSM51209"],"name":[225],"type":["dbl"],"align":["right"]},{"label":["GSM51210"],"name":[226],"type":["dbl"],"align":["right"]},{"label":["GSM51211"],"name":[227],"type":["dbl"],"align":["right"]},{"label":["GSM51212"],"name":[228],"type":["dbl"],"align":["right"]},{"label":["GSM51213"],"name":[229],"type":["dbl"],"align":["right"]},{"label":["GSM51214"],"name":[230],"type":["dbl"],"align":["right"]},{"label":["GSM51215"],"name":[231],"type":["dbl"],"align":["right"]},{"label":["GSM51216"],"name":[232],"type":["dbl"],"align":["right"]},{"label":["GSM51217"],"name":[233],"type":["dbl"],"align":["right"]},{"label":["GSM51218"],"name":[234],"type":["dbl"],"align":["right"]},{"label":["GSM51219"],"name":[235],"type":["dbl"],"align":["right"]},{"label":["GSM51220"],"name":[236],"type":["dbl"],"align":["right"]},{"label":["GSM51221"],"name":[237],"type":["dbl"],"align":["right"]},{"label":["GSM51222"],"name":[238],"type":["dbl"],"align":["right"]},{"label":["GSM51223"],"name":[239],"type":["dbl"],"align":["right"]},{"label":["GSM51224"],"name":[240],"type":["dbl"],"align":["right"]},{"label":["GSM51225"],"name":[241],"type":["dbl"],"align":["right"]},{"label":["GSM51226"],"name":[242],"type":["dbl"],"align":["right"]},{"label":["GSM51227"],"name":[243],"type":["dbl"],"align":["right"]},{"label":["GSM51228"],"name":[244],"type":["dbl"],"align":["right"]},{"label":["GSM51229"],"name":[245],"type":["dbl"],"align":["right"]},{"label":["GSM51230"],"name":[246],"type":["dbl"],"align":["right"]},{"label":["GSM51231"],"name":[247],"type":["dbl"],"align":["right"]},{"label":["GSM51232"],"name":[248],"type":["dbl"],"align":["right"]},{"label":["GSM51233"],"name":[249],"type":["dbl"],"align":["right"]},{"label":["GSM51234"],"name":[250],"type":["dbl"],"align":["right"]},{"label":["GSM51235"],"name":[251],"type":["dbl"],"align":["right"]},{"label":["GSM51236"],"name":[252],"type":["dbl"],"align":["right"]},{"label":["GSM51237"],"name":[253],"type":["dbl"],"align":["right"]},{"label":["GSM51238"],"name":[254],"type":["dbl"],"align":["right"]},{"label":["GSM51239"],"name":[255],"type":["dbl"],"align":["right"]},{"label":["GSM51240"],"name":[256],"type":["dbl"],"align":["right"]},{"label":["GSM51241"],"name":[257],"type":["dbl"],"align":["right"]},{"label":["GSM51242"],"name":[258],"type":["dbl"],"align":["right"]},{"label":["GSM51243"],"name":[259],"type":["dbl"],"align":["right"]},{"label":["GSM51244"],"name":[260],"type":["dbl"],"align":["right"]},{"label":["GSM51245"],"name":[261],"type":["dbl"],"align":["right"]},{"label":["GSM51246"],"name":[262],"type":["dbl"],"align":["right"]},{"label":["GSM51247"],"name":[263],"type":["dbl"],"align":["right"]},{"label":["GSM51248"],"name":[264],"type":["dbl"],"align":["right"]},{"label":["GSM51249"],"name":[265],"type":["dbl"],"align":["right"]},{"label":["GSM51250"],"name":[266],"type":["dbl"],"align":["right"]},{"label":["GSM51251"],"name":[267],"type":["dbl"],"align":["right"]},{"label":["GSM51252"],"name":[268],"type":["dbl"],"align":["right"]},{"label":["GSM51253"],"name":[269],"type":["dbl"],"align":["right"]},{"label":["GSM51254"],"name":[270],"type":["dbl"],"align":["right"]},{"label":["GSM51255"],"name":[271],"type":["dbl"],"align":["right"]},{"label":["GSM51256"],"name":[272],"type":["dbl"],"align":["right"]},{"label":["GSM51257"],"name":[273],"type":["dbl"],"align":["right"]},{"label":["GSM51258"],"name":[274],"type":["dbl"],"align":["right"]},{"label":["GSM51259"],"name":[275],"type":["dbl"],"align":["right"]},{"label":["GSM51260"],"name":[276],"type":["dbl"],"align":["right"]},{"label":["GSM51261"],"name":[277],"type":["dbl"],"align":["right"]},{"label":["GSM51262"],"name":[278],"type":["dbl"],"align":["right"]},{"label":["GSM51263"],"name":[279],"type":["dbl"],"align":["right"]},{"label":["GSM51264"],"name":[280],"type":["dbl"],"align":["right"]},{"label":["GSM51265"],"name":[281],"type":["dbl"],"align":["right"]},{"label":["GSM51266"],"name":[282],"type":["dbl"],"align":["right"]},{"label":["GSM51267"],"name":[283],"type":["dbl"],"align":["right"]},{"label":["GSM51268"],"name":[284],"type":["dbl"],"align":["right"]},{"label":["GSM51269"],"name":[285],"type":["dbl"],"align":["right"]},{"label":["GSM51270"],"name":[286],"type":["dbl"],"align":["right"]},{"label":["GSM51271"],"name":[287],"type":["dbl"],"align":["right"]},{"label":["GSM51272"],"name":[288],"type":["dbl"],"align":["right"]},{"label":["GSM51273"],"name":[289],"type":["dbl"],"align":["right"]},{"label":["GSM51274"],"name":[290],"type":["dbl"],"align":["right"]},{"label":["GSM51275"],"name":[291],"type":["dbl"],"align":["right"]},{"label":["GSM51276"],"name":[292],"type":["dbl"],"align":["right"]},{"label":["GSM51277"],"name":[293],"type":["dbl"],"align":["right"]},{"label":["GSM51278"],"name":[294],"type":["dbl"],"align":["right"]},{"label":["GSM51279"],"name":[295],"type":["dbl"],"align":["right"]},{"label":["GSM51280"],"name":[296],"type":["dbl"],"align":["right"]},{"label":["GSM51281"],"name":[297],"type":["dbl"],"align":["right"]},{"label":["GSM51282"],"name":[298],"type":["dbl"],"align":["right"]},{"label":["GSM51283"],"name":[299],"type":["dbl"],"align":["right"]},{"label":["GSM51284"],"name":[300],"type":["dbl"],"align":["right"]},{"label":["GSM51285"],"name":[301],"type":["dbl"],"align":["right"]},{"label":["GSM51286"],"name":[302],"type":["dbl"],"align":["right"]},{"label":["GSM51287"],"name":[303],"type":["dbl"],"align":["right"]},{"label":["GSM51288"],"name":[304],"type":["dbl"],"align":["right"]},{"label":["GSM51289"],"name":[305],"type":["dbl"],"align":["right"]},{"label":["GSM51290"],"name":[306],"type":["dbl"],"align":["right"]},{"label":["GSM51291"],"name":[307],"type":["dbl"],"align":["right"]},{"label":["GSM51292"],"name":[308],"type":["dbl"],"align":["right"]},{"label":["GSM51293"],"name":[309],"type":["dbl"],"align":["right"]},{"label":["GSM51294"],"name":[310],"type":["dbl"],"align":["right"]},{"label":["GSM51295"],"name":[311],"type":["dbl"],"align":["right"]},{"label":["GSM51296"],"name":[312],"type":["dbl"],"align":["right"]},{"label":["GSM51297"],"name":[313],"type":["dbl"],"align":["right"]},{"label":["GSM51298"],"name":[314],"type":["dbl"],"align":["right"]},{"label":["GSM51299"],"name":[315],"type":["dbl"],"align":["right"]},{"label":["GSM51300"],"name":[316],"type":["dbl"],"align":["right"]},{"label":["GSM51301"],"name":[317],"type":["dbl"],"align":["right"]},{"label":["GSM51302"],"name":[318],"type":["dbl"],"align":["right"]},{"label":["GSM51303"],"name":[319],"type":["dbl"],"align":["right"]},{"label":["GSM51304"],"name":[320],"type":["dbl"],"align":["right"]},{"label":["GSM51305"],"name":[321],"type":["dbl"],"align":["right"]},{"label":["GSM51306"],"name":[322],"type":["dbl"],"align":["right"]},{"label":["GSM51307"],"name":[323],"type":["dbl"],"align":["right"]},{"label":["GSM51308"],"name":[324],"type":["dbl"],"align":["right"]},{"label":["GSM51309"],"name":[325],"type":["dbl"],"align":["right"]},{"label":["GSM51310"],"name":[326],"type":["dbl"],"align":["right"]},{"label":["GSM51311"],"name":[327],"type":["dbl"],"align":["right"]},{"label":["GSM51312"],"name":[328],"type":["dbl"],"align":["right"]},{"label":["GSM51313"],"name":[329],"type":["dbl"],"align":["right"]},{"label":["GSM51314"],"name":[330],"type":["dbl"],"align":["right"]},{"label":["GSM51315"],"name":[331],"type":["dbl"],"align":["right"]},{"label":["GSM51316"],"name":[332],"type":["dbl"],"align":["right"]},{"label":["GSM51317"],"name":[333],"type":["dbl"],"align":["right"]},{"label":["GSM51318"],"name":[334],"type":["dbl"],"align":["right"]},{"label":["GSM51319"],"name":[335],"type":["dbl"],"align":["right"]},{"label":["GSM51320"],"name":[336],"type":["dbl"],"align":["right"]},{"label":["GSM51321"],"name":[337],"type":["dbl"],"align":["right"]},{"label":["GSM51322"],"name":[338],"type":["dbl"],"align":["right"]},{"label":["GSM51323"],"name":[339],"type":["dbl"],"align":["right"]},{"label":["GSM51324"],"name":[340],"type":["dbl"],"align":["right"]},{"label":["GSM51325"],"name":[341],"type":["dbl"],"align":["right"]},{"label":["GSM51326"],"name":[342],"type":["dbl"],"align":["right"]},{"label":["GSM51327"],"name":[343],"type":["dbl"],"align":["right"]},{"label":["GSM51328"],"name":[344],"type":["dbl"],"align":["right"]},{"label":["GSM51329"],"name":[345],"type":["dbl"],"align":["right"]},{"label":["GSM51330"],"name":[346],"type":["dbl"],"align":["right"]},{"label":["GSM51331"],"name":[347],"type":["dbl"],"align":["right"]},{"label":["GSM51332"],"name":[348],"type":["dbl"],"align":["right"]},{"label":["GSM51333"],"name":[349],"type":["dbl"],"align":["right"]},{"label":["GSM51334"],"name":[350],"type":["dbl"],"align":["right"]},{"label":["GSM51335"],"name":[351],"type":["dbl"],"align":["right"]},{"label":["GSM51336"],"name":[352],"type":["dbl"],"align":["right"]},{"label":["GSM95646"],"name":[353],"type":["dbl"],"align":["right"]},{"label":["GSM95647"],"name":[354],"type":["dbl"],"align":["right"]},{"label":["GSM95648"],"name":[355],"type":["dbl"],"align":["right"]},{"label":["GSM95649"],"name":[356],"type":["dbl"],"align":["right"]},{"label":["GSM95650"],"name":[357],"type":["dbl"],"align":["right"]},{"label":["GSM95651"],"name":[358],"type":["dbl"],"align":["right"]},{"label":["GSM95652"],"name":[359],"type":["dbl"],"align":["right"]},{"label":["GSM95653"],"name":[360],"type":["dbl"],"align":["right"]},{"label":["GSM95654"],"name":[361],"type":["dbl"],"align":["right"]},{"label":["GSM95655"],"name":[362],"type":["dbl"],"align":["right"]},{"label":["GSM95656"],"name":[363],"type":["dbl"],"align":["right"]},{"label":["GSM95657"],"name":[364],"type":["dbl"],"align":["right"]},{"label":["GSM95658"],"name":[365],"type":["dbl"],"align":["right"]},{"label":["GSM95659"],"name":[366],"type":["dbl"],"align":["right"]},{"label":["GSM95660"],"name":[367],"type":["dbl"],"align":["right"]},{"label":["GSM95661"],"name":[368],"type":["dbl"],"align":["right"]},{"label":["GSM95662"],"name":[369],"type":["dbl"],"align":["right"]},{"label":["GSM95663"],"name":[370],"type":["dbl"],"align":["right"]},{"label":["GSM95664"],"name":[371],"type":["dbl"],"align":["right"]},{"label":["GSM95665"],"name":[372],"type":["dbl"],"align":["right"]},{"label":["GSM95666"],"name":[373],"type":["dbl"],"align":["right"]},{"label":["GSM95667"],"name":[374],"type":["dbl"],"align":["right"]},{"label":["GSM95668"],"name":[375],"type":["dbl"],"align":["right"]},{"label":["GSM95669"],"name":[376],"type":["dbl"],"align":["right"]},{"label":["GSM95670"],"name":[377],"type":["dbl"],"align":["right"]},{"label":["GSM95671"],"name":[378],"type":["dbl"],"align":["right"]},{"label":["GSM95672"],"name":[379],"type":["dbl"],"align":["right"]},{"label":["GSM95673"],"name":[380],"type":["dbl"],"align":["right"]},{"label":["GSM95674"],"name":[381],"type":["dbl"],"align":["right"]},{"label":["GSM95675"],"name":[382],"type":["dbl"],"align":["right"]},{"label":["GSM95676"],"name":[383],"type":["dbl"],"align":["right"]},{"label":["GSM95677"],"name":[384],"type":["dbl"],"align":["right"]},{"label":["GSM95678"],"name":[385],"type":["dbl"],"align":["right"]},{"label":["GSM95679"],"name":[386],"type":["dbl"],"align":["right"]},{"label":["GSM95680"],"name":[387],"type":["dbl"],"align":["right"]},{"label":["GSM95681"],"name":[388],"type":["dbl"],"align":["right"]},{"label":["GSM95682"],"name":[389],"type":["dbl"],"align":["right"]},{"label":["GSM95683"],"name":[390],"type":["dbl"],"align":["right"]},{"label":["GSM95684"],"name":[391],"type":["dbl"],"align":["right"]},{"label":["GSM95685"],"name":[392],"type":["dbl"],"align":["right"]},{"label":["GSM95686"],"name":[393],"type":["dbl"],"align":["right"]},{"label":["GSM95687"],"name":[394],"type":["dbl"],"align":["right"]},{"label":["GSM95688"],"name":[395],"type":["dbl"],"align":["right"]},{"label":["GSM95689"],"name":[396],"type":["dbl"],"align":["right"]},{"label":["GSM95690"],"name":[397],"type":["dbl"],"align":["right"]},{"label":["GSM95691"],"name":[398],"type":["dbl"],"align":["right"]},{"label":["GSM95692"],"name":[399],"type":["dbl"],"align":["right"]},{"label":["GSM95693"],"name":[400],"type":["dbl"],"align":["right"]},{"label":["GSM95694"],"name":[401],"type":["dbl"],"align":["right"]},{"label":["GSM95695"],"name":[402],"type":["dbl"],"align":["right"]},{"label":["GSM95696"],"name":[403],"type":["dbl"],"align":["right"]},{"label":["GSM95697"],"name":[404],"type":["dbl"],"align":["right"]},{"label":["GSM95698"],"name":[405],"type":["dbl"],"align":["right"]},{"label":["GSM95699"],"name":[406],"type":["dbl"],"align":["right"]},{"label":["GSM95700"],"name":[407],"type":["dbl"],"align":["right"]},{"label":["GSM95701"],"name":[408],"type":["dbl"],"align":["right"]},{"label":["GSM95702"],"name":[409],"type":["dbl"],"align":["right"]},{"label":["GSM95703"],"name":[410],"type":["dbl"],"align":["right"]},{"label":["GSM95704"],"name":[411],"type":["dbl"],"align":["right"]},{"label":["GSM95705"],"name":[412],"type":["dbl"],"align":["right"]},{"label":["GSM95706"],"name":[413],"type":["dbl"],"align":["right"]},{"label":["GSM95707"],"name":[414],"type":["dbl"],"align":["right"]},{"label":["GSM95708"],"name":[415],"type":["dbl"],"align":["right"]},{"label":["GSM95709"],"name":[416],"type":["dbl"],"align":["right"]},{"label":["GSM95710"],"name":[417],"type":["dbl"],"align":["right"]},{"label":["GSM95711"],"name":[418],"type":["dbl"],"align":["right"]},{"label":["GSM95712"],"name":[419],"type":["dbl"],"align":["right"]},{"label":["GSM95713"],"name":[420],"type":["dbl"],"align":["right"]},{"label":["GSM95714"],"name":[421],"type":["dbl"],"align":["right"]},{"label":["GSM95715"],"name":[422],"type":["dbl"],"align":["right"]},{"label":["GSM95716"],"name":[423],"type":["dbl"],"align":["right"]},{"label":["GSM95717"],"name":[424],"type":["dbl"],"align":["right"]},{"label":["GSM95718"],"name":[425],"type":["dbl"],"align":["right"]},{"label":["GSM95719"],"name":[426],"type":["dbl"],"align":["right"]},{"label":["GSM95720"],"name":[427],"type":["dbl"],"align":["right"]},{"label":["GSM95721"],"name":[428],"type":["dbl"],"align":["right"]},{"label":["GSM95722"],"name":[429],"type":["dbl"],"align":["right"]},{"label":["GSM95723"],"name":[430],"type":["dbl"],"align":["right"]},{"label":["GSM95724"],"name":[431],"type":["dbl"],"align":["right"]},{"label":["GSM95725"],"name":[432],"type":["dbl"],"align":["right"]},{"label":["GSM95726"],"name":[433],"type":["dbl"],"align":["right"]},{"label":["GSM95727"],"name":[434],"type":["dbl"],"align":["right"]},{"label":["GSM95728"],"name":[435],"type":["dbl"],"align":["right"]},{"label":["GSM95729"],"name":[436],"type":["dbl"],"align":["right"]},{"label":["GSM95730"],"name":[437],"type":["dbl"],"align":["right"]},{"label":["GSM95731"],"name":[438],"type":["dbl"],"align":["right"]},{"label":["GSM95732"],"name":[439],"type":["dbl"],"align":["right"]},{"label":["GSM95733"],"name":[440],"type":["dbl"],"align":["right"]},{"label":["GSM95734"],"name":[441],"type":["dbl"],"align":["right"]},{"label":["GSM95735"],"name":[442],"type":["dbl"],"align":["right"]},{"label":["GSM95736"],"name":[443],"type":["dbl"],"align":["right"]},{"label":["GSM95737"],"name":[444],"type":["dbl"],"align":["right"]},{"label":["GSM95738"],"name":[445],"type":["dbl"],"align":["right"]},{"label":["GSM95739"],"name":[446],"type":["dbl"],"align":["right"]},{"label":["GSM95740"],"name":[447],"type":["dbl"],"align":["right"]},{"label":["GSM95741"],"name":[448],"type":["dbl"],"align":["right"]},{"label":["GSM95742"],"name":[449],"type":["dbl"],"align":["right"]},{"label":["GSM95743"],"name":[450],"type":["dbl"],"align":["right"]},{"label":["GSM95744"],"name":[451],"type":["dbl"],"align":["right"]},{"label":["GSM95745"],"name":[452],"type":["dbl"],"align":["right"]},{"label":["GSM95746"],"name":[453],"type":["dbl"],"align":["right"]},{"label":["GSM95747"],"name":[454],"type":["dbl"],"align":["right"]},{"label":["GSM95748"],"name":[455],"type":["dbl"],"align":["right"]},{"label":["GSM95749"],"name":[456],"type":["dbl"],"align":["right"]},{"label":["GSM95750"],"name":[457],"type":["dbl"],"align":["right"]},{"label":["GSM95751"],"name":[458],"type":["dbl"],"align":["right"]},{"label":["GSM95752"],"name":[459],"type":["dbl"],"align":["right"]},{"label":["GSM95753"],"name":[460],"type":["dbl"],"align":["right"]},{"label":["GSM95754"],"name":[461],"type":["dbl"],"align":["right"]},{"label":["GSM95755"],"name":[462],"type":["dbl"],"align":["right"]},{"label":["GSM95756"],"name":[463],"type":["dbl"],"align":["right"]},{"label":["GSM95757"],"name":[464],"type":["dbl"],"align":["right"]},{"label":["GSM95758"],"name":[465],"type":["dbl"],"align":["right"]},{"label":["GSM95759"],"name":[466],"type":["dbl"],"align":["right"]},{"label":["GSM95760"],"name":[467],"type":["dbl"],"align":["right"]},{"label":["GSM95761"],"name":[468],"type":["dbl"],"align":["right"]},{"label":["GSM95762"],"name":[469],"type":["dbl"],"align":["right"]},{"label":["GSM95763"],"name":[470],"type":["dbl"],"align":["right"]},{"label":["GSM95764"],"name":[471],"type":["dbl"],"align":["right"]},{"label":["GSM95765"],"name":[472],"type":["dbl"],"align":["right"]},{"label":["GSM95766"],"name":[473],"type":["dbl"],"align":["right"]},{"label":["GSM95767"],"name":[474],"type":["dbl"],"align":["right"]},{"label":["GSM95768"],"name":[475],"type":["dbl"],"align":["right"]},{"label":["GSM95769"],"name":[476],"type":["dbl"],"align":["right"]},{"label":["GSM95770"],"name":[477],"type":["dbl"],"align":["right"]},{"label":["GSM95771"],"name":[478],"type":["dbl"],"align":["right"]},{"label":["GSM95772"],"name":[479],"type":["dbl"],"align":["right"]},{"label":["GSM95773"],"name":[480],"type":["dbl"],"align":["right"]},{"label":["GSM95774"],"name":[481],"type":["dbl"],"align":["right"]},{"label":["GSM95775"],"name":[482],"type":["dbl"],"align":["right"]},{"label":["GSM95776"],"name":[483],"type":["dbl"],"align":["right"]},{"label":["GSM95777"],"name":[484],"type":["dbl"],"align":["right"]},{"label":["GSM95778"],"name":[485],"type":["dbl"],"align":["right"]},{"label":["GSM95779"],"name":[486],"type":["dbl"],"align":["right"]},{"label":["GSM95780"],"name":[487],"type":["dbl"],"align":["right"]},{"label":["GSM95781"],"name":[488],"type":["dbl"],"align":["right"]},{"label":["GSM95782"],"name":[489],"type":["dbl"],"align":["right"]},{"label":["GSM95783"],"name":[490],"type":["dbl"],"align":["right"]},{"label":["GSM95784"],"name":[491],"type":["dbl"],"align":["right"]},{"label":["GSM95785"],"name":[492],"type":["dbl"],"align":["right"]},{"label":["GSM95786"],"name":[493],"type":["dbl"],"align":["right"]},{"label":["GSM95787"],"name":[494],"type":["dbl"],"align":["right"]},{"label":["GSM95788"],"name":[495],"type":["dbl"],"align":["right"]},{"label":["GSM95789"],"name":[496],"type":["dbl"],"align":["right"]},{"label":["GSM95790"],"name":[497],"type":["dbl"],"align":["right"]},{"label":["GSM95791"],"name":[498],"type":["dbl"],"align":["right"]},{"label":["GSM95792"],"name":[499],"type":["dbl"],"align":["right"]},{"label":["GSM95793"],"name":[500],"type":["dbl"],"align":["right"]},{"label":["GSM95794"],"name":[501],"type":["dbl"],"align":["right"]},{"label":["GSM95795"],"name":[502],"type":["dbl"],"align":["right"]},{"label":["GSM95796"],"name":[503],"type":["dbl"],"align":["right"]},{"label":["GSM95797"],"name":[504],"type":["dbl"],"align":["right"]},{"label":["GSM95798"],"name":[505],"type":["dbl"],"align":["right"]},{"label":["GSM95799"],"name":[506],"type":["dbl"],"align":["right"]},{"label":["GSM95800"],"name":[507],"type":["dbl"],"align":["right"]},{"label":["GSM95801"],"name":[508],"type":["dbl"],"align":["right"]},{"label":["GSM95802"],"name":[509],"type":["dbl"],"align":["right"]},{"label":["GSM95803"],"name":[510],"type":["dbl"],"align":["right"]},{"label":["GSM95804"],"name":[511],"type":["dbl"],"align":["right"]},{"label":["GSM95805"],"name":[512],"type":["dbl"],"align":["right"]},{"label":["GSM95806"],"name":[513],"type":["dbl"],"align":["right"]},{"label":["GSM95807"],"name":[514],"type":["dbl"],"align":["right"]},{"label":["GSM95808"],"name":[515],"type":["dbl"],"align":["right"]},{"label":["GSM95809"],"name":[516],"type":["dbl"],"align":["right"]},{"label":["GSM95810"],"name":[517],"type":["dbl"],"align":["right"]},{"label":["GSM95811"],"name":[518],"type":["dbl"],"align":["right"]},{"label":["GSM95812"],"name":[519],"type":["dbl"],"align":["right"]},{"label":["GSM95813"],"name":[520],"type":["dbl"],"align":["right"]},{"label":["GSM95814"],"name":[521],"type":["dbl"],"align":["right"]},{"label":["GSM95815"],"name":[522],"type":["dbl"],"align":["right"]},{"label":["GSM95816"],"name":[523],"type":["dbl"],"align":["right"]},{"label":["GSM95817"],"name":[524],"type":["dbl"],"align":["right"]},{"label":["GSM95818"],"name":[525],"type":["dbl"],"align":["right"]},{"label":["GSM95819"],"name":[526],"type":["dbl"],"align":["right"]},{"label":["GSM95820"],"name":[527],"type":["dbl"],"align":["right"]},{"label":["GSM95821"],"name":[528],"type":["dbl"],"align":["right"]},{"label":["GSM95822"],"name":[529],"type":["dbl"],"align":["right"]},{"label":["GSM95823"],"name":[530],"type":["dbl"],"align":["right"]},{"label":["GSM95824"],"name":[531],"type":["dbl"],"align":["right"]},{"label":["GSM95825"],"name":[532],"type":["dbl"],"align":["right"]},{"label":["GSM95826"],"name":[533],"type":["dbl"],"align":["right"]},{"label":["GSM102606"],"name":[534],"type":["dbl"],"align":["right"]},{"label":["GSM102607"],"name":[535],"type":["dbl"],"align":["right"]},{"label":["GSM102609"],"name":[536],"type":["dbl"],"align":["right"]},{"label":["GSM102610"],"name":[537],"type":["dbl"],"align":["right"]},{"label":["GSM102611"],"name":[538],"type":["dbl"],"align":["right"]},{"label":["GSM102612"],"name":[539],"type":["dbl"],"align":["right"]},{"label":["GSM102613"],"name":[540],"type":["dbl"],"align":["right"]},{"label":["GSM102614"],"name":[541],"type":["dbl"],"align":["right"]},{"label":["GSM102615"],"name":[542],"type":["dbl"],"align":["right"]},{"label":["GSM102616"],"name":[543],"type":["dbl"],"align":["right"]},{"label":["GSM102617"],"name":[544],"type":["dbl"],"align":["right"]},{"label":["GSM102618"],"name":[545],"type":["dbl"],"align":["right"]},{"label":["GSM102620"],"name":[546],"type":["dbl"],"align":["right"]},{"label":["GSM102621"],"name":[547],"type":["dbl"],"align":["right"]},{"label":["GSM102622"],"name":[548],"type":["dbl"],"align":["right"]},{"label":["GSM102623"],"name":[549],"type":["dbl"],"align":["right"]},{"label":["GSM102624"],"name":[550],"type":["dbl"],"align":["right"]},{"label":["GSM102625"],"name":[551],"type":["dbl"],"align":["right"]},{"label":["GSM102626"],"name":[552],"type":["dbl"],"align":["right"]},{"label":["GSM102627"],"name":[553],"type":["dbl"],"align":["right"]},{"label":["GSM102628"],"name":[554],"type":["dbl"],"align":["right"]},{"label":["GSM102629"],"name":[555],"type":["dbl"],"align":["right"]},{"label":["GSM102630"],"name":[556],"type":["dbl"],"align":["right"]},{"label":["GSM102631"],"name":[557],"type":["dbl"],"align":["right"]},{"label":["GSM102632"],"name":[558],"type":["dbl"],"align":["right"]},{"label":["GSM102633"],"name":[559],"type":["dbl"],"align":["right"]},{"label":["GSM102634"],"name":[560],"type":["dbl"],"align":["right"]}],"data":[{"1":"1552256_a_at","2":"961.4","3":"966.9","4":"481.6","5":"405.3","6":"430.6","7":"2079","8":"181.1","9":"779","10":"1634.5","11":"716.9","12":"26.8","13":"414.5","14":"201.6","15":"568.4","16":"296.7","17":"514.8","18":"319.8","19":"196.8","20":"291.7","21":"208.9","22":"135.4","23":"779.1","24":"832","25":"374.3","26":"595.5","27":"1068","28":"285.1","29":"470.8","30":"463.3","31":"1175.7","32":"631.4","33":"33","34":"211.2","35":"450","36":"515.2","37":"383.5","38":"976.7","39":"404.7","40":"622.5","41":"713.5","42":"835.6","43":"921.7","44":"296.5","45":"281.9","46":"384.3","47":"464","48":"504.5","49":"597.9","50":"648.9","51":"498.7","52":"482.6","53":"192.3","54":"446.4","55":"1017","56":"184.2","57":"229.3","58":"341.7","59":"373.1","60":"437.2","61":"3654.4","62":"270.5","63":"367","64":"292.6","65":"518.3","66":"362.1","67":"840.2","68":"957.2","69":"92.9","70":"334.1","71":"350.3","72":"674.6","73":"957.2","74":"230.4","75":"828.9","76":"469.2","77":"457.6","78":"742.5","79":"425.9","80":"253.1","81":"388.3","82":"546.2","83":"468.1","84":"214.7","85":"216.6","86":"256.9","87":"252.6","88":"673.4","89":"745.4","90":"680.1","91":"1248.3","92":"337.3","93":"288","94":"156","95":"1032.5","96":"541.7","97":"242.9","98":"142.6","99":"1337.4","100":"492.7","101":"509.9","102":"248.7","103":"202.7","104":"324","105":"367.5","106":"218.1","107":"438.5","108":"325.1","109":"493.4","110":"537.7","111":"256","112":"935.7","113":"735.4","114":"831.4","115":"618.6","116":"555.2","117":"655.1","118":"477.3","119":"775.1","120":"2394.5","121":"742.5","122":"485.6","123":"90.8","124":"553.8","125":"26","126":"617.5","127":"442.3","128":"847.2","129":"613.4","130":"603.7","131":"523","132":"432.9","133":"702.9","134":"226.4","135":"304.5","136":"271.7","137":"238.1","138":"251.2","139":"391.2","140":"385.8","141":"344","142":"667.6","143":"792.8","144":"720.9","145":"2079.2","146":"918.7","147":"1138.2","148":"166.6","149":"836.8","150":"951.1","151":"708.5","152":"558.5","153":"140.2","154":"574","155":"656.3","156":"277.5","157":"754.8","158":"366.2","159":"191.8","160":"199.5","161":"137.2","162":"784.7","163":"815.9","164":"1338.2","165":"608","166":"467.2","167":"860.7","168":"316.3","169":"281.8","170":"392.1","171":"274.7","172":"504.9","173":"396.8","174":"620.7","175":"240.6","176":"1211.1","177":"465.8","178":"572.8","179":"517.1","180":"394.5","181":"372.1","182":"445.9","183":"10.4","184":"829.5","185":"241.7","186":"584.6","187":"703.7","188":"426.7","189":"356.9","190":"480","191":"385","192":"715.6","193":"838.2","194":"462.2","195":"714.9","196":"577.8","197":"695.5","198":"199","199":"592.3","200":"706","201":"258.2","202":"416.8","203":"548.3","204":"390.8","205":"408.4","206":"878","207":"129.2","208":"474.6","209":"538.8","210":"575.2","211":"295.9","212":"719.4","213":"201.2","214":"542.8","215":"3349.2","216":"423.6","217":"331.5","218":"303.4","219":"664.8","220":"552.3","221":"524.9","222":"474.4","223":"732.3","224":"403.6","225":"906.7","226":"355.9","227":"763.7","228":"476.5","229":"257.1","230":"509.6","231":"814","232":"1230.8","233":"411.7","234":"321.8","235":"274.8","236":"687","237":"213.6","238":"275.2","239":"1183.2","240":"411.7","241":"815.6","242":"181.7","243":"1032.3","244":"718.4","245":"379.3","246":"144.3","247":"222.7","248":"417.5","249":"1137","250":"752.6","251":"35.3","252":"297.8","253":"458.9","254":"1061","255":"814.7","256":"829.5","257":"251.6","258":"476.2","259":"313.7","260":"490.2","261":"438","262":"765.7","263":"622.9","264":"716.7","265":"764.8","266":"375.7","267":"728.2","268":"467.1","269":"351.6","270":"310.2","271":"867.3","272":"1020","273":"290.5","274":"808.3","275":"1316.1","276":"387.8","277":"57.6","278":"844.7","279":"441.4","280":"546.1","281":"626.3","282":"701.8","283":"300.1","284":"839.4","285":"533.9","286":"1609.9","287":"630.3","288":"3585.5","289":"787.1","290":"333.3","291":"283.6","292":"415.6","293":"1484.8","294":"703.5","295":"886.7","296":"322.4","297":"514.6","298":"447.3","299":"646.8","300":"502","301":"184.5","302":"656.7","303":"332.4","304":"976.9","305":"330.3","306":"661.5","307":"2139.8","308":"713.7","309":"1298.2","310":"554.1","311":"1096","312":"442.5","313":"506","314":"118.8","315":"469.8","316":"780.7","317":"1128.5","318":"622.4","319":"861.7","320":"771.9","321":"618.4","322":"625","323":"471.8","324":"580.3","325":"853","326":"678.7","327":"591.4","328":"924.1","329":"1279.8","330":"46.8","331":"322.7","332":"948.1","333":"484","334":"1044.2","335":"640.7","336":"711.6","337":"281.2","338":"623.6","339":"941.2","340":"1589.7","341":"673.6","342":"605.3","343":"1062","344":"811.1","345":"370.8","346":"835.7","347":"584.5","348":"101.7","349":"522.9","350":"604","351":"1186","352":"386.5","353":"NA","354":"NA","355":"NA","356":"NA","357":"NA","358":"NA","359":"NA","360":"NA","361":"NA","362":"NA","363":"NA","364":"NA","365":"NA","366":"NA","367":"NA","368":"NA","369":"NA","370":"NA","371":"NA","372":"NA","373":"NA","374":"NA","375":"NA","376":"NA","377":"NA","378":"NA","379":"NA","380":"NA","381":"NA","382":"NA","383":"NA","384":"NA","385":"NA","386":"NA","387":"NA","388":"NA","389":"NA","390":"NA","391":"NA","392":"NA","393":"NA","394":"NA","395":"NA","396":"NA","397":"NA","398":"NA","399":"NA","400":"NA","401":"NA","402":"NA","403":"NA","404":"NA","405":"NA","406":"NA","407":"NA","408":"NA","409":"NA","410":"NA","411":"NA","412":"NA","413":"NA","414":"NA","415":"NA","416":"NA","417":"NA","418":"NA","419":"NA","420":"NA","421":"NA","422":"NA","423":"NA","424":"NA","425":"NA","426":"NA","427":"NA","428":"NA","429":"NA","430":"NA","431":"NA","432":"NA","433":"NA","434":"NA","435":"NA","436":"NA","437":"NA","438":"NA","439":"NA","440":"NA","441":"NA","442":"NA","443":"NA","444":"NA","445":"NA","446":"NA","447":"NA","448":"NA","449":"NA","450":"NA","451":"NA","452":"NA","453":"NA","454":"NA","455":"NA","456":"NA","457":"NA","458":"NA","459":"NA","460":"NA","461":"NA","462":"NA","463":"NA","464":"NA","465":"NA","466":"NA","467":"NA","468":"NA","469":"NA","470":"NA","471":"NA","472":"NA","473":"NA","474":"NA","475":"NA","476":"NA","477":"NA","478":"NA","479":"NA","480":"NA","481":"NA","482":"NA","483":"NA","484":"NA","485":"NA","486":"NA","487":"NA","488":"NA","489":"NA","490":"NA","491":"NA","492":"NA","493":"NA","494":"NA","495":"NA","496":"NA","497":"NA","498":"NA","499":"NA","500":"NA","501":"NA","502":"NA","503":"NA","504":"NA","505":"NA","506":"NA","507":"NA","508":"NA","509":"NA","510":"NA","511":"NA","512":"NA","513":"NA","514":"NA","515":"NA","516":"NA","517":"NA","518":"NA","519":"NA","520":"NA","521":"NA","522":"NA","523":"NA","524":"NA","525":"NA","526":"NA","527":"NA","528":"NA","529":"NA","530":"NA","531":"NA","532":"NA","533":"NA","534":"862.6","535":"960.6","536":"481.6","537":"274.3","538":"536.8","539":"268.1","540":"562.2","541":"874.4","542":"379.2","543":"333.7","544":"1561.1","545":"440.5","546":"360","547":"852.9","548":"470.5","549":"173.2","550":"978.9","551":"371.4","552":"264.4","553":"1537.3","554":"699.4","555":"391","556":"177.1","557":"445","558":"649.9","559":"449.2","560":"828.3","_rn_":"14"}],"options":{"columns":{"min":{},"max":[10],"total":[560]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>get out feature (gene) data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyA8LSBmRGF0YShnc2UyNjU4X2xjKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_features &lt;- fData(gse2658_lc)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGltKGdzZTI2NThfZmVhdHVyZXMpXG5gYGAifQ== -->
<pre class="r"><code>dim(gse2658_features)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDU0Njc1ICAgIDE2XG4ifQ== -->
<pre><code>[1] 54675    16</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlc1sxOjEwLF1cbmBgYCJ9 -->
<pre class="r"><code>gse2658_features[1:10,]</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":10,"ncol":16,"summary":{"Description":["df [10 × 16]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["ID"],"name":[1],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[2],"type":["chr"],"align":["left"]},{"label":["SPOT_ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["Species Scientific Name"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Annotation Date"],"name":[5],"type":["chr"],"align":["left"]},{"label":["Sequence Type"],"name":[6],"type":["chr"],"align":["left"]},{"label":["Sequence Source"],"name":[7],"type":["chr"],"align":["left"]},{"label":["Target Description"],"name":[8],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[9],"type":["chr"],"align":["left"]},{"label":["Gene Title"],"name":[10],"type":["chr"],"align":["left"]},{"label":["Gene Symbol"],"name":[11],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[12],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[13],"type":["chr"],"align":["left"]},{"label":["Gene Ontology Biological Process"],"name":[14],"type":["chr"],"align":["left"]},{"label":["Gene Ontology Cellular Component"],"name":[15],"type":["chr"],"align":["left"]},{"label":["Gene Ontology Molecular Function"],"name":[16],"type":["chr"],"align":["left"]}],"data":[{"1":"1007_s_at","2":"U48705","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"Affymetrix Proprietary Database","8":"U48705 /FEATURE=mRNA /DEFINITION=HSU48705 Human receptor tyrosine kinase DDR gene, complete cds","9":"U48705","10":"discoidin domain receptor tyrosine kinase 1 /// microRNA 4640","11":"DDR1 /// MIR4640","12":"780 /// 100616237","13":"NM_001202521 /// NM_001202522 /// NM_001202523 /// NM_001954 /// NM_013993 /// NM_013994 /// NR_039783 /// XM_005249385 /// XM_005249386 /// XM_005249387 /// XM_005249389 /// XM_005272873 /// XM_005272874 /// XM_005272875 /// XM_005272877 /// XM_005275027 /// XM_005275028 /// XM_005275030 /// XM_005275031 /// XM_005275162 /// XM_005275163 /// XM_005275164 /// XM_005275166 /// XM_005275457 /// XM_005275458 /// XM_005275459 /// XM_005275461 /// XM_006715185 /// XM_006715186 /// XM_006715187 /// XM_006715188 /// XM_006715189 /// XM_006715190 /// XM_006725501 /// XM_006725502 /// XM_006725503 /// XM_006725504 /// XM_006725505 /// XM_006725506 /// XM_006725714 /// XM_006725715 /// XM_006725716 /// XM_006725717 /// XM_006725718 /// XM_006725719 /// XM_006725720 /// XM_006725721 /// XM_006725722 /// XM_006725827 /// XM_006725828 /// XM_006725829 /// XM_006725830 /// XM_006725831 /// XM_006725832 /// XM_006726017 /// XM_006726018 /// XM_006726019 /// XM_006726020 /// XM_006726021 /// XM_006726022 /// XR_427836 /// XR_430858 /// XR_430938 /// XR_430974 /// XR_431015","14":"0001558 // regulation of cell growth // inferred from electronic annotation /// 0001952 // regulation of cell-matrix adhesion // inferred from electronic annotation /// 0006468 // protein phosphorylation // inferred from electronic annotation /// 0007155 // cell adhesion // traceable author statement /// 0007169 // transmembrane receptor protein tyrosine kinase signaling pathway // inferred from electronic annotation /// 0007565 // female pregnancy // inferred from electronic annotation /// 0007566 // embryo implantation // inferred from electronic annotation /// 0007595 // lactation // inferred from electronic annotation /// 0008285 // negative regulation of cell proliferation // inferred from electronic annotation /// 0010715 // regulation of extracellular matrix disassembly // inferred from mutant phenotype /// 0014909 // smooth muscle cell migration // inferred from mutant phenotype /// 0016310 // phosphorylation // inferred from electronic annotation /// 0018108 // peptidyl-tyrosine phosphorylation // inferred from electronic annotation /// 0030198 // extracellular matrix organization // traceable author statement /// 0038063 // collagen-activated tyrosine kinase receptor signaling pathway // inferred from direct assay /// 0038063 // collagen-activated tyrosine kinase receptor signaling pathway // inferred from mutant phenotype /// 0038083 // peptidyl-tyrosine autophosphorylation // inferred from direct assay /// 0043583 // ear development // inferred from electronic annotation /// 0044319 // wound healing, spreading of cells // inferred from mutant phenotype /// 0046777 // protein autophosphorylation // inferred from direct assay /// 0060444 // branching involved in mammary gland duct morphogenesis // inferred from electronic annotation /// 0060749 // mammary gland alveolus development // inferred from electronic annotation /// 0061302 // smooth muscle cell-matrix adhesion // inferred from mutant phenotype","15":"0005576 // extracellular region // inferred from electronic annotation /// 0005615 // extracellular space // inferred from direct assay /// 0005886 // plasma membrane // traceable author statement /// 0005887 // integral component of plasma membrane // traceable author statement /// 0016020 // membrane // inferred from electronic annotation /// 0016021 // integral component of membrane // inferred from electronic annotation /// 0043235 // receptor complex // inferred from direct assay /// 0070062 // extracellular vesicular exosome // inferred from direct assay","16":"0000166 // nucleotide binding // inferred from electronic annotation /// 0004672 // protein kinase activity // inferred from electronic annotation /// 0004713 // protein tyrosine kinase activity // inferred from electronic annotation /// 0004714 // transmembrane receptor protein tyrosine kinase activity // traceable author statement /// 0005515 // protein binding // inferred from physical interaction /// 0005518 // collagen binding // inferred from direct assay /// 0005518 // collagen binding // inferred from mutant phenotype /// 0005524 // ATP binding // inferred from electronic annotation /// 0016301 // kinase activity // inferred from electronic annotation /// 0016740 // transferase activity // inferred from electronic annotation /// 0016772 // transferase activity, transferring phosphorus-containing groups // inferred from electronic annotation /// 0038062 // protein tyrosine kinase collagen receptor activity // inferred from direct assay /// 0046872 // metal ion binding // inferred from electronic annotation","_rn_":"1007_s_at"},{"1":"1053_at","2":"M87338","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"GenBank","8":"M87338 /FEATURE= /DEFINITION=HUMA1SBU Human replication factor C, 40-kDa subunit (A1) mRNA, complete cds","9":"M87338","10":"replication factor C (activator 1) 2, 40kDa","11":"RFC2","12":"5982","13":"NM_001278791 /// NM_001278792 /// NM_001278793 /// NM_002914 /// NM_181471 /// XM_006716080","14":"0000278 // mitotic cell cycle // traceable author statement /// 0000722 // telomere maintenance via recombination // traceable author statement /// 0000723 // telomere maintenance // traceable author statement /// 0006260 // DNA replication // traceable author statement /// 0006271 // DNA strand elongation involved in DNA replication // traceable author statement /// 0006281 // DNA repair // traceable author statement /// 0006283 // transcription-coupled nucleotide-excision repair // traceable author statement /// 0006289 // nucleotide-excision repair // traceable author statement /// 0006297 // nucleotide-excision repair, DNA gap filling // traceable author statement /// 0015979 // photosynthesis // inferred from electronic annotation /// 0015995 // chlorophyll biosynthetic process // inferred from electronic annotation /// 0032201 // telomere maintenance via semi-conservative replication // traceable author statement","15":"0005634 // nucleus // inferred from electronic annotation /// 0005654 // nucleoplasm // traceable author statement /// 0005663 // DNA replication factor C complex // inferred from direct assay","16":"0000166 // nucleotide binding // inferred from electronic annotation /// 0003677 // DNA binding // inferred from electronic annotation /// 0005515 // protein binding // inferred from physical interaction /// 0005524 // ATP binding // inferred from electronic annotation /// 0016851 // magnesium chelatase activity // inferred from electronic annotation /// 0017111 // nucleoside-triphosphatase activity // inferred from electronic annotation","_rn_":"1053_at"},{"1":"117_at","2":"X51757","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"Affymetrix Proprietary Database","8":"X51757 /FEATURE=cds /DEFINITION=HSP70B Human heat-shock protein HSP70B' gene","9":"X51757","10":"heat shock 70kDa protein 6 (HSP70B')","11":"HSPA6","12":"3310","13":"NM_002155","14":"0000902 // cell morphogenesis // inferred from electronic annotation /// 0006200 // ATP catabolic process // inferred from direct assay /// 0006950 // response to stress // inferred from electronic annotation /// 0006986 // response to unfolded protein // traceable author statement /// 0034605 // cellular response to heat // inferred from direct assay /// 0042026 // protein refolding // inferred from direct assay /// 0070370 // cellular heat acclimation // inferred from mutant phenotype","15":"0005737 // cytoplasm // inferred from direct assay /// 0005814 // centriole // inferred from direct assay /// 0005829 // cytosol // inferred from direct assay /// 0008180 // COP9 signalosome // inferred from direct assay /// 0070062 // extracellular vesicular exosome // inferred from direct assay /// 0072562 // blood microparticle // inferred from direct assay","16":"0000166 // nucleotide binding // inferred from electronic annotation /// 0005524 // ATP binding // inferred from electronic annotation /// 0019899 // enzyme binding // inferred from physical interaction /// 0031072 // heat shock protein binding // inferred from physical interaction /// 0042623 // ATPase activity, coupled // inferred from direct assay /// 0051082 // unfolded protein binding // inferred from direct assay","_rn_":"117_at"},{"1":"121_at","2":"X69699","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"GenBank","8":"X69699 /FEATURE= /DEFINITION=HSPAX8A H.sapiens Pax8 mRNA","9":"X69699","10":"paired box 8","11":"PAX8","12":"7849","13":"NM_003466 /// NM_013951 /// NM_013952 /// NM_013953 /// NM_013992","14":"0001655 // urogenital system development // inferred from sequence or structural similarity /// 0001656 // metanephros development // inferred from electronic annotation /// 0001658 // branching involved in ureteric bud morphogenesis // inferred from expression pattern /// 0001822 // kidney development // inferred from expression pattern /// 0001823 // mesonephros development // inferred from sequence or structural similarity /// 0003337 // mesenchymal to epithelial transition involved in metanephros morphogenesis // inferred from expression pattern /// 0006351 // transcription, DNA-templated // inferred from direct assay /// 0006355 // regulation of transcription, DNA-templated // inferred from electronic annotation /// 0007275 // multicellular organismal development // inferred from electronic annotation /// 0007417 // central nervous system development // inferred from expression pattern /// 0009653 // anatomical structure morphogenesis // traceable author statement /// 0030154 // cell differentiation // inferred from electronic annotation /// 0030878 // thyroid gland development // inferred from expression pattern /// 0030878 // thyroid gland development // inferred from mutant phenotype /// 0038194 // thyroid-stimulating hormone signaling pathway // traceable author statement /// 0039003 // pronephric field specification // inferred from sequence or structural similarity /// 0042472 // inner ear morphogenesis // inferred from sequence or structural similarity /// 0042981 // regulation of apoptotic process // inferred from sequence or structural similarity /// 0045893 // positive regulation of transcription, DNA-templated // inferred from direct assay /// 0045893 // positive regulation of transcription, DNA-templated // inferred from sequence or structural similarity /// 0045944 // positive regulation of transcription from RNA polymerase II promoter // inferred from direct assay /// 0048793 // pronephros development // inferred from sequence or structural similarity /// 0071371 // cellular response to gonadotropin stimulus // inferred from direct assay /// 0071599 // otic vesicle development // inferred from expression pattern /// 0072050 // S-shaped body morphogenesis // inferred from electronic annotation /// 0072073 // kidney epithelium development // inferred from electronic annotation /// 0072108 // positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis // inferred from sequence or structural similarity /// 0072164 // mesonephric tubule development // inferred from electronic annotation /// 0072207 // metanephric epithelium development // inferred from expression pattern /// 0072221 // metanephric distal convoluted tubule development // inferred from sequence or structural similarity /// 0072278 // metanephric comma-shaped body morphogenesis // inferred from expression pattern /// 0072284 // metanephric S-shaped body morphogenesis // inferred from expression pattern /// 0072289 // metanephric nephron tubule formation // inferred from sequence or structural similarity /// 0072305 // negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis // inferred from sequence or structural similarity /// 0072307 // regulation of metanephric nephron tubule epithelial cell differentiation // inferred from sequence or structural similarity /// 0090190 // positive regulation of branching involved in ureteric bud morphogenesis // inferred from sequence or structural similarity /// 1900212 // negative regulation of mesenchymal cell apoptotic process involved in metanephros development // inferred from sequence or structural similarity /// 1900215 // negative regulation of apoptotic process involved in metanephric collecting duct development // inferred from sequence or structural similarity /// 1900218 // negative regulation of apoptotic process involved in metanephric nephron tubule development // inferred from sequence or structural similarity /// 2000594 // positive regulation of metanephric DCT cell differentiation // inferred from sequence or structural similarity /// 2000611 // positive regulation of thyroid hormone generation // inferred from mutant phenotype /// 2000612 // regulation of thyroid-stimulating hormone secretion // inferred from mutant phenotype","15":"0005634 // nucleus // inferred from direct assay /// 0005654 // nucleoplasm // inferred from sequence or structural similarity /// 0005730 // nucleolus // inferred from direct assay","16":"0000979 // RNA polymerase II core promoter sequence-specific DNA binding // inferred from direct assay /// 0003677 // DNA binding // inferred from direct assay /// 0003677 // DNA binding // inferred from mutant phenotype /// 0003700 // sequence-specific DNA binding transcription factor activity // inferred from direct assay /// 0004996 // thyroid-stimulating hormone receptor activity // traceable author statement /// 0005515 // protein binding // inferred from physical interaction /// 0044212 // transcription regulatory region DNA binding // inferred from direct assay","_rn_":"121_at"},{"1":"1255_g_at","2":"L36861","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"Affymetrix Proprietary Database","8":"L36861 /FEATURE=expanded_cds /DEFINITION=HUMGCAPB Homo sapiens guanylate cyclase activating protein (GCAP) gene exons 1-4, complete cds","9":"L36861","10":"guanylate cyclase activator 1A (retina)","11":"GUCA1A","12":"2978","13":"NM_000409 /// XM_006715073","14":"0007165 // signal transduction // non-traceable author statement /// 0007601 // visual perception // inferred from electronic annotation /// 0007602 // phototransduction // inferred from electronic annotation /// 0007603 // phototransduction, visible light // traceable author statement /// 0016056 // rhodopsin mediated signaling pathway // traceable author statement /// 0022400 // regulation of rhodopsin mediated signaling pathway // traceable author statement /// 0030828 // positive regulation of cGMP biosynthetic process // inferred from electronic annotation /// 0031282 // regulation of guanylate cyclase activity // inferred from electronic annotation /// 0031284 // positive regulation of guanylate cyclase activity // inferred from electronic annotation /// 0050896 // response to stimulus // inferred from electronic annotation","15":"0001750 // photoreceptor outer segment // inferred from electronic annotation /// 0001917 // photoreceptor inner segment // inferred from electronic annotation /// 0005578 // proteinaceous extracellular matrix // inferred from electronic annotation /// 0005886 // plasma membrane // inferred from direct assay /// 0016020 // membrane // inferred from electronic annotation /// 0097381 // photoreceptor disc membrane // traceable author statement","16":"0005509 // calcium ion binding // inferred from electronic annotation /// 0008048 // calcium sensitive guanylate cyclase activator activity // inferred from electronic annotation /// 0030249 // guanylate cyclase regulator activity // inferred from electronic annotation /// 0046872 // metal ion binding // inferred from electronic annotation","_rn_":"1255_g_at"},{"1":"1294_at","2":"L13852","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"GenBank","8":"L13852 /FEATURE= /DEFINITION=HUME1URP Homo sapiens ubiquitin-activating enzyme E1 related protein mRNA, complete cds","9":"L13852","10":"microRNA 5193 /// ubiquitin-like modifier activating enzyme 7","11":"MIR5193 /// UBA7","12":"7318 /// 100847079","13":"NM_003335 /// NR_049825 /// XM_005265430 /// XM_006713321","14":"0006464 // cellular protein modification process // inferred from direct assay /// 0016567 // protein ubiquitination // not recorded /// 0016567 // protein ubiquitination // inferred from electronic annotation /// 0019221 // cytokine-mediated signaling pathway // traceable author statement /// 0019941 // modification-dependent protein catabolic process // not recorded /// 0032020 // ISG15-protein conjugation // inferred from direct assay /// 0032480 // negative regulation of type I interferon production // traceable author statement /// 0045087 // innate immune response // traceable author statement","15":"0005634 // nucleus // not recorded /// 0005829 // cytosol // not recorded /// 0005829 // cytosol // traceable author statement","16":"0000166 // nucleotide binding // inferred from electronic annotation /// 0003824 // catalytic activity // inferred from electronic annotation /// 0004839 // ubiquitin activating enzyme activity // not recorded /// 0004842 // ubiquitin-protein transferase activity // not recorded /// 0005524 // ATP binding // inferred from electronic annotation /// 0008641 // small protein activating enzyme activity // inferred from electronic annotation /// 0016874 // ligase activity // inferred from electronic annotation /// 0019782 // ISG15 activating enzyme activity // inferred from direct assay","_rn_":"1294_at"},{"1":"1316_at","2":"X55005","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"Affymetrix Proprietary Database","8":"X55005 /FEATURE=mRNA /DEFINITION=HSCERBAR Homo sapiens mRNA for thyroid hormone receptor alpha 1 THRA1, (c-erbA-1 gene)","9":"X55005","10":"thyroid hormone receptor, alpha","11":"THRA","12":"7067","13":"NM_001190918 /// NM_001190919 /// NM_003250 /// NM_199334","14":"0000122 // negative regulation of transcription from RNA polymerase II promoter // inferred from direct assay /// 0000122 // negative regulation of transcription from RNA polymerase II promoter // inferred from mutant phenotype /// 0001502 // cartilage condensation // inferred from electronic annotation /// 0001503 // ossification // inferred from electronic annotation /// 0002155 // regulation of thyroid hormone mediated signaling pathway // inferred from electronic annotation /// 0005978 // glycogen biosynthetic process // inferred from sequence or structural similarity /// 0006351 // transcription, DNA-templated // inferred from electronic annotation /// 0006355 // regulation of transcription, DNA-templated // inferred from electronic annotation /// 0006357 // regulation of transcription from RNA polymerase II promoter // inferred from direct assay /// 0006366 // transcription from RNA polymerase II promoter // inferred from direct assay /// 0006367 // transcription initiation from RNA polymerase II promoter // traceable author statement /// 0007611 // learning or memory // inferred from electronic annotation /// 0007623 // circadian rhythm // inferred from electronic annotation /// 0008016 // regulation of heart contraction // inferred from electronic annotation /// 0008050 // female courtship behavior // inferred from electronic annotation /// 0009409 // response to cold // inferred from electronic annotation /// 0009755 // hormone-mediated signaling pathway // inferred from direct assay /// 0009887 // organ morphogenesis // inferred from electronic annotation /// 0010467 // gene expression // traceable author statement /// 0010498 // proteasomal protein catabolic process // inferred from sequence or structural similarity /// 0010831 // positive regulation of myotube differentiation // inferred from electronic annotation /// 0010871 // negative regulation of receptor biosynthetic process // inferred from mutant phenotype /// 0017055 // negative regulation of RNA polymerase II transcriptional preinitiation complex assembly // inferred from direct assay /// 0019216 // regulation of lipid metabolic process // inferred from sequence or structural similarity /// 0030154 // cell differentiation // inferred from electronic annotation /// 0030218 // erythrocyte differentiation // inferred from electronic annotation /// 0030522 // intracellular receptor signaling pathway // inferred from electronic annotation /// 0030878 // thyroid gland development // inferred from electronic annotation /// 0032922 // circadian regulation of gene expression // inferred from sequence or structural similarity /// 0033032 // regulation of myeloid cell apoptotic process // inferred from electronic annotation /// 0034144 // negative regulation of toll-like receptor 4 signaling pathway // inferred from mutant phenotype /// 0035947 // regulation of gluconeogenesis by regulation of transcription from RNA polymerase II promoter // inferred from mutant phenotype /// 0042752 // regulation of circadian rhythm // inferred from sequence or structural similarity /// 0042994 // cytoplasmic sequestering of transcription factor // inferred from electronic annotation /// 0043401 // steroid hormone mediated signaling pathway // inferred from electronic annotation /// 0044321 // response to leptin // inferred from sequence or structural similarity /// 0045598 // regulation of fat cell differentiation // inferred from sequence or structural similarity /// 0045892 // negative regulation of transcription, DNA-templated // inferred from direct assay /// 0045893 // positive regulation of transcription, DNA-templated // inferred from sequence or structural similarity /// 0045925 // positive regulation of female receptivity // inferred from electronic annotation /// 0045944 // positive regulation of transcription from RNA polymerase II promoter // inferred from electronic annotation /// 0048511 // rhythmic process // inferred from electronic annotation /// 0050994 // regulation of lipid catabolic process // inferred from electronic annotation /// 0060086 // circadian temperature homeostasis // inferred from sequence or structural similarity /// 0060509 // Type I pneumocyte differentiation // inferred from electronic annotation /// 0061178 // regulation of insulin secretion involved in cellular response to glucose stimulus // inferred from sequence or structural similarity /// 0061469 // regulation of type B pancreatic cell proliferation // inferred from sequence or structural similarity /// 0070859 // positive regulation of bile acid biosynthetic process // inferred from sequence or structural similarity /// 0071222 // cellular response to lipopolysaccharide // inferred from mutant phenotype /// 2000143 // negative regulation of DNA-templated transcription, initiation // inferred from direct assay /// 2000188 // regulation of cholesterol homeostasis // inferred from sequence or structural similarity /// 2000189 // positive regulation of cholesterol homeostasis // inferred from direct assay","15":"0000790 // nuclear chromatin // inferred from direct assay /// 0005634 // nucleus // inferred from direct assay /// 0005654 // nucleoplasm // traceable author statement /// 0005737 // cytoplasm // inferred from electronic annotation /// 0005737 // cytoplasm // inferred from sequence or structural similarity /// 0005829 // cytosol // inferred from direct assay /// 0030425 // dendrite // inferred from electronic annotation /// 0030425 // dendrite // inferred from sequence or structural similarity /// 0042995 // cell projection // inferred from electronic annotation /// 0043197 // dendritic spine // inferred from electronic annotation /// 0043197 // dendritic spine // inferred from sequence or structural similarity","16":"0000978 // RNA polymerase II core promoter proximal region sequence-specific DNA binding // inferred from mutant phenotype /// 0001046 // core promoter sequence-specific DNA binding // inferred from direct assay /// 0001078 // RNA polymerase II core promoter proximal region sequence-specific DNA binding transcription factor activity involved in negative regulation of transcription // inferred from direct assay /// 0001222 // transcription corepressor binding // inferred from direct assay /// 0001222 // transcription corepressor binding // inferred from mutant phenotype /// 0002153 // steroid receptor RNA activator RNA binding // inferred from electronic annotation /// 0003677 // DNA binding // inferred from electronic annotation /// 0003700 // sequence-specific DNA binding transcription factor activity // inferred from direct assay /// 0003707 // steroid hormone receptor activity // inferred from electronic annotation /// 0003714 // transcription corepressor activity // traceable author statement /// 0003727 // single-stranded RNA binding // inferred from electronic annotation /// 0004879 // ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity // traceable author statement /// 0004879 // ligand-activated sequence-specific DNA binding RNA polymerase II transcription factor activity // inferred from electronic annotation /// 0004887 // thyroid hormone receptor activity // inferred from direct assay /// 0005515 // protein binding // inferred from physical interaction /// 0008134 // transcription factor binding // inferred from physical interaction /// 0008270 // zinc ion binding // inferred from electronic annotation /// 0017025 // TBP-class protein binding // inferred from direct assay /// 0019904 // protein domain specific binding // inferred from physical interaction /// 0020037 // heme binding // inferred from direct assay /// 0031490 // chromatin DNA binding // inferred from electronic annotation /// 0032403 // protein complex binding // inferred from electronic annotation /// 0043565 // sequence-specific DNA binding // inferred from electronic annotation /// 0044212 // transcription regulatory region DNA binding // inferred from direct assay /// 0046872 // metal ion binding // inferred from electronic annotation /// 0070324 // thyroid hormone binding // inferred from direct assay /// 0070324 // thyroid hormone binding // inferred from physical interaction","_rn_":"1316_at"},{"1":"1320_at","2":"X79510","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"Affymetrix Proprietary Database","8":"X79510 /FEATURE=cds /DEFINITION=HSPTPD1 H.sapiens mRNA for protein-tyrosine-phosphatase D1","9":"X79510","10":"protein tyrosine phosphatase, non-receptor type 21","11":"PTPN21","12":"11099","13":"NM_007039 /// XM_005267287 /// XM_006720011","14":"0006470 // protein dephosphorylation // traceable author statement /// 0016311 // dephosphorylation // inferred from electronic annotation /// 0035335 // peptidyl-tyrosine dephosphorylation // inferred from electronic annotation /// 0035335 // peptidyl-tyrosine dephosphorylation // traceable author statement","15":"0005737 // cytoplasm // inferred from electronic annotation /// 0005856 // cytoskeleton // inferred from electronic annotation","16":"0004721 // phosphoprotein phosphatase activity // inferred from electronic annotation /// 0004725 // protein tyrosine phosphatase activity // inferred from electronic annotation /// 0005515 // protein binding // inferred from physical interaction /// 0016787 // hydrolase activity // inferred from electronic annotation /// 0016791 // phosphatase activity // inferred from electronic annotation","_rn_":"1320_at"},{"1":"1405_i_at","2":"M21121","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"GenBank","8":"M21121 /FEATURE= /DEFINITION=HUMTCSM Human T cell-specific protein (RANTES) mRNA, complete cds","9":"M21121","10":"chemokine (C-C motif) ligand 5","11":"CCL5","12":"6352","13":"NM_001278736 /// NM_002985","14":"0000165 // MAPK cascade // inferred from mutant phenotype /// 0002407 // dendritic cell chemotaxis // traceable author statement /// 0002548 // monocyte chemotaxis // inferred by curator /// 0002676 // regulation of chronic inflammatory response // traceable author statement /// 0006468 // protein phosphorylation // inferred from direct assay /// 0006816 // calcium ion transport // inferred from direct assay /// 0006874 // cellular calcium ion homeostasis // inferred from direct assay /// 0006887 // exocytosis // inferred from direct assay /// 0006935 // chemotaxis // non-traceable author statement /// 0006954 // inflammatory response // inferred from direct assay /// 0006955 // immune response // inferred from electronic annotation /// 0007159 // leukocyte cell-cell adhesion // inferred from direct assay /// 0007267 // cell-cell signaling // inferred from direct assay /// 0009615 // response to virus // traceable author statement /// 0009636 // response to toxic substance // inferred from direct assay /// 0010535 // positive regulation of activation of JAK2 kinase activity // traceable author statement /// 0010759 // positive regulation of macrophage chemotaxis // inferred from direct assay /// 0010820 // positive regulation of T cell chemotaxis // inferred from direct assay /// 0014068 // positive regulation of phosphatidylinositol 3-kinase signaling // inferred from direct assay /// 0014911 // positive regulation of smooth muscle cell migration // inferred from direct assay /// 0030335 // positive regulation of cell migration // inferred from direct assay /// 0031328 // positive regulation of cellular biosynthetic process // inferred from direct assay /// 0031584 // activation of phospholipase D activity // inferred from direct assay /// 0031663 // lipopolysaccharide-mediated signaling pathway // inferred from direct assay /// 0033634 // positive regulation of cell-cell adhesion mediated by integrin // inferred from direct assay /// 0034097 // response to cytokine // inferred from electronic annotation /// 0034112 // positive regulation of homotypic cell-cell adhesion // inferred from direct assay /// 0034612 // response to tumor necrosis factor // inferred from electronic annotation /// 0042102 // positive regulation of T cell proliferation // inferred from direct assay /// 0042119 // neutrophil activation // inferred from direct assay /// 0042327 // positive regulation of phosphorylation // inferred from direct assay /// 0042531 // positive regulation of tyrosine phosphorylation of STAT protein // inferred from direct assay /// 0043491 // protein kinase B signaling // inferred from mutant phenotype /// 0043623 // cellular protein complex assembly // inferred from direct assay /// 0043922 // negative regulation by host of viral transcription // inferred from direct assay /// 0044344 // cellular response to fibroblast growth factor stimulus // inferred from expression pattern /// 0045070 // positive regulation of viral genome replication // traceable author statement /// 0045071 // negative regulation of viral genome replication // inferred from direct assay /// 0045089 // positive regulation of innate immune response // traceable author statement /// 0045744 // negative regulation of G-protein coupled receptor protein signaling pathway // inferred from direct assay /// 0045785 // positive regulation of cell adhesion // inferred from direct assay /// 0045948 // positive regulation of translational initiation // non-traceable author statement /// 0046427 // positive regulation of JAK-STAT cascade // traceable author statement /// 0048245 // eosinophil chemotaxis // inferred from direct assay /// 0048246 // macrophage chemotaxis // traceable author statement /// 0048661 // positive regulation of smooth muscle cell proliferation // inferred from direct assay /// 0050679 // positive regulation of epithelial cell proliferation // inferred from electronic annotation /// 0050863 // regulation of T cell activation // inferred from direct assay /// 0050918 // positive chemotaxis // inferred from direct assay /// 0051262 // protein tetramerization // inferred from direct assay /// 0051928 // positive regulation of calcium ion transport // inferred from direct assay /// 0060326 // cell chemotaxis // inferred from electronic annotation /// 0061098 // positive regulation of protein tyrosine kinase activity // inferred from direct assay /// 0070098 // chemokine-mediated signaling pathway // traceable author statement /// 0070100 // negative regulation of chemokine-mediated signaling pathway // inferred from direct assay /// 0070233 // negative regulation of T cell apoptotic process // inferred from direct assay /// 0070234 // positive regulation of T cell apoptotic process // inferred from direct assay /// 0071346 // cellular response to interferon-gamma // inferred from expression pattern /// 0071347 // cellular response to interleukin-1 // inferred from expression pattern /// 0071356 // cellular response to tumor necrosis factor // inferred from expression pattern /// 0071407 // cellular response to organic cyclic compound // inferred from direct assay /// 0090026 // positive regulation of monocyte chemotaxis // inferred from direct assay /// 2000110 // negative regulation of macrophage apoptotic process // inferred from electronic annotation /// 2000406 // positive regulation of T cell migration // inferred from direct assay /// 2000503 // positive regulation of natural killer cell chemotaxis // inferred from direct assay","15":"0005576 // extracellular region // traceable author statement /// 0005615 // extracellular space // inferred from electronic annotation /// 0005737 // cytoplasm // inferred from electronic annotation","16":"0004435 // phosphatidylinositol phospholipase C activity // inferred from direct assay /// 0004672 // protein kinase activity // inferred from direct assay /// 0005125 // cytokine activity // inferred from electronic annotation /// 0005515 // protein binding // inferred from physical interaction /// 0008009 // chemokine activity // inferred from direct assay /// 0008009 // chemokine activity // non-traceable author statement /// 0016004 // phospholipase activator activity // inferred from direct assay /// 0030298 // receptor signaling protein tyrosine kinase activator activity // inferred from direct assay /// 0031726 // CCR1 chemokine receptor binding // inferred from direct assay /// 0031726 // CCR1 chemokine receptor binding // inferred from physical interaction /// 0031726 // CCR1 chemokine receptor binding // traceable author statement /// 0031729 // CCR4 chemokine receptor binding // traceable author statement /// 0031730 // CCR5 chemokine receptor binding // inferred from physical interaction /// 0042056 // chemoattractant activity // inferred from direct assay /// 0042379 // chemokine receptor binding // inferred from physical interaction /// 0042803 // protein homodimerization activity // inferred from direct assay /// 0043621 // protein self-association // inferred from direct assay /// 0046817 // chemokine receptor antagonist activity // inferred from direct assay","_rn_":"1405_i_at"},{"1":"1431_at","2":"J02843","3":"","4":"Homo sapiens","5":"Oct 6, 2014","6":"Exemplar sequence","7":"Affymetrix Proprietary Database","8":"J02843 /FEATURE=cds /DEFINITION=HUMCYPIIE Human cytochrome P450IIE1 (ethanol-inducible) gene, complete cds","9":"J02843","10":"cytochrome P450, family 2, subfamily E, polypeptide 1","11":"CYP2E1","12":"1571","13":"NM_000773","14":"0006641 // triglyceride metabolic process // inferred from electronic annotation /// 0006805 // xenobiotic metabolic process // traceable author statement /// 0008202 // steroid metabolic process // inferred from mutant phenotype /// 0010193 // response to ozone // inferred from electronic annotation /// 0010243 // response to organonitrogen compound // inferred from electronic annotation /// 0016098 // monoterpenoid metabolic process // inferred from direct assay /// 0017144 // drug metabolic process // inferred from direct assay /// 0017144 // drug metabolic process // inferred from mutant phenotype /// 0042493 // response to drug // inferred from electronic annotation /// 0044281 // small molecule metabolic process // traceable author statement /// 0045471 // response to ethanol // inferred from electronic annotation /// 0046483 // heterocycle metabolic process // inferred from direct assay /// 0055114 // oxidation-reduction process // inferred from direct assay","15":"0000139 // Golgi membrane // inferred from electronic annotation /// 0005739 // mitochondrion // inferred from electronic annotation /// 0005783 // endoplasmic reticulum // inferred from electronic annotation /// 0005789 // endoplasmic reticulum membrane // traceable author statement /// 0016020 // membrane // inferred from electronic annotation /// 0031090 // organelle membrane // inferred from electronic annotation /// 0031227 // intrinsic component of endoplasmic reticulum membrane // inferred from electronic annotation /// 0043231 // intracellular membrane-bounded organelle // inferred from electronic annotation","16":"0004497 // monooxygenase activity // inferred from direct assay /// 0005506 // iron ion binding // inferred from electronic annotation /// 0009055 // electron carrier activity // inferred from electronic annotation /// 0016491 // oxidoreductase activity // inferred from direct assay /// 0016705 // oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen // inferred from electronic annotation /// 0016709 // oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen // traceable author statement /// 0016712 // oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen // inferred from electronic annotation /// 0019825 // oxygen binding // traceable author statement /// 0019899 // enzyme binding // inferred from physical interaction /// 0020037 // heme binding // inferred from direct assay /// 0046872 // metal ion binding // inferred from electronic annotation /// 0070330 // aromatase activity // inferred from electronic annotation","_rn_":"1431_at"}],"options":{"columns":{"min":{},"max":[10],"total":[16]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>there are several gene identifiers for each probe, unfortunately none are ensembl ID<br />
and none other than the probe ID (col==<code>ID</code>) are unique</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGVuZ3RoKHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJElEKSlcbmBgYCJ9 -->
<pre class="r"><code>length(unique(gse2658_features$ID))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDU0Njc1XG4ifQ== -->
<pre><code>[1] 54675</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>these are gene ID/names below</p>
<p>genbank accession</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGVuZ3RoKHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJEdCX0FDQykpXG5gYGAifQ== -->
<pre class="r"><code>length(unique(gse2658_features$GB_ACC))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDUxMjc3XG4ifQ== -->
<pre><code>[1] 51277</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGVuZ3RoKHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJGBSZXByZXNlbnRhdGl2ZSBQdWJsaWMgSURgKSlcbmBgYCJ9 -->
<pre class="r"><code>length(unique(gse2658_features$`Representative Public ID`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDUxMzM4XG4ifQ== -->
<pre><code>[1] 51338</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>this one is the most name like</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGVuZ3RoKHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJGBHZW5lIFN5bWJvbGApKVxuYGBgIn0= -->
<pre class="r"><code>length(unique(gse2658_features$`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDIzNTIxXG4ifQ== -->
<pre><code>[1] 23521</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgZ3JvdXBfYnkoYEdlbmUgU3ltYm9sYCkgJT4lIHN1bW1hcmlzZShuPW4oKSkgJT4lIGFycmFuZ2UoZGVzYyhuKSlcbmBgYCJ9 -->
<pre class="r"><code>gse2658_features %&gt;% group_by(`Gene Symbol`) %&gt;% summarise(n=n()) %&gt;% arrange(desc(n))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["tbl_df","tbl","data.frame"],"nrow":23521,"ncol":2,"summary":{"A tibble":["23,521 × 2"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["n"],"name":[2],"type":["int"],"align":["right"]}],"data":[{"1":"","2":"8893"},{"1":"HFE","2":"15"},{"1":"ARHGEF12","2":"13"},{"1":"CD44","2":"13"},{"1":"CSNK1A1","2":"13"},{"1":"DNAH1","2":"13"},{"1":"LOC100506403 /// LOC101928269 /// RUNX1","2":"13"},{"1":"TCF3","2":"13"},{"1":"CFLAR","2":"12"},{"1":"GNAS","2":"12"},{"1":"MAGI1","2":"12"},{"1":"MALAT1","2":"12"},{"1":"ZBTB20","2":"12"},{"1":"CALD1","2":"11"},{"1":"FGFR2","2":"11"},{"1":"IGK /// IGKC","2":"11"},{"1":"NRP2","2":"11"},{"1":"OFCC1","2":"11"},{"1":"PAPPA","2":"11"},{"1":"SLC8A1","2":"11"},{"1":"SPTBN1","2":"11"},{"1":"CALM1 /// CALM2 /// CALM3","2":"10"},{"1":"DST","2":"10"},{"1":"HCG18","2":"10"},{"1":"HIPK2","2":"10"},{"1":"IDS","2":"10"},{"1":"KMT2A","2":"10"},{"1":"MDM2","2":"10"},{"1":"MED28","2":"10"},{"1":"MEG3","2":"10"},{"1":"PDLIM5","2":"10"},{"1":"PML","2":"10"},{"1":"PTGER3","2":"10"},{"1":"QKI","2":"10"},{"1":"RGS12","2":"10"},{"1":"SLC25A37","2":"10"},{"1":"STRN","2":"10"},{"1":"ACTB /// ACTG1","2":"9"},{"1":"AKAP13","2":"9"},{"1":"ALDOB","2":"9"},{"1":"ARHGEF7","2":"9"},{"1":"ASPH","2":"9"},{"1":"C1orf86","2":"9"},{"1":"DCAF8","2":"9"},{"1":"EGFR","2":"9"},{"1":"ERICH1","2":"9"},{"1":"ESR1","2":"9"},{"1":"FAM120A","2":"9"},{"1":"FBXO9","2":"9"},{"1":"FOXP2","2":"9"},{"1":"GART","2":"9"},{"1":"GOSR2","2":"9"},{"1":"HMGA2","2":"9"},{"1":"IKZF1","2":"9"},{"1":"LMF1","2":"9"},{"1":"LOC101929336 /// RIF1","2":"9"},{"1":"LOC101930150 /// NF1","2":"9"},{"1":"LRRFIP1","2":"9"},{"1":"MIR612 /// NEAT1","2":"9"},{"1":"MSI2","2":"9"},{"1":"NPAS3","2":"9"},{"1":"NTRK3","2":"9"},{"1":"PPARA","2":"9"},{"1":"RHEB","2":"9"},{"1":"SMARCA4","2":"9"},{"1":"TNPO1","2":"9"},{"1":"TRIO","2":"9"},{"1":"VPS53","2":"9"},{"1":"YME1L1","2":"9"},{"1":"ZDHHC21","2":"9"},{"1":"ZNF207","2":"9"},{"1":"ADAM22","2":"8"},{"1":"AFF4","2":"8"},{"1":"APLP2","2":"8"},{"1":"ARSD","2":"8"},{"1":"BRWD1","2":"8"},{"1":"CAPRIN1","2":"8"},{"1":"CD84","2":"8"},{"1":"CDC14B","2":"8"},{"1":"CDK12","2":"8"},{"1":"COL6A1","2":"8"},{"1":"DIP2A","2":"8"},{"1":"DNAH6","2":"8"},{"1":"DOCK5","2":"8"},{"1":"DR1","2":"8"},{"1":"DTNA","2":"8"},{"1":"FOXP1","2":"8"},{"1":"FRMD4A","2":"8"},{"1":"GGA2","2":"8"},{"1":"GLS","2":"8"},{"1":"HDGFRP3","2":"8"},{"1":"HNRNPD","2":"8"},{"1":"ITSN1","2":"8"},{"1":"KLF12","2":"8"},{"1":"LPP","2":"8"},{"1":"MAATS1","2":"8"},{"1":"MACF1","2":"8"},{"1":"MATR3 /// SNHG4","2":"8"},{"1":"MBP","2":"8"},{"1":"MCF2L","2":"8"},{"1":"MLLT10","2":"8"},{"1":"N4BP2L1","2":"8"},{"1":"NAV1","2":"8"},{"1":"NF2","2":"8"},{"1":"NFIB","2":"8"},{"1":"NKTR","2":"8"},{"1":"NUCKS1","2":"8"},{"1":"PAX8","2":"8"},{"1":"PIAS2","2":"8"},{"1":"RBBP6","2":"8"},{"1":"RNF213","2":"8"},{"1":"RORA","2":"8"},{"1":"RPL13 /// SNORD68","2":"8"},{"1":"SLC6A2","2":"8"},{"1":"SOBP","2":"8"},{"1":"SOX6","2":"8"},{"1":"SRSF1","2":"8"},{"1":"TCF4","2":"8"},{"1":"TNRC18","2":"8"},{"1":"TOR1AIP2","2":"8"},{"1":"TRPM3","2":"8"},{"1":"UBE2H","2":"8"},{"1":"AAK1","2":"7"},{"1":"ABI2","2":"7"},{"1":"ACTR2","2":"7"},{"1":"AKT3","2":"7"},{"1":"ANK1","2":"7"},{"1":"ANKH","2":"7"},{"1":"APBB2","2":"7"},{"1":"ARID1B","2":"7"},{"1":"ARL17A /// ARL17B /// LOC100294341","2":"7"},{"1":"ARRB1","2":"7"},{"1":"ATP5S","2":"7"},{"1":"ATP6V0E1","2":"7"},{"1":"ATXN3","2":"7"},{"1":"BBX","2":"7"},{"1":"BCL2L11","2":"7"},{"1":"BMP1","2":"7"},{"1":"BRD4","2":"7"},{"1":"CA12","2":"7"},{"1":"CAMSAP1","2":"7"},{"1":"CAND1","2":"7"},{"1":"CASP2","2":"7"},{"1":"CCDC171","2":"7"},{"1":"CD47","2":"7"},{"1":"CD6","2":"7"},{"1":"CDK13","2":"7"},{"1":"CDK6","2":"7"},{"1":"CELF1","2":"7"},{"1":"CELF2","2":"7"},{"1":"CELF4","2":"7"},{"1":"CHD9","2":"7"},{"1":"CHDH","2":"7"},{"1":"COL4A3","2":"7"},{"1":"CREB1","2":"7"},{"1":"CYLD","2":"7"},{"1":"CYP19A1","2":"7"},{"1":"CYP2C9","2":"7"},{"1":"DCAF7","2":"7"},{"1":"DCN","2":"7"},{"1":"DLG1","2":"7"},{"1":"DNAJC21","2":"7"},{"1":"DNASE1","2":"7"},{"1":"DYNC1H1","2":"7"},{"1":"EFCAB14","2":"7"},{"1":"EFCAB6","2":"7"},{"1":"EHD4","2":"7"},{"1":"EIF1","2":"7"},{"1":"EPG5","2":"7"},{"1":"FBXO32","2":"7"},{"1":"FGD2","2":"7"},{"1":"FGFR1","2":"7"},{"1":"FGFR1OP2","2":"7"},{"1":"FN1","2":"7"},{"1":"FOXK2","2":"7"},{"1":"FOXN3","2":"7"},{"1":"FUT6","2":"7"},{"1":"G3BP1","2":"7"},{"1":"GAB1","2":"7"},{"1":"GATM","2":"7"},{"1":"GM2A","2":"7"},{"1":"GPATCH2L","2":"7"},{"1":"HIF3A","2":"7"},{"1":"HNRNPC","2":"7"},{"1":"IL6ST","2":"7"},{"1":"IPW /// LOC101930404 /// PWARSN /// SNORD107 /// SNORD115-13 /// SNORD115-26 /// SNORD115-7 /// SNORD116-22 /// SNORD116-28 /// SNORD116-4 /// SNRPN","2":"7"},{"1":"ITGB1","2":"7"},{"1":"ITGB3","2":"7"},{"1":"KALRN","2":"7"},{"1":"KDM4B","2":"7"},{"1":"KIAA1109","2":"7"},{"1":"KIAA1217","2":"7"},{"1":"LOC101928623 /// LOC401320","2":"7"},{"1":"LRCH3","2":"7"},{"1":"LZTS1","2":"7"},{"1":"MAP3K13","2":"7"},{"1":"MAP3K2","2":"7"},{"1":"MAP4","2":"7"},{"1":"MAPK1","2":"7"},{"1":"MAST4","2":"7"},{"1":"MBNL1","2":"7"},{"1":"METTL15","2":"7"},{"1":"MLLT4","2":"7"},{"1":"MS4A6A","2":"7"},{"1":"MTHFD2L","2":"7"},{"1":"MYH11","2":"7"},{"1":"NAP1L1","2":"7"},{"1":"NCAM1","2":"7"},{"1":"NFIA","2":"7"},{"1":"NR6A1","2":"7"},{"1":"OBSL1","2":"7"},{"1":"PARVA","2":"7"},{"1":"PAWR","2":"7"},{"1":"PCBP1-AS1","2":"7"},{"1":"PCNX","2":"7"},{"1":"PDE1A","2":"7"},{"1":"PDLIM7","2":"7"},{"1":"PHF20L1","2":"7"},{"1":"PIK3C2A","2":"7"},{"1":"PIK3C3","2":"7"},{"1":"PLD1","2":"7"},{"1":"POU2F2","2":"7"},{"1":"PRLR","2":"7"},{"1":"PSEN1","2":"7"},{"1":"PTEN","2":"7"},{"1":"PVR","2":"7"},{"1":"RAB3IP","2":"7"},{"1":"RASAL2","2":"7"},{"1":"RBM25","2":"7"},{"1":"RBM26","2":"7"},{"1":"RBM33","2":"7"},{"1":"RBMS3","2":"7"},{"1":"RC3H2","2":"7"},{"1":"RHOJ","2":"7"},{"1":"RPAIN","2":"7"},{"1":"RREB1","2":"7"},{"1":"RUFY2","2":"7"},{"1":"RUFY3","2":"7"},{"1":"RUNX1T1","2":"7"},{"1":"SCAF11","2":"7"},{"1":"SDHC","2":"7"},{"1":"SERBP1","2":"7"},{"1":"SESN3","2":"7"},{"1":"SLAIN2","2":"7"},{"1":"SLC38A10","2":"7"},{"1":"SMARCA2","2":"7"},{"1":"SNTB2","2":"7"},{"1":"SORBS2","2":"7"},{"1":"SRC","2":"7"},{"1":"ST3GAL3","2":"7"},{"1":"STK4","2":"7"},{"1":"SVEP1","2":"7"},{"1":"SYNCRIP","2":"7"},{"1":"SYNJ2","2":"7"},{"1":"SYNPO2","2":"7"},{"1":"TBX3","2":"7"},{"1":"TCF7L2","2":"7"},{"1":"TCP11L2","2":"7"},{"1":"THADA","2":"7"},{"1":"THBS1","2":"7"},{"1":"TIA1","2":"7"},{"1":"TLK1","2":"7"},{"1":"TMCC1","2":"7"},{"1":"TMEM67","2":"7"},{"1":"TNRC6B","2":"7"},{"1":"TP63","2":"7"},{"1":"TPGS2","2":"7"},{"1":"TTBK2","2":"7"},{"1":"TTC3 /// TTC3P1","2":"7"},{"1":"TTLL5","2":"7"},{"1":"UBA6","2":"7"},{"1":"UBE2B","2":"7"},{"1":"UBE3A","2":"7"},{"1":"UGGT2","2":"7"},{"1":"USP49","2":"7"},{"1":"WHSC1L1","2":"7"},{"1":"WNK1","2":"7"},{"1":"WTAP","2":"7"},{"1":"WWC1","2":"7"},{"1":"XIAP","2":"7"},{"1":"XIST","2":"7"},{"1":"ZADH2","2":"7"},{"1":"ZAK","2":"7"},{"1":"ZBTB10","2":"7"},{"1":"ZMYM6","2":"7"},{"1":"ZNF148","2":"7"},{"1":"ABHD2","2":"6"},{"1":"ACACB","2":"6"},{"1":"ACER3","2":"6"},{"1":"ACRV1","2":"6"},{"1":"ACTB","2":"6"},{"1":"ACVR1B","2":"6"},{"1":"ADAMTSL1","2":"6"},{"1":"ADD2","2":"6"},{"1":"AFF3","2":"6"},{"1":"AGFG2","2":"6"},{"1":"AGPAT3","2":"6"},{"1":"AK2","2":"6"},{"1":"AKT2","2":"6"},{"1":"ALS2CR11","2":"6"},{"1":"ANAPC5","2":"6"},{"1":"ANKRD11","2":"6"},{"1":"ANTXR1","2":"6"},{"1":"ARHGEF28","2":"6"},{"1":"ARHGEF40","2":"6"},{"1":"ARIH1","2":"6"},{"1":"ARMC8","2":"6"},{"1":"ARNT","2":"6"},{"1":"ARPP21","2":"6"},{"1":"ASB4","2":"6"},{"1":"ASXL1","2":"6"},{"1":"ASXL2","2":"6"},{"1":"ATM","2":"6"},{"1":"ATP11A","2":"6"},{"1":"ATP11B","2":"6"},{"1":"ATP2B2","2":"6"},{"1":"ATP9B","2":"6"},{"1":"AVL9","2":"6"},{"1":"AZI2","2":"6"},{"1":"B4GALT1","2":"6"},{"1":"BCAP29","2":"6"},{"1":"BCL2L14","2":"6"},{"1":"BCLAF1","2":"6"},{"1":"BICD1","2":"6"},{"1":"BMP2K","2":"6"},{"1":"BNC2","2":"6"},{"1":"BUB3","2":"6"},{"1":"C11orf30","2":"6"},{"1":"C11orf31","2":"6"},{"1":"C11orf57","2":"6"},{"1":"C16orf13","2":"6"},{"1":"C21orf58","2":"6"},{"1":"C5orf24","2":"6"},{"1":"CACNA1E","2":"6"},{"1":"CACNB2","2":"6"},{"1":"CADPS","2":"6"},{"1":"CAMTA1","2":"6"},{"1":"CARD14","2":"6"},{"1":"CBX5","2":"6"},{"1":"CCDC88A","2":"6"},{"1":"CD24","2":"6"},{"1":"CDH6","2":"6"},{"1":"CEP41","2":"6"},{"1":"CEP89","2":"6"},{"1":"CHD2","2":"6"},{"1":"CHML","2":"6"},{"1":"CHRM3","2":"6"},{"1":"CLASP2","2":"6"},{"1":"CLEC7A","2":"6"},{"1":"CLIP1","2":"6"},{"1":"CLN6","2":"6"},{"1":"CLTA","2":"6"},{"1":"CNIH4","2":"6"},{"1":"COPS8","2":"6"},{"1":"CPM","2":"6"},{"1":"CREBZF","2":"6"},{"1":"CREM","2":"6"},{"1":"CRIPT","2":"6"},{"1":"CSRNP3","2":"6"},{"1":"CTBP2","2":"6"},{"1":"DAB2 /// LOC101926921","2":"6"},{"1":"DAZ1 /// DAZ2 /// DAZ3 /// DAZ4","2":"6"},{"1":"DBT","2":"6"},{"1":"DCUN1D1","2":"6"},{"1":"DDX3X","2":"6"},{"1":"DENND1B","2":"6"},{"1":"DHX30","2":"6"},{"1":"DICER1","2":"6"},{"1":"DLEU2","2":"6"},{"1":"DTWD1","2":"6"},{"1":"EDA","2":"6"},{"1":"EEF1A1","2":"6"},{"1":"EHF","2":"6"},{"1":"EIF3B","2":"6"},{"1":"EIF5B","2":"6"},{"1":"ELK4","2":"6"},{"1":"EML4","2":"6"},{"1":"EMP1","2":"6"},{"1":"ENAH","2":"6"},{"1":"EPB41L4B","2":"6"},{"1":"EPS15L1","2":"6"},{"1":"ERC1","2":"6"},{"1":"ETNK1","2":"6"},{"1":"EXOSC3","2":"6"},{"1":"FBXL18","2":"6"},{"1":"FBXO3","2":"6"},{"1":"FGF18","2":"6"},{"1":"FHAD1","2":"6"},{"1":"FKBP15","2":"6"},{"1":"FLT1","2":"6"},{"1":"FRYL","2":"6"},{"1":"FTCD","2":"6"},{"1":"FUS","2":"6"},{"1":"FXR1","2":"6"},{"1":"GABPB1-AS1","2":"6"},{"1":"GAPDH","2":"6"},{"1":"GATAD2A","2":"6"},{"1":"GFM1","2":"6"},{"1":"GNA11","2":"6"},{"1":"GPLD1","2":"6"},{"1":"GPR161","2":"6"},{"1":"GPR180","2":"6"},{"1":"GRIK2","2":"6"},{"1":"GSN","2":"6"},{"1":"GSPT1","2":"6"},{"1":"GUCY1A2","2":"6"},{"1":"HBA1 /// HBA2","2":"6"},{"1":"HDLBP","2":"6"},{"1":"HECTD1","2":"6"},{"1":"HECTD4","2":"6"},{"1":"HERC4","2":"6"},{"1":"HNF4A","2":"6"},{"1":"HNMT","2":"6"},{"1":"HNRNPDL","2":"6"},{"1":"HNRNPM","2":"6"},{"1":"ICA1","2":"6"},{"1":"IGFBP5","2":"6"},{"1":"IMPAD1","2":"6"},{"1":"INADL","2":"6"},{"1":"INO80D","2":"6"},{"1":"INPP4A","2":"6"},{"1":"IQCH","2":"6"},{"1":"IRGQ","2":"6"},{"1":"ITCH","2":"6"},{"1":"ITPRIPL2","2":"6"},{"1":"JMJD1C","2":"6"},{"1":"JRK","2":"6"},{"1":"KCNJ5","2":"6"},{"1":"KIF13A","2":"6"},{"1":"KMT2C","2":"6"},{"1":"KPNA1","2":"6"},{"1":"KPNB1","2":"6"},{"1":"KRR1","2":"6"},{"1":"L3MBTL1","2":"6"},{"1":"LAMA3","2":"6"},{"1":"LARP1B","2":"6"},{"1":"LARP4B","2":"6"},{"1":"LCP2","2":"6"},{"1":"LEPR /// LEPROT","2":"6"},{"1":"LGALS8","2":"6"},{"1":"LIG3","2":"6"},{"1":"LINC01128","2":"6"},{"1":"LMBR1","2":"6"},{"1":"LMNA","2":"6"},{"1":"LOC100996724 /// LOC100996761 /// LOC101929792 /// LOC101930416 /// PDE4DIP","2":"6"},{"1":"LOC101060363 /// PPIA","2":"6"},{"1":"LOC101930112 /// SPG7","2":"6"},{"1":"LOC145783 /// ZNF280D","2":"6"},{"1":"LOC283788","2":"6"},{"1":"LOC642852","2":"6"},{"1":"LOC645513","2":"6"},{"1":"LST1","2":"6"},{"1":"LUC7L3","2":"6"},{"1":"MAN1A2","2":"6"},{"1":"MAP2K5","2":"6"},{"1":"MAPT","2":"6"},{"1":"MARCH6","2":"6"},{"1":"MCL1","2":"6"},{"1":"MDM4","2":"6"},{"1":"MPRIP","2":"6"},{"1":"MPZL1","2":"6"},{"1":"MR1","2":"6"},{"1":"MTAP","2":"6"},{"1":"MTHFSD","2":"6"},{"1":"MYEF2","2":"6"},{"1":"MYH14","2":"6"},{"1":"MYLIP","2":"6"},{"1":"N4BP2L2","2":"6"},{"1":"NAA15","2":"6"},{"1":"NADK","2":"6"},{"1":"NAV2","2":"6"},{"1":"NEBL","2":"6"},{"1":"NENF","2":"6"},{"1":"NFATC2IP","2":"6"},{"1":"NFATC3","2":"6"},{"1":"NFYA","2":"6"},{"1":"NFYC","2":"6"},{"1":"NIN","2":"6"},{"1":"NLN","2":"6"},{"1":"NOL4L","2":"6"},{"1":"NOS1","2":"6"},{"1":"NR2F2","2":"6"},{"1":"NRG1","2":"6"},{"1":"NRXN1","2":"6"},{"1":"NSFL1C","2":"6"},{"1":"NTRK2","2":"6"},{"1":"NUP50","2":"6"},{"1":"OGT","2":"6"},{"1":"ORAI2","2":"6"},{"1":"OTUD7B","2":"6"},{"1":"PAK2","2":"6"},{"1":"PANK2","2":"6"},{"1":"PAPOLA","2":"6"},{"1":"PARVB","2":"6"},{"1":"PATZ1","2":"6"},{"1":"PBRM1","2":"6"},{"1":"PCBP2","2":"6"},{"1":"PCM1","2":"6"},{"1":"PDE1C","2":"6"},{"1":"PDE4D","2":"6"},{"1":"PDE5A","2":"6"},{"1":"PDE7A","2":"6"},{"1":"PDS5B","2":"6"},{"1":"PDXK","2":"6"},{"1":"PGK1","2":"6"},{"1":"PHLDA1","2":"6"},{"1":"PIEZO2","2":"6"},{"1":"PLEKHA8","2":"6"},{"1":"PLIN5","2":"6"},{"1":"PLXDC2","2":"6"},{"1":"PNISR","2":"6"},{"1":"POLH","2":"6"},{"1":"PPIL2","2":"6"},{"1":"PPM1A","2":"6"},{"1":"PPM1L","2":"6"},{"1":"PPP2R2C","2":"6"},{"1":"PPP2R5C","2":"6"},{"1":"PRKCB","2":"6"},{"1":"PRMT2","2":"6"},{"1":"PRPF40A","2":"6"},{"1":"PRRC2C","2":"6"},{"1":"PTPN11","2":"6"},{"1":"PTPN2","2":"6"},{"1":"RAB18","2":"6"},{"1":"RAB2A","2":"6"},{"1":"RAB7A","2":"6"},{"1":"RBBP4","2":"6"},{"1":"RBM8A","2":"6"},{"1":"RBMS1","2":"6"},{"1":"RBMS2","2":"6"},{"1":"RBPMS","2":"6"},{"1":"RGS5","2":"6"},{"1":"RHOBTB3","2":"6"},{"1":"RHOQ","2":"6"},{"1":"RNASET2","2":"6"},{"1":"RNF130","2":"6"},{"1":"RNF207","2":"6"},{"1":"RPRD1A","2":"6"},{"1":"RQCD1","2":"6"},{"1":"RRBP1","2":"6"},{"1":"RSF1","2":"6"},{"1":"RUNX2","2":"6"},{"1":"SAMHD1","2":"6"},{"1":"SAP30L","2":"6"},{"1":"SARDH","2":"6"},{"1":"SCAMP1","2":"6"},{"1":"SCAND2P","2":"6"},{"1":"SCN8A","2":"6"},{"1":"SEC22C","2":"6"},{"1":"SERP2","2":"6"},{"1":"SERPINB13","2":"6"},{"1":"SETDB2","2":"6"},{"1":"SEZ6L","2":"6"},{"1":"SFT2D3 /// WDR33","2":"6"},{"1":"SGCD","2":"6"},{"1":"SIK3","2":"6"},{"1":"SKAP2","2":"6"},{"1":"SLC11A1","2":"6"},{"1":"SLC13A3","2":"6"},{"1":"SLC35E1","2":"6"},{"1":"SLC39A8","2":"6"},{"1":"SLC44A1","2":"6"},{"1":"SLFN5","2":"6"},{"1":"SMAD2","2":"6"},{"1":"SMCHD1","2":"6"},{"1":"SMEK2","2":"6"},{"1":"SMIM7","2":"6"},{"1":"SNX5","2":"6"},{"1":"SOS2","2":"6"},{"1":"SOX4","2":"6"},{"1":"SP100","2":"6"},{"1":"SREK1","2":"6"},{"1":"SRGAP1","2":"6"},{"1":"SRP72","2":"6"},{"1":"SRPK2","2":"6"},{"1":"SRSF3","2":"6"},{"1":"SSBP2","2":"6"},{"1":"SSR1","2":"6"},{"1":"SSX2IP","2":"6"},{"1":"STAT1","2":"6"},{"1":"SUB1","2":"6"},{"1":"SYNRG","2":"6"},{"1":"TACC1","2":"6"},{"1":"TAOK1","2":"6"},{"1":"TAPT1","2":"6"},{"1":"TBL1X","2":"6"},{"1":"TBL1XR1","2":"6"},{"1":"TBRG1","2":"6"},{"1":"TCL6","2":"6"},{"1":"THSD4","2":"6"},{"1":"TMED5","2":"6"},{"1":"TMEM165","2":"6"},{"1":"TMEM259","2":"6"},{"1":"TMF1","2":"6"},{"1":"TNRC6A","2":"6"},{"1":"TPM1","2":"6"},{"1":"TRIM2","2":"6"},{"1":"TSC22D2","2":"6"},{"1":"TSHZ2","2":"6"},{"1":"TTC17","2":"6"},{"1":"TUBA1B","2":"6"},{"1":"UBE2D3","2":"6"},{"1":"UBE2J1","2":"6"},{"1":"UBE2W","2":"6"},{"1":"UBE3B","2":"6"},{"1":"USP34","2":"6"},{"1":"VPS13A","2":"6"},{"1":"VRK3","2":"6"},{"1":"VSTM4","2":"6"},{"1":"WAC","2":"6"},{"1":"WHSC1","2":"6"},{"1":"WNK2","2":"6"},{"1":"XPNPEP3","2":"6"},{"1":"YY1","2":"6"},{"1":"ZBTB7A","2":"6"},{"1":"ZFHX3","2":"6"},{"1":"ZMYM2","2":"6"},{"1":"ZNF333","2":"6"},{"1":"ZNF654","2":"6"},{"1":"ZNF704","2":"6"},{"1":"ZNRD1","2":"6"},{"1":"ZXDC","2":"6"},{"1":"ABCC3","2":"5"},{"1":"ABCC9","2":"5"},{"1":"ABCF2","2":"5"},{"1":"ABLIM2","2":"5"},{"1":"ABTB1","2":"5"},{"1":"ACOX1","2":"5"},{"1":"ACSL6","2":"5"},{"1":"ACSS1","2":"5"},{"1":"ACTR3","2":"5"},{"1":"ADAM12","2":"5"},{"1":"ADAMTS9-AS2","2":"5"},{"1":"ADARB1","2":"5"},{"1":"ADCY1","2":"5"},{"1":"AGFG1","2":"5"},{"1":"AHI1","2":"5"},{"1":"AKAP12","2":"5"},{"1":"AKAP8L","2":"5"},{"1":"AKR1C1","2":"5"},{"1":"ALDH6A1","2":"5"},{"1":"ALG13","2":"5"},{"1":"ANK3","2":"5"},{"1":"ANKRD13C","2":"5"},{"1":"ANKRD44","2":"5"},{"1":"ANKS1B","2":"5"},{"1":"AP1S3","2":"5"},{"1":"AP5M1","2":"5"},{"1":"APC","2":"5"},{"1":"API5","2":"5"},{"1":"AQP4","2":"5"},{"1":"ARHGAP27","2":"5"},{"1":"ARHGAP35","2":"5"},{"1":"ARHGAP5","2":"5"},{"1":"ARID5B","2":"5"},{"1":"ARIH2","2":"5"},{"1":"ARMC9","2":"5"},{"1":"ARMCX4","2":"5"},{"1":"ASAH1","2":"5"},{"1":"ASAP1","2":"5"},{"1":"ASMTL-AS1","2":"5"},{"1":"ATF7","2":"5"},{"1":"ATP2A3","2":"5"},{"1":"ATP6V0A2","2":"5"},{"1":"ATXN1","2":"5"},{"1":"AURKAIP1","2":"5"},{"1":"AVPR1A","2":"5"},{"1":"BAIAP2-AS1","2":"5"},{"1":"BBS9","2":"5"},{"1":"BCAS4","2":"5"},{"1":"BCL2L13","2":"5"},{"1":"BIN1","2":"5"},{"1":"BIVM","2":"5"},{"1":"BLVRA","2":"5"},{"1":"BMPR1A","2":"5"},{"1":"BMPR2","2":"5"},{"1":"BPTF","2":"5"},{"1":"BTBD7","2":"5"},{"1":"BTF3L4","2":"5"},{"1":"BTNL9","2":"5"},{"1":"BTRC","2":"5"},{"1":"BUB1","2":"5"},{"1":"C11orf58","2":"5"},{"1":"C12orf49","2":"5"},{"1":"C17orf104","2":"5"},{"1":"C17orf85","2":"5"},{"1":"C18orf54","2":"5"},{"1":"C1orf21","2":"5"},{"1":"C1orf228","2":"5"},{"1":"C6orf89","2":"5"},{"1":"CACNA1A /// LOC100507353","2":"5"},{"1":"CACNA1G","2":"5"},{"1":"CACTIN","2":"5"},{"1":"CACUL1","2":"5"},{"1":"CADM1","2":"5"},{"1":"CADM2","2":"5"},{"1":"CADM4","2":"5"},{"1":"CALML4","2":"5"},{"1":"CALU","2":"5"},{"1":"CAMK2B","2":"5"},{"1":"CAMK2D","2":"5"},{"1":"CANX","2":"5"},{"1":"CARS2","2":"5"},{"1":"CASC2","2":"5"},{"1":"CASK","2":"5"},{"1":"CASP1","2":"5"},{"1":"CASR","2":"5"},{"1":"CAST","2":"5"},{"1":"CASZ1","2":"5"},{"1":"CBFA2T2","2":"5"},{"1":"CBL","2":"5"},{"1":"CCDC40","2":"5"},{"1":"CCDC50","2":"5"},{"1":"CCDC57","2":"5"},{"1":"CCNG2","2":"5"},{"1":"CCNY","2":"5"},{"1":"CD36","2":"5"},{"1":"CD58","2":"5"},{"1":"CD59","2":"5"},{"1":"CDC14A","2":"5"},{"1":"CDC20B","2":"5"},{"1":"CDC42","2":"5"},{"1":"CDC42BPA","2":"5"},{"1":"CDK11A /// CDK11B","2":"5"},{"1":"CDS2","2":"5"},{"1":"CEACAM1","2":"5"},{"1":"CEP128","2":"5"},{"1":"CEP152","2":"5"},{"1":"CEP57","2":"5"},{"1":"CEP68","2":"5"},{"1":"CEP70","2":"5"},{"1":"CFTR","2":"5"},{"1":"CIRBP","2":"5"},{"1":"CLCN4","2":"5"},{"1":"CLCN5","2":"5"},{"1":"CLIC5","2":"5"},{"1":"CLN8","2":"5"},{"1":"CNOT4","2":"5"},{"1":"CNOT6L","2":"5"},{"1":"COBLL1","2":"5"},{"1":"COL12A1","2":"5"},{"1":"COL1A1","2":"5"},{"1":"COL27A1","2":"5"},{"1":"CPD","2":"5"},{"1":"CR1","2":"5"},{"1":"CREBRF","2":"5"},{"1":"CRLS1","2":"5"},{"1":"CRTAP","2":"5"},{"1":"CRYZL1","2":"5"},{"1":"CSHL1","2":"5"},{"1":"CSMD1","2":"5"},{"1":"CSPP1","2":"5"},{"1":"CTDSPL","2":"5"},{"1":"CTLA4","2":"5"},{"1":"CTNNA1","2":"5"},{"1":"CTSB","2":"5"},{"1":"CTTN","2":"5"},{"1":"CUX1","2":"5"},{"1":"CYB561","2":"5"},{"1":"CYP3A4","2":"5"},{"1":"DAAM1","2":"5"},{"1":"DCAF5","2":"5"},{"1":"DCLRE1C","2":"5"},{"1":"DCTN5","2":"5"},{"1":"DDHD1","2":"5"},{"1":"DDX17","2":"5"},{"1":"DENND5B","2":"5"},{"1":"DENR","2":"5"},{"1":"DESI2","2":"5"},{"1":"DGCR14 /// TSSK2","2":"5"},{"1":"DGKE","2":"5"},{"1":"DGKH","2":"5"},{"1":"DIO2","2":"5"},{"1":"DIS3","2":"5"},{"1":"DKK3","2":"5"},{"1":"DLC1","2":"5"},{"1":"DLGAP4","2":"5"},{"1":"DNAH3","2":"5"},{"1":"DNAJC10","2":"5"},{"1":"DNAJC4","2":"5"},{"1":"DOCK1","2":"5"},{"1":"DOCK6","2":"5"},{"1":"DOCK9","2":"5"},{"1":"DPH5","2":"5"},{"1":"DTX3","2":"5"},{"1":"DTYMK","2":"5"},{"1":"DYNLRB1","2":"5"},{"1":"DYRK1A","2":"5"},{"1":"EFCAB13","2":"5"},{"1":"EHD1","2":"5"},{"1":"EIF3M","2":"5"},{"1":"EIF4E","2":"5"},{"1":"EIF4EBP2","2":"5"},{"1":"EIF5","2":"5"},{"1":"ELP2","2":"5"},{"1":"EMC1","2":"5"},{"1":"ENSA","2":"5"},{"1":"EPHA4","2":"5"},{"1":"EPOR","2":"5"},{"1":"EPPK1","2":"5"},{"1":"EPS8L1","2":"5"},{"1":"ERAP1","2":"5"},{"1":"ERAP2","2":"5"},{"1":"ERBB3","2":"5"},{"1":"ESR2","2":"5"},{"1":"ESYT2","2":"5"},{"1":"ETV1","2":"5"},{"1":"ETV5","2":"5"},{"1":"EXOC5","2":"5"},{"1":"EXOC7","2":"5"},{"1":"EZH1","2":"5"},{"1":"EZR","2":"5"},{"1":"FAF1","2":"5"},{"1":"FAM124A","2":"5"},{"1":"FAM13A","2":"5"},{"1":"FAM162A","2":"5"},{"1":"FAM84A","2":"5"},{"1":"FARP1","2":"5"},{"1":"FARP2","2":"5"},{"1":"FBLN1","2":"5"},{"1":"FBRSL1","2":"5"},{"1":"FBXL17","2":"5"},{"1":"FBXL20","2":"5"},{"1":"FBXO22","2":"5"},{"1":"FBXO28","2":"5"},{"1":"FBXW2","2":"5"},{"1":"FCAR","2":"5"},{"1":"FCRL2","2":"5"},{"1":"FCRL5","2":"5"},{"1":"FGD6","2":"5"},{"1":"FGF14","2":"5"},{"1":"FGFR1OP","2":"5"},{"1":"FHL1","2":"5"},{"1":"FNDC3B /// LOC101928615","2":"5"},{"1":"FNIP1","2":"5"},{"1":"FOSL2","2":"5"},{"1":"FRAS1","2":"5"},{"1":"FYB","2":"5"},{"1":"G2E3","2":"5"},{"1":"GABRB3","2":"5"},{"1":"GAD2","2":"5"},{"1":"GALNT5","2":"5"},{"1":"GAS7","2":"5"},{"1":"GATA4","2":"5"},{"1":"GDF11","2":"5"},{"1":"GGA1","2":"5"},{"1":"GGCX","2":"5"},{"1":"GIMAP1","2":"5"},{"1":"GIT2","2":"5"},{"1":"GLCCI1","2":"5"},{"1":"GLIPR1","2":"5"},{"1":"GLP1R","2":"5"},{"1":"GNAQ","2":"5"},{"1":"GNB5","2":"5"},{"1":"GNL1","2":"5"},{"1":"GPALPP1","2":"5"},{"1":"GPATCH2","2":"5"},{"1":"GPATCH4","2":"5"},{"1":"GPR98","2":"5"},{"1":"GPRIN3","2":"5"},{"1":"GRIA3","2":"5"},{"1":"GRIN1","2":"5"},{"1":"GSK3B","2":"5"},{"1":"GTDC1","2":"5"},{"1":"GTPBP1","2":"5"},{"1":"GTSE1","2":"5"},{"1":"GULP1","2":"5"},{"1":"GYPA","2":"5"},{"1":"H2AFY","2":"5"},{"1":"HDAC9","2":"5"},{"1":"HEATR1","2":"5"},{"1":"HELLS","2":"5"},{"1":"HELQ","2":"5"},{"1":"HGF","2":"5"},{"1":"HGSNAT","2":"5"},{"1":"HINT1","2":"5"},{"1":"HIST1H4A /// HIST1H4B /// HIST1H4C /// HIST1H4D /// HIST1H4E /// HIST1H4F /// HIST1H4H /// HIST1H4I /// HIST1H4J /// HIST1H4K /// HIST1H4L /// HIST2H4A /// HIST2H4B /// HIST4H4","2":"5"},{"1":"HIVEP3","2":"5"},{"1":"HLA-DOA","2":"5"},{"1":"HM13","2":"5"},{"1":"HMGB1","2":"5"},{"1":"HNRNPU","2":"5"},{"1":"HOOK3","2":"5"},{"1":"HOXB-AS3","2":"5"},{"1":"HPS1","2":"5"},{"1":"HSPD1","2":"5"},{"1":"HUWE1","2":"5"},{"1":"HYDIN /// HYDIN2 /// LOC101930373","2":"5"},{"1":"ICOSLG","2":"5"},{"1":"ID4","2":"5"},{"1":"IGF1","2":"5"},{"1":"IGF1R","2":"5"},{"1":"IGHD","2":"5"},{"1":"IGHM","2":"5"},{"1":"IGKC","2":"5"},{"1":"IGLC1","2":"5"},{"1":"IGLV1-44","2":"5"},{"1":"IL1RN","2":"5"},{"1":"ILF3","2":"5"},{"1":"INIP","2":"5"},{"1":"INSR","2":"5"},{"1":"INTS4","2":"5"},{"1":"IPO5","2":"5"},{"1":"IPP","2":"5"},{"1":"IQCA1","2":"5"},{"1":"IRF2BP2","2":"5"},{"1":"ITFG1","2":"5"},{"1":"ITGB4","2":"5"},{"1":"ITGB8","2":"5"},{"1":"ITGBL1","2":"5"},{"1":"ITPKB","2":"5"},{"1":"JAG1","2":"5"},{"1":"KANSL1L","2":"5"},{"1":"KAT6B","2":"5"},{"1":"KCNAB1","2":"5"},{"1":"KCNIP3","2":"5"},{"1":"KCNJ15","2":"5"},{"1":"KCNQ1OT1 /// LOC101927338","2":"5"},{"1":"KCTD15","2":"5"},{"1":"KDM5A","2":"5"},{"1":"KDM5B","2":"5"},{"1":"KDM6B","2":"5"},{"1":"KIAA0226","2":"5"},{"1":"KIAA2018","2":"5"},{"1":"KIDINS220","2":"5"},{"1":"KIF6","2":"5"},{"1":"KLF6","2":"5"},{"1":"KLF7","2":"5"},{"1":"KLF9","2":"5"},{"1":"KLHDC10","2":"5"},{"1":"KLHL22","2":"5"},{"1":"KLHL24","2":"5"},{"1":"KLK4","2":"5"},{"1":"KMT2D","2":"5"},{"1":"KPNA4","2":"5"},{"1":"KRAS","2":"5"},{"1":"KREMEN1","2":"5"},{"1":"LAMA4","2":"5"},{"1":"LARP4","2":"5"},{"1":"LDB3","2":"5"},{"1":"LDLR","2":"5"},{"1":"LIFR","2":"5"},{"1":"LIMD1","2":"5"},{"1":"LINC00662","2":"5"},{"1":"LINC00689","2":"5"},{"1":"LINC00957","2":"5"},{"1":"LINS","2":"5"},{"1":"LMO4","2":"5"},{"1":"LNPEP","2":"5"},{"1":"LOC100506639 /// ZNF131","2":"5"},{"1":"LOC101060747 /// PDPK1","2":"5"},{"1":"LOC101927933 /// LRRC8C","2":"5"},{"1":"LOC101928198 /// MFAP3L","2":"5"},{"1":"LOC101928717 /// SLC19A1","2":"5"},{"1":"LOC101928826 /// TPT1","2":"5"},{"1":"LOC101929036 /// PAH","2":"5"},{"1":"LPCAT4","2":"5"},{"1":"LRRFIP2","2":"5"},{"1":"LSAMP","2":"5"},{"1":"LSM14B","2":"5"},{"1":"LUC7L","2":"5"},{"1":"LUZP1","2":"5"},{"1":"LYRM2","2":"5"},{"1":"MAF","2":"5"},{"1":"MAGIX","2":"5"},{"1":"MAP2K7","2":"5"},{"1":"MAP4K4","2":"5"},{"1":"MAPK8","2":"5"},{"1":"MAPK8IP3","2":"5"},{"1":"MARCH7","2":"5"},{"1":"MARCKS","2":"5"},{"1":"MASP1","2":"5"},{"1":"MAU2","2":"5"},{"1":"MAX","2":"5"},{"1":"MBD1","2":"5"},{"1":"MCM3AP","2":"5"},{"1":"MCM4","2":"5"},{"1":"MCPH1","2":"5"},{"1":"MCTP2","2":"5"},{"1":"MECOM","2":"5"},{"1":"MED13L","2":"5"},{"1":"MED14","2":"5"},{"1":"MED16","2":"5"},{"1":"MED23","2":"5"},{"1":"METTL20","2":"5"},{"1":"MEX3C","2":"5"},{"1":"MGEA5","2":"5"},{"1":"MGST1","2":"5"},{"1":"MIB2","2":"5"},{"1":"MIER3","2":"5"},{"1":"MIR4745 /// PTBP1","2":"5"},{"1":"MKL1","2":"5"},{"1":"MKLN1","2":"5"},{"1":"MLX","2":"5"},{"1":"MMAA","2":"5"},{"1":"MMP16","2":"5"},{"1":"MMP28","2":"5"},{"1":"MOBP","2":"5"},{"1":"MRPL30","2":"5"},{"1":"MRPL41","2":"5"}],"options":{"columns":{"min":{},"max":[10],"total":[2]},"rows":{"min":[10],"max":[10],"total":[23521]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgZ3JvdXBfYnkoYEdlbmUgU3ltYm9sYCkgJT4lIHN1bW1hcmlzZShuPW4oKSkgJT4lIHN1bW1hcmlzZShzdW0obj4xKSlcbmBgYCJ9 -->
<pre class="r"><code>gse2658_features %&gt;% group_by(`Gene Symbol`) %&gt;% summarise(n=n()) %&gt;% summarise(sum(n&gt;1))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["sum(n > 1)"],"name":[1],"type":["int"],"align":["right"]}],"data":[{"1":"11272"}],"options":{"columns":{"min":{},"max":[10],"total":[1]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGVuZ3RoKHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJEVOVFJFWl9HRU5FX0lEKSlcbmBgYCJ9 -->
<pre class="r"><code>length(unique(gse2658_features$ENTREZ_GENE_ID))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDIxODgwXG4ifQ== -->
<pre><code>[1] 21880</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubGVuZ3RoKHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJGBSZWZTZXEgVHJhbnNjcmlwdCBJRGApKVxuYGBgIn0= -->
<pre class="r"><code>length(unique(gse2658_features$`RefSeq Transcript ID`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDIxNjA3XG4ifQ== -->
<pre><code>[1] 21607</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>for reference, this is the gene metadata from the commpass spectra derivation</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuI1wiY29tbXBhc3NfZ2VuZV9tZXRhZGF0YV8yMDIxMDYwMS5jc3ZcIlxuYGBgIn0= -->
<pre class="r"><code>#&quot;commpass_gene_metadata_20210601.csv&quot;</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>CoMMpass rotation matrix</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY21wc19zcGVjX3JtIDwtIFxuICByZWFkX2NzdihcIn4vRG9jdW1lbnRzL3N0YXRzL3N1cnZpdmFsL2NvbW1wYXNzX3Byb2ovc3BlY3RyYV9jb21tcGFzc19wcm9kdWN0L0NvTU1wYXNzX2luY2xmb2xsb3d1cF9maW5hbF9TcGVjdHJhRGF0YV8yMDIxMDYwMS9zcGVjdHJhX3JvdGF0aW9uX21hdHJpeC1nZW5lX2NlbnRlcnMtMjAyMS0wNi0wMS5jc3YuZ3pcIilcbmBgYCJ9 -->
<pre class="r"><code>cmps_spec_rm &lt;- 
  read_csv(&quot;~/Documents/stats/survival/commpass_proj/spectra_commpass_product/CoMMpass_inclfollowup_final_SpectraData_20210601/spectra_rotation_matrix-gene_centers-2021-06-01.csv.gz&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiUm93czogNzQ0OSBDb2x1bW5zOiA0MVxu4pSA4pSAIENvbHVtbiBzcGVjaWZpY2F0aW9uIOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgOKUgFxuRGVsaW1pdGVyOiBcIixcIlxuY2hyICAoMSk6IGdlbmVfaWRcbmRibCAoNDApOiBtZWFuLCBQQzEsIFBDMiwgUEMzLCBQQzQsIFBDNSwgUEM2LCBQQzcsIFBDOCwgUEM5LCBQQzEwLCBQQzExLCBQQzEyLCBQQzEzLCBQQzE0LCBQQzE1LCBQQzE2LCBQQzE3LCBQQzEuLi5cblxu4oS5IFVzZSBgc3BlYygpYCB0byByZXRyaWV2ZSB0aGUgZnVsbCBjb2x1bW4gc3BlY2lmaWNhdGlvbiBmb3IgdGhpcyBkYXRhLlxu4oS5IFNwZWNpZnkgdGhlIGNvbHVtbiB0eXBlcyBvciBzZXQgYHNob3dfY29sX3R5cGVzID0gRkFMU0VgIHRvIHF1aWV0IHRoaXMgbWVzc2FnZS5cbiJ9 -->
<pre><code>Rows: 7449 Columns: 41
 Column specification 
Delimiter: &quot;,&quot;
chr  (1): gene_id
dbl (40): mean, PC1, PC2, PC3, PC4, PC5, PC6, PC7, PC8, PC9, PC10, PC11, PC12, PC13, PC14, PC15, PC16, PC17, PC1...

 Use `spec()` to retrieve the full column specification for this data.
 Specify the column types or set `show_col_types = FALSE` to quiet this message.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>bring in gene annotation to get gene names</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2VuY29kZV9hbm5vdCA8LSBcbiAgcmVhZF9jc3YoXCJ+L0RvY3VtZW50cy9zdGF0cy9zdXJ2aXZhbC9jb21tcGFzc19wcm9qL2NvbW1wYXNzX3NwZWN0cmEvSG9tb19zYXBpZW5zLkdSQ2gzNy43NC5ndGYuZmxhdC5jc3ZcIilcbmBgYCJ9 -->
<pre class="r"><code>gencode_annot &lt;- 
  read_csv(&quot;~/Documents/stats/survival/commpass_proj/commpass_spectra/Homo_sapiens.GRCh37.74.gtf.flat.csv&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>Rows: 2244857 Columns: 15
 Column specification 
Delimiter: &quot;,&quot;
chr (12): chr, tx_type, feature, strand, phase, gene_id, transcript_id, gene_name, gene_biotype, transcript_name...
dbl  (3): start, end, exon_number

 Use `spec()` to retrieve the full column specification for this data.
 Specify the column types or set `show_col_types = FALSE` to quiet this message.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2lkX25hbWVzIDwtIGdlbmNvZGVfYW5ub3QgJT4lIGRpc3RpbmN0KGdlbmVfaWQsIC5rZWVwX2FsbCA9IFQpICU+JSBzZWxlY3QoZ2VuZV9pZCwgZ2VuZV9uYW1lKVxuYGBgIn0= -->
<pre class="r"><code>gid_names &lt;- gencode_annot %&gt;% distinct(gene_id, .keep_all = T) %&gt;% select(gene_id, gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY21wc19zcGVjX3JtX3duIDwtIGxlZnRfam9pbihjbXBzX3NwZWNfcm0sIGdpZF9uYW1lcywgYnk9XCJnZW5lX2lkXCIpICU+JSBcbiAgc2VsZWN0KC1tZWFuKSAlPiUgXG4gIHJlbG9jYXRlKGdlbmVfbmFtZSlcbmBgYCJ9 -->
<pre class="r"><code>cmps_spec_rm_wn &lt;- left_join(cmps_spec_rm, gid_names, by=&quot;gene_id&quot;) %&gt;% 
  select(-mean) %&gt;% 
  relocate(gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>are there any duplicate gene_names?</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY21wc19zcGVjX3JtX3duICU+JSBcbiAgICBhZGRfY291bnQoZ2VuZV9uYW1lKSAlPiUgXG4gICAgZmlsdGVyKG4+MSkgJT4lIFxuICBzZWxlY3QoZ2VuZV9uYW1lLCBnZW5lX2lkLCBuKVxuYGBgIn0= -->
<pre class="r"><code>cmps_spec_rm_wn %&gt;% 
    add_count(gene_name) %&gt;% 
    filter(n&gt;1) %&gt;% 
  select(gene_name, gene_id, n)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]},{"label":["gene_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["n"],"name":[3],"type":["int"],"align":["right"]}],"data":[{"1":"PAGR1","2":"ENSG00000185928","3":"2"},{"1":"PAGR1","2":"ENSG00000263136","3":"2"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[2]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>crap, yes there is one, these were apparently combined later. just going to leave them and see how it goes (note from future Brian, poorly)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGltKGNtcHNfc3BlY19ybV93bilcbmBgYCJ9 -->
<pre class="r"><code>dim(cmps_spec_rm_wn)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDc0NDkgICA0MVxuIn0= -->
<pre><code>[1] 7449   41</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="combining-datasets-by-gene-name" class="section level2">
<h2>combining datasets by gene name</h2>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY21wc19zcGVjX2dlbmVuYW1lcyA8LSBjbXBzX3NwZWNfcm1fd24gJT4lIGRpc3RpbmN0KGdlbmVfbmFtZSkgJT4lIHB1bGwoZ2VuZV9uYW1lKVxuYGBgIn0= -->
<pre class="r"><code>cmps_spec_genenames &lt;- cmps_spec_rm_wn %&gt;% distinct(gene_name) %&gt;% pull(gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgZmlsdGVyKGBHZW5lIFN5bWJvbGAgJWluJSBjbXBzX3NwZWNfZ2VuZW5hbWVzKSAlPiUgZGlzdGluY3QoYEdlbmUgU3ltYm9sYCkgJT4lIGRpbSgpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_features %&gt;% filter(`Gene Symbol` %in% cmps_spec_genenames) %&gt;% distinct(`Gene Symbol`) %&gt;% dim()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDcxOTMgICAgMVxuIn0= -->
<pre><code>[1] 7193    1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>7193 of 7449 genes in list with simple search (actually there are only 7448 unique gene names)</p>
<p>how many have multiple probe sets?</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgXG4gIGZpbHRlcihgR2VuZSBTeW1ib2xgICVpbiUgY21wc19zcGVjX2dlbmVuYW1lcykgJT4lIFxuICBncm91cF9ieShgR2VuZSBTeW1ib2xgKSAlPiUgXG4gIHN1bW1hcmlzZShuPW4oKSkgJT4lIFxuICBhcnJhbmdlKGRlc2MobikpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_features %&gt;% 
  filter(`Gene Symbol` %in% cmps_spec_genenames) %&gt;% 
  group_by(`Gene Symbol`) %&gt;% 
  summarise(n=n()) %&gt;% 
  arrange(desc(n))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["tbl_df","tbl","data.frame"],"nrow":7193,"ncol":2,"summary":{"A tibble":["7,193 × 2"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["n"],"name":[2],"type":["int"],"align":["right"]}],"data":[{"1":"ARHGEF12","2":"13"},{"1":"DNAH1","2":"13"},{"1":"TCF3","2":"13"},{"1":"SPTBN1","2":"11"},{"1":"HIPK2","2":"10"},{"1":"KMT2A","2":"10"},{"1":"MED28","2":"10"},{"1":"PDLIM5","2":"10"},{"1":"PML","2":"10"},{"1":"STRN","2":"10"},{"1":"AKAP13","2":"9"},{"1":"ARHGEF7","2":"9"},{"1":"ASPH","2":"9"},{"1":"C1orf86","2":"9"},{"1":"ERICH1","2":"9"},{"1":"ESR1","2":"9"},{"1":"FAM120A","2":"9"},{"1":"FBXO9","2":"9"},{"1":"FOXP2","2":"9"},{"1":"GART","2":"9"},{"1":"IKZF1","2":"9"},{"1":"LMF1","2":"9"},{"1":"LRRFIP1","2":"9"},{"1":"MSI2","2":"9"},{"1":"PPARA","2":"9"},{"1":"SMARCA4","2":"9"},{"1":"TNPO1","2":"9"},{"1":"VPS53","2":"9"},{"1":"YME1L1","2":"9"},{"1":"ZDHHC21","2":"9"},{"1":"AFF4","2":"8"},{"1":"APLP2","2":"8"},{"1":"BRWD1","2":"8"},{"1":"CAPRIN1","2":"8"},{"1":"CDC14B","2":"8"},{"1":"CDK12","2":"8"},{"1":"DIP2A","2":"8"},{"1":"DR1","2":"8"},{"1":"FOXP1","2":"8"},{"1":"GGA2","2":"8"},{"1":"GLS","2":"8"},{"1":"HNRNPD","2":"8"},{"1":"ITSN1","2":"8"},{"1":"LPP","2":"8"},{"1":"MLLT10","2":"8"},{"1":"N4BP2L1","2":"8"},{"1":"NAV1","2":"8"},{"1":"NF2","2":"8"},{"1":"NKTR","2":"8"},{"1":"NUCKS1","2":"8"},{"1":"PIAS2","2":"8"},{"1":"RBBP6","2":"8"},{"1":"RNF213","2":"8"},{"1":"RORA","2":"8"},{"1":"SRSF1","2":"8"},{"1":"TCF4","2":"8"},{"1":"TNRC18","2":"8"},{"1":"TOR1AIP2","2":"8"},{"1":"UBE2H","2":"8"},{"1":"ACTR2","2":"7"},{"1":"ANKH","2":"7"},{"1":"ARID1B","2":"7"},{"1":"ATP5S","2":"7"},{"1":"ATP6V0E1","2":"7"},{"1":"BBX","2":"7"},{"1":"BCL2L11","2":"7"},{"1":"BRD4","2":"7"},{"1":"CAMSAP1","2":"7"},{"1":"CAND1","2":"7"},{"1":"CASP2","2":"7"},{"1":"CD47","2":"7"},{"1":"CDK13","2":"7"},{"1":"CELF1","2":"7"},{"1":"CELF2","2":"7"},{"1":"CHD9","2":"7"},{"1":"COL4A3","2":"7"},{"1":"CREB1","2":"7"},{"1":"CYLD","2":"7"},{"1":"DCAF7","2":"7"},{"1":"DLG1","2":"7"},{"1":"DNAJC21","2":"7"},{"1":"DYNC1H1","2":"7"},{"1":"EFCAB14","2":"7"},{"1":"EHD4","2":"7"},{"1":"EIF1","2":"7"},{"1":"EPG5","2":"7"},{"1":"FBXO32","2":"7"},{"1":"FGD2","2":"7"},{"1":"FGFR1OP2","2":"7"},{"1":"FOXK2","2":"7"},{"1":"FOXN3","2":"7"},{"1":"G3BP1","2":"7"},{"1":"GAB1","2":"7"},{"1":"GATM","2":"7"},{"1":"GM2A","2":"7"},{"1":"GPATCH2L","2":"7"},{"1":"HNRNPC","2":"7"},{"1":"IL6ST","2":"7"},{"1":"ITGB1","2":"7"},{"1":"KDM4B","2":"7"},{"1":"KIAA1109","2":"7"},{"1":"LRCH3","2":"7"},{"1":"MAP3K2","2":"7"},{"1":"MAP4","2":"7"},{"1":"MAPK1","2":"7"},{"1":"MAST4","2":"7"},{"1":"MBNL1","2":"7"},{"1":"METTL15","2":"7"},{"1":"MLLT4","2":"7"},{"1":"PAWR","2":"7"},{"1":"PCNX","2":"7"},{"1":"PHF20L1","2":"7"},{"1":"PIK3C2A","2":"7"},{"1":"POU2F2","2":"7"},{"1":"PSEN1","2":"7"},{"1":"PTEN","2":"7"},{"1":"RBM25","2":"7"},{"1":"RBM26","2":"7"},{"1":"RBM33","2":"7"},{"1":"RC3H2","2":"7"},{"1":"RPAIN","2":"7"},{"1":"RREB1","2":"7"},{"1":"RUFY2","2":"7"},{"1":"RUFY3","2":"7"},{"1":"SCAF11","2":"7"},{"1":"SERBP1","2":"7"},{"1":"SLAIN2","2":"7"},{"1":"SLC38A10","2":"7"},{"1":"SMARCA2","2":"7"},{"1":"SNTB2","2":"7"},{"1":"SRC","2":"7"},{"1":"ST3GAL3","2":"7"},{"1":"STK4","2":"7"},{"1":"SYNCRIP","2":"7"},{"1":"SYNJ2","2":"7"},{"1":"TCP11L2","2":"7"},{"1":"THADA","2":"7"},{"1":"TIA1","2":"7"},{"1":"TLK1","2":"7"},{"1":"TMCC1","2":"7"},{"1":"TNRC6B","2":"7"},{"1":"TPGS2","2":"7"},{"1":"TTBK2","2":"7"},{"1":"TTLL5","2":"7"},{"1":"UBA6","2":"7"},{"1":"UBE2B","2":"7"},{"1":"UBE3A","2":"7"},{"1":"UGGT2","2":"7"},{"1":"USP49","2":"7"},{"1":"WHSC1L1","2":"7"},{"1":"WNK1","2":"7"},{"1":"WTAP","2":"7"},{"1":"ZADH2","2":"7"},{"1":"ZBTB10","2":"7"},{"1":"ZMYM6","2":"7"},{"1":"ZNF148","2":"7"},{"1":"ABHD2","2":"6"},{"1":"ACACB","2":"6"},{"1":"ACER3","2":"6"},{"1":"ACTB","2":"6"},{"1":"ACVR1B","2":"6"},{"1":"AGPAT3","2":"6"},{"1":"ANAPC5","2":"6"},{"1":"ARMC8","2":"6"},{"1":"ARNT","2":"6"},{"1":"ASXL1","2":"6"},{"1":"ASXL2","2":"6"},{"1":"ATM","2":"6"},{"1":"ATP11B","2":"6"},{"1":"ATP9B","2":"6"},{"1":"AVL9","2":"6"},{"1":"AZI2","2":"6"},{"1":"B4GALT1","2":"6"},{"1":"BCAP29","2":"6"},{"1":"BCLAF1","2":"6"},{"1":"BICD1","2":"6"},{"1":"BUB3","2":"6"},{"1":"C11orf30","2":"6"},{"1":"C11orf31","2":"6"},{"1":"C11orf57","2":"6"},{"1":"C16orf13","2":"6"},{"1":"CBX5","2":"6"},{"1":"CCDC88A","2":"6"},{"1":"CEP89","2":"6"},{"1":"CHD2","2":"6"},{"1":"CHML","2":"6"},{"1":"CLASP2","2":"6"},{"1":"CLIP1","2":"6"},{"1":"CLN6","2":"6"},{"1":"CLTA","2":"6"},{"1":"COPS8","2":"6"},{"1":"CREBZF","2":"6"},{"1":"CREM","2":"6"},{"1":"CRIPT","2":"6"},{"1":"DBT","2":"6"},{"1":"DCUN1D1","2":"6"},{"1":"DENND1B","2":"6"},{"1":"DHX30","2":"6"},{"1":"DICER1","2":"6"},{"1":"EIF3B","2":"6"},{"1":"ELK4","2":"6"},{"1":"EML4","2":"6"},{"1":"ENAH","2":"6"},{"1":"EPS15L1","2":"6"},{"1":"ERC1","2":"6"},{"1":"ETNK1","2":"6"},{"1":"EXOSC3","2":"6"},{"1":"FBXL18","2":"6"},{"1":"FBXO3","2":"6"},{"1":"FKBP15","2":"6"},{"1":"FRYL","2":"6"},{"1":"FUS","2":"6"},{"1":"GAPDH","2":"6"},{"1":"GATAD2A","2":"6"},{"1":"GFM1","2":"6"},{"1":"GPR180","2":"6"},{"1":"GSPT1","2":"6"},{"1":"HDLBP","2":"6"},{"1":"HECTD1","2":"6"},{"1":"HECTD4","2":"6"},{"1":"HERC4","2":"6"},{"1":"HNRNPDL","2":"6"},{"1":"HNRNPM","2":"6"},{"1":"IMPAD1","2":"6"},{"1":"INADL","2":"6"},{"1":"INO80D","2":"6"},{"1":"INPP4A","2":"6"},{"1":"ITCH","2":"6"},{"1":"JMJD1C","2":"6"},{"1":"KMT2C","2":"6"},{"1":"KPNA1","2":"6"},{"1":"KPNB1","2":"6"},{"1":"L3MBTL1","2":"6"},{"1":"LARP1B","2":"6"},{"1":"LARP4B","2":"6"},{"1":"LIG3","2":"6"},{"1":"LMBR1","2":"6"},{"1":"LMNA","2":"6"},{"1":"MAN1A2","2":"6"},{"1":"MAP2K5","2":"6"},{"1":"MARCH6","2":"6"},{"1":"MCL1","2":"6"},{"1":"MDM4","2":"6"},{"1":"MPZL1","2":"6"},{"1":"MR1","2":"6"},{"1":"MTAP","2":"6"},{"1":"MTHFSD","2":"6"},{"1":"MYEF2","2":"6"},{"1":"MYLIP","2":"6"},{"1":"N4BP2L2","2":"6"},{"1":"NAA15","2":"6"},{"1":"NADK","2":"6"},{"1":"NENF","2":"6"},{"1":"NFATC2IP","2":"6"},{"1":"NFYA","2":"6"},{"1":"NFYC","2":"6"},{"1":"NIN","2":"6"},{"1":"NLN","2":"6"},{"1":"NSFL1C","2":"6"},{"1":"NUP50","2":"6"},{"1":"ORAI2","2":"6"},{"1":"OTUD7B","2":"6"},{"1":"PAK2","2":"6"},{"1":"PANK2","2":"6"},{"1":"PAPOLA","2":"6"},{"1":"PARVB","2":"6"},{"1":"PATZ1","2":"6"},{"1":"PBRM1","2":"6"},{"1":"PCM1","2":"6"},{"1":"PDE5A","2":"6"},{"1":"PDS5B","2":"6"},{"1":"PLEKHA8","2":"6"},{"1":"PNISR","2":"6"},{"1":"POLH","2":"6"},{"1":"PPIL2","2":"6"},{"1":"PPM1A","2":"6"},{"1":"PRKCB","2":"6"},{"1":"PRMT2","2":"6"},{"1":"PRPF40A","2":"6"},{"1":"PRRC2C","2":"6"},{"1":"PTPN11","2":"6"},{"1":"PTPN2","2":"6"},{"1":"RAB18","2":"6"},{"1":"RAB2A","2":"6"},{"1":"RAB7A","2":"6"},{"1":"RBMS1","2":"6"},{"1":"RHOBTB3","2":"6"},{"1":"RPRD1A","2":"6"},{"1":"RQCD1","2":"6"},{"1":"RRBP1","2":"6"},{"1":"RSF1","2":"6"},{"1":"SAMHD1","2":"6"},{"1":"SCAMP1","2":"6"},{"1":"SEC22C","2":"6"},{"1":"SETDB2","2":"6"},{"1":"SIK3","2":"6"},{"1":"SKAP2","2":"6"},{"1":"SLC39A8","2":"6"},{"1":"SLFN5","2":"6"},{"1":"SMCHD1","2":"6"},{"1":"SMEK2","2":"6"},{"1":"SNX5","2":"6"},{"1":"SOS2","2":"6"},{"1":"SREK1","2":"6"},{"1":"SRP72","2":"6"},{"1":"SRPK2","2":"6"},{"1":"SRSF3","2":"6"},{"1":"SSBP2","2":"6"},{"1":"SSR1","2":"6"},{"1":"SSX2IP","2":"6"},{"1":"STAT1","2":"6"},{"1":"SYNRG","2":"6"},{"1":"TACC1","2":"6"},{"1":"TAOK1","2":"6"},{"1":"TAPT1","2":"6"},{"1":"TBL1XR1","2":"6"},{"1":"TBRG1","2":"6"},{"1":"TMED5","2":"6"},{"1":"TMEM165","2":"6"},{"1":"TMEM259","2":"6"},{"1":"TMF1","2":"6"},{"1":"TNRC6A","2":"6"},{"1":"TSC22D2","2":"6"},{"1":"TTC17","2":"6"},{"1":"UBE2D3","2":"6"},{"1":"UBE2J1","2":"6"},{"1":"UBE2W","2":"6"},{"1":"UBE3B","2":"6"},{"1":"VPS13A","2":"6"},{"1":"VRK3","2":"6"},{"1":"WAC","2":"6"},{"1":"WHSC1","2":"6"},{"1":"XPNPEP3","2":"6"},{"1":"YY1","2":"6"},{"1":"ZBTB7A","2":"6"},{"1":"ZMYM2","2":"6"},{"1":"ZNF333","2":"6"},{"1":"ZNF654","2":"6"},{"1":"ZXDC","2":"6"},{"1":"ABCC9","2":"5"},{"1":"ABCF2","2":"5"},{"1":"ABTB1","2":"5"},{"1":"ACOX1","2":"5"},{"1":"ACSS1","2":"5"},{"1":"ACTR3","2":"5"},{"1":"AGFG1","2":"5"},{"1":"AHI1","2":"5"},{"1":"AKAP8L","2":"5"},{"1":"ALDH6A1","2":"5"},{"1":"ANKRD13C","2":"5"},{"1":"ANKRD44","2":"5"},{"1":"AP5M1","2":"5"},{"1":"APC","2":"5"},{"1":"API5","2":"5"},{"1":"ARHGAP27","2":"5"},{"1":"ARHGAP35","2":"5"},{"1":"ARHGAP5","2":"5"},{"1":"ARID5B","2":"5"},{"1":"ARIH2","2":"5"},{"1":"ASAP1","2":"5"},{"1":"ATF7","2":"5"},{"1":"ATP2A3","2":"5"},{"1":"ATP6V0A2","2":"5"},{"1":"ATXN1","2":"5"},{"1":"AURKAIP1","2":"5"},{"1":"BBS9","2":"5"},{"1":"BCL2L13","2":"5"},{"1":"BMPR1A","2":"5"},{"1":"BMPR2","2":"5"},{"1":"BPTF","2":"5"},{"1":"BTBD7","2":"5"},{"1":"BTF3L4","2":"5"},{"1":"BTRC","2":"5"},{"1":"BUB1","2":"5"},{"1":"C12orf49","2":"5"},{"1":"C17orf85","2":"5"},{"1":"C6orf89","2":"5"},{"1":"CACTIN","2":"5"},{"1":"CACUL1","2":"5"},{"1":"CALU","2":"5"},{"1":"CAMK2D","2":"5"},{"1":"CANX","2":"5"},{"1":"CARS2","2":"5"},{"1":"CASP1","2":"5"},{"1":"CAST","2":"5"},{"1":"CBFA2T2","2":"5"},{"1":"CBL","2":"5"},{"1":"CCDC50","2":"5"},{"1":"CCNG2","2":"5"},{"1":"CCNY","2":"5"},{"1":"CD59","2":"5"},{"1":"CDC42","2":"5"},{"1":"CDS2","2":"5"},{"1":"CEP128","2":"5"},{"1":"CEP152","2":"5"},{"1":"CEP57","2":"5"},{"1":"CEP68","2":"5"},{"1":"CEP70","2":"5"},{"1":"CIRBP","2":"5"},{"1":"CLN8","2":"5"},{"1":"CNOT4","2":"5"},{"1":"CNOT6L","2":"5"},{"1":"COBLL1","2":"5"},{"1":"CPD","2":"5"},{"1":"CREBRF","2":"5"},{"1":"CRLS1","2":"5"},{"1":"CRTAP","2":"5"},{"1":"CRYZL1","2":"5"},{"1":"CSPP1","2":"5"},{"1":"CTNNA1","2":"5"},{"1":"CTSB","2":"5"},{"1":"CTTN","2":"5"},{"1":"CUX1","2":"5"},{"1":"CYB561","2":"5"},{"1":"DAAM1","2":"5"},{"1":"DCAF5","2":"5"},{"1":"DCLRE1C","2":"5"},{"1":"DCTN5","2":"5"},{"1":"DDHD1","2":"5"},{"1":"DDX17","2":"5"},{"1":"DENND5B","2":"5"},{"1":"DENR","2":"5"},{"1":"DESI2","2":"5"},{"1":"DGKE","2":"5"},{"1":"DIS3","2":"5"},{"1":"DLGAP4","2":"5"},{"1":"DNAJC10","2":"5"},{"1":"DNAJC4","2":"5"},{"1":"DOCK9","2":"5"},{"1":"DPH5","2":"5"},{"1":"DTX3","2":"5"},{"1":"DTYMK","2":"5"},{"1":"DYNLRB1","2":"5"},{"1":"EFCAB13","2":"5"},{"1":"EHD1","2":"5"},{"1":"EIF4EBP2","2":"5"},{"1":"EIF5","2":"5"},{"1":"ELP2","2":"5"},{"1":"EMC1","2":"5"},{"1":"ENSA","2":"5"},{"1":"ERAP1","2":"5"},{"1":"ERAP2","2":"5"},{"1":"ESYT2","2":"5"},{"1":"ETV5","2":"5"},{"1":"EXOC5","2":"5"},{"1":"EZH1","2":"5"},{"1":"EZR","2":"5"},{"1":"FAF1","2":"5"},{"1":"FAM13A","2":"5"},{"1":"FAM162A","2":"5"},{"1":"FARP2","2":"5"},{"1":"FBRSL1","2":"5"},{"1":"FBXL17","2":"5"},{"1":"FBXL20","2":"5"},{"1":"FBXO28","2":"5"},{"1":"FBXW2","2":"5"},{"1":"FCRL2","2":"5"},{"1":"FCRL5","2":"5"},{"1":"FNIP1","2":"5"},{"1":"FOSL2","2":"5"},{"1":"G2E3","2":"5"},{"1":"GGA1","2":"5"},{"1":"GIT2","2":"5"},{"1":"GLCCI1","2":"5"},{"1":"GNB5","2":"5"},{"1":"GPALPP1","2":"5"},{"1":"GPATCH2","2":"5"},{"1":"GPATCH4","2":"5"},{"1":"GPRIN3","2":"5"},{"1":"GSK3B","2":"5"},{"1":"GTDC1","2":"5"},{"1":"GTPBP1","2":"5"},{"1":"HDAC9","2":"5"},{"1":"HELLS","2":"5"},{"1":"HELQ","2":"5"},{"1":"HGSNAT","2":"5"},{"1":"HINT1","2":"5"},{"1":"HNRNPU","2":"5"},{"1":"HOOK3","2":"5"},{"1":"HPS1","2":"5"},{"1":"HSPD1","2":"5"},{"1":"ILF3","2":"5"},{"1":"INIP","2":"5"},{"1":"INSR","2":"5"},{"1":"INTS4","2":"5"},{"1":"IPO5","2":"5"},{"1":"IPP","2":"5"},{"1":"IRF2BP2","2":"5"},{"1":"ITFG1","2":"5"},{"1":"ITPKB","2":"5"},{"1":"JAG1","2":"5"},{"1":"KANSL1L","2":"5"},{"1":"KAT6B","2":"5"},{"1":"KCNAB1","2":"5"},{"1":"KDM5A","2":"5"},{"1":"KDM5B","2":"5"},{"1":"KDM6B","2":"5"},{"1":"KIAA0226","2":"5"},{"1":"KIAA2018","2":"5"},{"1":"KIDINS220","2":"5"},{"1":"KIF6","2":"5"},{"1":"KLF6","2":"5"},{"1":"KLF7","2":"5"},{"1":"KLF9","2":"5"},{"1":"KLHDC10","2":"5"},{"1":"KLHL22","2":"5"},{"1":"KLHL24","2":"5"},{"1":"KMT2D","2":"5"},{"1":"KPNA4","2":"5"},{"1":"LARP4","2":"5"},{"1":"LIMD1","2":"5"},{"1":"LINS","2":"5"},{"1":"LMO4","2":"5"},{"1":"LPCAT4","2":"5"},{"1":"LRRFIP2","2":"5"},{"1":"LSM14B","2":"5"},{"1":"LUC7L","2":"5"},{"1":"LUZP1","2":"5"},{"1":"LYRM2","2":"5"},{"1":"MAP2K7","2":"5"},{"1":"MAPK8","2":"5"},{"1":"MAPK8IP3","2":"5"},{"1":"MARCKS","2":"5"},{"1":"MAU2","2":"5"},{"1":"MAX","2":"5"},{"1":"MBD1","2":"5"},{"1":"MCM3AP","2":"5"},{"1":"MCM4","2":"5"},{"1":"MCPH1","2":"5"},{"1":"MCTP2","2":"5"},{"1":"MED13L","2":"5"},{"1":"MED16","2":"5"},{"1":"MED23","2":"5"},{"1":"MEX3C","2":"5"},{"1":"MGEA5","2":"5"},{"1":"MIB2","2":"5"},{"1":"MIER3","2":"5"},{"1":"MKL1","2":"5"},{"1":"MKLN1","2":"5"},{"1":"MLX","2":"5"},{"1":"MTDH","2":"5"},{"1":"MTF2","2":"5"},{"1":"MTG2","2":"5"},{"1":"MTHFR","2":"5"},{"1":"MTO1","2":"5"},{"1":"MYLK3","2":"5"},{"1":"MYNN","2":"5"},{"1":"NAP1L4","2":"5"},{"1":"NAPEPLD","2":"5"},{"1":"NBN","2":"5"},{"1":"NCAPH2","2":"5"},{"1":"NCOA3","2":"5"},{"1":"NCOR1","2":"5"},{"1":"NCOR2","2":"5"},{"1":"NDUFS1","2":"5"},{"1":"NEDD9","2":"5"},{"1":"NEK1","2":"5"},{"1":"NFX1","2":"5"},{"1":"NIPAL3","2":"5"},{"1":"NIPBL","2":"5"},{"1":"NR3C1","2":"5"},{"1":"NRF1","2":"5"},{"1":"NUB1","2":"5"},{"1":"NUMA1","2":"5"},{"1":"NUP210","2":"5"},{"1":"OCIAD1","2":"5"},{"1":"OSBPL10","2":"5"},{"1":"OXR1","2":"5"},{"1":"PAPOLG","2":"5"},{"1":"PATL1","2":"5"},{"1":"PCGF5","2":"5"},{"1":"PDCD2","2":"5"},{"1":"PDE4A","2":"5"},{"1":"PDXDC1","2":"5"},{"1":"PERP","2":"5"},{"1":"PEX13","2":"5"},{"1":"PHC3","2":"5"},{"1":"PHF3","2":"5"},{"1":"PHIP","2":"5"},{"1":"PHTF2","2":"5"},{"1":"PICALM","2":"5"},{"1":"PKNOX1","2":"5"},{"1":"PKP4","2":"5"},{"1":"PMS1","2":"5"},{"1":"PNN","2":"5"},{"1":"PPA2","2":"5"},{"1":"PPHLN1","2":"5"},{"1":"PPM1K","2":"5"},{"1":"PPP2R1B","2":"5"},{"1":"PRKAA1","2":"5"},{"1":"PRKAG2","2":"5"},{"1":"PRKCA","2":"5"},{"1":"PRKD3","2":"5"},{"1":"PROSC","2":"5"},{"1":"PSPC1","2":"5"},{"1":"PTBP3","2":"5"},{"1":"PTP4A1","2":"5"},{"1":"PURA","2":"5"},{"1":"RAB27A","2":"5"},{"1":"RAB30","2":"5"},{"1":"RAB3B","2":"5"},{"1":"RABEP1","2":"5"},{"1":"RABGAP1L","2":"5"},{"1":"RAD1","2":"5"},{"1":"RALGAPA2","2":"5"},{"1":"RALGPS1","2":"5"},{"1":"RALGPS2","2":"5"},{"1":"RAP2A","2":"5"},{"1":"RAPGEF2","2":"5"},{"1":"RARA","2":"5"},{"1":"RARS2","2":"5"},{"1":"RBM15","2":"5"},{"1":"RBM47","2":"5"},{"1":"RECQL5","2":"5"},{"1":"RERE","2":"5"},{"1":"RHBDD1","2":"5"},{"1":"RHOB","2":"5"},{"1":"RIOK3","2":"5"},{"1":"RIT1","2":"5"},{"1":"ROCK1","2":"5"},{"1":"RPUSD3","2":"5"},{"1":"RRP12","2":"5"},{"1":"RSBN1","2":"5"},{"1":"RSU1","2":"5"},{"1":"RTFDC1","2":"5"},{"1":"SAR1B","2":"5"},{"1":"SAV1","2":"5"},{"1":"SBF1","2":"5"},{"1":"SBNO1","2":"5"},{"1":"SCAF4","2":"5"},{"1":"SCARB1","2":"5"},{"1":"SEC62","2":"5"},{"1":"SEC63","2":"5"},{"1":"SEPSECS","2":"5"},{"1":"SEPT2","2":"5"},{"1":"SETD5","2":"5"},{"1":"SF3B1","2":"5"},{"1":"SFPQ","2":"5"},{"1":"SFT2D1","2":"5"},{"1":"SH3BP2","2":"5"},{"1":"SIKE1","2":"5"},{"1":"SKIL","2":"5"},{"1":"SLC11A2","2":"5"},{"1":"SLC12A4","2":"5"},{"1":"SLC16A1","2":"5"},{"1":"SLC16A7","2":"5"},{"1":"SLC1A4","2":"5"},{"1":"SLC25A36","2":"5"},{"1":"SLC2A13","2":"5"},{"1":"SLC30A5","2":"5"},{"1":"SLC6A6","2":"5"},{"1":"SLC7A1","2":"5"},{"1":"SMAD4","2":"5"},{"1":"SMAD5","2":"5"},{"1":"SMIM14","2":"5"},{"1":"SMIM4","2":"5"},{"1":"SNX13","2":"5"},{"1":"SNX24","2":"5"},{"1":"SNX25","2":"5"},{"1":"SON","2":"5"},{"1":"SOS1","2":"5"},{"1":"SP3","2":"5"},{"1":"SPAG9","2":"5"},{"1":"SPPL3","2":"5"},{"1":"SPTLC2","2":"5"},{"1":"SRRT","2":"5"},{"1":"SRSF4","2":"5"},{"1":"ST3GAL2","2":"5"},{"1":"ST7L","2":"5"},{"1":"ST8SIA4","2":"5"},{"1":"STAM2","2":"5"},{"1":"STK38","2":"5"},{"1":"STRBP","2":"5"},{"1":"STX17","2":"5"},{"1":"STX6","2":"5"},{"1":"STYXL1","2":"5"},{"1":"SUGP2","2":"5"},{"1":"SUPT20H","2":"5"},{"1":"SYNE2","2":"5"},{"1":"TAF6L","2":"5"},{"1":"TAF8","2":"5"},{"1":"TAGAP","2":"5"},{"1":"TBC1D1","2":"5"},{"1":"TCAIM","2":"5"},{"1":"TCEB3","2":"5"},{"1":"TERF2","2":"5"},{"1":"TFPI","2":"5"},{"1":"TFRC","2":"5"},{"1":"TGOLN2","2":"5"},{"1":"TLE4","2":"5"},{"1":"TM2D1","2":"5"},{"1":"TM9SF3","2":"5"},{"1":"TMED4","2":"5"},{"1":"TMEM107","2":"5"},{"1":"TMEM245","2":"5"},{"1":"TMEM33","2":"5"},{"1":"TMEM50B","2":"5"},{"1":"TMPO","2":"5"},{"1":"TNPO2","2":"5"},{"1":"TNRC6C","2":"5"},{"1":"TOR1AIP1","2":"5"},{"1":"TOX4","2":"5"},{"1":"TPD52","2":"5"},{"1":"TPR","2":"5"},{"1":"TRA2A","2":"5"},{"1":"TRAK1","2":"5"},{"1":"TRIM8","2":"5"},{"1":"TRPM7","2":"5"},{"1":"TRUB1","2":"5"},{"1":"TSPAN3","2":"5"},{"1":"TTN","2":"5"},{"1":"TWF1","2":"5"},{"1":"U2SURP","2":"5"},{"1":"UBE2D4","2":"5"},{"1":"UBE2I","2":"5"},{"1":"UBE3C","2":"5"},{"1":"UBE4B","2":"5"},{"1":"UBN2","2":"5"},{"1":"UBTF","2":"5"},{"1":"UGGT1","2":"5"},{"1":"USP25","2":"5"},{"1":"USP31","2":"5"},{"1":"USP36","2":"5"},{"1":"USP42","2":"5"},{"1":"USP47","2":"5"},{"1":"USP48","2":"5"},{"1":"VPRBP","2":"5"},{"1":"VPS13D","2":"5"},{"1":"VPS35","2":"5"},{"1":"VTI1A","2":"5"},{"1":"WDR1","2":"5"},{"1":"WDR26","2":"5"},{"1":"WIPI2","2":"5"},{"1":"WSB1","2":"5"},{"1":"WWOX","2":"5"},{"1":"YTHDC1","2":"5"},{"1":"YWHAZ","2":"5"},{"1":"ZBTB38","2":"5"},{"1":"ZBTB43","2":"5"},{"1":"ZBTB44","2":"5"},{"1":"ZC3H7B","2":"5"},{"1":"ZCCHC6","2":"5"},{"1":"ZFAND5","2":"5"},{"1":"ZFYVE16","2":"5"},{"1":"ZMAT3","2":"5"},{"1":"ZMYND8","2":"5"},{"1":"ZNF24","2":"5"},{"1":"ZNF397","2":"5"},{"1":"ZNF451","2":"5"},{"1":"ZNF496","2":"5"},{"1":"ZNF688","2":"5"},{"1":"ZNF710","2":"5"},{"1":"ZNF827","2":"5"},{"1":"ZSCAN30","2":"5"},{"1":"ABCA1","2":"4"},{"1":"ABHD5","2":"4"},{"1":"ACAD10","2":"4"},{"1":"ACOT11","2":"4"},{"1":"ACP1","2":"4"},{"1":"ADCK2","2":"4"},{"1":"ADD1","2":"4"},{"1":"ADD3","2":"4"},{"1":"AGGF1","2":"4"},{"1":"AGO1","2":"4"},{"1":"AGO3","2":"4"},{"1":"AGO4","2":"4"},{"1":"AGPS","2":"4"},{"1":"AHCYL1","2":"4"},{"1":"AHNAK","2":"4"},{"1":"AKAP1","2":"4"},{"1":"AKAP10","2":"4"},{"1":"ALKBH7","2":"4"},{"1":"ALOX5","2":"4"},{"1":"ALPK1","2":"4"},{"1":"AMBRA1","2":"4"},{"1":"ANAPC16","2":"4"},{"1":"ANKFY1","2":"4"},{"1":"ANKRD10","2":"4"},{"1":"ANKRD12","2":"4"},{"1":"ANKRD28","2":"4"},{"1":"ANKS6","2":"4"},{"1":"ANTXR2","2":"4"},{"1":"AP2A1","2":"4"},{"1":"AP2A2","2":"4"},{"1":"AP4E1","2":"4"},{"1":"APOL6","2":"4"},{"1":"APPBP2","2":"4"},{"1":"AQR","2":"4"},{"1":"ARFGEF2","2":"4"},{"1":"ARGLU1","2":"4"},{"1":"ARHGAP1","2":"4"},{"1":"ARHGAP23","2":"4"},{"1":"ARHGAP26","2":"4"},{"1":"ARHGDIA","2":"4"},{"1":"ARHGEF2","2":"4"},{"1":"ARID1A","2":"4"},{"1":"ARPC5L","2":"4"},{"1":"ARSB","2":"4"},{"1":"ATAD2","2":"4"},{"1":"ATE1","2":"4"},{"1":"ATF5","2":"4"},{"1":"ATF6","2":"4"},{"1":"ATG2B","2":"4"},{"1":"ATN1","2":"4"},{"1":"ATP2A2","2":"4"},{"1":"ATP2C1","2":"4"},{"1":"ATP5C1","2":"4"},{"1":"ATP6V1C1","2":"4"},{"1":"ATP6V1D","2":"4"},{"1":"B3GALNT2","2":"4"},{"1":"BAZ1B","2":"4"},{"1":"BAZ2A","2":"4"},{"1":"BCL2","2":"4"},{"1":"BCL2L1","2":"4"},{"1":"BHLHE41","2":"4"},{"1":"BICD2","2":"4"},{"1":"BLZF1","2":"4"},{"1":"BRAP","2":"4"},{"1":"BRD7","2":"4"},{"1":"BRF1","2":"4"},{"1":"BTBD9","2":"4"},{"1":"BTD","2":"4"},{"1":"BTF3","2":"4"},{"1":"BTG3","2":"4"},{"1":"BTN2A1","2":"4"},{"1":"C11orf1","2":"4"},{"1":"C18orf25","2":"4"},{"1":"C21orf2","2":"4"},{"1":"C2CD3","2":"4"},{"1":"C2orf68","2":"4"},{"1":"C3orf38","2":"4"},{"1":"C5orf56","2":"4"},{"1":"C9orf16","2":"4"},{"1":"CACYBP","2":"4"},{"1":"CALCOCO2","2":"4"},{"1":"CAMK2G","2":"4"},{"1":"CAMKK2","2":"4"},{"1":"CAPS","2":"4"},{"1":"CAPZB","2":"4"},{"1":"CARD8","2":"4"},{"1":"CARHSP1","2":"4"},{"1":"CARS","2":"4"},{"1":"CASP10","2":"4"},{"1":"CBX3","2":"4"},{"1":"CC2D1A","2":"4"},{"1":"CCDC132","2":"4"},{"1":"CCDC71L","2":"4"},{"1":"CCDC82","2":"4"},{"1":"CCDC93","2":"4"},{"1":"CCNL1","2":"4"},{"1":"CCNT2","2":"4"},{"1":"CCSAP","2":"4"},{"1":"CCSER2","2":"4"},{"1":"CD40","2":"4"},{"1":"CDADC1","2":"4"},{"1":"CDC27","2":"4"},{"1":"CDC42EP3","2":"4"},{"1":"CDC42SE1","2":"4"},{"1":"CDC5L","2":"4"},{"1":"CDK19","2":"4"},{"1":"CENPN","2":"4"},{"1":"CEP350","2":"4"},{"1":"CEP57L1","2":"4"},{"1":"CEP95","2":"4"},{"1":"CFL1","2":"4"},{"1":"CHAF1A","2":"4"},{"1":"CHD1L","2":"4"},{"1":"CHD6","2":"4"},{"1":"CHD7","2":"4"},{"1":"CHEK1","2":"4"},{"1":"CIZ1","2":"4"},{"1":"CLCN3","2":"4"},{"1":"CLDND1","2":"4"},{"1":"CLK4","2":"4"},{"1":"CLMN","2":"4"},{"1":"CLOCK","2":"4"},{"1":"CLTB","2":"4"},{"1":"CNOT2","2":"4"},{"1":"CNOT7","2":"4"},{"1":"CNPY3","2":"4"},{"1":"CNST","2":"4"},{"1":"CNTROB","2":"4"},{"1":"COL4A3BP","2":"4"},{"1":"COMT","2":"4"},{"1":"COPA","2":"4"},{"1":"COX15","2":"4"},{"1":"COX5B","2":"4"},{"1":"CPEB3","2":"4"},{"1":"CPEB4","2":"4"},{"1":"CPT1A","2":"4"},{"1":"CREBBP","2":"4"},{"1":"CSE1L","2":"4"},{"1":"CSNK1G1","2":"4"},{"1":"CSNK2A1","2":"4"},{"1":"CTBP1","2":"4"},{"1":"CTDSPL2","2":"4"},{"1":"CTSC","2":"4"},{"1":"CTU2","2":"4"},{"1":"CUL5","2":"4"},{"1":"CUL7","2":"4"},{"1":"CWF19L2","2":"4"},{"1":"CYB5B","2":"4"},{"1":"CYB5RL","2":"4"},{"1":"CYHR1","2":"4"},{"1":"CYP3A5","2":"4"},{"1":"CYP4V2","2":"4"},{"1":"DAGLB","2":"4"},{"1":"DAPP1","2":"4"},{"1":"DAZAP2","2":"4"},{"1":"DCAF10","2":"4"},{"1":"DCAF13","2":"4"},{"1":"DCAF15","2":"4"},{"1":"DCP2","2":"4"},{"1":"DDR2","2":"4"},{"1":"DDX11","2":"4"},{"1":"DDX18","2":"4"},{"1":"DDX28","2":"4"},{"1":"DDX52","2":"4"},{"1":"DERL1","2":"4"},{"1":"DHFR","2":"4"},{"1":"DHX36","2":"4"},{"1":"DIAPH1","2":"4"},{"1":"DIDO1","2":"4"},{"1":"DIEXF","2":"4"},{"1":"DIMT1","2":"4"},{"1":"DIS3L2","2":"4"},{"1":"DNAJB12","2":"4"},{"1":"DNAJC27","2":"4"},{"1":"DNAJC3","2":"4"},{"1":"DNHD1","2":"4"},{"1":"DOCK8","2":"4"},{"1":"DOPEY1","2":"4"},{"1":"DPY19L1","2":"4"},{"1":"DSTYK","2":"4"},{"1":"DYNC1LI2","2":"4"},{"1":"DYNC2LI1","2":"4"},{"1":"DYRK2","2":"4"},{"1":"EARS2","2":"4"},{"1":"ECHDC1","2":"4"},{"1":"EFCAB2","2":"4"},{"1":"EGLN1","2":"4"},{"1":"EHBP1L1","2":"4"},{"1":"EIF3K","2":"4"},{"1":"EIF4E3","2":"4"},{"1":"EIF4G3","2":"4"},{"1":"ELAVL1","2":"4"},{"1":"ELL2","2":"4"},{"1":"ELMO2","2":"4"},{"1":"ELMOD2","2":"4"},{"1":"ELOVL5","2":"4"},{"1":"ELP6","2":"4"},{"1":"EML2","2":"4"},{"1":"ENDOV","2":"4"},{"1":"ENO1","2":"4"},{"1":"ENOSF1","2":"4"},{"1":"ENTHD2","2":"4"},{"1":"ENTPD1","2":"4"},{"1":"EP400","2":"4"},{"1":"EPB41L4A","2":"4"},{"1":"EPB41L5","2":"4"},{"1":"EPC1","2":"4"},{"1":"ERCC6L2","2":"4"},{"1":"ERCC8","2":"4"},{"1":"ERGIC1","2":"4"},{"1":"ERGIC2","2":"4"},{"1":"ESD","2":"4"},{"1":"ETV6","2":"4"},{"1":"EVI5L","2":"4"},{"1":"EWSR1","2":"4"},{"1":"EYA3","2":"4"},{"1":"FAHD2A","2":"4"},{"1":"FAM120AOS","2":"4"},{"1":"FAM126A","2":"4"},{"1":"FAM126B","2":"4"},{"1":"FAM134A","2":"4"},{"1":"FAM149B1","2":"4"},{"1":"FAM161A","2":"4"},{"1":"FAM178A","2":"4"},{"1":"FAM192A","2":"4"},{"1":"FAM208B","2":"4"},{"1":"FAM63B","2":"4"},{"1":"FAM76B","2":"4"},{"1":"FANCD2","2":"4"},{"1":"FANCM","2":"4"},{"1":"FBXO42","2":"4"},{"1":"FBXW7","2":"4"},{"1":"FKBP4","2":"4"},{"1":"FLCN","2":"4"},{"1":"FLI1","2":"4"},{"1":"FNBP1","2":"4"},{"1":"FNBP4","2":"4"},{"1":"FNDC3A","2":"4"},{"1":"FNIP2","2":"4"},{"1":"FOXK1","2":"4"},{"1":"FOXO3","2":"4"},{"1":"FRMD8","2":"4"},{"1":"FUBP1","2":"4"},{"1":"FZD3","2":"4"},{"1":"FZR1","2":"4"},{"1":"GADD45B","2":"4"}],"options":{"columns":{"min":{},"max":[10],"total":[2]},"rows":{"min":[10],"max":[10],"total":[7193]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgXG4gIGZpbHRlcihgR2VuZSBTeW1ib2xgICVpbiUgY21wc19zcGVjX2dlbmVuYW1lcykgJT4lIFxuICBncm91cF9ieShgR2VuZSBTeW1ib2xgKSAlPiUgXG4gIHN1bW1hcmlzZShuPW4oKSkgJT4lIFxuICBzdW1tYXJpc2Uoc3VtKG4+MSkpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_features %&gt;% 
  filter(`Gene Symbol` %in% cmps_spec_genenames) %&gt;% 
  group_by(`Gene Symbol`) %&gt;% 
  summarise(n=n()) %&gt;% 
  summarise(sum(n&gt;1))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin eyJtZXRhZGF0YSI6eyJjbGFzc2VzIjpbInRibF9kZiIsInRibCIsImRhdGEuZnJhbWUiXSwibnJvdyI6MSwibmNvbCI6MSwic3VtbWFyeSI6eyJBIHRpYmJsZSI6WyIxIMOXIDEiXX19LCJyZGYiOiJINHNJQUFBQUFBQUFBMlZQUVE2Q01CQmNLdFZJb2lIaEF4ejFBTkZ3OGVUSitBQ2pDZGVLcUVSc0RaVG8wWmVEVzZTUjFDYnRkaWN6c3p1N1RSdzVzUU1BQTdBdEFnT0tYNkNIL1RaWUFkZ0VHd3RzR0t2NlFwTFhBZ0NUYi9YT0JvbHlkazlML0xnOTBDbXIrNHo3YTM4NU4rampRanhETFZHZTVJMVBnOGYwVFhKVy92bWVtR1RodVVBOWRyVWhHWW1IekFSSEVWRmJVME5zRlFiZ1ZseHRjZ3FTYThWdlFiUlFFN3E0OEl2Y2o2K3Vta21hem90MlhzT1VYektlNnVWemRrenpycGxpNURaeCtDZ3lMblVVUk10UUNzazB6MGxFcnBFMkhOUWZNZ29qeEswQkFBQT0ifQ== -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["sum(n > 1)"],"name":[1],"type":["int"],"align":["right"]}],"data":[{"1":"4966"}],"options":{"columns":{"min":{},"max":[10],"total":[1]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>4966 out of 7193 have multiple probesets</p>
<p>which genes that are in the spectra rotation matrix are not in the expression set?</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY21wc19zcGVjX3JtX3duICU+JSBkaXN0aW5jdChnZW5lX25hbWUpICU+JSBmaWx0ZXIoIWdlbmVfbmFtZSAlaW4lIHVuaXF1ZShnc2UyNjU4X2ZlYXR1cmVzJGBHZW5lIFN5bWJvbGApKVxuYGBgIn0= -->
<pre class="r"><code>cmps_spec_rm_wn %&gt;% distinct(gene_name) %&gt;% filter(!gene_name %in% unique(gse2658_features$`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]}],"data":[{"1":"ST7"},{"1":"ZNF263"},{"1":"JHDM1D"},{"1":"RTEL1-TNFRSF6B"},{"1":"MAP2K3"},{"1":"FAM136A"},{"1":"PHF15"},{"1":"ZC3H11A"},{"1":"DNAJC25"},{"1":"MEF2BNB-MEF2B"},{"1":"PDIA5"},{"1":"ELOVL1"},{"1":"BCL3"},{"1":"EPN2"},{"1":"P4HA2"},{"1":"ZNF37A"},{"1":"ARHGAP15"},{"1":"PHF17"},{"1":"SP140"},{"1":"RABL2B"},{"1":"RIF1"},{"1":"TAF9"},{"1":"METTL2A"},{"1":"FKBP1A"},{"1":"MAEA"},{"1":"PABPC4"},{"1":"DTX2"},{"1":"HAUS4"},{"1":"FAM21A"},{"1":"PSME2"},{"1":"NOP56"},{"1":"NUTF2"},{"1":"LONP2"},{"1":"EEF2K"},{"1":"NOMO1"},{"1":"PLEKHJ1"},{"1":"BBC3"},{"1":"DKFZP761J1410"},{"1":"C10orf137"},{"1":"CASC3"},{"1":"FRG1"},{"1":"ZNF259"},{"1":"HSPA8"},{"1":"POU2AF1"},{"1":"LTA4H"},{"1":"SRSF9"},{"1":"APBB3"},{"1":"EEF1B2"},{"1":"SF3B14"},{"1":"PDCL3"},{"1":"GPR89A"},{"1":"RAB7L1"},{"1":"EBNA1BP2"},{"1":"C1orf63"},{"1":"ACOT2"},{"1":"TCP1"},{"1":"MTERFD3"},{"1":"MTERFD2"},{"1":"RPL5"},{"1":"PMS2"},{"1":"C12orf44"},{"1":"TTC21B"},{"1":"MXD4"},{"1":"GPR108"},{"1":"SBDS"},{"1":"FAM78A"},{"1":"MTERF"},{"1":"DGCR8"},{"1":"ATP6V1F"},{"1":"NARG2"},{"1":"TMEM66"},{"1":"TMBIM1"},{"1":"DBNL"},{"1":"SMPD4"},{"1":"WDR33"},{"1":"ANKRD42"},{"1":"ZNF280D"},{"1":"C4orf21"},{"1":"C12orf52"},{"1":"CDR2"},{"1":"SLC16A3"},{"1":"AZI1"},{"1":"hsa-mir-1199"},{"1":"UCK2"},{"1":"TARS2"},{"1":"CEP170"},{"1":"SNAP47"},{"1":"PYCR2"},{"1":"RABL2A"},{"1":"FAHD2B"},{"1":"CCDC39"},{"1":"PYURF"},{"1":"MMS22L"},{"1":"NAPRT1"},{"1":"RPL7A"},{"1":"USP6NL"},{"1":"ZEB1"},{"1":"CSRP2BP"},{"1":"C12orf23"},{"1":"SCLT1"},{"1":"MLF1IP"},{"1":"ZNF773"},{"1":"MED21"},{"1":"ANAPC1"},{"1":"GOLGA8I"},{"1":"C17orf103"},{"1":"FAM105B"},{"1":"MKI67IP"},{"1":"ACPL2"},{"1":"NDUFAF6"},{"1":"MTERFD1"},{"1":"SMG1"},{"1":"DHRS4"},{"1":"SLC35B2"},{"1":"RUNX1"},{"1":"CALM3"},{"1":"LRWD1"},{"1":"SRSF2"},{"1":"AMDHD2"},{"1":"C11orf48"},{"1":"SELRC1"},{"1":"MAGOH"},{"1":"ARL5A"},{"1":"FBXO41"},{"1":"CCT3"},{"1":"NUAK2"},{"1":"ZC3H12A"},{"1":"KIAA0947"},{"1":"PRMT10"},{"1":"C10orf118"},{"1":"MARS"},{"1":"C19orf55"},{"1":"UBXN6"},{"1":"C19orf48"},{"1":"OTUB1"},{"1":"RAB4A"},{"1":"NDUFS5"},{"1":"RP11-231C14.4"},{"1":"BOLA2B"},{"1":"RGPD8"},{"1":"TAS1R3"},{"1":"GLB1"},{"1":"FAM115C"},{"1":"HARS"},{"1":"ACYP2"},{"1":"ZNF561"},{"1":"LRRC8C"},{"1":"QARS"},{"1":"ZNF131"},{"1":"AGAP5"},{"1":"FAM21C"},{"1":"MRP63"},{"1":"GMPPB"},{"1":"CCDC41"},{"1":"RP11-1407O15.2"},{"1":"AGAP8"},{"1":"APITD1"},{"1":"AMIGO3"},{"1":"PIDD"},{"1":"GBA"},{"1":"KIAA0195"},{"1":"RIC8A"},{"1":"PER1"},{"1":"C7orf41"},{"1":"ZNF707"},{"1":"UBA7"},{"1":"TTC3"},{"1":"RPS17L"},{"1":"LSMD1"},{"1":"RGPD6"},{"1":"AC138969.4"},{"1":"ACTG1"},{"1":"NELFA"},{"1":"LRRC37B"},{"1":"NRBP2"},{"1":"TMEM179B"},{"1":"C11orf35"},{"1":"C16orf52"},{"1":"NPIPB4"},{"1":"AP003068.6"},{"1":"DHRS4L2"},{"1":"VMAC"},{"1":"TMEM256-PLSCR3"},{"1":"ARHGAP11B"},{"1":"RINL"},{"1":"CTD-2228K2.5"},{"1":"BLOC1S5"},{"1":"SUMO2"},{"1":"NUGGC"},{"1":"RP11-113D6.10"},{"1":"SLC35E2B"},{"1":"C1orf186"},{"1":"GPR89C"},{"1":"TRAPPC4"},{"1":"HIST1H2AG"},{"1":"ZNF720"},{"1":"CCDC180"},{"1":"HIST4H4"},{"1":"ZNF181"},{"1":"FAM212B"},{"1":"KTI12"},{"1":"KIAA1737"},{"1":"AGAP10"},{"1":"NELFE"},{"1":"GNB2L1"},{"1":"CBWD6"},{"1":"FBXO48"},{"1":"FLJ00104"},{"1":"SMN2"},{"1":"SERF1B"},{"1":"AL590867.1"},{"1":"C19orf38"},{"1":"SPDYE3"},{"1":"AL162389.1"},{"1":"C22orf29"},{"1":"CBWD7"},{"1":"GOLGA8B"},{"1":"AC009403.2"},{"1":"AC007390.5"},{"1":"RPA3-AS1"},{"1":"GLTPD1"},{"1":"RP4-758J18.2"},{"1":"ARL17B"},{"1":"RP11-47I22.3"},{"1":"RP11-1212A22.4"},{"1":"WASH4P"},{"1":"AC015987.2"},{"1":"RP11-295P9.3"},{"1":"AMY2B"},{"1":"TMEM189"},{"1":"PISD"},{"1":"AP5Z1"},{"1":"RP5-966M1.6"},{"1":"NPIPB5"},{"1":"ZMYM6NB"},{"1":"TMEM199"},{"1":"CDK11B"},{"1":"ABHD14A"},{"1":"ARPC4-TTLL3"},{"1":"CTC-534A2.2"},{"1":"ALG11"},{"1":"AP001816.1"},{"1":"MIR3654"},{"1":"TRAPPC2P1"},{"1":"RP11-286N22.8"},{"1":"TVP23C-CDRT4"},{"1":"GOLGA8S"},{"1":"RP11-345J4.5"},{"1":"CTC-479C5.12"},{"1":"UPK3BL"},{"1":"AC137932.1"},{"1":"AC008443.1"},{"1":"AL591479.1"},{"1":"AC040977.1"},{"1":"RP11-574K11.31"}],"options":{"columns":{"min":{},"max":[10],"total":[1]},"rows":{"min":[10],"max":[10],"total":[255]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>255 genes that are in the spectra rotation matrix are not in the microarray expression data</p>
<p>although there are some genes with double names like <code>&quot;DDR1 /// MIR4640&quot;</code></p>
<p>need to sort out genes that are buried in there with weird names</p>
</div>
<div id="fishing-through-multiple-names" class="section level2">
<h2>fishing through multiple names</h2>
<p>test runs</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuTUFQMkszX3NtIDwtIGdzZTI2NThfZmVhdHVyZXMgJT4lIFxuICBmaWx0ZXIoZ3JlcGwoXCJNQVAySzNcIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBcbiAgc2VsZWN0KGBHZW5lIFN5bWJvbGA6YFJlZlNlcSBUcmFuc2NyaXB0IElEYCwgR0JfQUNDLCBgUmVwcmVzZW50YXRpdmUgUHVibGljIElEYClcbk1BUDJLM19zbVxuYGBgIn0= -->
<pre class="r"><code>MAP2K3_sm &lt;- gse2658_features %&gt;% 
  filter(grepl(&quot;MAP2K3&quot;, `Gene Symbol`)) %&gt;% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
MAP2K3_sm</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"LOC100996792 /// MAP2K3","2":"5606 /// 100996792","3":"NM_002756 /// NM_145109 /// NM_145110 /// XM_003846747 /// XM_005256721 /// XM_005256722 /// XM_005256723 /// XR_429863 /// XR_429864","4":"NM_002756","5":"NM_002756","_rn_":"207667_s_at"},{"1":"LOC100996792 /// MAP2K3","2":"5606 /// 100996792","3":"NM_002756 /// NM_145109 /// NM_145110 /// XM_003846747 /// XM_005256721 /// XM_005256722 /// XM_005256723 /// XR_429863 /// XR_429864","4":"AA780381","5":"AA780381","_rn_":"215498_s_at"},{"1":"LOC100996792 /// MAP2K3","2":"5606 /// 100996792","3":"NM_002756 /// NM_145109 /// NM_145110 /// XM_003846747 /// XM_005256721 /// XM_005256722 /// XM_005256723 /// XR_429863 /// XR_429864","4":"AA780381","5":"AA780381","_rn_":"215499_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuTUFQMkszX3NtICU+JSBmaWx0ZXIoZ3JlcGwoXCIoXFxcXHNNQVAySzMpfChNQVAySzNcXFxccylcIixgR2VuZSBTeW1ib2xgKSlcbmBgYCJ9 -->
<pre class="r"><code>MAP2K3_sm %&gt;% filter(grepl(&quot;(\\sMAP2K3)|(MAP2K3\\s)&quot;,`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"LOC100996792 /// MAP2K3","2":"5606 /// 100996792","3":"NM_002756 /// NM_145109 /// NM_145110 /// XM_003846747 /// XM_005256721 /// XM_005256722 /// XM_005256723 /// XR_429863 /// XR_429864","4":"NM_002756","5":"NM_002756","_rn_":"207667_s_at"},{"1":"LOC100996792 /// MAP2K3","2":"5606 /// 100996792","3":"NM_002756 /// NM_145109 /// NM_145110 /// XM_003846747 /// XM_005256721 /// XM_005256722 /// XM_005256723 /// XR_429863 /// XR_429864","4":"AA780381","5":"AA780381","_rn_":"215498_s_at"},{"1":"LOC100996792 /// MAP2K3","2":"5606 /// 100996792","3":"NM_002756 /// NM_145109 /// NM_145110 /// XM_003846747 /// XM_005256721 /// XM_005256722 /// XM_005256723 /// XR_429863 /// XR_429864","4":"AA780381","5":"AA780381","_rn_":"215499_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuWk5GMjYzX3NtIDwtIGdzZTI2NThfZmVhdHVyZXMgJT4lIFxuICBmaWx0ZXIoZ3JlcGwoXCJaTkYyNjNcIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBcbiAgc2VsZWN0KGBHZW5lIFN5bWJvbGA6YFJlZlNlcSBUcmFuc2NyaXB0IElEYCwgR0JfQUNDLCBgUmVwcmVzZW50YXRpdmUgUHVibGljIElEYClcblpORjI2M19zbVxuYGBgIn0= -->
<pre class="r"><code>ZNF263_sm &lt;- gse2658_features %&gt;% 
  filter(grepl(&quot;ZNF263&quot;, `Gene Symbol`)) %&gt;% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
ZNF263_sm</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"LINC00921 /// ZNF263","2":"10127 /// 283876","3":"NM_005741 /// NR_033904 /// XM_005255031 /// XM_006720831 /// XM_006720832 /// XM_006720833 /// XM_006720834 /// XM_006720835","4":"NM_005741","5":"NM_005741","_rn_":"203707_at"},{"1":"LINC00921 /// TIGD7 /// ZNF263","2":"10127 /// 91151 /// 283876","3":"NM_005741 /// NM_033208 /// NR_033904 /// XM_005255031 /// XM_006720831 /// XM_006720832 /// XM_006720833 /// XM_006720834 /// XM_006720835","4":"AI765123","5":"AI765123","_rn_":"232089_at"},{"1":"LINC00921 /// ZNF263","2":"10127 /// 283876","3":"NM_005741 /// NR_033904 /// XM_005255031 /// XM_006720831 /// XM_006720832 /// XM_006720833 /// XM_006720834 /// XM_006720835","4":"BE176531","5":"BE176531","_rn_":"243547_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuWk5GMjYzX3NtICU+JSBmaWx0ZXIoZ3JlcGwoXCIoXFxcXHNaTkYyNjMpfChaTkYyNjNcXFxccylcIixgR2VuZSBTeW1ib2xgKSlcbmBgYCJ9 -->
<pre class="r"><code>ZNF263_sm %&gt;% filter(grepl(&quot;(\\sZNF263)|(ZNF263\\s)&quot;,`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin eyJtZXRhZGF0YSI6eyJjbGFzc2VzIjpbImRhdGEuZnJhbWUiXSwibnJvdyI6MywibmNvbCI6NSwic3VtbWFyeSI6eyJEZXNjcmlwdGlvbiI6WyJkZiBbMyDDlyA1XSJdfX0sInJkZiI6Ikg0c0lBQUFBQUFBQUE4V1VUVS9iTUJqSFRkdEFtMmxUcFhGQU8wejVBbTM5a2pUdEVkcFFWUm9SQ2tXcXVFUnVNRnUwNEhSSkN1eXdUN0R2WEhBU0p6UXBOdzRjTFB2NVBTLytQN1psWjdvazZsSUZBRFJCNjZBQm1vcFlBdVY2Y2Q0YkFkQnFDT01BdEVBbm5aOUUwTmZVSzBZM3o4Z2N4ei9tOWdUQ01VYmFZRERRYnV4elBDVFM5NzNxVzh4blUzTS82dTBLMVYyNkNDS2M1K0lSR1psRHliKzk4akZDQnRxUDJNK3NWdjVuWDdnUUdxYWU1OXFPQ3drWlF6MnpscGtQR3dZazZCVU1UUXhIK3dEWEFha0R2UTRNS2VKL1RjUkZLa0lFZktDa0R6Nlg2aVYxU2pFU3RFL241dEJBdUhoRDdUTUxDVURRT3hJcjcxM2g5SjdGc3BvaTRhY1o0MHk3K251L0NnT0p2bGoyd3JGdTNKbGxXKzU4V2p4cGg5MWRzVC9hSXFJODlpSi9uV2lsNzNCMjVwNU9KdEk2Y2RnNllqSGpDVTM4QjZaZGJsYUI3NlhSVlQyZEtIenM3Mm9xTzhTUW1OQjBhVktDOU9XTWQ0Rk9ERDJMcVBYb0JUUXU2aFZRdmFVSjdkOUZZaXRoYldzcFIrRTY4VU11a2hxN24wSDVTMFExME4zd1ZQUnR6L3UxNGI5NzJjV3FtVDhmbitYYzNGa3IrWjZONTlycEh6TCswK2VzRUIvUUZTdHZRWnhPZGpqOWRlVHpvbkZWMExpZmhBa3Q0bFF2REFxU05RZTJMMytacGZVRUJRQUEifQ== -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"LINC00921 /// ZNF263","2":"10127 /// 283876","3":"NM_005741 /// NR_033904 /// XM_005255031 /// XM_006720831 /// XM_006720832 /// XM_006720833 /// XM_006720834 /// XM_006720835","4":"NM_005741","5":"NM_005741","_rn_":"203707_at"},{"1":"LINC00921 /// TIGD7 /// ZNF263","2":"10127 /// 91151 /// 283876","3":"NM_005741 /// NM_033208 /// NR_033904 /// XM_005255031 /// XM_006720831 /// XM_006720832 /// XM_006720833 /// XM_006720834 /// XM_006720835","4":"AI765123","5":"AI765123","_rn_":"232089_at"},{"1":"LINC00921 /// ZNF263","2":"10127 /// 283876","3":"NM_005741 /// NR_033904 /// XM_005255031 /// XM_006720831 /// XM_006720832 /// XM_006720833 /// XM_006720834 /// XM_006720835","4":"BE176531","5":"BE176531","_rn_":"243547_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuSkhETTFEX3NtIDwtIGdzZTI2NThfZmVhdHVyZXMgJT4lIFxuICBmaWx0ZXIoZ3JlcGwoXCJKSERNMURcIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBcbiAgc2VsZWN0KGBHZW5lIFN5bWJvbGA6YFJlZlNlcSBUcmFuc2NyaXB0IElEYCwgR0JfQUNDLCBgUmVwcmVzZW50YXRpdmUgUHVibGljIElEYClcbkpIRE0xRF9zbVxuYGBgIn0= -->
<pre class="r"><code>JHDM1D_sm &lt;- gse2658_features %&gt;% 
  filter(grepl(&quot;JHDM1D&quot;, `Gene Symbol`)) %&gt;% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
JHDM1D_sm</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"JHDM1D-AS1","2":"100134229","3":"NR_024451","4":"AK026372","5":"AK026372","_rn_":"232579_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuSkhETTFEX3NtICU+JSBmaWx0ZXIoZ3JlcGwoXCIoXFxcXHNKSERNMUQpfChKSERNMURcXFxccylcIixgR2VuZSBTeW1ib2xgKSlcbmBgYCJ9 -->
<pre class="r"><code>JHDM1D_sm %&gt;% filter(grepl(&quot;(\\sJHDM1D)|(JHDM1D\\s)&quot;,`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[0]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuUlRFTDFfVE5GUlNGNkJfc20gPC0gZ3NlMjY1OF9mZWF0dXJlcyAlPiUgXG4gIGZpbHRlcihncmVwbChcIlJURUwxLVRORlJTRjZCXCIsIGBHZW5lIFN5bWJvbGApKSAlPiUgXG4gIHNlbGVjdChgR2VuZSBTeW1ib2xgOmBSZWZTZXEgVHJhbnNjcmlwdCBJRGAsIEdCX0FDQywgYFJlcHJlc2VudGF0aXZlIFB1YmxpYyBJRGApXG5SVEVMMV9UTkZSU0Y2Ql9zbVxuYGBgIn0= -->
<pre class="r"><code>RTEL1_TNFRSF6B_sm &lt;- gse2658_features %&gt;% 
  filter(grepl(&quot;RTEL1-TNFRSF6B&quot;, `Gene Symbol`)) %&gt;% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
RTEL1_TNFRSF6B_sm</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"RTEL1-TNFRSF6B /// TNFRSF6B","2":"8771 /// 100533107","3":"NM_003823 /// NM_032945 /// NR_037882","4":"NM_003823","5":"NM_003823","_rn_":"206467_x_at"},{"1":"RTEL1 /// RTEL1-TNFRSF6B","2":"51750 /// 100533107","3":"NM_001283009 /// NM_001283010 /// NM_016434 /// NM_032957 /// NR_037882","4":"BC000673","5":"BC000673","_rn_":"211526_s_at"},{"1":"RTEL1 /// RTEL1-TNFRSF6B","2":"51750 /// 100533107","3":"NM_001283009 /// NM_001283010 /// NM_016434 /// NM_032957 /// NR_037882","4":"AF217796","5":"AF217796","_rn_":"216325_x_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuUlRFTDFfVE5GUlNGNkJfc20gJT4lIGZpbHRlcihncmVwbChcIihcXFxcc1JURUwxLVRORlJTRjZCKXwoUlRFTDEtVE5GUlNGNkJcXFxccylcIixgR2VuZSBTeW1ib2xgKSlcbmBgYCJ9 -->
<pre class="r"><code>RTEL1_TNFRSF6B_sm %&gt;% filter(grepl(&quot;(\\sRTEL1-TNFRSF6B)|(RTEL1-TNFRSF6B\\s)&quot;,`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"RTEL1-TNFRSF6B /// TNFRSF6B","2":"8771 /// 100533107","3":"NM_003823 /// NM_032945 /// NR_037882","4":"NM_003823","5":"NM_003823","_rn_":"206467_x_at"},{"1":"RTEL1 /// RTEL1-TNFRSF6B","2":"51750 /// 100533107","3":"NM_001283009 /// NM_001283010 /// NM_016434 /// NM_032957 /// NR_037882","4":"BC000673","5":"BC000673","_rn_":"211526_s_at"},{"1":"RTEL1 /// RTEL1-TNFRSF6B","2":"51750 /// 100533107","3":"NM_001283009 /// NM_001283010 /// NM_016434 /// NM_032957 /// NR_037882","4":"AF217796","5":"AF217796","_rn_":"216325_x_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuU1Q3X3NtIDwtIGdzZTI2NThfZmVhdHVyZXMgJT4lIFxuICBmaWx0ZXIoZ3JlcGwoXCJTVDdcIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBcbiAgc2VsZWN0KGBHZW5lIFN5bWJvbGA6YFJlZlNlcSBUcmFuc2NyaXB0IElEYCwgR0JfQUNDLCBgUmVwcmVzZW50YXRpdmUgUHVibGljIElEYClcblNUN19zbVxuYGBgIn0= -->
<pre class="r"><code>ST7_sm &lt;- gse2658_features %&gt;% 
  filter(grepl(&quot;ST7&quot;, `Gene Symbol`)) %&gt;% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
ST7_sm</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"ST7L","2":"54879","3":"NM_017744 /// NM_138727 /// NM_138728 /// NM_138729 /// NM_198327 /// NM_198328 /// XM_005270963 /// XM_005270964 /// XM_005270966 /// XM_005270970 /// XM_006710708 /// XM_006710709 /// XR_246280","4":"NM_138729","5":"NM_138729","_rn_":"1552738_a_at"},{"1":"ST7L","2":"54879","3":"NM_017744 /// NM_138727 /// NM_138728 /// NM_138729 /// NM_198327 /// NM_198328 /// XM_005270963 /// XM_005270964 /// XM_005270966 /// XM_005270970 /// XM_006710708 /// XM_006710709 /// XR_246280","4":"NM_138729","5":"NM_138729","_rn_":"1552739_s_at"},{"1":"ST7-AS1","2":"93653","3":"NR_002330","4":"AI016213","5":"AI016213","_rn_":"1555912_at"},{"1":"ST7-OT4","2":"338069","3":"NR_002329","4":"AA969986","5":"AA969986","_rn_":"1559208_at"},{"1":"ST7-AS2","2":"93654","3":"NR_002331 /// NR_109980 /// NR_109981","4":"AF400045","5":"AF400045","_rn_":"1564790_at"},{"1":"CHST7","2":"56548","3":"NM_019886","4":"NM_019886","5":"NM_019886","_rn_":"206756_at"},{"1":"MIR6132 /// ST7 /// ST7-OT3","2":"7982 /// 93655 /// 102466616","3":"NM_018412 /// NM_021908 /// NR_002332 /// NR_106748","4":"NM_021908","5":"NM_021908","_rn_":"207524_at"},{"1":"MIR6132 /// ST7 /// ST7-OT3","2":"7982 /// 93655 /// 102466616","3":"NM_018412 /// NM_021908 /// NR_002332 /// NR_106748","4":"NM_018412","5":"NM_018412","_rn_":"207871_s_at"},{"1":"CST7","2":"8530","3":"NM_003650","4":"AF031824","5":"AF031824","_rn_":"210140_at"},{"1":"ST7L","2":"54879","3":"NM_017744 /// NM_138727 /// NM_138728 /// NM_138729 /// NM_198327 /// NM_198328 /// XM_005270963 /// XM_005270964 /// XM_005270966 /// XM_005270970 /// XM_006710708 /// XM_006710709 /// XR_246280","4":"NM_017744","5":"NM_017744","_rn_":"219964_at"},{"1":"ST7L","2":"54879","3":"NM_017744 /// NM_138727 /// NM_138728 /// NM_138729 /// NM_198327 /// NM_198328 /// XM_005270963 /// XM_005270964 /// XM_005270966 /// XM_005270970 /// XM_006710708 /// XM_006710709 /// XR_246280","4":"BF109854","5":"BF109854","_rn_":"230079_at"},{"1":"ST7L","2":"54879","3":"NM_017744 /// NM_138727 /// NM_138728 /// NM_138729 /// NM_198327 /// NM_198328 /// XM_005270963 /// XM_005270964 /// XM_005270966 /// XM_005270970 /// XM_006710708 /// XM_006710709 /// XR_246280","4":"AK021719","5":"AK021719","_rn_":"233141_s_at"},{"1":"ST7-AS2","2":"93654","3":"NR_002331 /// NR_109980 /// NR_109981","4":"AI421301","5":"AI421301","_rn_":"237808_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[13]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuU1Q3X3NtICU+JSBmaWx0ZXIoZ3JlcGwoXCIoXFxcXHNTVDcpfChTVDdcXFxccylcIixgR2VuZSBTeW1ib2xgKSlcbmBgYCJ9 -->
<pre class="r"><code>ST7_sm %&gt;% filter(grepl(&quot;(\\sST7)|(ST7\\s)&quot;,`Gene Symbol`))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["Gene Symbol"],"name":[1],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["RefSeq Transcript ID"],"name":[3],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[4],"type":["chr"],"align":["left"]},{"label":["Representative Public ID"],"name":[5],"type":["chr"],"align":["left"]}],"data":[{"1":"MIR6132 /// ST7 /// ST7-OT3","2":"7982 /// 93655 /// 102466616","3":"NM_018412 /// NM_021908 /// NR_002332 /// NR_106748","4":"NM_021908","5":"NM_021908","_rn_":"207524_at"},{"1":"MIR6132 /// ST7 /// ST7-OT3","2":"7982 /// 93655 /// 102466616","3":"NM_018412 /// NM_021908 /// NR_002332 /// NR_106748","4":"NM_018412","5":"NM_018412","_rn_":"207871_s_at"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[2]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>will need to extract the simple (or RNAseq matching) name out of the multiples<br />
example with a complicated one<br />
just looking for space before or after as above with <code>grepl</code> seems to work.</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuc3RyX21hdGNoKFNUN19zbSAlPiUgZmlsdGVyKGdyZXBsKFwiKFxcXFxzU1Q3KXwoU1Q3XFxcXHMpXCIsYEdlbmUgU3ltYm9sYCkpICU+JSBwdWxsKGBHZW5lIFN5bWJvbGApLCBcbiAgICAgICAgICBwYXR0ZXJuPVwiKFxcXFxzU1Q3KXwoU1Q3XFxcXHMpXCIpWywyXSAlPiUgc3RyX3RyaW0oKVxuYGBgIn0= -->
<pre class="r"><code>str_match(ST7_sm %&gt;% filter(grepl(&quot;(\\sST7)|(ST7\\s)&quot;,`Gene Symbol`)) %&gt;% pull(`Gene Symbol`), 
          pattern=&quot;(\\sST7)|(ST7\\s)&quot;)[,2] %&gt;% str_trim()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIFwiU1Q3XCIgXCJTVDdcIlxuIn0= -->
<pre><code>[1] &quot;ST7&quot; &quot;ST7&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>fix all names need list of genes that are in the spectra rotation matrix but not in the expression set</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubWlzc19nZW5lcyA8LSBjbXBzX3NwZWNfcm1fd24gJT4lIFxuICBkaXN0aW5jdChnZW5lX25hbWUpICU+JSBcbiAgZmlsdGVyKCFnZW5lX25hbWUgJWluJSB1bmlxdWUoZ3NlMjY1OF9mZWF0dXJlcyRgR2VuZSBTeW1ib2xgKSkgJT4lIFxuICBwdWxsKGdlbmVfbmFtZSlcbmBgYCJ9 -->
<pre class="r"><code>miss_genes &lt;- cmps_spec_rm_wn %&gt;% 
  distinct(gene_name) %&gt;% 
  filter(!gene_name %in% unique(gse2658_features$`Gene Symbol`)) %&gt;% 
  pull(gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>subset of <code>gse2658_features</code> that have multiple names</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2VuZXMyZml4IDwtIGdzZTI2NThfZmVhdHVyZXMgJT4lIFxuICBmaWx0ZXIoZ3JlcGwoXCIvLy9cIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBcbiAgc2VsZWN0KElELCBgR2VuZSBTeW1ib2xgKSBcbmdlbmVzMmZpeFxuYGBgIn0= -->
<pre class="r"><code>genes2fix &lt;- gse2658_features %&gt;% 
  filter(grepl(&quot;///&quot;, `Gene Symbol`)) %&gt;% 
  select(ID, `Gene Symbol`) 
genes2fix</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":2796,"ncol":2,"summary":{"Description":["df [2,796 × 2]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["ID"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Gene Symbol"],"name":[2],"type":["chr"],"align":["left"]}],"data":[{"1":"1007_s_at","2":"DDR1 /// MIR4640","_rn_":"1007_s_at"},{"1":"1294_at","2":"MIR5193 /// UBA7","_rn_":"1294_at"},{"1":"1552258_at","2":"LINC00152 /// LOC101930489","_rn_":"1552258_at"},{"1":"1552283_s_at","2":"ZDHHC11 /// ZDHHC11B","_rn_":"1552283_s_at"},{"1":"1552388_at","2":"FLJ30901 /// SCUBE1","_rn_":"1552388_at"},{"1":"1552401_a_at","2":"BACH1 /// GRIK1-AS2","_rn_":"1552401_a_at"},{"1":"1552411_at","2":"DEFB106A /// DEFB106B","_rn_":"1552411_at"},{"1":"1552412_a_at","2":"DEFB106A /// DEFB106B","_rn_":"1552412_a_at"},{"1":"1552436_a_at","2":"CDH23 /// LOC100653137","_rn_":"1552436_a_at"},{"1":"1552449_a_at","2":"LOC653486 /// SCGB1C1","_rn_":"1552449_a_at"},{"1":"1552607_at","2":"FAM223A /// FAM223B","_rn_":"1552607_at"},{"1":"1552609_s_at","2":"IFNL2 /// IFNL3","_rn_":"1552609_s_at"},{"1":"1552621_at","2":"POLR2J /// POLR2J2 /// POLR2J3 /// UPK3BL","_rn_":"1552621_at"},{"1":"1552622_s_at","2":"LOC441259 /// POLR2J /// POLR2J2 /// POLR2J3 /// UPK3BL","_rn_":"1552622_s_at"},{"1":"1552641_s_at","2":"ATAD3A /// ATAD3B","_rn_":"1552641_s_at"},{"1":"1552649_a_at","2":"RAD51L3-RFFL /// RFFL","_rn_":"1552649_a_at"},{"1":"1552651_a_at","2":"RAD51L3-RFFL /// RFFL","_rn_":"1552651_a_at"},{"1":"1552703_s_at","2":"CARD16 /// CASP1","_rn_":"1552703_s_at"},{"1":"1552717_s_at","2":"CEP170 /// CEP170P1","_rn_":"1552717_s_at"},{"1":"1552729_at","2":"SNHG7 /// SNORA17 /// SNORA43","_rn_":"1552729_at"},{"1":"1552819_at","2":"LINC00205 /// LOC102723489 /// LOC102725097","_rn_":"1552819_at"},{"1":"1552860_at","2":"LOC101060464 /// LOC101929858 /// LOC101930165 /// LOC101930171 /// TCEB3C /// TCEB3CL /// TCEB3CL2","_rn_":"1552860_at"},{"1":"1552937_s_at","2":"ATRIP /// TREX1","_rn_":"1552937_s_at"},{"1":"1552952_at","2":"LOC100652931 /// RBMY2FP","_rn_":"1552952_at"},{"1":"1553002_at","2":"DEFB105A /// DEFB105B","_rn_":"1553002_at"},{"1":"1553094_at","2":"FLJ45513 /// TAC4","_rn_":"1553094_at"},{"1":"1553323_a_at","2":"CATSPER2 /// CATSPER2P1 /// LOC101930343","_rn_":"1553323_a_at"},{"1":"1553340_s_at","2":"SLC35G3 /// SLC35G4P /// SLC35G5","_rn_":"1553340_s_at"},{"1":"1553366_s_at","2":"ANKRD23 /// ANKRD39","_rn_":"1553366_s_at"},{"1":"1553392_at","2":"EFCAB3 /// LOC102724660","_rn_":"1553392_at"},{"1":"1553399_a_at","2":"CRHR1-IT1 /// MGC57346","_rn_":"1553399_a_at"},{"1":"1553400_a_at","2":"CRHR1-IT1 /// MGC57346","_rn_":"1553400_a_at"},{"1":"1553432_s_at","2":"LOC101060424 /// LOC653786 /// OTOA","_rn_":"1553432_s_at"},{"1":"1553467_at","2":"DCAF8L2 /// FLJ32742 /// LOC101928481","_rn_":"1553467_at"},{"1":"1553502_a_at","2":"AKAP2 /// PALM2 /// PALM2-AKAP2","_rn_":"1553502_a_at"},{"1":"1553518_at","2":"DEFT1P /// DEFT1P2","_rn_":"1553518_at"},{"1":"1553521_at","2":"DEFB104A /// DEFB104B","_rn_":"1553521_at"},{"1":"1553562_at","2":"CD8B /// LOC100996919","_rn_":"1553562_at"},{"1":"1553579_a_at","2":"SPAG11A /// SPAG11B","_rn_":"1553579_a_at"},{"1":"1553582_a_at","2":"SPAG11A /// SPAG11B","_rn_":"1553582_a_at"},{"1":"1553585_a_at","2":"MAGEA10-MAGEA5 /// MAGEA5","_rn_":"1553585_a_at"},{"1":"1553588_at","2":"ND3 /// SH3KBP1","_rn_":"1553588_at"},{"1":"1553590_at","2":"FAM27E2 /// FAM27E3","_rn_":"1553590_at"},{"1":"1553607_at","2":"BACH1 /// GRIK1-AS2 /// LINC00189","_rn_":"1553607_at"},{"1":"1553614_a_at","2":"FLJ25694 /// LOC101929344","_rn_":"1553614_a_at"},{"1":"1553618_at","2":"TRIM43 /// TRIM43B","_rn_":"1553618_at"},{"1":"1553619_a_at","2":"TRIM43 /// TRIM43B","_rn_":"1553619_a_at"},{"1":"1553633_s_at","2":"LOC101929373 /// SLC9B1","_rn_":"1553633_s_at"},{"1":"1553717_at","2":"KCTD7 /// RABGEF1","_rn_":"1553717_at"},{"1":"1553817_at","2":"LOC102725315 /// LOC727983 /// POM121L10P /// POM121L1P /// POM121L4P /// POM121L8P /// POM121L9P","_rn_":"1553817_at"},{"1":"1553818_x_at","2":"LOC102725315 /// LOC727983 /// POM121L10P /// POM121L1P /// POM121L4P /// POM121L8P /// POM121L9P","_rn_":"1553818_x_at"},{"1":"1553830_s_at","2":"MAGEA2 /// MAGEA2B","_rn_":"1553830_s_at"},{"1":"1553882_at","2":"LINC00504 /// LINC00504 /// MGC4836","_rn_":"1553882_at"},{"1":"1553900_s_at","2":"POM121L1P /// POM121L8P /// POM121L9P","_rn_":"1553900_s_at"},{"1":"1553944_at","2":"CTAGE5 /// MIA2","_rn_":"1553944_at"},{"1":"1553991_s_at","2":"LOC101928274 /// VSIG10","_rn_":"1553991_s_at"},{"1":"1553993_s_at","2":"MED25 /// MIR6800","_rn_":"1553993_s_at"},{"1":"1553998_at","2":"DMRTC1 /// DMRTC1B","_rn_":"1553998_at"},{"1":"1554017_at","2":"RILPL1 /// SNRNP35","_rn_":"1554017_at"},{"1":"1554089_s_at","2":"SBDS /// SBDSP1","_rn_":"1554089_s_at"},{"1":"1554182_at","2":"TRIM73 /// TRIM74","_rn_":"1554182_at"},{"1":"1554183_s_at","2":"TRIM73 /// TRIM74","_rn_":"1554183_s_at"},{"1":"1554233_at","2":"C1QTNF9 /// C1QTNF9B","_rn_":"1554233_at"},{"1":"1554245_x_at","2":"ARL17A /// ARL17B /// LOC100294341","_rn_":"1554245_x_at"},{"1":"1554249_a_at","2":"ZNF638 /// ZNF638-IT1","_rn_":"1554249_a_at"},{"1":"1554250_s_at","2":"STAG3L2 /// STAG3L3 /// TRIM73","_rn_":"1554250_s_at"},{"1":"1554290_at","2":"HERC3 /// LOC101929134","_rn_":"1554290_at"},{"1":"1554318_at","2":"LOC100101148 /// LOC541473","_rn_":"1554318_at"},{"1":"1554344_s_at","2":"AQP12A /// AQP12B","_rn_":"1554344_s_at"},{"1":"1554368_at","2":"NT5C1B /// NT5C1B-RDH14","_rn_":"1554368_at"},{"1":"1554413_s_at","2":"SNX29P1 /// SNX29P2","_rn_":"1554413_s_at"},{"1":"1554465_s_at","2":"KRBOX4 /// ZNF674","_rn_":"1554465_s_at"},{"1":"1554741_s_at","2":"FGF7 /// KGFLP1 /// KGFLP2","_rn_":"1554741_s_at"},{"1":"1554762_a_at","2":"CLDN22 /// WWC2","_rn_":"1554762_a_at"},{"1":"1554837_a_at","2":"CYP4A11 /// CYP4A22","_rn_":"1554837_a_at"},{"1":"1554884_at","2":"PRIM2 /// PRIM2B","_rn_":"1554884_at"},{"1":"1554885_a_at","2":"PRIM2 /// PRIM2B","_rn_":"1554885_a_at"},{"1":"1554907_a_at","2":"HYDIN /// HYDIN2 /// LOC101930373","_rn_":"1554907_a_at"},{"1":"1554931_at","2":"CYP4A11 /// CYP4A22","_rn_":"1554931_at"},{"1":"1554996_at","2":"LOC285902 /// ZNF273 /// ZNF479 /// ZNF733P","_rn_":"1554996_at"},{"1":"1555027_at","2":"LOC101927705 /// P4HA2","_rn_":"1555027_at"},{"1":"1555063_at","2":"USP32 /// USP6","_rn_":"1555063_at"},{"1":"1555065_x_at","2":"USP32 /// USP6","_rn_":"1555065_x_at"},{"1":"1555141_a_at","2":"LOC101929373 /// SLC9B1","_rn_":"1555141_a_at"},{"1":"1555142_at","2":"LOC101929373 /// SLC9B1","_rn_":"1555142_at"},{"1":"1555144_at","2":"ARL17A /// ARL17B","_rn_":"1555144_at"},{"1":"1555162_at","2":"ARHGAP8 /// PRR5-ARHGAP8","_rn_":"1555162_at"},{"1":"1555179_at","2":"IGHV7-81 /// IGHV7-81","_rn_":"1555179_at"},{"1":"1555216_a_at","2":"LOC101060604 /// SLC7A5P1 /// SLC7A5P2","_rn_":"1555216_a_at"},{"1":"1555272_at","2":"RSPH10B /// RSPH10B2","_rn_":"1555272_at"},{"1":"1555367_at","2":"LOC285902 /// ZNF273 /// ZNF479","_rn_":"1555367_at"},{"1":"1555368_x_at","2":"LOC285902 /// ZNF273 /// ZNF479","_rn_":"1555368_x_at"},{"1":"1555408_at","2":"BAGE2 /// BAGE4","_rn_":"1555408_at"},{"1":"1555409_a_at","2":"BAGE2 /// BAGE3 /// BAGE5 /// KMT2C","_rn_":"1555409_a_at"},{"1":"1555485_s_at","2":"FAM153A /// FAM153B /// LOC100507387","_rn_":"1555485_s_at"},{"1":"1555522_s_at","2":"DPY30 /// MEMO1","_rn_":"1555522_s_at"},{"1":"1555569_a_at","2":"KCTD7 /// RABGEF1","_rn_":"1555569_a_at"},{"1":"1555630_a_at","2":"NARR /// RAB34","_rn_":"1555630_a_at"},{"1":"1555673_at","2":"KRTAP2-3 /// KRTAP2-4","_rn_":"1555673_at"},{"1":"1555691_a_at","2":"KLRC4-KLRK1 /// KLRK1","_rn_":"1555691_a_at"},{"1":"1555790_a_at","2":"TMEM192 /// ZNF320","_rn_":"1555790_a_at"},{"1":"1555794_at","2":"ARL17A /// ARL17B /// LOC100294341","_rn_":"1555794_at"},{"1":"1555822_at","2":"FAM138A /// FAM138B /// FAM138C /// FAM138D /// FAM138E /// FAM138F","_rn_":"1555822_at"},{"1":"1555826_at","2":"BIRC5 /// EPR-1","_rn_":"1555826_at"},{"1":"1555847_a_at","2":"LOC284454 /// MIR23A /// MIR24-2","_rn_":"1555847_a_at"},{"1":"1555854_at","2":"AKR1C1 /// AKR1C2 /// LOC101930400","_rn_":"1555854_at"},{"1":"1555872_a_at","2":"GLIDR /// LOC728903","_rn_":"1555872_a_at"},{"1":"1555890_at","2":"LOC101928605 /// OR2A1-AS1 /// OR2A20P /// OR2A9P","_rn_":"1555890_at"},{"1":"1555893_at","2":"BC038731 /// CTD-2284J15.1","_rn_":"1555893_at"},{"1":"1555952_at","2":"LOC101928717 /// SLC19A1","_rn_":"1555952_at"},{"1":"1555953_at","2":"LOC101928717 /// SLC19A1","_rn_":"1555953_at"},{"1":"1555964_at","2":"ARL17A /// ARL17B /// LOC100294341","_rn_":"1555964_at"},{"1":"1555996_s_at","2":"EIF4A2 /// MIR1248 /// SNORA4 /// SNORA63 /// SNORA81 /// SNORD2","_rn_":"1555996_s_at"},{"1":"1556001_at","2":"LOC284939 /// MAPK8IP2","_rn_":"1556001_at"},{"1":"1556046_a_at","2":"LINC00599 /// MIR124-1","_rn_":"1556046_a_at"},{"1":"1556113_at","2":"DKFZp451A211 /// LOC101928841","_rn_":"1556113_at"},{"1":"1556114_a_at","2":"DKFZp451A211 /// LOC101928841","_rn_":"1556114_a_at"},{"1":"1556161_a_at","2":"AF086294 /// RP11-485M7.3","_rn_":"1556161_a_at"},{"1":"1556216_s_at","2":"BC042372 /// RP11-45P15.4","_rn_":"1556216_s_at"},{"1":"1556224_a_at","2":"LOC155060 /// ZNF783","_rn_":"1556224_a_at"},{"1":"1556235_at","2":"LOC101927468 /// LOC101929257 /// LOC102724558","_rn_":"1556235_at"},{"1":"1556256_a_at","2":"AF086125 /// RP11-61A14.1","_rn_":"1556256_a_at"},{"1":"1556262_at","2":"LOC101928818 /// PWRN1","_rn_":"1556262_at"},{"1":"1556263_s_at","2":"LOC101928818 /// PWRN1","_rn_":"1556263_s_at"},{"1":"1556333_at","2":"BC042382 /// RP11-408H20.3","_rn_":"1556333_at"},{"1":"1556334_s_at","2":"BC042382 /// RP11-408H20.3","_rn_":"1556334_s_at"},{"1":"1556336_at","2":"LOC101928747 /// RBMX /// SNORD61","_rn_":"1556336_at"},{"1":"1556374_s_at","2":"BC039357 /// RP11-661G16.2","_rn_":"1556374_s_at"},{"1":"1556378_a_at","2":"LOC101927424 /// LOC101929800 /// LOC440896","_rn_":"1556378_a_at"},{"1":"1556400_at","2":"AK054708 /// RP11-547D24.1","_rn_":"1556400_at"},{"1":"1556401_a_at","2":"AK054708 /// RP11-547D24.1","_rn_":"1556401_a_at"},{"1":"1556422_at","2":"AC007228.11 /// BX647249","_rn_":"1556422_at"},{"1":"1556489_at","2":"LOC101805491 /// TMEM247","_rn_":"1556489_at"},{"1":"1556490_a_at","2":"LOC101805491 /// TMEM247","_rn_":"1556490_a_at"},{"1":"1556504_at","2":"BC040646 /// RP11-732A21.2","_rn_":"1556504_at"},{"1":"1556516_at","2":"BC042022 /// LOC100506331","_rn_":"1556516_at"},{"1":"1556645_s_at","2":"BC043400 /// RP11-875O11.1","_rn_":"1556645_s_at"},{"1":"1556687_a_at","2":"CLDN10 /// LOC101927308","_rn_":"1556687_a_at"},{"1":"1556704_s_at","2":"LOC100133920 /// LOC100996643 /// LOC101928195 /// LOC101929583 /// LOC286297","_rn_":"1556704_s_at"},{"1":"1556739_at","2":"GOLGA8I /// GOLGA8M","_rn_":"1556739_at"},{"1":"1556742_at","2":"GUSBP1 /// GUSBP4","_rn_":"1556742_at"},{"1":"1556749_at","2":"BC035096 /// RP11-433J8.1","_rn_":"1556749_at"},{"1":"1556755_s_at","2":"LOC286149 /// MIR3150A /// MIR3150B","_rn_":"1556755_s_at"},{"1":"1556775_at","2":"AC092155.4 /// BC038779","_rn_":"1556775_at"},{"1":"1556776_a_at","2":"AF075036 /// OR7D2","_rn_":"1556776_a_at"},{"1":"1556777_a_at","2":"AF075036 /// OR7D2","_rn_":"1556777_a_at"},{"1":"1556786_at","2":"AX746903 /// PDE5A","_rn_":"1556786_at"},{"1":"1556787_s_at","2":"AX746903 /// PDE5A","_rn_":"1556787_s_at"},{"1":"1556839_s_at","2":"LOC100289090 /// RP11-23P13.6","_rn_":"1556839_s_at"},{"1":"1556846_at","2":"AX748294 /// RP11-1006G14.1","_rn_":"1556846_at"},{"1":"1556847_s_at","2":"AX748294 /// RP11-1006G14.1","_rn_":"1556847_s_at"},{"1":"1556850_at","2":"BC033323 /// CEP290","_rn_":"1556850_at"},{"1":"1556876_s_at","2":"LOC101930578 /// TPTE2P2","_rn_":"1556876_s_at"},{"1":"1556883_a_at","2":"LOC101927424 /// LOC101929800 /// LOC440896 /// PGM5","_rn_":"1556883_a_at"},{"1":"1556944_at","2":"AK057554 /// RP11-144L1.4","_rn_":"1556944_at"},{"1":"1556945_a_at","2":"AK057554 /// RP11-144L1.4","_rn_":"1556945_a_at"},{"1":"1556992_at","2":"LOC550113 /// UBA6-AS1","_rn_":"1556992_at"},{"1":"1556997_a_at","2":"LEPR /// LEPROT","_rn_":"1556997_a_at"},{"1":"1557004_at","2":"LOC100505902 /// LOC285389","_rn_":"1557004_at"},{"1":"1557034_s_at","2":"LOC100134445 /// LOC100288778 /// LOC100653296 /// WASH1 /// WASH2P /// WASH3P /// WASH5P /// WASH7P","_rn_":"1557034_s_at"},{"1":"1557036_at","2":"AK055910 /// ZBTB1","_rn_":"1557036_at"},{"1":"1557060_at","2":"BC036830 /// OVAAL /// RP11-522D2.1","_rn_":"1557060_at"},{"1":"1557065_at","2":"AK096592 /// YLPM1","_rn_":"1557065_at"},{"1":"1557124_at","2":"AX747140 /// TMEM198B","_rn_":"1557124_at"},{"1":"1557135_at","2":"AC002310.12 /// AK056973","_rn_":"1557135_at"},{"1":"1557141_at","2":"FAM188B /// INMT /// INMT-FAM188B","_rn_":"1557141_at"},{"1":"1557149_at","2":"AF086154 /// RP11-432J24.5","_rn_":"1557149_at"},{"1":"1557203_at","2":"PABPC1L2A /// PABPC1L2B","_rn_":"1557203_at"},{"1":"1557261_at","2":"WHAMMP2 /// WHAMMP3","_rn_":"1557261_at"},{"1":"1557278_s_at","2":"AX746492 /// TNPO1","_rn_":"1557278_s_at"},{"1":"1557330_at","2":"BC027619 /// RP11-236J17.3","_rn_":"1557330_at"},{"1":"1557342_a_at","2":"hsa-let-7a-3 /// hsa-let-7b /// hsa-mir-4763 /// MIRLET7BHG /// RP4-695O20__B.10","_rn_":"1557342_a_at"},{"1":"1557366_at","2":"CCDC144A /// CCDC144B /// CCDC144CP /// LOC101929141","_rn_":"1557366_at"},{"1":"1557372_at","2":"ATP6V1E2 /// FLJ41757","_rn_":"1557372_at"},{"1":"1557384_at","2":"LOC100506639 /// ZNF131","_rn_":"1557384_at"},{"1":"1557399_at","2":"LOC284009 /// METTL16","_rn_":"1557399_at"},{"1":"1557417_s_at","2":"RSPH10B /// RSPH10B2","_rn_":"1557417_s_at"},{"1":"1557560_at","2":"AK093256 /// RP3-486I3.7","_rn_":"1557560_at"},{"1":"1557584_at","2":"LOC403323 /// RP11-791G15.1","_rn_":"1557584_at"},{"1":"1557601_s_at","2":"KIAA1257 /// LOC100132731","_rn_":"1557601_s_at"},{"1":"1557769_at","2":"AC007255.8 /// BC038570","_rn_":"1557769_at"},{"1":"1557788_a_at","2":"LINC00476 /// LOC101930476","_rn_":"1557788_a_at"},{"1":"1557878_at","2":"BC040577 /// RP11-10K16.1","_rn_":"1557878_at"},{"1":"1557880_at","2":"PCDH11X /// PCDH11Y","_rn_":"1557880_at"},{"1":"1557896_at","2":"BC041003 /// RP11-495P10.3","_rn_":"1557896_at"},{"1":"1557897_at","2":"BC043355 /// RP11-481J13.1","_rn_":"1557897_at"},{"1":"1557944_s_at","2":"CTNND1 /// TMX2-CTNND1","_rn_":"1557944_s_at"},{"1":"1557945_at","2":"AK023627 /// TCTE3","_rn_":"1557945_at"},{"1":"1557996_at","2":"AC004951.6 /// AX747182","_rn_":"1557996_at"},{"1":"1558045_a_at","2":"LOC389906 /// LOC441528","_rn_":"1558045_a_at"},{"1":"1558093_s_at","2":"MATR3 /// SNHG4","_rn_":"1558093_s_at"},{"1":"1558118_at","2":"DGCR5 /// LOC100287576","_rn_":"1558118_at"},{"1":"1558139_at","2":"LINC01296 /// LOC100653149 /// LOC102725127","_rn_":"1558139_at"},{"1":"1558168_at","2":"H1FX-AS1 /// H1FX-AS1","_rn_":"1558168_at"},{"1":"1558176_at","2":"CYAT1 /// IGLC1 /// IGLV1-44","_rn_":"1558176_at"},{"1":"1558185_at","2":"CLLU1 /// LOC100507616","_rn_":"1558185_at"},{"1":"1558186_s_at","2":"CLLU1 /// LOC100507616","_rn_":"1558186_s_at"},{"1":"1558189_a_at","2":"GPR37L1 /// LOC284570","_rn_":"1558189_a_at"},{"1":"1558202_at","2":"LOC145783 /// ZNF280D","_rn_":"1558202_at"},{"1":"1558212_at","2":"LOC101930048 /// LOC101930053 /// VLDLR-AS1","_rn_":"1558212_at"},{"1":"1558251_a_at","2":"ZNF417 /// ZNF587","_rn_":"1558251_a_at"},{"1":"1558253_x_at","2":"ZNF417 /// ZNF587","_rn_":"1558253_x_at"},{"1":"1558290_a_at","2":"MIR1204 /// PVT1","_rn_":"1558290_a_at"},{"1":"1558412_at","2":"LOC113230 /// MIR1199","_rn_":"1558412_at"},{"1":"1558423_at","2":"LINC00265 /// LOC101929038","_rn_":"1558423_at"},{"1":"1558425_x_at","2":"LINC00265 /// LOC101929038","_rn_":"1558425_x_at"},{"1":"1558438_a_at","2":"IGH /// IGHE /// IGHE /// IGHE","_rn_":"1558438_a_at"},{"1":"1558458_at","2":"LOC101928623 /// LOC401320","_rn_":"1558458_at"},{"1":"1558459_s_at","2":"LOC101928623 /// LOC401320","_rn_":"1558459_s_at"},{"1":"1558517_s_at","2":"LOC101927933 /// LRRC8C","_rn_":"1558517_s_at"},{"1":"1558534_at","2":"LOC101060604 /// SLC7A5P1 /// SMG1P1 /// SMG1P3","_rn_":"1558534_at"},{"1":"1558541_at","2":"KIAA1456 /// LOC101927137","_rn_":"1558541_at"},{"1":"1558556_at","2":"AX748417 /// CAMK1","_rn_":"1558556_at"},{"1":"1558570_at","2":"LOC145783 /// ZNF280D","_rn_":"1558570_at"},{"1":"1558578_a_at","2":"C7orf73 /// LOC101930655 /// SLC13A4","_rn_":"1558578_a_at"},{"1":"1558588_at","2":"LINC00869 /// LOC100996741","_rn_":"1558588_at"},{"1":"1558589_at","2":"C21orf15 /// LINC00417","_rn_":"1558589_at"},{"1":"1558611_at","2":"CRHR1-IT1 /// MGC57346","_rn_":"1558611_at"},{"1":"1558654_at","2":"AK024134 /// PPM1H","_rn_":"1558654_at"},{"1":"1558724_at","2":"AC004158.3 /// AK055364","_rn_":"1558724_at"},{"1":"1558745_at","2":"LOC101929304 /// SNX29","_rn_":"1558745_at"},{"1":"1558750_a_at","2":"ARHGAP11B /// LOC100288637","_rn_":"1558750_a_at"},{"1":"1558780_a_at","2":"CTC-203F4.2 /// H2AFY","_rn_":"1558780_a_at"},{"1":"1558841_at","2":"RP11-307L14.1 /// RP11-307L14.2","_rn_":"1558841_at"},{"1":"1558848_at","2":"AX747192 /// RP11-783K16.14","_rn_":"1558848_at"},{"1":"1558859_at","2":"LOC101928623 /// LOC401320","_rn_":"1558859_at"},{"1":"1558862_at","2":"NBPF4 /// NBPF5P","_rn_":"1558862_at"},{"1":"1558887_at","2":"ZNF321P /// ZNF816-ZNF321P","_rn_":"1558887_at"},{"1":"1558888_x_at","2":"ZNF321P /// ZNF816-ZNF321P","_rn_":"1558888_x_at"},{"1":"1558944_at","2":"CACNA1A /// LOC100507353","_rn_":"1558944_at"},{"1":"1558945_s_at","2":"CACNA1A /// LOC100507353","_rn_":"1558945_s_at"},{"1":"1558999_x_at","2":"LOC283922 /// PDPR","_rn_":"1558999_x_at"},{"1":"1559036_at","2":"C4A /// C4B /// C4B_2","_rn_":"1559036_at"},{"1":"1559064_at","2":"NUP153 /// RP11-500C11.3","_rn_":"1559064_at"},{"1":"1559066_at","2":"LOC158402 /// RP11-4O1.2","_rn_":"1559066_at"},{"1":"1559067_a_at","2":"LOC158402 /// RP11-4O1.2","_rn_":"1559067_a_at"},{"1":"1559069_at","2":"MTHFS /// ST20-MTHFS","_rn_":"1559069_at"},{"1":"1559136_s_at","2":"LINC00893 /// LINC00894","_rn_":"1559136_s_at"},{"1":"1559140_at","2":"FAM87A /// FAM87B","_rn_":"1559140_at"},{"1":"1559141_s_at","2":"FAM87A /// FAM87B","_rn_":"1559141_s_at"},{"1":"1559170_at","2":"ANKRD20A5P /// ANKRD20A5P","_rn_":"1559170_at"},{"1":"1559220_at","2":"BC039681 /// RP5-1157M23.2","_rn_":"1559220_at"},{"1":"1559287_at","2":"AX747750 /// RP11-532F6.3","_rn_":"1559287_at"},{"1":"1559313_at","2":"DQ573539 /// SNX18P3 /// SNX18P3","_rn_":"1559313_at"},{"1":"1559316_at","2":"AK093362 /// RP11-774D14.1","_rn_":"1559316_at"},{"1":"1559324_at","2":"BC019672 /// USP32P2","_rn_":"1559324_at"},{"1":"1559342_a_at","2":"IPW /// LOC101930404 /// PWARSN /// SNORD107 /// SNORD115-13 /// SNORD115-26 /// SNORD115-7 /// SNORD116-22 /// SNORD116-28 /// SNORD116-4 /// SNRPN","_rn_":"1559342_a_at"},{"1":"1559343_at","2":"IPW /// LOC101930404 /// PWARSN /// SNORD107 /// SNORD115-13 /// SNORD115-26 /// SNORD115-7 /// SNORD116-22 /// SNORD116-28 /// SNORD116-4 /// SNRPN","_rn_":"1559343_at"},{"1":"1559361_at","2":"LOC101927668 /// MACC1","_rn_":"1559361_at"},{"1":"1559370_at","2":"DAB2 /// LOC101926921","_rn_":"1559370_at"},{"1":"1559474_at","2":"LOC100996693 /// SPEG","_rn_":"1559474_at"},{"1":"1559504_at","2":"MIR137 /// MIR137HG /// MIR2682","_rn_":"1559504_at"},{"1":"1559506_x_at","2":"MIR137 /// MIR137HG /// MIR2682","_rn_":"1559506_x_at"},{"1":"1559534_at","2":"BC040901 /// CTC-241N9.1 /// LOC100996419","_rn_":"1559534_at"},{"1":"1559535_s_at","2":"BC040901 /// CTC-241N9.1 /// LOC100996419","_rn_":"1559535_s_at"},{"1":"1559545_at","2":"IPW /// LOC101930404 /// PWARSN /// SNORD107 /// SNORD115-13 /// SNORD115-26 /// SNORD115-7 /// SNORD116-22 /// SNORD116-28 /// SNORD116-4 /// SNRPN","_rn_":"1559545_at"},{"1":"1559546_s_at","2":"IPW /// LOC101930404 /// PWARSN /// SNORD107 /// SNORD115-13 /// SNORD115-26 /// SNORD115-7 /// SNORD116-22 /// SNORD116-28 /// SNORD116-4 /// SNRPN","_rn_":"1559546_s_at"},{"1":"1559575_a_at","2":"AQP12A /// AQP12B","_rn_":"1559575_a_at"},{"1":"1559593_a_at","2":"CTD-3222D19.5 /// MED26","_rn_":"1559593_a_at"},{"1":"1559620_at","2":"LOC101927768 /// LOC101927794","_rn_":"1559620_at"},{"1":"1559640_at","2":"ANKFN1 /// BC037494","_rn_":"1559640_at"},{"1":"1559654_s_at","2":"GRTP1-AS1 /// LOC101930007 /// LOC101930262","_rn_":"1559654_s_at"},{"1":"1559681_a_at","2":"LOC101930301 /// LOC101930303 /// TRIM16L","_rn_":"1559681_a_at"},{"1":"1559746_a_at","2":"ZNF595 /// ZNF718","_rn_":"1559746_a_at"},{"1":"1559800_a_at","2":"AX748066 /// RP11-709D24.6","_rn_":"1559800_a_at"},{"1":"1559804_at","2":"AK093370 /// CTD-3046C4.1","_rn_":"1559804_at"},{"1":"1559950_at","2":"FAM66B /// FAM66C /// FAM66D /// LOC101928910 /// LOC102725108","_rn_":"1559950_at"},{"1":"1559952_x_at","2":"FAM66B /// FAM66C /// FAM66D /// LOC101928910 /// LOC102725108","_rn_":"1559952_x_at"},{"1":"1559986_at","2":"LIFR-AS1 /// MIR3650","_rn_":"1559986_at"},{"1":"1560011_at","2":"AX747544 /// JRK","_rn_":"1560011_at"},{"1":"1560145_at","2":"AK057978 /// MKLN1","_rn_":"1560145_at"},{"1":"1560207_at","2":"MIR3610 /// RAD21-AS1","_rn_":"1560207_at"},{"1":"1560208_at","2":"LOC101930593 /// LOC102724352","_rn_":"1560208_at"},{"1":"1560219_at","2":"ASB3 /// AX747197","_rn_":"1560219_at"},{"1":"1560224_at","2":"AHCTF1 /// AHCTF1P1","_rn_":"1560224_at"},{"1":"1560300_a_at","2":"DMRTC1 /// DMRTC1B","_rn_":"1560300_a_at"},{"1":"1560352_at","2":"ENTPD1-AS1 /// LOC101927104","_rn_":"1560352_at"},{"1":"1560383_at","2":"BC042091 /// RP11-752D24.2","_rn_":"1560383_at"},{"1":"1560384_a_at","2":"BC042091 /// RP11-752D24.2","_rn_":"1560384_a_at"},{"1":"1560455_at","2":"LOC339166 /// WSCD1","_rn_":"1560455_at"},{"1":"1560482_at","2":"BC034423 /// RP11-966I7.2","_rn_":"1560482_at"},{"1":"1560566_at","2":"LOC101926951 /// PCDH20","_rn_":"1560566_at"},{"1":"1560581_at","2":"BC040886 /// RP11-804F13.1","_rn_":"1560581_at"},{"1":"1560582_a_at","2":"BC040886 /// RP11-804F13.1","_rn_":"1560582_a_at"},{"1":"1560617_at","2":"AP000266.7 /// BC034802 /// LOC100128198","_rn_":"1560617_at"},{"1":"1560634_a_at","2":"AC007557.2 /// BC031974","_rn_":"1560634_a_at"},{"1":"1560637_at","2":"BC039537 /// RP11-30L15.6","_rn_":"1560637_at"},{"1":"1560638_a_at","2":"BC039537 /// RP11-30L15.6","_rn_":"1560638_a_at"},{"1":"1560662_s_at","2":"WHAMMP2 /// WHAMMP3","_rn_":"1560662_s_at"},{"1":"1560692_at","2":"VSTM2A /// VSTM2A-OT1","_rn_":"1560692_at"},{"1":"1560734_at","2":"LOC101927079 /// LOC727924 /// OR4N4","_rn_":"1560734_at"},{"1":"1560735_s_at","2":"LOC101927079 /// LOC102723532 /// LOC727924 /// OR4N4","_rn_":"1560735_s_at"},{"1":"1560741_at","2":"SNRPN /// SNURF","_rn_":"1560741_at"},{"1":"1560773_at","2":"DLGAP1 /// LOC102724716","_rn_":"1560773_at"},{"1":"1560797_s_at","2":"LOC101927830 /// TMLHE-AS1","_rn_":"1560797_s_at"},{"1":"1560806_at","2":"LOC646743 /// TISP43","_rn_":"1560806_at"},{"1":"1560833_at","2":"LINC01189 /// LOC101927827","_rn_":"1560833_at"},{"1":"1560844_at","2":"BC040898 /// RP11-244K5.6","_rn_":"1560844_at"},{"1":"1561035_at","2":"BC032026 /// RP11-526I2.1","_rn_":"1561035_at"},{"1":"1561036_at","2":"BC032899 /// RP11-396C23.2","_rn_":"1561036_at"},{"1":"1561037_a_at","2":"BC032899 /// RP11-396C23.2","_rn_":"1561037_a_at"},{"1":"1561042_at","2":"AGO2 /// CASC7 /// CASC7","_rn_":"1561042_at"},{"1":"1561052_s_at","2":"AF086219 /// CTD-2647L4.1","_rn_":"1561052_s_at"},{"1":"1561069_at","2":"BC036309 /// RP11-298H24.1","_rn_":"1561069_at"},{"1":"1561084_at","2":"BC044611 /// RP13-539F13.3","_rn_":"1561084_at"},{"1":"1561089_at","2":"CTD-2199O4.3 /// CTD-2199O4.7","_rn_":"1561089_at"},{"1":"1561110_at","2":"BC042825 /// RP1-179N16.6","_rn_":"1561110_at"},{"1":"1561171_a_at","2":"GOLGA6L1 /// GOLGA6L22 /// GOLGA6L6","_rn_":"1561171_a_at"},{"1":"1561197_at","2":"FLJ43315 /// LOC101927088 /// LOC101927527 /// LOC101929518 /// LOC442028","_rn_":"1561197_at"},{"1":"1561306_s_at","2":"LOC101930630 /// STRC","_rn_":"1561306_s_at"},{"1":"1561307_at","2":"BC043266 /// RP4-568F9.6","_rn_":"1561307_at"},{"1":"1561309_x_at","2":"BC043266 /// RP4-568F9.6","_rn_":"1561309_x_at"},{"1":"1561313_at","2":"AL832615 /// AX747639","_rn_":"1561313_at"},{"1":"1561314_at","2":"AK055055 /// RP11-752D24.2","_rn_":"1561314_at"},{"1":"1561386_at","2":"AX747135 /// RP11-863K10.7","_rn_":"1561386_at"},{"1":"1561390_at","2":"FAM41AY1 /// FAM41AY2","_rn_":"1561390_at"},{"1":"1561405_s_at","2":"CATSPER2 /// LOC101930343 /// STRC","_rn_":"1561405_s_at"},{"1":"1561407_at","2":"ARAP2 /// LOC101928667","_rn_":"1561407_at"},{"1":"1561421_a_at","2":"AK057259 /// AK096803","_rn_":"1561421_a_at"},{"1":"1561448_at","2":"BC041947 /// RP4-630C24.3","_rn_":"1561448_at"},{"1":"1561468_at","2":"BC043223 /// RP1-274L7.1","_rn_":"1561468_at"},{"1":"1561489_at","2":"ARHGAP15 /// LOC101928361","_rn_":"1561489_at"},{"1":"1561493_at","2":"BC037892 /// RP11-1129I3.1","_rn_":"1561493_at"},{"1":"1561497_at","2":"MIR3180-1 /// MIR3180-2 /// MIR3180-3","_rn_":"1561497_at"},{"1":"1561581_at","2":"BC035247 /// RP11-18H7.1","_rn_":"1561581_at"},{"1":"1561584_at","2":"BC044765 /// RP11-96B5.4","_rn_":"1561584_at"},{"1":"1561593_at","2":"BC032916 /// RP11-400D2.2","_rn_":"1561593_at"},{"1":"1561705_at","2":"BC037861 /// CTD-2036P10.3","_rn_":"1561705_at"},{"1":"1561889_at","2":"AC078842.4 /// AK094915","_rn_":"1561889_at"},{"1":"1561894_at","2":"C7orf49 /// LOC653739","_rn_":"1561894_at"},{"1":"1561909_at","2":"BC052578 /// RP11-398G24.2","_rn_":"1561909_at"},{"1":"1561916_at","2":"BC042811 /// RP11-340I6.8","_rn_":"1561916_at"},{"1":"1561937_x_at","2":"IGHA1 /// IGHG1 /// IGHM /// IGHV4-31","_rn_":"1561937_x_at"},{"1":"1561940_at","2":"CHFR /// LOC100128843","_rn_":"1561940_at"},{"1":"1561967_at","2":"BC041347 /// FLNB-AS1 /// FLNB-AS1","_rn_":"1561967_at"},{"1":"1562022_s_at","2":"LOC100130987 /// RAD9A","_rn_":"1562022_s_at"},{"1":"1562023_at","2":"BC037970 /// RP11-94M14.2","_rn_":"1562023_at"},{"1":"1562051_at","2":"LOC729296 /// MIR646HG","_rn_":"1562051_at"},{"1":"1562058_at","2":"AK094733 /// RP11-114G22.1","_rn_":"1562058_at"},{"1":"1562153_a_at","2":"MIR1204 /// PVT1","_rn_":"1562153_a_at"},{"1":"1562341_at","2":"LOC101927560 /// LOC101927587","_rn_":"1562341_at"},{"1":"1562351_at","2":"LDHAL6CP /// LDHAL6CP","_rn_":"1562351_at"},{"1":"1562418_at","2":"AP001604.3 /// BC043580","_rn_":"1562418_at"},{"1":"1562439_at","2":"BC036778 /// NCOA3","_rn_":"1562439_at"},{"1":"1562583_s_at","2":"AK054988 /// TPTE2P1 /// TPTE2P1","_rn_":"1562583_s_at"},{"1":"1562603_at","2":"RAD51L3-RFFL /// RFFL","_rn_":"1562603_at"},{"1":"1562610_at","2":"AC004538.3 /// BC040327","_rn_":"1562610_at"},{"1":"1562661_at","2":"AX746690 /// RP4-564F22.5","_rn_":"1562661_at"},{"1":"1562670_at","2":"AK093301 /// RP11-862G15.1","_rn_":"1562670_at"},{"1":"1562671_s_at","2":"AK093301 /// RP11-862G15.1","_rn_":"1562671_s_at"},{"1":"1562693_at","2":"AK097836 /// RP5-971N18.3","_rn_":"1562693_at"},{"1":"1562712_at","2":"LOC101927933 /// LRRC8C","_rn_":"1562712_at"},{"1":"1562722_at","2":"PRR20A /// PRR20B /// PRR20C /// PRR20D /// PRR20E","_rn_":"1562722_at"},{"1":"1562737_at","2":"BC041448 /// RP11-422J15.1","_rn_":"1562737_at"},{"1":"1562743_at","2":"ZNF33B /// ZNF33B","_rn_":"1562743_at"},{"1":"1562810_at","2":"AC003986.5 /// BC043576","_rn_":"1562810_at"},{"1":"1562825_at","2":"CEACAMP3 /// CEACAMP3","_rn_":"1562825_at"},{"1":"1562854_at","2":"BC041451 /// RP1-206D15.3","_rn_":"1562854_at"},{"1":"1562873_at","2":"LOC101928818 /// PWRN1","_rn_":"1562873_at"},{"1":"1562876_s_at","2":"MIR4435-1HG /// RP11-181E10.3","_rn_":"1562876_s_at"},{"1":"1562944_at","2":"LOC101928160 /// ZNF707","_rn_":"1562944_at"},{"1":"1562969_at","2":"DNMBP /// LOC101927371","_rn_":"1562969_at"},{"1":"1562997_a_at","2":"BC041484 /// RP11-90K6.1","_rn_":"1562997_a_at"},{"1":"1563009_at","2":"BC039485 /// LOC284930","_rn_":"1563009_at"},{"1":"1563038_at","2":"BC038194 /// RP11-550P17.5","_rn_":"1563038_at"},{"1":"1563079_at","2":"LOC100289090 /// RP11-23P13.6","_rn_":"1563079_at"},{"1":"1563108_at","2":"ELFN2 /// RP1-63G5.8","_rn_":"1563108_at"},{"1":"1563120_at","2":"LOC100129029 /// LOC100131270","_rn_":"1563120_at"},{"1":"1563157_at","2":"BC040624 /// FOXP1-AS1 /// FOXP1-AS1","_rn_":"1563157_at"},{"1":"1563181_a_at","2":"BC047942 /// RP11-122K13.14","_rn_":"1563181_a_at"},{"1":"1563185_at","2":"LOC101930566 /// LOC102800447","_rn_":"1563185_at"},{"1":"1563190_at","2":"BC037214 /// RP11-58G13.1","_rn_":"1563190_at"},{"1":"1563229_at","2":"DLEU2 /// MIR15A","_rn_":"1563229_at"},{"1":"1563271_at","2":"BC039545 /// RP11-1008C21.1","_rn_":"1563271_at"},{"1":"1563420_at","2":"XG /// XGY2","_rn_":"1563420_at"},{"1":"1563450_at","2":"DEFB107A /// DEFB107B","_rn_":"1563450_at"},{"1":"1563529_at","2":"HYDIN /// HYDIN2 /// LOC101930373","_rn_":"1563529_at"},{"1":"1563591_at","2":"LOC100506403 /// LOC101928269 /// RUNX1","_rn_":"1563591_at"},{"1":"1563707_at","2":"AL831948 /// RP1-197B17.3","_rn_":"1563707_at"},{"1":"1563709_at","2":"LOC100127955 /// LOC100128374","_rn_":"1563709_at"},{"1":"1563753_at","2":"BPI /// LOC149684","_rn_":"1563753_at"},{"1":"1563781_at","2":"LOC101928623 /// LOC401320","_rn_":"1563781_at"},{"1":"1563800_at","2":"LOC100506870 /// LOC283140","_rn_":"1563800_at"},{"1":"1563845_at","2":"FAM153A /// FAM153B /// LOC100507387","_rn_":"1563845_at"},{"1":"1564027_a_at","2":"FAM115C /// FAM115D /// LOC101928422","_rn_":"1564027_a_at"},{"1":"1564028_s_at","2":"FAM115C /// FAM115D /// LOC101928422","_rn_":"1564028_s_at"},{"1":"1564112_at","2":"FAM71A /// FAM71A /// RP11-338C15.5","_rn_":"1564112_at"},{"1":"1564240_at","2":"LOC100130856 /// PSPN","_rn_":"1564240_at"},{"1":"1564277_a_at","2":"LOC100133920 /// LOC100996643 /// LOC101928195 /// LOC101929583 /// LOC286297","_rn_":"1564277_a_at"},{"1":"1564331_at","2":"LOC100505555 /// ZNF846","_rn_":"1564331_at"},{"1":"1564357_at","2":"ABHD12B /// MIR4454","_rn_":"1564357_at"},{"1":"1564463_at","2":"KLF13 /// LOC100499221","_rn_":"1564463_at"},{"1":"1564787_at","2":"ELMOD1 /// LOC643923","_rn_":"1564787_at"},{"1":"1564855_at","2":"LOC101927079 /// LOC727924","_rn_":"1564855_at"},{"1":"1564856_s_at","2":"LOC101927079 /// LOC727924","_rn_":"1564856_s_at"},{"1":"1564906_at","2":"MATR3 /// SNHG4","_rn_":"1564906_at"},{"1":"1564907_s_at","2":"MATR3 /// SNHG4","_rn_":"1564907_s_at"},{"1":"1565325_at","2":"MATR3 /// SNHG4","_rn_":"1565325_at"},{"1":"1565495_at","2":"CYAT1 /// IGLC1 /// IGLV1-44","_rn_":"1565495_at"},{"1":"1565674_at","2":"FCGR2A /// FCGR2C","_rn_":"1565674_at"},{"1":"1565728_at","2":"LOC284630 /// TTC34","_rn_":"1565728_at"},{"1":"1565759_at","2":"RPL13 /// SNORD68","_rn_":"1565759_at"},{"1":"1565867_a_at","2":"LOC441155 /// ZC3H11A","_rn_":"1565867_a_at"},{"1":"1566082_at","2":"RP11-210K20.4 /// RP11-452K12.7","_rn_":"1566082_at"},{"1":"1566108_at","2":"MYNN /// RP11-362K14.5","_rn_":"1566108_at"},{"1":"1566126_at","2":"AK097242 /// CTB-127C13.1","_rn_":"1566126_at"},{"1":"1566127_at","2":"AC010095.5 /// RP13-1039J1.3","_rn_":"1566127_at"},{"1":"1566145_s_at","2":"LOC101928669 /// LOC101930100 /// LOC644450","_rn_":"1566145_s_at"},{"1":"1566152_a_at","2":"AK096335 /// AP000662.4","_rn_":"1566152_a_at"},{"1":"1566253_at","2":"SH3GL1P1 /// SH3GL1P2","_rn_":"1566253_at"},{"1":"1566269_at","2":"RALGAPA1 /// RALGAPA1P","_rn_":"1566269_at"},{"1":"1566271_x_at","2":"RALGAPA1 /// RALGAPA1P","_rn_":"1566271_x_at"},{"1":"1566403_at","2":"RPL18A /// SNORA68","_rn_":"1566403_at"},{"1":"1566427_at","2":"LOC102724888 /// LOC102725420","_rn_":"1566427_at"},{"1":"1566472_s_at","2":"LOC100996506 /// RETSAT","_rn_":"1566472_s_at"},{"1":"1566605_at","2":"RP11-48G14.2 /// TEX9","_rn_":"1566605_at"},{"1":"1566630_at","2":"LOC102725016 /// PPP2R3B","_rn_":"1566630_at"},{"1":"1566643_a_at","2":"BC022568 /// CTC-265F19.1","_rn_":"1566643_a_at"},{"1":"1566836_at","2":"MRPL49P1 /// MRPL49P1","_rn_":"1566836_at"},{"1":"1566984_at","2":"LRRC37A16P /// LRRC37A16P","_rn_":"1566984_at"},{"1":"1567014_s_at","2":"CSNK2A1 /// NFE2L2","_rn_":"1567014_s_at"},{"1":"1567183_s_at","2":"AC069277.2 /// AF279782","_rn_":"1567183_s_at"},{"1":"1567912_s_at","2":"CT45A1 /// CT45A2 /// CT45A3 /// CT45A4 /// CT45A5 /// CT45A6 /// LOC101060211 /// LOC102723631 /// LOC102723680 /// LOC102723737","_rn_":"1567912_s_at"},{"1":"1568249_at","2":"SNHG17 /// SNORA71B","_rn_":"1568249_at"},{"1":"1568609_s_at","2":"LINC00623 /// LINC00869 /// LINC01138 /// LOC103091866","_rn_":"1568609_s_at"},{"1":"1568623_a_at","2":"LOC101929728 /// SLC35E4","_rn_":"1568623_a_at"},{"1":"1568650_a_at","2":"BC031952 /// RP11-540O11.1","_rn_":"1568650_a_at"},{"1":"1568658_at","2":"C2orf74 /// KIAA1841","_rn_":"1568658_at"},{"1":"1568685_at","2":"BC034456 /// RP11-229P13.25","_rn_":"1568685_at"},{"1":"1568711_a_at","2":"BC045810 /// RP11-38F22.1","_rn_":"1568711_a_at"},{"1":"1568749_at","2":"BC030116 /// RP11-716O23.1","_rn_":"1568749_at"},{"1":"1568762_at","2":"LOC728613 /// PDCD6","_rn_":"1568762_at"},{"1":"1568763_s_at","2":"LOC102724884 /// LOC728613 /// PDCD6","_rn_":"1568763_s_at"},{"1":"1568764_x_at","2":"LOC728613 /// PDCD6","_rn_":"1568764_x_at"},{"1":"1568838_at","2":"WASIR1 /// WASIR1 /// WASIR2 /// WASIR2","_rn_":"1568838_at"},{"1":"1568865_at","2":"BC052775 /// FNTB","_rn_":"1568865_at"},{"1":"1568915_at","2":"BC033528 /// U73166.2","_rn_":"1568915_at"},{"1":"1568921_at","2":"LOC101930149 /// LOC101930286","_rn_":"1568921_at"},{"1":"1568932_at","2":"BC034636 /// CTB-113P19.4","_rn_":"1568932_at"},{"1":"1568951_at","2":"LOC145783 /// ZNF280D","_rn_":"1568951_at"},{"1":"1568955_at","2":"SRGAP2 /// SRGAP2B /// SRGAP2C","_rn_":"1568955_at"},{"1":"1568957_x_at","2":"SRGAP2 /// SRGAP2B /// SRGAP2C","_rn_":"1568957_x_at"},{"1":"1568964_x_at","2":"LOC101929889 /// SPN","_rn_":"1568964_x_at"},{"1":"1568987_at","2":"CRHR1-IT1 /// MGC57346","_rn_":"1568987_at"},{"1":"1568999_at","2":"PSG4 /// PSG6","_rn_":"1568999_at"},{"1":"1569008_at","2":"FAM201B /// LOC648761","_rn_":"1569008_at"},{"1":"1569009_s_at","2":"FAM201B /// LOC648761","_rn_":"1569009_s_at"},{"1":"1569013_s_at","2":"BMS1P20 /// LOC101929959","_rn_":"1569013_s_at"},{"1":"1569034_a_at","2":"LOC440864 /// MSH6","_rn_":"1569034_a_at"},{"1":"1569114_at","2":"AC099850.1 /// BC017255","_rn_":"1569114_at"},{"1":"1569146_s_at","2":"KIAA0408 /// SOGA3","_rn_":"1569146_s_at"},{"1":"1569156_at","2":"LOC100505555 /// ZNF846","_rn_":"1569156_at"},{"1":"1569157_s_at","2":"LOC100505555 /// ZNF846","_rn_":"1569157_s_at"},{"1":"1569190_at","2":"LOC101927137 /// SCLT1","_rn_":"1569190_at"},{"1":"1569300_at","2":"LOC101928198 /// MFAP3L","_rn_":"1569300_at"},{"1":"1569305_a_at","2":"BC040412 /// CTC-400I9.1","_rn_":"1569305_a_at"},{"1":"1569348_at","2":"LOC102725451 /// TPTEP1","_rn_":"1569348_at"},{"1":"1569387_at","2":"BC048103 /// CSGALNACT1","_rn_":"1569387_at"},{"1":"1569407_at","2":"BC036308 /// RP1-117O3.2","_rn_":"1569407_at"},{"1":"1569472_s_at","2":"TTC3 /// TTC3P1","_rn_":"1569472_s_at"},{"1":"1569473_s_at","2":"LOC155060 /// ZNF783","_rn_":"1569473_s_at"},{"1":"1569495_at","2":"LOC101927137 /// SCLT1","_rn_":"1569495_at"},{"1":"1569503_at","2":"HEATR5B /// HEATR5B","_rn_":"1569503_at"},{"1":"1569519_at","2":"LOC102724250 /// NBPF1 /// NBPF10 /// NBPF11 /// NBPF12 /// NBPF14 /// NBPF15 /// NBPF26 /// NBPF8 /// NBPF9","_rn_":"1569519_at"},{"1":"1569525_s_at","2":"BMS1P17 /// BMS1P18","_rn_":"1569525_s_at"},{"1":"1569554_at","2":"ESR2 /// RP11-544I20.2","_rn_":"1569554_at"},{"1":"1569607_s_at","2":"ANKRD20A1 /// ANKRD20A11P /// ANKRD20A2 /// ANKRD20A3 /// ANKRD20A4 /// ANKRD20A5P /// ANKRD20A9P /// LOC102723891 /// LOC102725051","_rn_":"1569607_s_at"},{"1":"1569629_x_at","2":"LOC389906 /// LOC441528","_rn_":"1569629_x_at"},{"1":"1569675_at","2":"LOC101928620 /// POU2AF1","_rn_":"1569675_at"},{"1":"1569736_at","2":"BC048982 /// RP11-1102P16.1","_rn_":"1569736_at"},{"1":"1569740_at","2":"BC038755 /// PRKRIRP5 /// PRKRIRP5","_rn_":"1569740_at"},{"1":"1569751_at","2":"LOC101930296 /// TBC1D26 /// ZNF286A","_rn_":"1569751_at"},{"1":"1569760_at","2":"LRRC37A7P /// LRRC37A7P","_rn_":"1569760_at"},{"1":"1569761_x_at","2":"LRRC37A7P /// LRRC37A7P","_rn_":"1569761_x_at"},{"1":"1569765_at","2":"BC037833 /// RP11-492E3.2","_rn_":"1569765_at"},{"1":"1569784_at","2":"LOC101930028 /// LOC101930449","_rn_":"1569784_at"},{"1":"1569789_at","2":"BC031255 /// RP11-260O18.1","_rn_":"1569789_at"},{"1":"1569819_at","2":"LOC101928818 /// PWRN1","_rn_":"1569819_at"},{"1":"1569839_s_at","2":"LOC101929953 /// LRRC37A5P","_rn_":"1569839_s_at"},{"1":"1569847_at","2":"CGNL1 /// LOC101930344 /// LOC101930349","_rn_":"1569847_at"},{"1":"1569850_at","2":"LOC101927458 /// LPHN2","_rn_":"1569850_at"},{"1":"1569900_at","2":"FLJ16124 /// LOC101927533","_rn_":"1569900_at"},{"1":"1569934_at","2":"BC036055 /// PREX2","_rn_":"1569934_at"},{"1":"1569973_at","2":"BC015774 /// SEPT7P2","_rn_":"1569973_at"},{"1":"1569974_x_at","2":"BC015774 /// SEPT7P2","_rn_":"1569974_x_at"},{"1":"1570007_at","2":"LOC101927933 /// LRRC8C","_rn_":"1570007_at"},{"1":"1570071_at","2":"LOC101929865 /// LOC101930243","_rn_":"1570071_at"},{"1":"1570120_at","2":"BC024027 /// RP11-268G12.1","_rn_":"1570120_at"},{"1":"1570140_at","2":"ANXA8 /// ANXA8L1 /// LOC100996760 /// LOC102725207","_rn_":"1570140_at"},{"1":"1570190_at","2":"AK311120 /// LSAMP","_rn_":"1570190_at"},{"1":"1570255_s_at","2":"ANKRD20A1 /// ANKRD20A12P /// ANKRD20A2 /// ANKRD20A3 /// ANKRD20A4 /// ANKRD20A5P /// ANKRD20A8P","_rn_":"1570255_s_at"},{"1":"1570261_at","2":"AC011997.1 /// BC021693","_rn_":"1570261_at"},{"1":"1570285_at","2":"BC016972 /// RP11-443B7.1","_rn_":"1570285_at"},{"1":"1570388_a_at","2":"LOC101927424 /// LOC101929800 /// LOC440896","_rn_":"1570388_a_at"},{"1":"1570395_a_at","2":"FAM66C /// LOC101928910","_rn_":"1570395_a_at"},{"1":"1570396_at","2":"FAM66C /// LOC101928910","_rn_":"1570396_at"},{"1":"1570397_x_at","2":"FAM66C /// LOC101928910","_rn_":"1570397_x_at"},{"1":"1570469_at","2":"BC017988 /// RP11-308N19.1","_rn_":"1570469_at"},{"1":"1570587_at","2":"MPRIP-AS1 /// MPRIP-AS1","_rn_":"1570587_at"},{"1":"1773_at","2":"CHURC1-FNTB /// FNTB","_rn_":"1773_at"},{"1":"200003_s_at","2":"MIR6805 /// RPL28","_rn_":"200003_s_at"},{"1":"200012_x_at","2":"RPL21 /// RPL21P28 /// SNORA27 /// SNORD102","_rn_":"200012_x_at"},{"1":"200016_x_at","2":"HNRNPA1 /// HNRNPA1P10","_rn_":"200016_x_at"},{"1":"200018_at","2":"LOC100508408 /// RPS13 /// SNORD14B","_rn_":"200018_at"},{"1":"200031_s_at","2":"RPS11 /// SNORD35B","_rn_":"200031_s_at"},{"1":"200033_at","2":"DDX5 /// MIR3064 /// MIR5047","_rn_":"200033_at"},{"1":"200038_s_at","2":"C18orf32 /// RPL17 /// RPL17-C18orf32 /// SNORD58A /// SNORD58B /// SNORD58C","_rn_":"200038_s_at"},{"1":"200041_s_at","2":"ATP6V1G2-DDX39B /// DDX39B /// SNORD84","_rn_":"200041_s_at"},{"1":"200044_at","2":"GATC /// SRSF9","_rn_":"200044_at"},{"1":"200058_s_at","2":"LOC101929240 /// SNRNP200","_rn_":"200058_s_at"},{"1":"200065_s_at","2":"ARF1 /// MIR3620","_rn_":"200065_s_at"},{"1":"200080_s_at","2":"H3F3A /// H3F3AP4 /// H3F3B","_rn_":"200080_s_at"},{"1":"200088_x_at","2":"NBEAL1 /// RPL12","_rn_":"200088_x_at"},{"1":"200089_s_at","2":"RPL4 /// SNORD16 /// SNORD18A /// SNORD18B /// SNORD18C","_rn_":"200089_s_at"},{"1":"200099_s_at","2":"RPS3A /// SNORD73A","_rn_":"200099_s_at"},{"1":"200598_s_at","2":"HSP90B1 /// MIR3652","_rn_":"200598_s_at"},{"1":"200599_s_at","2":"HSP90B1 /// MIR3652","_rn_":"200599_s_at"},{"1":"200622_x_at","2":"CALM1 /// CALM2 /// CALM3","_rn_":"200622_x_at"},{"1":"200623_s_at","2":"CALM1 /// CALM2 /// CALM3","_rn_":"200623_s_at"},{"1":"200624_s_at","2":"MATR3 /// SNHG4","_rn_":"200624_s_at"},{"1":"200626_s_at","2":"MATR3 /// SNHG4","_rn_":"200626_s_at"},{"1":"200630_x_at","2":"SET /// SETSIP","_rn_":"200630_x_at"},{"1":"200631_s_at","2":"SET /// SETSIP","_rn_":"200631_s_at"},{"1":"200647_x_at","2":"EIF3C /// EIF3CL","_rn_":"200647_x_at"},{"1":"200651_at","2":"GNB2L1 /// SNORD95 /// SNORD96A","_rn_":"200651_at"},{"1":"200653_s_at","2":"CALM1 /// CALM2 /// CALM3","_rn_":"200653_s_at"},{"1":"200655_s_at","2":"CALM1 /// CALM2 /// CALM3","_rn_":"200655_s_at"},{"1":"200689_x_at","2":"EEF1G /// MIR3654","_rn_":"200689_x_at"},{"1":"200705_s_at","2":"EEF1B2 /// SNORA41","_rn_":"200705_s_at"},{"1":"200709_at","2":"FKBP1A /// LOC101929368","_rn_":"200709_at"},{"1":"200715_x_at","2":"RPL13A /// SNORD32A /// SNORD33 /// SNORD34 /// SNORD35A","_rn_":"200715_x_at"},{"1":"200716_x_at","2":"RPL13A /// RPL13AP5 /// SNORD32A /// SNORD33 /// SNORD34 /// SNORD35A","_rn_":"200716_x_at"},{"1":"200724_at","2":"RPL10 /// SNORA70","_rn_":"200724_at"},{"1":"200725_x_at","2":"RPL10 /// SNORA70","_rn_":"200725_x_at"},{"1":"200753_x_at","2":"MIR636 /// SRSF2","_rn_":"200753_x_at"},{"1":"200754_x_at","2":"MIR636 /// SRSF2","_rn_":"200754_x_at"},{"1":"200772_x_at","2":"LOC100506248 /// LOC728026 /// MIR1244-1 /// MIR1244-2 /// MIR1244-3 /// PTMA","_rn_":"200772_x_at"},{"1":"200799_at","2":"HSPA1A /// HSPA1B","_rn_":"200799_at"},{"1":"200800_s_at","2":"HSPA1A /// HSPA1B /// HSPA1L","_rn_":"200800_s_at"},{"1":"200858_s_at","2":"RPS8 /// SNORD38B /// SNORD55","_rn_":"200858_s_at"},{"1":"200869_at","2":"RPL18A /// SNORA68","_rn_":"200869_at"},{"1":"200874_s_at","2":"MIR1292 /// NOP56 /// SNORD110 /// SNORD57 /// SNORD86","_rn_":"200874_s_at"},{"1":"200875_s_at","2":"MIR1292 /// NOP56 /// SNORD110 /// SNORD57 /// SNORD86","_rn_":"200875_s_at"},{"1":"200888_s_at","2":"RPL23 /// SNORA21","_rn_":"200888_s_at"},{"1":"200901_s_at","2":"M6PR /// PHC1","_rn_":"200901_s_at"},{"1":"200909_s_at","2":"RPLP2 /// SNORA52","_rn_":"200909_s_at"},{"1":"200910_at","2":"CCT3 /// LOC101927137","_rn_":"200910_at"},{"1":"200912_s_at","2":"EIF4A2 /// MIR1248 /// SNORA4 /// SNORA63 /// SNORA81 /// SNORD2","_rn_":"200912_s_at"},{"1":"200937_s_at","2":"RPL5 /// SNORD21","_rn_":"200937_s_at"},{"1":"200944_s_at","2":"HMGN1 /// LOC101927733","_rn_":"200944_s_at"},{"1":"200949_x_at","2":"RPS20 /// SNORD54","_rn_":"200949_x_at"},{"1":"200969_at","2":"LOC101928061 /// SERP1","_rn_":"200969_at"},{"1":"200971_s_at","2":"LOC101928061 /// SERP1","_rn_":"200971_s_at"},{"1":"200997_at","2":"RBM14-RBM4 /// RBM4","_rn_":"200997_at"},{"1":"201001_s_at","2":"TMEM189 /// TMEM189-UBE2V1 /// UBE2V1 /// UBE2V2","_rn_":"201001_s_at"},{"1":"201002_s_at","2":"TMEM189 /// TMEM189-UBE2V1 /// UBE2V1 /// UBE2V2","_rn_":"201002_s_at"},{"1":"201003_x_at","2":"TMEM189 /// TMEM189-UBE2V1 /// UBE2V1 /// UBE2V2","_rn_":"201003_x_at"},{"1":"201045_s_at","2":"RAB6A /// WTH3DI","_rn_":"201045_s_at"},{"1":"201047_x_at","2":"RAB6A /// WTH3DI","_rn_":"201047_x_at"},{"1":"201048_x_at","2":"RAB6A /// WTH3DI","_rn_":"201048_x_at"},{"1":"201064_s_at","2":"LOC100996696 /// PABPC4","_rn_":"201064_s_at"},{"1":"201065_s_at","2":"GTF2I /// GTF2IP1 /// LOC100093631","_rn_":"201065_s_at"},{"1":"201077_s_at","2":"ANXA2 /// NHP2L1","_rn_":"201077_s_at"},{"1":"201082_s_at","2":"DCTN1 /// SLC4A5","_rn_":"201082_s_at"},{"1":"201103_x_at","2":"NBPF10 /// NBPF11 /// NBPF12 /// NBPF14 /// NBPF15 /// NBPF20 /// NBPF8 /// NBPF9","_rn_":"201103_x_at"},{"1":"201104_x_at","2":"NBPF10 /// NBPF11 /// NBPF14 /// NBPF15 /// NBPF19 /// NBPF20 /// NBPF25P /// NBPF26 /// NBPF8 /// NBPF9","_rn_":"201104_x_at"},{"1":"201132_at","2":"HNRNPH2 /// RPL36A-HNRNPH2","_rn_":"201132_at"},{"1":"201154_x_at","2":"RPL4 /// SNORD16 /// SNORD18A /// SNORD18B /// SNORD18C","_rn_":"201154_x_at"},{"1":"201217_x_at","2":"RNU86 /// RPL3 /// SNORD83B","_rn_":"201217_x_at"},{"1":"201245_s_at","2":"LOC101927673 /// OTUB1","_rn_":"201245_s_at"},{"1":"201246_s_at","2":"LOC101927673 /// OTUB1","_rn_":"201246_s_at"},{"1":"201257_x_at","2":"RPS3A /// SNORD73A","_rn_":"201257_x_at"},{"1":"201268_at","2":"NME1-NME2 /// NME2","_rn_":"201268_at"},{"1":"201278_at","2":"DAB2 /// LOC101926921","_rn_":"201278_at"},{"1":"201279_s_at","2":"DAB2 /// LOC101926921","_rn_":"201279_s_at"},{"1":"201280_s_at","2":"DAB2 /// LOC101926921","_rn_":"201280_s_at"},{"1":"201293_x_at","2":"LOC101060363 /// PPIA","_rn_":"201293_x_at"},{"1":"201318_s_at","2":"MYL12A /// MYL12B","_rn_":"201318_s_at"},{"1":"201323_at","2":"EBNA1BP2 /// MIR6733","_rn_":"201323_at"},{"1":"201406_at","2":"RPL36A /// RPL36A-HNRNPH2","_rn_":"201406_at"},{"1":"201422_at","2":"IFI30 /// PIK3R2","_rn_":"201422_at"},{"1":"201475_x_at","2":"MARS /// MIR6758","_rn_":"201475_x_at"},{"1":"201478_s_at","2":"DKC1 /// MIR664B /// SNORA56","_rn_":"201478_s_at"},{"1":"201479_at","2":"DKC1 /// MIR664B /// SNORA56","_rn_":"201479_at"},{"1":"201522_x_at","2":"SNRPN /// SNURF","_rn_":"201522_x_at"},{"1":"201527_at","2":"ATP6V1F /// LOC101927180","_rn_":"201527_at"},{"1":"201530_x_at","2":"EIF4A1 /// LOC101928634 /// SENP3-EIF4A1 /// SNORA48 /// SNORA67 /// SNORD10","_rn_":"201530_x_at"},{"1":"201544_x_at","2":"BCL2L2 /// BCL2L2-PABPN1 /// PABPN1","_rn_":"201544_x_at"},{"1":"201545_s_at","2":"BCL2L2-PABPN1 /// PABPN1","_rn_":"201545_s_at"},{"1":"201550_x_at","2":"ACTB /// ACTG1","_rn_":"201550_x_at"},{"1":"201576_s_at","2":"GLB1 /// TMPPE","_rn_":"201576_s_at"},{"1":"201601_x_at","2":"IFITM1 /// IFITM2","_rn_":"201601_x_at"},{"1":"201639_s_at","2":"CPSF1 /// MIR1234 /// MIR6849 /// MIR939","_rn_":"201639_s_at"},{"1":"201698_s_at","2":"GATC /// SRSF9","_rn_":"201698_s_at"},{"1":"201757_at","2":"NDUFS5 /// RPL10","_rn_":"201757_at"},{"1":"201762_s_at","2":"MIR7703 /// PSME2","_rn_":"201762_s_at"},{"1":"201812_s_at","2":"C4orf46 /// TOMM7","_rn_":"201812_s_at"},{"1":"201973_s_at","2":"CCZ1 /// CCZ1B","_rn_":"201973_s_at"},{"1":"202010_s_at","2":"PTGR2 /// ZNF410","_rn_":"202010_s_at"},{"1":"202039_at","2":"MYO18A /// TIAF1","_rn_":"202039_at"},{"1":"202042_at","2":"HARS /// LOC101928623","_rn_":"202042_at"},{"1":"202104_s_at","2":"LOC101930112 /// SPG7","_rn_":"202104_s_at"},{"1":"202168_at","2":"AK6 /// TAF9","_rn_":"202168_at"},{"1":"202189_x_at","2":"MIR4745 /// PTBP1","_rn_":"202189_x_at"},{"1":"202233_s_at","2":"UQCRH /// UQCRHL","_rn_":"202233_s_at"},{"1":"202237_at","2":"LOC101928916 /// NNMT","_rn_":"202237_at"},{"1":"202238_s_at","2":"LOC101928916 /// NNMT","_rn_":"202238_s_at"},{"1":"202265_at","2":"BMI1 /// COMMD3-BMI1","_rn_":"202265_at"},{"1":"202314_at","2":"CYP51A1 /// LRRD1","_rn_":"202314_at"},{"1":"202327_s_at","2":"LOC101930075 /// PKD1","_rn_":"202327_s_at"},{"1":"202328_s_at","2":"LOC101930075 /// PKD1","_rn_":"202328_s_at"},{"1":"202332_at","2":"CSNK1E /// CSNK1E","_rn_":"202332_at"},{"1":"202350_s_at","2":"LOC100506558 /// MATN2","_rn_":"202350_s_at"},{"1":"202372_at","2":"AURKAPS1 /// RAB3GAP2","_rn_":"202372_at"},{"1":"202373_s_at","2":"AURKAPS1 /// RAB3GAP2","_rn_":"202373_s_at"},{"1":"202374_s_at","2":"AURKAPS1 /// RAB3GAP2","_rn_":"202374_s_at"},{"1":"202392_s_at","2":"MIR7109 /// PISD","_rn_":"202392_s_at"},{"1":"202395_at","2":"LOC101930324 /// NSF","_rn_":"202395_at"},{"1":"202397_at","2":"NUTF2 /// NUTF2P4","_rn_":"202397_at"},{"1":"202398_at","2":"AP3S2 /// C15orf38-AP3S2","_rn_":"202398_at"},{"1":"202399_s_at","2":"AP3S2 /// C15orf38-AP3S2","_rn_":"202399_s_at"},{"1":"202409_at","2":"IGF2 /// INS-IGF2","_rn_":"202409_at"},{"1":"202410_x_at","2":"IGF2 /// INS-IGF2","_rn_":"202410_x_at"},{"1":"202493_x_at","2":"CSH1 /// CSHL1 /// GH1","_rn_":"202493_x_at"},{"1":"202551_s_at","2":"CRIM1 /// LOC101929500","_rn_":"202551_s_at"},{"1":"202552_s_at","2":"CRIM1 /// LOC101929500","_rn_":"202552_s_at"},{"1":"202576_s_at","2":"DDX19A /// DDX19B","_rn_":"202576_s_at"},{"1":"202581_at","2":"HSPA1A /// HSPA1B","_rn_":"202581_at"},{"1":"202632_at","2":"DPH1 /// OVCA2","_rn_":"202632_at"},{"1":"202650_s_at","2":"KIAA0195 /// MIR6785","_rn_":"202650_s_at"},{"1":"202681_at","2":"C3orf62 /// MIR4271 /// USP4","_rn_":"202681_at"},{"1":"202712_s_at","2":"CKMT1A /// CKMT1B","_rn_":"202712_s_at"},{"1":"202713_s_at","2":"KIAA0391 /// PSMA6","_rn_":"202713_s_at"},{"1":"202730_s_at","2":"MIR4680 /// PDCD4","_rn_":"202730_s_at"},{"1":"202731_at","2":"MIR4680 /// PDCD4","_rn_":"202731_at"},{"1":"202733_at","2":"LOC101927705 /// P4HA2","_rn_":"202733_at"},{"1":"202740_at","2":"ABHD14A-ACY1 /// ACY1","_rn_":"202740_at"},{"1":"202759_s_at","2":"AKAP2 /// PALM2-AKAP2","_rn_":"202759_s_at"},{"1":"202760_s_at","2":"AKAP2 /// PALM2-AKAP2","_rn_":"202760_s_at"},{"1":"202855_s_at","2":"MIR6787 /// SLC16A3","_rn_":"202855_s_at"},{"1":"202856_s_at","2":"MIR6787 /// SLC16A3","_rn_":"202856_s_at"},{"1":"202861_at","2":"MIR6883 /// PER1","_rn_":"202861_at"},{"1":"202918_s_at","2":"HSPE1-MOB4 /// MOB4","_rn_":"202918_s_at"},{"1":"202929_s_at","2":"DDT /// DDTL","_rn_":"202929_s_at"},{"1":"202938_x_at","2":"RRP7A /// RRP7B","_rn_":"202938_x_at"},{"1":"202961_s_at","2":"ARMC2-AS1 /// ATP5J2","_rn_":"202961_s_at"},{"1":"202982_s_at","2":"ACOT1 /// ACOT2","_rn_":"202982_s_at"},{"1":"203034_s_at","2":"RPL27A /// SNORA45A","_rn_":"203034_s_at"},{"1":"203055_s_at","2":"ARHGEF1 /// LOC100505585","_rn_":"203055_s_at"},{"1":"203071_at","2":"MIR6872 /// SEMA3B","_rn_":"203071_at"},{"1":"203074_at","2":"ANXA8 /// ANXA8L1","_rn_":"203074_at"},{"1":"203107_x_at","2":"RPS2 /// SNORA64","_rn_":"203107_x_at"},{"1":"203112_s_at","2":"MIR943 /// NELFA","_rn_":"203112_s_at"},{"1":"203189_s_at","2":"MIR4691 /// MIR7113 /// NDUFS8","_rn_":"203189_s_at"},{"1":"203190_at","2":"MIR4691 /// MIR7113 /// NDUFS8","_rn_":"203190_at"},{"1":"203274_at","2":"F8A1 /// F8A2 /// F8A3","_rn_":"203274_at"},{"1":"203281_s_at","2":"MIR5193 /// UBA7","_rn_":"203281_s_at"},{"1":"203359_s_at","2":"GJA9-MYCBP /// MYCBP","_rn_":"203359_s_at"},{"1":"203360_s_at","2":"GJA9 /// GJA9-MYCBP /// MYCBP","_rn_":"203360_s_at"},{"1":"203361_s_at","2":"GJA9-MYCBP /// MYCBP","_rn_":"203361_s_at"},{"1":"203399_x_at","2":"PSG11 /// PSG3","_rn_":"203399_x_at"},{"1":"203433_at","2":"MTHFS /// ST20-MTHFS","_rn_":"203433_at"},{"1":"203463_s_at","2":"EPN2 /// EPN2-IT1","_rn_":"203463_s_at"},{"1":"203464_s_at","2":"EPN2 /// EPN2-IT1","_rn_":"203464_s_at"},{"1":"203507_at","2":"CD68 /// LOC101928634 /// SNORA67","_rn_":"203507_at"},{"1":"203581_at","2":"RAB4A /// SPHAR","_rn_":"203581_at"},{"1":"203582_s_at","2":"RAB4A /// SPHAR","_rn_":"203582_s_at"},{"1":"203614_at","2":"ALG11 /// UTP14C","_rn_":"203614_at"},{"1":"203670_at","2":"ARPC4 /// ARPC4-TTLL3 /// TTLL3","_rn_":"203670_at"},{"1":"203707_at","2":"LINC00921 /// ZNF263","_rn_":"203707_at"},{"1":"203742_s_at","2":"LOC732360 /// TDG","_rn_":"203742_s_at"},{"1":"203799_at","2":"CD302 /// LY75 /// LY75-CD302","_rn_":"203799_at"},{"1":"203807_x_at","2":"CSH1 /// CSH2 /// CSHL1 /// GH1","_rn_":"203807_x_at"},{"1":"203852_s_at","2":"SMN1 /// SMN2","_rn_":"203852_s_at"},{"1":"203857_s_at","2":"MIR7110 /// PDIA5","_rn_":"203857_s_at"},{"1":"203880_at","2":"COX17 /// POPDC2","_rn_":"203880_at"},{"1":"203890_s_at","2":"DAPK3 /// MIR637","_rn_":"203890_s_at"},{"1":"203891_s_at","2":"DAPK3 /// MIR637","_rn_":"203891_s_at"},{"1":"203986_at","2":"FAM47E /// FAM47E-STBD1 /// STBD1","_rn_":"203986_at"},{"1":"203993_x_at","2":"AP001062.7 /// C21orf2","_rn_":"203993_x_at"},{"1":"204006_s_at","2":"FCGR3A /// FCGR3B","_rn_":"204006_s_at"},{"1":"204018_x_at","2":"HBA1 /// HBA2","_rn_":"204018_x_at"},{"1":"204030_s_at","2":"IQCJ-SCHIP1 /// SCHIP1","_rn_":"204030_s_at"},{"1":"204060_s_at","2":"PRKX /// PRKY","_rn_":"204060_s_at"},{"1":"204132_s_at","2":"FOXO3 /// FOXO3B","_rn_":"204132_s_at"},{"1":"204145_at","2":"FRG1 /// LOC100289097 /// LOC101930278 /// LOC101930531","_rn_":"204145_at"},{"1":"204148_s_at","2":"POMZP3 /// ZP3","_rn_":"204148_s_at"},{"1":"204317_at","2":"GTSE1 /// TRMU","_rn_":"204317_at"},{"1":"204323_x_at","2":"LOC101930150 /// NF1","_rn_":"204323_x_at"},{"1":"204325_s_at","2":"LOC101930150 /// NF1","_rn_":"204325_s_at"},{"1":"204347_at","2":"AK4 /// LOC100507855","_rn_":"204347_at"},{"1":"204348_s_at","2":"AK4 /// LOC100507855","_rn_":"204348_s_at"},{"1":"204358_s_at","2":"FLRT2 /// LOC100506718","_rn_":"204358_s_at"},{"1":"204359_at","2":"FLRT2 /// LOC100506718","_rn_":"204359_at"},{"1":"204383_at","2":"DGCR14 /// TSSK2","_rn_":"204383_at"},{"1":"204403_x_at","2":"FAM115A /// LOC100294033","_rn_":"204403_x_at"},{"1":"204419_x_at","2":"HBG1 /// HBG2","_rn_":"204419_x_at"},{"1":"204486_at","2":"KCNQ1OT1 /// LOC101927338","_rn_":"204486_at"},{"1":"204524_at","2":"LOC101060747 /// PDPK1","_rn_":"204524_at"},{"1":"204532_x_at","2":"UGT1A1 /// UGT1A10 /// UGT1A4 /// UGT1A6 /// UGT1A8 /// UGT1A9","_rn_":"204532_x_at"},{"1":"204534_at","2":"SEBOX /// VTN","_rn_":"204534_at"},{"1":"204537_s_at","2":"GABRE /// MIR224 /// MIR452","_rn_":"204537_s_at"},{"1":"204561_x_at","2":"APOC2 /// APOC4 /// APOC4-APOC2","_rn_":"204561_x_at"},{"1":"204650_s_at","2":"APBB3 /// MIR6831","_rn_":"204650_s_at"},{"1":"204670_x_at","2":"HLA-DRB1 /// HLA-DRB4 /// LOC100996809","_rn_":"204670_x_at"},{"1":"204692_at","2":"LRCH4 /// SAP25","_rn_":"204692_at"},{"1":"204737_s_at","2":"MYH6 /// MYH7","_rn_":"204737_s_at"},{"1":"204760_s_at","2":"NR1D1 /// THRA","_rn_":"204760_s_at"},{"1":"204761_at","2":"USP6NL /// USP6NL-IT1","_rn_":"204761_at"},{"1":"204764_at","2":"CHURC1-FNTB /// FNTB","_rn_":"204764_at"},{"1":"204820_s_at","2":"BTN3A2 /// BTN3A3","_rn_":"204820_s_at"},{"1":"204848_x_at","2":"HBG1 /// HBG2","_rn_":"204848_x_at"},{"1":"204907_s_at","2":"BCL3 /// MIR8085","_rn_":"204907_s_at"},{"1":"204908_s_at","2":"BCL3 /// MIR8085","_rn_":"204908_s_at"},{"1":"204919_at","2":"PRH1-PRR4 /// PRR4","_rn_":"204919_at"},{"1":"204961_s_at","2":"NCF1 /// NCF1B /// NCF1C","_rn_":"204961_s_at"},{"1":"204962_s_at","2":"CENPA /// SLC35F6","_rn_":"204962_s_at"},{"1":"205013_s_at","2":"ADORA2A /// SPECC1L-ADORA2A","_rn_":"205013_s_at"},{"1":"205033_s_at","2":"DEFA1 /// DEFA1B /// DEFA3","_rn_":"205033_s_at"},{"1":"205041_s_at","2":"ORM1 /// ORM2","_rn_":"205041_s_at"},{"1":"205106_at","2":"CMC4 /// MTCP1","_rn_":"205106_at"},{"1":"205109_s_at","2":"ARHGEF4 /// LOC101930241","_rn_":"205109_s_at"},{"1":"205114_s_at","2":"CCL3 /// CCL3L1 /// CCL3L3","_rn_":"205114_s_at"},{"1":"205122_at","2":"MSANTD3-TMEFF1 /// TMEFF1","_rn_":"205122_at"},{"1":"205123_s_at","2":"MSANTD3-TMEFF1 /// TMEFF1","_rn_":"205123_s_at"},{"1":"205124_at","2":"MEF2B /// MEF2BNB /// MEF2BNB-MEF2B","_rn_":"205124_at"},{"1":"205157_s_at","2":"JUP /// KRT17","_rn_":"205157_s_at"},{"1":"205200_at","2":"CLEC3B /// EXOSC7","_rn_":"205200_at"},{"1":"205265_s_at","2":"LOC100996693 /// SPEG","_rn_":"205265_s_at"},{"1":"205267_at","2":"LOC101928620 /// POU2AF1","_rn_":"205267_at"},{"1":"205272_s_at","2":"PRH1 /// PRH1-PRR4 /// PRH2","_rn_":"205272_s_at"},{"1":"205347_s_at","2":"TMSB15A /// TMSB15B","_rn_":"205347_s_at"},{"1":"205387_s_at","2":"CGB /// CGB1 /// CGB5 /// CGB7 /// CGB8","_rn_":"205387_s_at"},{"1":"205392_s_at","2":"CCL14 /// CCL15-CCL14","_rn_":"205392_s_at"},{"1":"205442_at","2":"LOC101928198 /// MFAP3L","_rn_":"205442_at"},{"1":"205557_at","2":"BPI /// LOC149684","_rn_":"205557_at"},{"1":"205611_at","2":"TNFSF12 /// TNFSF12-TNFSF13","_rn_":"205611_at"},{"1":"205616_at","2":"GALNT8 /// KCNA6","_rn_":"205616_at"},{"1":"205717_x_at","2":"PCDHGA1 /// PCDHGA10 /// PCDHGA11 /// PCDHGA12 /// PCDHGA2 /// PCDHGA3 /// PCDHGA4 /// PCDHGA5 /// PCDHGA6 /// PCDHGA7 /// PCDHGA8 /// PCDHGA9 /// PCDHGB1 /// PCDHGB2 /// PCDHGB3 /// PCDHGB4 /// PCDHGB5 /// PCDHGB6 /// PCDHGB7 /// PCDHGC3 /// PCDHGC4 /// PCDHGC5","_rn_":"205717_x_at"},{"1":"205719_s_at","2":"LOC101929036 /// PAH","_rn_":"205719_s_at"},{"1":"205787_x_at","2":"LOC441155 /// ZC3H11A","_rn_":"205787_x_at"},{"1":"205788_s_at","2":"LOC441155 /// ZC3H11A","_rn_":"205788_s_at"},{"1":"205821_at","2":"KLRC4-KLRK1 /// KLRK1","_rn_":"205821_at"},{"1":"205860_x_at","2":"FOLH1 /// FOLH1B","_rn_":"205860_x_at"},{"1":"205869_at","2":"PRSS1 /// PRSS2","_rn_":"205869_at"},{"1":"205871_at","2":"PLGLB1 /// PLGLB2","_rn_":"205871_at"},{"1":"205875_s_at","2":"ATRIP /// TREX1","_rn_":"205875_s_at"},{"1":"205890_s_at","2":"GABBR1 /// UBD","_rn_":"205890_s_at"},{"1":"205905_s_at","2":"MICA /// MICB","_rn_":"205905_s_at"},{"1":"205931_s_at","2":"CREB5 /// LOC401317","_rn_":"205931_s_at"},{"1":"205939_at","2":"CYP3A7 /// CYP3A7-CYP3AP1","_rn_":"205939_at"},{"1":"205967_at","2":"HIST1H4A /// HIST1H4B /// HIST1H4C /// HIST1H4D /// HIST1H4E /// HIST1H4F /// HIST1H4H /// HIST1H4I /// HIST1H4J /// HIST1H4K /// HIST1H4L /// HIST2H4A /// HIST2H4B /// HIST4H4","_rn_":"205967_at"},{"1":"205971_s_at","2":"CTRB1 /// CTRB2","_rn_":"205971_s_at"},{"1":"205980_s_at","2":"ARHGAP8 /// PRR5-ARHGAP8","_rn_":"205980_s_at"},{"1":"206012_at","2":"LEFTY1 /// LEFTY2","_rn_":"206012_at"},{"1":"206042_x_at","2":"SNRPN /// SNURF","_rn_":"206042_x_at"},{"1":"206044_s_at","2":"BRAF /// KIAA1549","_rn_":"206044_s_at"},{"1":"206056_x_at","2":"LOC101929889 /// SPN","_rn_":"206056_x_at"},{"1":"206057_x_at","2":"LOC101929889 /// SPN","_rn_":"206057_x_at"},{"1":"206090_s_at","2":"DISC1 /// TSNAX-DISC1","_rn_":"206090_s_at"},{"1":"206093_x_at","2":"TNXA /// TNXB","_rn_":"206093_x_at"},{"1":"206094_x_at","2":"UGT1A1 /// UGT1A10 /// UGT1A3 /// UGT1A4 /// UGT1A5 /// UGT1A6 /// UGT1A7 /// UGT1A8 /// UGT1A9","_rn_":"206094_x_at"},{"1":"206110_at","2":"HIST1H3A /// HIST1H3B /// HIST1H3C /// HIST1H3D /// HIST1H3E /// HIST1H3F /// HIST1H3G /// HIST1H3H /// HIST1H3I /// HIST1H3J","_rn_":"206110_at"},{"1":"206163_at","2":"MAB21L1 /// MIR548F5","_rn_":"206163_at"},{"1":"206183_s_at","2":"HERC3 /// LOC101929134","_rn_":"206183_s_at"},{"1":"206272_at","2":"RAB4A /// SPHAR","_rn_":"206272_at"},{"1":"206286_s_at","2":"TDGF1 /// TDGF1P3","_rn_":"206286_s_at"},{"1":"206302_s_at","2":"NUDT4 /// NUDT4P1 /// NUDT4P2","_rn_":"206302_s_at"},{"1":"206303_s_at","2":"NUDT4 /// NUDT4P1 /// NUDT4P2","_rn_":"206303_s_at"},{"1":"206318_at","2":"EPPIN /// EPPIN-WFDC6","_rn_":"206318_at"},{"1":"206319_s_at","2":"EPPIN /// EPPIN-WFDC6","_rn_":"206319_s_at"},{"1":"206374_at","2":"DUSP8 /// LOC101927562","_rn_":"206374_at"},{"1":"206397_x_at","2":"CERS1 /// GDF1","_rn_":"206397_x_at"},{"1":"206399_x_at","2":"CACNA1A /// LOC100507353","_rn_":"206399_x_at"},{"1":"206400_at","2":"LGALS7 /// LGALS7B","_rn_":"206400_at"},{"1":"206405_x_at","2":"USP32 /// USP6","_rn_":"206405_x_at"},{"1":"206446_s_at","2":"CELA2A /// CELA2B","_rn_":"206446_s_at"},{"1":"206447_at","2":"CELA2A /// CELA2B","_rn_":"206447_at"},{"1":"206467_x_at","2":"RTEL1-TNFRSF6B /// TNFRSF6B","_rn_":"206467_x_at"},{"1":"206475_x_at","2":"CSH1 /// CSHL1 /// GH1","_rn_":"206475_x_at"},{"1":"206512_at","2":"SRP19 /// ZRSR1","_rn_":"206512_at"},{"1":"206514_s_at","2":"CYP4F2 /// CYP4F3","_rn_":"206514_s_at"},{"1":"206516_at","2":"AMH /// MIR4321","_rn_":"206516_at"},{"1":"206601_s_at","2":"HOXD3 /// HOXD4 /// LOC401021","_rn_":"206601_s_at"},{"1":"206602_s_at","2":"HOXD3 /// HOXD4 /// LOC401021","_rn_":"206602_s_at"},{"1":"206640_x_at","2":"GAGE12B /// GAGE12C /// GAGE12D /// GAGE12E /// GAGE12F /// GAGE12G /// GAGE12H /// GAGE12I /// GAGE2A /// GAGE2C /// GAGE4 /// GAGE5 /// GAGE6 /// GAGE7","_rn_":"206640_x_at"},{"1":"206655_s_at","2":"GP1BB /// SEPT5 /// SEPT5-GP1BB","_rn_":"206655_s_at"},{"1":"206659_at","2":"AC009237.8 /// AK055967","_rn_":"206659_at"},{"1":"206738_at","2":"APOC2 /// APOC4 /// APOC4-APOC2","_rn_":"206738_at"},{"1":"206742_at","2":"FIGF /// PIR-FIGF","_rn_":"206742_at"},{"1":"206754_s_at","2":"CYP2B6 /// CYP2B7P","_rn_":"206754_s_at"},{"1":"206777_s_at","2":"CRYBB2 /// CRYBB2P1","_rn_":"206777_s_at"},{"1":"206785_s_at","2":"KLRC1 /// KLRC2","_rn_":"206785_s_at"},{"1":"206791_s_at","2":"LOC729966 /// PDE4C","_rn_":"206791_s_at"},{"1":"206792_x_at","2":"LOC729966 /// PDE4C","_rn_":"206792_x_at"},{"1":"206809_s_at","2":"HNRNPA3 /// HNRNPA3P1","_rn_":"206809_s_at"},{"1":"206810_at","2":"LOC101060181 /// ZNF44","_rn_":"206810_at"},{"1":"206833_s_at","2":"ACYP2 /// LOC101927144","_rn_":"206833_s_at"},{"1":"206922_at","2":"VCY /// VCY1B","_rn_":"206922_at"},{"1":"206953_s_at","2":"LOC101927458 /// LPHN2","_rn_":"206953_s_at"},{"1":"206955_at","2":"AQP7 /// LOC100509620 /// LOC101930168","_rn_":"206955_at"},{"1":"206956_at","2":"BGLAP /// PMF1 /// PMF1-BGLAP","_rn_":"206956_at"},{"1":"206963_s_at","2":"NAT8 /// NAT8B","_rn_":"206963_s_at"},{"1":"206969_at","2":"KRT34 /// LOC100653049","_rn_":"206969_at"},{"1":"207016_s_at","2":"ALDH1A2 /// LOC101928635","_rn_":"207016_s_at"},{"1":"207046_at","2":"HIST1H4A /// HIST1H4B /// HIST1H4C /// HIST1H4D /// HIST1H4E /// HIST1H4F /// HIST1H4H /// HIST1H4I /// HIST1H4J /// HIST1H4K /// HIST1H4L /// HIST2H4A /// HIST2H4B /// HIST4H4","_rn_":"207046_at"},{"1":"207047_s_at","2":"CLCNKA /// CLCNKB","_rn_":"207047_s_at"},{"1":"207063_at","2":"NCRNA00185 /// TTTY14","_rn_":"207063_at"},{"1":"207086_x_at","2":"GAGE1 /// GAGE12B /// GAGE12C /// GAGE12D /// GAGE12E /// GAGE12F /// GAGE12G /// GAGE12H /// GAGE12I /// GAGE12J /// GAGE13 /// GAGE2A /// GAGE2C /// GAGE2D /// GAGE2E /// GAGE4 /// GAGE5 /// GAGE6 /// GAGE7 /// GAGE8","_rn_":"207086_x_at"},{"1":"207093_s_at","2":"LOC101927057 /// OMG","_rn_":"207093_s_at"},{"1":"207096_at","2":"SAA2-SAA4 /// SAA4","_rn_":"207096_at"},{"1":"207110_at","2":"KCNJ12 /// KCNJ18 /// LOC100996843","_rn_":"207110_at"},{"1":"207118_s_at","2":"MMP23A /// MMP23B","_rn_":"207118_s_at"},{"1":"207126_x_at","2":"UGT1A1 /// UGT1A10 /// UGT1A4 /// UGT1A6 /// UGT1A8 /// UGT1A9","_rn_":"207126_x_at"},{"1":"207131_x_at","2":"GGT1 /// GGT2 /// GGTLC1 /// GGTLC2","_rn_":"207131_x_at"},{"1":"207156_at","2":"HIST1H2AG /// HIST1H2AH /// HIST1H2AI /// HIST1H2AK /// HIST1H2AL /// HIST1H2AM","_rn_":"207156_at"},{"1":"207169_x_at","2":"DDR1 /// MIR4640","_rn_":"207169_x_at"},{"1":"207188_at","2":"CDK3 /// TEN1-CDK3","_rn_":"207188_at"},{"1":"207198_s_at","2":"LIMS1 /// LIMS3L","_rn_":"207198_s_at"},{"1":"207222_at","2":"LOC100652777 /// PLA2G10","_rn_":"207222_at"},{"1":"207243_s_at","2":"CALM1 /// CALM2 /// CALM3","_rn_":"207243_s_at"},{"1":"207247_s_at","2":"ZFX /// ZFY","_rn_":"207247_s_at"},{"1":"207255_at","2":"LEPR /// LEPROT","_rn_":"207255_at"},{"1":"207271_x_at","2":"SPAG11A /// SPAG11B","_rn_":"207271_x_at"},{"1":"207313_x_at","2":"KIR3DL1 /// KIR3DL2","_rn_":"207313_x_at"},{"1":"207314_x_at","2":"KIR3DL1 /// KIR3DL2","_rn_":"207314_x_at"},{"1":"207356_at","2":"DEFB4A /// DEFB4B","_rn_":"207356_at"},{"1":"207414_s_at","2":"LOC100507472 /// PCSK6","_rn_":"207414_s_at"},{"1":"207417_s_at","2":"ZNF177 /// ZNF559-ZNF177","_rn_":"207417_s_at"},{"1":"207428_x_at","2":"CDK11A /// CDK11B","_rn_":"207428_x_at"},{"1":"207434_s_at","2":"FXYD2 /// FXYD6-FXYD2","_rn_":"207434_s_at"},{"1":"207457_s_at","2":"LY6G6D /// LY6G6F","_rn_":"207457_s_at"},{"1":"207489_at","2":"RPS2P45 /// RPS2P45","_rn_":"207489_at"},{"1":"207493_x_at","2":"SSX2 /// SSX2B","_rn_":"207493_x_at"},{"1":"207498_s_at","2":"CYP2D6 /// CYP2D7P /// LOC101929829","_rn_":"207498_s_at"},{"1":"207524_at","2":"MIR6132 /// ST7 /// ST7-OT3","_rn_":"207524_at"},{"1":"207545_s_at","2":"LOC101928143 /// LOC101930388 /// NUMB","_rn_":"207545_s_at"},{"1":"207548_at","2":"GRM7 /// LOC100996542","_rn_":"207548_at"},{"1":"207561_s_at","2":"ABCB8 /// ASIC3","_rn_":"207561_s_at"},{"1":"207646_s_at","2":"CDY1 /// CDY1B /// CDY2A /// CDY2B","_rn_":"207646_s_at"},{"1":"207667_s_at","2":"LOC100996792 /// MAP2K3","_rn_":"207667_s_at"},{"1":"207719_x_at","2":"CEP170 /// CEP170P1","_rn_":"207719_x_at"},{"1":"207739_s_at","2":"GAGE1 /// GAGE12B /// GAGE12C /// GAGE12D /// GAGE12E /// GAGE12F /// GAGE12G /// GAGE12H /// GAGE12I /// GAGE12J /// GAGE13 /// GAGE2A /// GAGE2B /// GAGE2C /// GAGE2D /// GAGE2E /// GAGE3 /// GAGE4 /// GAGE5 /// GAGE6 /// GAGE7 /// GAGE8","_rn_":"207739_s_at"},{"1":"207748_at","2":"DUTP1 /// DUTP1","_rn_":"207748_at"},{"1":"207750_at","2":"EPS15P1 /// EPS15P1","_rn_":"207750_at"},{"1":"207759_s_at","2":"DISC1 /// TSNAX-DISC1","_rn_":"207759_s_at"},{"1":"207770_x_at","2":"CSH1 /// CSH2","_rn_":"207770_x_at"},{"1":"207777_s_at","2":"LOC101928789 /// SP140","_rn_":"207777_s_at"},{"1":"207842_s_at","2":"CASC3 /// MIR6866","_rn_":"207842_s_at"},{"1":"207856_s_at","2":"LOC150776 /// SMPD4","_rn_":"207856_s_at"},{"1":"207871_s_at","2":"MIR6132 /// ST7 /// ST7-OT3","_rn_":"207871_s_at"},{"1":"207891_s_at","2":"HAUS7 /// TREX2","_rn_":"207891_s_at"},{"1":"207909_x_at","2":"DAZ1 /// DAZ2 /// DAZ3 /// DAZ4","_rn_":"207909_x_at"},{"1":"207912_s_at","2":"DAZ1 /// DAZ2 /// DAZ3 /// DAZ4","_rn_":"207912_s_at"},{"1":"207915_at","2":"MYCLP1 /// MYCLP1","_rn_":"207915_at"},{"1":"207916_at","2":"AC009947.3 /// RBMY2AP /// RBMY2AP /// RBMY2BP /// RBMY2BP /// RBMY2DP /// RBMY2DP","_rn_":"207916_at"},{"1":"207918_s_at","2":"TSPY1 /// TSPY10 /// TSPY3 /// TSPY4 /// TSPY8","_rn_":"207918_s_at"},{"1":"207922_s_at","2":"LOC101928676 /// MAEA","_rn_":"207922_s_at"},{"1":"207958_at","2":"UGT2A1 /// UGT2A2","_rn_":"207958_at"},{"1":"207979_s_at","2":"CD8B /// LOC100996919","_rn_":"207979_s_at"},{"1":"208015_at","2":"BC069804 /// SMAD1","_rn_":"208015_at"},{"1":"208024_s_at","2":"DGCR6 /// DGCR6L","_rn_":"208024_s_at"},{"1":"208026_at","2":"HIST1H4F /// HIST1H4G","_rn_":"208026_at"},{"1":"208068_x_at","2":"CSH1 /// CSHL1 /// GH1 /// GH2","_rn_":"208068_x_at"},{"1":"208069_x_at","2":"CSH1 /// CSHL1 /// GH1 /// GH2","_rn_":"208069_x_at"},{"1":"208073_x_at","2":"TTC3 /// TTC3P1","_rn_":"208073_x_at"},{"1":"208082_x_at","2":"MKRN4P /// MKRN4P","_rn_":"208082_x_at"},{"1":"208083_s_at","2":"ITGB6 /// LOC100505984","_rn_":"208083_s_at"},{"1":"208084_at","2":"ITGB6 /// LOC100505984","_rn_":"208084_at"},{"1":"208098_at","2":"OR12D3 /// OR5V1","_rn_":"208098_at"},{"1":"208118_x_at","2":"LOC101060604 /// SLC7A5P1 /// SLC7A5P2 /// SMG1P3","_rn_":"208118_x_at"},{"1":"208129_x_at","2":"LOC100506403 /// LOC101928269 /// RUNX1","_rn_":"208129_x_at"},{"1":"208155_x_at","2":"GAGE1 /// GAGE12B /// GAGE12C /// GAGE12D /// GAGE12E /// GAGE12F /// GAGE12G /// GAGE12H /// GAGE12I /// GAGE12J /// GAGE13 /// GAGE2D /// GAGE4 /// GAGE5 /// GAGE6 /// GAGE7","_rn_":"208155_x_at"},{"1":"208181_at","2":"HIST1H4A /// HIST1H4B /// HIST1H4C /// HIST1H4D /// HIST1H4E /// HIST1H4F /// HIST1H4H /// HIST1H4I /// HIST1H4J /// HIST1H4K /// HIST1H4L /// HIST2H4A /// HIST2H4B /// HIST4H4","_rn_":"208181_at"},{"1":"208184_s_at","2":"LOC102724200 /// TRAPPC10","_rn_":"208184_s_at"},{"1":"208201_at","2":"DBET /// DUX3 /// DUX4 /// DUX4L1 /// DUX4L2 /// DUX4L24 /// DUX4L3 /// DUX4L4 /// DUX4L5 /// DUX4L6 /// DUX4L7 /// DUX4L8 /// LOC100133400 /// LOC100287823 /// LOC100288289 /// LOC100291626 /// LOC652301","_rn_":"208201_at"},{"1":"208235_x_at","2":"GAGE12B /// GAGE12F /// GAGE12G /// GAGE12I /// GAGE4 /// GAGE5 /// GAGE6 /// GAGE7","_rn_":"208235_x_at"},{"1":"208273_at","2":"ZNF670 /// ZNF670-ZNF695 /// ZNF695","_rn_":"208273_at"},{"1":"208281_x_at","2":"DAZ1 /// DAZ2 /// DAZ3 /// DAZ4","_rn_":"208281_x_at"},{"1":"208282_x_at","2":"DAZ1 /// DAZ2 /// DAZ3 /// DAZ4","_rn_":"208282_x_at"},{"1":"208284_x_at","2":"GGT1 /// GGT2 /// GGTLC1 /// GGTLC2","_rn_":"208284_x_at"},{"1":"208286_x_at","2":"POU5F1 /// POU5F1B /// POU5F1P3 /// POU5F1P4","_rn_":"208286_x_at"},{"1":"208306_x_at","2":"HLA-DRB1 /// HLA-DRB1","_rn_":"208306_x_at"},{"1":"208307_at","2":"RBMY1A1 /// RBMY1B /// RBMY1D /// RBMY1E /// RBMY1F /// RBMY1J","_rn_":"208307_at"},{"1":"208310_s_at","2":"CCZ1 /// CCZ1B","_rn_":"208310_s_at"},{"1":"208312_s_at","2":"PRAMEF1 /// PRAMEF2","_rn_":"208312_s_at"},{"1":"208332_at","2":"LOC100509646 /// PRY /// PRY2","_rn_":"208332_at"},{"1":"208339_at","2":"XKRY /// XKRY2","_rn_":"208339_at"},{"1":"208341_x_at","2":"CSH1 /// CSH2","_rn_":"208341_x_at"},{"1":"208342_x_at","2":"CSH1 /// CSH2","_rn_":"208342_x_at"},{"1":"208344_x_at","2":"IFNA1 /// IFNA13","_rn_":"208344_x_at"},{"1":"208347_at","2":"HMGN2P9 /// HMGN2P9","_rn_":"208347_at"},{"1":"208356_x_at","2":"CSH1 /// CSHL1 /// GH1","_rn_":"208356_x_at"},{"1":"208407_s_at","2":"CTNND1 /// TMX2-CTNND1","_rn_":"208407_s_at"},{"1":"208409_at","2":"LOC101930602 /// SLC14A2","_rn_":"208409_at"},{"1":"208451_s_at","2":"C4A /// C4B /// C4B_2","_rn_":"208451_s_at"},{"1":"208469_s_at","2":"EGFL8 /// PPT2 /// PPT2-EGFL8","_rn_":"208469_s_at"},{"1":"208470_s_at","2":"HP /// HPR","_rn_":"208470_s_at"},{"1":"208480_s_at","2":"ABCC6 /// LOC101930322","_rn_":"208480_s_at"},{"1":"208490_x_at","2":"HIST1H2BC /// HIST1H2BE /// HIST1H2BF /// HIST1H2BG /// HIST1H2BI","_rn_":"208490_x_at"},{"1":"208498_s_at","2":"ACTG1P4 /// AMY1A /// AMY1B /// AMY1C /// AMY2A /// AMY2B","_rn_":"208498_s_at"},{"1":"208523_x_at","2":"HIST1H2BC /// HIST1H2BE /// HIST1H2BF /// HIST1H2BG /// HIST1H2BI","_rn_":"208523_x_at"},{"1":"208525_s_at","2":"OR2F1 /// OR2F2","_rn_":"208525_s_at"},{"1":"208528_x_at","2":"SSX3 /// SSX5 /// SSX7","_rn_":"208528_x_at"},{"1":"208534_s_at","2":"LOC102725198 /// RASA4 /// RASA4B /// RASA4CP","_rn_":"208534_s_at"},{"1":"208540_x_at","2":"S100A11P1 /// S100A11P1","_rn_":"208540_x_at"},{"1":"208542_x_at","2":"ZNF208 /// ZNF595 /// ZNF718","_rn_":"208542_x_at"},{"1":"208548_at","2":"IFNA5 /// IFNA6","_rn_":"208548_at"},{"1":"208567_s_at","2":"KCNJ12 /// KCNJ18 /// LOC100996843","_rn_":"208567_s_at"},{"1":"208580_x_at","2":"HIST1H4A /// HIST1H4B /// HIST1H4C /// HIST1H4D /// HIST1H4E /// HIST1H4F /// HIST1H4H /// HIST1H4I /// HIST1H4J /// HIST1H4K /// HIST1H4L /// HIST2H4A /// HIST2H4B /// HIST4H4","_rn_":"208580_x_at"},{"1":"208582_s_at","2":"DUX1 /// DUX3 /// DUX5","_rn_":"208582_s_at"},{"1":"208586_s_at","2":"SSX4 /// SSX4B","_rn_":"208586_s_at"},{"1":"208587_s_at","2":"OR1E1 /// OR1E2","_rn_":"208587_s_at"},{"1":"208596_s_at","2":"UGT1A1 /// UGT1A10 /// UGT1A3 /// UGT1A4 /// UGT1A5 /// UGT1A6 /// UGT1A7 /// UGT1A8 /// UGT1A9","_rn_":"208596_s_at"},{"1":"208607_s_at","2":"SAA1 /// SAA2 /// SAA2-SAA4","_rn_":"208607_s_at"},{"1":"208609_s_at","2":"TNXA /// TNXB","_rn_":"208609_s_at"},{"1":"208661_s_at","2":"TTC3 /// TTC3P1","_rn_":"208661_s_at"},{"1":"208662_s_at","2":"TTC3 /// TTC3P1","_rn_":"208662_s_at"},{"1":"208663_s_at","2":"TTC3 /// TTC3P1","_rn_":"208663_s_at"},{"1":"208664_s_at","2":"TTC3 /// TTC3P1","_rn_":"208664_s_at"},{"1":"208687_x_at","2":"HSPA8 /// SNORD14C /// SNORD14D","_rn_":"208687_x_at"},{"1":"208738_x_at","2":"LOC101929087 /// SUMO2 /// SUMO3","_rn_":"208738_x_at"},{"1":"208739_x_at","2":"LOC101929087 /// SUMO2 /// SUMO3","_rn_":"208739_x_at"},{"1":"208750_s_at","2":"ARF1 /// MIR3620","_rn_":"208750_s_at"},{"1":"208755_x_at","2":"H3F3A /// H3F3AP4 /// H3F3B","_rn_":"208755_x_at"},{"1":"208771_s_at","2":"LOC101928830 /// LTA4H","_rn_":"208771_s_at"},{"1":"208772_at","2":"ANKHD1 /// ANKHD1-EIF4EBP3","_rn_":"208772_at"},{"1":"208773_s_at","2":"ANKHD1 /// ANKHD1-EIF4EBP3","_rn_":"208773_s_at"},{"1":"208778_s_at","2":"SNORA29 /// TCP1","_rn_":"208778_s_at"},{"1":"208779_x_at","2":"DDR1 /// MIR4640","_rn_":"208779_x_at"},{"1":"208805_at","2":"KIAA0391 /// PSMA6","_rn_":"208805_at"},{"1":"208810_at","2":"DNAJB6 /// TMEM135","_rn_":"208810_at"},{"1":"208811_s_at","2":"DNAJB6 /// TMEM135","_rn_":"208811_s_at"},{"1":"208825_x_at","2":"RPL23A /// SNORD42A","_rn_":"208825_x_at"},{"1":"208834_x_at","2":"RPL23A /// SNORD42A","_rn_":"208834_x_at"},{"1":"208862_s_at","2":"CTNND1 /// TMX2-CTNND1","_rn_":"208862_s_at"},{"1":"208906_at","2":"BSCL2 /// HNRNPUL2-BSCL2","_rn_":"208906_at"},{"1":"208929_x_at","2":"RPL13 /// SNORD68","_rn_":"208929_x_at"},{"1":"208962_s_at","2":"FADS1 /// MIR1908","_rn_":"208962_s_at"},{"1":"208963_x_at","2":"FADS1 /// MIR1908","_rn_":"208963_x_at"},{"1":"208964_s_at","2":"FADS1 /// MIR1908","_rn_":"208964_s_at"},{"1":"209006_s_at","2":"LOC101928189 /// RSRP1","_rn_":"209006_s_at"},{"1":"209007_s_at","2":"LOC101928189 /// RSRP1","_rn_":"209007_s_at"},{"1":"209069_s_at","2":"H3F3A /// H3F3B /// MIR4738","_rn_":"209069_s_at"},{"1":"209073_s_at","2":"LOC101928143 /// LOC101930388 /// NUMB","_rn_":"209073_s_at"},{"1":"209079_x_at","2":"PCDHGA1 /// PCDHGA10 /// PCDHGA11 /// PCDHGA12 /// PCDHGA2 /// PCDHGA3 /// PCDHGA4 /// PCDHGA5 /// PCDHGA6 /// PCDHGA7 /// PCDHGA8 /// PCDHGA9 /// PCDHGB1 /// PCDHGB2 /// PCDHGB3 /// PCDHGB4 /// PCDHGB5 /// PCDHGB6 /// PCDHGB7 /// PCDHGC3 /// PCDHGC4 /// PCDHGC5","_rn_":"209079_x_at"},{"1":"209086_x_at","2":"MCAM /// MIR6756","_rn_":"209086_x_at"},{"1":"209093_s_at","2":"GBA /// GBAP1","_rn_":"209093_s_at"},{"1":"209111_at","2":"RNF5 /// RNF5P1","_rn_":"209111_at"},{"1":"209150_s_at","2":"IPO4 /// TM9SF1","_rn_":"209150_s_at"},{"1":"209154_at","2":"P2RX5-TAX1BP3 /// TAX1BP3","_rn_":"209154_at"},{"1":"209181_s_at","2":"RABGGTB /// SNORD45A /// SNORD45B /// SNORD45C","_rn_":"209181_s_at"},{"1":"209206_at","2":"LOC102724364 /// SEC22B","_rn_":"209206_at"},{"1":"209207_s_at","2":"LOC100996517 /// LOC102724364 /// SEC22B","_rn_":"209207_s_at"},{"1":"209219_at","2":"MIR1236 /// NELFE","_rn_":"209219_at"},{"1":"209312_x_at","2":"HLA-DQB1 /// HLA-DRB1 /// HLA-DRB4 /// HLA-DRB5 /// LOC100996809 /// LOC101060835","_rn_":"209312_x_at"},{"1":"209359_x_at","2":"LOC100506403 /// LOC101928269 /// RUNX1","_rn_":"209359_x_at"},{"1":"209360_s_at","2":"LOC100506403 /// LOC101928269 /// RUNX1","_rn_":"209360_s_at"},{"1":"209362_at","2":"LOC101928625 /// MED21","_rn_":"209362_at"},{"1":"209363_s_at","2":"LOC101928625 /// MED21","_rn_":"209363_s_at"},{"1":"209372_x_at","2":"TUBB2A /// TUBB2B","_rn_":"209372_x_at"},{"1":"209403_at","2":"LOC101060321 /// LOC101060351 /// LOC101060376 /// LOC101060389 /// LOC102723859 /// LOC102724862 /// TBC1D3 /// TBC1D3C /// TBC1D3F /// TBC1D3H","_rn_":"209403_at"},{"1":"209404_s_at","2":"TMED7 /// TMED7-TICAM2","_rn_":"209404_s_at"},{"1":"209412_at","2":"LOC102724200 /// TRAPPC10","_rn_":"209412_at"},{"1":"209424_s_at","2":"AMACR /// C1QTNF3-AMACR","_rn_":"209424_s_at"},{"1":"209425_at","2":"AMACR /// C1QTNF3-AMACR","_rn_":"209425_at"},{"1":"209426_s_at","2":"AMACR /// C1QTNF3-AMACR","_rn_":"209426_s_at"},{"1":"209458_x_at","2":"HBA1 /// HBA2","_rn_":"209458_x_at"},{"1":"209475_at","2":"MIR6125 /// USP15","_rn_":"209475_at"},{"1":"209490_s_at","2":"EGFL8 /// PPT2","_rn_":"209490_s_at"},{"1":"209491_s_at","2":"AMPD3 /// CAND1.11","_rn_":"209491_s_at"},{"1":"209499_x_at","2":"TNFSF12-TNFSF13 /// TNFSF13","_rn_":"209499_x_at"},{"1":"209500_x_at","2":"TNFSF12-TNFSF13 /// TNFSF13","_rn_":"209500_x_at"},{"1":"209501_at","2":"CDR2 /// LOC101060399","_rn_":"209501_at"},{"1":"209506_s_at","2":"NR2F1 /// NR2F2","_rn_":"209506_s_at"},{"1":"209563_x_at","2":"CALM1 /// CALM2 /// CALM3","_rn_":"209563_x_at"},{"1":"209607_x_at","2":"LOC101929857 /// SLX1A-SULT1A3 /// SLX1B-SULT1A4 /// SULT1A3 /// SULT1A4","_rn_":"209607_x_at"},{"1":"209616_s_at","2":"CES1 /// LOC100653057","_rn_":"209616_s_at"},{"1":"209631_s_at","2":"GPR37 /// SEL1L2","_rn_":"209631_s_at"},{"1":"209697_at","2":"AK125860 /// RP11-582J16.4","_rn_":"209697_at"},{"1":"209699_x_at","2":"AKR1C2 /// LOC101930400","_rn_":"209699_x_at"},{"1":"209751_s_at","2":"TRAPPC2 /// TRAPPC2P1","_rn_":"209751_s_at"},{"1":"209767_s_at","2":"GP1BB /// SEPT5 /// SEPT5-GP1BB","_rn_":"209767_s_at"},{"1":"209776_s_at","2":"LOC101928717 /// SLC19A1","_rn_":"209776_s_at"},{"1":"209777_s_at","2":"LOC101928717 /// SLC19A1","_rn_":"209777_s_at"},{"1":"209805_at","2":"PMS2 /// PMS2CL","_rn_":"209805_at"},{"1":"209813_x_at","2":"TARP /// TRGC2 /// TRGV9","_rn_":"209813_x_at"},{"1":"209823_x_at","2":"HLA-DQB1 /// LOC101060835","_rn_":"209823_x_at"},{"1":"209825_s_at","2":"MIR3658 /// UCK2","_rn_":"209825_s_at"},{"1":"209826_at","2":"EGFL8 /// PPT2 /// PPT2-EGFL8","_rn_":"209826_at"},{"1":"209836_x_at","2":"BOLA2 /// BOLA2B","_rn_":"209836_x_at"},{"1":"209894_at","2":"LEPR /// LEPROT","_rn_":"209894_at"},{"1":"209905_at","2":"HOXA10-HOXA9 /// HOXA9 /// MIR196B","_rn_":"209905_at"},{"1":"209912_s_at","2":"AP5Z1 /// MIR4656","_rn_":"209912_s_at"},{"1":"209913_x_at","2":"AP5Z1 /// MIR4656","_rn_":"209913_x_at"},{"1":"209919_x_at","2":"GGT1 /// GGT2 /// GGTLC1 /// GGTLC2","_rn_":"209919_x_at"},{"1":"209931_s_at","2":"FKBP1B /// MFSD2B","_rn_":"209931_s_at"},{"1":"209942_x_at","2":"MAGEA3 /// MAGEA6","_rn_":"209942_x_at"},{"1":"209944_at","2":"PTGR2 /// ZNF410","_rn_":"209944_at"},{"1":"209978_s_at","2":"LPA /// PLG","_rn_":"209978_s_at"}],"options":{"columns":{"min":{},"max":[10],"total":[2]},"rows":{"min":[10],"max":[10],"total":[2796]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>grabbing genes missing from microarray set so far that have names hidden in the multiple name structure</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>probe_name &lt;- list() #vector(mode=&quot;character&quot;)
for(i in seq(1, length(miss_genes))){
  tname &lt;- miss_genes[i]
  probe_name[[tname]] &lt;- genes2fix %&gt;% 
    filter(grepl(pattern = paste0(&quot;(\\s&quot;,tname,&quot;)|(&quot;,tname,&quot;\\s)&quot;), `Gene Symbol`)) %&gt;% pull(ID)
    # str_match(genes2fix$`Gene Symbol`, pattern=paste0(&quot;(\\s&quot;,i,&quot;)|(&quot;,i,&quot;\\s)&quot;))[,2] %&gt;% str_trim()
  # names(probe_name[[]]) &lt;- i
}</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>making dataframe out of list</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxucHJvYmVfbmFtZXNfZGYgPC0gc3RhY2socHJvYmVfbmFtZSkgJT4lIFxuICBzZWxlY3QoZ2VuZV9uYW1lPWluZCwgcHJvYmVfSUQ9dmFsdWVzKVxuYGBgIn0= -->
<pre class="r"><code>probe_names_df &lt;- stack(probe_name) %&gt;% 
  select(gene_name=ind, probe_ID=values)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>number of unique genes recovered</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxucHJvYmVfbmFtZXNfZGYgJT4lIGRpc3RpbmN0KGdlbmVfbmFtZSkgJT4lIGRpbSgpXG5gYGAifQ== -->
<pre class="r"><code>probe_names_df %&gt;% distinct(gene_name) %&gt;% dim()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDE3MSAgIDFcbiJ9 -->
<pre><code>[1] 171   1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuMjU1LTE3MVxuYGBgIn0= -->
<pre class="r"><code>255-171</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDg0XG4ifQ== -->
<pre><code>[1] 84</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>now there are only 84 genes with no probes in the microarray gene expression data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxubm90aW5fbWljcm9hIDwtIG5hbWVzKHByb2JlX25hbWVbbGFwcGx5KHByb2JlX25hbWUsbGVuZ3RoKT09MF0pXG5ub3Rpbl9taWNyb2FcbmBgYCJ9 -->
<pre class="r"><code>notin_microa &lt;- names(probe_name[lapply(probe_name,length)==0])
notin_microa</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code> [1] &quot;JHDM1D&quot;         &quot;PHF15&quot;          &quot;PHF17&quot;          &quot;DKFZP761J1410&quot;  &quot;C10orf137&quot;      &quot;ZNF259&quot;        
 [7] &quot;SF3B14&quot;         &quot;RAB7L1&quot;         &quot;C1orf63&quot;        &quot;MTERFD3&quot;        &quot;MTERFD2&quot;        &quot;C12orf44&quot;      
[13] &quot;MTERF&quot;          &quot;NARG2&quot;          &quot;TMEM66&quot;         &quot;ANKRD42&quot;        &quot;C4orf21&quot;        &quot;C12orf52&quot;      
[19] &quot;AZI1&quot;           &quot;hsa-mir-1199&quot;   &quot;MMS22L&quot;         &quot;NAPRT1&quot;         &quot;C12orf23&quot;       &quot;MLF1IP&quot;        
[25] &quot;ZNF773&quot;         &quot;C17orf103&quot;      &quot;FAM105B&quot;        &quot;MKI67IP&quot;        &quot;ACPL2&quot;          &quot;MTERFD1&quot;       
[31] &quot;SELRC1&quot;         &quot;KIAA0947&quot;       &quot;PRMT10&quot;         &quot;C10orf118&quot;      &quot;C19orf55&quot;       &quot;RP11-231C14.4&quot; 
[37] &quot;TAS1R3&quot;         &quot;MRP63&quot;          &quot;CCDC41&quot;         &quot;RP11-1407O15.2&quot; &quot;AGAP8&quot;          &quot;PIDD&quot;          
[43] &quot;C7orf41&quot;        &quot;RPS17L&quot;         &quot;LSMD1&quot;          &quot;AC138969.4&quot;     &quot;C11orf35&quot;       &quot;AP003068.6&quot;    
[49] &quot;VMAC&quot;           &quot;RINL&quot;           &quot;CTD-2228K2.5&quot;   &quot;NUGGC&quot;          &quot;RP11-113D6.10&quot;  &quot;GPR89C&quot;        
[55] &quot;ZNF181&quot;         &quot;KIAA1737&quot;       &quot;FBXO48&quot;         &quot;FLJ00104&quot;       &quot;AL590867.1&quot;     &quot;C19orf38&quot;      
[61] &quot;SPDYE3&quot;         &quot;AL162389.1&quot;     &quot;AC009403.2&quot;     &quot;AC007390.5&quot;     &quot;RPA3-AS1&quot;       &quot;GLTPD1&quot;        
[67] &quot;RP4-758J18.2&quot;   &quot;RP11-47I22.3&quot;   &quot;RP11-1212A22.4&quot; &quot;WASH4P&quot;         &quot;AC015987.2&quot;     &quot;RP11-295P9.3&quot;  
[73] &quot;RP5-966M1.6&quot;    &quot;CTC-534A2.2&quot;    &quot;AP001816.1&quot;     &quot;RP11-286N22.8&quot;  &quot;GOLGA8S&quot;        &quot;RP11-345J4.5&quot;  
[79] &quot;CTC-479C5.12&quot;   &quot;AC137932.1&quot;     &quot;AC008443.1&quot;     &quot;AL591479.1&quot;     &quot;AC040977.1&quot;     &quot;RP11-574K11.31&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>checked many of the genes (esp those with real looking names) and only these looked like I need to deal with them:</p>
<p>this one is the same gene (listed as alias, same entrez gene id)<br />
MTERF==MTERF1<br />
<a href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=MTERF1&amp;keywords=MTERF" class="uri">https://www.genecards.org/cgi-bin/carddisp.pl?gene=MTERF1&amp;keywords=MTERF</a></p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgXG4gIGZpbHRlcihncmVwbChcIk1URVJGXCIsIGBHZW5lIFN5bWJvbGApKSAlPiUgXG4gIHNlbGVjdChJRCwgYEdlbmUgU3ltYm9sYCwgRU5UUkVaX0dFTkVfSUQpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_features %&gt;% 
  filter(grepl(&quot;MTERF&quot;, `Gene Symbol`)) %&gt;% 
  select(ID, `Gene Symbol`, ENTREZ_GENE_ID)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["ID"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Gene Symbol"],"name":[2],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[3],"type":["chr"],"align":["left"]}],"data":[{"1":"1557965_at","2":"MTERF4","3":"130916","_rn_":"1557965_at"},{"1":"1557966_x_at","2":"MTERF4","3":"130916","_rn_":"1557966_x_at"},{"1":"204871_at","2":"MTERF1","3":"7978","_rn_":"204871_at"},{"1":"214364_at","2":"MTERF4","3":"130916","_rn_":"214364_at"},{"1":"219363_s_at","2":"MTERF3","3":"51001","_rn_":"219363_s_at"},{"1":"225341_at","2":"MTERF2","3":"80298","_rn_":"225341_at"},{"1":"225346_at","2":"MTERF2","3":"80298","_rn_":"225346_at"},{"1":"226486_at","2":"MTERF4","3":"130916","_rn_":"226486_at"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[8]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>this one is the same gene (listed as alias, same entrez gene id)<br />
PIDD==PIDD1<br />
<a href="https://www.genecards.org/cgi-bin/carddisp.pl?gene=PIDD1&amp;keywords=PIDD" class="uri">https://www.genecards.org/cgi-bin/carddisp.pl?gene=PIDD1&amp;keywords=PIDD</a></p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgXG4gIGZpbHRlcihncmVwbChcIlBJRERcIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBcbiAgc2VsZWN0KElELCBgR2VuZSBTeW1ib2xgLCBFTlRSRVpfR0VORV9JRCkgXG5gYGAifQ== -->
<pre class="r"><code>gse2658_features %&gt;% 
  filter(grepl(&quot;PIDD&quot;, `Gene Symbol`)) %&gt;% 
  select(ID, `Gene Symbol`, ENTREZ_GENE_ID) </code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin eyJtZXRhZGF0YSI6eyJjbGFzc2VzIjpbImRhdGEuZnJhbWUiXSwibnJvdyI6MiwibmNvbCI6Mywic3VtbWFyeSI6eyJEZXNjcmlwdGlvbiI6WyJkZiBbMiDDlyAzXSJdfX0sInJkZiI6Ikg0c0lBQUFBQUFBQUE0MVF3VTdETUF4MTB3YlVJTkFrZm9BZmFMVjJkTEI3eTdUTGhNYVFKaTVWMWdXbzZKS3B6UVQ4L0NEdEVyVDB4Q0Z5L1B6OGJMOUZ1aHFSRlFFQUZ6d0hnWXZWRi9EejhpRzRCL0NRU2h6d3dHL2pseUpkZDB5QWdYcElGL3c0bWd5alNVNmxCaTdpT0JyZkR2T21oV3d1ZnB5bGFXUW5QVWFTak1aM2RtSXZnam5kc2thM3VScEVzOVJNbnpMT2JwNit0MnRSYWVncW15OFgyVXMremVaWnJvaTJubCtMei9CVTg1K0gyVXNWRlcyTWdBSEpoa29hdnRaS1cyV0hYc3U1Mk1sU2NOV0VXbHR4cjltcGU4Qmd6OXN0TjBIeHZ1Y2ZRZEk2UjdyNjhWM3FpRTcrN25FbSt0RmFXR3VkTWY1V2NtYVdyK2lhL1ptbDdPamNDSGQxeWMzcFJLRk5LSVdraGtjS1VSbWtPdzRPdjF0ZzJJbE9BZ0FBIn0= -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["ID"],"name":[1],"type":["chr"],"align":["left"]},{"label":["Gene Symbol"],"name":[2],"type":["chr"],"align":["left"]},{"label":["ENTREZ_GENE_ID"],"name":[3],"type":["chr"],"align":["left"]}],"data":[{"1":"219019_at","2":"PIDD1","3":"55367","_rn_":"219019_at"},{"1":"221640_s_at","2":"PIDD1","3":"55367","_rn_":"221640_s_at"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[2]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>need to join all the names back to the microarray expression<br />
then deal with the missing 84 genes</p>
<p>spectra info from: <code>cmps_spec_rm_wn</code><br />
names of genes in spectra rotation matrux: <code>cmps_spec_genenames</code><br />
microarray probe to gene name from: <code>gse2658_features</code><br />
<code>probe_names_df</code> has the names of genes recovered from multiple name structure and their probes</p>
<p>easy ones with same gene names</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9maW5fY21wc19zcGVjIDwtIGdzZTI2NThfZmVhdHVyZXMgJT4lIFxuICBmaWx0ZXIoYEdlbmUgU3ltYm9sYCAlaW4lIGNtcHNfc3BlY19nZW5lbmFtZXMpICU+JSBcbiAgc2VsZWN0KGdlbmVfbmFtZT1gR2VuZSBTeW1ib2xgLCBwcm9iZV9JRD1JRCkgJT4lIFxuICB0aWJibGU6OnJlbW92ZV9yb3duYW1lcygpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_fin_cmps_spec &lt;- gse2658_features %&gt;% 
  filter(`Gene Symbol` %in% cmps_spec_genenames) %&gt;% 
  select(gene_name=`Gene Symbol`, probe_ID=ID) %&gt;% 
  tibble::remove_rownames()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>adding on ones recovered from multiple name structure</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9maW5fY21wc19zcGVjIDwtIFxuICBiaW5kX3Jvd3MoZ3NlMjY1OF9maW5fY21wc19zcGVjLCBwcm9iZV9uYW1lc19kZilcbmBgYCJ9 -->
<pre class="r"><code>gse2658_fin_cmps_spec &lt;- 
  bind_rows(gse2658_fin_cmps_spec, probe_names_df)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>now the last few stragglers from above (gene name changes)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9maW5fY21wc19zcGVjIDwtIGJpbmRfcm93cyhnc2UyNjU4X2Zpbl9jbXBzX3NwZWMsIFxuICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICBnc2UyNjU4X2ZlYXR1cmVzICU+JSBcbiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICBmaWx0ZXIoYEdlbmUgU3ltYm9sYCAlaW4lIGMoXCJNVEVSRjFcIixcIlBJREQxXCIpKSAlPiUgXG4gICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgc2VsZWN0KGdlbmVfbmFtZT1gR2VuZSBTeW1ib2xgLCBwcm9iZV9JRD1JRCkgJT4lIFxuICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHRpYmJsZTo6cmVtb3ZlX3Jvd25hbWVzKCkpXG5nc2UyNjU4X2Zpbl9jbXBzX3NwZWMkZ2VuZV9uYW1lIDwtIGdzdWIoXCJNVEVSRjFcIiwgXCJNVEVSRlwiLCBnc2UyNjU4X2Zpbl9jbXBzX3NwZWMkZ2VuZV9uYW1lKVxuZ3NlMjY1OF9maW5fY21wc19zcGVjJGdlbmVfbmFtZSA8LSBnc3ViKFwiUElERDFcIiwgXCJQSUREXCIsIGdzZTI2NThfZmluX2NtcHNfc3BlYyRnZW5lX25hbWUpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_fin_cmps_spec &lt;- bind_rows(gse2658_fin_cmps_spec, 
                                   gse2658_features %&gt;% 
                                     filter(`Gene Symbol` %in% c(&quot;MTERF1&quot;,&quot;PIDD1&quot;)) %&gt;% 
                                     select(gene_name=`Gene Symbol`, probe_ID=ID) %&gt;% 
                                     tibble::remove_rownames())
gse2658_fin_cmps_spec$gene_name &lt;- gsub(&quot;MTERF1&quot;, &quot;MTERF&quot;, gse2658_fin_cmps_spec$gene_name)
gse2658_fin_cmps_spec$gene_name &lt;- gsub(&quot;PIDD1&quot;, &quot;PIDD&quot;, gse2658_fin_cmps_spec$gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>check it</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9maW5fY21wc19zcGVjICU+JSBkaXN0aW5jdChnZW5lX25hbWUpICU+JSBkaW0oKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_fin_cmps_spec %&gt;% distinct(gene_name) %&gt;% dim()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDczNjYgICAgMVxuIn0= -->
<pre><code>[1] 7366    1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY21wc19zcGVjX3JtX3duICU+JSBkaXN0aW5jdChnZW5lX25hbWUpICU+JSBkaW0oKVxuYGBgIn0= -->
<pre class="r"><code>cmps_spec_rm_wn %&gt;% distinct(gene_name) %&gt;% dim()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDc0NDggICAgMVxuIn0= -->
<pre><code>[1] 7448    1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuNzQ0OC03MzY2XG5gYGAifQ== -->
<pre class="r"><code>7448-7366</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDgyXG4ifQ== -->
<pre><code>[1] 82</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>back to the expression matrix</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY29sbmFtZXMoZ3NlMjY1OF9leHBycylbMV0gPC0gXCJwcm9iZV9JRFwiXG4jIGdzZTI2NThfZXhwcnMgJT4lIGZpbHRlcihwcm9iZV9JRCAlaW4lIGdzZTI2NThfZmluX2NtcHNfc3BlYyRwcm9iZV9JRClcbmdzZTI2NThfZXhwcnNfc21fd2duIDwtIGxlZnRfam9pbihnc2UyNjU4X2Zpbl9jbXBzX3NwZWMsIGdzZTI2NThfZXhwcnMsIGJ5PVwicHJvYmVfSURcIikgXG5kaW0oZ3NlMjY1OF9leHByc19zbV93Z24pXG5gYGAifQ== -->
<pre class="r"><code>colnames(gse2658_exprs)[1] &lt;- &quot;probe_ID&quot;
# gse2658_exprs %&gt;% filter(probe_ID %in% gse2658_fin_cmps_spec$probe_ID)
gse2658_exprs_sm_wgn &lt;- left_join(gse2658_fin_cmps_spec, gse2658_exprs, by=&quot;probe_ID&quot;) 
dim(gse2658_exprs_sm_wgn)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDE4NDE3ICAgNTYxXG4ifQ== -->
<pre><code>[1] 18417   561</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIGRpc3RpbmN0KGdlbmVfbmFtZSkgJT4lIGRpbSgpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_sm_wgn %&gt;% distinct(gene_name) %&gt;% dim()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDczNjYgICAgMVxuIn0= -->
<pre><code>[1] 7366    1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>treat multiple probesets like transcripts going into the expectra pipeline?</p>
<p>unclear how to get length not sure the transcript idea works since these probes do not uniquely match a transcript</p>
<p>how consistent are the probes for the same gene?</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIGdyb3VwX2J5KGdlbmVfbmFtZSkgJT4lIHN1bW1hcmlzZShuPW4oKSkgJT4lIGFycmFuZ2UoZGVzYyhuKSlcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_sm_wgn %&gt;% group_by(gene_name) %&gt;% summarise(n=n()) %&gt;% arrange(desc(n))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["tbl_df","tbl","data.frame"],"nrow":7366,"ncol":2,"summary":{"A tibble":["7,366 × 2"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]},{"label":["n"],"name":[2],"type":["int"],"align":["right"]}],"data":[{"1":"ARHGEF12","2":"13"},{"1":"DNAH1","2":"13"},{"1":"RUNX1","2":"13"},{"1":"TCF3","2":"13"},{"1":"SPTBN1","2":"11"},{"1":"ARL17B","2":"10"},{"1":"CALM3","2":"10"},{"1":"HIPK2","2":"10"},{"1":"KMT2A","2":"10"},{"1":"MED28","2":"10"},{"1":"PDLIM5","2":"10"},{"1":"PML","2":"10"},{"1":"SMG1","2":"10"},{"1":"STRN","2":"10"},{"1":"ACTG1","2":"9"},{"1":"AKAP13","2":"9"},{"1":"ARHGEF7","2":"9"},{"1":"ASPH","2":"9"},{"1":"C1orf86","2":"9"},{"1":"ERICH1","2":"9"},{"1":"ESR1","2":"9"},{"1":"FAM120A","2":"9"},{"1":"FBXO9","2":"9"},{"1":"FOXP2","2":"9"},{"1":"GART","2":"9"},{"1":"IKZF1","2":"9"},{"1":"LMF1","2":"9"},{"1":"LRRFIP1","2":"9"},{"1":"MSI2","2":"9"},{"1":"PPARA","2":"9"},{"1":"RIF1","2":"9"},{"1":"SMARCA4","2":"9"},{"1":"TNPO1","2":"9"},{"1":"VPS53","2":"9"},{"1":"YME1L1","2":"9"},{"1":"ZDHHC21","2":"9"},{"1":"AFF4","2":"8"},{"1":"APLP2","2":"8"},{"1":"BRWD1","2":"8"},{"1":"CAPRIN1","2":"8"},{"1":"CDC14B","2":"8"},{"1":"CDK12","2":"8"},{"1":"DIP2A","2":"8"},{"1":"DR1","2":"8"},{"1":"FOXP1","2":"8"},{"1":"GGA2","2":"8"},{"1":"GLS","2":"8"},{"1":"HNRNPD","2":"8"},{"1":"ITSN1","2":"8"},{"1":"LPP","2":"8"},{"1":"MLLT10","2":"8"},{"1":"N4BP2L1","2":"8"},{"1":"NAV1","2":"8"},{"1":"NF2","2":"8"},{"1":"NKTR","2":"8"},{"1":"NUCKS1","2":"8"},{"1":"PIAS2","2":"8"},{"1":"RBBP6","2":"8"},{"1":"RNF213","2":"8"},{"1":"RORA","2":"8"},{"1":"SRSF1","2":"8"},{"1":"TCF4","2":"8"},{"1":"TNRC18","2":"8"},{"1":"TOR1AIP2","2":"8"},{"1":"TTC3","2":"8"},{"1":"UBE2H","2":"8"},{"1":"ACTR2","2":"7"},{"1":"ANKH","2":"7"},{"1":"ARID1B","2":"7"},{"1":"ATP5S","2":"7"},{"1":"ATP6V0E1","2":"7"},{"1":"BBX","2":"7"},{"1":"BCL2L11","2":"7"},{"1":"BRD4","2":"7"},{"1":"CAMSAP1","2":"7"},{"1":"CAND1","2":"7"},{"1":"CASP2","2":"7"},{"1":"CD47","2":"7"},{"1":"CDK13","2":"7"},{"1":"CELF1","2":"7"},{"1":"CELF2","2":"7"},{"1":"CHD9","2":"7"},{"1":"COL4A3","2":"7"},{"1":"CREB1","2":"7"},{"1":"CYLD","2":"7"},{"1":"DCAF7","2":"7"},{"1":"DLG1","2":"7"},{"1":"DNAJC21","2":"7"},{"1":"DYNC1H1","2":"7"},{"1":"EFCAB14","2":"7"},{"1":"EHD4","2":"7"},{"1":"EIF1","2":"7"},{"1":"EPG5","2":"7"},{"1":"FBXO32","2":"7"},{"1":"FGD2","2":"7"},{"1":"FGFR1OP2","2":"7"},{"1":"FOXK2","2":"7"},{"1":"FOXN3","2":"7"},{"1":"G3BP1","2":"7"},{"1":"GAB1","2":"7"},{"1":"GATM","2":"7"},{"1":"GM2A","2":"7"},{"1":"GPATCH2L","2":"7"},{"1":"HNRNPC","2":"7"},{"1":"IL6ST","2":"7"},{"1":"ITGB1","2":"7"},{"1":"KDM4B","2":"7"},{"1":"KIAA1109","2":"7"},{"1":"LRCH3","2":"7"},{"1":"MAP3K2","2":"7"},{"1":"MAP4","2":"7"},{"1":"MAPK1","2":"7"},{"1":"MAST4","2":"7"},{"1":"MBNL1","2":"7"},{"1":"METTL15","2":"7"},{"1":"MLLT4","2":"7"},{"1":"PAWR","2":"7"},{"1":"PCNX","2":"7"},{"1":"PHF20L1","2":"7"},{"1":"PIK3C2A","2":"7"},{"1":"PMS2","2":"7"},{"1":"POU2F2","2":"7"},{"1":"PSEN1","2":"7"},{"1":"PTEN","2":"7"},{"1":"RBM25","2":"7"},{"1":"RBM26","2":"7"},{"1":"RBM33","2":"7"},{"1":"RC3H2","2":"7"},{"1":"RPAIN","2":"7"},{"1":"RREB1","2":"7"},{"1":"RUFY2","2":"7"},{"1":"RUFY3","2":"7"},{"1":"SCAF11","2":"7"},{"1":"SERBP1","2":"7"},{"1":"SLAIN2","2":"7"},{"1":"SLC38A10","2":"7"},{"1":"SMARCA2","2":"7"},{"1":"SNTB2","2":"7"},{"1":"SRC","2":"7"},{"1":"ST3GAL3","2":"7"},{"1":"STK4","2":"7"},{"1":"SYNCRIP","2":"7"},{"1":"SYNJ2","2":"7"},{"1":"TCP11L2","2":"7"},{"1":"THADA","2":"7"},{"1":"TIA1","2":"7"},{"1":"TLK1","2":"7"},{"1":"TMCC1","2":"7"},{"1":"TNRC6B","2":"7"},{"1":"TPGS2","2":"7"},{"1":"TTBK2","2":"7"},{"1":"TTLL5","2":"7"},{"1":"UBA6","2":"7"},{"1":"UBE2B","2":"7"},{"1":"UBE3A","2":"7"},{"1":"UGGT2","2":"7"},{"1":"USP49","2":"7"},{"1":"WHSC1L1","2":"7"},{"1":"WNK1","2":"7"},{"1":"WTAP","2":"7"},{"1":"ZADH2","2":"7"},{"1":"ZBTB10","2":"7"},{"1":"ZMYM6","2":"7"},{"1":"ZNF148","2":"7"},{"1":"ABHD2","2":"6"},{"1":"ACACB","2":"6"},{"1":"ACER3","2":"6"},{"1":"ACTB","2":"6"},{"1":"ACVR1B","2":"6"},{"1":"AGPAT3","2":"6"},{"1":"ANAPC5","2":"6"},{"1":"ARMC8","2":"6"},{"1":"ARNT","2":"6"},{"1":"ASXL1","2":"6"},{"1":"ASXL2","2":"6"},{"1":"ATM","2":"6"},{"1":"ATP11B","2":"6"},{"1":"ATP9B","2":"6"},{"1":"AVL9","2":"6"},{"1":"AZI2","2":"6"},{"1":"B4GALT1","2":"6"},{"1":"BCAP29","2":"6"},{"1":"BCLAF1","2":"6"},{"1":"BICD1","2":"6"},{"1":"BUB3","2":"6"},{"1":"C11orf30","2":"6"},{"1":"C11orf31","2":"6"},{"1":"C11orf57","2":"6"},{"1":"C16orf13","2":"6"},{"1":"CBX5","2":"6"},{"1":"CCDC88A","2":"6"},{"1":"CEP89","2":"6"},{"1":"CHD2","2":"6"},{"1":"CHML","2":"6"},{"1":"CLASP2","2":"6"},{"1":"CLIP1","2":"6"},{"1":"CLN6","2":"6"},{"1":"CLTA","2":"6"},{"1":"COPS8","2":"6"},{"1":"CREBZF","2":"6"},{"1":"CREM","2":"6"},{"1":"CRIPT","2":"6"},{"1":"DBT","2":"6"},{"1":"DCUN1D1","2":"6"},{"1":"DENND1B","2":"6"},{"1":"DHX30","2":"6"},{"1":"DICER1","2":"6"},{"1":"EIF3B","2":"6"},{"1":"ELK4","2":"6"},{"1":"EML4","2":"6"},{"1":"ENAH","2":"6"},{"1":"EPS15L1","2":"6"},{"1":"ERC1","2":"6"},{"1":"ETNK1","2":"6"},{"1":"EXOSC3","2":"6"},{"1":"FBXL18","2":"6"},{"1":"FBXO3","2":"6"},{"1":"FKBP15","2":"6"},{"1":"FRYL","2":"6"},{"1":"FUS","2":"6"},{"1":"GAPDH","2":"6"},{"1":"GATAD2A","2":"6"},{"1":"GFM1","2":"6"},{"1":"GPR180","2":"6"},{"1":"GSPT1","2":"6"},{"1":"HDLBP","2":"6"},{"1":"HECTD1","2":"6"},{"1":"HECTD4","2":"6"},{"1":"HERC4","2":"6"},{"1":"HNRNPDL","2":"6"},{"1":"HNRNPM","2":"6"},{"1":"IMPAD1","2":"6"},{"1":"INADL","2":"6"},{"1":"INO80D","2":"6"},{"1":"INPP4A","2":"6"},{"1":"ITCH","2":"6"},{"1":"JMJD1C","2":"6"},{"1":"KMT2C","2":"6"},{"1":"KPNA1","2":"6"},{"1":"KPNB1","2":"6"},{"1":"L3MBTL1","2":"6"},{"1":"LARP1B","2":"6"},{"1":"LARP4B","2":"6"},{"1":"LIG3","2":"6"},{"1":"LMBR1","2":"6"},{"1":"LMNA","2":"6"},{"1":"MAN1A2","2":"6"},{"1":"MAP2K5","2":"6"},{"1":"MARCH6","2":"6"},{"1":"MCL1","2":"6"},{"1":"MDM4","2":"6"},{"1":"MPZL1","2":"6"},{"1":"MR1","2":"6"},{"1":"MTAP","2":"6"},{"1":"MTHFSD","2":"6"},{"1":"MYEF2","2":"6"},{"1":"MYLIP","2":"6"},{"1":"N4BP2L2","2":"6"},{"1":"NAA15","2":"6"},{"1":"NADK","2":"6"},{"1":"NENF","2":"6"},{"1":"NFATC2IP","2":"6"},{"1":"NFYA","2":"6"},{"1":"NFYC","2":"6"},{"1":"NIN","2":"6"},{"1":"NLN","2":"6"},{"1":"NSFL1C","2":"6"},{"1":"NUP50","2":"6"},{"1":"ORAI2","2":"6"},{"1":"OTUD7B","2":"6"},{"1":"PAK2","2":"6"},{"1":"PANK2","2":"6"},{"1":"PAPOLA","2":"6"},{"1":"PARVB","2":"6"},{"1":"PATZ1","2":"6"},{"1":"PBRM1","2":"6"},{"1":"PCM1","2":"6"},{"1":"PDE5A","2":"6"},{"1":"PDS5B","2":"6"},{"1":"PLEKHA8","2":"6"},{"1":"PNISR","2":"6"},{"1":"POLH","2":"6"},{"1":"PPIL2","2":"6"},{"1":"PPM1A","2":"6"},{"1":"PRKCB","2":"6"},{"1":"PRMT2","2":"6"},{"1":"PRPF40A","2":"6"},{"1":"PRRC2C","2":"6"},{"1":"PTPN11","2":"6"},{"1":"PTPN2","2":"6"},{"1":"RAB18","2":"6"},{"1":"RAB2A","2":"6"},{"1":"RAB7A","2":"6"},{"1":"RBMS1","2":"6"},{"1":"RHOBTB3","2":"6"},{"1":"RPRD1A","2":"6"},{"1":"RQCD1","2":"6"},{"1":"RRBP1","2":"6"},{"1":"RSF1","2":"6"},{"1":"SAMHD1","2":"6"},{"1":"SCAMP1","2":"6"},{"1":"SEC22C","2":"6"},{"1":"SETDB2","2":"6"},{"1":"SIK3","2":"6"},{"1":"SKAP2","2":"6"},{"1":"SLC39A8","2":"6"},{"1":"SLFN5","2":"6"},{"1":"SMCHD1","2":"6"},{"1":"SMEK2","2":"6"},{"1":"SNX5","2":"6"},{"1":"SOS2","2":"6"},{"1":"SREK1","2":"6"},{"1":"SRP72","2":"6"},{"1":"SRPK2","2":"6"},{"1":"SRSF3","2":"6"},{"1":"SSBP2","2":"6"},{"1":"SSR1","2":"6"},{"1":"SSX2IP","2":"6"},{"1":"STAT1","2":"6"},{"1":"SYNRG","2":"6"},{"1":"TACC1","2":"6"},{"1":"TAOK1","2":"6"},{"1":"TAPT1","2":"6"},{"1":"TBL1XR1","2":"6"},{"1":"TBRG1","2":"6"},{"1":"TMED5","2":"6"},{"1":"TMEM165","2":"6"},{"1":"TMEM259","2":"6"},{"1":"TMF1","2":"6"},{"1":"TNRC6A","2":"6"},{"1":"TSC22D2","2":"6"},{"1":"TTC17","2":"6"},{"1":"UBE2D3","2":"6"},{"1":"UBE2J1","2":"6"},{"1":"UBE2W","2":"6"},{"1":"UBE3B","2":"6"},{"1":"VPS13A","2":"6"},{"1":"VRK3","2":"6"},{"1":"WAC","2":"6"},{"1":"WDR33","2":"6"},{"1":"WHSC1","2":"6"},{"1":"XPNPEP3","2":"6"},{"1":"YY1","2":"6"},{"1":"ZBTB7A","2":"6"},{"1":"ZMYM2","2":"6"},{"1":"ZNF280D","2":"6"},{"1":"ZNF333","2":"6"},{"1":"ZNF654","2":"6"},{"1":"ZXDC","2":"6"},{"1":"ABCC9","2":"5"},{"1":"ABCF2","2":"5"},{"1":"ABTB1","2":"5"},{"1":"ACOX1","2":"5"},{"1":"ACSS1","2":"5"},{"1":"ACTR3","2":"5"},{"1":"AGFG1","2":"5"},{"1":"AHI1","2":"5"},{"1":"AKAP8L","2":"5"},{"1":"ALDH6A1","2":"5"},{"1":"ANKRD13C","2":"5"},{"1":"ANKRD44","2":"5"},{"1":"AP5M1","2":"5"},{"1":"APC","2":"5"},{"1":"API5","2":"5"},{"1":"ARHGAP27","2":"5"},{"1":"ARHGAP35","2":"5"},{"1":"ARHGAP5","2":"5"},{"1":"ARID5B","2":"5"},{"1":"ARIH2","2":"5"},{"1":"ASAP1","2":"5"},{"1":"ATF7","2":"5"},{"1":"ATP2A3","2":"5"},{"1":"ATP6V0A2","2":"5"},{"1":"ATXN1","2":"5"},{"1":"AURKAIP1","2":"5"},{"1":"BBS9","2":"5"},{"1":"BCL2L13","2":"5"},{"1":"BMPR1A","2":"5"},{"1":"BMPR2","2":"5"},{"1":"BPTF","2":"5"},{"1":"BTBD7","2":"5"},{"1":"BTF3L4","2":"5"},{"1":"BTRC","2":"5"},{"1":"BUB1","2":"5"},{"1":"C12orf49","2":"5"},{"1":"C17orf85","2":"5"},{"1":"C6orf89","2":"5"},{"1":"CACTIN","2":"5"},{"1":"CACUL1","2":"5"},{"1":"CALU","2":"5"},{"1":"CAMK2D","2":"5"},{"1":"CANX","2":"5"},{"1":"CARS2","2":"5"},{"1":"CASP1","2":"5"},{"1":"CAST","2":"5"},{"1":"CBFA2T2","2":"5"},{"1":"CBL","2":"5"},{"1":"CCDC50","2":"5"},{"1":"CCNG2","2":"5"},{"1":"CCNY","2":"5"},{"1":"CD59","2":"5"},{"1":"CDC42","2":"5"},{"1":"CDK11B","2":"5"},{"1":"CDS2","2":"5"},{"1":"CEP128","2":"5"},{"1":"CEP152","2":"5"},{"1":"CEP57","2":"5"},{"1":"CEP68","2":"5"},{"1":"CEP70","2":"5"},{"1":"CIRBP","2":"5"},{"1":"CLN8","2":"5"},{"1":"CNOT4","2":"5"},{"1":"CNOT6L","2":"5"},{"1":"COBLL1","2":"5"},{"1":"CPD","2":"5"},{"1":"CREBRF","2":"5"},{"1":"CRLS1","2":"5"},{"1":"CRTAP","2":"5"},{"1":"CRYZL1","2":"5"},{"1":"CSPP1","2":"5"},{"1":"CTNNA1","2":"5"},{"1":"CTSB","2":"5"},{"1":"CTTN","2":"5"},{"1":"CUX1","2":"5"},{"1":"CYB561","2":"5"},{"1":"DAAM1","2":"5"},{"1":"DCAF5","2":"5"},{"1":"DCLRE1C","2":"5"},{"1":"DCTN5","2":"5"},{"1":"DDHD1","2":"5"},{"1":"DDX17","2":"5"},{"1":"DENND5B","2":"5"},{"1":"DENR","2":"5"},{"1":"DESI2","2":"5"},{"1":"DGKE","2":"5"},{"1":"DIS3","2":"5"},{"1":"DLGAP4","2":"5"},{"1":"DNAJC10","2":"5"},{"1":"DNAJC4","2":"5"},{"1":"DOCK9","2":"5"},{"1":"DPH5","2":"5"},{"1":"DTX3","2":"5"},{"1":"DTYMK","2":"5"},{"1":"DYNLRB1","2":"5"},{"1":"EFCAB13","2":"5"},{"1":"EHD1","2":"5"},{"1":"EIF4EBP2","2":"5"},{"1":"EIF5","2":"5"},{"1":"ELP2","2":"5"},{"1":"EMC1","2":"5"},{"1":"ENSA","2":"5"},{"1":"ERAP1","2":"5"},{"1":"ERAP2","2":"5"},{"1":"ESYT2","2":"5"},{"1":"ETV5","2":"5"},{"1":"EXOC5","2":"5"},{"1":"EZH1","2":"5"},{"1":"EZR","2":"5"},{"1":"FAF1","2":"5"},{"1":"FAM13A","2":"5"},{"1":"FAM162A","2":"5"},{"1":"FARP2","2":"5"},{"1":"FBRSL1","2":"5"},{"1":"FBXL17","2":"5"},{"1":"FBXL20","2":"5"},{"1":"FBXO28","2":"5"},{"1":"FBXW2","2":"5"},{"1":"FCRL2","2":"5"},{"1":"FCRL5","2":"5"},{"1":"FNIP1","2":"5"},{"1":"FOSL2","2":"5"},{"1":"G2E3","2":"5"},{"1":"GGA1","2":"5"},{"1":"GIT2","2":"5"},{"1":"GLCCI1","2":"5"},{"1":"GNB5","2":"5"},{"1":"GPALPP1","2":"5"},{"1":"GPATCH2","2":"5"},{"1":"GPATCH4","2":"5"},{"1":"GPRIN3","2":"5"},{"1":"GSK3B","2":"5"},{"1":"GTDC1","2":"5"},{"1":"GTPBP1","2":"5"},{"1":"HDAC9","2":"5"},{"1":"HELLS","2":"5"},{"1":"HELQ","2":"5"},{"1":"HGSNAT","2":"5"},{"1":"HINT1","2":"5"},{"1":"HIST4H4","2":"5"},{"1":"HNRNPU","2":"5"},{"1":"HOOK3","2":"5"},{"1":"HPS1","2":"5"},{"1":"HSPD1","2":"5"},{"1":"ILF3","2":"5"},{"1":"INIP","2":"5"},{"1":"INSR","2":"5"},{"1":"INTS4","2":"5"},{"1":"IPO5","2":"5"},{"1":"IPP","2":"5"},{"1":"IRF2BP2","2":"5"},{"1":"ITFG1","2":"5"},{"1":"ITPKB","2":"5"},{"1":"JAG1","2":"5"},{"1":"KANSL1L","2":"5"},{"1":"KAT6B","2":"5"},{"1":"KCNAB1","2":"5"},{"1":"KDM5A","2":"5"},{"1":"KDM5B","2":"5"},{"1":"KDM6B","2":"5"},{"1":"KIAA0226","2":"5"},{"1":"KIAA2018","2":"5"},{"1":"KIDINS220","2":"5"},{"1":"KIF6","2":"5"},{"1":"KLF6","2":"5"},{"1":"KLF7","2":"5"},{"1":"KLF9","2":"5"},{"1":"KLHDC10","2":"5"},{"1":"KLHL22","2":"5"},{"1":"KLHL24","2":"5"},{"1":"KMT2D","2":"5"},{"1":"KPNA4","2":"5"},{"1":"LARP4","2":"5"},{"1":"LIMD1","2":"5"},{"1":"LINS","2":"5"},{"1":"LMO4","2":"5"},{"1":"LONP2","2":"5"},{"1":"LPCAT4","2":"5"},{"1":"LRRC8C","2":"5"},{"1":"LRRFIP2","2":"5"},{"1":"LSM14B","2":"5"},{"1":"LUC7L","2":"5"},{"1":"LUZP1","2":"5"},{"1":"LYRM2","2":"5"},{"1":"MAP2K7","2":"5"},{"1":"MAPK8","2":"5"},{"1":"MAPK8IP3","2":"5"},{"1":"MARCKS","2":"5"},{"1":"MAU2","2":"5"},{"1":"MAX","2":"5"},{"1":"MBD1","2":"5"},{"1":"MCM3AP","2":"5"},{"1":"MCM4","2":"5"},{"1":"MCPH1","2":"5"},{"1":"MCTP2","2":"5"},{"1":"MED13L","2":"5"},{"1":"MED16","2":"5"},{"1":"MED23","2":"5"},{"1":"MEX3C","2":"5"},{"1":"MGEA5","2":"5"},{"1":"MIB2","2":"5"},{"1":"MIER3","2":"5"},{"1":"MKL1","2":"5"},{"1":"MKLN1","2":"5"},{"1":"MLX","2":"5"},{"1":"MTDH","2":"5"},{"1":"MTF2","2":"5"},{"1":"MTG2","2":"5"},{"1":"MTHFR","2":"5"},{"1":"MTO1","2":"5"},{"1":"MYLK3","2":"5"},{"1":"MYNN","2":"5"},{"1":"NAP1L4","2":"5"},{"1":"NAPEPLD","2":"5"},{"1":"NBN","2":"5"},{"1":"NCAPH2","2":"5"},{"1":"NCOA3","2":"5"},{"1":"NCOR1","2":"5"},{"1":"NCOR2","2":"5"},{"1":"NDUFS1","2":"5"},{"1":"NEDD9","2":"5"},{"1":"NEK1","2":"5"},{"1":"NFX1","2":"5"},{"1":"NIPAL3","2":"5"},{"1":"NIPBL","2":"5"},{"1":"NPIPB4","2":"5"},{"1":"NPIPB5","2":"5"},{"1":"NR3C1","2":"5"},{"1":"NRF1","2":"5"},{"1":"NUB1","2":"5"},{"1":"NUMA1","2":"5"},{"1":"NUP210","2":"5"},{"1":"OCIAD1","2":"5"},{"1":"OSBPL10","2":"5"},{"1":"OXR1","2":"5"},{"1":"PAPOLG","2":"5"},{"1":"PATL1","2":"5"},{"1":"PCGF5","2":"5"},{"1":"PDCD2","2":"5"},{"1":"PDE4A","2":"5"},{"1":"PDXDC1","2":"5"},{"1":"PERP","2":"5"},{"1":"PEX13","2":"5"},{"1":"PHC3","2":"5"},{"1":"PHF3","2":"5"},{"1":"PHIP","2":"5"},{"1":"PHTF2","2":"5"},{"1":"PICALM","2":"5"},{"1":"PKNOX1","2":"5"},{"1":"PKP4","2":"5"},{"1":"PMS1","2":"5"},{"1":"PNN","2":"5"},{"1":"PPA2","2":"5"},{"1":"PPHLN1","2":"5"},{"1":"PPM1K","2":"5"},{"1":"PPP2R1B","2":"5"},{"1":"PRKAA1","2":"5"},{"1":"PRKAG2","2":"5"},{"1":"PRKCA","2":"5"},{"1":"PRKD3","2":"5"},{"1":"PROSC","2":"5"},{"1":"PSPC1","2":"5"},{"1":"PTBP3","2":"5"},{"1":"PTP4A1","2":"5"},{"1":"PURA","2":"5"},{"1":"RAB27A","2":"5"},{"1":"RAB30","2":"5"},{"1":"RAB3B","2":"5"},{"1":"RABEP1","2":"5"},{"1":"RABGAP1L","2":"5"},{"1":"RAD1","2":"5"},{"1":"RALGAPA2","2":"5"},{"1":"RALGPS1","2":"5"},{"1":"RALGPS2","2":"5"},{"1":"RAP2A","2":"5"},{"1":"RAPGEF2","2":"5"},{"1":"RARA","2":"5"},{"1":"RARS2","2":"5"},{"1":"RBM15","2":"5"},{"1":"RBM47","2":"5"},{"1":"RECQL5","2":"5"},{"1":"RERE","2":"5"},{"1":"RHBDD1","2":"5"},{"1":"RHOB","2":"5"},{"1":"RIOK3","2":"5"},{"1":"RIT1","2":"5"},{"1":"ROCK1","2":"5"},{"1":"RPL7A","2":"5"},{"1":"RPUSD3","2":"5"},{"1":"RRP12","2":"5"},{"1":"RSBN1","2":"5"},{"1":"RSU1","2":"5"},{"1":"RTFDC1","2":"5"},{"1":"SAR1B","2":"5"},{"1":"SAV1","2":"5"},{"1":"SBF1","2":"5"},{"1":"SBNO1","2":"5"},{"1":"SCAF4","2":"5"},{"1":"SCARB1","2":"5"},{"1":"SEC62","2":"5"},{"1":"SEC63","2":"5"},{"1":"SEPSECS","2":"5"},{"1":"SEPT2","2":"5"},{"1":"SETD5","2":"5"},{"1":"SF3B1","2":"5"},{"1":"SFPQ","2":"5"},{"1":"SFT2D1","2":"5"},{"1":"SH3BP2","2":"5"},{"1":"SIKE1","2":"5"},{"1":"SKIL","2":"5"},{"1":"SLC11A2","2":"5"},{"1":"SLC12A4","2":"5"},{"1":"SLC16A1","2":"5"},{"1":"SLC16A7","2":"5"},{"1":"SLC1A4","2":"5"},{"1":"SLC25A36","2":"5"},{"1":"SLC2A13","2":"5"},{"1":"SLC30A5","2":"5"},{"1":"SLC6A6","2":"5"},{"1":"SLC7A1","2":"5"},{"1":"SMAD4","2":"5"},{"1":"SMAD5","2":"5"},{"1":"SMIM14","2":"5"},{"1":"SMIM4","2":"5"},{"1":"SNX13","2":"5"},{"1":"SNX24","2":"5"},{"1":"SNX25","2":"5"},{"1":"SON","2":"5"},{"1":"SOS1","2":"5"},{"1":"SP3","2":"5"},{"1":"SPAG9","2":"5"},{"1":"SPPL3","2":"5"},{"1":"SPTLC2","2":"5"},{"1":"SRRT","2":"5"},{"1":"SRSF4","2":"5"},{"1":"ST3GAL2","2":"5"},{"1":"ST7L","2":"5"},{"1":"ST8SIA4","2":"5"},{"1":"STAM2","2":"5"},{"1":"STK38","2":"5"},{"1":"STRBP","2":"5"},{"1":"STX17","2":"5"},{"1":"STX6","2":"5"},{"1":"STYXL1","2":"5"},{"1":"SUGP2","2":"5"},{"1":"SUPT20H","2":"5"},{"1":"SYNE2","2":"5"},{"1":"TAF6L","2":"5"},{"1":"TAF8","2":"5"},{"1":"TAGAP","2":"5"},{"1":"TBC1D1","2":"5"},{"1":"TCAIM","2":"5"},{"1":"TCEB3","2":"5"},{"1":"TERF2","2":"5"},{"1":"TFPI","2":"5"},{"1":"TFRC","2":"5"},{"1":"TGOLN2","2":"5"},{"1":"TLE4","2":"5"},{"1":"TM2D1","2":"5"},{"1":"TM9SF3","2":"5"},{"1":"TMED4","2":"5"},{"1":"TMEM107","2":"5"},{"1":"TMEM245","2":"5"},{"1":"TMEM33","2":"5"},{"1":"TMEM50B","2":"5"},{"1":"TMPO","2":"5"},{"1":"TNPO2","2":"5"},{"1":"TNRC6C","2":"5"},{"1":"TOR1AIP1","2":"5"},{"1":"TOX4","2":"5"},{"1":"TPD52","2":"5"},{"1":"TPR","2":"5"},{"1":"TRA2A","2":"5"},{"1":"TRAK1","2":"5"},{"1":"TRIM8","2":"5"},{"1":"TRPM7","2":"5"},{"1":"TRUB1","2":"5"},{"1":"TSPAN3","2":"5"},{"1":"TTN","2":"5"},{"1":"TWF1","2":"5"},{"1":"U2SURP","2":"5"},{"1":"UBE2D4","2":"5"},{"1":"UBE2I","2":"5"},{"1":"UBE3C","2":"5"},{"1":"UBE4B","2":"5"},{"1":"UBN2","2":"5"},{"1":"UBTF","2":"5"},{"1":"UGGT1","2":"5"},{"1":"USP25","2":"5"},{"1":"USP31","2":"5"},{"1":"USP36","2":"5"},{"1":"USP42","2":"5"},{"1":"USP47","2":"5"},{"1":"USP48","2":"5"},{"1":"VPRBP","2":"5"},{"1":"VPS13D","2":"5"},{"1":"VPS35","2":"5"},{"1":"VTI1A","2":"5"},{"1":"WDR1","2":"5"},{"1":"WDR26","2":"5"},{"1":"WIPI2","2":"5"},{"1":"WSB1","2":"5"},{"1":"WWOX","2":"5"},{"1":"YTHDC1","2":"5"},{"1":"YWHAZ","2":"5"},{"1":"ZBTB38","2":"5"},{"1":"ZBTB43","2":"5"},{"1":"ZBTB44","2":"5"},{"1":"ZC3H7B","2":"5"},{"1":"ZCCHC6","2":"5"},{"1":"ZFAND5","2":"5"},{"1":"ZFYVE16","2":"5"},{"1":"ZMAT3","2":"5"},{"1":"ZMYND8","2":"5"},{"1":"ZNF131","2":"5"},{"1":"ZNF24","2":"5"},{"1":"ZNF397","2":"5"},{"1":"ZNF451","2":"5"},{"1":"ZNF496","2":"5"},{"1":"ZNF688","2":"5"},{"1":"ZNF710","2":"5"},{"1":"ZNF827","2":"5"},{"1":"ZSCAN30","2":"5"},{"1":"ABCA1","2":"4"},{"1":"ABHD5","2":"4"},{"1":"ACAD10","2":"4"},{"1":"ACOT11","2":"4"},{"1":"ACP1","2":"4"},{"1":"ADCK2","2":"4"},{"1":"ADD1","2":"4"},{"1":"ADD3","2":"4"},{"1":"AGGF1","2":"4"},{"1":"AGO1","2":"4"},{"1":"AGO3","2":"4"},{"1":"AGO4","2":"4"},{"1":"AGPS","2":"4"},{"1":"AHCYL1","2":"4"},{"1":"AHNAK","2":"4"},{"1":"AKAP1","2":"4"},{"1":"AKAP10","2":"4"},{"1":"ALKBH7","2":"4"},{"1":"ALOX5","2":"4"},{"1":"ALPK1","2":"4"},{"1":"AMBRA1","2":"4"},{"1":"ANAPC16","2":"4"},{"1":"ANKFY1","2":"4"},{"1":"ANKRD10","2":"4"},{"1":"ANKRD12","2":"4"},{"1":"ANKRD28","2":"4"},{"1":"ANKS6","2":"4"},{"1":"ANTXR2","2":"4"},{"1":"AP2A1","2":"4"},{"1":"AP2A2","2":"4"},{"1":"AP4E1","2":"4"},{"1":"APOL6","2":"4"},{"1":"APPBP2","2":"4"},{"1":"AQR","2":"4"},{"1":"ARFGEF2","2":"4"},{"1":"ARGLU1","2":"4"},{"1":"ARHGAP1","2":"4"},{"1":"ARHGAP23","2":"4"},{"1":"ARHGAP26","2":"4"},{"1":"ARHGDIA","2":"4"},{"1":"ARHGEF2","2":"4"},{"1":"ARID1A","2":"4"},{"1":"ARPC4-TTLL3","2":"4"},{"1":"ARPC5L","2":"4"},{"1":"ARSB","2":"4"},{"1":"ATAD2","2":"4"},{"1":"ATE1","2":"4"},{"1":"ATF5","2":"4"},{"1":"ATF6","2":"4"},{"1":"ATG2B","2":"4"},{"1":"ATN1","2":"4"},{"1":"ATP2A2","2":"4"},{"1":"ATP2C1","2":"4"},{"1":"ATP5C1","2":"4"},{"1":"ATP6V1C1","2":"4"},{"1":"ATP6V1D","2":"4"},{"1":"B3GALNT2","2":"4"},{"1":"BAZ1B","2":"4"},{"1":"BAZ2A","2":"4"},{"1":"BCL2","2":"4"},{"1":"BCL2L1","2":"4"},{"1":"BHLHE41","2":"4"},{"1":"BICD2","2":"4"},{"1":"BLZF1","2":"4"},{"1":"BRAP","2":"4"},{"1":"BRD7","2":"4"},{"1":"BRF1","2":"4"},{"1":"BTBD9","2":"4"},{"1":"BTD","2":"4"},{"1":"BTF3","2":"4"},{"1":"BTG3","2":"4"},{"1":"BTN2A1","2":"4"},{"1":"C11orf1","2":"4"},{"1":"C16orf52","2":"4"},{"1":"C18orf25","2":"4"},{"1":"C21orf2","2":"4"},{"1":"C2CD3","2":"4"},{"1":"C2orf68","2":"4"},{"1":"C3orf38","2":"4"},{"1":"C5orf56","2":"4"},{"1":"C9orf16","2":"4"},{"1":"CACYBP","2":"4"},{"1":"CALCOCO2","2":"4"},{"1":"CAMK2G","2":"4"},{"1":"CAMKK2","2":"4"},{"1":"CAPS","2":"4"},{"1":"CAPZB","2":"4"},{"1":"CARD8","2":"4"},{"1":"CARHSP1","2":"4"},{"1":"CARS","2":"4"},{"1":"CASP10","2":"4"},{"1":"CBX3","2":"4"},{"1":"CC2D1A","2":"4"},{"1":"CCDC132","2":"4"},{"1":"CCDC71L","2":"4"},{"1":"CCDC82","2":"4"},{"1":"CCDC93","2":"4"},{"1":"CCNL1","2":"4"},{"1":"CCNT2","2":"4"},{"1":"CCSAP","2":"4"},{"1":"CCSER2","2":"4"},{"1":"CD40","2":"4"},{"1":"CDADC1","2":"4"},{"1":"CDC27","2":"4"},{"1":"CDC42EP3","2":"4"},{"1":"CDC42SE1","2":"4"},{"1":"CDC5L","2":"4"},{"1":"CDK19","2":"4"},{"1":"CENPN","2":"4"},{"1":"CEP350","2":"4"},{"1":"CEP57L1","2":"4"},{"1":"CEP95","2":"4"},{"1":"CFL1","2":"4"},{"1":"CHAF1A","2":"4"},{"1":"CHD1L","2":"4"},{"1":"CHD6","2":"4"},{"1":"CHD7","2":"4"},{"1":"CHEK1","2":"4"},{"1":"CIZ1","2":"4"},{"1":"CLCN3","2":"4"},{"1":"CLDND1","2":"4"},{"1":"CLK4","2":"4"},{"1":"CLMN","2":"4"},{"1":"CLOCK","2":"4"},{"1":"CLTB","2":"4"},{"1":"CNOT2","2":"4"},{"1":"CNOT7","2":"4"},{"1":"CNPY3","2":"4"},{"1":"CNST","2":"4"},{"1":"CNTROB","2":"4"},{"1":"COL4A3BP","2":"4"},{"1":"COMT","2":"4"},{"1":"COPA","2":"4"},{"1":"COX15","2":"4"},{"1":"COX5B","2":"4"},{"1":"CPEB3","2":"4"},{"1":"CPEB4","2":"4"},{"1":"CPT1A","2":"4"},{"1":"CREBBP","2":"4"},{"1":"CSE1L","2":"4"},{"1":"CSNK1G1","2":"4"},{"1":"CSNK2A1","2":"4"},{"1":"CTBP1","2":"4"},{"1":"CTDSPL2","2":"4"},{"1":"CTSC","2":"4"},{"1":"CTU2","2":"4"},{"1":"CUL5","2":"4"},{"1":"CUL7","2":"4"},{"1":"CWF19L2","2":"4"},{"1":"CYB5B","2":"4"},{"1":"CYB5RL","2":"4"},{"1":"CYHR1","2":"4"},{"1":"CYP3A5","2":"4"},{"1":"CYP4V2","2":"4"},{"1":"DAGLB","2":"4"},{"1":"DAPP1","2":"4"},{"1":"DAZAP2","2":"4"},{"1":"DCAF10","2":"4"},{"1":"DCAF13","2":"4"},{"1":"DCAF15","2":"4"},{"1":"DCP2","2":"4"},{"1":"DDR2","2":"4"},{"1":"DDX11","2":"4"},{"1":"DDX18","2":"4"},{"1":"DDX28","2":"4"},{"1":"DDX52","2":"4"},{"1":"DERL1","2":"4"},{"1":"DGCR8","2":"4"},{"1":"DHFR","2":"4"},{"1":"DHX36","2":"4"},{"1":"DIAPH1","2":"4"},{"1":"DIDO1","2":"4"},{"1":"DIEXF","2":"4"},{"1":"DIMT1","2":"4"},{"1":"DIS3L2","2":"4"},{"1":"DNAJB12","2":"4"},{"1":"DNAJC27","2":"4"},{"1":"DNAJC3","2":"4"},{"1":"DNHD1","2":"4"},{"1":"DOCK8","2":"4"},{"1":"DOPEY1","2":"4"},{"1":"DPY19L1","2":"4"},{"1":"DSTYK","2":"4"},{"1":"DYNC1LI2","2":"4"},{"1":"DYNC2LI1","2":"4"},{"1":"DYRK2","2":"4"},{"1":"EARS2","2":"4"},{"1":"ECHDC1","2":"4"},{"1":"EFCAB2","2":"4"},{"1":"EGLN1","2":"4"},{"1":"EHBP1L1","2":"4"},{"1":"EIF3K","2":"4"},{"1":"EIF4E3","2":"4"},{"1":"EIF4G3","2":"4"},{"1":"ELAVL1","2":"4"},{"1":"ELL2","2":"4"},{"1":"ELMO2","2":"4"},{"1":"ELMOD2","2":"4"},{"1":"ELOVL5","2":"4"},{"1":"ELP6","2":"4"},{"1":"EML2","2":"4"},{"1":"ENDOV","2":"4"},{"1":"ENO1","2":"4"},{"1":"ENOSF1","2":"4"},{"1":"ENTHD2","2":"4"},{"1":"ENTPD1","2":"4"},{"1":"EP400","2":"4"},{"1":"EPB41L4A","2":"4"},{"1":"EPB41L5","2":"4"},{"1":"EPC1","2":"4"},{"1":"ERCC6L2","2":"4"},{"1":"ERCC8","2":"4"},{"1":"ERGIC1","2":"4"},{"1":"ERGIC2","2":"4"},{"1":"ESD","2":"4"},{"1":"ETV6","2":"4"},{"1":"EVI5L","2":"4"},{"1":"EWSR1","2":"4"},{"1":"EYA3","2":"4"},{"1":"FAHD2A","2":"4"},{"1":"FAM120AOS","2":"4"},{"1":"FAM126A","2":"4"},{"1":"FAM126B","2":"4"},{"1":"FAM134A","2":"4"},{"1":"FAM149B1","2":"4"},{"1":"FAM161A","2":"4"},{"1":"FAM178A","2":"4"},{"1":"FAM192A","2":"4"}],"options":{"columns":{"min":{},"max":[10],"total":[2]},"rows":{"min":[10],"max":[10],"total":[7366]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIGdyb3VwX2J5KGdlbmVfbmFtZSkgJT4lIHN1bW1hcmlzZShuPW4oKSkgJT4lIHN1bW1hcmlzZShzdW0obj4xKSkgXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_sm_wgn %&gt;% group_by(gene_name) %&gt;% summarise(n=n()) %&gt;% summarise(sum(n&gt;1)) </code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["sum(n > 1)"],"name":[1],"type":["int"],"align":["right"]}],"data":[{"1":"5075"}],"options":{"columns":{"min":{},"max":[10],"total":[1]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>5075 of 7366 have multiple probes.</p>
<p>problem row (has NAs):</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIGZpbHRlcihwcm9iZV9JRD09XCIxNTUyMjU2X2FfYXRcIilcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_sm_wgn %&gt;% filter(probe_ID==&quot;1552256_a_at&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin eyJtZXRhZGF0YSI6eyJjbGFzc2VzIjpbImRhdGEuZnJhbWUiXSwibnJvdyI6MSwibmNvbCI6NTYxLCJzdW1tYXJ5Ijp7IkRlc2NyaXB0aW9uIjpbImRmIFsxIMOXIDU2MV0iXX19LCJyZGYiOiJINHNJQUFBQUFBQUFBKzJjZTJ4ZVpSM0hYOG9LYk9BeU1rRXhHQkVJb3NEUzMrOTUzL09jQTRJYkxBNGlJSElkQWRuSzFtN2RTcS92MW5aZDI3ZjN5eTUwbDhDcWhJeEJVSlNJT2hHTUpBWWhoTVNTYU1RWjR5WHpBZ0taaGo4SVF1UmlPOXUzZmovODVmOXRzdER2T2UvemV6N1BjODU1UHVlY3Z1SEdsYXZEb3RXTGNybmNpYmtGSjFUa1RxeWMralZYZWN2Tlg3NGt6ZVVXVkV5RkUzSUxjZ3VuLzlzKzlhR2x1VnlGVFlVbC83UGpwSnV1V25IamxkeDZtaFVLN29Wa1RmV2E2dUpVWGp5OWIvbnVVOFBsVCt4Nlp5NUh6ZDFuVFR4eXhsdDNsWFBIelpNL3Y2SGxsSExlOXJydVAzaEZidWJudjduMjRYRDFSYTg5VTg0anEzWC94Smptb1EzYS82V1RrODlVL3ViaXVmNWYwOC9YQmEzZis1eTJiOW1odVhSbWJmV0YyWUp5Ym4xUHg3TnhZdnJuRzNQdEw5UDJtODZlZk9ybFQ2d3M1N1hITkkrczFucmw0YzNrdHZXNnYrOEIzVC8rZmMzTnY5TDU3YXJYOXR2ZjByejNyc21wbjVmS3VmK255cis4cFBVMzFSNy9tYXQzanU0dm5UWHg0RzlmZUcrTy94M2R2M3RROTNkOFJmdnJMK3JuaDY3VlBIYTI4dTk4U2V1MWpHQStIcXk5NDQxVEQ1Vnord0p0MzRYNTdrSDd2aWVVYjJDVjVwNkxjUDUvWHVkLzQwSTlQenBmVlo1N1g5VCtOcHlrODF2L21MYmZjb2YyMS9ZMTdhL3pKdDMvK003Sm4vM2dqdHZLdVFuWHc5WTNOYmRjby9WS3J1Zi8xb2QwLzlnS25mOWRyMnUrTFp0NDZQMHpOcFZ6OGMvYWZzdmY5SGdNZmx3ejY5VlA2dlV6K25jZGJ4Zkd2MzFDK3h2TzYzaTM0ZnhveFByVHZsSjVlazlYbnE0VlduL1RFVDErbTVkcXZhYkY2RytmN2gvRStqcU02Mk53dWZMczZ3M1RQM1B6aWZscm1SM3VURjVYMGp4K3J1YlNQM1I4RFhmcWZGZi9Xbm4zdjZMblovY3ZjSDM4Q2VNOVUrZW43bGJOeGVYS3N4WHJ4K2FydFAvT2picS9pT3VoKzRqMlg4SjYwWVQ1MlhXNTdoLzZ0NDVuRkxrZmZ1dTlYZHNQdEdPOWVWbnpTS3I1MEpQS3cvTzErM1lkMzYySHc1ZGVyRDgyMS8vMWVyMWVpdkgxWXozdGZBVCs2VkQrZnF4dmZYL1UvU1g0dVJQbjkrQy90SDM5dFhvK3RaNmk3WnN3di9jOHA4ZTdFZjVwYjlYUHQ4TVBXMHBhZitBUG1QOFhkTDZHaHJYZXdTdTB2NTFQNnZqM3ZLaitYSS9yWSt3Q3JiL3JhZTEvNkh6bDY0WC9xb2UwLzk0M01aNCtyZCtNNHpGOEg5YnZ2K3I0TnJ5cjErOUcxSysrUVBzZmdiOUhlN1RlL3Rkd1A1SFRlbDFCUHovMml0WnJmVjducC9rQnplMjlldjQzNC96czJRM2ZUMnI3L2hxc2IxaWY5eDdUOFhiaGZPcDlWZWV6ZENINHZxM2piWU1mT3JFZW5qK3A4elY2VE5zM0pNclRCeDhOdnEvajJmWmRuWSt0MTJ0LzNUZ2U3VXMwRDkySjljQzAvbmFjUDBPM1lYMVlyUE16K0l6VzMzaFVjeC9PM3lId05KMm45YmVkaHVOeHJyWnZ4LzF1eDVDT2YwZVQxbCtMODd2ck1kei9ITkg2dmUvaWZyTmI2dzkxS204ZDZwZmUxbnJmK1lMdTM5YWgvUmVmVnQ2V3Q3Vy9BYXhmdlZmaS9NVHpVZGVqNFAyTGZyNGowLzUzM3FMajNYcUZ0aCtHRDdwd1A5dDB1dGJyK1ozbVVSeVBmWmZwL1V3SG5rZUt1QjZiTDhiMTBLNzFOaDNXNjdzWjY4L2U3WHI5c2IvUjdWcS85c2Q2dk1ZL3E3eEQ4RkhiajdUOTNYZ2UySXo3eFcyZlZQNDl6MnNlSHRCNkt4NnR2YXZpamZ2bXpnK3NsOXUvcDhkcmZML1dHOTJDOVJ6clQyT3J6bDhYbnBkYnY0bm5uNGMxZDY0RlArNHYrOXV3bm1COUhzWjYyNGJyYStoWm5IK0c1NHQzTmJldTAvWTdQcVgxN3oycXZDMFhZcjV3ZmUwZngvM0lGM1grcjhYN2lER01yL00rUFQ2OVMrQ3J2VmhQLzZtNTVWazhqK0g5UXduUHJ4T2YwL092LzRkYTcvRVRkYndqQjVTbmlQdlg1cC9nZlEvbSsvNmcxOGZnZTFwL0IrNm5paGZnZmgzUE01MTRmekdRS0gvUFdxMi9ZWW5tQWR5L0ZGL1EvbmJqL3ErSSsrT0J4N1hld2FkMFBvZXUwL3I3cjliMXBmY0dyYmZuSEszWGlmdUhub09hdjM1WTU3TUx2aDdCK2JYbmtMYnZ4L28waHV0eDVETjR2c0h6ZEQvZWozUmhmZXlEajhjd25zR0M5dGVINjNublVUemZmcWpqWFZXcjYxMFI5Mys3RG1yNzd1WGEvL2dOZWp3R0t2RzhoK3UzZVIvR2ovSHVxdFAyQjQ1by9VSGNyL1M5b2ZNemZrRDVSdkUrc0ExK0cvczA1bStsdHIrOVh2c3Y4ZjdzcUg1K0w0NW51NjUzUFc5Ty8zcnlvZms4bitmemZKN1A4M2sreitmNVBKL244LytmbDQvaCtYVTMvaDdONzA4MG42LzdTM2pmMTRUbi85NDkrbnl3QTg5dmJZZnhmUHQ3elFmVzYvdU1UandmYkMxcEh2c1czaS9pNzNFMWoycTkzZmVESjlIbjd5YThyejFRaWZjSDRHMXYwdjVxejhQZkIzK3Ard2UraXI4UEw4WDd2dG4zb2ZMVm1jcUc2bnRxV25QSHZ5QlRZVE1iRjI2b2FhaFpNNzFuWnNNcFRTMk5kOWVzdVdibGJGNTEwM1dGcWl4TmtDTnlpcHhwenFxUURkbVJBM0lldVlBTXZneDhHZmd5NGJPcXFpcGtRM2JrZ0p4SExpQW55QkU1UlFhZmdjL0FaK0F6OEJuNERId0dQZ09mZ2MvQTUrQno4RG40SEh3T1BnZWZnOC9CNStCejhBWHdCZkFGOEFYd0JmQUY4QVh3QmZBRjhBWHc1Y0dYQjE4ZWZIbnc1Y0dYQjE4ZWZIbnc1Y0dYQjE4QmZBWHdGY0JYQUY4QmZBWHdGY0JYQUY4QmZBWHdKZUJMd0plQUx3RmZBcjRFZkFuNEV2QWw0RXZBRjhFWHdSZkJGOEVYd1JmQkY4RVh3UmZCRjhHWGdpOEZYd3ErRkh3cCtGTHdwZUJMd1plQ0x3VmZCcjRNZkJuNE12Qmw0TXZBbDRFdkExOEdQdmpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENEErRFB3eitNUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGpENFErSFB4eitjUGdqd0I4Qi9nandSNEEvQXZ3UjRJOEFmd1Q0SThBZkFmNEk4RWVBUHdMOEVlQ1BBSDhFK0NQQUh3SCtDUEJIZ0Q4Qy9CSGdqd0IvQlBnandCOEIvZ2p3UjRBL0F2d1I0SThBZndUNEk4QWZBZjRJOEVlQVA0TDRJeXNrZWVhSW5DSm5tbVc5bnM2RzdNZ0JPWTljUUFaZkFYd0Y4QlhBbDRBdkFWOEN2Z1I4Q2ZnUzhDWGdTOENYZ0M4Qlh3UmZCRjhFWHdSZkJGOEVYd1JmQkY4RVh3UmZDcjRVZkNuNFV2Q2w0RXZCbDRJdkJWOEt2aFI4R2ZneThHWGd5OENYZ1M4RFh3YStESHdaK0RMbGkxVlZ5SWJzeUFFNWoxeEFUcEFqY29vTVBnT2ZnYy9BWitBejhCbjRESHdHUGdPZmdjL0I1K0J6OERuNEhId09QZ2VmZzgvQjUrQUw0QXZnQytBTDRBdmdDK0REZWgwRCtBTDRBdmp5NE11REx3KytQUGp5NE11REQvNkk4RWVFUHlMOEVlR1BDSDlFK0NQQ0h4SCtpUEJIaEQ4aS9CSGhqd2gvUlBnandoOFIvb2p3UjRRL0l2d1I0WThJZjBUNEk4SWZFZjZJOEVlRVB5TDhFZUdQQ0g5RStDUENIeEgraVBCSGhEOGkvQkhoandoL1JQZ2p3aDhSL29qd1I0US9JdndSNFk4SWYwVDRJOElmRWY2SThFZUVQeUw4RWVHUENIK2s4RWNLZjZUd1J3cC9wUEJIQ24razhFY0tmNlR3UndwL3BQQkhDbitrOEVjS2Y2VHdSd3AvcFBCSENuK2s4RWNLZjZUd1J3cC9wUEJIQ24razhFY0tmNlJsZnl5Y3l0Ti92cTc2eUliSURSazJsT2V3dk1HNHdia2hjRU9lR3dyY1FEQWpXSGt1WnpjNHdaeGdUakFubUJQTUNmYVJLWFNDK1VmQU9JV0JwSUdrZ2FTQnBGTXExaS9TTEd4cGJGczIrMldhangzZmNmeWZmdHRtWFgxMTY4eTNiY29iRjYydkxsWXZxMjJaL3JwTkx2Y0JtcHpjMkZTc2EyeVlhbFN4ZExvQ0dwL1FnZzFMdGpSTVU2eS9aTjNHTFEyYkw1bFN6bFFQTXpnNVJadjlmZnAvbXpQZFo4V0hNN1VxWjJxZFZOT3dvYTVoOWt0QWxmWFZkOWZVejRURlU4TTlQdHBsVFMxMURjWFpvVXh0YlYxV2JDeFd6MzV1MGJyRyt0a3R4d2VYKytBL0Y4TW9sdGxIQUFBPSJ9 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]},{"label":["probe_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["GSM50986"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["GSM50987"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["GSM50988"],"name":[5],"type":["dbl"],"align":["right"]},{"label":["GSM50989"],"name":[6],"type":["dbl"],"align":["right"]},{"label":["GSM50990"],"name":[7],"type":["dbl"],"align":["right"]},{"label":["GSM50991"],"name":[8],"type":["dbl"],"align":["right"]},{"label":["GSM50992"],"name":[9],"type":["dbl"],"align":["right"]},{"label":["GSM50993"],"name":[10],"type":["dbl"],"align":["right"]},{"label":["GSM50994"],"name":[11],"type":["dbl"],"align":["right"]},{"label":["GSM50995"],"name":[12],"type":["dbl"],"align":["right"]},{"label":["GSM50996"],"name":[13],"type":["dbl"],"align":["right"]},{"label":["GSM50997"],"name":[14],"type":["dbl"],"align":["right"]},{"label":["GSM50998"],"name":[15],"type":["dbl"],"align":["right"]},{"label":["GSM50999"],"name":[16],"type":["dbl"],"align":["right"]},{"label":["GSM51000"],"name":[17],"type":["dbl"],"align":["right"]},{"label":["GSM51001"],"name":[18],"type":["dbl"],"align":["right"]},{"label":["GSM51002"],"name":[19],"type":["dbl"],"align":["right"]},{"label":["GSM51003"],"name":[20],"type":["dbl"],"align":["right"]},{"label":["GSM51004"],"name":[21],"type":["dbl"],"align":["right"]},{"label":["GSM51005"],"name":[22],"type":["dbl"],"align":["right"]},{"label":["GSM51006"],"name":[23],"type":["dbl"],"align":["right"]},{"label":["GSM51007"],"name":[24],"type":["dbl"],"align":["right"]},{"label":["GSM51008"],"name":[25],"type":["dbl"],"align":["right"]},{"label":["GSM51009"],"name":[26],"type":["dbl"],"align":["right"]},{"label":["GSM51010"],"name":[27],"type":["dbl"],"align":["right"]},{"label":["GSM51011"],"name":[28],"type":["dbl"],"align":["right"]},{"label":["GSM51012"],"name":[29],"type":["dbl"],"align":["right"]},{"label":["GSM51013"],"name":[30],"type":["dbl"],"align":["right"]},{"label":["GSM51014"],"name":[31],"type":["dbl"],"align":["right"]},{"label":["GSM51015"],"name":[32],"type":["dbl"],"align":["right"]},{"label":["GSM51016"],"name":[33],"type":["dbl"],"align":["right"]},{"label":["GSM51017"],"name":[34],"type":["dbl"],"align":["right"]},{"label":["GSM51018"],"name":[35],"type":["dbl"],"align":["right"]},{"label":["GSM51019"],"name":[36],"type":["dbl"],"align":["right"]},{"label":["GSM51020"],"name":[37],"type":["dbl"],"align":["right"]},{"label":["GSM51021"],"name":[38],"type":["dbl"],"align":["right"]},{"label":["GSM51022"],"name":[39],"type":["dbl"],"align":["right"]},{"label":["GSM51023"],"name":[40],"type":["dbl"],"align":["right"]},{"label":["GSM51024"],"name":[41],"type":["dbl"],"align":["right"]},{"label":["GSM51025"],"name":[42],"type":["dbl"],"align":["right"]},{"label":["GSM51026"],"name":[43],"type":["dbl"],"align":["right"]},{"label":["GSM51027"],"name":[44],"type":["dbl"],"align":["right"]},{"label":["GSM51028"],"name":[45],"type":["dbl"],"align":["right"]},{"label":["GSM51029"],"name":[46],"type":["dbl"],"align":["right"]},{"label":["GSM51030"],"name":[47],"type":["dbl"],"align":["right"]},{"label":["GSM51031"],"name":[48],"type":["dbl"],"align":["right"]},{"label":["GSM51032"],"name":[49],"type":["dbl"],"align":["right"]},{"label":["GSM51033"],"name":[50],"type":["dbl"],"align":["right"]},{"label":["GSM51034"],"name":[51],"type":["dbl"],"align":["right"]},{"label":["GSM51035"],"name":[52],"type":["dbl"],"align":["right"]},{"label":["GSM51036"],"name":[53],"type":["dbl"],"align":["right"]},{"label":["GSM51037"],"name":[54],"type":["dbl"],"align":["right"]},{"label":["GSM51038"],"name":[55],"type":["dbl"],"align":["right"]},{"label":["GSM51039"],"name":[56],"type":["dbl"],"align":["right"]},{"label":["GSM51040"],"name":[57],"type":["dbl"],"align":["right"]},{"label":["GSM51041"],"name":[58],"type":["dbl"],"align":["right"]},{"label":["GSM51042"],"name":[59],"type":["dbl"],"align":["right"]},{"label":["GSM51043"],"name":[60],"type":["dbl"],"align":["right"]},{"label":["GSM51044"],"name":[61],"type":["dbl"],"align":["right"]},{"label":["GSM51045"],"name":[62],"type":["dbl"],"align":["right"]},{"label":["GSM51046"],"name":[63],"type":["dbl"],"align":["right"]},{"label":["GSM51047"],"name":[64],"type":["dbl"],"align":["right"]},{"label":["GSM51048"],"name":[65],"type":["dbl"],"align":["right"]},{"label":["GSM51049"],"name":[66],"type":["dbl"],"align":["right"]},{"label":["GSM51050"],"name":[67],"type":["dbl"],"align":["right"]},{"label":["GSM51051"],"name":[68],"type":["dbl"],"align":["right"]},{"label":["GSM51052"],"name":[69],"type":["dbl"],"align":["right"]},{"label":["GSM51053"],"name":[70],"type":["dbl"],"align":["right"]},{"label":["GSM51054"],"name":[71],"type":["dbl"],"align":["right"]},{"label":["GSM51055"],"name":[72],"type":["dbl"],"align":["right"]},{"label":["GSM51056"],"name":[73],"type":["dbl"],"align":["right"]},{"label":["GSM51057"],"name":[74],"type":["dbl"],"align":["right"]},{"label":["GSM51058"],"name":[75],"type":["dbl"],"align":["right"]},{"label":["GSM51059"],"name":[76],"type":["dbl"],"align":["right"]},{"label":["GSM51060"],"name":[77],"type":["dbl"],"align":["right"]},{"label":["GSM51061"],"name":[78],"type":["dbl"],"align":["right"]},{"label":["GSM51062"],"name":[79],"type":["dbl"],"align":["right"]},{"label":["GSM51063"],"name":[80],"type":["dbl"],"align":["right"]},{"label":["GSM51064"],"name":[81],"type":["dbl"],"align":["right"]},{"label":["GSM51065"],"name":[82],"type":["dbl"],"align":["right"]},{"label":["GSM51066"],"name":[83],"type":["dbl"],"align":["right"]},{"label":["GSM51067"],"name":[84],"type":["dbl"],"align":["right"]},{"label":["GSM51068"],"name":[85],"type":["dbl"],"align":["right"]},{"label":["GSM51069"],"name":[86],"type":["dbl"],"align":["right"]},{"label":["GSM51070"],"name":[87],"type":["dbl"],"align":["right"]},{"label":["GSM51071"],"name":[88],"type":["dbl"],"align":["right"]},{"label":["GSM51072"],"name":[89],"type":["dbl"],"align":["right"]},{"label":["GSM51073"],"name":[90],"type":["dbl"],"align":["right"]},{"label":["GSM51074"],"name":[91],"type":["dbl"],"align":["right"]},{"label":["GSM51075"],"name":[92],"type":["dbl"],"align":["right"]},{"label":["GSM51076"],"name":[93],"type":["dbl"],"align":["right"]},{"label":["GSM51077"],"name":[94],"type":["dbl"],"align":["right"]},{"label":["GSM51078"],"name":[95],"type":["dbl"],"align":["right"]},{"label":["GSM51079"],"name":[96],"type":["dbl"],"align":["right"]},{"label":["GSM51080"],"name":[97],"type":["dbl"],"align":["right"]},{"label":["GSM51081"],"name":[98],"type":["dbl"],"align":["right"]},{"label":["GSM51082"],"name":[99],"type":["dbl"],"align":["right"]},{"label":["GSM51083"],"name":[100],"type":["dbl"],"align":["right"]},{"label":["GSM51084"],"name":[101],"type":["dbl"],"align":["right"]},{"label":["GSM51085"],"name":[102],"type":["dbl"],"align":["right"]},{"label":["GSM51086"],"name":[103],"type":["dbl"],"align":["right"]},{"label":["GSM51087"],"name":[104],"type":["dbl"],"align":["right"]},{"label":["GSM51088"],"name":[105],"type":["dbl"],"align":["right"]},{"label":["GSM51089"],"name":[106],"type":["dbl"],"align":["right"]},{"label":["GSM51090"],"name":[107],"type":["dbl"],"align":["right"]},{"label":["GSM51091"],"name":[108],"type":["dbl"],"align":["right"]},{"label":["GSM51092"],"name":[109],"type":["dbl"],"align":["right"]},{"label":["GSM51093"],"name":[110],"type":["dbl"],"align":["right"]},{"label":["GSM51094"],"name":[111],"type":["dbl"],"align":["right"]},{"label":["GSM51095"],"name":[112],"type":["dbl"],"align":["right"]},{"label":["GSM51096"],"name":[113],"type":["dbl"],"align":["right"]},{"label":["GSM51097"],"name":[114],"type":["dbl"],"align":["right"]},{"label":["GSM51098"],"name":[115],"type":["dbl"],"align":["right"]},{"label":["GSM51099"],"name":[116],"type":["dbl"],"align":["right"]},{"label":["GSM51100"],"name":[117],"type":["dbl"],"align":["right"]},{"label":["GSM51101"],"name":[118],"type":["dbl"],"align":["right"]},{"label":["GSM51102"],"name":[119],"type":["dbl"],"align":["right"]},{"label":["GSM51103"],"name":[120],"type":["dbl"],"align":["right"]},{"label":["GSM51104"],"name":[121],"type":["dbl"],"align":["right"]},{"label":["GSM51105"],"name":[122],"type":["dbl"],"align":["right"]},{"label":["GSM51106"],"name":[123],"type":["dbl"],"align":["right"]},{"label":["GSM51107"],"name":[124],"type":["dbl"],"align":["right"]},{"label":["GSM51108"],"name":[125],"type":["dbl"],"align":["right"]},{"label":["GSM51109"],"name":[126],"type":["dbl"],"align":["right"]},{"label":["GSM51110"],"name":[127],"type":["dbl"],"align":["right"]},{"label":["GSM51111"],"name":[128],"type":["dbl"],"align":["right"]},{"label":["GSM51112"],"name":[129],"type":["dbl"],"align":["right"]},{"label":["GSM51113"],"name":[130],"type":["dbl"],"align":["right"]},{"label":["GSM51114"],"name":[131],"type":["dbl"],"align":["right"]},{"label":["GSM51115"],"name":[132],"type":["dbl"],"align":["right"]},{"label":["GSM51116"],"name":[133],"type":["dbl"],"align":["right"]},{"label":["GSM51117"],"name":[134],"type":["dbl"],"align":["right"]},{"label":["GSM51118"],"name":[135],"type":["dbl"],"align":["right"]},{"label":["GSM51119"],"name":[136],"type":["dbl"],"align":["right"]},{"label":["GSM51120"],"name":[137],"type":["dbl"],"align":["right"]},{"label":["GSM51121"],"name":[138],"type":["dbl"],"align":["right"]},{"label":["GSM51122"],"name":[139],"type":["dbl"],"align":["right"]},{"label":["GSM51123"],"name":[140],"type":["dbl"],"align":["right"]},{"label":["GSM51124"],"name":[141],"type":["dbl"],"align":["right"]},{"label":["GSM51125"],"name":[142],"type":["dbl"],"align":["right"]},{"label":["GSM51126"],"name":[143],"type":["dbl"],"align":["right"]},{"label":["GSM51127"],"name":[144],"type":["dbl"],"align":["right"]},{"label":["GSM51128"],"name":[145],"type":["dbl"],"align":["right"]},{"label":["GSM51129"],"name":[146],"type":["dbl"],"align":["right"]},{"label":["GSM51130"],"name":[147],"type":["dbl"],"align":["right"]},{"label":["GSM51131"],"name":[148],"type":["dbl"],"align":["right"]},{"label":["GSM51132"],"name":[149],"type":["dbl"],"align":["right"]},{"label":["GSM51133"],"name":[150],"type":["dbl"],"align":["right"]},{"label":["GSM51134"],"name":[151],"type":["dbl"],"align":["right"]},{"label":["GSM51135"],"name":[152],"type":["dbl"],"align":["right"]},{"label":["GSM51136"],"name":[153],"type":["dbl"],"align":["right"]},{"label":["GSM51137"],"name":[154],"type":["dbl"],"align":["right"]},{"label":["GSM51138"],"name":[155],"type":["dbl"],"align":["right"]},{"label":["GSM51139"],"name":[156],"type":["dbl"],"align":["right"]},{"label":["GSM51140"],"name":[157],"type":["dbl"],"align":["right"]},{"label":["GSM51141"],"name":[158],"type":["dbl"],"align":["right"]},{"label":["GSM51142"],"name":[159],"type":["dbl"],"align":["right"]},{"label":["GSM51143"],"name":[160],"type":["dbl"],"align":["right"]},{"label":["GSM51144"],"name":[161],"type":["dbl"],"align":["right"]},{"label":["GSM51145"],"name":[162],"type":["dbl"],"align":["right"]},{"label":["GSM51146"],"name":[163],"type":["dbl"],"align":["right"]},{"label":["GSM51147"],"name":[164],"type":["dbl"],"align":["right"]},{"label":["GSM51148"],"name":[165],"type":["dbl"],"align":["right"]},{"label":["GSM51149"],"name":[166],"type":["dbl"],"align":["right"]},{"label":["GSM51150"],"name":[167],"type":["dbl"],"align":["right"]},{"label":["GSM51151"],"name":[168],"type":["dbl"],"align":["right"]},{"label":["GSM51152"],"name":[169],"type":["dbl"],"align":["right"]},{"label":["GSM51153"],"name":[170],"type":["dbl"],"align":["right"]},{"label":["GSM51154"],"name":[171],"type":["dbl"],"align":["right"]},{"label":["GSM51155"],"name":[172],"type":["dbl"],"align":["right"]},{"label":["GSM51156"],"name":[173],"type":["dbl"],"align":["right"]},{"label":["GSM51157"],"name":[174],"type":["dbl"],"align":["right"]},{"label":["GSM51158"],"name":[175],"type":["dbl"],"align":["right"]},{"label":["GSM51159"],"name":[176],"type":["dbl"],"align":["right"]},{"label":["GSM51160"],"name":[177],"type":["dbl"],"align":["right"]},{"label":["GSM51161"],"name":[178],"type":["dbl"],"align":["right"]},{"label":["GSM51162"],"name":[179],"type":["dbl"],"align":["right"]},{"label":["GSM51163"],"name":[180],"type":["dbl"],"align":["right"]},{"label":["GSM51164"],"name":[181],"type":["dbl"],"align":["right"]},{"label":["GSM51165"],"name":[182],"type":["dbl"],"align":["right"]},{"label":["GSM51166"],"name":[183],"type":["dbl"],"align":["right"]},{"label":["GSM51167"],"name":[184],"type":["dbl"],"align":["right"]},{"label":["GSM51168"],"name":[185],"type":["dbl"],"align":["right"]},{"label":["GSM51169"],"name":[186],"type":["dbl"],"align":["right"]},{"label":["GSM51170"],"name":[187],"type":["dbl"],"align":["right"]},{"label":["GSM51171"],"name":[188],"type":["dbl"],"align":["right"]},{"label":["GSM51172"],"name":[189],"type":["dbl"],"align":["right"]},{"label":["GSM51173"],"name":[190],"type":["dbl"],"align":["right"]},{"label":["GSM51174"],"name":[191],"type":["dbl"],"align":["right"]},{"label":["GSM51175"],"name":[192],"type":["dbl"],"align":["right"]},{"label":["GSM51176"],"name":[193],"type":["dbl"],"align":["right"]},{"label":["GSM51177"],"name":[194],"type":["dbl"],"align":["right"]},{"label":["GSM51178"],"name":[195],"type":["dbl"],"align":["right"]},{"label":["GSM51179"],"name":[196],"type":["dbl"],"align":["right"]},{"label":["GSM51180"],"name":[197],"type":["dbl"],"align":["right"]},{"label":["GSM51181"],"name":[198],"type":["dbl"],"align":["right"]},{"label":["GSM51182"],"name":[199],"type":["dbl"],"align":["right"]},{"label":["GSM51183"],"name":[200],"type":["dbl"],"align":["right"]},{"label":["GSM51184"],"name":[201],"type":["dbl"],"align":["right"]},{"label":["GSM51185"],"name":[202],"type":["dbl"],"align":["right"]},{"label":["GSM51186"],"name":[203],"type":["dbl"],"align":["right"]},{"label":["GSM51187"],"name":[204],"type":["dbl"],"align":["right"]},{"label":["GSM51188"],"name":[205],"type":["dbl"],"align":["right"]},{"label":["GSM51189"],"name":[206],"type":["dbl"],"align":["right"]},{"label":["GSM51190"],"name":[207],"type":["dbl"],"align":["right"]},{"label":["GSM51191"],"name":[208],"type":["dbl"],"align":["right"]},{"label":["GSM51192"],"name":[209],"type":["dbl"],"align":["right"]},{"label":["GSM51193"],"name":[210],"type":["dbl"],"align":["right"]},{"label":["GSM51194"],"name":[211],"type":["dbl"],"align":["right"]},{"label":["GSM51195"],"name":[212],"type":["dbl"],"align":["right"]},{"label":["GSM51196"],"name":[213],"type":["dbl"],"align":["right"]},{"label":["GSM51197"],"name":[214],"type":["dbl"],"align":["right"]},{"label":["GSM51198"],"name":[215],"type":["dbl"],"align":["right"]},{"label":["GSM51199"],"name":[216],"type":["dbl"],"align":["right"]},{"label":["GSM51200"],"name":[217],"type":["dbl"],"align":["right"]},{"label":["GSM51201"],"name":[218],"type":["dbl"],"align":["right"]},{"label":["GSM51202"],"name":[219],"type":["dbl"],"align":["right"]},{"label":["GSM51203"],"name":[220],"type":["dbl"],"align":["right"]},{"label":["GSM51204"],"name":[221],"type":["dbl"],"align":["right"]},{"label":["GSM51205"],"name":[222],"type":["dbl"],"align":["right"]},{"label":["GSM51206"],"name":[223],"type":["dbl"],"align":["right"]},{"label":["GSM51207"],"name":[224],"type":["dbl"],"align":["right"]},{"label":["GSM51208"],"name":[225],"type":["dbl"],"align":["right"]},{"label":["GSM51209"],"name":[226],"type":["dbl"],"align":["right"]},{"label":["GSM51210"],"name":[227],"type":["dbl"],"align":["right"]},{"label":["GSM51211"],"name":[228],"type":["dbl"],"align":["right"]},{"label":["GSM51212"],"name":[229],"type":["dbl"],"align":["right"]},{"label":["GSM51213"],"name":[230],"type":["dbl"],"align":["right"]},{"label":["GSM51214"],"name":[231],"type":["dbl"],"align":["right"]},{"label":["GSM51215"],"name":[232],"type":["dbl"],"align":["right"]},{"label":["GSM51216"],"name":[233],"type":["dbl"],"align":["right"]},{"label":["GSM51217"],"name":[234],"type":["dbl"],"align":["right"]},{"label":["GSM51218"],"name":[235],"type":["dbl"],"align":["right"]},{"label":["GSM51219"],"name":[236],"type":["dbl"],"align":["right"]},{"label":["GSM51220"],"name":[237],"type":["dbl"],"align":["right"]},{"label":["GSM51221"],"name":[238],"type":["dbl"],"align":["right"]},{"label":["GSM51222"],"name":[239],"type":["dbl"],"align":["right"]},{"label":["GSM51223"],"name":[240],"type":["dbl"],"align":["right"]},{"label":["GSM51224"],"name":[241],"type":["dbl"],"align":["right"]},{"label":["GSM51225"],"name":[242],"type":["dbl"],"align":["right"]},{"label":["GSM51226"],"name":[243],"type":["dbl"],"align":["right"]},{"label":["GSM51227"],"name":[244],"type":["dbl"],"align":["right"]},{"label":["GSM51228"],"name":[245],"type":["dbl"],"align":["right"]},{"label":["GSM51229"],"name":[246],"type":["dbl"],"align":["right"]},{"label":["GSM51230"],"name":[247],"type":["dbl"],"align":["right"]},{"label":["GSM51231"],"name":[248],"type":["dbl"],"align":["right"]},{"label":["GSM51232"],"name":[249],"type":["dbl"],"align":["right"]},{"label":["GSM51233"],"name":[250],"type":["dbl"],"align":["right"]},{"label":["GSM51234"],"name":[251],"type":["dbl"],"align":["right"]},{"label":["GSM51235"],"name":[252],"type":["dbl"],"align":["right"]},{"label":["GSM51236"],"name":[253],"type":["dbl"],"align":["right"]},{"label":["GSM51237"],"name":[254],"type":["dbl"],"align":["right"]},{"label":["GSM51238"],"name":[255],"type":["dbl"],"align":["right"]},{"label":["GSM51239"],"name":[256],"type":["dbl"],"align":["right"]},{"label":["GSM51240"],"name":[257],"type":["dbl"],"align":["right"]},{"label":["GSM51241"],"name":[258],"type":["dbl"],"align":["right"]},{"label":["GSM51242"],"name":[259],"type":["dbl"],"align":["right"]},{"label":["GSM51243"],"name":[260],"type":["dbl"],"align":["right"]},{"label":["GSM51244"],"name":[261],"type":["dbl"],"align":["right"]},{"label":["GSM51245"],"name":[262],"type":["dbl"],"align":["right"]},{"label":["GSM51246"],"name":[263],"type":["dbl"],"align":["right"]},{"label":["GSM51247"],"name":[264],"type":["dbl"],"align":["right"]},{"label":["GSM51248"],"name":[265],"type":["dbl"],"align":["right"]},{"label":["GSM51249"],"name":[266],"type":["dbl"],"align":["right"]},{"label":["GSM51250"],"name":[267],"type":["dbl"],"align":["right"]},{"label":["GSM51251"],"name":[268],"type":["dbl"],"align":["right"]},{"label":["GSM51252"],"name":[269],"type":["dbl"],"align":["right"]},{"label":["GSM51253"],"name":[270],"type":["dbl"],"align":["right"]},{"label":["GSM51254"],"name":[271],"type":["dbl"],"align":["right"]},{"label":["GSM51255"],"name":[272],"type":["dbl"],"align":["right"]},{"label":["GSM51256"],"name":[273],"type":["dbl"],"align":["right"]},{"label":["GSM51257"],"name":[274],"type":["dbl"],"align":["right"]},{"label":["GSM51258"],"name":[275],"type":["dbl"],"align":["right"]},{"label":["GSM51259"],"name":[276],"type":["dbl"],"align":["right"]},{"label":["GSM51260"],"name":[277],"type":["dbl"],"align":["right"]},{"label":["GSM51261"],"name":[278],"type":["dbl"],"align":["right"]},{"label":["GSM51262"],"name":[279],"type":["dbl"],"align":["right"]},{"label":["GSM51263"],"name":[280],"type":["dbl"],"align":["right"]},{"label":["GSM51264"],"name":[281],"type":["dbl"],"align":["right"]},{"label":["GSM51265"],"name":[282],"type":["dbl"],"align":["right"]},{"label":["GSM51266"],"name":[283],"type":["dbl"],"align":["right"]},{"label":["GSM51267"],"name":[284],"type":["dbl"],"align":["right"]},{"label":["GSM51268"],"name":[285],"type":["dbl"],"align":["right"]},{"label":["GSM51269"],"name":[286],"type":["dbl"],"align":["right"]},{"label":["GSM51270"],"name":[287],"type":["dbl"],"align":["right"]},{"label":["GSM51271"],"name":[288],"type":["dbl"],"align":["right"]},{"label":["GSM51272"],"name":[289],"type":["dbl"],"align":["right"]},{"label":["GSM51273"],"name":[290],"type":["dbl"],"align":["right"]},{"label":["GSM51274"],"name":[291],"type":["dbl"],"align":["right"]},{"label":["GSM51275"],"name":[292],"type":["dbl"],"align":["right"]},{"label":["GSM51276"],"name":[293],"type":["dbl"],"align":["right"]},{"label":["GSM51277"],"name":[294],"type":["dbl"],"align":["right"]},{"label":["GSM51278"],"name":[295],"type":["dbl"],"align":["right"]},{"label":["GSM51279"],"name":[296],"type":["dbl"],"align":["right"]},{"label":["GSM51280"],"name":[297],"type":["dbl"],"align":["right"]},{"label":["GSM51281"],"name":[298],"type":["dbl"],"align":["right"]},{"label":["GSM51282"],"name":[299],"type":["dbl"],"align":["right"]},{"label":["GSM51283"],"name":[300],"type":["dbl"],"align":["right"]},{"label":["GSM51284"],"name":[301],"type":["dbl"],"align":["right"]},{"label":["GSM51285"],"name":[302],"type":["dbl"],"align":["right"]},{"label":["GSM51286"],"name":[303],"type":["dbl"],"align":["right"]},{"label":["GSM51287"],"name":[304],"type":["dbl"],"align":["right"]},{"label":["GSM51288"],"name":[305],"type":["dbl"],"align":["right"]},{"label":["GSM51289"],"name":[306],"type":["dbl"],"align":["right"]},{"label":["GSM51290"],"name":[307],"type":["dbl"],"align":["right"]},{"label":["GSM51291"],"name":[308],"type":["dbl"],"align":["right"]},{"label":["GSM51292"],"name":[309],"type":["dbl"],"align":["right"]},{"label":["GSM51293"],"name":[310],"type":["dbl"],"align":["right"]},{"label":["GSM51294"],"name":[311],"type":["dbl"],"align":["right"]},{"label":["GSM51295"],"name":[312],"type":["dbl"],"align":["right"]},{"label":["GSM51296"],"name":[313],"type":["dbl"],"align":["right"]},{"label":["GSM51297"],"name":[314],"type":["dbl"],"align":["right"]},{"label":["GSM51298"],"name":[315],"type":["dbl"],"align":["right"]},{"label":["GSM51299"],"name":[316],"type":["dbl"],"align":["right"]},{"label":["GSM51300"],"name":[317],"type":["dbl"],"align":["right"]},{"label":["GSM51301"],"name":[318],"type":["dbl"],"align":["right"]},{"label":["GSM51302"],"name":[319],"type":["dbl"],"align":["right"]},{"label":["GSM51303"],"name":[320],"type":["dbl"],"align":["right"]},{"label":["GSM51304"],"name":[321],"type":["dbl"],"align":["right"]},{"label":["GSM51305"],"name":[322],"type":["dbl"],"align":["right"]},{"label":["GSM51306"],"name":[323],"type":["dbl"],"align":["right"]},{"label":["GSM51307"],"name":[324],"type":["dbl"],"align":["right"]},{"label":["GSM51308"],"name":[325],"type":["dbl"],"align":["right"]},{"label":["GSM51309"],"name":[326],"type":["dbl"],"align":["right"]},{"label":["GSM51310"],"name":[327],"type":["dbl"],"align":["right"]},{"label":["GSM51311"],"name":[328],"type":["dbl"],"align":["right"]},{"label":["GSM51312"],"name":[329],"type":["dbl"],"align":["right"]},{"label":["GSM51313"],"name":[330],"type":["dbl"],"align":["right"]},{"label":["GSM51314"],"name":[331],"type":["dbl"],"align":["right"]},{"label":["GSM51315"],"name":[332],"type":["dbl"],"align":["right"]},{"label":["GSM51316"],"name":[333],"type":["dbl"],"align":["right"]},{"label":["GSM51317"],"name":[334],"type":["dbl"],"align":["right"]},{"label":["GSM51318"],"name":[335],"type":["dbl"],"align":["right"]},{"label":["GSM51319"],"name":[336],"type":["dbl"],"align":["right"]},{"label":["GSM51320"],"name":[337],"type":["dbl"],"align":["right"]},{"label":["GSM51321"],"name":[338],"type":["dbl"],"align":["right"]},{"label":["GSM51322"],"name":[339],"type":["dbl"],"align":["right"]},{"label":["GSM51323"],"name":[340],"type":["dbl"],"align":["right"]},{"label":["GSM51324"],"name":[341],"type":["dbl"],"align":["right"]},{"label":["GSM51325"],"name":[342],"type":["dbl"],"align":["right"]},{"label":["GSM51326"],"name":[343],"type":["dbl"],"align":["right"]},{"label":["GSM51327"],"name":[344],"type":["dbl"],"align":["right"]},{"label":["GSM51328"],"name":[345],"type":["dbl"],"align":["right"]},{"label":["GSM51329"],"name":[346],"type":["dbl"],"align":["right"]},{"label":["GSM51330"],"name":[347],"type":["dbl"],"align":["right"]},{"label":["GSM51331"],"name":[348],"type":["dbl"],"align":["right"]},{"label":["GSM51332"],"name":[349],"type":["dbl"],"align":["right"]},{"label":["GSM51333"],"name":[350],"type":["dbl"],"align":["right"]},{"label":["GSM51334"],"name":[351],"type":["dbl"],"align":["right"]},{"label":["GSM51335"],"name":[352],"type":["dbl"],"align":["right"]},{"label":["GSM51336"],"name":[353],"type":["dbl"],"align":["right"]},{"label":["GSM95646"],"name":[354],"type":["dbl"],"align":["right"]},{"label":["GSM95647"],"name":[355],"type":["dbl"],"align":["right"]},{"label":["GSM95648"],"name":[356],"type":["dbl"],"align":["right"]},{"label":["GSM95649"],"name":[357],"type":["dbl"],"align":["right"]},{"label":["GSM95650"],"name":[358],"type":["dbl"],"align":["right"]},{"label":["GSM95651"],"name":[359],"type":["dbl"],"align":["right"]},{"label":["GSM95652"],"name":[360],"type":["dbl"],"align":["right"]},{"label":["GSM95653"],"name":[361],"type":["dbl"],"align":["right"]},{"label":["GSM95654"],"name":[362],"type":["dbl"],"align":["right"]},{"label":["GSM95655"],"name":[363],"type":["dbl"],"align":["right"]},{"label":["GSM95656"],"name":[364],"type":["dbl"],"align":["right"]},{"label":["GSM95657"],"name":[365],"type":["dbl"],"align":["right"]},{"label":["GSM95658"],"name":[366],"type":["dbl"],"align":["right"]},{"label":["GSM95659"],"name":[367],"type":["dbl"],"align":["right"]},{"label":["GSM95660"],"name":[368],"type":["dbl"],"align":["right"]},{"label":["GSM95661"],"name":[369],"type":["dbl"],"align":["right"]},{"label":["GSM95662"],"name":[370],"type":["dbl"],"align":["right"]},{"label":["GSM95663"],"name":[371],"type":["dbl"],"align":["right"]},{"label":["GSM95664"],"name":[372],"type":["dbl"],"align":["right"]},{"label":["GSM95665"],"name":[373],"type":["dbl"],"align":["right"]},{"label":["GSM95666"],"name":[374],"type":["dbl"],"align":["right"]},{"label":["GSM95667"],"name":[375],"type":["dbl"],"align":["right"]},{"label":["GSM95668"],"name":[376],"type":["dbl"],"align":["right"]},{"label":["GSM95669"],"name":[377],"type":["dbl"],"align":["right"]},{"label":["GSM95670"],"name":[378],"type":["dbl"],"align":["right"]},{"label":["GSM95671"],"name":[379],"type":["dbl"],"align":["right"]},{"label":["GSM95672"],"name":[380],"type":["dbl"],"align":["right"]},{"label":["GSM95673"],"name":[381],"type":["dbl"],"align":["right"]},{"label":["GSM95674"],"name":[382],"type":["dbl"],"align":["right"]},{"label":["GSM95675"],"name":[383],"type":["dbl"],"align":["right"]},{"label":["GSM95676"],"name":[384],"type":["dbl"],"align":["right"]},{"label":["GSM95677"],"name":[385],"type":["dbl"],"align":["right"]},{"label":["GSM95678"],"name":[386],"type":["dbl"],"align":["right"]},{"label":["GSM95679"],"name":[387],"type":["dbl"],"align":["right"]},{"label":["GSM95680"],"name":[388],"type":["dbl"],"align":["right"]},{"label":["GSM95681"],"name":[389],"type":["dbl"],"align":["right"]},{"label":["GSM95682"],"name":[390],"type":["dbl"],"align":["right"]},{"label":["GSM95683"],"name":[391],"type":["dbl"],"align":["right"]},{"label":["GSM95684"],"name":[392],"type":["dbl"],"align":["right"]},{"label":["GSM95685"],"name":[393],"type":["dbl"],"align":["right"]},{"label":["GSM95686"],"name":[394],"type":["dbl"],"align":["right"]},{"label":["GSM95687"],"name":[395],"type":["dbl"],"align":["right"]},{"label":["GSM95688"],"name":[396],"type":["dbl"],"align":["right"]},{"label":["GSM95689"],"name":[397],"type":["dbl"],"align":["right"]},{"label":["GSM95690"],"name":[398],"type":["dbl"],"align":["right"]},{"label":["GSM95691"],"name":[399],"type":["dbl"],"align":["right"]},{"label":["GSM95692"],"name":[400],"type":["dbl"],"align":["right"]},{"label":["GSM95693"],"name":[401],"type":["dbl"],"align":["right"]},{"label":["GSM95694"],"name":[402],"type":["dbl"],"align":["right"]},{"label":["GSM95695"],"name":[403],"type":["dbl"],"align":["right"]},{"label":["GSM95696"],"name":[404],"type":["dbl"],"align":["right"]},{"label":["GSM95697"],"name":[405],"type":["dbl"],"align":["right"]},{"label":["GSM95698"],"name":[406],"type":["dbl"],"align":["right"]},{"label":["GSM95699"],"name":[407],"type":["dbl"],"align":["right"]},{"label":["GSM95700"],"name":[408],"type":["dbl"],"align":["right"]},{"label":["GSM95701"],"name":[409],"type":["dbl"],"align":["right"]},{"label":["GSM95702"],"name":[410],"type":["dbl"],"align":["right"]},{"label":["GSM95703"],"name":[411],"type":["dbl"],"align":["right"]},{"label":["GSM95704"],"name":[412],"type":["dbl"],"align":["right"]},{"label":["GSM95705"],"name":[413],"type":["dbl"],"align":["right"]},{"label":["GSM95706"],"name":[414],"type":["dbl"],"align":["right"]},{"label":["GSM95707"],"name":[415],"type":["dbl"],"align":["right"]},{"label":["GSM95708"],"name":[416],"type":["dbl"],"align":["right"]},{"label":["GSM95709"],"name":[417],"type":["dbl"],"align":["right"]},{"label":["GSM95710"],"name":[418],"type":["dbl"],"align":["right"]},{"label":["GSM95711"],"name":[419],"type":["dbl"],"align":["right"]},{"label":["GSM95712"],"name":[420],"type":["dbl"],"align":["right"]},{"label":["GSM95713"],"name":[421],"type":["dbl"],"align":["right"]},{"label":["GSM95714"],"name":[422],"type":["dbl"],"align":["right"]},{"label":["GSM95715"],"name":[423],"type":["dbl"],"align":["right"]},{"label":["GSM95716"],"name":[424],"type":["dbl"],"align":["right"]},{"label":["GSM95717"],"name":[425],"type":["dbl"],"align":["right"]},{"label":["GSM95718"],"name":[426],"type":["dbl"],"align":["right"]},{"label":["GSM95719"],"name":[427],"type":["dbl"],"align":["right"]},{"label":["GSM95720"],"name":[428],"type":["dbl"],"align":["right"]},{"label":["GSM95721"],"name":[429],"type":["dbl"],"align":["right"]},{"label":["GSM95722"],"name":[430],"type":["dbl"],"align":["right"]},{"label":["GSM95723"],"name":[431],"type":["dbl"],"align":["right"]},{"label":["GSM95724"],"name":[432],"type":["dbl"],"align":["right"]},{"label":["GSM95725"],"name":[433],"type":["dbl"],"align":["right"]},{"label":["GSM95726"],"name":[434],"type":["dbl"],"align":["right"]},{"label":["GSM95727"],"name":[435],"type":["dbl"],"align":["right"]},{"label":["GSM95728"],"name":[436],"type":["dbl"],"align":["right"]},{"label":["GSM95729"],"name":[437],"type":["dbl"],"align":["right"]},{"label":["GSM95730"],"name":[438],"type":["dbl"],"align":["right"]},{"label":["GSM95731"],"name":[439],"type":["dbl"],"align":["right"]},{"label":["GSM95732"],"name":[440],"type":["dbl"],"align":["right"]},{"label":["GSM95733"],"name":[441],"type":["dbl"],"align":["right"]},{"label":["GSM95734"],"name":[442],"type":["dbl"],"align":["right"]},{"label":["GSM95735"],"name":[443],"type":["dbl"],"align":["right"]},{"label":["GSM95736"],"name":[444],"type":["dbl"],"align":["right"]},{"label":["GSM95737"],"name":[445],"type":["dbl"],"align":["right"]},{"label":["GSM95738"],"name":[446],"type":["dbl"],"align":["right"]},{"label":["GSM95739"],"name":[447],"type":["dbl"],"align":["right"]},{"label":["GSM95740"],"name":[448],"type":["dbl"],"align":["right"]},{"label":["GSM95741"],"name":[449],"type":["dbl"],"align":["right"]},{"label":["GSM95742"],"name":[450],"type":["dbl"],"align":["right"]},{"label":["GSM95743"],"name":[451],"type":["dbl"],"align":["right"]},{"label":["GSM95744"],"name":[452],"type":["dbl"],"align":["right"]},{"label":["GSM95745"],"name":[453],"type":["dbl"],"align":["right"]},{"label":["GSM95746"],"name":[454],"type":["dbl"],"align":["right"]},{"label":["GSM95747"],"name":[455],"type":["dbl"],"align":["right"]},{"label":["GSM95748"],"name":[456],"type":["dbl"],"align":["right"]},{"label":["GSM95749"],"name":[457],"type":["dbl"],"align":["right"]},{"label":["GSM95750"],"name":[458],"type":["dbl"],"align":["right"]},{"label":["GSM95751"],"name":[459],"type":["dbl"],"align":["right"]},{"label":["GSM95752"],"name":[460],"type":["dbl"],"align":["right"]},{"label":["GSM95753"],"name":[461],"type":["dbl"],"align":["right"]},{"label":["GSM95754"],"name":[462],"type":["dbl"],"align":["right"]},{"label":["GSM95755"],"name":[463],"type":["dbl"],"align":["right"]},{"label":["GSM95756"],"name":[464],"type":["dbl"],"align":["right"]},{"label":["GSM95757"],"name":[465],"type":["dbl"],"align":["right"]},{"label":["GSM95758"],"name":[466],"type":["dbl"],"align":["right"]},{"label":["GSM95759"],"name":[467],"type":["dbl"],"align":["right"]},{"label":["GSM95760"],"name":[468],"type":["dbl"],"align":["right"]},{"label":["GSM95761"],"name":[469],"type":["dbl"],"align":["right"]},{"label":["GSM95762"],"name":[470],"type":["dbl"],"align":["right"]},{"label":["GSM95763"],"name":[471],"type":["dbl"],"align":["right"]},{"label":["GSM95764"],"name":[472],"type":["dbl"],"align":["right"]},{"label":["GSM95765"],"name":[473],"type":["dbl"],"align":["right"]},{"label":["GSM95766"],"name":[474],"type":["dbl"],"align":["right"]},{"label":["GSM95767"],"name":[475],"type":["dbl"],"align":["right"]},{"label":["GSM95768"],"name":[476],"type":["dbl"],"align":["right"]},{"label":["GSM95769"],"name":[477],"type":["dbl"],"align":["right"]},{"label":["GSM95770"],"name":[478],"type":["dbl"],"align":["right"]},{"label":["GSM95771"],"name":[479],"type":["dbl"],"align":["right"]},{"label":["GSM95772"],"name":[480],"type":["dbl"],"align":["right"]},{"label":["GSM95773"],"name":[481],"type":["dbl"],"align":["right"]},{"label":["GSM95774"],"name":[482],"type":["dbl"],"align":["right"]},{"label":["GSM95775"],"name":[483],"type":["dbl"],"align":["right"]},{"label":["GSM95776"],"name":[484],"type":["dbl"],"align":["right"]},{"label":["GSM95777"],"name":[485],"type":["dbl"],"align":["right"]},{"label":["GSM95778"],"name":[486],"type":["dbl"],"align":["right"]},{"label":["GSM95779"],"name":[487],"type":["dbl"],"align":["right"]},{"label":["GSM95780"],"name":[488],"type":["dbl"],"align":["right"]},{"label":["GSM95781"],"name":[489],"type":["dbl"],"align":["right"]},{"label":["GSM95782"],"name":[490],"type":["dbl"],"align":["right"]},{"label":["GSM95783"],"name":[491],"type":["dbl"],"align":["right"]},{"label":["GSM95784"],"name":[492],"type":["dbl"],"align":["right"]},{"label":["GSM95785"],"name":[493],"type":["dbl"],"align":["right"]},{"label":["GSM95786"],"name":[494],"type":["dbl"],"align":["right"]},{"label":["GSM95787"],"name":[495],"type":["dbl"],"align":["right"]},{"label":["GSM95788"],"name":[496],"type":["dbl"],"align":["right"]},{"label":["GSM95789"],"name":[497],"type":["dbl"],"align":["right"]},{"label":["GSM95790"],"name":[498],"type":["dbl"],"align":["right"]},{"label":["GSM95791"],"name":[499],"type":["dbl"],"align":["right"]},{"label":["GSM95792"],"name":[500],"type":["dbl"],"align":["right"]},{"label":["GSM95793"],"name":[501],"type":["dbl"],"align":["right"]},{"label":["GSM95794"],"name":[502],"type":["dbl"],"align":["right"]},{"label":["GSM95795"],"name":[503],"type":["dbl"],"align":["right"]},{"label":["GSM95796"],"name":[504],"type":["dbl"],"align":["right"]},{"label":["GSM95797"],"name":[505],"type":["dbl"],"align":["right"]},{"label":["GSM95798"],"name":[506],"type":["dbl"],"align":["right"]},{"label":["GSM95799"],"name":[507],"type":["dbl"],"align":["right"]},{"label":["GSM95800"],"name":[508],"type":["dbl"],"align":["right"]},{"label":["GSM95801"],"name":[509],"type":["dbl"],"align":["right"]},{"label":["GSM95802"],"name":[510],"type":["dbl"],"align":["right"]},{"label":["GSM95803"],"name":[511],"type":["dbl"],"align":["right"]},{"label":["GSM95804"],"name":[512],"type":["dbl"],"align":["right"]},{"label":["GSM95805"],"name":[513],"type":["dbl"],"align":["right"]},{"label":["GSM95806"],"name":[514],"type":["dbl"],"align":["right"]},{"label":["GSM95807"],"name":[515],"type":["dbl"],"align":["right"]},{"label":["GSM95808"],"name":[516],"type":["dbl"],"align":["right"]},{"label":["GSM95809"],"name":[517],"type":["dbl"],"align":["right"]},{"label":["GSM95810"],"name":[518],"type":["dbl"],"align":["right"]},{"label":["GSM95811"],"name":[519],"type":["dbl"],"align":["right"]},{"label":["GSM95812"],"name":[520],"type":["dbl"],"align":["right"]},{"label":["GSM95813"],"name":[521],"type":["dbl"],"align":["right"]},{"label":["GSM95814"],"name":[522],"type":["dbl"],"align":["right"]},{"label":["GSM95815"],"name":[523],"type":["dbl"],"align":["right"]},{"label":["GSM95816"],"name":[524],"type":["dbl"],"align":["right"]},{"label":["GSM95817"],"name":[525],"type":["dbl"],"align":["right"]},{"label":["GSM95818"],"name":[526],"type":["dbl"],"align":["right"]},{"label":["GSM95819"],"name":[527],"type":["dbl"],"align":["right"]},{"label":["GSM95820"],"name":[528],"type":["dbl"],"align":["right"]},{"label":["GSM95821"],"name":[529],"type":["dbl"],"align":["right"]},{"label":["GSM95822"],"name":[530],"type":["dbl"],"align":["right"]},{"label":["GSM95823"],"name":[531],"type":["dbl"],"align":["right"]},{"label":["GSM95824"],"name":[532],"type":["dbl"],"align":["right"]},{"label":["GSM95825"],"name":[533],"type":["dbl"],"align":["right"]},{"label":["GSM95826"],"name":[534],"type":["dbl"],"align":["right"]},{"label":["GSM102606"],"name":[535],"type":["dbl"],"align":["right"]},{"label":["GSM102607"],"name":[536],"type":["dbl"],"align":["right"]},{"label":["GSM102609"],"name":[537],"type":["dbl"],"align":["right"]},{"label":["GSM102610"],"name":[538],"type":["dbl"],"align":["right"]},{"label":["GSM102611"],"name":[539],"type":["dbl"],"align":["right"]},{"label":["GSM102612"],"name":[540],"type":["dbl"],"align":["right"]},{"label":["GSM102613"],"name":[541],"type":["dbl"],"align":["right"]},{"label":["GSM102614"],"name":[542],"type":["dbl"],"align":["right"]},{"label":["GSM102615"],"name":[543],"type":["dbl"],"align":["right"]},{"label":["GSM102616"],"name":[544],"type":["dbl"],"align":["right"]},{"label":["GSM102617"],"name":[545],"type":["dbl"],"align":["right"]},{"label":["GSM102618"],"name":[546],"type":["dbl"],"align":["right"]},{"label":["GSM102620"],"name":[547],"type":["dbl"],"align":["right"]},{"label":["GSM102621"],"name":[548],"type":["dbl"],"align":["right"]},{"label":["GSM102622"],"name":[549],"type":["dbl"],"align":["right"]},{"label":["GSM102623"],"name":[550],"type":["dbl"],"align":["right"]},{"label":["GSM102624"],"name":[551],"type":["dbl"],"align":["right"]},{"label":["GSM102625"],"name":[552],"type":["dbl"],"align":["right"]},{"label":["GSM102626"],"name":[553],"type":["dbl"],"align":["right"]},{"label":["GSM102627"],"name":[554],"type":["dbl"],"align":["right"]},{"label":["GSM102628"],"name":[555],"type":["dbl"],"align":["right"]},{"label":["GSM102629"],"name":[556],"type":["dbl"],"align":["right"]},{"label":["GSM102630"],"name":[557],"type":["dbl"],"align":["right"]},{"label":["GSM102631"],"name":[558],"type":["dbl"],"align":["right"]},{"label":["GSM102632"],"name":[559],"type":["dbl"],"align":["right"]},{"label":["GSM102633"],"name":[560],"type":["dbl"],"align":["right"]},{"label":["GSM102634"],"name":[561],"type":["dbl"],"align":["right"]}],"data":[{"1":"SCARB1","2":"1552256_a_at","3":"961.4","4":"966.9","5":"481.6","6":"405.3","7":"430.6","8":"2079","9":"181.1","10":"779","11":"1634.5","12":"716.9","13":"26.8","14":"414.5","15":"201.6","16":"568.4","17":"296.7","18":"514.8","19":"319.8","20":"196.8","21":"291.7","22":"208.9","23":"135.4","24":"779.1","25":"832","26":"374.3","27":"595.5","28":"1068","29":"285.1","30":"470.8","31":"463.3","32":"1175.7","33":"631.4","34":"33","35":"211.2","36":"450","37":"515.2","38":"383.5","39":"976.7","40":"404.7","41":"622.5","42":"713.5","43":"835.6","44":"921.7","45":"296.5","46":"281.9","47":"384.3","48":"464","49":"504.5","50":"597.9","51":"648.9","52":"498.7","53":"482.6","54":"192.3","55":"446.4","56":"1017","57":"184.2","58":"229.3","59":"341.7","60":"373.1","61":"437.2","62":"3654.4","63":"270.5","64":"367","65":"292.6","66":"518.3","67":"362.1","68":"840.2","69":"957.2","70":"92.9","71":"334.1","72":"350.3","73":"674.6","74":"957.2","75":"230.4","76":"828.9","77":"469.2","78":"457.6","79":"742.5","80":"425.9","81":"253.1","82":"388.3","83":"546.2","84":"468.1","85":"214.7","86":"216.6","87":"256.9","88":"252.6","89":"673.4","90":"745.4","91":"680.1","92":"1248.3","93":"337.3","94":"288","95":"156","96":"1032.5","97":"541.7","98":"242.9","99":"142.6","100":"1337.4","101":"492.7","102":"509.9","103":"248.7","104":"202.7","105":"324","106":"367.5","107":"218.1","108":"438.5","109":"325.1","110":"493.4","111":"537.7","112":"256","113":"935.7","114":"735.4","115":"831.4","116":"618.6","117":"555.2","118":"655.1","119":"477.3","120":"775.1","121":"2394.5","122":"742.5","123":"485.6","124":"90.8","125":"553.8","126":"26","127":"617.5","128":"442.3","129":"847.2","130":"613.4","131":"603.7","132":"523","133":"432.9","134":"702.9","135":"226.4","136":"304.5","137":"271.7","138":"238.1","139":"251.2","140":"391.2","141":"385.8","142":"344","143":"667.6","144":"792.8","145":"720.9","146":"2079.2","147":"918.7","148":"1138.2","149":"166.6","150":"836.8","151":"951.1","152":"708.5","153":"558.5","154":"140.2","155":"574","156":"656.3","157":"277.5","158":"754.8","159":"366.2","160":"191.8","161":"199.5","162":"137.2","163":"784.7","164":"815.9","165":"1338.2","166":"608","167":"467.2","168":"860.7","169":"316.3","170":"281.8","171":"392.1","172":"274.7","173":"504.9","174":"396.8","175":"620.7","176":"240.6","177":"1211.1","178":"465.8","179":"572.8","180":"517.1","181":"394.5","182":"372.1","183":"445.9","184":"10.4","185":"829.5","186":"241.7","187":"584.6","188":"703.7","189":"426.7","190":"356.9","191":"480","192":"385","193":"715.6","194":"838.2","195":"462.2","196":"714.9","197":"577.8","198":"695.5","199":"199","200":"592.3","201":"706","202":"258.2","203":"416.8","204":"548.3","205":"390.8","206":"408.4","207":"878","208":"129.2","209":"474.6","210":"538.8","211":"575.2","212":"295.9","213":"719.4","214":"201.2","215":"542.8","216":"3349.2","217":"423.6","218":"331.5","219":"303.4","220":"664.8","221":"552.3","222":"524.9","223":"474.4","224":"732.3","225":"403.6","226":"906.7","227":"355.9","228":"763.7","229":"476.5","230":"257.1","231":"509.6","232":"814","233":"1230.8","234":"411.7","235":"321.8","236":"274.8","237":"687","238":"213.6","239":"275.2","240":"1183.2","241":"411.7","242":"815.6","243":"181.7","244":"1032.3","245":"718.4","246":"379.3","247":"144.3","248":"222.7","249":"417.5","250":"1137","251":"752.6","252":"35.3","253":"297.8","254":"458.9","255":"1061","256":"814.7","257":"829.5","258":"251.6","259":"476.2","260":"313.7","261":"490.2","262":"438","263":"765.7","264":"622.9","265":"716.7","266":"764.8","267":"375.7","268":"728.2","269":"467.1","270":"351.6","271":"310.2","272":"867.3","273":"1020","274":"290.5","275":"808.3","276":"1316.1","277":"387.8","278":"57.6","279":"844.7","280":"441.4","281":"546.1","282":"626.3","283":"701.8","284":"300.1","285":"839.4","286":"533.9","287":"1609.9","288":"630.3","289":"3585.5","290":"787.1","291":"333.3","292":"283.6","293":"415.6","294":"1484.8","295":"703.5","296":"886.7","297":"322.4","298":"514.6","299":"447.3","300":"646.8","301":"502","302":"184.5","303":"656.7","304":"332.4","305":"976.9","306":"330.3","307":"661.5","308":"2139.8","309":"713.7","310":"1298.2","311":"554.1","312":"1096","313":"442.5","314":"506","315":"118.8","316":"469.8","317":"780.7","318":"1128.5","319":"622.4","320":"861.7","321":"771.9","322":"618.4","323":"625","324":"471.8","325":"580.3","326":"853","327":"678.7","328":"591.4","329":"924.1","330":"1279.8","331":"46.8","332":"322.7","333":"948.1","334":"484","335":"1044.2","336":"640.7","337":"711.6","338":"281.2","339":"623.6","340":"941.2","341":"1589.7","342":"673.6","343":"605.3","344":"1062","345":"811.1","346":"370.8","347":"835.7","348":"584.5","349":"101.7","350":"522.9","351":"604","352":"1186","353":"386.5","354":"NA","355":"NA","356":"NA","357":"NA","358":"NA","359":"NA","360":"NA","361":"NA","362":"NA","363":"NA","364":"NA","365":"NA","366":"NA","367":"NA","368":"NA","369":"NA","370":"NA","371":"NA","372":"NA","373":"NA","374":"NA","375":"NA","376":"NA","377":"NA","378":"NA","379":"NA","380":"NA","381":"NA","382":"NA","383":"NA","384":"NA","385":"NA","386":"NA","387":"NA","388":"NA","389":"NA","390":"NA","391":"NA","392":"NA","393":"NA","394":"NA","395":"NA","396":"NA","397":"NA","398":"NA","399":"NA","400":"NA","401":"NA","402":"NA","403":"NA","404":"NA","405":"NA","406":"NA","407":"NA","408":"NA","409":"NA","410":"NA","411":"NA","412":"NA","413":"NA","414":"NA","415":"NA","416":"NA","417":"NA","418":"NA","419":"NA","420":"NA","421":"NA","422":"NA","423":"NA","424":"NA","425":"NA","426":"NA","427":"NA","428":"NA","429":"NA","430":"NA","431":"NA","432":"NA","433":"NA","434":"NA","435":"NA","436":"NA","437":"NA","438":"NA","439":"NA","440":"NA","441":"NA","442":"NA","443":"NA","444":"NA","445":"NA","446":"NA","447":"NA","448":"NA","449":"NA","450":"NA","451":"NA","452":"NA","453":"NA","454":"NA","455":"NA","456":"NA","457":"NA","458":"NA","459":"NA","460":"NA","461":"NA","462":"NA","463":"NA","464":"NA","465":"NA","466":"NA","467":"NA","468":"NA","469":"NA","470":"NA","471":"NA","472":"NA","473":"NA","474":"NA","475":"NA","476":"NA","477":"NA","478":"NA","479":"NA","480":"NA","481":"NA","482":"NA","483":"NA","484":"NA","485":"NA","486":"NA","487":"NA","488":"NA","489":"NA","490":"NA","491":"NA","492":"NA","493":"NA","494":"NA","495":"NA","496":"NA","497":"NA","498":"NA","499":"NA","500":"NA","501":"NA","502":"NA","503":"NA","504":"NA","505":"NA","506":"NA","507":"NA","508":"NA","509":"NA","510":"NA","511":"NA","512":"NA","513":"NA","514":"NA","515":"NA","516":"NA","517":"NA","518":"NA","519":"NA","520":"NA","521":"NA","522":"NA","523":"NA","524":"NA","525":"NA","526":"NA","527":"NA","528":"NA","529":"NA","530":"NA","531":"NA","532":"NA","533":"NA","534":"NA","535":"862.6","536":"960.6","537":"481.6","538":"274.3","539":"536.8","540":"268.1","541":"562.2","542":"874.4","543":"379.2","544":"333.7","545":"1561.1","546":"440.5","547":"360","548":"852.9","549":"470.5","550":"173.2","551":"978.9","552":"371.4","553":"264.4","554":"1537.3","555":"699.4","556":"391","557":"177.1","558":"445","559":"649.9","560":"449.2","561":"828.3"}],"options":{"columns":{"min":{},"max":[10],"total":[561]},"rows":{"min":[10],"max":[10],"total":[1]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>gene names with multiple probes</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV9nZW5lc19tcG8gPC0gZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIFxuICBncm91cF9ieShnZW5lX25hbWUpICU+JSBcbiAgc3VtbWFyaXNlKG49bigpKSAlPiUgXG4gIGZpbHRlcihuPjEwKSAlPiUgXG4gIHB1bGwoZ2VuZV9uYW1lKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_sm_genes_mpo &lt;- gse2658_exprs_sm_wgn %&gt;% 
  group_by(gene_name) %&gt;% 
  summarise(n=n()) %&gt;% 
  filter(n&gt;10) %&gt;% 
  pull(gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIFxuICBmaWx0ZXIoZ2VuZV9uYW1lICVpbiUgZ3NlMjY1OF9leHByc19zbV9nZW5lc19tcG8pICU+JSBcbiAgZ3JvdXBfYnkoZ2VuZV9uYW1lLCBwcm9iZV9JRCkgJT4lIFxuICByb3d3aXNlKCkgJT4lXG4gIHN1bW1hcmlzZShyb3dfbWVhbj1tZWFuKGNfYWNyb3NzKGNvbnRhaW5zKFwiR1NNXCIpKSksXG4gICAgICAgICAgICByb3dfc2Q9c2QoY19hY3Jvc3MoY29udGFpbnMoXCJHU01cIikpKSkgJT4lIFxuICBhcnJhbmdlKGdlbmVfbmFtZSlcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_sm_wgn %&gt;% 
  filter(gene_name %in% gse2658_exprs_sm_genes_mpo) %&gt;% 
  group_by(gene_name, probe_ID) %&gt;% 
  rowwise() %&gt;%
  summarise(row_mean=mean(c_across(contains(&quot;GSM&quot;))),
            row_sd=sd(c_across(contains(&quot;GSM&quot;)))) %&gt;% 
  arrange(gene_name)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN1bW1hcmlzZSgpYCBoYXMgZ3JvdXBlZCBvdXRwdXQgYnkgJ2dlbmVfbmFtZScsICdwcm9iZV9JRCcuIFlvdSBjYW4gb3ZlcnJpZGUgdXNpbmcgdGhlIGAuZ3JvdXBzYCBhcmd1bWVudC5cbiJ9 -->
<pre><code>`summarise()` has grouped output by &#39;gene_name&#39;, &#39;probe_ID&#39;. You can override using the `.groups` argument.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]},{"label":["probe_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["row_mean"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["row_sd"],"name":[4],"type":["dbl"],"align":["right"]}],"data":[{"1":"ARHGEF12","2":"1559833_at","3":"68.66923","4":"64.47650"},{"1":"ARHGEF12","2":"1566093_at","3":"344.23578","4":"235.50379"},{"1":"ARHGEF12","2":"1570471_at","3":"112.07764","4":"90.94364"},{"1":"ARHGEF12","2":"201333_s_at","3":"411.15528","4":"238.01247"},{"1":"ARHGEF12","2":"201334_s_at","3":"2909.38748","4":"1466.21710"},{"1":"ARHGEF12","2":"201335_s_at","3":"167.01610","4":"96.87116"},{"1":"ARHGEF12","2":"210741_at","3":"131.14168","4":"86.94997"},{"1":"ARHGEF12","2":"233620_at","3":"21.35474","4":"27.68782"},{"1":"ARHGEF12","2":"233621_s_at","3":"25.76512","4":"37.25385"},{"1":"ARHGEF12","2":"234129_at","3":"63.09857","4":"51.47659"},{"1":"ARHGEF12","2":"234541_s_at","3":"188.04186","4":"94.39031"},{"1":"ARHGEF12","2":"234542_at","3":"39.29571","4":"36.28142"},{"1":"ARHGEF12","2":"234544_at","3":"39.82612","4":"41.32077"},{"1":"DNAH1","2":"1558768_at","3":"192.37782","4":"111.78089"},{"1":"DNAH1","2":"1558769_s_at","3":"45.05993","4":"53.39995"},{"1":"DNAH1","2":"1562278_at","3":"162.19606","4":"92.00096"},{"1":"DNAH1","2":"1566775_at","3":"376.18265","4":"233.82954"},{"1":"DNAH1","2":"1566776_at","3":"162.75420","4":"122.95362"},{"1":"DNAH1","2":"1567376_at","3":"168.82487","4":"112.74146"},{"1":"DNAH1","2":"1567377_at","3":"90.49982","4":"75.67273"},{"1":"DNAH1","2":"1567378_x_at","3":"107.55707","4":"85.57589"},{"1":"DNAH1","2":"228111_s_at","3":"346.44526","4":"192.96787"},{"1":"DNAH1","2":"228112_at","3":"347.06297","4":"159.89210"},{"1":"DNAH1","2":"232005_at","3":"39.55993","4":"50.19206"},{"1":"DNAH1","2":"239059_at","3":"69.29463","4":"59.99208"},{"1":"DNAH1","2":"242591_at","3":"67.60179","4":"50.05518"},{"1":"RUNX1","2":"1563591_at","3":"40.93399","4":"57.42314"},{"1":"RUNX1","2":"208129_x_at","3":"229.22451","4":"126.26292"},{"1":"RUNX1","2":"209359_x_at","3":"214.26852","4":"133.03206"},{"1":"RUNX1","2":"209360_s_at","3":"941.04168","4":"721.05130"},{"1":"RUNX1","2":"210365_at","3":"419.58712","4":"254.40006"},{"1":"RUNX1","2":"210805_x_at","3":"36.05331","4":"35.04945"},{"1":"RUNX1","2":"211179_at","3":"35.94741","4":"31.30000"},{"1":"RUNX1","2":"211180_x_at","3":"214.55725","4":"149.83060"},{"1":"RUNX1","2":"211181_x_at","3":"190.40197","4":"160.90170"},{"1":"RUNX1","2":"211182_x_at","3":"231.74615","4":"222.57075"},{"1":"RUNX1","2":"211620_x_at","3":"356.14043","4":"234.48501"},{"1":"RUNX1","2":"217263_x_at","3":"165.56726","4":"103.64343"},{"1":"RUNX1","2":"237697_at","3":"33.44186","4":"48.03559"},{"1":"SPTBN1","2":"200671_s_at","3":"469.38301","4":"312.02894"},{"1":"SPTBN1","2":"200672_x_at","3":"1005.20054","4":"472.17267"},{"1":"SPTBN1","2":"212071_s_at","3":"6846.90323","4":"3138.44136"},{"1":"SPTBN1","2":"213914_s_at","3":"74.20948","4":"62.03973"},{"1":"SPTBN1","2":"214856_at","3":"95.57370","4":"72.77547"},{"1":"SPTBN1","2":"215918_s_at","3":"227.42916","4":"164.23880"},{"1":"SPTBN1","2":"226342_at","3":"171.55707","4":"245.19492"},{"1":"SPTBN1","2":"226765_at","3":"236.33685","4":"150.95368"},{"1":"SPTBN1","2":"228246_s_at","3":"87.12683","4":"68.74207"},{"1":"SPTBN1","2":"230540_at","3":"79.53614","4":"62.45448"},{"1":"SPTBN1","2":"242220_at","3":"135.71753","4":"77.20194"},{"1":"TCF3","2":"202648_at","3":"172.64275","4":"212.77884"},{"1":"TCF3","2":"209151_x_at","3":"630.67746","4":"360.47766"},{"1":"TCF3","2":"209152_s_at","3":"1256.75241","4":"555.13356"},{"1":"TCF3","2":"209153_s_at","3":"1638.48802","4":"809.13335"},{"1":"TCF3","2":"210776_x_at","3":"3434.86512","4":"1445.46453"},{"1":"TCF3","2":"213730_x_at","3":"2707.78229","4":"998.70685"},{"1":"TCF3","2":"213731_s_at","3":"63.44258","4":"60.74709"},{"1":"TCF3","2":"213732_at","3":"356.51700","4":"163.35165"},{"1":"TCF3","2":"213809_x_at","3":"46.60930","4":"46.81405"},{"1":"TCF3","2":"213811_x_at","3":"3258.20107","4":"1402.31542"},{"1":"TCF3","2":"215260_s_at","3":"740.63506","4":"289.06568"},{"1":"TCF3","2":"216647_at","3":"606.87925","4":"251.07563"},{"1":"TCF3","2":"228052_x_at","3":"118.56494","4":"85.34240"}],"options":{"columns":{"min":{},"max":[10],"total":[4]},"rows":{"min":[10],"max":[10],"total":[63]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z24gJT4lIFxuICBmaWx0ZXIoZ2VuZV9uYW1lICVpbiUgZ3NlMjY1OF9leHByc19zbV9nZW5lc19tcG8pICU+JSBcbiAgcGl2b3RfbG9uZ2VyKC1jKGdlbmVfbmFtZSwgcHJvYmVfSUQpLCBuYW1lc190byA9IFwic2FtcGxlX2lkXCIsIHZhbHVlc190byA9IFwiZXhwclwiKSAlPiUgXG4gIGdyb3VwX2J5KGdlbmVfbmFtZSwgc2FtcGxlX2lkKSAlPiUgXG4gIHN1bW1hcmlzZShtZWFuX2V4cHI9bWVhbihleHByKSwgbWVkaWFuX2V4cHI9bWVkaWFuKGV4cHIpLCBzZF9leHByPXNkKGV4cHIpKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_sm_wgn %&gt;% 
  filter(gene_name %in% gse2658_exprs_sm_genes_mpo) %&gt;% 
  pivot_longer(-c(gene_name, probe_ID), names_to = &quot;sample_id&quot;, values_to = &quot;expr&quot;) %&gt;% 
  group_by(gene_name, sample_id) %&gt;% 
  summarise(mean_expr=mean(expr), median_expr=median(expr), sd_expr=sd(expr))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN1bW1hcmlzZSgpYCBoYXMgZ3JvdXBlZCBvdXRwdXQgYnkgJ2dlbmVfbmFtZScuIFlvdSBjYW4gb3ZlcnJpZGUgdXNpbmcgdGhlIGAuZ3JvdXBzYCBhcmd1bWVudC5cbiJ9 -->
<pre><code>`summarise()` has grouped output by &#39;gene_name&#39;. You can override using the `.groups` argument.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["grouped_df","tbl_df","tbl","data.frame"],"nrow":2795,"ncol":5,"summary":{"A tibble":["2,795 × 5"],"Groups":["gene_name [5]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["mean_expr"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["median_expr"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["sd_expr"],"name":[5],"type":["dbl"],"align":["right"]}],"data":[{"1":"ARHGEF12","2":"GSM102606","3":"290.96923","4":"50.5","5":"666.40426"},{"1":"ARHGEF12","2":"GSM102607","3":"320.76154","4":"61.0","5":"886.22770"},{"1":"ARHGEF12","2":"GSM102609","3":"113.32308","4":"27.6","5":"249.32670"},{"1":"ARHGEF12","2":"GSM102610","3":"414.69999","4":"46.2","5":"1028.84325"},{"1":"ARHGEF12","2":"GSM102611","3":"696.79230","4":"62.2","5":"1975.73462"},{"1":"ARHGEF12","2":"GSM102612","3":"451.06923","4":"91.5","5":"1074.76765"},{"1":"ARHGEF12","2":"GSM102613","3":"376.55384","4":"51.3","5":"967.44221"},{"1":"ARHGEF12","2":"GSM102614","3":"216.11538","4":"35.5","5":"522.13310"},{"1":"ARHGEF12","2":"GSM102615","3":"245.19232","4":"40.9","5":"639.99290"},{"1":"ARHGEF12","2":"GSM102616","3":"533.86923","4":"62.9","5":"1439.69329"},{"1":"ARHGEF12","2":"GSM102617","3":"138.33846","4":"63.5","5":"231.76551"},{"1":"ARHGEF12","2":"GSM102618","3":"357.92308","4":"92.0","5":"860.51767"},{"1":"ARHGEF12","2":"GSM102620","3":"324.44615","4":"56.5","5":"757.10068"},{"1":"ARHGEF12","2":"GSM102621","3":"363.96922","4":"79.8","5":"854.90110"},{"1":"ARHGEF12","2":"GSM102622","3":"270.17693","4":"19.3","5":"646.70945"},{"1":"ARHGEF12","2":"GSM102623","3":"620.25386","4":"141.9","5":"1712.41497"},{"1":"ARHGEF12","2":"GSM102624","3":"238.17692","4":"46.0","5":"527.79241"},{"1":"ARHGEF12","2":"GSM102625","3":"483.01537","4":"41.1","5":"1389.85640"},{"1":"ARHGEF12","2":"GSM102626","3":"176.99231","4":"74.5","5":"267.93962"},{"1":"ARHGEF12","2":"GSM102627","3":"286.33077","4":"78.2","5":"738.14058"},{"1":"ARHGEF12","2":"GSM102628","3":"187.10769","4":"78.9","5":"275.95674"},{"1":"ARHGEF12","2":"GSM102629","3":"570.49998","4":"197.8","5":"1212.52042"},{"1":"ARHGEF12","2":"GSM102630","3":"388.55385","4":"38.0","5":"927.44858"},{"1":"ARHGEF12","2":"GSM102631","3":"180.36154","4":"63.9","5":"369.63689"},{"1":"ARHGEF12","2":"GSM102632","3":"167.35385","4":"42.1","5":"402.59756"},{"1":"ARHGEF12","2":"GSM102633","3":"200.60000","4":"79.8","5":"335.04210"},{"1":"ARHGEF12","2":"GSM102634","3":"350.42309","4":"77.8","5":"656.08631"},{"1":"ARHGEF12","2":"GSM50986","3":"498.93076","4":"142.2","5":"1290.02780"},{"1":"ARHGEF12","2":"GSM50987","3":"195.11539","4":"58.7","5":"480.94815"},{"1":"ARHGEF12","2":"GSM50988","3":"521.20769","4":"93.0","5":"1471.17389"},{"1":"ARHGEF12","2":"GSM50989","3":"349.84615","4":"123.3","5":"786.57569"},{"1":"ARHGEF12","2":"GSM50990","3":"233.72307","4":"66.9","5":"564.97885"},{"1":"ARHGEF12","2":"GSM50991","3":"190.93846","4":"83.4","5":"359.91910"},{"1":"ARHGEF12","2":"GSM50992","3":"374.24616","4":"69.3","5":"1042.86419"},{"1":"ARHGEF12","2":"GSM50993","3":"454.89231","4":"87.1","5":"1302.57994"},{"1":"ARHGEF12","2":"GSM50994","3":"257.22308","4":"91.6","5":"571.55918"},{"1":"ARHGEF12","2":"GSM50995","3":"950.70766","4":"158.6","5":"2720.41114"},{"1":"ARHGEF12","2":"GSM50996","3":"437.62308","4":"72.5","5":"928.34100"},{"1":"ARHGEF12","2":"GSM50997","3":"454.40002","4":"86.7","5":"1129.53213"},{"1":"ARHGEF12","2":"GSM50998","3":"498.94615","4":"186.9","5":"1085.00527"},{"1":"ARHGEF12","2":"GSM50999","3":"361.16154","4":"115.2","5":"641.41529"},{"1":"ARHGEF12","2":"GSM51000","3":"275.49231","4":"74.2","5":"611.20062"},{"1":"ARHGEF12","2":"GSM51001","3":"274.60769","4":"69.3","5":"625.25450"},{"1":"ARHGEF12","2":"GSM51002","3":"195.45385","4":"40.8","5":"481.66365"},{"1":"ARHGEF12","2":"GSM51003","3":"629.21540","4":"131.3","5":"1749.61493"},{"1":"ARHGEF12","2":"GSM51004","3":"455.88462","4":"134.6","5":"1070.22137"},{"1":"ARHGEF12","2":"GSM51005","3":"350.94616","4":"87.7","5":"669.11437"},{"1":"ARHGEF12","2":"GSM51006","3":"483.00769","4":"139.4","5":"1052.54246"},{"1":"ARHGEF12","2":"GSM51007","3":"276.26924","4":"98.0","5":"687.23706"},{"1":"ARHGEF12","2":"GSM51008","3":"480.83847","4":"107.0","5":"1176.14884"},{"1":"ARHGEF12","2":"GSM51009","3":"464.56923","4":"173.5","5":"964.89171"},{"1":"ARHGEF12","2":"GSM51010","3":"269.39231","4":"110.5","5":"581.31966"},{"1":"ARHGEF12","2":"GSM51011","3":"200.98462","4":"64.2","5":"414.30065"},{"1":"ARHGEF12","2":"GSM51012","3":"865.92307","4":"168.6","5":"2108.24375"},{"1":"ARHGEF12","2":"GSM51013","3":"387.16155","4":"110.4","5":"808.49905"},{"1":"ARHGEF12","2":"GSM51014","3":"379.20769","4":"118.6","5":"854.37172"},{"1":"ARHGEF12","2":"GSM51015","3":"270.88461","4":"98.0","5":"586.71870"},{"1":"ARHGEF12","2":"GSM51016","3":"237.02308","4":"93.3","5":"396.87780"},{"1":"ARHGEF12","2":"GSM51017","3":"472.42308","4":"151.2","5":"1029.11762"},{"1":"ARHGEF12","2":"GSM51018","3":"297.08462","4":"83.8","5":"522.15347"},{"1":"ARHGEF12","2":"GSM51019","3":"117.27692","4":"53.2","5":"140.73184"},{"1":"ARHGEF12","2":"GSM51020","3":"451.27692","4":"143.7","5":"1006.27036"},{"1":"ARHGEF12","2":"GSM51021","3":"419.12308","4":"57.0","5":"1207.63033"},{"1":"ARHGEF12","2":"GSM51022","3":"297.04615","4":"162.2","5":"465.15745"},{"1":"ARHGEF12","2":"GSM51023","3":"210.81538","4":"126.4","5":"287.89524"},{"1":"ARHGEF12","2":"GSM51024","3":"344.97693","4":"137.8","5":"594.92334"},{"1":"ARHGEF12","2":"GSM51025","3":"402.72308","4":"118.0","5":"854.77826"},{"1":"ARHGEF12","2":"GSM51026","3":"319.28462","4":"66.0","5":"714.04354"},{"1":"ARHGEF12","2":"GSM51027","3":"453.02308","4":"62.1","5":"943.20278"},{"1":"ARHGEF12","2":"GSM51028","3":"228.47692","4":"133.2","5":"272.72949"},{"1":"ARHGEF12","2":"GSM51029","3":"317.82308","4":"121.8","5":"659.74260"},{"1":"ARHGEF12","2":"GSM51030","3":"489.22307","4":"111.9","5":"1309.58154"},{"1":"ARHGEF12","2":"GSM51031","3":"457.09231","4":"133.4","5":"1033.22932"},{"1":"ARHGEF12","2":"GSM51032","3":"309.75385","4":"107.7","5":"619.28886"},{"1":"ARHGEF12","2":"GSM51033","3":"373.33077","4":"104.7","5":"825.12901"},{"1":"ARHGEF12","2":"GSM51034","3":"435.59232","4":"157.9","5":"834.72641"},{"1":"ARHGEF12","2":"GSM51035","3":"421.61538","4":"134.5","5":"903.52955"},{"1":"ARHGEF12","2":"GSM51036","3":"354.60769","4":"237.7","5":"450.32471"},{"1":"ARHGEF12","2":"GSM51037","3":"564.18461","4":"116.1","5":"1492.08417"},{"1":"ARHGEF12","2":"GSM51038","3":"312.95385","4":"57.4","5":"578.62007"},{"1":"ARHGEF12","2":"GSM51039","3":"268.31538","4":"87.8","5":"653.98797"},{"1":"ARHGEF12","2":"GSM51040","3":"505.29229","4":"153.2","5":"1261.83557"},{"1":"ARHGEF12","2":"GSM51041","3":"553.88462","4":"108.1","5":"1403.84222"},{"1":"ARHGEF12","2":"GSM51042","3":"367.60770","4":"150.3","5":"841.39479"},{"1":"ARHGEF12","2":"GSM51043","3":"235.53077","4":"117.9","5":"338.21060"},{"1":"ARHGEF12","2":"GSM51044","3":"382.03846","4":"96.9","5":"919.83682"},{"1":"ARHGEF12","2":"GSM51045","3":"183.80769","4":"48.1","5":"416.57370"},{"1":"ARHGEF12","2":"GSM51046","3":"674.40771","4":"181.2","5":"1563.74542"},{"1":"ARHGEF12","2":"GSM51047","3":"389.55385","4":"85.9","5":"810.05604"},{"1":"ARHGEF12","2":"GSM51048","3":"511.10000","4":"160.5","5":"1056.61689"},{"1":"ARHGEF12","2":"GSM51049","3":"528.03847","4":"125.0","5":"1272.56765"},{"1":"ARHGEF12","2":"GSM51050","3":"216.06923","4":"70.2","5":"461.47114"},{"1":"ARHGEF12","2":"GSM51051","3":"330.21538","4":"128.3","5":"678.04078"},{"1":"ARHGEF12","2":"GSM51052","3":"179.78462","4":"86.7","5":"301.10255"},{"1":"ARHGEF12","2":"GSM51053","3":"335.84616","4":"148.6","5":"700.72616"},{"1":"ARHGEF12","2":"GSM51054","3":"187.04615","4":"53.9","5":"385.15009"},{"1":"ARHGEF12","2":"GSM51055","3":"378.72308","4":"97.9","5":"912.21121"},{"1":"ARHGEF12","2":"GSM51056","3":"287.86153","4":"64.4","5":"703.41933"},{"1":"ARHGEF12","2":"GSM51057","3":"344.96923","4":"116.0","5":"703.08706"},{"1":"ARHGEF12","2":"GSM51058","3":"295.50000","4":"125.1","5":"446.89620"},{"1":"ARHGEF12","2":"GSM51059","3":"216.99231","4":"133.0","5":"410.00734"},{"1":"ARHGEF12","2":"GSM51060","3":"364.74614","4":"101.2","5":"783.22768"},{"1":"ARHGEF12","2":"GSM51061","3":"185.90000","4":"45.2","5":"386.23582"},{"1":"ARHGEF12","2":"GSM51062","3":"262.00769","4":"66.8","5":"729.18229"},{"1":"ARHGEF12","2":"GSM51063","3":"408.03847","4":"146.5","5":"909.09666"},{"1":"ARHGEF12","2":"GSM51064","3":"442.06924","4":"101.6","5":"1136.71000"},{"1":"ARHGEF12","2":"GSM51065","3":"643.51540","4":"112.5","5":"1583.50798"},{"1":"ARHGEF12","2":"GSM51066","3":"255.33846","4":"68.4","5":"619.01117"},{"1":"ARHGEF12","2":"GSM51067","3":"518.53845","4":"28.9","5":"1494.62813"},{"1":"ARHGEF12","2":"GSM51068","3":"472.20001","4":"104.9","5":"1188.40619"},{"1":"ARHGEF12","2":"GSM51069","3":"645.53847","4":"129.3","5":"1692.77992"},{"1":"ARHGEF12","2":"GSM51070","3":"417.03847","4":"90.6","5":"1017.19232"},{"1":"ARHGEF12","2":"GSM51071","3":"276.02308","4":"82.1","5":"578.46475"},{"1":"ARHGEF12","2":"GSM51072","3":"305.37693","4":"100.8","5":"688.68532"},{"1":"ARHGEF12","2":"GSM51073","3":"314.12308","4":"160.1","5":"523.67705"},{"1":"ARHGEF12","2":"GSM51074","3":"252.23846","4":"96.6","5":"409.02757"},{"1":"ARHGEF12","2":"GSM51075","3":"208.46154","4":"47.3","5":"376.15511"},{"1":"ARHGEF12","2":"GSM51076","3":"235.36923","4":"123.4","5":"518.28626"},{"1":"ARHGEF12","2":"GSM51077","3":"222.75385","4":"69.7","5":"473.15022"},{"1":"ARHGEF12","2":"GSM51078","3":"352.06924","4":"108.5","5":"842.15512"},{"1":"ARHGEF12","2":"GSM51079","3":"459.89230","4":"110.8","5":"1113.38793"},{"1":"ARHGEF12","2":"GSM51080","3":"352.40001","4":"94.7","5":"684.69932"},{"1":"ARHGEF12","2":"GSM51081","3":"424.99231","4":"195.7","5":"932.90304"},{"1":"ARHGEF12","2":"GSM51082","3":"202.00000","4":"45.7","5":"431.02192"},{"1":"ARHGEF12","2":"GSM51083","3":"309.75385","4":"85.5","5":"664.92284"},{"1":"ARHGEF12","2":"GSM51084","3":"373.40000","4":"86.7","5":"780.40634"},{"1":"ARHGEF12","2":"GSM51085","3":"346.06154","4":"189.9","5":"579.41741"},{"1":"ARHGEF12","2":"GSM51086","3":"261.80769","4":"64.6","5":"642.13481"},{"1":"ARHGEF12","2":"GSM51087","3":"330.16154","4":"105.3","5":"656.36969"},{"1":"ARHGEF12","2":"GSM51088","3":"135.41539","4":"76.2","5":"197.91052"},{"1":"ARHGEF12","2":"GSM51089","3":"225.13077","4":"116.7","5":"303.70589"},{"1":"ARHGEF12","2":"GSM51090","3":"629.71538","4":"136.4","5":"1674.80018"},{"1":"ARHGEF12","2":"GSM51091","3":"282.19231","4":"95.4","5":"679.46401"},{"1":"ARHGEF12","2":"GSM51092","3":"348.91538","4":"105.3","5":"868.42167"},{"1":"ARHGEF12","2":"GSM51093","3":"717.06922","4":"86.8","5":"1938.82950"},{"1":"ARHGEF12","2":"GSM51094","3":"387.46923","4":"119.7","5":"967.97948"},{"1":"ARHGEF12","2":"GSM51095","3":"566.89999","4":"262.9","5":"1356.00087"},{"1":"ARHGEF12","2":"GSM51096","3":"439.89999","4":"116.5","5":"1066.53075"},{"1":"ARHGEF12","2":"GSM51097","3":"587.52309","4":"169.8","5":"1564.89227"},{"1":"ARHGEF12","2":"GSM51098","3":"383.86924","4":"140.9","5":"977.59947"},{"1":"ARHGEF12","2":"GSM51099","3":"249.62308","4":"93.0","5":"454.77974"},{"1":"ARHGEF12","2":"GSM51100","3":"538.61537","4":"157.8","5":"1379.48268"},{"1":"ARHGEF12","2":"GSM51101","3":"283.28461","4":"51.9","5":"801.09051"},{"1":"ARHGEF12","2":"GSM51102","3":"418.46922","4":"111.4","5":"1084.39951"},{"1":"ARHGEF12","2":"GSM51103","3":"570.09232","4":"62.6","5":"1560.54885"},{"1":"ARHGEF12","2":"GSM51104","3":"354.75386","4":"92.9","5":"818.20383"},{"1":"ARHGEF12","2":"GSM51105","3":"400.95385","4":"72.9","5":"768.17580"},{"1":"ARHGEF12","2":"GSM51106","3":"413.82308","4":"121.7","5":"944.69104"},{"1":"ARHGEF12","2":"GSM51107","3":"435.89230","4":"18.8","5":"1204.42609"},{"1":"ARHGEF12","2":"GSM51108","3":"275.10000","4":"120.4","5":"410.17536"},{"1":"ARHGEF12","2":"GSM51109","3":"315.83078","4":"41.1","5":"762.09090"},{"1":"ARHGEF12","2":"GSM51110","3":"393.50000","4":"104.1","5":"998.68247"},{"1":"ARHGEF12","2":"GSM51111","3":"390.05385","4":"94.5","5":"872.65481"},{"1":"ARHGEF12","2":"GSM51112","3":"349.57692","4":"114.4","5":"555.57943"},{"1":"ARHGEF12","2":"GSM51113","3":"363.21537","4":"94.0","5":"836.27843"},{"1":"ARHGEF12","2":"GSM51114","3":"349.13076","4":"138.5","5":"764.92406"},{"1":"ARHGEF12","2":"GSM51115","3":"417.14614","4":"167.9","5":"877.29194"},{"1":"ARHGEF12","2":"GSM51116","3":"266.28462","4":"57.6","5":"391.35568"},{"1":"ARHGEF12","2":"GSM51117","3":"330.85384","4":"67.7","5":"788.45284"},{"1":"ARHGEF12","2":"GSM51118","3":"327.46154","4":"149.3","5":"460.40805"},{"1":"ARHGEF12","2":"GSM51119","3":"293.35385","4":"109.3","5":"621.32190"},{"1":"ARHGEF12","2":"GSM51120","3":"285.76923","4":"131.9","5":"533.56819"},{"1":"ARHGEF12","2":"GSM51121","3":"253.43077","4":"119.2","5":"424.06081"},{"1":"ARHGEF12","2":"GSM51122","3":"473.56154","4":"157.3","5":"922.73953"},{"1":"ARHGEF12","2":"GSM51123","3":"200.46923","4":"106.4","5":"265.56420"},{"1":"ARHGEF12","2":"GSM51124","3":"159.06154","4":"33.6","5":"233.93604"},{"1":"ARHGEF12","2":"GSM51125","3":"517.13078","4":"131.7","5":"1322.53381"},{"1":"ARHGEF12","2":"GSM51126","3":"426.03846","4":"128.1","5":"1003.40318"},{"1":"ARHGEF12","2":"GSM51127","3":"321.09230","4":"91.2","5":"819.65030"},{"1":"ARHGEF12","2":"GSM51128","3":"393.96922","4":"175.7","5":"644.93575"},{"1":"ARHGEF12","2":"GSM51129","3":"401.69230","4":"117.0","5":"1056.82465"},{"1":"ARHGEF12","2":"GSM51130","3":"141.70769","4":"95.1","5":"230.79095"},{"1":"ARHGEF12","2":"GSM51131","3":"423.81537","4":"136.3","5":"842.26056"},{"1":"ARHGEF12","2":"GSM51132","3":"438.03076","4":"104.2","5":"1161.01422"},{"1":"ARHGEF12","2":"GSM51133","3":"270.88462","4":"68.4","5":"607.42743"},{"1":"ARHGEF12","2":"GSM51134","3":"317.51539","4":"67.8","5":"734.13575"},{"1":"ARHGEF12","2":"GSM51135","3":"311.29999","4":"69.6","5":"732.43936"},{"1":"ARHGEF12","2":"GSM51136","3":"385.90769","4":"167.9","5":"752.86402"},{"1":"ARHGEF12","2":"GSM51137","3":"601.65386","4":"111.6","5":"1700.39905"},{"1":"ARHGEF12","2":"GSM51138","3":"467.83846","4":"271.4","5":"791.87199"},{"1":"ARHGEF12","2":"GSM51139","3":"349.81539","4":"120.6","5":"672.10972"},{"1":"ARHGEF12","2":"GSM51140","3":"279.32307","4":"65.3","5":"746.71971"},{"1":"ARHGEF12","2":"GSM51141","3":"516.39999","4":"73.9","5":"1415.06863"},{"1":"ARHGEF12","2":"GSM51142","3":"303.90000","4":"57.8","5":"649.32318"},{"1":"ARHGEF12","2":"GSM51143","3":"602.74617","4":"70.7","5":"1697.36932"},{"1":"ARHGEF12","2":"GSM51144","3":"306.24615","4":"78.0","5":"687.14013"},{"1":"ARHGEF12","2":"GSM51145","3":"596.90769","4":"50.1","5":"1600.36537"},{"1":"ARHGEF12","2":"GSM51146","3":"186.17692","4":"68.5","5":"344.23075"},{"1":"ARHGEF12","2":"GSM51147","3":"609.71539","4":"123.5","5":"1459.27202"},{"1":"ARHGEF12","2":"GSM51148","3":"355.82307","4":"122.0","5":"793.92892"},{"1":"ARHGEF12","2":"GSM51149","3":"354.91539","4":"119.3","5":"721.32562"},{"1":"ARHGEF12","2":"GSM51150","3":"639.83077","4":"176.8","5":"1650.54703"},{"1":"ARHGEF12","2":"GSM51151","3":"203.76154","4":"54.8","5":"337.52977"},{"1":"ARHGEF12","2":"GSM51152","3":"334.37692","4":"166.8","5":"568.21494"},{"1":"ARHGEF12","2":"GSM51153","3":"235.16154","4":"55.9","5":"492.76723"},{"1":"ARHGEF12","2":"GSM51154","3":"366.75385","4":"99.4","5":"793.94983"},{"1":"ARHGEF12","2":"GSM51155","3":"548.95386","4":"68.9","5":"1470.55398"},{"1":"ARHGEF12","2":"GSM51156","3":"385.40769","4":"187.0","5":"589.21329"},{"1":"ARHGEF12","2":"GSM51157","3":"384.15384","4":"173.2","5":"690.55784"},{"1":"ARHGEF12","2":"GSM51158","3":"377.59230","4":"111.8","5":"840.22469"},{"1":"ARHGEF12","2":"GSM51159","3":"437.20000","4":"109.4","5":"1012.71717"},{"1":"ARHGEF12","2":"GSM51160","3":"440.83845","4":"88.1","5":"1098.37341"},{"1":"ARHGEF12","2":"GSM51161","3":"383.18462","4":"168.0","5":"698.70477"},{"1":"ARHGEF12","2":"GSM51162","3":"276.92308","4":"191.6","5":"451.87365"},{"1":"ARHGEF12","2":"GSM51163","3":"282.82307","4":"50.4","5":"707.10188"},{"1":"ARHGEF12","2":"GSM51164","3":"315.03845","4":"61.2","5":"670.70325"},{"1":"ARHGEF12","2":"GSM51165","3":"335.14615","4":"117.5","5":"713.43893"},{"1":"ARHGEF12","2":"GSM51166","3":"398.93846","4":"54.3","5":"871.44001"},{"1":"ARHGEF12","2":"GSM51167","3":"527.51537","4":"63.5","5":"1493.38222"},{"1":"ARHGEF12","2":"GSM51168","3":"282.47693","4":"110.1","5":"677.24546"},{"1":"ARHGEF12","2":"GSM51169","3":"483.86154","4":"260.2","5":"696.91116"},{"1":"ARHGEF12","2":"GSM51170","3":"263.56923","4":"55.7","5":"594.72767"},{"1":"ARHGEF12","2":"GSM51171","3":"488.48462","4":"90.5","5":"1246.91183"},{"1":"ARHGEF12","2":"GSM51172","3":"525.06153","4":"215.9","5":"1042.17440"},{"1":"ARHGEF12","2":"GSM51173","3":"330.82308","4":"132.8","5":"608.53209"},{"1":"ARHGEF12","2":"GSM51174","3":"243.62308","4":"102.2","5":"396.19691"},{"1":"ARHGEF12","2":"GSM51175","3":"447.40769","4":"123.5","5":"1055.69502"},{"1":"ARHGEF12","2":"GSM51176","3":"248.66923","4":"61.6","5":"521.18382"},{"1":"ARHGEF12","2":"GSM51177","3":"360.60768","4":"125.1","5":"611.55387"},{"1":"ARHGEF12","2":"GSM51178","3":"442.64614","4":"57.2","5":"1230.68462"},{"1":"ARHGEF12","2":"GSM51179","3":"271.82307","4":"119.1","5":"487.57240"},{"1":"ARHGEF12","2":"GSM51180","3":"619.44615","4":"110.9","5":"1614.07545"},{"1":"ARHGEF12","2":"GSM51181","3":"529.83846","4":"52.5","5":"1463.94162"},{"1":"ARHGEF12","2":"GSM51182","3":"532.23848","4":"104.5","5":"1381.91568"},{"1":"ARHGEF12","2":"GSM51183","3":"204.00000","4":"38.3","5":"456.48978"},{"1":"ARHGEF12","2":"GSM51184","3":"393.02308","4":"172.8","5":"795.41276"},{"1":"ARHGEF12","2":"GSM51185","3":"365.96923","4":"160.4","5":"581.10266"},{"1":"ARHGEF12","2":"GSM51186","3":"555.72309","4":"89.1","5":"1398.71752"},{"1":"ARHGEF12","2":"GSM51187","3":"242.53846","4":"128.7","5":"387.23994"},{"1":"ARHGEF12","2":"GSM51188","3":"438.19999","4":"56.9","5":"1143.19787"},{"1":"ARHGEF12","2":"GSM51189","3":"393.31539","4":"88.7","5":"905.71732"},{"1":"ARHGEF12","2":"GSM51190","3":"124.08462","4":"70.9","5":"168.07961"},{"1":"ARHGEF12","2":"GSM51191","3":"218.40769","4":"37.2","5":"415.64081"},{"1":"ARHGEF12","2":"GSM51192","3":"476.66154","4":"108.6","5":"1242.19657"},{"1":"ARHGEF12","2":"GSM51193","3":"209.88461","4":"122.0","5":"314.24970"},{"1":"ARHGEF12","2":"GSM51194","3":"256.49231","4":"35.4","5":"547.66394"},{"1":"ARHGEF12","2":"GSM51195","3":"393.24616","4":"161.7","5":"791.11918"},{"1":"ARHGEF12","2":"GSM51196","3":"290.75385","4":"166.9","5":"481.39278"},{"1":"ARHGEF12","2":"GSM51197","3":"389.94615","4":"82.1","5":"1071.40696"},{"1":"ARHGEF12","2":"GSM51198","3":"413.10000","4":"101.2","5":"761.06918"},{"1":"ARHGEF12","2":"GSM51199","3":"381.77692","4":"55.4","5":"897.94589"},{"1":"ARHGEF12","2":"GSM51200","3":"179.26923","4":"124.2","5":"208.47878"},{"1":"ARHGEF12","2":"GSM51201","3":"187.32308","4":"47.0","5":"357.93616"},{"1":"ARHGEF12","2":"GSM51202","3":"365.12308","4":"71.5","5":"899.34849"},{"1":"ARHGEF12","2":"GSM51203","3":"310.39230","4":"192.4","5":"354.02815"},{"1":"ARHGEF12","2":"GSM51204","3":"382.02308","4":"178.3","5":"625.81649"},{"1":"ARHGEF12","2":"GSM51205","3":"414.00769","4":"114.3","5":"1014.38979"},{"1":"ARHGEF12","2":"GSM51206","3":"380.70001","4":"113.6","5":"907.51505"},{"1":"ARHGEF12","2":"GSM51207","3":"353.25385","4":"220.0","5":"608.68014"},{"1":"ARHGEF12","2":"GSM51208","3":"571.11540","4":"154.4","5":"1599.77921"},{"1":"ARHGEF12","2":"GSM51209","3":"244.36923","4":"63.5","5":"563.40706"},{"1":"ARHGEF12","2":"GSM51210","3":"527.30771","4":"114.3","5":"1274.77909"},{"1":"ARHGEF12","2":"GSM51211","3":"201.26923","4":"28.6","5":"488.77225"},{"1":"ARHGEF12","2":"GSM51212","3":"198.35385","4":"82.1","5":"279.14561"},{"1":"ARHGEF12","2":"GSM51213","3":"551.62309","4":"98.8","5":"1576.03436"},{"1":"ARHGEF12","2":"GSM51214","3":"295.77692","4":"33.0","5":"707.02674"},{"1":"ARHGEF12","2":"GSM51215","3":"361.95384","4":"111.0","5":"906.30289"},{"1":"ARHGEF12","2":"GSM51216","3":"253.14616","4":"72.4","5":"589.59557"},{"1":"ARHGEF12","2":"GSM51217","3":"137.41538","4":"31.6","5":"234.85431"},{"1":"ARHGEF12","2":"GSM51218","3":"432.60000","4":"164.1","5":"880.23977"},{"1":"ARHGEF12","2":"GSM51219","3":"317.81538","4":"59.2","5":"712.95268"},{"1":"ARHGEF12","2":"GSM51220","3":"226.50769","4":"86.2","5":"428.67247"},{"1":"ARHGEF12","2":"GSM51221","3":"463.82308","4":"37.0","5":"1335.85744"},{"1":"ARHGEF12","2":"GSM51222","3":"314.13076","4":"35.7","5":"824.26467"},{"1":"ARHGEF12","2":"GSM51223","3":"276.53077","4":"114.1","5":"649.73795"},{"1":"ARHGEF12","2":"GSM51224","3":"162.30769","4":"75.4","5":"204.76631"},{"1":"ARHGEF12","2":"GSM51225","3":"238.43077","4":"78.8","5":"450.75595"},{"1":"ARHGEF12","2":"GSM51226","3":"328.25385","4":"205.1","5":"434.34661"},{"1":"ARHGEF12","2":"GSM51227","3":"380.63846","4":"179.6","5":"682.34941"},{"1":"ARHGEF12","2":"GSM51228","3":"245.20770","4":"57.7","5":"557.02457"},{"1":"ARHGEF12","2":"GSM51229","3":"254.09231","4":"112.8","5":"416.00474"},{"1":"ARHGEF12","2":"GSM51230","3":"224.56923","4":"78.9","5":"488.08911"},{"1":"ARHGEF12","2":"GSM51231","3":"539.42309","4":"206.6","5":"1229.40525"},{"1":"ARHGEF12","2":"GSM51232","3":"188.91539","4":"135.1","5":"199.57958"},{"1":"ARHGEF12","2":"GSM51233","3":"250.20000","4":"32.2","5":"599.46685"},{"1":"ARHGEF12","2":"GSM51234","3":"196.47692","4":"41.0","5":"454.43747"},{"1":"ARHGEF12","2":"GSM51235","3":"410.33845","4":"57.3","5":"1161.10582"},{"1":"ARHGEF12","2":"GSM51236","3":"394.35385","4":"88.3","5":"954.22101"},{"1":"ARHGEF12","2":"GSM51237","3":"536.91539","4":"71.5","5":"1421.69191"},{"1":"ARHGEF12","2":"GSM51238","3":"417.24615","4":"48.8","5":"1105.69814"},{"1":"ARHGEF12","2":"GSM51239","3":"312.76154","4":"95.3","5":"711.95981"},{"1":"ARHGEF12","2":"GSM51240","3":"234.70000","4":"60.4","5":"366.53215"},{"1":"ARHGEF12","2":"GSM51241","3":"249.72307","4":"71.1","5":"586.33580"},{"1":"ARHGEF12","2":"GSM51242","3":"417.32308","4":"69.2","5":"1136.50490"},{"1":"ARHGEF12","2":"GSM51243","3":"255.50769","4":"74.2","5":"522.97054"},{"1":"ARHGEF12","2":"GSM51244","3":"201.11539","4":"67.7","5":"283.76182"},{"1":"ARHGEF12","2":"GSM51245","3":"340.46923","4":"220.6","5":"485.41306"},{"1":"ARHGEF12","2":"GSM51246","3":"268.23845","4":"75.2","5":"570.90075"},{"1":"ARHGEF12","2":"GSM51247","3":"325.73846","4":"150.7","5":"501.53510"},{"1":"ARHGEF12","2":"GSM51248","3":"841.98464","4":"56.6","5":"2299.35984"},{"1":"ARHGEF12","2":"GSM51249","3":"245.50000","4":"57.1","5":"448.70318"},{"1":"ARHGEF12","2":"GSM51250","3":"298.08462","4":"226.2","5":"363.09537"},{"1":"ARHGEF12","2":"GSM51251","3":"384.83846","4":"102.6","5":"879.47750"},{"1":"ARHGEF12","2":"GSM51252","3":"408.00770","4":"173.9","5":"790.10039"},{"1":"ARHGEF12","2":"GSM51253","3":"334.34615","4":"122.6","5":"733.70558"},{"1":"ARHGEF12","2":"GSM51254","3":"456.38461","4":"106.7","5":"1323.61581"},{"1":"ARHGEF12","2":"GSM51255","3":"355.04616","4":"147.0","5":"650.72291"},{"1":"ARHGEF12","2":"GSM51256","3":"245.30000","4":"120.0","5":"454.99189"},{"1":"ARHGEF12","2":"GSM51257","3":"378.23846","4":"91.2","5":"867.60059"},{"1":"ARHGEF12","2":"GSM51258","3":"556.83846","4":"124.7","5":"1434.02786"},{"1":"ARHGEF12","2":"GSM51259","3":"517.46153","4":"55.0","5":"1481.77782"},{"1":"ARHGEF12","2":"GSM51260","3":"348.26154","4":"91.6","5":"815.49171"},{"1":"ARHGEF12","2":"GSM51261","3":"516.81539","4":"185.2","5":"1174.70458"},{"1":"ARHGEF12","2":"GSM51262","3":"164.88461","4":"87.1","5":"175.56216"},{"1":"ARHGEF12","2":"GSM51263","3":"286.97693","4":"115.2","5":"606.20981"},{"1":"ARHGEF12","2":"GSM51264","3":"381.41538","4":"166.1","5":"886.57530"},{"1":"ARHGEF12","2":"GSM51265","3":"411.14615","4":"122.5","5":"965.62949"},{"1":"ARHGEF12","2":"GSM51266","3":"307.60769","4":"83.4","5":"587.38627"},{"1":"ARHGEF12","2":"GSM51267","3":"256.66154","4":"136.6","5":"448.90300"},{"1":"ARHGEF12","2":"GSM51268","3":"138.78462","4":"79.6","5":"174.28643"},{"1":"ARHGEF12","2":"GSM51269","3":"349.20000","4":"79.2","5":"880.85299"},{"1":"ARHGEF12","2":"GSM51270","3":"112.61538","4":"25.5","5":"174.21034"},{"1":"ARHGEF12","2":"GSM51271","3":"452.82309","4":"91.5","5":"1251.56896"},{"1":"ARHGEF12","2":"GSM51272","3":"271.53076","4":"57.6","5":"662.09274"},{"1":"ARHGEF12","2":"GSM51273","3":"271.70770","4":"80.4","5":"700.52274"},{"1":"ARHGEF12","2":"GSM51274","3":"502.15384","4":"83.7","5":"1346.62938"},{"1":"ARHGEF12","2":"GSM51275","3":"284.87692","4":"91.0","5":"579.06319"},{"1":"ARHGEF12","2":"GSM51276","3":"500.73078","4":"65.4","5":"1304.73742"},{"1":"ARHGEF12","2":"GSM51277","3":"261.67692","4":"50.5","5":"671.30554"},{"1":"ARHGEF12","2":"GSM51278","3":"334.81538","4":"79.9","5":"695.55280"},{"1":"ARHGEF12","2":"GSM51279","3":"430.34617","4":"63.4","5":"1123.08532"},{"1":"ARHGEF12","2":"GSM51280","3":"321.26923","4":"73.0","5":"726.31918"},{"1":"ARHGEF12","2":"GSM51281","3":"310.11539","4":"197.1","5":"349.03090"},{"1":"ARHGEF12","2":"GSM51282","3":"446.90769","4":"69.6","5":"1237.28061"},{"1":"ARHGEF12","2":"GSM51283","3":"403.50770","4":"105.7","5":"996.08386"},{"1":"ARHGEF12","2":"GSM51284","3":"225.74615","4":"132.3","5":"273.25948"},{"1":"ARHGEF12","2":"GSM51285","3":"446.53077","4":"89.7","5":"1114.29244"},{"1":"ARHGEF12","2":"GSM51286","3":"258.27693","4":"143.1","5":"419.53589"},{"1":"ARHGEF12","2":"GSM51287","3":"300.50768","4":"20.3","5":"807.50384"},{"1":"ARHGEF12","2":"GSM51288","3":"292.86154","4":"61.9","5":"692.46775"},{"1":"ARHGEF12","2":"GSM51289","3":"309.99231","4":"62.3","5":"760.18176"},{"1":"ARHGEF12","2":"GSM51290","3":"326.04616","4":"72.3","5":"824.45639"},{"1":"ARHGEF12","2":"GSM51291","3":"273.23077","4":"52.7","5":"590.82709"},{"1":"ARHGEF12","2":"GSM51292","3":"505.86153","4":"88.4","5":"1381.18693"},{"1":"ARHGEF12","2":"GSM51293","3":"291.98461","4":"91.7","5":"687.37040"},{"1":"ARHGEF12","2":"GSM51294","3":"182.90000","4":"50.3","5":"287.75526"},{"1":"ARHGEF12","2":"GSM51295","3":"727.96153","4":"64.0","5":"2118.11196"},{"1":"ARHGEF12","2":"GSM51296","3":"516.77693","4":"172.2","5":"1311.31430"},{"1":"ARHGEF12","2":"GSM51297","3":"330.66923","4":"63.7","5":"802.43319"},{"1":"ARHGEF12","2":"GSM51298","3":"199.79231","4":"68.8","5":"354.02646"},{"1":"ARHGEF12","2":"GSM51299","3":"497.84614","4":"82.5","5":"1324.88299"},{"1":"ARHGEF12","2":"GSM51300","3":"386.61539","4":"179.7","5":"624.95522"},{"1":"ARHGEF12","2":"GSM51301","3":"365.13077","4":"132.7","5":"782.62330"},{"1":"ARHGEF12","2":"GSM51302","3":"371.56923","4":"128.6","5":"924.54273"},{"1":"ARHGEF12","2":"GSM51303","3":"260.23077","4":"80.3","5":"544.08136"},{"1":"ARHGEF12","2":"GSM51304","3":"266.56154","4":"53.2","5":"546.55701"},{"1":"ARHGEF12","2":"GSM51305","3":"438.12308","4":"107.4","5":"1105.35660"},{"1":"ARHGEF12","2":"GSM51306","3":"367.83078","4":"132.5","5":"872.00537"},{"1":"ARHGEF12","2":"GSM51307","3":"402.43077","4":"21.9","5":"1065.35221"},{"1":"ARHGEF12","2":"GSM51308","3":"220.46923","4":"63.4","5":"468.93121"},{"1":"ARHGEF12","2":"GSM51309","3":"297.26155","4":"82.7","5":"706.72917"},{"1":"ARHGEF12","2":"GSM51310","3":"442.69999","4":"71.5","5":"1148.03036"},{"1":"ARHGEF12","2":"GSM51311","3":"363.36922","4":"148.7","5":"816.47598"},{"1":"ARHGEF12","2":"GSM51312","3":"392.95384","4":"64.4","5":"1087.89403"},{"1":"ARHGEF12","2":"GSM51313","3":"536.88461","4":"53.7","5":"1471.45945"},{"1":"ARHGEF12","2":"GSM51314","3":"292.75385","4":"53.0","5":"677.99795"},{"1":"ARHGEF12","2":"GSM51315","3":"376.84615","4":"42.2","5":"993.24459"},{"1":"ARHGEF12","2":"GSM51316","3":"303.11539","4":"86.3","5":"692.95514"},{"1":"ARHGEF12","2":"GSM51317","3":"149.34615","4":"55.1","5":"242.00804"},{"1":"ARHGEF12","2":"GSM51318","3":"382.10769","4":"98.4","5":"944.01228"},{"1":"ARHGEF12","2":"GSM51319","3":"501.13844","4":"116.2","5":"1266.89393"},{"1":"ARHGEF12","2":"GSM51320","3":"323.70770","4":"50.7","5":"791.44571"},{"1":"ARHGEF12","2":"GSM51321","3":"350.36154","4":"75.2","5":"924.88212"},{"1":"ARHGEF12","2":"GSM51322","3":"250.47692","4":"77.6","5":"501.31102"},{"1":"ARHGEF12","2":"GSM51323","3":"190.53846","4":"84.8","5":"332.89551"},{"1":"ARHGEF12","2":"GSM51324","3":"370.50769","4":"120.0","5":"695.90281"},{"1":"ARHGEF12","2":"GSM51325","3":"265.57691","4":"109.5","5":"610.16791"},{"1":"ARHGEF12","2":"GSM51326","3":"417.59999","4":"42.1","5":"1206.14511"},{"1":"ARHGEF12","2":"GSM51327","3":"274.62308","4":"58.8","5":"539.49568"},{"1":"ARHGEF12","2":"GSM51328","3":"434.98462","4":"87.6","5":"1002.45256"},{"1":"ARHGEF12","2":"GSM51329","3":"395.49230","4":"142.4","5":"926.72148"},{"1":"ARHGEF12","2":"GSM51330","3":"498.93845","4":"93.5","5":"1354.08202"},{"1":"ARHGEF12","2":"GSM51331","3":"653.89232","4":"61.7","5":"1801.25862"},{"1":"ARHGEF12","2":"GSM51332","3":"192.92308","4":"66.4","5":"462.94145"},{"1":"ARHGEF12","2":"GSM51333","3":"417.01538","4":"145.1","5":"871.69240"},{"1":"ARHGEF12","2":"GSM51334","3":"361.10768","4":"141.3","5":"773.00531"},{"1":"ARHGEF12","2":"GSM51335","3":"216.76923","4":"164.1","5":"165.36939"},{"1":"ARHGEF12","2":"GSM51336","3":"309.10000","4":"99.7","5":"653.02898"},{"1":"ARHGEF12","2":"GSM95646","3":"378.49230","4":"87.4","5":"957.84775"},{"1":"ARHGEF12","2":"GSM95647","3":"322.43846","4":"144.0","5":"591.77533"},{"1":"ARHGEF12","2":"GSM95648","3":"449.88462","4":"83.0","5":"1125.77958"},{"1":"ARHGEF12","2":"GSM95649","3":"501.06925","4":"100.1","5":"1209.54846"},{"1":"ARHGEF12","2":"GSM95650","3":"538.40768","4":"109.4","5":"1506.45196"},{"1":"ARHGEF12","2":"GSM95651","3":"619.09230","4":"107.1","5":"1673.34663"},{"1":"ARHGEF12","2":"GSM95652","3":"363.39231","4":"124.9","5":"724.48502"},{"1":"ARHGEF12","2":"GSM95653","3":"242.77692","4":"90.6","5":"429.38345"},{"1":"ARHGEF12","2":"GSM95654","3":"323.42307","4":"88.1","5":"776.36270"},{"1":"ARHGEF12","2":"GSM95655","3":"123.14615","4":"43.0","5":"260.79759"},{"1":"ARHGEF12","2":"GSM95656","3":"641.20769","4":"151.5","5":"1761.30735"},{"1":"ARHGEF12","2":"GSM95657","3":"259.20769","4":"85.3","5":"432.70582"},{"1":"ARHGEF12","2":"GSM95658","3":"169.73846","4":"33.9","5":"363.60078"},{"1":"ARHGEF12","2":"GSM95659","3":"532.34614","4":"81.3","5":"1339.40528"},{"1":"ARHGEF12","2":"GSM95660","3":"559.00769","4":"60.3","5":"1472.85202"},{"1":"ARHGEF12","2":"GSM95661","3":"104.66154","4":"24.9","5":"179.58168"},{"1":"ARHGEF12","2":"GSM95662","3":"529.02309","4":"181.7","5":"1134.75778"},{"1":"ARHGEF12","2":"GSM95663","3":"274.74615","4":"40.8","5":"599.10556"},{"1":"ARHGEF12","2":"GSM95664","3":"380.31538","4":"90.3","5":"956.59696"},{"1":"ARHGEF12","2":"GSM95665","3":"347.93078","4":"50.1","5":"808.89556"},{"1":"ARHGEF12","2":"GSM95666","3":"335.89231","4":"79.6","5":"498.12329"},{"1":"ARHGEF12","2":"GSM95667","3":"126.61538","4":"99.3","5":"165.93677"},{"1":"ARHGEF12","2":"GSM95668","3":"173.33846","4":"123.0","5":"213.43769"},{"1":"ARHGEF12","2":"GSM95669","3":"326.82308","4":"41.6","5":"811.17237"},{"1":"ARHGEF12","2":"GSM95670","3":"389.18461","4":"99.8","5":"871.34937"},{"1":"ARHGEF12","2":"GSM95671","3":"270.78462","4":"100.0","5":"627.69206"},{"1":"ARHGEF12","2":"GSM95672","3":"225.39231","4":"84.2","5":"502.33794"},{"1":"ARHGEF12","2":"GSM95673","3":"337.68461","4":"52.7","5":"740.13439"},{"1":"ARHGEF12","2":"GSM95674","3":"266.00769","4":"69.8","5":"682.75443"},{"1":"ARHGEF12","2":"GSM95675","3":"261.20769","4":"24.6","5":"668.53969"},{"1":"ARHGEF12","2":"GSM95676","3":"310.36923","4":"111.7","5":"668.64880"},{"1":"ARHGEF12","2":"GSM95677","3":"516.20001","4":"114.3","5":"1370.44593"},{"1":"ARHGEF12","2":"GSM95678","3":"275.68462","4":"117.9","5":"513.86391"},{"1":"ARHGEF12","2":"GSM95679","3":"296.26923","4":"99.7","5":"639.65614"},{"1":"ARHGEF12","2":"GSM95680","3":"465.87691","4":"87.4","5":"1163.79608"},{"1":"ARHGEF12","2":"GSM95681","3":"301.31539","4":"95.2","5":"722.50715"},{"1":"ARHGEF12","2":"GSM95682","3":"440.20769","4":"22.2","5":"1261.98147"},{"1":"ARHGEF12","2":"GSM95683","3":"237.46923","4":"45.1","5":"578.71286"},{"1":"ARHGEF12","2":"GSM95684","3":"324.49231","4":"89.0","5":"694.76944"},{"1":"ARHGEF12","2":"GSM95685","3":"310.32308","4":"88.0","5":"603.79842"},{"1":"ARHGEF12","2":"GSM95686","3":"248.14615","4":"101.0","5":"340.84006"},{"1":"ARHGEF12","2":"GSM95687","3":"343.85384","4":"69.7","5":"798.76561"},{"1":"ARHGEF12","2":"GSM95688","3":"220.37692","4":"66.7","5":"394.58723"},{"1":"ARHGEF12","2":"GSM95689","3":"259.86154","4":"91.0","5":"567.92171"},{"1":"ARHGEF12","2":"GSM95690","3":"283.02309","4":"84.7","5":"676.23714"},{"1":"ARHGEF12","2":"GSM95691","3":"319.09230","4":"105.7","5":"731.64192"},{"1":"ARHGEF12","2":"GSM95692","3":"459.16154","4":"62.9","5":"1097.39123"},{"1":"ARHGEF12","2":"GSM95693","3":"625.41537","4":"32.4","5":"1762.88927"},{"1":"ARHGEF12","2":"GSM95694","3":"254.28461","4":"64.2","5":"583.44012"},{"1":"ARHGEF12","2":"GSM95695","3":"350.89999","4":"45.0","5":"809.18959"},{"1":"ARHGEF12","2":"GSM95696","3":"313.54615","4":"73.6","5":"768.23540"},{"1":"ARHGEF12","2":"GSM95697","3":"819.98462","4":"63.2","5":"2487.56622"},{"1":"ARHGEF12","2":"GSM95698","3":"272.78462","4":"160.7","5":"429.62927"},{"1":"ARHGEF12","2":"GSM95699","3":"379.19999","4":"87.4","5":"830.39927"},{"1":"ARHGEF12","2":"GSM95700","3":"299.00000","4":"238.7","5":"223.80703"},{"1":"ARHGEF12","2":"GSM95701","3":"184.95385","4":"74.8","5":"295.07294"},{"1":"ARHGEF12","2":"GSM95702","3":"373.54616","4":"64.1","5":"955.74607"},{"1":"ARHGEF12","2":"GSM95703","3":"276.48462","4":"108.0","5":"616.90411"},{"1":"ARHGEF12","2":"GSM95704","3":"304.66923","4":"160.3","5":"552.47587"},{"1":"ARHGEF12","2":"GSM95705","3":"245.29231","4":"87.1","5":"329.28045"},{"1":"ARHGEF12","2":"GSM95706","3":"367.77692","4":"88.0","5":"756.46290"},{"1":"ARHGEF12","2":"GSM95707","3":"365.31538","4":"133.2","5":"755.87632"},{"1":"ARHGEF12","2":"GSM95708","3":"273.07693","4":"61.6","5":"675.25385"},{"1":"ARHGEF12","2":"GSM95709","3":"249.34616","4":"77.8","5":"465.96486"},{"1":"ARHGEF12","2":"GSM95710","3":"296.06923","4":"69.7","5":"637.95054"},{"1":"ARHGEF12","2":"GSM95711","3":"286.18462","4":"101.2","5":"481.39195"},{"1":"ARHGEF12","2":"GSM95712","3":"241.40769","4":"183.8","5":"254.86622"},{"1":"ARHGEF12","2":"GSM95713","3":"375.01538","4":"46.3","5":"1004.14794"},{"1":"ARHGEF12","2":"GSM95714","3":"131.58462","4":"77.7","5":"227.81164"},{"1":"ARHGEF12","2":"GSM95715","3":"320.52309","4":"63.3","5":"805.02608"},{"1":"ARHGEF12","2":"GSM95716","3":"346.44616","4":"44.5","5":"914.87609"},{"1":"ARHGEF12","2":"GSM95717","3":"157.94615","4":"84.5","5":"310.38899"},{"1":"ARHGEF12","2":"GSM95718","3":"550.36152","4":"94.9","5":"1535.65595"},{"1":"ARHGEF12","2":"GSM95719","3":"319.77692","4":"77.0","5":"829.82765"},{"1":"ARHGEF12","2":"GSM95720","3":"282.33845","4":"81.1","5":"603.93143"},{"1":"ARHGEF12","2":"GSM95721","3":"206.61539","4":"67.4","5":"393.46572"},{"1":"ARHGEF12","2":"GSM95722","3":"486.66153","4":"119.0","5":"1221.04004"},{"1":"ARHGEF12","2":"GSM95723","3":"253.15385","4":"68.9","5":"510.43057"},{"1":"ARHGEF12","2":"GSM95724","3":"345.21538","4":"58.3","5":"719.43508"},{"1":"ARHGEF12","2":"GSM95725","3":"331.38461","4":"43.6","5":"791.51906"},{"1":"ARHGEF12","2":"GSM95726","3":"293.27692","4":"46.3","5":"754.37135"},{"1":"ARHGEF12","2":"GSM95727","3":"466.08460","4":"60.4","5":"1294.25337"},{"1":"ARHGEF12","2":"GSM95728","3":"744.79231","4":"79.2","5":"2103.69460"},{"1":"ARHGEF12","2":"GSM95729","3":"392.57693","4":"100.0","5":"1025.71739"},{"1":"ARHGEF12","2":"GSM95730","3":"429.84615","4":"114.1","5":"1070.98418"},{"1":"ARHGEF12","2":"GSM95731","3":"353.31538","4":"146.8","5":"763.02278"},{"1":"ARHGEF12","2":"GSM95732","3":"273.91539","4":"92.6","5":"326.32741"},{"1":"ARHGEF12","2":"GSM95733","3":"460.46155","4":"63.9","5":"1188.07415"},{"1":"ARHGEF12","2":"GSM95734","3":"332.35385","4":"28.2","5":"868.64402"},{"1":"ARHGEF12","2":"GSM95735","3":"270.41538","4":"38.2","5":"653.38191"},{"1":"ARHGEF12","2":"GSM95736","3":"244.83077","4":"66.2","5":"560.48818"},{"1":"ARHGEF12","2":"GSM95737","3":"271.14615","4":"105.9","5":"585.47202"},{"1":"ARHGEF12","2":"GSM95738","3":"392.93076","4":"49.2","5":"961.94533"},{"1":"ARHGEF12","2":"GSM95739","3":"185.58461","4":"51.6","5":"329.62732"},{"1":"ARHGEF12","2":"GSM95740","3":"270.10000","4":"28.8","5":"580.79650"},{"1":"ARHGEF12","2":"GSM95741","3":"221.51539","4":"82.3","5":"277.15692"},{"1":"ARHGEF12","2":"GSM95742","3":"274.90769","4":"45.2","5":"583.45739"},{"1":"ARHGEF12","2":"GSM95743","3":"301.66923","4":"31.4","5":"797.16058"},{"1":"ARHGEF12","2":"GSM95744","3":"416.22307","4":"53.4","5":"1113.09405"},{"1":"ARHGEF12","2":"GSM95745","3":"200.06923","4":"43.0","5":"412.90169"},{"1":"ARHGEF12","2":"GSM95746","3":"276.50769","4":"78.0","5":"531.60533"},{"1":"ARHGEF12","2":"GSM95747","3":"366.30768","4":"53.7","5":"1006.65800"},{"1":"ARHGEF12","2":"GSM95748","3":"311.14615","4":"88.6","5":"708.37266"},{"1":"ARHGEF12","2":"GSM95749","3":"544.76924","4":"99.7","5":"1456.59903"},{"1":"ARHGEF12","2":"GSM95750","3":"227.10000","4":"145.2","5":"238.27640"},{"1":"ARHGEF12","2":"GSM95751","3":"240.31538","4":"127.3","5":"398.84582"},{"1":"ARHGEF12","2":"GSM95752","3":"339.90769","4":"33.4","5":"815.87541"},{"1":"ARHGEF12","2":"GSM95753","3":"323.30000","4":"33.6","5":"709.62916"},{"1":"ARHGEF12","2":"GSM95754","3":"287.91538","4":"91.5","5":"686.46885"},{"1":"ARHGEF12","2":"GSM95755","3":"255.60000","4":"79.2","5":"522.42213"},{"1":"ARHGEF12","2":"GSM95756","3":"417.97692","4":"205.9","5":"412.44816"},{"1":"ARHGEF12","2":"GSM95757","3":"202.53077","4":"96.6","5":"407.84053"},{"1":"ARHGEF12","2":"GSM95758","3":"226.91539","4":"62.6","5":"587.73406"},{"1":"ARHGEF12","2":"GSM95759","3":"214.41538","4":"51.4","5":"413.95741"},{"1":"ARHGEF12","2":"GSM95760","3":"261.59231","4":"58.9","5":"562.10953"},{"1":"ARHGEF12","2":"GSM95761","3":"232.65385","4":"104.5","5":"370.97210"},{"1":"ARHGEF12","2":"GSM95762","3":"197.03846","4":"76.8","5":"448.76341"},{"1":"ARHGEF12","2":"GSM95763","3":"428.09999","4":"56.1","5":"1184.07636"},{"1":"ARHGEF12","2":"GSM95764","3":"227.23077","4":"115.6","5":"396.17625"},{"1":"ARHGEF12","2":"GSM95765","3":"303.19231","4":"70.8","5":"664.38753"},{"1":"ARHGEF12","2":"GSM95766","3":"518.15385","4":"48.6","5":"1525.09825"},{"1":"ARHGEF12","2":"GSM95767","3":"467.51538","4":"86.9","5":"1102.03702"},{"1":"ARHGEF12","2":"GSM95768","3":"193.92308","4":"58.5","5":"476.01717"},{"1":"ARHGEF12","2":"GSM95769","3":"301.36923","4":"184.2","5":"558.47228"},{"1":"ARHGEF12","2":"GSM95770","3":"229.33846","4":"100.8","5":"366.47308"},{"1":"ARHGEF12","2":"GSM95771","3":"311.61538","4":"74.6","5":"654.88676"},{"1":"ARHGEF12","2":"GSM95772","3":"372.76154","4":"116.9","5":"763.46496"},{"1":"ARHGEF12","2":"GSM95773","3":"254.79231","4":"108.2","5":"516.22648"},{"1":"ARHGEF12","2":"GSM95774","3":"429.28461","4":"91.3","5":"734.70527"},{"1":"ARHGEF12","2":"GSM95775","3":"296.10770","4":"97.0","5":"568.46061"},{"1":"ARHGEF12","2":"GSM95776","3":"243.20769","4":"74.9","5":"479.77970"},{"1":"ARHGEF12","2":"GSM95777","3":"167.11538","4":"26.7","5":"322.76404"},{"1":"ARHGEF12","2":"GSM95778","3":"266.20768","4":"66.9","5":"621.73006"},{"1":"ARHGEF12","2":"GSM95779","3":"324.76922","4":"79.8","5":"711.65751"},{"1":"ARHGEF12","2":"GSM95780","3":"287.22308","4":"115.1","5":"630.69991"},{"1":"ARHGEF12","2":"GSM95781","3":"367.37693","4":"59.5","5":"870.66838"},{"1":"ARHGEF12","2":"GSM95782","3":"292.17692","4":"90.2","5":"594.22879"},{"1":"ARHGEF12","2":"GSM95783","3":"352.25384","4":"41.0","5":"1012.37074"},{"1":"ARHGEF12","2":"GSM95784","3":"280.91539","4":"64.0","5":"649.34767"},{"1":"ARHGEF12","2":"GSM95785","3":"232.99231","4":"47.9","5":"429.06964"},{"1":"ARHGEF12","2":"GSM95786","3":"274.92308","4":"141.5","5":"506.67237"},{"1":"ARHGEF12","2":"GSM95787","3":"329.03846","4":"72.2","5":"835.62056"},{"1":"ARHGEF12","2":"GSM95788","3":"363.20000","4":"65.8","5":"948.71392"},{"1":"ARHGEF12","2":"GSM95789","3":"400.24615","4":"65.5","5":"1079.53604"},{"1":"ARHGEF12","2":"GSM95790","3":"222.83846","4":"94.3","5":"454.52126"},{"1":"ARHGEF12","2":"GSM95791","3":"251.35384","4":"119.2","5":"531.16897"},{"1":"ARHGEF12","2":"GSM95792","3":"419.21539","4":"69.5","5":"1041.54485"},{"1":"ARHGEF12","2":"GSM95793","3":"388.88462","4":"135.0","5":"935.67118"},{"1":"ARHGEF12","2":"GSM95794","3":"202.27692","4":"48.8","5":"322.87574"},{"1":"ARHGEF12","2":"GSM95795","3":"272.29231","4":"96.3","5":"593.31092"},{"1":"ARHGEF12","2":"GSM95796","3":"278.50769","4":"69.5","5":"627.90976"},{"1":"ARHGEF12","2":"GSM95797","3":"284.32308","4":"142.8","5":"458.80292"},{"1":"ARHGEF12","2":"GSM95798","3":"593.59231","4":"147.5","5":"1366.69266"},{"1":"ARHGEF12","2":"GSM95799","3":"682.62306","4":"96.3","5":"1737.71945"},{"1":"ARHGEF12","2":"GSM95800","3":"245.84615","4":"71.6","5":"525.57855"},{"1":"ARHGEF12","2":"GSM95801","3":"402.77693","4":"80.7","5":"924.97568"},{"1":"ARHGEF12","2":"GSM95802","3":"198.80769","4":"91.4","5":"327.97612"},{"1":"ARHGEF12","2":"GSM95803","3":"219.59231","4":"37.1","5":"522.99982"},{"1":"ARHGEF12","2":"GSM95804","3":"161.92308","4":"74.0","5":"374.76114"},{"1":"ARHGEF12","2":"GSM95805","3":"391.03846","4":"196.5","5":"769.55818"},{"1":"ARHGEF12","2":"GSM95806","3":"359.13078","4":"109.1","5":"841.36320"},{"1":"ARHGEF12","2":"GSM95807","3":"230.38462","4":"78.9","5":"525.19778"},{"1":"ARHGEF12","2":"GSM95808","3":"256.86923","4":"49.4","5":"576.54432"},{"1":"ARHGEF12","2":"GSM95809","3":"159.08462","4":"108.8","5":"167.63766"},{"1":"ARHGEF12","2":"GSM95810","3":"249.04615","4":"82.8","5":"563.77108"},{"1":"ARHGEF12","2":"GSM95811","3":"365.70769","4":"93.3","5":"959.89452"},{"1":"ARHGEF12","2":"GSM95812","3":"143.75384","4":"46.5","5":"230.72019"},{"1":"ARHGEF12","2":"GSM95813","3":"396.33077","4":"73.5","5":"862.21278"},{"1":"ARHGEF12","2":"GSM95814","3":"252.44616","4":"43.7","5":"562.45290"},{"1":"ARHGEF12","2":"GSM95815","3":"215.95385","4":"86.5","5":"475.40147"},{"1":"ARHGEF12","2":"GSM95816","3":"436.44615","4":"38.7","5":"1170.99792"},{"1":"ARHGEF12","2":"GSM95817","3":"294.46154","4":"69.5","5":"691.94756"},{"1":"ARHGEF12","2":"GSM95818","3":"204.48462","4":"76.0","5":"360.22299"},{"1":"ARHGEF12","2":"GSM95819","3":"370.19231","4":"64.3","5":"808.15619"},{"1":"ARHGEF12","2":"GSM95820","3":"297.52308","4":"90.1","5":"496.79542"},{"1":"ARHGEF12","2":"GSM95821","3":"341.58462","4":"151.3","5":"607.05867"},{"1":"ARHGEF12","2":"GSM95822","3":"258.31539","4":"123.0","5":"439.73635"},{"1":"ARHGEF12","2":"GSM95823","3":"336.33847","4":"112.3","5":"805.66194"},{"1":"ARHGEF12","2":"GSM95824","3":"341.32308","4":"168.7","5":"578.24228"},{"1":"ARHGEF12","2":"GSM95825","3":"187.36923","4":"80.4","5":"336.95402"},{"1":"ARHGEF12","2":"GSM95826","3":"360.17692","4":"96.4","5":"752.77371"},{"1":"DNAH1","2":"GSM102606","3":"108.53077","4":"97.5","5":"68.79472"},{"1":"DNAH1","2":"GSM102607","3":"170.82308","4":"86.3","5":"238.24251"},{"1":"DNAH1","2":"GSM102609","3":"130.44615","4":"46.7","5":"222.04742"},{"1":"DNAH1","2":"GSM102610","3":"133.42308","4":"60.1","5":"170.29583"},{"1":"DNAH1","2":"GSM102611","3":"113.93077","4":"43.3","5":"125.33056"},{"1":"DNAH1","2":"GSM102612","3":"168.96923","4":"112.2","5":"182.70250"},{"1":"DNAH1","2":"GSM102613","3":"134.01539","4":"53.9","5":"166.78572"},{"1":"DNAH1","2":"GSM102614","3":"84.21538","4":"64.8","5":"61.53094"},{"1":"DNAH1","2":"GSM102615","3":"85.05385","4":"75.1","5":"74.05558"},{"1":"DNAH1","2":"GSM102616","3":"106.68462","4":"85.1","5":"80.90136"},{"1":"DNAH1","2":"GSM102617","3":"128.43077","4":"80.0","5":"158.14926"},{"1":"DNAH1","2":"GSM102618","3":"107.13846","4":"86.4","5":"121.58003"},{"1":"DNAH1","2":"GSM102620","3":"107.79231","4":"134.1","5":"92.66274"},{"1":"DNAH1","2":"GSM102621","3":"154.11538","4":"97.5","5":"149.32984"},{"1":"DNAH1","2":"GSM102622","3":"88.44616","4":"49.1","5":"97.80987"},{"1":"DNAH1","2":"GSM102623","3":"202.74616","4":"144.7","5":"219.12490"},{"1":"DNAH1","2":"GSM102624","3":"94.26154","4":"78.4","5":"73.00051"},{"1":"DNAH1","2":"GSM102625","3":"109.64615","4":"73.5","5":"92.50092"},{"1":"DNAH1","2":"GSM102626","3":"103.96923","4":"64.2","5":"83.61243"},{"1":"DNAH1","2":"GSM102627","3":"102.23077","4":"104.4","5":"60.49910"},{"1":"DNAH1","2":"GSM102628","3":"203.76154","4":"124.2","5":"267.25835"},{"1":"DNAH1","2":"GSM102629","3":"204.82308","4":"131.4","5":"207.85778"},{"1":"DNAH1","2":"GSM102630","3":"140.09231","4":"110.2","5":"112.86793"},{"1":"DNAH1","2":"GSM102631","3":"142.63077","4":"83.7","5":"144.15822"},{"1":"DNAH1","2":"GSM102632","3":"158.63846","4":"89.1","5":"184.40441"},{"1":"DNAH1","2":"GSM102633","3":"179.23846","4":"104.9","5":"201.97147"},{"1":"DNAH1","2":"GSM102634","3":"207.65384","4":"215.2","5":"171.64099"},{"1":"DNAH1","2":"GSM50986","3":"221.80000","4":"143.3","5":"215.92505"},{"1":"DNAH1","2":"GSM50987","3":"139.41538","4":"93.5","5":"137.11993"},{"1":"DNAH1","2":"GSM50988","3":"108.96923","4":"72.9","5":"93.35359"},{"1":"DNAH1","2":"GSM50989","3":"291.15385","4":"108.5","5":"326.79671"},{"1":"DNAH1","2":"GSM50990","3":"128.89231","4":"119.3","5":"90.84331"},{"1":"DNAH1","2":"GSM50991","3":"222.54615","4":"196.6","5":"201.25351"},{"1":"DNAH1","2":"GSM50992","3":"87.98462","4":"84.5","5":"65.71915"},{"1":"DNAH1","2":"GSM50993","3":"108.54615","4":"80.9","5":"101.10520"},{"1":"DNAH1","2":"GSM50994","3":"191.38462","4":"137.5","5":"197.25891"},{"1":"DNAH1","2":"GSM50995","3":"182.26154","4":"132.0","5":"133.16467"},{"1":"DNAH1","2":"GSM50996","3":"179.29231","4":"148.2","5":"175.24974"},{"1":"DNAH1","2":"GSM50997","3":"123.08462","4":"115.0","5":"103.76977"},{"1":"DNAH1","2":"GSM50998","3":"236.00770","4":"204.2","5":"252.45956"},{"1":"DNAH1","2":"GSM50999","3":"227.43077","4":"235.0","5":"141.66004"},{"1":"DNAH1","2":"GSM51000","3":"145.86154","4":"89.3","5":"133.95961"},{"1":"DNAH1","2":"GSM51001","3":"167.63077","4":"90.3","5":"158.97952"},{"1":"DNAH1","2":"GSM51002","3":"90.40769","4":"54.7","5":"86.49287"},{"1":"DNAH1","2":"GSM51003","3":"139.44615","4":"94.0","5":"116.44707"},{"1":"DNAH1","2":"GSM51004","3":"188.76923","4":"130.4","5":"184.29752"},{"1":"DNAH1","2":"GSM51005","3":"170.24615","4":"80.9","5":"220.42942"},{"1":"DNAH1","2":"GSM51006","3":"189.16154","4":"150.1","5":"163.96549"},{"1":"DNAH1","2":"GSM51007","3":"200.06153","4":"137.7","5":"242.56492"},{"1":"DNAH1","2":"GSM51008","3":"132.62308","4":"101.2","5":"137.57060"},{"1":"DNAH1","2":"GSM51009","3":"255.21538","4":"203.8","5":"222.43922"},{"1":"DNAH1","2":"GSM51010","3":"125.11539","4":"91.0","5":"146.59913"},{"1":"DNAH1","2":"GSM51011","3":"145.63846","4":"121.7","5":"85.69816"},{"1":"DNAH1","2":"GSM51012","3":"228.65385","4":"172.1","5":"210.35121"},{"1":"DNAH1","2":"GSM51013","3":"193.41539","4":"147.8","5":"217.63755"},{"1":"DNAH1","2":"GSM51014","3":"220.78462","4":"185.9","5":"190.47491"},{"1":"DNAH1","2":"GSM51015","3":"144.75385","4":"78.9","5":"179.64151"},{"1":"DNAH1","2":"GSM51016","3":"301.49231","4":"245.3","5":"221.04374"},{"1":"DNAH1","2":"GSM51017","3":"336.79231","4":"251.4","5":"346.81093"},{"1":"DNAH1","2":"GSM51018","3":"236.45385","4":"157.3","5":"215.66652"},{"1":"DNAH1","2":"GSM51019","3":"224.03846","4":"185.8","5":"172.53717"},{"1":"DNAH1","2":"GSM51020","3":"148.58462","4":"90.9","5":"139.62532"},{"1":"DNAH1","2":"GSM51021","3":"171.63846","4":"171.1","5":"142.94611"},{"1":"DNAH1","2":"GSM51022","3":"187.33846","4":"188.1","5":"162.69036"},{"1":"DNAH1","2":"GSM51023","3":"142.90769","4":"127.6","5":"157.94642"},{"1":"DNAH1","2":"GSM51024","3":"284.46923","4":"213.6","5":"222.87615"},{"1":"DNAH1","2":"GSM51025","3":"229.38461","4":"193.2","5":"183.65493"},{"1":"DNAH1","2":"GSM51026","3":"111.66154","4":"78.4","5":"99.59754"},{"1":"DNAH1","2":"GSM51027","3":"360.48462","4":"257.0","5":"345.99415"},{"1":"DNAH1","2":"GSM51028","3":"272.30000","4":"227.5","5":"253.35221"},{"1":"DNAH1","2":"GSM51029","3":"171.07693","4":"124.6","5":"164.83216"},{"1":"DNAH1","2":"GSM51030","3":"188.13077","4":"119.6","5":"161.91056"},{"1":"DNAH1","2":"GSM51031","3":"207.16153","4":"143.0","5":"232.57704"},{"1":"DNAH1","2":"GSM51032","3":"194.34615","4":"170.4","5":"177.09069"},{"1":"DNAH1","2":"GSM51033","3":"175.76923","4":"115.6","5":"147.52691"},{"1":"DNAH1","2":"GSM51034","3":"250.58462","4":"133.3","5":"293.68910"},{"1":"DNAH1","2":"GSM51035","3":"244.50000","4":"193.1","5":"196.63981"},{"1":"DNAH1","2":"GSM51036","3":"298.73846","4":"323.5","5":"203.15616"},{"1":"DNAH1","2":"GSM51037","3":"210.80769","4":"187.5","5":"216.63674"},{"1":"DNAH1","2":"GSM51038","3":"224.46154","4":"176.9","5":"167.37894"},{"1":"DNAH1","2":"GSM51039","3":"110.56154","4":"78.1","5":"97.30517"},{"1":"DNAH1","2":"GSM51040","3":"229.83846","4":"184.0","5":"194.72239"},{"1":"DNAH1","2":"GSM51041","3":"211.55385","4":"144.1","5":"226.57934"},{"1":"DNAH1","2":"GSM51042","3":"248.58462","4":"178.7","5":"206.72945"},{"1":"DNAH1","2":"GSM51043","3":"229.80000","4":"157.8","5":"257.16786"},{"1":"DNAH1","2":"GSM51044","3":"198.92308","4":"133.7","5":"163.54090"},{"1":"DNAH1","2":"GSM51045","3":"113.74616","4":"83.0","5":"106.49278"},{"1":"DNAH1","2":"GSM51046","3":"166.38461","4":"111.8","5":"153.62383"},{"1":"DNAH1","2":"GSM51047","3":"216.33846","4":"169.6","5":"186.84892"},{"1":"DNAH1","2":"GSM51048","3":"208.41539","4":"165.7","5":"241.01304"},{"1":"DNAH1","2":"GSM51049","3":"229.43847","4":"168.0","5":"194.65661"},{"1":"DNAH1","2":"GSM51050","3":"162.91538","4":"116.8","5":"131.66659"},{"1":"DNAH1","2":"GSM51051","3":"302.55385","4":"252.6","5":"280.94201"},{"1":"DNAH1","2":"GSM51052","3":"185.88461","4":"100.0","5":"234.20333"},{"1":"DNAH1","2":"GSM51053","3":"294.38462","4":"240.1","5":"243.58728"},{"1":"DNAH1","2":"GSM51054","3":"168.05385","4":"112.9","5":"167.29515"},{"1":"DNAH1","2":"GSM51055","3":"114.59231","4":"107.3","5":"97.09920"},{"1":"DNAH1","2":"GSM51056","3":"170.96154","4":"183.7","5":"187.61481"},{"1":"DNAH1","2":"GSM51057","3":"186.57692","4":"141.2","5":"177.47587"},{"1":"DNAH1","2":"GSM51058","3":"210.16923","4":"174.5","5":"211.72140"},{"1":"DNAH1","2":"GSM51059","3":"142.26154","4":"121.0","5":"102.90329"},{"1":"DNAH1","2":"GSM51060","3":"157.47692","4":"119.8","5":"164.34657"},{"1":"DNAH1","2":"GSM51061","3":"196.72307","4":"148.5","5":"213.08846"},{"1":"DNAH1","2":"GSM51062","3":"158.31539","4":"139.2","5":"113.77226"},{"1":"DNAH1","2":"GSM51063","3":"146.57692","4":"120.4","5":"138.87309"},{"1":"DNAH1","2":"GSM51064","3":"140.58462","4":"90.0","5":"99.91882"},{"1":"DNAH1","2":"GSM51065","3":"153.47692","4":"107.0","5":"150.44797"},{"1":"DNAH1","2":"GSM51066","3":"146.65385","4":"105.2","5":"128.56752"},{"1":"DNAH1","2":"GSM51067","3":"129.76154","4":"71.1","5":"124.52690"},{"1":"DNAH1","2":"GSM51068","3":"182.39231","4":"116.4","5":"197.29378"},{"1":"DNAH1","2":"GSM51069","3":"229.83846","4":"154.2","5":"219.73482"},{"1":"DNAH1","2":"GSM51070","3":"225.76923","4":"69.1","5":"313.21775"},{"1":"DNAH1","2":"GSM51071","3":"218.11539","4":"122.1","5":"219.23735"},{"1":"DNAH1","2":"GSM51072","3":"178.65385","4":"121.3","5":"175.05462"},{"1":"DNAH1","2":"GSM51073","3":"221.84615","4":"170.7","5":"223.71104"},{"1":"DNAH1","2":"GSM51074","3":"223.45384","4":"129.1","5":"231.17173"},{"1":"DNAH1","2":"GSM51075","3":"196.53077","4":"209.8","5":"176.87204"},{"1":"DNAH1","2":"GSM51076","3":"143.72308","4":"103.6","5":"119.24290"},{"1":"DNAH1","2":"GSM51077","3":"127.24615","4":"87.6","5":"121.36657"},{"1":"DNAH1","2":"GSM51078","3":"250.00000","4":"210.6","5":"219.38151"},{"1":"DNAH1","2":"GSM51079","3":"186.96923","4":"85.7","5":"215.23380"},{"1":"DNAH1","2":"GSM51080","3":"242.59231","4":"253.5","5":"177.01311"},{"1":"DNAH1","2":"GSM51081","3":"207.30000","4":"181.5","5":"215.35185"},{"1":"DNAH1","2":"GSM51082","3":"112.46923","4":"90.8","5":"103.90582"},{"1":"DNAH1","2":"GSM51083","3":"159.53846","4":"117.9","5":"173.84419"},{"1":"DNAH1","2":"GSM51084","3":"188.46154","4":"138.8","5":"196.35726"},{"1":"DNAH1","2":"GSM51085","3":"211.78462","4":"212.6","5":"162.16032"},{"1":"DNAH1","2":"GSM51086","3":"136.34615","4":"84.7","5":"149.29284"},{"1":"DNAH1","2":"GSM51087","3":"249.79231","4":"215.2","5":"259.92134"},{"1":"DNAH1","2":"GSM51088","3":"168.16154","4":"134.0","5":"137.62661"},{"1":"DNAH1","2":"GSM51089","3":"195.30000","4":"183.0","5":"185.00963"},{"1":"DNAH1","2":"GSM51090","3":"162.30000","4":"118.0","5":"186.31828"},{"1":"DNAH1","2":"GSM51091","3":"159.60769","4":"131.7","5":"126.19338"},{"1":"DNAH1","2":"GSM51092","3":"186.74615","4":"78.1","5":"193.23406"},{"1":"DNAH1","2":"GSM51093","3":"244.29231","4":"112.1","5":"323.85563"},{"1":"DNAH1","2":"GSM51094","3":"153.53077","4":"179.3","5":"118.98380"},{"1":"DNAH1","2":"GSM51095","3":"182.76154","4":"115.3","5":"188.15971"},{"1":"DNAH1","2":"GSM51096","3":"197.13846","4":"130.1","5":"218.81193"},{"1":"DNAH1","2":"GSM51097","3":"137.27692","4":"139.7","5":"78.09409"},{"1":"DNAH1","2":"GSM51098","3":"178.39231","4":"155.2","5":"156.66343"},{"1":"DNAH1","2":"GSM51099","3":"165.83846","4":"92.2","5":"124.03885"},{"1":"DNAH1","2":"GSM51100","3":"196.03077","4":"96.2","5":"173.88998"},{"1":"DNAH1","2":"GSM51101","3":"117.00000","4":"73.3","5":"129.79435"},{"1":"DNAH1","2":"GSM51102","3":"162.72308","4":"112.8","5":"159.28994"},{"1":"DNAH1","2":"GSM51103","3":"130.44615","4":"123.7","5":"123.11806"},{"1":"DNAH1","2":"GSM51104","3":"149.77693","4":"97.5","5":"145.14548"},{"1":"DNAH1","2":"GSM51105","3":"196.23077","4":"162.4","5":"196.45488"},{"1":"DNAH1","2":"GSM51106","3":"207.80769","4":"140.5","5":"185.70391"},{"1":"DNAH1","2":"GSM51107","3":"91.94615","4":"74.0","5":"76.72210"},{"1":"DNAH1","2":"GSM51108","3":"166.56154","4":"62.1","5":"201.63769"},{"1":"DNAH1","2":"GSM51109","3":"112.17692","4":"53.0","5":"117.37661"},{"1":"DNAH1","2":"GSM51110","3":"141.79231","4":"143.9","5":"90.70971"},{"1":"DNAH1","2":"GSM51111","3":"172.43077","4":"142.2","5":"128.63338"},{"1":"DNAH1","2":"GSM51112","3":"260.93846","4":"173.7","5":"247.54698"},{"1":"DNAH1","2":"GSM51113","3":"168.17692","4":"102.1","5":"142.25205"},{"1":"DNAH1","2":"GSM51114","3":"162.62308","4":"123.0","5":"124.24674"},{"1":"DNAH1","2":"GSM51115","3":"303.99231","4":"263.9","5":"252.24111"},{"1":"DNAH1","2":"GSM51116","3":"233.01539","4":"188.5","5":"217.26238"},{"1":"DNAH1","2":"GSM51117","3":"109.12308","4":"103.7","5":"94.24043"},{"1":"DNAH1","2":"GSM51118","3":"293.39231","4":"250.4","5":"222.79689"},{"1":"DNAH1","2":"GSM51119","3":"125.98462","4":"79.8","5":"114.06661"},{"1":"DNAH1","2":"GSM51120","3":"179.24615","4":"108.8","5":"159.12412"},{"1":"DNAH1","2":"GSM51121","3":"198.52308","4":"164.8","5":"201.85256"},{"1":"DNAH1","2":"GSM51122","3":"228.96923","4":"202.4","5":"164.13505"},{"1":"DNAH1","2":"GSM51123","3":"174.59231","4":"134.4","5":"126.62342"},{"1":"DNAH1","2":"GSM51124","3":"245.49231","4":"170.1","5":"258.98965"},{"1":"DNAH1","2":"GSM51125","3":"181.60000","4":"163.6","5":"134.02584"},{"1":"DNAH1","2":"GSM51126","3":"108.95385","4":"91.2","5":"68.95336"},{"1":"DNAH1","2":"GSM51127","3":"117.79230","4":"81.6","5":"112.03584"},{"1":"DNAH1","2":"GSM51128","3":"201.43846","4":"186.1","5":"163.22214"},{"1":"DNAH1","2":"GSM51129","3":"99.52308","4":"78.5","5":"88.25935"},{"1":"DNAH1","2":"GSM51130","3":"164.23077","4":"71.5","5":"177.03709"},{"1":"DNAH1","2":"GSM51131","3":"248.63847","4":"178.3","5":"216.20799"},{"1":"DNAH1","2":"GSM51132","3":"145.31538","4":"106.6","5":"137.39269"},{"1":"DNAH1","2":"GSM51133","3":"175.53077","4":"72.8","5":"220.00770"},{"1":"DNAH1","2":"GSM51134","3":"129.07693","4":"45.8","5":"156.42317"},{"1":"DNAH1","2":"GSM51135","3":"168.40000","4":"117.0","5":"166.70395"},{"1":"DNAH1","2":"GSM51136","3":"209.77692","4":"209.7","5":"178.60556"},{"1":"DNAH1","2":"GSM51137","3":"156.16154","4":"93.5","5":"201.54985"},{"1":"DNAH1","2":"GSM51138","3":"214.22308","4":"156.5","5":"184.86912"},{"1":"DNAH1","2":"GSM51139","3":"224.60000","4":"261.4","5":"203.20271"},{"1":"DNAH1","2":"GSM51140","3":"135.71539","4":"76.5","5":"169.44190"},{"1":"DNAH1","2":"GSM51141","3":"173.26923","4":"64.9","5":"215.26413"},{"1":"DNAH1","2":"GSM51142","3":"202.87692","4":"107.6","5":"205.99574"},{"1":"DNAH1","2":"GSM51143","3":"97.90769","4":"61.3","5":"96.36266"},{"1":"DNAH1","2":"GSM51144","3":"107.26923","4":"68.1","5":"115.33944"},{"1":"DNAH1","2":"GSM51145","3":"198.20769","4":"59.5","5":"248.66591"},{"1":"DNAH1","2":"GSM51146","3":"173.48462","4":"169.1","5":"158.42788"},{"1":"DNAH1","2":"GSM51147","3":"181.19231","4":"150.5","5":"143.47179"},{"1":"DNAH1","2":"GSM51148","3":"178.80769","4":"138.9","5":"138.92248"},{"1":"DNAH1","2":"GSM51149","3":"256.90000","4":"235.9","5":"212.70444"},{"1":"DNAH1","2":"GSM51150","3":"244.93846","4":"209.0","5":"193.95021"},{"1":"DNAH1","2":"GSM51151","3":"236.71538","4":"125.0","5":"227.35087"},{"1":"DNAH1","2":"GSM51152","3":"270.36923","4":"146.6","5":"276.95062"},{"1":"DNAH1","2":"GSM51153","3":"108.00000","4":"68.7","5":"114.19009"},{"1":"DNAH1","2":"GSM51154","3":"155.87692","4":"143.7","5":"108.98029"},{"1":"DNAH1","2":"GSM51155","3":"163.26154","4":"102.0","5":"140.73205"},{"1":"DNAH1","2":"GSM51156","3":"265.22308","4":"242.3","5":"185.68018"},{"1":"DNAH1","2":"GSM51157","3":"165.53077","4":"138.1","5":"122.57862"},{"1":"DNAH1","2":"GSM51158","3":"212.40769","4":"206.1","5":"188.21523"},{"1":"DNAH1","2":"GSM51159","3":"237.26923","4":"150.8","5":"225.40421"},{"1":"DNAH1","2":"GSM51160","3":"210.45385","4":"161.9","5":"204.74218"},{"1":"DNAH1","2":"GSM51161","3":"289.28462","4":"321.8","5":"229.15658"},{"1":"DNAH1","2":"GSM51162","3":"263.66923","4":"290.9","5":"177.71914"},{"1":"DNAH1","2":"GSM51163","3":"170.66923","4":"106.6","5":"161.84513"},{"1":"DNAH1","2":"GSM51164","3":"169.86154","4":"147.3","5":"105.55669"},{"1":"DNAH1","2":"GSM51165","3":"170.48462","4":"153.1","5":"123.38458"},{"1":"DNAH1","2":"GSM51166","3":"146.60770","4":"123.2","5":"150.30662"},{"1":"DNAH1","2":"GSM51167","3":"90.20769","4":"73.3","5":"86.87684"},{"1":"DNAH1","2":"GSM51168","3":"152.41538","4":"130.3","5":"152.10010"},{"1":"DNAH1","2":"GSM51169","3":"301.68462","4":"311.2","5":"274.47031"},{"1":"DNAH1","2":"GSM51170","3":"139.93077","4":"83.3","5":"109.70155"},{"1":"DNAH1","2":"GSM51171","3":"134.85385","4":"116.2","5":"114.23192"},{"1":"DNAH1","2":"GSM51172","3":"305.95385","4":"324.3","5":"223.62432"},{"1":"DNAH1","2":"GSM51173","3":"216.05385","4":"144.5","5":"200.55324"},{"1":"DNAH1","2":"GSM51174","3":"193.36923","4":"139.5","5":"164.23116"},{"1":"DNAH1","2":"GSM51175","3":"193.09231","4":"129.6","5":"166.18865"},{"1":"DNAH1","2":"GSM51176","3":"118.10000","4":"67.1","5":"113.30926"},{"1":"DNAH1","2":"GSM51177","3":"237.43077","4":"161.4","5":"267.46916"},{"1":"DNAH1","2":"GSM51178","3":"104.21538","4":"51.6","5":"89.51362"},{"1":"DNAH1","2":"GSM51179","3":"172.55385","4":"142.3","5":"176.29392"},{"1":"DNAH1","2":"GSM51180","3":"172.87692","4":"138.8","5":"204.24619"},{"1":"DNAH1","2":"GSM51181","3":"127.20000","4":"154.0","5":"84.84009"},{"1":"DNAH1","2":"GSM51182","3":"187.39231","4":"158.5","5":"188.49372"},{"1":"DNAH1","2":"GSM51183","3":"172.59231","4":"108.7","5":"152.82078"},{"1":"DNAH1","2":"GSM51184","3":"168.00000","4":"203.4","5":"106.11254"},{"1":"DNAH1","2":"GSM51185","3":"297.41538","4":"221.7","5":"261.08365"},{"1":"DNAH1","2":"GSM51186","3":"160.13077","4":"109.3","5":"144.31683"},{"1":"DNAH1","2":"GSM51187","3":"169.28462","4":"151.6","5":"141.05026"},{"1":"DNAH1","2":"GSM51188","3":"153.28462","4":"91.1","5":"139.68048"},{"1":"DNAH1","2":"GSM51189","3":"196.67692","4":"125.2","5":"216.45718"},{"1":"DNAH1","2":"GSM51190","3":"111.66154","4":"108.2","5":"60.22956"},{"1":"DNAH1","2":"GSM51191","3":"144.96923","4":"142.8","5":"105.27252"},{"1":"DNAH1","2":"GSM51192","3":"256.66154","4":"154.5","5":"249.11460"},{"1":"DNAH1","2":"GSM51193","3":"246.83846","4":"264.0","5":"193.66836"},{"1":"DNAH1","2":"GSM51194","3":"172.03846","4":"96.9","5":"172.86290"},{"1":"DNAH1","2":"GSM51195","3":"274.14615","4":"243.9","5":"262.08687"},{"1":"DNAH1","2":"GSM51196","3":"222.55385","4":"212.5","5":"148.01745"},{"1":"DNAH1","2":"GSM51197","3":"162.23077","4":"90.2","5":"202.88886"},{"1":"DNAH1","2":"GSM51198","3":"198.21538","4":"74.1","5":"256.92009"},{"1":"DNAH1","2":"GSM51199","3":"145.21538","4":"119.8","5":"145.21098"},{"1":"DNAH1","2":"GSM51200","3":"191.06923","4":"141.9","5":"208.34276"},{"1":"DNAH1","2":"GSM51201","3":"131.40000","4":"104.4","5":"116.42219"},{"1":"DNAH1","2":"GSM51202","3":"134.30000","4":"86.4","5":"109.26839"},{"1":"DNAH1","2":"GSM51203","3":"233.56154","4":"199.2","5":"159.89686"},{"1":"DNAH1","2":"GSM51204","3":"283.09231","4":"243.3","5":"213.50084"},{"1":"DNAH1","2":"GSM51205","3":"182.04615","4":"163.5","5":"175.45757"},{"1":"DNAH1","2":"GSM51206","3":"208.86923","4":"156.2","5":"155.58718"},{"1":"DNAH1","2":"GSM51207","3":"255.97692","4":"234.6","5":"236.31045"},{"1":"DNAH1","2":"GSM51208","3":"205.37693","4":"158.1","5":"166.90268"},{"1":"DNAH1","2":"GSM51209","3":"140.99231","4":"140.9","5":"104.75895"},{"1":"DNAH1","2":"GSM51210","3":"183.82308","4":"167.4","5":"176.25541"},{"1":"DNAH1","2":"GSM51211","3":"161.38461","4":"144.9","5":"144.51430"},{"1":"DNAH1","2":"GSM51212","3":"311.81539","4":"165.2","5":"359.55047"},{"1":"DNAH1","2":"GSM51213","3":"165.66154","4":"127.5","5":"166.07959"},{"1":"DNAH1","2":"GSM51214","3":"160.87693","4":"74.4","5":"159.98812"},{"1":"DNAH1","2":"GSM51215","3":"258.26923","4":"178.4","5":"238.60745"},{"1":"DNAH1","2":"GSM51216","3":"169.74615","4":"119.0","5":"174.41141"},{"1":"DNAH1","2":"GSM51217","3":"139.06923","4":"122.9","5":"91.12740"},{"1":"DNAH1","2":"GSM51218","3":"222.68462","4":"261.6","5":"140.18633"},{"1":"DNAH1","2":"GSM51219","3":"143.62307","4":"102.8","5":"127.11985"},{"1":"DNAH1","2":"GSM51220","3":"221.30000","4":"114.7","5":"236.85263"},{"1":"DNAH1","2":"GSM51221","3":"194.97693","4":"121.0","5":"196.20617"},{"1":"DNAH1","2":"GSM51222","3":"134.84615","4":"101.6","5":"125.72476"},{"1":"DNAH1","2":"GSM51223","3":"127.55385","4":"78.9","5":"143.83838"},{"1":"DNAH1","2":"GSM51224","3":"200.94615","4":"160.9","5":"147.83588"},{"1":"DNAH1","2":"GSM51225","3":"144.05385","4":"95.3","5":"148.36756"},{"1":"DNAH1","2":"GSM51226","3":"268.15385","4":"280.6","5":"236.69273"},{"1":"DNAH1","2":"GSM51227","3":"336.49231","4":"301.5","5":"332.04163"},{"1":"DNAH1","2":"GSM51228","3":"136.80000","4":"141.8","5":"88.62337"},{"1":"DNAH1","2":"GSM51229","3":"155.48461","4":"150.2","5":"113.81236"},{"1":"DNAH1","2":"GSM51230","3":"129.58461","4":"89.4","5":"159.40991"},{"1":"DNAH1","2":"GSM51231","3":"221.55385","4":"96.1","5":"254.36308"},{"1":"DNAH1","2":"GSM51232","3":"273.22308","4":"98.8","5":"286.92372"},{"1":"DNAH1","2":"GSM51233","3":"109.63846","4":"60.8","5":"105.43667"},{"1":"DNAH1","2":"GSM51234","3":"120.35385","4":"117.3","5":"85.30305"},{"1":"DNAH1","2":"GSM51235","3":"134.47692","4":"110.6","5":"132.57751"},{"1":"DNAH1","2":"GSM51236","3":"153.55384","4":"76.2","5":"194.11255"},{"1":"DNAH1","2":"GSM51237","3":"103.73846","4":"71.8","5":"84.49108"},{"1":"DNAH1","2":"GSM51238","3":"174.45385","4":"115.5","5":"144.43519"},{"1":"DNAH1","2":"GSM51239","3":"73.26923","4":"47.3","5":"73.05372"},{"1":"DNAH1","2":"GSM51240","3":"161.86154","4":"169.2","5":"105.93214"},{"1":"DNAH1","2":"GSM51241","3":"99.47692","4":"85.7","5":"57.60559"},{"1":"DNAH1","2":"GSM51242","3":"127.04615","4":"65.6","5":"126.22418"},{"1":"DNAH1","2":"GSM51243","3":"143.41539","4":"124.2","5":"115.78499"},{"1":"DNAH1","2":"GSM51244","3":"212.12308","4":"187.1","5":"151.95414"},{"1":"DNAH1","2":"GSM51245","3":"231.91538","4":"168.8","5":"195.34339"},{"1":"DNAH1","2":"GSM51246","3":"69.60000","4":"50.5","5":"60.65837"},{"1":"DNAH1","2":"GSM51247","3":"272.18462","4":"225.9","5":"255.32542"},{"1":"DNAH1","2":"GSM51248","3":"197.90769","4":"86.6","5":"239.23995"},{"1":"DNAH1","2":"GSM51249","3":"156.35385","4":"129.8","5":"135.97677"},{"1":"DNAH1","2":"GSM51250","3":"264.52308","4":"232.5","5":"183.30163"},{"1":"DNAH1","2":"GSM51251","3":"96.90769","4":"45.7","5":"86.55698"},{"1":"DNAH1","2":"GSM51252","3":"195.66154","4":"240.1","5":"142.61162"},{"1":"DNAH1","2":"GSM51253","3":"149.40000","4":"108.9","5":"133.29918"},{"1":"DNAH1","2":"GSM51254","3":"123.06923","4":"71.1","5":"127.44335"},{"1":"DNAH1","2":"GSM51255","3":"152.28462","4":"126.4","5":"135.42747"},{"1":"DNAH1","2":"GSM51256","3":"141.03077","4":"91.5","5":"144.63501"},{"1":"DNAH1","2":"GSM51257","3":"184.51538","4":"97.8","5":"239.01644"},{"1":"DNAH1","2":"GSM51258","3":"130.79231","4":"86.0","5":"118.46694"},{"1":"DNAH1","2":"GSM51259","3":"108.93077","4":"82.4","5":"92.83792"},{"1":"DNAH1","2":"GSM51260","3":"134.98461","4":"100.7","5":"106.38806"},{"1":"DNAH1","2":"GSM51261","3":"195.03077","4":"165.8","5":"125.09582"},{"1":"DNAH1","2":"GSM51262","3":"158.14615","4":"120.2","5":"151.54537"},{"1":"DNAH1","2":"GSM51263","3":"133.36923","4":"113.5","5":"153.62799"},{"1":"DNAH1","2":"GSM51264","3":"200.03846","4":"166.2","5":"165.08292"},{"1":"DNAH1","2":"GSM51265","3":"190.63077","4":"175.7","5":"143.07289"},{"1":"DNAH1","2":"GSM51266","3":"152.17692","4":"95.7","5":"139.92477"},{"1":"DNAH1","2":"GSM51267","3":"139.53846","4":"139.5","5":"109.25521"},{"1":"DNAH1","2":"GSM51268","3":"153.55385","4":"127.4","5":"124.20278"},{"1":"DNAH1","2":"GSM51269","3":"125.61539","4":"123.3","5":"100.68697"},{"1":"DNAH1","2":"GSM51270","3":"117.74616","4":"86.6","5":"113.27528"},{"1":"DNAH1","2":"GSM51271","3":"129.74615","4":"76.0","5":"116.59098"},{"1":"DNAH1","2":"GSM51272","3":"183.06154","4":"130.8","5":"165.12336"},{"1":"DNAH1","2":"GSM51273","3":"83.83846","4":"70.5","5":"66.82893"},{"1":"DNAH1","2":"GSM51274","3":"105.08462","4":"69.9","5":"101.21381"},{"1":"DNAH1","2":"GSM51275","3":"142.08462","4":"165.9","5":"88.57397"},{"1":"DNAH1","2":"GSM51276","3":"105.07692","4":"76.5","5":"96.06984"},{"1":"DNAH1","2":"GSM51277","3":"126.86154","4":"105.9","5":"104.90247"},{"1":"DNAH1","2":"GSM51278","3":"154.64616","4":"128.6","5":"105.65200"},{"1":"DNAH1","2":"GSM51279","3":"122.57693","4":"101.2","5":"91.31120"},{"1":"DNAH1","2":"GSM51280","3":"157.08461","4":"112.4","5":"158.31666"},{"1":"DNAH1","2":"GSM51281","3":"248.36154","4":"226.1","5":"200.99716"},{"1":"DNAH1","2":"GSM51282","3":"185.46154","4":"136.7","5":"158.54732"},{"1":"DNAH1","2":"GSM51283","3":"161.27692","4":"74.7","5":"164.58521"},{"1":"DNAH1","2":"GSM51284","3":"230.76923","4":"221.3","5":"154.97913"},{"1":"DNAH1","2":"GSM51285","3":"115.66154","4":"113.5","5":"97.39390"},{"1":"DNAH1","2":"GSM51286","3":"129.65385","4":"107.5","5":"94.64069"},{"1":"DNAH1","2":"GSM51287","3":"109.37692","4":"87.4","5":"106.21112"},{"1":"DNAH1","2":"GSM51288","3":"165.80000","4":"115.2","5":"197.03905"},{"1":"DNAH1","2":"GSM51289","3":"79.51539","4":"48.4","5":"72.79006"},{"1":"DNAH1","2":"GSM51290","3":"102.25385","4":"84.9","5":"84.41096"},{"1":"DNAH1","2":"GSM51291","3":"115.44615","4":"91.5","5":"75.78274"},{"1":"DNAH1","2":"GSM51292","3":"123.80000","4":"55.4","5":"147.30454"},{"1":"DNAH1","2":"GSM51293","3":"149.47692","4":"87.0","5":"120.98580"},{"1":"DNAH1","2":"GSM51294","3":"183.06154","4":"166.5","5":"120.77014"},{"1":"DNAH1","2":"GSM51295","3":"113.28461","4":"68.2","5":"99.54113"},{"1":"DNAH1","2":"GSM51296","3":"185.28462","4":"182.1","5":"145.56560"},{"1":"DNAH1","2":"GSM51297","3":"79.57692","4":"31.4","5":"96.80482"},{"1":"DNAH1","2":"GSM51298","3":"112.90000","4":"101.2","5":"82.85730"},{"1":"DNAH1","2":"GSM51299","3":"154.96923","4":"69.9","5":"129.32409"},{"1":"DNAH1","2":"GSM51300","3":"308.57692","4":"167.0","5":"355.76896"},{"1":"DNAH1","2":"GSM51301","3":"162.76154","4":"118.5","5":"147.16965"},{"1":"DNAH1","2":"GSM51302","3":"117.48462","4":"58.2","5":"112.72876"},{"1":"DNAH1","2":"GSM51303","3":"115.82308","4":"61.8","5":"141.73174"},{"1":"DNAH1","2":"GSM51304","3":"156.20000","4":"93.4","5":"154.53751"},{"1":"DNAH1","2":"GSM51305","3":"151.92308","4":"148.2","5":"126.28484"},{"1":"DNAH1","2":"GSM51306","3":"97.88461","4":"96.3","5":"71.34875"},{"1":"DNAH1","2":"GSM51307","3":"130.31538","4":"94.1","5":"143.71673"},{"1":"DNAH1","2":"GSM51308","3":"106.88461","4":"62.1","5":"93.07974"},{"1":"DNAH1","2":"GSM51309","3":"125.43846","4":"104.7","5":"92.74637"},{"1":"DNAH1","2":"GSM51310","3":"152.03077","4":"124.0","5":"139.38704"},{"1":"DNAH1","2":"GSM51311","3":"138.72308","4":"112.4","5":"116.76780"},{"1":"DNAH1","2":"GSM51312","3":"111.12308","4":"88.0","5":"107.14231"},{"1":"DNAH1","2":"GSM51313","3":"90.60769","4":"52.6","5":"82.54002"},{"1":"DNAH1","2":"GSM51314","3":"105.06923","4":"124.9","5":"100.29464"},{"1":"DNAH1","2":"GSM51315","3":"117.96154","4":"109.9","5":"83.10664"},{"1":"DNAH1","2":"GSM51316","3":"117.05385","4":"65.6","5":"109.82615"},{"1":"DNAH1","2":"GSM51317","3":"155.91539","4":"96.5","5":"153.54230"},{"1":"DNAH1","2":"GSM51318","3":"132.30000","4":"119.5","5":"87.54652"},{"1":"DNAH1","2":"GSM51319","3":"169.77692","4":"101.8","5":"163.38006"},{"1":"DNAH1","2":"GSM51320","3":"141.40770","4":"91.8","5":"113.42299"},{"1":"DNAH1","2":"GSM51321","3":"232.25384","4":"156.4","5":"197.92561"},{"1":"DNAH1","2":"GSM51322","3":"169.79231","4":"118.5","5":"152.99588"},{"1":"DNAH1","2":"GSM51323","3":"164.90769","4":"103.3","5":"144.86586"},{"1":"DNAH1","2":"GSM51324","3":"153.82308","4":"111.1","5":"106.75509"},{"1":"DNAH1","2":"GSM51325","3":"179.06923","4":"88.7","5":"202.59795"},{"1":"DNAH1","2":"GSM51326","3":"122.01538","4":"113.5","5":"117.76002"},{"1":"DNAH1","2":"GSM51327","3":"212.16923","4":"118.2","5":"223.50847"},{"1":"DNAH1","2":"GSM51328","3":"138.30769","4":"144.0","5":"106.26430"},{"1":"DNAH1","2":"GSM51329","3":"113.82308","4":"140.7","5":"67.60220"},{"1":"DNAH1","2":"GSM51330","3":"115.70769","4":"88.7","5":"92.89379"},{"1":"DNAH1","2":"GSM51331","3":"112.83077","4":"78.5","5":"138.58044"},{"1":"DNAH1","2":"GSM51332","3":"195.20770","4":"128.0","5":"172.02205"},{"1":"DNAH1","2":"GSM51333","3":"120.63077","4":"128.1","5":"84.40553"},{"1":"DNAH1","2":"GSM51334","3":"184.86154","4":"176.9","5":"154.62755"},{"1":"DNAH1","2":"GSM51335","3":"334.92308","4":"370.3","5":"192.62255"},{"1":"DNAH1","2":"GSM51336","3":"177.47692","4":"165.0","5":"114.61372"},{"1":"DNAH1","2":"GSM95646","3":"136.30769","4":"67.6","5":"158.79205"},{"1":"DNAH1","2":"GSM95647","3":"150.48461","4":"134.1","5":"156.50267"},{"1":"DNAH1","2":"GSM95648","3":"161.57693","4":"129.6","5":"141.83679"},{"1":"DNAH1","2":"GSM95649","3":"135.39231","4":"70.1","5":"135.18316"},{"1":"DNAH1","2":"GSM95650","3":"142.99231","4":"87.9","5":"166.37123"},{"1":"DNAH1","2":"GSM95651","3":"134.65384","4":"111.2","5":"114.74315"},{"1":"DNAH1","2":"GSM95652","3":"164.92307","4":"134.3","5":"126.42796"},{"1":"DNAH1","2":"GSM95653","3":"198.13077","4":"140.1","5":"222.99241"},{"1":"DNAH1","2":"GSM95654","3":"119.60000","4":"123.2","5":"105.67181"},{"1":"DNAH1","2":"GSM95655","3":"156.37692","4":"115.6","5":"183.68218"},{"1":"DNAH1","2":"GSM95656","3":"91.78462","4":"78.5","5":"74.19282"},{"1":"DNAH1","2":"GSM95657","3":"167.26154","4":"157.8","5":"135.67186"},{"1":"DNAH1","2":"GSM95658","3":"95.05384","4":"103.2","5":"81.45270"},{"1":"DNAH1","2":"GSM95659","3":"97.50769","4":"105.7","5":"79.79003"},{"1":"DNAH1","2":"GSM95660","3":"145.85384","4":"54.7","5":"155.71467"},{"1":"DNAH1","2":"GSM95661","3":"125.61538","4":"95.5","5":"108.27460"},{"1":"DNAH1","2":"GSM95662","3":"145.60000","4":"136.0","5":"99.71251"},{"1":"DNAH1","2":"GSM95663","3":"112.16923","4":"100.0","5":"82.34191"},{"1":"DNAH1","2":"GSM95664","3":"79.81539","4":"102.8","5":"59.49739"},{"1":"DNAH1","2":"GSM95665","3":"168.00000","4":"142.9","5":"154.91933"},{"1":"DNAH1","2":"GSM95666","3":"222.63077","4":"178.4","5":"196.43579"},{"1":"DNAH1","2":"GSM95667","3":"107.73077","4":"70.8","5":"114.32516"},{"1":"DNAH1","2":"GSM95668","3":"156.55385","4":"128.3","5":"141.74564"},{"1":"DNAH1","2":"GSM95669","3":"133.06923","4":"103.5","5":"116.14562"},{"1":"DNAH1","2":"GSM95670","3":"86.75385","4":"80.3","5":"65.97926"},{"1":"DNAH1","2":"GSM95671","3":"94.10000","4":"65.9","5":"91.11484"},{"1":"DNAH1","2":"GSM95672","3":"94.30769","4":"59.7","5":"91.09889"},{"1":"DNAH1","2":"GSM95673","3":"143.44615","4":"105.5","5":"140.65255"},{"1":"DNAH1","2":"GSM95674","3":"118.02308","4":"80.7","5":"105.48124"},{"1":"DNAH1","2":"GSM95675","3":"93.06154","4":"57.2","5":"110.45529"},{"1":"DNAH1","2":"GSM95676","3":"155.83077","4":"95.5","5":"135.06231"},{"1":"DNAH1","2":"GSM95677","3":"88.94615","4":"49.6","5":"92.91114"},{"1":"DNAH1","2":"GSM95678","3":"144.68462","4":"127.2","5":"124.25762"},{"1":"DNAH1","2":"GSM95679","3":"120.10769","4":"114.8","5":"92.65171"},{"1":"DNAH1","2":"GSM95680","3":"135.60769","4":"63.1","5":"136.53589"},{"1":"DNAH1","2":"GSM95681","3":"127.37692","4":"95.6","5":"108.08158"},{"1":"DNAH1","2":"GSM95682","3":"183.75384","4":"88.3","5":"190.89648"},{"1":"DNAH1","2":"GSM95683","3":"96.80769","4":"54.3","5":"102.75162"},{"1":"DNAH1","2":"GSM95684","3":"147.19231","4":"125.9","5":"143.35879"},{"1":"DNAH1","2":"GSM95685","3":"144.66923","4":"77.6","5":"135.82278"},{"1":"DNAH1","2":"GSM95686","3":"231.22308","4":"177.7","5":"176.00336"},{"1":"DNAH1","2":"GSM95687","3":"80.43077","4":"78.0","5":"46.68830"},{"1":"DNAH1","2":"GSM95688","3":"191.72308","4":"142.0","5":"153.83024"},{"1":"DNAH1","2":"GSM95689","3":"169.82308","4":"100.4","5":"226.55648"},{"1":"DNAH1","2":"GSM95690","3":"148.54615","4":"146.7","5":"102.68543"},{"1":"DNAH1","2":"GSM95691","3":"123.08461","4":"117.5","5":"88.76995"},{"1":"DNAH1","2":"GSM95692","3":"223.60000","4":"166.9","5":"194.33135"},{"1":"DNAH1","2":"GSM95693","3":"121.36923","4":"85.7","5":"107.70204"},{"1":"DNAH1","2":"GSM95694","3":"120.43846","4":"106.4","5":"109.18930"},{"1":"DNAH1","2":"GSM95695","3":"141.16154","4":"117.3","5":"117.77105"},{"1":"DNAH1","2":"GSM95696","3":"120.05385","4":"91.5","5":"100.06510"},{"1":"DNAH1","2":"GSM95697","3":"125.20000","4":"87.7","5":"146.62377"},{"1":"DNAH1","2":"GSM95698","3":"191.66923","4":"181.8","5":"146.73017"},{"1":"DNAH1","2":"GSM95699","3":"280.57692","4":"159.6","5":"329.36578"},{"1":"DNAH1","2":"GSM95700","3":"467.69231","4":"471.8","5":"284.10268"},{"1":"DNAH1","2":"GSM95701","3":"213.24615","4":"73.1","5":"217.66518"},{"1":"DNAH1","2":"GSM95702","3":"129.26154","4":"79.0","5":"108.68480"},{"1":"DNAH1","2":"GSM95703","3":"103.46923","4":"95.7","5":"86.70616"},{"1":"DNAH1","2":"GSM95704","3":"317.69231","4":"302.1","5":"177.44644"},{"1":"DNAH1","2":"GSM95705","3":"313.56154","4":"191.1","5":"232.12718"},{"1":"DNAH1","2":"GSM95706","3":"166.38461","4":"140.4","5":"129.43035"},{"1":"DNAH1","2":"GSM95707","3":"202.16923","4":"117.4","5":"171.26663"},{"1":"DNAH1","2":"GSM95708","3":"108.04616","4":"89.2","5":"79.03489"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[2795]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z25fbG9uZyA8LSBnc2UyNjU4X2V4cHJzX3NtX3dnbiAlPiUgXG4gIHBpdm90X2xvbmdlcigtYyhnZW5lX25hbWUsIHByb2JlX0lEKSwgbmFtZXNfdG8gPSBcInNhbXBsZV9pZFwiLCB2YWx1ZXNfdG8gPSBcImV4cHJcIilcbmhlYWQoZ3NlMjY1OF9leHByc19zbV93Z25fbG9uZywgMTApXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_sm_wgn_long &lt;- gse2658_exprs_sm_wgn %&gt;% 
  pivot_longer(-c(gene_name, probe_ID), names_to = &quot;sample_id&quot;, values_to = &quot;expr&quot;)
head(gse2658_exprs_sm_wgn_long, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_name"],"name":[1],"type":["chr"],"align":["left"]},{"label":["probe_ID"],"name":[2],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[3],"type":["chr"],"align":["left"]},{"label":["expr"],"name":[4],"type":["dbl"],"align":["right"]}],"data":[{"1":"RFC2","2":"1053_at","3":"GSM50986","4":"421.0"},{"1":"RFC2","2":"1053_at","3":"GSM50987","4":"468.9"},{"1":"RFC2","2":"1053_at","3":"GSM50988","4":"335.6"},{"1":"RFC2","2":"1053_at","3":"GSM50989","4":"334.1"},{"1":"RFC2","2":"1053_at","3":"GSM50990","4":"571.5"},{"1":"RFC2","2":"1053_at","3":"GSM50991","4":"416.7"},{"1":"RFC2","2":"1053_at","3":"GSM50992","4":"376.9"},{"1":"RFC2","2":"1053_at","3":"GSM50993","4":"376.0"},{"1":"RFC2","2":"1053_at","3":"GSM50994","4":"431.9"},{"1":"RFC2","2":"1053_at","3":"GSM50995","4":"354.5"}],"options":{"columns":{"min":{},"max":[10],"total":[4]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>plot histogram of raw expr values</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2dwbG90KGdzZTI2NThfZXhwcnNfc21fd2duX2xvbmcpICsgXG4gIGdlb21faGlzdG9ncmFtKGFlcyhleHByKSkgKyB0aGVtZV9taW5pbWFsKCkgKyBcbiAgbGFicyh4PShcImV4cHJlc3Npb24gdmFsdWVcIiksIFxuICAgICAgIHRpdGxlPVwiR1NFMjY1OCBtaWNyb2FycmF5IGV4cHJlc3Npb24gdmFsdWVzIGFzIGRvd25sb2FkZWRcIilcbmBgYCJ9 -->
<pre class="r"><code>ggplot(gse2658_exprs_sm_wgn_long) + 
  geom_histogram(aes(expr)) + theme_minimal() + 
  labs(x=(&quot;expression value&quot;), 
       title=&quot;GSE2658 microarray expression values as downloaded&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG5XYXJuaW5nOiBSZW1vdmVkIDE4MSByb3dzIGNvbnRhaW5pbmcgbm9uLWZpbml0ZSB2YWx1ZXMgKHN0YXRfYmluKS5cbiJ9 -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.
Warning: Removed 181 rows containing non-finite values (stat_bin).</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo5LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,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" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>plot histogram of log2(raw expr values)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2dwbG90KGdzZTI2NThfZXhwcnNfc21fd2duX2xvbmcpICsgXG4gIGdlb21faGlzdG9ncmFtKGFlcyhsb2cyKGV4cHIpKSkgKyB0aGVtZV9taW5pbWFsKCkgKyBcbiAgbGFicyh4PShcImV4cHJlc3Npb24gdmFsdWVcIiksIFxuICAgICAgIHRpdGxlPVwiR1NFMjY1OCBsb2cyIG1pY3JvYXJyYXkgZXhwcmVzc2lvbiB2YWx1ZXMgYXMgZG93bmxvYWRlZFwiKVxuYGBgIn0= -->
<pre class="r"><code>ggplot(gse2658_exprs_sm_wgn_long) + 
  geom_histogram(aes(log2(expr))) + theme_minimal() + 
  labs(x=(&quot;expression value&quot;), 
       title=&quot;GSE2658 log2 microarray expression values as downloaded&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG5XYXJuaW5nOiBSZW1vdmVkIDE4MSByb3dzIGNvbnRhaW5pbmcgbm9uLWZpbml0ZSB2YWx1ZXMgKHN0YXRfYmluKS5cbiJ9 -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.
Warning: Removed 181 rows containing non-finite values (stat_bin).</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo5LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,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" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>get gene length by gene_id</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2VuY29kZV9nZW5lX2xlbiA8LSBnZW5jb2RlX2Fubm90ICU+JSBmaWx0ZXIoZmVhdHVyZT09XCJleG9uXCIpICU+JSBcbiAgbXV0YXRlKGV4X3NpemU9KGVuZC1zdGFydCkrMSkgJT4lIGdyb3VwX2J5KGdlbmVfaWQpICU+JSBcbiAgZHBseXI6OnN1bW1hcmlzZShsZW5ndGggPSBzdW0oZXhfc2l6ZSkpXG5gYGAifQ== -->
<pre class="r"><code>gencode_gene_len &lt;- gencode_annot %&gt;% filter(feature==&quot;exon&quot;) %&gt;% 
  mutate(ex_size=(end-start)+1) %&gt;% group_by(gene_id) %&gt;% 
  dplyr::summarise(length = sum(ex_size))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p><strong><em>have to convert to gene_id</em></strong> since the commpass loadings use gene_id and there is one gene name that has 2 IDs everything will get messed up unless I convert to gene_id now.</p>
<p>gene name <code>PAGR1</code> has 2 ensembl IDs: <code>ENSG00000185928</code> and <code>ENSG00000263136</code> in the CoMMpass data, but those 2 have been merged in newest ensembl.<br />
I need to try to map these probes to one, the other, or both</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9mZWF0dXJlcyAlPiUgZmlsdGVyKGdyZXBsKFwiUEFHUjFcIiwgYEdlbmUgU3ltYm9sYCkpICU+JSBzZWxlY3QoSUQsIEdCX0FDQywgYEdlbmUgU3ltYm9sYClcbmBgYCJ9 -->
<pre class="r"><code>gse2658_features %&gt;% filter(grepl(&quot;PAGR1&quot;, `Gene Symbol`)) %&gt;% select(ID, GB_ACC, `Gene Symbol`)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["ID"],"name":[1],"type":["chr"],"align":["left"]},{"label":["GB_ACC"],"name":[2],"type":["chr"],"align":["left"]},{"label":["Gene Symbol"],"name":[3],"type":["chr"],"align":["left"]}],"data":[{"1":"1559125_at","2":"BC029255","3":"PAGR1","_rn_":"1559125_at"},{"1":"218300_at","2":"NM_024516","3":"PAGR1","_rn_":"218300_at"},{"1":"231878_at","2":"AK026112","3":"PAGR1","_rn_":"231878_at"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[3]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p><code>1559125_at</code> actually misses the gene in the newest ensembl and the GB_ACC is unhelpful</p>
<p>how different are the probes in expression?</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z25fbG9uZyAlPiUgXG4gIGZpbHRlcihnZW5lX25hbWU9PVwiUEFHUjFcIikgJT4lICBcbiAgZ2dwbG90KCkgKyBnZW9tX2hpc3RvZ3JhbShhZXMoZXhwcikpICsgZmFjZXRfd3JhcChcInByb2JlX0lEXCIsIG5jb2w9MSkgKyB0aGVtZV9taW5pbWFsKClcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_sm_wgn_long %&gt;% 
  filter(gene_name==&quot;PAGR1&quot;) %&gt;%  
  ggplot() + geom_histogram(aes(expr)) + facet_wrap(&quot;probe_ID&quot;, ncol=1) + theme_minimal()</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG4ifQ== -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo1LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,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" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>PAGR1 gene id garbage</p>
<p>In the CoMMpass expression data, the PAGR1 gene has 2 ENSG IDs, which is annoying and creates problems since the microarray data only has one row for PAGR1.<br />
Later, these two ENSG IDs were merged into one (ENSG00000280789).<br />
It gets worse since there are 3 probesets assigned to that gene name in the microarray data and the probeset 1559125_at doesnt really match any of the ENSG IDs old or new.</p>
<p>Probeset: 218300_at Chromosome 16: 29,819,557-29,819,872<br />
in ENSE00003711437 of ENST00000320330.8 from gene ENSG00000185928<br />
in ENSE00001241136 of ENST00000609618.2 from gene ENSG00000263136</p>
<p>Probeset: 231878_at Chromosome 16: 29,822,107-29,822,455<br />
in ENSE00003711437 of ENST00000320330.8 from gene ENSG00000185928</p>
<p>Gene: ENSG00000185928<br />
ENST00000320330.8 PAGR1-201 Chromosome 16: 29,816,152-29,822,489 forward strand.<br />
ENST00000562285.1 Chromosome 16: 29,817,239-29,830,627 forward strand.</p>
<p>Gene: ENSG00000263136<br />
ENST00000609618.2 Chromosome 16: 29,812,261-29,820,092 forward strand.</p>
<p><strong>Plan:</strong><br />
1559125_at: remove<br />
218300_at: ENSG00000263136<br />
231878_at: ENSG00000185928</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin 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 -->
<pre class="r"><code>gse2658_exprs_sm_long_gid &lt;- 
  left_join(gse2658_exprs_sm_wgn_long %&gt;% filter(probe_ID!=&quot;1559125_at&quot;), # remove 1559125_at
            gid_names %&gt;% filter(gene_id %in% cmps_spec_rm$gene_id &amp; gene_name!=&quot;PAGR1&quot;), # join back in gene_ids except PAGR1 
            by=&quot;gene_name&quot;) %&gt;% 
  mutate(gene_id=case_when(gene_name==&quot;PAGR1&quot; &amp; probe_ID==&quot;218300_at&quot; ~ &quot;ENSG00000263136&quot;,
                           gene_name==&quot;PAGR1&quot; &amp; probe_ID==&quot;231878_at&quot; ~ &quot;ENSG00000185928&quot;, 
                           TRUE ~ gene_id)) %&gt;% 
  relocate(gene_id)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p><strong><em>now back to our regularly scheduled program</em></strong> of normalizing the expression values, now by gene_id</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV9naWRfc3VtIDwtIGdzZTI2NThfZXhwcnNfc21fbG9uZ19naWQgJT4lIFxuICBncm91cF9ieShnZW5lX2lkLCBzYW1wbGVfaWQpICU+JSBcbiAgc3VtbWFyaXNlKGdlbmVfZXhwcj1zdW0oZXhwcikpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_sm_gid_sum &lt;- gse2658_exprs_sm_long_gid %&gt;% 
  group_by(gene_id, sample_id) %&gt;% 
  summarise(gene_expr=sum(expr))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN1bW1hcmlzZSgpYCBoYXMgZ3JvdXBlZCBvdXRwdXQgYnkgJ2dlbmVfaWQnLiBZb3UgY2FuIG92ZXJyaWRlIHVzaW5nIHRoZSBgLmdyb3Vwc2AgYXJndW1lbnQuXG4ifQ== -->
<pre><code>`summarise()` has grouped output by &#39;gene_id&#39;. You can override using the `.groups` argument.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaGVhZChnc2UyNjU4X2V4cHJzX3NtX2dpZF9zdW0sIDEwKVxuYGBgIn0= -->
<pre class="r"><code>head(gse2658_exprs_sm_gid_sum, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["gene_expr"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000000419","2":"GSM102606","3":"7510.6"},{"1":"ENSG00000000419","2":"GSM102607","3":"5238.3"},{"1":"ENSG00000000419","2":"GSM102609","3":"5572.0"},{"1":"ENSG00000000419","2":"GSM102610","3":"3834.4"},{"1":"ENSG00000000419","2":"GSM102611","3":"4012.9"},{"1":"ENSG00000000419","2":"GSM102612","3":"3970.1"},{"1":"ENSG00000000419","2":"GSM102613","3":"4203.8"},{"1":"ENSG00000000419","2":"GSM102614","3":"3476.8"},{"1":"ENSG00000000419","2":"GSM102615","3":"4353.5"},{"1":"ENSG00000000419","2":"GSM102616","3":"3341.4"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>2nd way to do the sum, just in case I messed up (though I think its ok the way I did it)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV9naWRfc3VtMiA8LSBcbiAgbGVmdF9qb2luKGdzZTI2NThfZXhwcnNfc21fbG9uZ19naWQsIGdlbmNvZGVfZ2VuZV9sZW4sIGJ5PVwiZ2VuZV9pZFwiKSAlPiUgXG4gIGdyb3VwX2J5KGdlbmVfaWQsIHNhbXBsZV9pZCkgJT4lIFxuICBtdXRhdGUoY3BrPWV4cHIvKGxlbmd0aC8xMDAwKSkgJT4lIFxuICBzdW1tYXJpc2UoZ2VuZV9leHByPXN1bShjcGspKSBcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_sm_gid_sum2 &lt;- 
  left_join(gse2658_exprs_sm_long_gid, gencode_gene_len, by=&quot;gene_id&quot;) %&gt;% 
  group_by(gene_id, sample_id) %&gt;% 
  mutate(cpk=expr/(length/1000)) %&gt;% 
  summarise(gene_expr=sum(cpk)) </code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN1bW1hcmlzZSgpYCBoYXMgZ3JvdXBlZCBvdXRwdXQgYnkgJ2dlbmVfaWQnLiBZb3UgY2FuIG92ZXJyaWRlIHVzaW5nIHRoZSBgLmdyb3Vwc2AgYXJndW1lbnQuXG4ifQ== -->
<pre><code>`summarise()` has grouped output by &#39;gene_id&#39;. You can override using the `.groups` argument.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaGVhZChnc2UyNjU4X2V4cHJzX3NtX2dpZF9zdW0yLCAxMClcbmBgYCJ9 -->
<pre class="r"><code>head(gse2658_exprs_sm_gid_sum2, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin eyJtZXRhZGF0YSI6eyJjbGFzc2VzIjpbImdyb3VwZWRfZGYiLCJ0YmxfZGYiLCJ0YmwiLCJkYXRhLmZyYW1lIl0sIm5yb3ciOjEwLCJuY29sIjozLCJzdW1tYXJ5Ijp7IkEgdGliYmxlIjpbIjEwIMOXIDMiXSwiR3JvdXBzIjpbImdlbmVfaWQgWzFdIl19fSwicmRmIjoiSDRzSUFBQUFBQUFBQXd0eWlURG1pdUJpWUdCZ1ptQmhaR0pnWmdVeUdWaERROXgwTFJnWVdKaUFIRVlHRmdaT0VGMEJWQ1FNVnNuQUlBREVYRkFKZmxlL1lIY0RLREF4dEJ4dXdxaSs1WFFQOWpVME1ESXpNRU1YTUVjWHNFUVRNRFJBRnpCRUZ6QkNGekJHRnpCQkZ6QkZGekFEY3ZoQUxuYVlhQ3hkYURZNzBxSDk3N3VTQldzVkhUcGJqUUphVmw5M2FPeS9wUlp3OG9wRFU2TEsyOVRETWc1TmV0L0VBdFc0SEpvZGZxNlorUDJsUS8xTlJUNVZWV21INWcvMTl4S1BjenZVelo0YjVpYmxqcFlnV0pOekVvdUxvY0VERStSS1NTeEoxRXNyU3N4TlJWUE9XWlJmcnBjSEZBZHA0UVZpcGdZZzhmLy8vMi9vNXNJVUNVQ1NKVmlRUFQwMUx6VStNd1ZtV0hGaWJrRU9zZ0JZUHJXaW9BakkrWWRtSW50K1FVbG1maDdRVENaUUFtWkZjek5qRVpxQVFHa2V5QTBwdXNrWnBYblp1dVltNFBnSHlVTUFMNVROaGNSbWh0ako4aDlxRml2VUxMYlV2UFRNdkZTWTMzSVNrMUp6b0J3K1lJaUEvYXBYVUpTWlZ3SUxRYUJvc1Y1SmZra2lUQjFYY240T1RBVHNPWVovQUxMQzhQdTRBd0FBIn0= -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["gene_expr"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000000419","2":"GSM102606","3":"1100.7768"},{"1":"ENSG00000000419","2":"GSM102607","3":"767.7414"},{"1":"ENSG00000000419","2":"GSM102609","3":"816.6496"},{"1":"ENSG00000000419","2":"GSM102610","3":"561.9815"},{"1":"ENSG00000000419","2":"GSM102611","3":"588.1430"},{"1":"ENSG00000000419","2":"GSM102612","3":"581.8702"},{"1":"ENSG00000000419","2":"GSM102613","3":"616.1219"},{"1":"ENSG00000000419","2":"GSM102614","3":"509.5706"},{"1":"ENSG00000000419","2":"GSM102615","3":"638.0624"},{"1":"ENSG00000000419","2":"GSM102616","3":"489.7259"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z25fc3VtX3dnbCA8LSBsZWZ0X2pvaW4oZ3NlMjY1OF9leHByc19zbV9naWRfc3VtLCBnZW5jb2RlX2dlbmVfbGVuLCBieT1cImdlbmVfaWRcIilcbmhlYWQoZ3NlMjY1OF9leHByc19zbV93Z25fc3VtX3dnbCwgMTApXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_sm_wgn_sum_wgl &lt;- left_join(gse2658_exprs_sm_gid_sum, gencode_gene_len, by=&quot;gene_id&quot;)
head(gse2658_exprs_sm_wgn_sum_wgl, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["gene_expr"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["length"],"name":[4],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000000419","2":"GSM102606","3":"7510.6","4":"6823"},{"1":"ENSG00000000419","2":"GSM102607","3":"5238.3","4":"6823"},{"1":"ENSG00000000419","2":"GSM102609","3":"5572.0","4":"6823"},{"1":"ENSG00000000419","2":"GSM102610","3":"3834.4","4":"6823"},{"1":"ENSG00000000419","2":"GSM102611","3":"4012.9","4":"6823"},{"1":"ENSG00000000419","2":"GSM102612","3":"3970.1","4":"6823"},{"1":"ENSG00000000419","2":"GSM102613","3":"4203.8","4":"6823"},{"1":"ENSG00000000419","2":"GSM102614","3":"3476.8","4":"6823"},{"1":"ENSG00000000419","2":"GSM102615","3":"4353.5","4":"6823"},{"1":"ENSG00000000419","2":"GSM102616","3":"3341.4","4":"6823"}],"options":{"columns":{"min":{},"max":[10],"total":[4]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z25fc3VtX3dnbCA8LSBnc2UyNjU4X2V4cHJzX3NtX3dnbl9zdW1fd2dsICU+JSBtdXRhdGUoY3BrPWdlbmVfZXhwci9sZW5ndGgpXG5oZWFkKGdzZTI2NThfZXhwcnNfc21fd2duX3N1bV93Z2wsMTApXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_sm_wgn_sum_wgl &lt;- gse2658_exprs_sm_wgn_sum_wgl %&gt;% mutate(cpk=gene_expr/length)
head(gse2658_exprs_sm_wgn_sum_wgl,10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["gene_expr"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["length"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["cpk"],"name":[5],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000000419","2":"GSM102606","3":"7510.6","4":"6823","5":"1.1007768"},{"1":"ENSG00000000419","2":"GSM102607","3":"5238.3","4":"6823","5":"0.7677414"},{"1":"ENSG00000000419","2":"GSM102609","3":"5572.0","4":"6823","5":"0.8166496"},{"1":"ENSG00000000419","2":"GSM102610","3":"3834.4","4":"6823","5":"0.5619815"},{"1":"ENSG00000000419","2":"GSM102611","3":"4012.9","4":"6823","5":"0.5881430"},{"1":"ENSG00000000419","2":"GSM102612","3":"3970.1","4":"6823","5":"0.5818702"},{"1":"ENSG00000000419","2":"GSM102613","3":"4203.8","4":"6823","5":"0.6161219"},{"1":"ENSG00000000419","2":"GSM102614","3":"3476.8","4":"6823","5":"0.5095706"},{"1":"ENSG00000000419","2":"GSM102615","3":"4353.5","4":"6823","5":"0.6380624"},{"1":"ENSG00000000419","2":"GSM102616","3":"3341.4","4":"6823","5":"0.4897259"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>plot histogram of log2(cpk)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2dwbG90KGdzZTI2NThfZXhwcnNfc21fd2duX3N1bV93Z2wpICsgXG4gIGdlb21faGlzdG9ncmFtKGFlcyhsb2cyKGNwaykpKSArIHRoZW1lX21pbmltYWwoKSArIFxuICBsYWJzKHg9KFwiZXhwcmVzc2lvbiB2YWx1ZVwiKSwgXG4gICAgICAgdGl0bGU9XCJHU0UyNjU4IGxvZzIoY3BrKSBtaWNyb2FycmF5IGV4cHJlc3Npb24gdmFsdWVzXCIpXG5gYGAifQ== -->
<pre class="r"><code>ggplot(gse2658_exprs_sm_wgn_sum_wgl) + 
  geom_histogram(aes(log2(cpk))) + theme_minimal() + 
  labs(x=(&quot;expression value&quot;), 
       title=&quot;GSE2658 log2(cpk) microarray expression values&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG5XYXJuaW5nOiBSZW1vdmVkIDE4MSByb3dzIGNvbnRhaW5pbmcgbm9uLWZpbml0ZSB2YWx1ZXMgKHN0YXRfYmluKS5cbiJ9 -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.
Warning: Removed 181 rows containing non-finite values (stat_bin).</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo5LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAA2AAAAJACAMAAADcl/UUAAADAFBMVEUAAAABAQECAgIDAwMEBAQFBQUGBgYHBwcICAgJCQkKCgoLCwsMDAwNDQ0ODg4PDw8QEBARERESEhITExMUFBQVFRUWFhYXFxcYGBgZGRkaGhobGxscHBwdHR0eHh4fHx8gICAhISEiIiIjIyMkJCQlJSUmJiYnJycoKCgpKSkqKiorKyssLCwtLS0uLi4vLy8wMDAxMTEyMjIzMzM0NDQ1NTU2NjY3Nzc4ODg5OTk6Ojo7Ozs8PDw9PT0+Pj4/Pz9AQEBBQUFCQkJDQ0NERERFRUVGRkZHR0dISEhJSUlKSkpLS0tMTExNTU1OTk5PT09QUFBRUVFSUlJTU1NUVFRVVVVWVlZXV1dYWFhZWVlaWlpbW1tcXFxdXV1eXl5fX19gYGBhYWFiYmJjY2NkZGRlZWVmZmZnZ2doaGhpaWlqampra2tsbGxtbW1ubm5vb29wcHBxcXFycnJzc3N0dHR1dXV2dnZ3d3d4eHh5eXl6enp7e3t8fHx9fX1+fn5/f3+AgICBgYGCgoKDg4OEhISFhYWGhoaHh4eIiIiJiYmKioqLi4uMjIyNjY2Ojo6Pj4+QkJCRkZGSkpKTk5OUlJSVlZWWlpaXl5eYmJiZmZmampqbm5ucnJydnZ2enp6fn5+goKChoaGioqKjo6OkpKSlpaWmpqanp6eoqKipqamqqqqrq6usrKytra2urq6vr6+wsLCxsbGysrKzs7O0tLS1tbW2tra3t7e4uLi5ubm6urq7u7u8vLy9vb2+vr6/v7/AwMDBwcHCwsLDw8PExMTFxcXGxsbHx8fIyMjJycnKysrLy8vMzMzNzc3Ozs7Pz8/Q0NDR0dHS0tLT09PU1NTV1dXW1tbX19fY2NjZ2dna2trb29vc3Nzd3d3e3t7f39/g4ODh4eHi4uLj4+Pk5OTl5eXm5ubn5+fo6Ojp6enq6urr6+vs7Ozt7e3u7u7v7+/w8PDx8fHy8vLz8/P09PT19fX29vb39/f4+Pj5+fn6+vr7+/v8/Pz9/f3+/v7////isF19AAAACXBIWXMAAA7DAAAOwwHHb6hkAAAgAElEQVR4nO3dCZgU1b2w8QIGEVGURcENUYnrver9BMHoh4lxiwY1YkRxBLn6RdRRjAsuUTEhAldxAVEx6k2+BI1BTYwxuFwVEReuGxqJMhGuiBqDM8DQAwzOwrlVPd01NT3LOXX+VV018L7P43RPdfWpM6frN93TIOMoIootJ+kJEG3JAYwoxgBGFGMAI4oxgBHFGMCIYiwqYFU3DNmp79A7NnjXKyf+a4/eRz3sXZ3l5JrufvLGabvufOLb3uZNEw/d8fi/ulfKG2+d4159afiOe479Mj/eYWe2caCmQdTiQxpa26NkWuPlykGZtmZ7wPkhv7yYCjmPNheFUltEwN7s0+WEa6/9jrPf10qtHrj9xfdO/a5zofKAXTY9m0vixe773zp1QNfFStUct+NVtw/o+w+l5jkXXefmbnu50+F33dRr0IbcgG2dS02DqIbBf2h1lzwwdcVlbU33hInWX2mkhZwHwDpe0QD7cseBb3qXf+52klLXOdknmCudVz1gi/ydDt/D1ffP3t9X6qFO85Va6PxMqZmda3K3Ht9/veftV7lP2zqXmgZRTw3c3Py2usYLH9in23wZuLW2YO9mrdPc0vbtrVVnMnCr1bf6nJwPYB2vaID9P2dh45XLu69UJ/TLXi0f+MtmwL7pdJV38aOdlTrySO/aoy8oNWFg/uaBnpn1zvW5T7Pn0gvH7LTvuNXep38cttP3FvefHhxEHXujd/XPw3seMqleVTm/P73TTie+rxqBfdTn6I1KDf9pfvRh4y8o2e7Y5X/73o57zXY//Zfzm+6pBl/x/JDS4MH+c0jPPt97XeVvyd2e2zqpi7fPI85ruZEXn7xz3zPL1eud7nQ/OX7fjYGJ5O6Y20Opr8fv1f2g+4NXsvPwDzys7NbtO+8zMzfwmdtv8m50ftM0H29RBo1Xua+xlYEpdUUCrK7XcYHPSjv9f/96AFj1LW94F4cPUJucSfmNpxw8qs+uI//HvTZiwDdKveo8mrvBO5fmdh569w077FWt1OOdfzBrVI9u0wODqFWdvCfN33Q66d7LSs5ygfXd9ZZbduvxQfbk+2yPQ6vcG28flD/OsO32f/i27nvtctNvD+r8UeOJnb+nGnxCnyv/K3Cwqc6PHrh2756r87c0fsxvfS/7A+MZe+SeDxd0G3LXlD16faLG7/CFesx5KTiRxjv6e6hv71R253BnbuCKN4+mAw8bsNO0OUc6zzWO/LvslfHdM03zaQ6slYEpdUUCbJlzdeCzv+3s7H3pk5XZ67OcK+7Otip345/cp6DPnHsm7t/rOO+F5P7OiXdO7LnDCtfW9sfNmbnb4dW5/dxzqW6fwa6515wpqmG/E9zz+dzsOyX5QdSj27jf4Wt2O8W9ZZzzeZXTbblSK7c/wzv5vt5/0D+9/RY6K3L3GNbDfbU4yrlHqT94QNwT27+nGuzMV4GDqaHfcp/WXndeVI235D76Wwe4Jtd3vzI38P85wt381U6jVVX/M9ftdoFSgYk03tHf43PnLvfmg65tuuLNI3DgYd6L6orOuSfxTLdL3Z8z+48KzKc5sJYDU/qKBNg7zh3exUDvDUH3kV91+7HdnU5H/0UF3kV8J7tj/fQuh65Tbzu7HDxt2rdKXGE/nuqe5e93cV9I1Yx29+rsfxd2z6UPnV971474v+qv2e/OC3LAGgdRVx7kXp+f/Tb/2ex/VDmjvdvGd9usSm443FmQ3XOt80RuuGHfcT/McL5wJ+c8lD2x/Xuqwfu5V5oOpr7xfoT6nfOMarwl99HfelnPb9Rc578bx/2H85/exTm7KvV75+h+azxg/kSyd2za4+tOxzR696948wgceNgB3rVdrsjNecQAD97Tgfk0A9bKwJS+IgG22rnUu/jl9Om3d2p8h+GbV6/t3emx5m9yuD80HOaMcWm87RxQ4579O/uvK493fxL7fq+5VSuvcPKvLt1z6U+NZ/HY3dVTznvulS8ageUGUaPdU1I9lH+OqnJ+4V3c6xoq2WZAl7Mat3adlRtu2A+UN5n1SlXmgPn3dF/JuR+aDqbUi1f/YL9OWWAn+Lc3bX3JeUGdtXfuvgty3z+6ute/7zzSfCLZOwb2+HnnzkOv9/5wwr/iziNw4GEnedf654H92vlAXdm7NjCfZsBaG5hSVzRvcvT7du7Kp8606jnl2atf9jq8ANiMrod7P6q7L2kmeRfn7pi/4cfbqjecrIWj9sptcs+lpxpPvXH93CcM7235r7LA8oOoU73T9z73JV62KudW72K286kq6b/sUu/FllvPqbnhWgLz76kGn+5+aDqYutoZftMj/5UFdrp/e9PWul6XbexxXe6+/+3c/04290Xmoc7E5hPJ3jGwh/r71GO36XRH4Io7j8CBs5NsAram5Bdq4PjgfJqAdZ7W+sCUtqIBdonzfOOVO1xgTu6HgSEHNgf2W+cnje9f126bfXfv7F3V4vEfe9dO/lf1dOMI5/fI7eyeS391fuNdO/Lb6t3sS73XPWD+IOrCIcp7k+1l9+MX4xdXOaXexsu61quSKWp173/z3u+ua3wVpVoD5t+z0UHTwVZ3nuRe+VsBsMDW0r2ezIL3qnC8NyXV8+7kp3Yf1/VDD5g/kewdm/ZYs8T9YeurI7Zr8K9482g6cCEwdfzQ99xvFIEjZ4FdpLxvUdNaGzjUY0ZFKRpgq3sPfMu7fKG7+8gP3zF7+r1TckkzYPV7Ds9fvWBgtffj+Y/Uys7e2fhx14nqy87eibNuz+/mdnHPpdqBR7ivj95wfq427XGyu+l8F1hgkMneq7l1vX/ofrzV+bTK2dZ9yfdlz5Mb3wCY6TFSK713BrK1BObfs9FB08Hech5Q3luJzYEFtj7uHLqf/5UfdeBapd7rMlF9su3kmr2P3qwCE2m8u7/Hs85T7qeXbl/vX/Hm0XTgFsBmd7pgwObgkT1gBx/rfvZz70fdlgPLHkSKo4j+Jscru3U5+YYbju98277TVPkBJWfd/Ivzeuy7JvAu4mPuiXLSLV53KlXe94Dp0/bs+alSVzkjZ9/Ya6D7M9VPndPvm/atbu/lBvTOpcc6HTXr5p7eG9i/dX44u3Swc3dwkIXOP5T3s86IB67ZptQ9r/vsceute3Z/rxFY3UH9Mko9sU3+L4a0BObfM+fAP9iGfgPumHPOns6PvwoCC2yt7ubc5H/hr3Y7+D/u3KvfF+q739qk/uw8HJxI4939PTK79540+7ySi5uuZOfR9FUWAvtn507XNTuytyjjncufuKJLt2mtDUzpK6q/i1jxkyN77HzGInXnH5XKXHNM716H3eL92an/LuIw9Vju2h7u5vLT+u9+1qfe/X41fMdBF631rj0ybMc9zvgoP172D5qfG77TPo1/9vvoIX3OXuK+4AsMUrvj494tc4/cft8bNrrn9Yyf7b/TcZ7P7B/CPu/9QHTF9/LDtQIsf8+cg6aDvX309oMmVI/dfk6zn8GatqqTnSVNX/g7J/Tpd+bf1cPOC+4np/apCEwkN3BuD6WWnNqv+4FTvwlcyc7DP3AhMDXc+bDZkb1FWXd+X6frjAOmtTowpa4O8bfp62d7bwTMy783nuuKkYFPqpxZqrCG3R6PZTon/ks7N7Y2kYhbU63fh1JShwCmhgx4c/17hxzVfOOyHhVNn7R2Xs8bGMtPJZ93mdzOrUUARh2ojgFs+TD3ZeHxnxdsvfaqpuutnddDn45hKjW/GNq1cCLBAEbBOgYw92njvZb/c9fGG5vemP7m7vdb3GV64ZYoqu5/SLt/6a+VidBWXEcBRtQhAxhRjAGMKMYARhRjACOKMYARxRjAiGKsGMDqNkU6XLR/564m0r/t0f6/ChW2dC9cnX4f8+ojfRjqavT7hEiycMUAtn51pMOF/JfQNFVE+ljURHoSb0j1wm2McrRNkX4v2VgZ5WiihQMYwOwCmFEAA5hdADMKYACzC2BGAQxgdgHMKIABzC6AGQUwgNkFMKMABjC7AGYUwABmF8CMAhjA7AKYUQADmF0AMwpgALMLYEYBDGB2AcwogAHMLoAZBTCA2QUwowAGMLsAZhTAAGYXwIwCGMDsAphRAAOYXQAzKgpgdRvbr6pSs0O41kQ6WkUmytEy1VGOti7VC7cuytEykT4MKVi4/DeMKIA11LVfZrVmh3BVRTpaxYYoR9uwMcrRqlO9cOujHG1DpA/D+sooR7NauPw/4sNLRF4i2sVLRKMAtkUBO6eNsjcCzDKACQKYZQAzCmAAswtgRgEMYHYBzCiAAcwugBkFMIDZBTCjAAYwuwBmFMAAZhfAjAIYwOwCmFEAA5hdADMKYACzC2BGAQxgdgHMKIABzC6AGQUwgNkFMKMABjC7AGYUwABmF8CMAhjA7AKYUQADmF0AMwpgALMLYEYBDGB2AcwogAHMLoAZBTCA2QUwowAGMLsAZhTAAGYXwIwCGMDsAphRAAOYXQAzCmAAswtgRgEMYHYBzCiAAcwugBkFMIDZBTCjAAYwuwBmFMAAZhfAjAIYwOwCmFEAA5hdADMKYACzC2BGAaxDAmsLEsCyAUwSwACmCWCSAAYwTQCTBDCAaQKYJIABTBPAJAEMYJoAJglgANMEMEkAA5gmgEkCGMA0AUwSwACmCWCSAAYwTQCTBDCAaQKYJIABTBPAJAEMYJoAJglgANMEMEkAA5gmgEkCGMA0AUwSwACmCWCSAAYwTQCTBDCAaQKYJIABTBPAJAEMYJoAJglgANMEMEkAA5imDgLsnzeOvrG6cOOSsjEPNih11YgRI2YbHgNglgHMso4BbPP4t+run1OwsX7cBzUT5ytVmqmtrTc8BsAsA5hlHQPY4uuUql3jXpZdMKM2v/Hda5RaOEnVlIY4BsAsA5hlHQPYvCn/cdGdGVV1zoqGu+/3Nrzq/vfsTKVWXKI+Lb1s9OQ1uR1r17ff2krNDuFaHeloFVVRjla1LtLR2ly4sMDaSjC5aBduXZEWziqbMy7/DaMdYHNPfXvDnber56co9cm53oYJ3sYHlVpVqpZOWV1/x9TcjjVr2q+yQrNDuCojHa1idZSjrY52tDa/1KiACSZXEenjEPHCJX/G5d+8aAfYM+6rwb+PUo+OmeCWBzbvHvcZbHz29vJRbd+3WbxEtCy6l4htJZgcLxGNagfYWy6w5aPVvAfcL3+ZWlBWNrKsbOm77g9mb0xS5eXubaY/hwHMMoBZ1jGA1Y7+ePOMu9SqMSvq7pvhbfCewerHLm+4+SX12rhVDTNmGR4DYJYBzLKOAUx9WHbetIxSr48vnZzxPs++Tvz48ose3qzUkxeOvWuD4TEAZhnALOsgwKIKYJYBzDKASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNWxiwbzLtt6ZCs0O4Vkc6WsXaKEdbWxXpaJVt3RIVMMHkol24qmgfhuTPuPy3H57BeAazi2cwowAGMLsAZhTAAGYXwIwCGMDsAphRAAOYXQAzCmAAswtgRgEMYHYBzCiAAcwugBkFMIDZBTCjAAYwuwBmFMAAZhfAjAIYwOwCmFEAA5hdADMKYACzC2BGAQxgdgHMKIABzC6AGQUwgNkFMKMAlmpgUUECmCSACQKYZQAzCmAAswtgRgEMYHYBzCiAAcwugBkFMIDZBTCjAAYwuwBmFMAAZhfAjAIYwOwCmFEAA5hdADMKYACzC2BGAQxgdgHMKIABzC6AGQUwgNkFMKMABjC7AGYUwABmF8CMAhjA7AKYUQDbqoEJ4AHMKIABDGCaACYIYADTBTBBAAOYLoAJAhjAdAFMEMAApgtgggAGMF0AEwQwgOkCmCCAAUwXwAQBDGC6ACYIYADTBTBBAAOYLoAJAhjAdAFMEMAApgtgggAGMF0AEwQwgOkCmCCAAUwXwAQBDGC6ACYIYADTBTBBAAOYLoAJAhjAdAFMEMAApgtgggAGMF0AEwQwgOkCmCCAAUwXwAQBDGC64gNW80yLTUvKxjzYoNRVI0aMmG14DIBZBjDLOgywmT8u3FI/7oOaifOVKs3U1tYbHgNglgHMso4C7M0JHrDFZRfMqM1vevcapRZOUjWlIY4BMMsAZlkHAbbm8iUusKpzVjTcfb/3+avuf8/OVGrFJerT0stGT16T22+zpvWrdXuEal2ko1VsjHK0mk1RjrY+MWAGk6vYEOWXWlMT5WgbKqMcze6M0wPbPGnxZy6w56co9cm53oYJ7n9zH1RqValaOmV1/R1TczturKCYSgpY0l93xy//rNcOsGd+qTxgj46Z4JYHNu8e9xlsfPb28lG5Hetq2q+qUrNDuNZGOlpFJsrRMtVRjrauMilgBpOLduGqI124TPJnXP5nhXaA3XX22WedenbVvAfcV8jL1IKyspFlZUvfvU6pNyap8nKllpv+HMbPYJbxM5hlHeRnMJV9Bls1ZkXdfTO8z7xnsPqxyxtufkm9Nm5Vw4xZhscAmGUAs6xDAVOvjy+dnPE+y75O/Pjyix52f4B78sKxd20wPAbALAOYZR0GWDQBzDKAWQYwSQADmCaASQIYwDQBTBLAAKYJYJIABjBNAJMEMIBpApgkgAFME8AkAQxgmgAmCWAA0wQwSQADmCaASQIYwDQBTBLAAKYpncBOyn5cO1I2mVYCmGUAsyyFwKqnT3eme13SJ4opNQtglgHMshQC+/roo52jvYY/FMWUmgUwywBmWQqBuQ0WT6SNAGYZwCxLJzBVsyybdDotAphlALMsncAe39bJJp5PYQCzDGCWpRPYPmeXV3qJ51MYwCwDmGXpBLbt38QzaT2AWQYwy9IJ7KAnxTNpPYBZBjDL0gnsD7tPef4VN/F8CgOYZQCzLJ3ASnKJ51MYwCwDmGXpBBZbALMMYJalE1hVLvF8CgOYZQCzLJ3AHIc/B5MGMMu2BmBL3T6cM+AB8XwKA5hlALMsncAae7EkIxiu1QBmGcAsSzOwJZ0j/VK9AGYZwCxLJ7AlXq+dcqB4PoUBzDKAWZZOYI1vcezynHg+hQHMMoBZlk5g67OJZ9MygFkGMMvSCUxtfmX2rPmb29zVOoBZBjDL0gmsYnCXfQaVDOF/VxEEMMu2BmCjh36m1Mph54nnUxjALAOYZekE1i/79+gX9hfOpmUAswxglqUaWD/hbFoGMMsAZlk6gY0eutJ7iXiueD6FAcwygFmWTmAVQ7oMGlQyuEI8n8IAZhnALEsnMLV5/r33vszb9JIAZtnWAKzuyn9XasjVkZ5w2QBmGcAsSyew6/v9Wqlf7v4T8XwKA5hlALMsncD2fsT7+LvdhLNpGcAsA5hl6QTW9w3v41v8dhVBALNsawB21olrlcqMOEM8n8IAZhnALEsnsK8P7TH02z33/1I8n8IAZhnALEsnMNXwl2mTn6yTzqZlALMMYJalFFhcAcwygFkGMEkAA5gmgEkCGMA0AUwSwACmCWCSAAYwTQCTBDCAaQKYJIABTBPAJAEMYJoAJglgANMEMEkAA5gmgEkCGMA0AUwSwACmCWCSAAYwTVsYsLqa9quq1OwQrrWRjlaRiXK0THWUo62rTAqYweSiXbjqSBcuk/wZl/9OGwWw+k3tt65Ss0O41kY6WkV1lKNVr49ytExiwAwmV5GJ8ktdH+nDkEn+jKuNEJguXiJaxktEy7awl4i6AGYZwCwDmCSAAUwTwCQBDGCaACYJYMkVmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAIYwEIUmBzAjAJYKoAlDce0wJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZhTAABaiwJQBZlR7wN4sG33T14Ubl5SNebBBqatGjBgx2/AYANOWNBzTAlMGmFHtAFs1qrxm1s8KNtaP+6Bm4nylSjO1tfWGxwCYtqThmBaYMsCMagfY/FuV+ny0UovLLphRm9/47jVKLZykakpDHANg2pKGY1pgygAzqh1gNdVKvXKTqjpnRcPd93sbXnX/e3amUisuUZ+WXjZ68prcjnUb26+qUrNDuNZGOlpFJsrRMtV290sajmmBKVesi2TFcmUifRjWJX/G5b9htP8mx6tjP1bPT1Hqk3O9zya4/8190H3tWKqWTlldf8fU3F4bK9uvokKzQ7i2xNGShmNa8EuNduWiLflHNWMALDN5wgqlHh0zwS0PbN497jPY+OzN5aPaxdkULxG1JQ3HtMCUeYloVDvAaq94eLN7Me8B98tfphaUlY0sK1v67nVKvTFJlZcrtdz05zCAaUsajmmBKQPMqHaALbg+e7FqzIq6+2Z417xnsPqxyxtufkm9Nm5Vw4xZhscAmLak4ZgWmDLAjGoH2MMj3Nwfvl4fXzo5+4oy+zrx48sv8p7Ynrxw7F0bDI8BMG1JwzEtMGWAGcXf5ABYiAJTBphRAANYiAJTBphRAANYiAJTBphRAANYiAJTBphRAANYiAJTBphRAANYiAJTBphRAANYiAJTBphRAANYiAJTBphRAANYBIkXDmCCAKYtaSDSxAsHMEEA05Y0EGnihQOYIIBpSxqINPHCAUwQwLQlDUSaeOEAJghg2pIGIk28cAATBDBtSQORJl44gAkCmLakgUgTLxzABAFMW9JApIkXDmCCAKYtaSDSxAsHMEEA05Y0EGnihQOYIIBpSxqINPHCAUwQwLQlDUSaeOEAJghg2pIGIk28cAATBDBtSQORJl44gAkCmLakgUgTLxzABAFMW9JApIkXDmCCAKYtaSDSxAsHMEEA05Y0EGnihQOYIIBpSxqINPHCAUwQwLQlDUSaeOEAJghg2pIGIk28cAATBDBtSQORJl44gAkCmLakgUgTLxzABAFMW9JApIkXDmCCAKYtaSDSxAsHMEEA05Y0EGnihQOYIIBpSxqINPHCAUwQwPyShhBX4oUDmCCA+SUNIa7ECwcwQQDzSxpCXIkXDmCCAOaXNIS4Ei8cwAQBzC9pCHElXjiACQKYX9IQ4kq8cAATBDC/pCHElXjhACYIYH5JQ4gr8cIBTBDA/JKGEFfihQOYIID5JQ0hrsQLBzBBAPNLGkJciRcOYIIA5pc0hLgSLxzABAHML2kIcSVeOIAJAphf0hDiSrxwABMEML+kIcSVeOEAJghgfklDiCvxwgFMEMD8koYQV+KFA5gggPklDSGuxAsHMEEA80saQlyJFw5gggDmlzSEuBIvHMAEAcwvaQjFznjhACYIYH5Jn/DFznjhACYIYH5Jn/DFznjhACYIYH5Jn/DFznjhANZO32Tab02FZodwrY50tIq1UY62tqr925M+4Yud8cJVRfswJH/GbYwQmC6ewfySPuGLnfHC8QwmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmCGB+SZ/wxc544QAmaGsElvSZnZKMFw5gggC21Wa8cAATBLCtNuOFA5gggG21GS8cwAQBbKvNeOEAJghgW23GCwcwQQDbajNeOIAJAhgV1GLhACYIYFRQi4UDmCCAUUEtFg5gggBGBbVYOIAJAhgV1GLhACYIYFRQi4UDmCCAUUEtFg5gggBGBbVYOIAJAhgV1GLhACYIYFRQi4UDmCCAUUEtFg5gggBGBbVYOIAJAhgV1GLhACYIYFRQi4UDmKAtGVjSZ2oHrcU6AkwQwKigFusIMEEAo4JarCPABAGMCmqxjgATBDAyK6LHFGCiALbFFtFjCjBRANtii+gxBVsK6k4AAAaYSURBVJgogG2xRfSYAkwUwLbYInpMASYKYFtsET2mABOVCLCkT72to6geVIBJAtgWW1QPKsAkAWyLLaoHFWCSALbVFfZBBZgkgG11hX1QASYJYFtdYR9UgEmKFVjSpxK1VtgHFWCSALbVFfZBBZgkgFGuth7UDgJsSdmYBxva2NjqbW0EMIqnth7UjgGsftwHNRPnt76x1dvaKo3Akj41KIraenQ7BrB3r1Fq4SSlFpddMKO2YGP+NqMARvHU1qPbMYA9O1OpFZeoqnNWNNx9v7fh1aaNuQuzkgSW9ClASdQxgM19UKlVper5KUp9cq63YULTxtxFYxsr26+iQrNDuFodLemHlDpyNmecpowe2Lx73Gep8erRMRPc8sByG3MXjdVtbL+qSs0O4Vob6WgVmShHy1RHOdq6VC/cuihHy0T6MKRg4fL/iE97P4Ndp9Qbk9S8B5TatEwtKCsbWVa2NLcxd2FWGn8G84vpX/aNpA2pXriNUY62Nf6rUvVjlzfc/JJaNWZF3X0zvA0TmjbmLswCmGUAs6xjAFMfX37Rw5uVen186eTsK8oJgY25C6MAZhnALOsgwKIKYJYBzDKASQKYZQCzDGCCAGYZwIwCGMDsAphRAAOYXQAzCmAAswtgRgEMYHYBzCiAAcwugBkFMIDZBTCjAAYwuwBmFMAAZhfAjAIYwOwCmFEAA5hdADMKYACzC2BGAQxgdgHMKIABzC6AGQUwgNkFMKMABjC7AGZUMYDVRnoOq0gfCrWxLsrR6uqjHK020nM41QtXH+nC1aVn4YoBjGirDWBEMQYwohgDGFGMAYwoxgBGFGNFAPa698vFrhoxYsTs+I8Vuuzkwvy6zqKW1lVL8ZJ5pWnZ4gf2xagN7sfSTG1tpH/UEU3ZyYX6dZ1FLaWrluYl80rTssUObNqZI9xzuKZUv2cCNU4u1K/rLGYpXTWV4iXzStWyFeEl4kj3HP609LLRk9fEf6zQeZML9es6i1lqVy29S+aVqmUrErClU1bX3zE1/mOFzptcs1/XmaZSu2rpXTKvVC1bnMCeu/ji91TjOexVPirGY4UuMLlmv64zLeXml7JVy5fKJQuWmmUr0jNYeblSy9P4Hc+bXKhf11nMUrtq6V0yr1QtW5GAvTZuVcOMWfEfK3Te5EL9us5iltpVS++SeaVq2YoETD154di7NsR/rNBlJxfm13UWtbSuWoqXzCtNy8bf5CCKMYARxRjAiGIMYEQxBjCiGAMYUYwBjCjGALbltMl532CvemdR7DMhP4BtOdVd/aXBXgAragDrgIn+lgLAihrAUtu6iwb0/MHnat52y1XdITcs6vvgrjsc+5H7iC064dT8berpw7oPvCt/4b1ErCztv+u5FUqV/PHg7vs+kR3n1DPdD7P61n5y2i47HPO+B2y9s0SppU6VPwzFFsBS27HfWfDW6IPWqvOOV1MO2rSo866Pv3pK33XKOXLO5/nbPtvmurdvc97IXbjANg85Yv78I4a4wHZ/fMnZ22b/zfJHergXx1yuDvzuSy8PH9IMWP4QFFsAS2uLuronfn2/h9TqXW7q8ZZa5LjPRxt3mamcKU23vdhpmVLPrMhduMDmd/lMqRVdFqgSd69yZ5k3UGbbP6mvOr+7efr/KPWbvkFg/iEotgCW1n7llLg5P1dqrnONa8rxfmPI6eOV81zTbRuP7Hb6zJUqd+ECu2+Qd9d9ZquS55WqbASmzjhfzTpYqZrf/3Rkr2bAmg5BcQWwtPaH/vlr9zg/zAMbeaFyXgvctnnhjf+2zR9zFy6we7PABs1SJa80AXusT93w21T1YYNv+/Ovm4B96FQ1HYLiCmBprbzTR0p9MfQDtWz73+3whAvsSfdJaNc7s8Dyt73kvhBUp/0wd+ECe7nkc6VWlsxvBmz9dnO6fqme3maNUnNywNwx5jhV/iEotgCW2s7Y79mXjjm4fvPwi9TM/msXOXs+9eZpvddmgeVve7nzPUvm9ro1d+G9yTH4yNcWHjl4czNg6kd9T1TqdeehlU/utV2F9zb9zqcseXmAU5UfJtEvcwsPYKltw8V77HT6CjVj1yrVcMS/L3L+csgO33Ff2mWB5W5Td+/Tba/r63IX3tv0FaP79c++TR8E9oTziPvx1v69z1x64BAP2HMHdC6Z7QLLD0OxBbAO0iIn0ieaTdH+PllqK4B1kCIGRkUKYB2kxQMB1hEDGFGMAYwoxgBGFGMAI4oxgBHFGMCIYgxgRDEGMKIY+1/9U14wWIFZiQAAAABJRU5ErkJggg==" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zemZjdHJzIDwtIGdzZTI2NThfZXhwcnNfc21fd2duX3N1bV93Z2wgJT4lIHVuZ3JvdXAoKSAlPiUgZ3JvdXBfYnkoc2FtcGxlX2lkKSAlPiUgc3VtbWFyaXNlKHN6ZmN0cj1tZWRpYW4oY3BrLCBuYS5ybSA9IFQpKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_szfctrs &lt;- gse2658_exprs_sm_wgn_sum_wgl %&gt;% ungroup() %&gt;% group_by(sample_id) %&gt;% summarise(szfctr=median(cpk, na.rm = T))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>write out size factors for later use (like for normalizaing genes for UAMS or SBUK)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyB3cml0ZV9jc3YoZ3NlMjY1OF9leHByc19zemZjdHJzLCBcImdzZTI2NThfc2FtcGxlX3NpemVfZmFjdG9ycy5jc3ZcIilcbmBgYCJ9 -->
<pre class="r"><code># write_csv(gse2658_exprs_szfctrs, &quot;gse2658_sample_size_factors.csv&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z25fc3VtX3dnbF9zeiA8LSBsZWZ0X2pvaW4oZ3NlMjY1OF9leHByc19zbV93Z25fc3VtX3dnbCwgZ3NlMjY1OF9leHByc19zemZjdHJzLCBieT1cInNhbXBsZV9pZFwiKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_sm_wgn_sum_wgl_sz &lt;- left_join(gse2658_exprs_sm_wgn_sum_wgl, gse2658_exprs_szfctrs, by=&quot;sample_id&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGogPC0gZ3NlMjY1OF9leHByc19zbV93Z25fc3VtX3dnbF9zeiAlPiUgXG4gIG11dGF0ZShhZGpsb2djcGttZWQ9bG9nMihjcGsvc3pmY3RyKSlcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_adj &lt;- gse2658_exprs_sm_wgn_sum_wgl_sz %&gt;% 
  mutate(adjlogcpkmed=log2(cpk/szfctr))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>plot histogram of adjlogcpkmed</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2dwbG90KGdzZTI2NThfZXhwcnNfYWRqKSArIFxuICBnZW9tX2hpc3RvZ3JhbShhZXMoYWRqbG9nY3BrbWVkKSkgKyB0aGVtZV9taW5pbWFsKCkgKyBcbiAgbGFicyh4PShcImV4cHJlc3Npb24gdmFsdWVcIiksIFxuICAgICAgIHRpdGxlPVwiR1NFMjY1OCBhZGpsb2djcGttZWQgbWljcm9hcnJheSBleHByZXNzaW9uIHZhbHVlc1wiKVxuYGBgIn0= -->
<pre class="r"><code>ggplot(gse2658_exprs_adj) + 
  geom_histogram(aes(adjlogcpkmed)) + theme_minimal() + 
  labs(x=(&quot;expression value&quot;), 
       title=&quot;GSE2658 adjlogcpkmed microarray expression values&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG5XYXJuaW5nOiBSZW1vdmVkIDE4MSByb3dzIGNvbnRhaW5pbmcgbm9uLWZpbml0ZSB2YWx1ZXMgKHN0YXRfYmluKS5cbiJ9 -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.
Warning: Removed 181 rows containing non-finite values (stat_bin).</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo5LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,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" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>2nd way continued</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zemZjdHJzMiA8LSBnc2UyNjU4X2V4cHJzX3NtX2dpZF9zdW0yICU+JSB1bmdyb3VwKCkgJT4lIFxuICBncm91cF9ieShzYW1wbGVfaWQpICU+JSBcbiAgc3VtbWFyaXNlKHN6ZmN0cj1tZWRpYW4oZ2VuZV9leHByLCBuYS5ybSA9IFQpKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_szfctrs2 &lt;- gse2658_exprs_sm_gid_sum2 %&gt;% ungroup() %&gt;% 
  group_by(sample_id) %&gt;% 
  summarise(szfctr=median(gene_expr, na.rm = T))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zbV93Z25fc3VtMl9zeiA8LSBsZWZ0X2pvaW4oZ3NlMjY1OF9leHByc19zbV9naWRfc3VtMiwgZ3NlMjY1OF9leHByc19zemZjdHJzMiwgXG4gICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICBieT1cInNhbXBsZV9pZFwiKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_sm_wgn_sum2_sz &lt;- left_join(gse2658_exprs_sm_gid_sum2, gse2658_exprs_szfctrs2, 
                                          by=&quot;sample_id&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGoyIDwtIGdzZTI2NThfZXhwcnNfc21fd2duX3N1bTJfc3ogJT4lIFxuICBtdXRhdGUoYWRqbG9nY3BrbWVkPWxvZzIoZ2VuZV9leHByL3N6ZmN0cikpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_adj2 &lt;- gse2658_exprs_sm_wgn_sum2_sz %&gt;% 
  mutate(adjlogcpkmed=log2(gene_expr/szfctr))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>both ways to do sum for CPK are the same, but this plot takes a long time to render</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBwbG90KGdzZTI2NThfZXhwcnNfYWRqJGFkamxvZ2Nwa21lZCwgZ3NlMjY1OF9leHByc19hZGoyJGFkamxvZ2Nwa21lZClcbmBgYCJ9 -->
<pre class="r"><code># plot(gse2658_exprs_adj$adjlogcpkmed, gse2658_exprs_adj2$adjlogcpkmed)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>using original way</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZGltKGdzZTI2NThfZXhwcnNfYWRqKVxuYGBgIn0= -->
<pre class="r"><code>dim(gse2658_exprs_adj)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDQxMTgxNTMgICAgICAgN1xuIn0= -->
<pre><code>[1] 4118153       7</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="nas-and-missing-genes" class="section level2">
<h2>NAs and missing genes</h2>
<p>deal with NA values for SCARB1 here,<br />
as well as putting in the TCGA gene_center values for the missing genes</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2VuZXNfc3RpbGxfbWlzIDwtIGNtcHNfc3BlY19ybSAlPiUgIFxuICBmaWx0ZXIoIWdlbmVfaWQgJWluJSBnc2UyNjU4X2V4cHJzX2FkaiRnZW5lX2lkKSAlPiUgXG4gIHB1bGwoZ2VuZV9pZClcbmBgYCJ9 -->
<pre class="r"><code>genes_still_mis &lt;- cmps_spec_rm %&gt;%  
  filter(!gene_id %in% gse2658_exprs_adj$gene_id) %&gt;% 
  pull(gene_id)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyB3cml0ZV9jc3YoZGF0YS5mcmFtZShnZW5lX2lkPWdlbmVzX3N0aWxsX21pcyksIFwiZ2VuZXNfbWlzc2luZ19HU0UyNjU4X2Zyb21fY29tbXBhc3NfMjAyMjA0MTQuY3N2XCIpXG5gYGAifQ== -->
<pre class="r"><code># write_csv(data.frame(gene_id=genes_still_mis), &quot;genes_missing_GSE2658_from_commpass_20220414.csv&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>gene means for values to fill in</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2VuZV9tZWFucyA8LSBsZWZ0X2pvaW4oY21wc19zcGVjX3JtLCBnaWRfbmFtZXMsIGJ5PVwiZ2VuZV9pZFwiKSAlPiUgXG4gICAgc2VsZWN0KGdlbmVfaWQsIG1lYW4pXG5gYGAifQ== -->
<pre class="r"><code>gene_means &lt;- left_join(cmps_spec_rm, gid_names, by=&quot;gene_id&quot;) %&gt;% 
    select(gene_id, mean)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>get things in order just to be sure</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGogPC0gZ3NlMjY1OF9leHByc19hZGogJT4lIGFycmFuZ2UoZ2VuZV9pZCwgc2FtcGxlX2lkKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_adj &lt;- gse2658_exprs_adj %&gt;% arrange(gene_id, sample_id)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9zaWRzIDwtIHVuaXF1ZShnc2UyNjU4X2V4cHJzX2FkaiRzYW1wbGVfaWQpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_sids &lt;- unique(gse2658_exprs_adj$sample_id)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>put in genes that are missing from the microarray data<br />
use mean value for that gene from the CoMMpass loadings matrix</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyBtYWtlcyBlbXB0eSBERiBmb3IgYWRkaW5nIHRoZSBnZW5lcyAgXG5yZXN1bHRzIDwtIGRhdGEuZnJhbWUoKVxuZm9yKGcgaW4gZ2VuZXNfc3RpbGxfbWlzKXtcbiAgcmVzdWx0cyA8LSBiaW5kX3Jvd3MocmVzdWx0cywgZGF0YS5mcmFtZShnZW5lX2lkPXJlcChnLDU1OSksIHNhbXBsZV9pZD1nc2UyNjU4X3NpZHMpKVxufVxuIyBqb2lucyBvbiB0aGUgbWVhbiB2YWx1ZXMgYW5kIG1ha2VzIHRoZW0gdGhlIGFkamxvZ2Nwa21lZFxucmVzdWx0cyA8LSBsZWZ0X2pvaW4ocmVzdWx0cywgZ2VuZV9tZWFucywgYnkgPSBcImdlbmVfaWRcIikgJT4lIFxuICByZW5hbWUoYWRqbG9nY3BrbWVkPW1lYW4pXG5gYGAifQ== -->
<pre class="r"><code># makes empty DF for adding the genes  
results &lt;- data.frame()
for(g in genes_still_mis){
  results &lt;- bind_rows(results, data.frame(gene_id=rep(g,559), sample_id=gse2658_sids))
}
# joins on the mean values and makes them the adjlogcpkmed
results &lt;- left_join(results, gene_means, by = &quot;gene_id&quot;) %&gt;% 
  rename(adjlogcpkmed=mean)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>put it all back together</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGpfY21wbHQgPC0gXG4gIGJpbmRfcm93cyhnc2UyNjU4X2V4cHJzX2FkaiAlPiUgc2VsZWN0KGdlbmVfaWQsIHNhbXBsZV9pZCwgYWRqbG9nY3BrbWVkKSwgXG4gICAgICAgICAgICByZXN1bHRzKVxuaGVhZChnc2UyNjU4X2V4cHJzX2Fkal9jbXBsdCwgMTApXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_adj_cmplt &lt;- 
  bind_rows(gse2658_exprs_adj %&gt;% select(gene_id, sample_id, adjlogcpkmed), 
            results)
head(gse2658_exprs_adj_cmplt, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxudGFpbChnc2UyNjU4X2V4cHJzX2Fkal9jbXBsdCwgMTApXG5gYGAifQ== -->
<pre class="r"><code>tail(gse2658_exprs_adj_cmplt, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin eyJtZXRhZGF0YSI6eyJjbGFzc2VzIjpbImdyb3VwZWRfZGYiLCJ0YmxfZGYiLCJ0YmwiLCJkYXRhLmZyYW1lIl0sIm5yb3ciOjEwLCJuY29sIjozLCJzdW1tYXJ5Ijp7IkEgdGliYmxlIjpbIjEwIMOXIDMiXSwiR3JvdXBzIjpbImdlbmVfaWQgWzFdIl19fSwicmRmIjoiSDRzSUFBQUFBQUFBQTkyU3pVNkRRQkRIcDN4WUliYVMrQnlRUXNYQ1hlMUpZNndtUFppWUZkYUtoWVVBalI1OW03NkdUK1d4dUF0czBzN1prNXNzTzcvL0RzUE1NUGVYeTZtNU5BRkFCVzJnZ0twekUvVEhoMnM3QU5BVURnUFF3QkRuSjNjNmF6MEJMTDdOL3VMMDZuWXhuNGpsemJ6UXZmaHY4bUcxeC9QRlRlZ0g3Z3h4Z0RnOFpHK0MyRVhzSVo0aVBrZnNJeFo1amtXZTM4WVQzVzd2NnI4NjBSam9VVXFxcW0rS0ZNMlkxTVI1TFVsR2tidFI1aDhPNDdwNFpjUzM4c1VmVGRQODRMalN5ZXFHc1JXSEs4cm9jeExMWUJYSmluUlBPQ0h4ZTVxdm9tS2QwWmp6RGdVZDVrV2Q1SXlIVmNUazZpanRRWWtFYThORUdyRWR2VzNZMmc3OTlzZUwrMjZOZXR2Y3M5WHVtMXJUeDlMN1dFZVVyUkpHWlhrcGVhRnBEMlBlbExaY3B5Z1RWc3NtY3JWeTZyd20wcytNOGxRcWJYR3crd1VpdGJYRHNRTUFBQT09In0= -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["adjlogcpkmed"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000272916","2":"GSM95817","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95818","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95819","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95820","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95821","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95822","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95823","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95824","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95825","3":"-3.170116"},{"1":"ENSG00000272916","2":"GSM95826","3":"-3.170116"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>still need to deal with NAs</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGpfY21wbHQgJT4lIGZpbHRlcihpZl9hbnkoZXZlcnl0aGluZygpLCBpcy5uYSkpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_adj_cmplt %&gt;% filter(if_any(everything(), is.na))</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["adjlogcpkmed"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000073060","2":"GSM95646","3":"NA"},{"1":"ENSG00000073060","2":"GSM95647","3":"NA"},{"1":"ENSG00000073060","2":"GSM95648","3":"NA"},{"1":"ENSG00000073060","2":"GSM95649","3":"NA"},{"1":"ENSG00000073060","2":"GSM95650","3":"NA"},{"1":"ENSG00000073060","2":"GSM95651","3":"NA"},{"1":"ENSG00000073060","2":"GSM95652","3":"NA"},{"1":"ENSG00000073060","2":"GSM95653","3":"NA"},{"1":"ENSG00000073060","2":"GSM95654","3":"NA"},{"1":"ENSG00000073060","2":"GSM95655","3":"NA"},{"1":"ENSG00000073060","2":"GSM95656","3":"NA"},{"1":"ENSG00000073060","2":"GSM95657","3":"NA"},{"1":"ENSG00000073060","2":"GSM95658","3":"NA"},{"1":"ENSG00000073060","2":"GSM95659","3":"NA"},{"1":"ENSG00000073060","2":"GSM95660","3":"NA"},{"1":"ENSG00000073060","2":"GSM95661","3":"NA"},{"1":"ENSG00000073060","2":"GSM95662","3":"NA"},{"1":"ENSG00000073060","2":"GSM95663","3":"NA"},{"1":"ENSG00000073060","2":"GSM95664","3":"NA"},{"1":"ENSG00000073060","2":"GSM95665","3":"NA"},{"1":"ENSG00000073060","2":"GSM95666","3":"NA"},{"1":"ENSG00000073060","2":"GSM95667","3":"NA"},{"1":"ENSG00000073060","2":"GSM95668","3":"NA"},{"1":"ENSG00000073060","2":"GSM95669","3":"NA"},{"1":"ENSG00000073060","2":"GSM95670","3":"NA"},{"1":"ENSG00000073060","2":"GSM95671","3":"NA"},{"1":"ENSG00000073060","2":"GSM95672","3":"NA"},{"1":"ENSG00000073060","2":"GSM95673","3":"NA"},{"1":"ENSG00000073060","2":"GSM95674","3":"NA"},{"1":"ENSG00000073060","2":"GSM95675","3":"NA"},{"1":"ENSG00000073060","2":"GSM95676","3":"NA"},{"1":"ENSG00000073060","2":"GSM95677","3":"NA"},{"1":"ENSG00000073060","2":"GSM95678","3":"NA"},{"1":"ENSG00000073060","2":"GSM95679","3":"NA"},{"1":"ENSG00000073060","2":"GSM95680","3":"NA"},{"1":"ENSG00000073060","2":"GSM95681","3":"NA"},{"1":"ENSG00000073060","2":"GSM95682","3":"NA"},{"1":"ENSG00000073060","2":"GSM95683","3":"NA"},{"1":"ENSG00000073060","2":"GSM95684","3":"NA"},{"1":"ENSG00000073060","2":"GSM95685","3":"NA"},{"1":"ENSG00000073060","2":"GSM95686","3":"NA"},{"1":"ENSG00000073060","2":"GSM95687","3":"NA"},{"1":"ENSG00000073060","2":"GSM95688","3":"NA"},{"1":"ENSG00000073060","2":"GSM95689","3":"NA"},{"1":"ENSG00000073060","2":"GSM95690","3":"NA"},{"1":"ENSG00000073060","2":"GSM95691","3":"NA"},{"1":"ENSG00000073060","2":"GSM95692","3":"NA"},{"1":"ENSG00000073060","2":"GSM95693","3":"NA"},{"1":"ENSG00000073060","2":"GSM95694","3":"NA"},{"1":"ENSG00000073060","2":"GSM95695","3":"NA"},{"1":"ENSG00000073060","2":"GSM95696","3":"NA"},{"1":"ENSG00000073060","2":"GSM95697","3":"NA"},{"1":"ENSG00000073060","2":"GSM95698","3":"NA"},{"1":"ENSG00000073060","2":"GSM95699","3":"NA"},{"1":"ENSG00000073060","2":"GSM95700","3":"NA"},{"1":"ENSG00000073060","2":"GSM95701","3":"NA"},{"1":"ENSG00000073060","2":"GSM95702","3":"NA"},{"1":"ENSG00000073060","2":"GSM95703","3":"NA"},{"1":"ENSG00000073060","2":"GSM95704","3":"NA"},{"1":"ENSG00000073060","2":"GSM95705","3":"NA"},{"1":"ENSG00000073060","2":"GSM95706","3":"NA"},{"1":"ENSG00000073060","2":"GSM95707","3":"NA"},{"1":"ENSG00000073060","2":"GSM95708","3":"NA"},{"1":"ENSG00000073060","2":"GSM95709","3":"NA"},{"1":"ENSG00000073060","2":"GSM95710","3":"NA"},{"1":"ENSG00000073060","2":"GSM95711","3":"NA"},{"1":"ENSG00000073060","2":"GSM95712","3":"NA"},{"1":"ENSG00000073060","2":"GSM95713","3":"NA"},{"1":"ENSG00000073060","2":"GSM95714","3":"NA"},{"1":"ENSG00000073060","2":"GSM95715","3":"NA"},{"1":"ENSG00000073060","2":"GSM95716","3":"NA"},{"1":"ENSG00000073060","2":"GSM95717","3":"NA"},{"1":"ENSG00000073060","2":"GSM95718","3":"NA"},{"1":"ENSG00000073060","2":"GSM95719","3":"NA"},{"1":"ENSG00000073060","2":"GSM95720","3":"NA"},{"1":"ENSG00000073060","2":"GSM95721","3":"NA"},{"1":"ENSG00000073060","2":"GSM95722","3":"NA"},{"1":"ENSG00000073060","2":"GSM95723","3":"NA"},{"1":"ENSG00000073060","2":"GSM95724","3":"NA"},{"1":"ENSG00000073060","2":"GSM95725","3":"NA"},{"1":"ENSG00000073060","2":"GSM95726","3":"NA"},{"1":"ENSG00000073060","2":"GSM95727","3":"NA"},{"1":"ENSG00000073060","2":"GSM95728","3":"NA"},{"1":"ENSG00000073060","2":"GSM95729","3":"NA"},{"1":"ENSG00000073060","2":"GSM95730","3":"NA"},{"1":"ENSG00000073060","2":"GSM95731","3":"NA"},{"1":"ENSG00000073060","2":"GSM95732","3":"NA"},{"1":"ENSG00000073060","2":"GSM95733","3":"NA"},{"1":"ENSG00000073060","2":"GSM95734","3":"NA"},{"1":"ENSG00000073060","2":"GSM95735","3":"NA"},{"1":"ENSG00000073060","2":"GSM95736","3":"NA"},{"1":"ENSG00000073060","2":"GSM95737","3":"NA"},{"1":"ENSG00000073060","2":"GSM95738","3":"NA"},{"1":"ENSG00000073060","2":"GSM95739","3":"NA"},{"1":"ENSG00000073060","2":"GSM95740","3":"NA"},{"1":"ENSG00000073060","2":"GSM95741","3":"NA"},{"1":"ENSG00000073060","2":"GSM95742","3":"NA"},{"1":"ENSG00000073060","2":"GSM95743","3":"NA"},{"1":"ENSG00000073060","2":"GSM95744","3":"NA"},{"1":"ENSG00000073060","2":"GSM95745","3":"NA"},{"1":"ENSG00000073060","2":"GSM95746","3":"NA"},{"1":"ENSG00000073060","2":"GSM95747","3":"NA"},{"1":"ENSG00000073060","2":"GSM95748","3":"NA"},{"1":"ENSG00000073060","2":"GSM95749","3":"NA"},{"1":"ENSG00000073060","2":"GSM95750","3":"NA"},{"1":"ENSG00000073060","2":"GSM95751","3":"NA"},{"1":"ENSG00000073060","2":"GSM95752","3":"NA"},{"1":"ENSG00000073060","2":"GSM95753","3":"NA"},{"1":"ENSG00000073060","2":"GSM95754","3":"NA"},{"1":"ENSG00000073060","2":"GSM95755","3":"NA"},{"1":"ENSG00000073060","2":"GSM95756","3":"NA"},{"1":"ENSG00000073060","2":"GSM95757","3":"NA"},{"1":"ENSG00000073060","2":"GSM95758","3":"NA"},{"1":"ENSG00000073060","2":"GSM95759","3":"NA"},{"1":"ENSG00000073060","2":"GSM95760","3":"NA"},{"1":"ENSG00000073060","2":"GSM95761","3":"NA"},{"1":"ENSG00000073060","2":"GSM95762","3":"NA"},{"1":"ENSG00000073060","2":"GSM95763","3":"NA"},{"1":"ENSG00000073060","2":"GSM95764","3":"NA"},{"1":"ENSG00000073060","2":"GSM95765","3":"NA"},{"1":"ENSG00000073060","2":"GSM95766","3":"NA"},{"1":"ENSG00000073060","2":"GSM95767","3":"NA"},{"1":"ENSG00000073060","2":"GSM95768","3":"NA"},{"1":"ENSG00000073060","2":"GSM95769","3":"NA"},{"1":"ENSG00000073060","2":"GSM95770","3":"NA"},{"1":"ENSG00000073060","2":"GSM95771","3":"NA"},{"1":"ENSG00000073060","2":"GSM95772","3":"NA"},{"1":"ENSG00000073060","2":"GSM95773","3":"NA"},{"1":"ENSG00000073060","2":"GSM95774","3":"NA"},{"1":"ENSG00000073060","2":"GSM95775","3":"NA"},{"1":"ENSG00000073060","2":"GSM95776","3":"NA"},{"1":"ENSG00000073060","2":"GSM95777","3":"NA"},{"1":"ENSG00000073060","2":"GSM95778","3":"NA"},{"1":"ENSG00000073060","2":"GSM95779","3":"NA"},{"1":"ENSG00000073060","2":"GSM95780","3":"NA"},{"1":"ENSG00000073060","2":"GSM95781","3":"NA"},{"1":"ENSG00000073060","2":"GSM95782","3":"NA"},{"1":"ENSG00000073060","2":"GSM95783","3":"NA"},{"1":"ENSG00000073060","2":"GSM95784","3":"NA"},{"1":"ENSG00000073060","2":"GSM95785","3":"NA"},{"1":"ENSG00000073060","2":"GSM95786","3":"NA"},{"1":"ENSG00000073060","2":"GSM95787","3":"NA"},{"1":"ENSG00000073060","2":"GSM95788","3":"NA"},{"1":"ENSG00000073060","2":"GSM95789","3":"NA"},{"1":"ENSG00000073060","2":"GSM95790","3":"NA"},{"1":"ENSG00000073060","2":"GSM95791","3":"NA"},{"1":"ENSG00000073060","2":"GSM95792","3":"NA"},{"1":"ENSG00000073060","2":"GSM95793","3":"NA"},{"1":"ENSG00000073060","2":"GSM95794","3":"NA"},{"1":"ENSG00000073060","2":"GSM95795","3":"NA"},{"1":"ENSG00000073060","2":"GSM95796","3":"NA"},{"1":"ENSG00000073060","2":"GSM95797","3":"NA"},{"1":"ENSG00000073060","2":"GSM95798","3":"NA"},{"1":"ENSG00000073060","2":"GSM95799","3":"NA"},{"1":"ENSG00000073060","2":"GSM95800","3":"NA"},{"1":"ENSG00000073060","2":"GSM95801","3":"NA"},{"1":"ENSG00000073060","2":"GSM95802","3":"NA"},{"1":"ENSG00000073060","2":"GSM95803","3":"NA"},{"1":"ENSG00000073060","2":"GSM95804","3":"NA"},{"1":"ENSG00000073060","2":"GSM95805","3":"NA"},{"1":"ENSG00000073060","2":"GSM95806","3":"NA"},{"1":"ENSG00000073060","2":"GSM95807","3":"NA"},{"1":"ENSG00000073060","2":"GSM95808","3":"NA"},{"1":"ENSG00000073060","2":"GSM95809","3":"NA"},{"1":"ENSG00000073060","2":"GSM95810","3":"NA"},{"1":"ENSG00000073060","2":"GSM95811","3":"NA"},{"1":"ENSG00000073060","2":"GSM95812","3":"NA"},{"1":"ENSG00000073060","2":"GSM95813","3":"NA"},{"1":"ENSG00000073060","2":"GSM95814","3":"NA"},{"1":"ENSG00000073060","2":"GSM95815","3":"NA"},{"1":"ENSG00000073060","2":"GSM95816","3":"NA"},{"1":"ENSG00000073060","2":"GSM95817","3":"NA"},{"1":"ENSG00000073060","2":"GSM95818","3":"NA"},{"1":"ENSG00000073060","2":"GSM95819","3":"NA"},{"1":"ENSG00000073060","2":"GSM95820","3":"NA"},{"1":"ENSG00000073060","2":"GSM95821","3":"NA"},{"1":"ENSG00000073060","2":"GSM95822","3":"NA"},{"1":"ENSG00000073060","2":"GSM95823","3":"NA"},{"1":"ENSG00000073060","2":"GSM95824","3":"NA"},{"1":"ENSG00000073060","2":"GSM95825","3":"NA"},{"1":"ENSG00000073060","2":"GSM95826","3":"NA"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[181]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>replace NAs in <code>SCARB1</code> gene (<code>ENSG00000073060</code>) with mean value from loadings matrix</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGpfY21wbHQgPC0gbGVmdF9qb2luKGdzZTI2NThfZXhwcnNfYWRqX2NtcGx0LCBnZW5lX21lYW5zLCBieSA9IFwiZ2VuZV9pZFwiKSAlPiUgXG4gIG11dGF0ZShhZGpsb2djcGttZWQ9Y29hbGVzY2UoYWRqbG9nY3BrbWVkLCBtZWFuKSkgJT4lIFxuICBzZWxlY3QoLW1lYW4pXG5nc2UyNjU4X2V4cHJzX2Fkal9jbXBsdCAlPiUgZmlsdGVyKGdlbmVfaWQ9PVwiRU5TRzAwMDAwMDczMDYwXCIpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_adj_cmplt &lt;- left_join(gse2658_exprs_adj_cmplt, gene_means, by = &quot;gene_id&quot;) %&gt;% 
  mutate(adjlogcpkmed=coalesce(adjlogcpkmed, mean)) %&gt;% 
  select(-mean)
gse2658_exprs_adj_cmplt %&gt;% filter(gene_id==&quot;ENSG00000073060&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["grouped_df","tbl_df","tbl","data.frame"],"nrow":559,"ncol":3,"summary":{"A tibble":["559 × 3"],"Groups":["gene_id [1]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["adjlogcpkmed"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000073060","2":"GSM102606","3":"-0.987007909"},{"1":"ENSG00000073060","2":"GSM102607","3":"-1.259564289"},{"1":"ENSG00000073060","2":"GSM102609","3":"-1.920778143"},{"1":"ENSG00000073060","2":"GSM102610","3":"-2.750313297"},{"1":"ENSG00000073060","2":"GSM102611","3":"-1.794780472"},{"1":"ENSG00000073060","2":"GSM102612","3":"-2.569471477"},{"1":"ENSG00000073060","2":"GSM102613","3":"-1.774573134"},{"1":"ENSG00000073060","2":"GSM102614","3":"-1.250720197"},{"1":"ENSG00000073060","2":"GSM102615","3":"-2.683223483"},{"1":"ENSG00000073060","2":"GSM102616","3":"-2.437424118"},{"1":"ENSG00000073060","2":"GSM102617","3":"-0.516815624"},{"1":"ENSG00000073060","2":"GSM102618","3":"-1.983319948"},{"1":"ENSG00000073060","2":"GSM102620","3":"-2.411644632"},{"1":"ENSG00000073060","2":"GSM102621","3":"-1.253710065"},{"1":"ENSG00000073060","2":"GSM102622","3":"-1.783704974"},{"1":"ENSG00000073060","2":"GSM102623","3":"-3.005693760"},{"1":"ENSG00000073060","2":"GSM102624","3":"-1.047511258"},{"1":"ENSG00000073060","2":"GSM102625","3":"-2.356536689"},{"1":"ENSG00000073060","2":"GSM102626","3":"-2.711919979"},{"1":"ENSG00000073060","2":"GSM102627","3":"-0.436927553"},{"1":"ENSG00000073060","2":"GSM102628","3":"-1.430072330"},{"1":"ENSG00000073060","2":"GSM102629","3":"-1.846446544"},{"1":"ENSG00000073060","2":"GSM102630","3":"-3.382071459"},{"1":"ENSG00000073060","2":"GSM102631","3":"-2.138904428"},{"1":"ENSG00000073060","2":"GSM102632","3":"-1.647180894"},{"1":"ENSG00000073060","2":"GSM102633","3":"-2.150400764"},{"1":"ENSG00000073060","2":"GSM102634","3":"-0.969494818"},{"1":"ENSG00000073060","2":"GSM50986","3":"-1.169302717"},{"1":"ENSG00000073060","2":"GSM50987","3":"-1.119778199"},{"1":"ENSG00000073060","2":"GSM50988","3":"-2.343778193"},{"1":"ENSG00000073060","2":"GSM50989","3":"-1.695452648"},{"1":"ENSG00000073060","2":"GSM50990","3":"-2.213982277"},{"1":"ENSG00000073060","2":"GSM50991","3":"0.383076089"},{"1":"ENSG00000073060","2":"GSM50992","3":"-2.913757644"},{"1":"ENSG00000073060","2":"GSM50993","3":"-1.405868796"},{"1":"ENSG00000073060","2":"GSM50994","3":"-0.266429214"},{"1":"ENSG00000073060","2":"GSM50995","3":"-1.469290203"},{"1":"ENSG00000073060","2":"GSM50996","3":"-3.081902848"},{"1":"ENSG00000073060","2":"GSM50997","3":"-2.326112863"},{"1":"ENSG00000073060","2":"GSM50998","3":"-2.127697843"},{"1":"ENSG00000073060","2":"GSM50999","3":"-1.622499010"},{"1":"ENSG00000073060","2":"GSM51000","3":"-2.347031020"},{"1":"ENSG00000073060","2":"GSM51001","3":"-1.517958611"},{"1":"ENSG00000073060","2":"GSM51002","3":"-2.681561411"},{"1":"ENSG00000073060","2":"GSM51003","3":"-2.681681406"},{"1":"ENSG00000073060","2":"GSM51004","3":"-2.384628876"},{"1":"ENSG00000073060","2":"GSM51005","3":"-2.576005333"},{"1":"ENSG00000073060","2":"GSM51006","3":"-2.344896207"},{"1":"ENSG00000073060","2":"GSM51007","3":"-1.370701872"},{"1":"ENSG00000073060","2":"GSM51008","3":"-1.658462324"},{"1":"ENSG00000073060","2":"GSM51009","3":"-1.730072676"},{"1":"ENSG00000073060","2":"GSM51010","3":"-1.598996911"},{"1":"ENSG00000073060","2":"GSM51011","3":"-1.061863144"},{"1":"ENSG00000073060","2":"GSM51012","3":"-1.914809537"},{"1":"ENSG00000073060","2":"GSM51013","3":"-2.019931504"},{"1":"ENSG00000073060","2":"GSM51014","3":"-2.090514655"},{"1":"ENSG00000073060","2":"GSM51015","3":"-0.730681315"},{"1":"ENSG00000073060","2":"GSM51016","3":"-1.058652172"},{"1":"ENSG00000073060","2":"GSM51017","3":"-1.770364844"},{"1":"ENSG00000073060","2":"GSM51018","3":"-2.587475030"},{"1":"ENSG00000073060","2":"GSM51019","3":"-1.945779822"},{"1":"ENSG00000073060","2":"GSM51020","3":"-2.005506453"},{"1":"ENSG00000073060","2":"GSM51021","3":"-1.779983179"},{"1":"ENSG00000073060","2":"GSM51022","3":"-1.081802087"},{"1":"ENSG00000073060","2":"GSM51023","3":"-2.198291893"},{"1":"ENSG00000073060","2":"GSM51024","3":"-1.392294493"},{"1":"ENSG00000073060","2":"GSM51025","3":"-1.432911493"},{"1":"ENSG00000073060","2":"GSM51026","3":"-1.101146493"},{"1":"ENSG00000073060","2":"GSM51027","3":"-0.440341705"},{"1":"ENSG00000073060","2":"GSM51028","3":"-1.898124596"},{"1":"ENSG00000073060","2":"GSM51029","3":"-2.647877254"},{"1":"ENSG00000073060","2":"GSM51030","3":"-2.022952707"},{"1":"ENSG00000073060","2":"GSM51031","3":"-1.729785184"},{"1":"ENSG00000073060","2":"GSM51032","3":"-1.781723525"},{"1":"ENSG00000073060","2":"GSM51033","3":"-1.584561932"},{"1":"ENSG00000073060","2":"GSM51034","3":"-1.071056019"},{"1":"ENSG00000073060","2":"GSM51035","3":"-1.849405263"},{"1":"ENSG00000073060","2":"GSM51036","3":"-1.329420024"},{"1":"ENSG00000073060","2":"GSM51037","3":"-2.847746326"},{"1":"ENSG00000073060","2":"GSM51038","3":"-1.662189621"},{"1":"ENSG00000073060","2":"GSM51039","3":"-0.854691324"},{"1":"ENSG00000073060","2":"GSM51040","3":"-2.274664789"},{"1":"ENSG00000073060","2":"GSM51041","3":"-2.520044058"},{"1":"ENSG00000073060","2":"GSM51042","3":"-2.173872197"},{"1":"ENSG00000073060","2":"GSM51043","3":"-1.753351745"},{"1":"ENSG00000073060","2":"GSM51044","3":"-1.749746892"},{"1":"ENSG00000073060","2":"GSM51045","3":"0.593436857"},{"1":"ENSG00000073060","2":"GSM51046","3":"-2.513120478"},{"1":"ENSG00000073060","2":"GSM51047","3":"-1.872822469"},{"1":"ENSG00000073060","2":"GSM51048","3":"-2.909343626"},{"1":"ENSG00000073060","2":"GSM51049","3":"-1.808559269"},{"1":"ENSG00000073060","2":"GSM51050","3":"-1.982465757"},{"1":"ENSG00000073060","2":"GSM51051","3":"-1.390987359"},{"1":"ENSG00000073060","2":"GSM51052","3":"-0.938250278"},{"1":"ENSG00000073060","2":"GSM51053","3":"-2.257200586"},{"1":"ENSG00000073060","2":"GSM51054","3":"-2.836956910"},{"1":"ENSG00000073060","2":"GSM51055","3":"-2.465149896"},{"1":"ENSG00000073060","2":"GSM51056","3":"-1.616613515"},{"1":"ENSG00000073060","2":"GSM51057","3":"-1.009287051"},{"1":"ENSG00000073060","2":"GSM51058","3":"-2.339008159"},{"1":"ENSG00000073060","2":"GSM51059","3":"-1.165014107"},{"1":"ENSG00000073060","2":"GSM51060","3":"-2.221016152"},{"1":"ENSG00000073060","2":"GSM51061","3":"-1.979184160"},{"1":"ENSG00000073060","2":"GSM51062","3":"-1.266816987"},{"1":"ENSG00000073060","2":"GSM51063","3":"-2.030585844"},{"1":"ENSG00000073060","2":"GSM51064","3":"-2.821550013"},{"1":"ENSG00000073060","2":"GSM51065","3":"-1.724254741"},{"1":"ENSG00000073060","2":"GSM51066","3":"-1.901161836"},{"1":"ENSG00000073060","2":"GSM51067","3":"-2.113710672"},{"1":"ENSG00000073060","2":"GSM51068","3":"-2.107029037"},{"1":"ENSG00000073060","2":"GSM51069","3":"-3.138013780"},{"1":"ENSG00000073060","2":"GSM51070","3":"-1.913050178"},{"1":"ENSG00000073060","2":"GSM51071","3":"-2.364425279"},{"1":"ENSG00000073060","2":"GSM51072","3":"-1.502442780"},{"1":"ENSG00000073060","2":"GSM51073","3":"-0.716219864"},{"1":"ENSG00000073060","2":"GSM51074","3":"-1.017289330"},{"1":"ENSG00000073060","2":"GSM51075","3":"-0.743628025"},{"1":"ENSG00000073060","2":"GSM51076","3":"-2.001452747"},{"1":"ENSG00000073060","2":"GSM51077","3":"-2.904603937"},{"1":"ENSG00000073060","2":"GSM51078","3":"-2.568132034"},{"1":"ENSG00000073060","2":"GSM51079","3":"-1.012875596"},{"1":"ENSG00000073060","2":"GSM51080","3":"-1.379087418"},{"1":"ENSG00000073060","2":"GSM51081","3":"-2.352775473"},{"1":"ENSG00000073060","2":"GSM51082","3":"-2.859864883"},{"1":"ENSG00000073060","2":"GSM51083","3":"-0.692272438"},{"1":"ENSG00000073060","2":"GSM51084","3":"-1.731973398"},{"1":"ENSG00000073060","2":"GSM51085","3":"-1.724375566"},{"1":"ENSG00000073060","2":"GSM51086","3":"-2.818999643"},{"1":"ENSG00000073060","2":"GSM51087","3":"-2.101471526"},{"1":"ENSG00000073060","2":"GSM51088","3":"-2.266087327"},{"1":"ENSG00000073060","2":"GSM51089","3":"-1.979573889"},{"1":"ENSG00000073060","2":"GSM51090","3":"-2.358737443"},{"1":"ENSG00000073060","2":"GSM51091","3":"-2.123189940"},{"1":"ENSG00000073060","2":"GSM51092","3":"-1.655729597"},{"1":"ENSG00000073060","2":"GSM51093","3":"-1.626605180"},{"1":"ENSG00000073060","2":"GSM51094","3":"-1.265440995"},{"1":"ENSG00000073060","2":"GSM51095","3":"-1.666009209"},{"1":"ENSG00000073060","2":"GSM51096","3":"-1.338722566"},{"1":"ENSG00000073060","2":"GSM51097","3":"-1.254348174"},{"1":"ENSG00000073060","2":"GSM51098","3":"-1.519229380"},{"1":"ENSG00000073060","2":"GSM51099","3":"-1.848801345"},{"1":"ENSG00000073060","2":"GSM51100","3":"-2.022024855"},{"1":"ENSG00000073060","2":"GSM51101","3":"-1.359134891"},{"1":"ENSG00000073060","2":"GSM51102","3":"-1.837544926"},{"1":"ENSG00000073060","2":"GSM51103","3":"-1.619055734"},{"1":"ENSG00000073060","2":"GSM51104","3":"0.049279175"},{"1":"ENSG00000073060","2":"GSM51105","3":"-1.228656821"},{"1":"ENSG00000073060","2":"GSM51106","3":"-1.706046371"},{"1":"ENSG00000073060","2":"GSM51107","3":"-4.168418878"},{"1":"ENSG00000073060","2":"GSM51108","3":"-1.462819945"},{"1":"ENSG00000073060","2":"GSM51109","3":"-3.997280645"},{"1":"ENSG00000073060","2":"GSM51110","3":"-1.791637061"},{"1":"ENSG00000073060","2":"GSM51111","3":"-1.981208993"},{"1":"ENSG00000073060","2":"GSM51112","3":"-1.600485276"},{"1":"ENSG00000073060","2":"GSM51113","3":"-1.737094751"},{"1":"ENSG00000073060","2":"GSM51114","3":"-1.715639566"},{"1":"ENSG00000073060","2":"GSM51115","3":"-1.115756588"},{"1":"ENSG00000073060","2":"GSM51116","3":"-1.759011370"},{"1":"ENSG00000073060","2":"GSM51117","3":"-1.569711450"},{"1":"ENSG00000073060","2":"GSM51118","3":"-2.041814298"},{"1":"ENSG00000073060","2":"GSM51119","3":"-2.430043174"},{"1":"ENSG00000073060","2":"GSM51120","3":"-2.242002025"},{"1":"ENSG00000073060","2":"GSM51121","3":"-2.169074130"},{"1":"ENSG00000073060","2":"GSM51122","3":"-2.327538940"},{"1":"ENSG00000073060","2":"GSM51123","3":"-2.139356298"},{"1":"ENSG00000073060","2":"GSM51124","3":"-2.144410761"},{"1":"ENSG00000073060","2":"GSM51125","3":"-1.867176934"},{"1":"ENSG00000073060","2":"GSM51126","3":"-1.450162088"},{"1":"ENSG00000073060","2":"GSM51127","3":"-1.330955925"},{"1":"ENSG00000073060","2":"GSM51128","3":"-1.167341037"},{"1":"ENSG00000073060","2":"GSM51129","3":"-0.009471971"},{"1":"ENSG00000073060","2":"GSM51130","3":"-1.034575432"},{"1":"ENSG00000073060","2":"GSM51131","3":"-0.933856784"},{"1":"ENSG00000073060","2":"GSM51132","3":"-2.963991590"},{"1":"ENSG00000073060","2":"GSM51133","3":"-1.337141695"},{"1":"ENSG00000073060","2":"GSM51134","3":"-0.804212120"},{"1":"ENSG00000073060","2":"GSM51135","3":"-1.629637913"},{"1":"ENSG00000073060","2":"GSM51136","3":"-1.784756844"},{"1":"ENSG00000073060","2":"GSM51137","3":"-3.302387381"},{"1":"ENSG00000073060","2":"GSM51138","3":"-1.534110818"},{"1":"ENSG00000073060","2":"GSM51139","3":"-1.408265323"},{"1":"ENSG00000073060","2":"GSM51140","3":"-3.009445276"},{"1":"ENSG00000073060","2":"GSM51141","3":"-1.602289547"},{"1":"ENSG00000073060","2":"GSM51142","3":"-1.904632130"},{"1":"ENSG00000073060","2":"GSM51143","3":"-2.719273164"},{"1":"ENSG00000073060","2":"GSM51144","3":"-3.471853443"},{"1":"ENSG00000073060","2":"GSM51145","3":"-2.654534833"},{"1":"ENSG00000073060","2":"GSM51146","3":"-1.627071429"},{"1":"ENSG00000073060","2":"GSM51147","3":"-1.306689823"},{"1":"ENSG00000073060","2":"GSM51148","3":"-0.513586895"},{"1":"ENSG00000073060","2":"GSM51149","3":"-1.229756684"},{"1":"ENSG00000073060","2":"GSM51150","3":"-1.505463729"},{"1":"ENSG00000073060","2":"GSM51151","3":"-1.208701265"},{"1":"ENSG00000073060","2":"GSM51152","3":"-1.419706031"},{"1":"ENSG00000073060","2":"GSM51153","3":"-2.529402559"},{"1":"ENSG00000073060","2":"GSM51154","3":"-1.964067324"},{"1":"ENSG00000073060","2":"GSM51155","3":"-2.253537475"},{"1":"ENSG00000073060","2":"GSM51156","3":"-1.288669085"},{"1":"ENSG00000073060","2":"GSM51157","3":"-1.945080017"},{"1":"ENSG00000073060","2":"GSM51158","3":"-1.507724156"},{"1":"ENSG00000073060","2":"GSM51159","3":"-2.543055749"},{"1":"ENSG00000073060","2":"GSM51160","3":"-0.659745750"},{"1":"ENSG00000073060","2":"GSM51161","3":"-1.391116355"},{"1":"ENSG00000073060","2":"GSM51162","3":"-1.772131157"},{"1":"ENSG00000073060","2":"GSM51163","3":"-1.993831344"},{"1":"ENSG00000073060","2":"GSM51164","3":"-2.420972454"},{"1":"ENSG00000073060","2":"GSM51165","3":"-2.148771286"},{"1":"ENSG00000073060","2":"GSM51166","3":"-1.733716271"},{"1":"ENSG00000073060","2":"GSM51167","3":"-4.441381567"},{"1":"ENSG00000073060","2":"GSM51168","3":"-1.294102729"},{"1":"ENSG00000073060","2":"GSM51169","3":"-1.532519457"},{"1":"ENSG00000073060","2":"GSM51170","3":"-1.599421472"},{"1":"ENSG00000073060","2":"GSM51171","3":"-1.503357421"},{"1":"ENSG00000073060","2":"GSM51172","3":"-1.691408164"},{"1":"ENSG00000073060","2":"GSM51173","3":"-2.039579816"},{"1":"ENSG00000073060","2":"GSM51174","3":"-1.869369126"},{"1":"ENSG00000073060","2":"GSM51175","3":"-1.821673077"},{"1":"ENSG00000073060","2":"GSM51176","3":"-1.399571135"},{"1":"ENSG00000073060","2":"GSM51177","3":"-1.370001901"},{"1":"ENSG00000073060","2":"GSM51178","3":"-2.117504187"},{"1":"ENSG00000073060","2":"GSM51179","3":"-1.515144672"},{"1":"ENSG00000073060","2":"GSM51180","3":"-1.545722332"},{"1":"ENSG00000073060","2":"GSM51181","3":"-1.559892581"},{"1":"ENSG00000073060","2":"GSM51182","3":"-2.030418215"},{"1":"ENSG00000073060","2":"GSM51183","3":"-1.439111526"},{"1":"ENSG00000073060","2":"GSM51184","3":"-1.400783287"},{"1":"ENSG00000073060","2":"GSM51185","3":"-2.529870674"},{"1":"ENSG00000073060","2":"GSM51186","3":"-1.862429134"},{"1":"ENSG00000073060","2":"GSM51187","3":"-1.543902261"},{"1":"ENSG00000073060","2":"GSM51188","3":"-2.433815415"},{"1":"ENSG00000073060","2":"GSM51189","3":"-1.956325619"},{"1":"ENSG00000073060","2":"GSM51190","3":"-1.213963764"},{"1":"ENSG00000073060","2":"GSM51191","3":"-3.158739013"},{"1":"ENSG00000073060","2":"GSM51192","3":"-1.250133984"},{"1":"ENSG00000073060","2":"GSM51193","3":"-1.660710873"},{"1":"ENSG00000073060","2":"GSM51194","3":"-1.715419807"},{"1":"ENSG00000073060","2":"GSM51195","3":"-2.790854967"},{"1":"ENSG00000073060","2":"GSM51196","3":"-1.290496626"},{"1":"ENSG00000073060","2":"GSM51197","3":"-2.774519169"},{"1":"ENSG00000073060","2":"GSM51198","3":"-1.685059403"},{"1":"ENSG00000073060","2":"GSM51199","3":"0.628306775"},{"1":"ENSG00000073060","2":"GSM51200","3":"-2.451601599"},{"1":"ENSG00000073060","2":"GSM51201","3":"-2.422129668"},{"1":"ENSG00000073060","2":"GSM51202","3":"-2.236131770"},{"1":"ENSG00000073060","2":"GSM51203","3":"-1.627408576"},{"1":"ENSG00000073060","2":"GSM51204","3":"-1.754130340"},{"1":"ENSG00000073060","2":"GSM51205","3":"-1.495369223"},{"1":"ENSG00000073060","2":"GSM51206","3":"-2.113629020"},{"1":"ENSG00000073060","2":"GSM51207","3":"-1.076207687"},{"1":"ENSG00000073060","2":"GSM51208","3":"-2.071372239"},{"1":"ENSG00000073060","2":"GSM51209","3":"-0.957171295"},{"1":"ENSG00000073060","2":"GSM51210","3":"-2.353672105"},{"1":"ENSG00000073060","2":"GSM51211","3":"-1.419742656"},{"1":"ENSG00000073060","2":"GSM51212","3":"-1.650407376"},{"1":"ENSG00000073060","2":"GSM51213","3":"-2.652577030"},{"1":"ENSG00000073060","2":"GSM51214","3":"-1.960729440"},{"1":"ENSG00000073060","2":"GSM51215","3":"-1.263795897"},{"1":"ENSG00000073060","2":"GSM51216","3":"-0.781926989"},{"1":"ENSG00000073060","2":"GSM51217","3":"-2.038430888"},{"1":"ENSG00000073060","2":"GSM51218","3":"-1.714821614"},{"1":"ENSG00000073060","2":"GSM51219","3":"-2.494763451"},{"1":"ENSG00000073060","2":"GSM51220","3":"-1.410006930"},{"1":"ENSG00000073060","2":"GSM51221","3":"-2.738159021"},{"1":"ENSG00000073060","2":"GSM51222","3":"-2.296210793"},{"1":"ENSG00000073060","2":"GSM51223","3":"-1.031284459"},{"1":"ENSG00000073060","2":"GSM51224","3":"-1.694676654"},{"1":"ENSG00000073060","2":"GSM51225","3":"-1.157267143"},{"1":"ENSG00000073060","2":"GSM51226","3":"-2.296422174"},{"1":"ENSG00000073060","2":"GSM51227","3":"-0.911292718"},{"1":"ENSG00000073060","2":"GSM51228","3":"-1.446630306"},{"1":"ENSG00000073060","2":"GSM51229","3":"-1.751981858"},{"1":"ENSG00000073060","2":"GSM51230","3":"-2.912086508"},{"1":"ENSG00000073060","2":"GSM51231","3":"-1.901376909"},{"1":"ENSG00000073060","2":"GSM51232","3":"-1.455317957"},{"1":"ENSG00000073060","2":"GSM51233","3":"-0.825683100"},{"1":"ENSG00000073060","2":"GSM51234","3":"-1.298899741"},{"1":"ENSG00000073060","2":"GSM51235","3":"-3.154690813"},{"1":"ENSG00000073060","2":"GSM51236","3":"-2.700911645"},{"1":"ENSG00000073060","2":"GSM51237","3":"-2.000544044"},{"1":"ENSG00000073060","2":"GSM51238","3":"-1.016413946"},{"1":"ENSG00000073060","2":"GSM51239","3":"-1.353821769"},{"1":"ENSG00000073060","2":"GSM51240","3":"-0.977532162"},{"1":"ENSG00000073060","2":"GSM51241","3":"-2.572265825"},{"1":"ENSG00000073060","2":"GSM51242","3":"-2.115878752"},{"1":"ENSG00000073060","2":"GSM51243","3":"-2.204044133"},{"1":"ENSG00000073060","2":"GSM51244","3":"-1.755943327"},{"1":"ENSG00000073060","2":"GSM51245","3":"-1.592074835"},{"1":"ENSG00000073060","2":"GSM51246","3":"-1.204673176"},{"1":"ENSG00000073060","2":"GSM51247","3":"-1.500545251"},{"1":"ENSG00000073060","2":"GSM51248","3":"-1.568612782"},{"1":"ENSG00000073060","2":"GSM51249","3":"-1.804957430"},{"1":"ENSG00000073060","2":"GSM51250","3":"-1.965210019"},{"1":"ENSG00000073060","2":"GSM51251","3":"-1.470234840"},{"1":"ENSG00000073060","2":"GSM51252","3":"-1.661335590"},{"1":"ENSG00000073060","2":"GSM51253","3":"-2.460365195"},{"1":"ENSG00000073060","2":"GSM51254","3":"-2.516201510"},{"1":"ENSG00000073060","2":"GSM51255","3":"-0.912705602"},{"1":"ENSG00000073060","2":"GSM51256","3":"-1.146319820"},{"1":"ENSG00000073060","2":"GSM51257","3":"-2.440744065"},{"1":"ENSG00000073060","2":"GSM51258","3":"-1.558465952"},{"1":"ENSG00000073060","2":"GSM51259","3":"-0.559961530"},{"1":"ENSG00000073060","2":"GSM51260","3":"-2.043931801"},{"1":"ENSG00000073060","2":"GSM51261","3":"-2.631353599"},{"1":"ENSG00000073060","2":"GSM51262","3":"-1.294520511"},{"1":"ENSG00000073060","2":"GSM51263","3":"-2.013412625"},{"1":"ENSG00000073060","2":"GSM51264","3":"-1.960071511"},{"1":"ENSG00000073060","2":"GSM51265","3":"-1.546516387"},{"1":"ENSG00000073060","2":"GSM51266","3":"-1.836969192"},{"1":"ENSG00000073060","2":"GSM51267","3":"-1.798322049"},{"1":"ENSG00000073060","2":"GSM51268","3":"-0.984731938"},{"1":"ENSG00000073060","2":"GSM51269","3":"-1.938441152"},{"1":"ENSG00000073060","2":"GSM51270","3":"-0.533720393"},{"1":"ENSG00000073060","2":"GSM51271","3":"-1.624776638"},{"1":"ENSG00000073060","2":"GSM51272","3":"0.646946038"},{"1":"ENSG00000073060","2":"GSM51273","3":"-1.246832129"},{"1":"ENSG00000073060","2":"GSM51274","3":"-2.869971023"},{"1":"ENSG00000073060","2":"GSM51275","3":"-2.756992135"},{"1":"ENSG00000073060","2":"GSM51276","3":"-2.320160100"},{"1":"ENSG00000073060","2":"GSM51277","3":"-0.445220641"},{"1":"ENSG00000073060","2":"GSM51278","3":"-1.430900845"},{"1":"ENSG00000073060","2":"GSM51279","3":"-1.368795782"},{"1":"ENSG00000073060","2":"GSM51280","3":"-2.276362697"},{"1":"ENSG00000073060","2":"GSM51281","3":"-1.439248916"},{"1":"ENSG00000073060","2":"GSM51282","3":"-2.226471776"},{"1":"ENSG00000073060","2":"GSM51283","3":"-1.663753029"},{"1":"ENSG00000073060","2":"GSM51284","3":"-1.694814976"},{"1":"ENSG00000073060","2":"GSM51285","3":"-2.830746287"},{"1":"ENSG00000073060","2":"GSM51286","3":"-1.073487302"},{"1":"ENSG00000073060","2":"GSM51287","3":"-2.856427569"},{"1":"ENSG00000073060","2":"GSM51288","3":"-1.189756276"},{"1":"ENSG00000073060","2":"GSM51289","3":"-2.572242081"},{"1":"ENSG00000073060","2":"GSM51290","3":"-1.626410361"},{"1":"ENSG00000073060","2":"GSM51291","3":"-0.112092908"},{"1":"ENSG00000073060","2":"GSM51292","3":"-1.660691907"},{"1":"ENSG00000073060","2":"GSM51293","3":"-0.697849733"},{"1":"ENSG00000073060","2":"GSM51294","3":"-1.379215131"},{"1":"ENSG00000073060","2":"GSM51295","3":"-0.970798814"},{"1":"ENSG00000073060","2":"GSM51296","3":"-2.268167946"},{"1":"ENSG00000073060","2":"GSM51297","3":"-1.677587412"},{"1":"ENSG00000073060","2":"GSM51298","3":"-2.695951885"},{"1":"ENSG00000073060","2":"GSM51299","3":"-1.475312125"},{"1":"ENSG00000073060","2":"GSM51300","3":"-1.053136928"},{"1":"ENSG00000073060","2":"GSM51301","3":"-0.763024257"},{"1":"ENSG00000073060","2":"GSM51302","3":"-1.530076377"},{"1":"ENSG00000073060","2":"GSM51303","3":"-1.535949590"},{"1":"ENSG00000073060","2":"GSM51304","3":"-1.168650037"},{"1":"ENSG00000073060","2":"GSM51305","3":"-1.709326326"},{"1":"ENSG00000073060","2":"GSM51306","3":"-1.750416192"},{"1":"ENSG00000073060","2":"GSM51307","3":"-1.818251644"},{"1":"ENSG00000073060","2":"GSM51308","3":"-1.908020994"},{"1":"ENSG00000073060","2":"GSM51309","3":"-1.172840508"},{"1":"ENSG00000073060","2":"GSM51310","3":"-1.651626208"},{"1":"ENSG00000073060","2":"GSM51311","3":"-2.262900520"},{"1":"ENSG00000073060","2":"GSM51312","3":"-1.201578170"},{"1":"ENSG00000073060","2":"GSM51313","3":"-0.810994251"},{"1":"ENSG00000073060","2":"GSM51314","3":"-4.532928832"},{"1":"ENSG00000073060","2":"GSM51315","3":"-2.042086880"},{"1":"ENSG00000073060","2":"GSM51316","3":"-1.207978198"},{"1":"ENSG00000073060","2":"GSM51317","3":"-1.931679267"},{"1":"ENSG00000073060","2":"GSM51318","3":"-0.818252174"},{"1":"ENSG00000073060","2":"GSM51319","3":"-1.654436571"},{"1":"ENSG00000073060","2":"GSM51320","3":"-1.428266504"},{"1":"ENSG00000073060","2":"GSM51321","3":"-2.472446108"},{"1":"ENSG00000073060","2":"GSM51322","3":"-1.621661220"},{"1":"ENSG00000073060","2":"GSM51323","3":"-0.892964410"},{"1":"ENSG00000073060","2":"GSM51324","3":"-0.169056029"},{"1":"ENSG00000073060","2":"GSM51325","3":"-1.454191806"},{"1":"ENSG00000073060","2":"GSM51326","3":"-1.928970951"},{"1":"ENSG00000073060","2":"GSM51327","3":"-0.823915377"},{"1":"ENSG00000073060","2":"GSM51328","3":"-1.526648628"},{"1":"ENSG00000073060","2":"GSM51329","3":"-2.428311963"},{"1":"ENSG00000073060","2":"GSM51330","3":"-1.360985537"},{"1":"ENSG00000073060","2":"GSM51331","3":"-1.883266853"},{"1":"ENSG00000073060","2":"GSM51332","3":"-2.634420255"},{"1":"ENSG00000073060","2":"GSM51333","3":"-1.979880608"},{"1":"ENSG00000073060","2":"GSM51334","3":"-1.688028228"},{"1":"ENSG00000073060","2":"GSM51335","3":"-0.477765750"},{"1":"ENSG00000073060","2":"GSM51336","3":"-2.446839373"},{"1":"ENSG00000073060","2":"GSM95646","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95647","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95648","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95649","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95650","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95651","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95652","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95653","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95654","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95655","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95656","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95657","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95658","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95659","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95660","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95661","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95662","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95663","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95664","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95665","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95666","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95667","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95668","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95669","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95670","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95671","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95672","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95673","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95674","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95675","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95676","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95677","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95678","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95679","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95680","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95681","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95682","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95683","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95684","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95685","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95686","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95687","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95688","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95689","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95690","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95691","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95692","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95693","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95694","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95695","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95696","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95697","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95698","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95699","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95700","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95701","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95702","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95703","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95704","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95705","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95706","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95707","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95708","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95709","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95710","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95711","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95712","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95713","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95714","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95715","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95716","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95717","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95718","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95719","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95720","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95721","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95722","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95723","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95724","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95725","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95726","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95727","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95728","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95729","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95730","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95731","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95732","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95733","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95734","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95735","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95736","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95737","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95738","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95739","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95740","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95741","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95742","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95743","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95744","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95745","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95746","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95747","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95748","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95749","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95750","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95751","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95752","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95753","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95754","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95755","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95756","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95757","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95758","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95759","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95760","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95761","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95762","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95763","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95764","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95765","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95766","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95767","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95768","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95769","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95770","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95771","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95772","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95773","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95774","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95775","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95776","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95777","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95778","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95779","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95780","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95781","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95782","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95783","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95784","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95785","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95786","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95787","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95788","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95789","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95790","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95791","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95792","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95793","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95794","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95795","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95796","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95797","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95798","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95799","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95800","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95801","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95802","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95803","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95804","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95805","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95806","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95807","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95808","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95809","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95810","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95811","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95812","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95813","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95814","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95815","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95816","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95817","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95818","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95819","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95820","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95821","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95822","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95823","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95824","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95825","3":"-1.453292095"},{"1":"ENSG00000073060","2":"GSM95826","3":"-1.453292095"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[559]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>plot histogram of adjlogcpkmed from final version (with missing genes and NAs corrected)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2dwbG90KGdzZTI2NThfZXhwcnNfYWRqX2NtcGx0KSArIFxuICBnZW9tX2hpc3RvZ3JhbShhZXMoYWRqbG9nY3BrbWVkKSkgKyB0aGVtZV9taW5pbWFsKCkgKyBcbiAgbGFicyh4PShcImV4cHJlc3Npb24gdmFsdWVcIiksIFxuICAgICAgIHRpdGxlPVwiR1NFMjY1OCBhZGpsb2djcGttZWQgbWljcm9hcnJheSBleHByZXNzaW9uIHZhbHVlcyB3aXRoIG1pc3NpbmcgZ2VuZXMgYW5kIE5BcyBjb3JyZWN0ZWRcIilcbmBgYCJ9 -->
<pre class="r"><code>ggplot(gse2658_exprs_adj_cmplt) + 
  geom_histogram(aes(adjlogcpkmed)) + theme_minimal() + 
  labs(x=(&quot;expression value&quot;), 
       title=&quot;GSE2658 adjlogcpkmed microarray expression values with missing genes and NAs corrected&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG4ifQ== -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo5LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,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" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>final version (with missing genes and NAs corrected) with gene_ids</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyB3cml0ZV9jc3YoZ3NlMjY1OF9leHByc19hZGpfY21wbHQsIFwiZ3NlMjY1OF9leHByc19hZGpfMjAyMjA1MDMuY3N2XCIpXG5gYGAifQ== -->
<pre class="r"><code># write_csv(gse2658_exprs_adj_cmplt, &quot;gse2658_exprs_adj_20220503.csv&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
<div id="normalization-equation" class="section level2">
<h2>normalization equation</h2>
<p><span class="math display">\[e_g=log_2 \left (\frac{cpk}{size factor}\right)\]</span></p>
<p><span class="math display">\[cpk=\frac{ \sum_{s=1}^{m}c_s }{gene \, length_{kb}}\]</span></p>
<p><span class="math display">\[size \, factor= median(sample \, cpk)\]</span></p>
</div>
<div id="phenotype-data" class="section level2">
<h2>phenotype data</h2>
<p>column structure is weird</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuY29sbmFtZXMoZ3NlMjY1OF9wZGF0YSlcbmBgYCJ9 -->
<pre class="r"><code>colnames(gse2658_pdata)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code> [1] &quot;title&quot;                   &quot;geo_accession&quot;           &quot;status&quot;                  &quot;submission_date&quot;        
 [5] &quot;last_update_date&quot;        &quot;type&quot;                    &quot;channel_count&quot;           &quot;source_name_ch1&quot;        
 [9] &quot;organism_ch1&quot;            &quot;characteristics_ch1&quot;     &quot;characteristics_ch1.1&quot;   &quot;characteristics_ch1.2&quot;  
[13] &quot;characteristics_ch1.3&quot;   &quot;characteristics_ch1.4&quot;   &quot;characteristics_ch1.5&quot;   &quot;characteristics_ch1.6&quot;  
[17] &quot;characteristics_ch1.7&quot;   &quot;characteristics_ch1.8&quot;   &quot;characteristics_ch1.9&quot;   &quot;characteristics_ch1.10&quot; 
[21] &quot;characteristics_ch1.11&quot;  &quot;molecule_ch1&quot;            &quot;extract_protocol_ch1&quot;    &quot;label_ch1&quot;              
[25] &quot;label_protocol_ch1&quot;      &quot;taxid_ch1&quot;               &quot;hyb_protocol&quot;            &quot;scan_protocol&quot;          
[29] &quot;description&quot;             &quot;description.1&quot;           &quot;description.2&quot;           &quot;description.3&quot;          
[33] &quot;description.4&quot;           &quot;description.5&quot;           &quot;data_processing&quot;         &quot;data_processing.1&quot;      
[37] &quot;data_processing.2&quot;       &quot;data_processing.3&quot;       &quot;platform_id&quot;             &quot;contact_name&quot;           
[41] &quot;contact_email&quot;           &quot;contact_phone&quot;           &quot;contact_laboratory&quot;      &quot;contact_department&quot;     
[45] &quot;contact_institute&quot;       &quot;contact_address&quot;         &quot;contact_city&quot;            &quot;contact_state&quot;          
[49] &quot;contact_zip/postal_code&quot; &quot;contact_country&quot;         &quot;supplementary_file&quot;      &quot;data_row_count&quot;         </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<div id="important-variables-for-me-now" class="section level3">
<h3>important variables for me now:</h3>
<p>ID that matches expression data: <code>geo_accession</code></p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaGVhZChnc2UyNjU4X3BkYXRhJGdlb19hY2Nlc3Npb24pXG5gYGAifQ== -->
<pre class="r"><code>head(gse2658_pdata$geo_accession)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIFwiR1NNNTA5ODZcIiBcIkdTTTUwOTg3XCIgXCJHU001MDk4OFwiIFwiR1NNNTA5ODlcIiBcIkdTTTUwOTkwXCIgXCJHU001MDk5MVwiXG4ifQ== -->
<pre><code>[1] &quot;GSM50986&quot; &quot;GSM50987&quot; &quot;GSM50988&quot; &quot;GSM50989&quot; &quot;GSM50990&quot; &quot;GSM50991&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>treatment info: <code>source_name_ch1</code><br />
looks like all samples are pre-treatment? doesnt really jive with whats in the paper, but</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxudGFibGUoZ3NlMjY1OF9wZGF0YSRzb3VyY2VfbmFtZV9jaDEsIHVzZU5BPVwiYVwiKVxuYGBgIn0= -->
<pre class="r"><code>table(gse2658_pdata$source_name_ch1, useNA=&quot;a&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiXG5wcmUtdHJlYXRtZW50IGJvbmUgbWFycm93ICAgICAgICAgICAgICAgICAgICAgIDxOQT4gXG4gICAgICAgICAgICAgICAgICAgICAgNTU5ICAgICAgICAgICAgICAgICAgICAgICAgIDAgXG4ifQ== -->
<pre><code>
pre-treatment bone marrow                      &lt;NA&gt; 
                      559                         0 </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>survival indicator: <code>characteristics_ch1</code><br />
info <code>(Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)</code><br />
will need to extract the 1/0 version</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaGVhZChnc2UyNjU4X3BkYXRhJGNoYXJhY3RlcmlzdGljc19jaDEpXG5gYGAifQ== -->
<pre class="r"><code>head(gse2658_pdata$characteristics_ch1)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>[1] &quot;[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]&quot;
[2] &quot;[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]&quot;
[3] &quot;[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]&quot;
[4] &quot;[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]&quot;
[5] &quot;[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]&quot;
[6] &quot;[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]&quot;</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>survival indicator: <code>characteristics_ch1.2</code><br />
info: <code>(Follow-up time in months from Pre-Treatment baseline; integer)</code><br />
will have to extract <code>SURTIM</code> to get the value in months</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuaGVhZChnc2UyNjU4X3BkYXRhJGNoYXJhY3RlcmlzdGljc19jaDEuMilcbmBgYCJ9 -->
<pre class="r"><code>head(gse2658_pdata$characteristics_ch1.2)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin 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 -->
<pre><code>[1] &quot;[SURTIM=69.24 (Follow-up time in months from Pre-Treatment baseline; integer)]&quot;
[2] &quot;[SURTIM=66.67 (Follow-up time in months from Pre-Treatment baseline; integer)]&quot;
[3] &quot;[SURTIM=66.43 (Follow-up time in months from Pre-Treatment baseline; integer)]&quot;
[4] &quot;[SURTIM=66.5 (Follow-up time in months from Pre-Treatment baseline; integer)]&quot; 
[5] &quot;[SURTIM=42.67 (Follow-up time in months from Pre-Treatment baseline; integer)]&quot;
[6] &quot;[SURTIM=65 (Follow-up time in months from Pre-Treatment baseline; integer)]&quot;   </code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>making survival dataframe:</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9zdXJ2ZCA8LSBnc2UyNjU4X3BkYXRhICU+JSBcbiAgc2VsZWN0KHNhbXBsZV9pZD1nZW9fYWNjZXNzaW9uLCBjaGFyYWN0ZXJpc3RpY3NfY2gxLCBjaGFyYWN0ZXJpc3RpY3NfY2gxLjIpXG5nc2UyNjU4X3N1cnZkJGNlbnNvcyA8LSBzdHJfbWF0Y2goZ3NlMjY1OF9zdXJ2ZCRjaGFyYWN0ZXJpc3RpY3NfY2gxLCBwYXR0ZXJuPVwiXFxcXFtTVVJJTkQ9KC4/KVxcXFxzXCIpWywyXVxuZ3NlMjY1OF9zdXJ2ZCR0dGNvcyA8LSBzdHJfbWF0Y2goZ3NlMjY1OF9zdXJ2ZCRjaGFyYWN0ZXJpc3RpY3NfY2gxLjIsIHBhdHRlcm49XCJcXFxcW1NVUlRJTT0oLj8pXFxcXHNcIilbLDJdXG5gYGAifQ== -->
<pre class="r"><code>gse2658_survd &lt;- gse2658_pdata %&gt;% 
  select(sample_id=geo_accession, characteristics_ch1, characteristics_ch1.2)
gse2658_survd$censos &lt;- str_match(gse2658_survd$characteristics_ch1, pattern=&quot;\\[SURIND=(.?)\\s&quot;)[,2]
gse2658_survd$ttcos &lt;- str_match(gse2658_survd$characteristics_ch1.2, pattern=&quot;\\[SURTIM=(.?)\\s&quot;)[,2]</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9zdXJ2ZCA8LSBnc2UyNjU4X3BkYXRhICU+JSBcbiAgc2VsZWN0KHNhbXBsZV9pZD1nZW9fYWNjZXNzaW9uLCBjaGFyYWN0ZXJpc3RpY3NfY2gxLCBjaGFyYWN0ZXJpc3RpY3NfY2gxLjIpICU+JSBcbiAgbXV0YXRlKGNlbnNvcz1hcy5udW1lcmljKHN0cl9tYXRjaChjaGFyYWN0ZXJpc3RpY3NfY2gxLCBwYXR0ZXJuPVwiXFxcXFtTVVJJTkQ9KC4/KVxcXFxzXCIpWywyXSkpICU+JSBcbiAgbXV0YXRlKHR0Y29zPWdzdWIoXCJcXFxcW1NVUlRJTT1cIixcIlwiLCBjaGFyYWN0ZXJpc3RpY3NfY2gxLjIpKSAlPiUgXG4gIG11dGF0ZSh0dGNvcz1hcy5udW1lcmljKGdzdWIoXCJcXFxccypcXFxcKEZvbGxvdy11cCB0aW1lIGluIG1vbnRocyBmcm9tIFByZS1UcmVhdG1lbnQgYmFzZWxpbmU7IGludGVnZXIpXVxcXFxzKlwiLFwiXCIsIHR0Y29zKSkpICU+JSBcbiAgdGliYmxlOjpyZW1vdmVfcm93bmFtZXMoKVxuZ3NlMjY1OF9zdXJ2ZFxuYGBgIn0= -->
<pre class="r"><code>gse2658_survd &lt;- gse2658_pdata %&gt;% 
  select(sample_id=geo_accession, characteristics_ch1, characteristics_ch1.2) %&gt;% 
  mutate(censos=as.numeric(str_match(characteristics_ch1, pattern=&quot;\\[SURIND=(.?)\\s&quot;)[,2])) %&gt;% 
  mutate(ttcos=gsub(&quot;\\[SURTIM=&quot;,&quot;&quot;, characteristics_ch1.2)) %&gt;% 
  mutate(ttcos=as.numeric(gsub(&quot;\\s*\\(Follow-up time in months from Pre-Treatment baseline; integer)]\\s*&quot;,&quot;&quot;, ttcos))) %&gt;% 
  tibble::remove_rownames()
gse2658_survd</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["data.frame"],"nrow":559,"ncol":5,"summary":{"Description":["df [559 × 5]"]}},"rdf":"H4sIAAAAAAAAA+2dC4we11XHvzhx2lh9OImdNM+u7cSxE+947r0zc2dsr/dbe9ePXa/jpIkoEFo29qY2tXfN7pqUAhISikAVIiBAiPIQUASoSAUJIQICBK14CMpLgCIQILVIgGiFKlUBiiAwn++Zb2f/IbKd3H86Xp+VrPGdx5nfPffc878zc2e+Jyff7za9f1Ov17u5d8tNG3o3b6z/29v49FNHRste75YNdeGm3i292wbLj9Q73TnYWv/b3Ott2Csb3n70fbN5WpUFlD2USyhXa8tVCmUDZQtlB+UMyjmUga8Cvgr4qjV8Jk1TKBsoWyg7KGdQzqFcQNlDuYQy8BngM8BngM8AnwE+A3wG+AzwGeAzwGeBzwKfBT4LfBb4LPBZ4LPAZ4HPAp8DPgd8Dvgc8Dngc8DngM8BnwM+B3wZ8GXAlwFfBnwZ8GXAlwFfBnwZ8GXAlwNfDnw58OXAlwNfDnw58OXAlwNfDnwF8BXAVwBfAXwF8BXAVwBfAXwF8BXA54HPA58HPg98Hvg88Hng88Dngc8DXwl8JfCVwFcCXwl8JfCVwFcCXwl8JfBVwFcBXwV8FfBVwFcBXwV8FfBVwAf6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8G9MOAfhjQDwP6YUA/DOiHAf0woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv6YUE/LOiHBf2woB8W9MOCfljQDwv64UA/HOiHA/1woB8O9MOBfjjQDwf64UA/HOiHA/1woB8O9MOBfjjQDwf64UA/HOiHA/1woB8O9MOBfjjQDwf64UA/HOiHA/1woB8O9MOBfjjQDwf64UA/HOiHA/1woB9ujX5UeZFh2UO5hHK1trwmXw/KBsoWyg7KGZRzKANfDnw58OXAVwBfAXwF8BXAVwBfAXwF8BXAVwBfAXwe+DzweeDzwOeBzwOfBz4PfB74PPCVwFcCXwl8JfCVwFcCXwl8JfCVwFcCXwV8FfBVwFcBXwV8FfBVwFcBXwV81Vo+n6ZQNlC2UHZQzqCcQ7mAsodyCWXgM8BngM8AnwE+A3wG+AzwGeAzwGeAzwKfBT4LfBb4LPBZ4LPAZ4HPAp8FPgd8Dvgc8Dngc8DngA/ytXfA54DPAV8GfBnwZcCXAV8GfBnwgX540A8P+uFBPzzohwf98KAfHvTDg3540A8P+uFBPzzohwf98KAfHvTDg3540A8P+uFBPzzohwf98KAfHvTDg3540A8P+uFBPzzohwf98KAfHvTDg3540A8P+uFBPzzohwf98KAfHvTDg3540A8P+uFBPzzohwf98KAfHvTDg3540A8P+uFBPzzohwf9KEE/StCPEvSjBP0oQT9K0I8S9KME/ShBP0rQjxL0owT9KEE/StCPEvSjBP0oQT9K0I8S9KME/ShBP0rQjxL0owT9KEE/StCPcqgft9XlwePr9DUrPK6oYMXQh8MVBldYXOFwRYYrclyBYAbBhr5sVlgEswhmEcwimEUwi2CvcaFFMPsaMHShQ1KHpA5JHZLWUrx2SsyLX/++p588fnJyLB3ZdXzhzLnTcyuLSyOLz42cObc8P7c8P7o0f35uZf7MyJn5uZWz+0fOLazMf2h+ac9IOjZ3/ty3zI/Ue1/eNPLst44srpydXxo5PXdpeX7PiBkTEyNrTOwZWZgbC0dc3nHk0sKZ+ZX5pQvnFubP7P4GxVqHWKabWB31VkextBEVS2NLsa63RlQsjS3F6gKWxpZ6S72lWNqI6i31lnpLsW7I2FKsdRBbHcXSRlQsxeoCVkd7YkextBHXgbcUS2NLsbqApbG1DrC0EdVbN5i3FEtj6wbD6mgjdhRLG1GxFEuxFGs9Y2mWVyzF6gJWR3uiYq0DrI6GvGJpbN1g3uooljaiYt1gWB0NecVSLMXqApbmLcVSLMVSLMVSLMXSEcQN6S3FWgex1VEsbcR14K2OYnW0ERVLsbQnKpY24nrG0kZULMVSLMVaz1gdzfIdxepoI3YUSxtRvaVYiqVYiqVYiqWaqFiKpViKpViKpVg3MJYObBRLY6sLWB31VkexOtqIHcXSRlRv3WBY2ojqLcXqApbGlmIplmIplmIplmIp1g2JpcNAxVIsxVIsTaeKpY2oWIqlWIqlWIqlWIqlWF3D0tGpYimWYimWplP1lnpr3XhLsRRLsRRL06liKZZiKdYNiaVZXrEUS7EUS7EUS7HWDZYObBRLsRTresPSvKVYiqVYiqXpVLEUS7EUS7EUS7F0BHEdeEuxFOsGw9IEoVg3GJaGvGIplmIplmIplmKtGywd2CiWYnUBS3uiYmlsKZZiKZZidRpL06liKVYXsLQnKpZiKZZiKZaKT6e91VEsbUTFUizFUizFUizFWjdYOrBRLMXqApb2RMVSLMVSLMVSLMVaNyOIjmJ1tBEVS7G0JyqWYimWYimWYimWYimWYimWYumVj3pLsRRLsRRLsRRLsRRLBzaKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpViKpVhvJVavt7nX27BX8E4O8J46PjtWVInNRnYdWTx/fvH50UsXR1bOXZivaUYuLC6snF0eeW5p8cLIqaX50aeWatsX5hdWRp6tz32+tjqEHlZ61WqRFJ5hNXOxrM62rObRUTMb0QEzQ9RooKu1zxMbvfauTCyh+bPER2v+tlXXcasnGqs+KeOT2qQitJVLXLS4GgZrmZTRctXQqCsSE73+Nk0MIapM4gmsVWLix1VeByshr+ZJEd8DtV/j9dZhYFmfEEIgTTyhsWySEpQ1JfQsVw9YosXVMLOapIjv1Cpx8Zuq7q1l/LDKa8WObzXLkorA6hnjgNqvJFZCd00Zml3HAGHQbouIkbUq2mm83Do0mlVJ/EuhOgsQRgJ1XBFGrTaLOMBaMxKgeMDEH1/UfYAzFnLxlTBzSUrIAkWSxverNQyr9bgtj+/XejBk41+71HmA0FhVUlAGA1W0TjDbEgJCfy0Y1wO1W+PdaFq1mlGu3hxlLFAw9KW2Gq9ntfMg4UozzxmjzDq3MPyaMy7fqiSNlgWGtzBNFcvkdGMyZfgzI1y5UeK0vh4mXGEUtQcIWSVL8vhWM0/J1pZyPZglLloMzKxajT9ccYR7zXXt4+Wpk21UQv53lKGVo8SqY/Qrk0cUgDZrvOu2drjGF8DaKOE6wBFuikZNVqsj9oh3RYdGfURpHd6+jdhQbbmOJ6yzrZYi3GGxEe8xtVEJg3WTlIT4d5QHOImPllW5TxoMJf/7xEcbra+OVyl3AwcPceNbNSaxBAWsQ4BwHRAzXbVZCR7IisQRri7SpCLk1jTxhNFlyhhdmixixmqzpoS71xXliWPFuB9YW80Jcxkoz4ezMrHRPDCzysoALQk3A2JWf/XJIGPmVW2UMEtuYJXQAwrGIwHDuMWSxZx7uvrAuWZlaHYaX7Hq63aCtgw0m3A5UETMgauNxXiQn+VJFX/ikSM8FDMp49FFXX/CravrzKohJOycMRCynBjIGA8bOVZNzCnYsy1WwkggY4wvDWVyQJ2x491raLuVIC5Zksa/gctBjfkUf7ZllRCsLmFcDdRCSNBsx7jRYCkTJV3K6FgDqwy3xhPC1nwDwtsdmSWM242lXLlRZrPVDiA8yadZZQyw6ks3QsauWTlWCSnbUAaDhhIDJuL7HWusUp6QcPIAYZZEljKeu9RWCXecs5hSuMYqYYiRMmb01VY5MRBvRsdsyyrlNS/GGKtK8vjplcZKuIcx8ADl8SvhTq4rExe/w7qYr7u2bznGv9ngGUnAUV4dMimlD1hKHygZkwVqvxIekeQRVXu2hUoYDNXDQYIOeMbdURezZ60KIeOBZp1aGUmgvs4gpNY8MYQQoMwaHrAS5qEy7jfVDoin2bNtqwyvMmQgY8xCqq2S+gAlWnPC8+ecMhzOKfPbYnat1U7gCEo4CFdKfyXElWNcv9OsEu4KWENJ2S7iZIF2YBHeSxvkQY4HKPEa75332dZoKFpybRsltJWNOL9x9UM9lHsCLuLN0fY8LMaojfBxApdG7KzkeWgx3x9ZzawxXyA+2XIA4VkGyWrM7/S0Q4DwycY0KQmBlTI+fOIoj4hqq5xOQHjfqfYr44KIk7EYMxAGPYswY8ow3iS2lIcOA6uUSSiMr/9UjLnDlvJ4wBZJSWCtEh/N6sxqaxEeORBaKqoMtFAZ+donVfx8bSifLq5ZC0Ko+iSnWCU8HRh8ujb+AGswv48SWJQcSLjXNsisBKs55SVtSmOVlIGAjzgfeU3PIrDGfOGrbZXhgYLxIUTOh0vrTkAYs8T8hjsZNadoVk6J1pzxcprNCHdwLOWpU42axZ+SPXArA5VxkZUxJnjWVgkv5ljKs+dBCBD6K6W1TMG4KWAdRV8t43d36rEAYfp43VqEaR2W8gHngRRyrBLiNWXcxyRdaGSU6zfH+LhK3VqED5ZYyperOJFVj10ZnxrOI14Wtl/7IsiWpXzBNebT17ZVwtweG/Pxa9sq406uoUgsZbbE4KOIlORSUFgZg2LDePNtMCCixEC8OX6tDwMyUDk/vGApd1xYCsv4wSTLeFY6SNqUFwpLSodl3M20pB8KYbBSPo5obMT0uppcUsKUVBvze4MU1NWPglXx5s21H2sSemvMn3aaWXUqw6WUz8sQJvlayouvHFZTMl6prj1QUazGuxxofcw4/tiibivCRP/Bx5Cui65aMlxK+eayifkVmHanYjR/SXjmYGK+R9r6kWPCVzVqVMIU7zquCG971VYZcVUwpqMPHjnEN+oZ3yyivPRMygEZJV/FnDDWbqz4U9tqBxC+C8vpVzF/6bz1KjXj8+gxvwzctspI2EXEGYNtGSRcBnNUoGRM7RtYvU4GF5wxG+dCmPK9Jlp3jXcp2H7vn9BbGb+YamKitr1KmIJnYn77YrbtAYpbCekqJ7ztGNMoR6/aXu261bZb4z9pGnzL//ogLSI+xm+PgwnjFcrXaw1jWqeh/AxzjUr4hQzKh5oGH3G/Xj4NX1ulXAkSwiqnfA015vev2g6gGKW85MXIK4wv1NRGCRmgtkq4a0H5FcaICji0yfieljGU+7aWYjUm62zLKuUD7vEuV4YBQHl0E3Oeycyq1W67lGO1HVOEUbVlXFYaxgdQDeURc22Vw8oYq8T8XG1rKjPhFzwGIUB4yEh4YbCKeFl9YtUo4QEbRVMoH9iP+niF4dR2qoo3/G0N1Ag3wNJ4Qt0Cjf9TU6ReGi9Lt4Y+HR/7tkjjzy4sGXm/ZNykrCKK6fTQKKHuhPv+MY22wonxYRvCXN2SccWTx6v9idXax780Z7RSzJ+8aM9Tjh+jlnAHLWdIU8yZFG3S+O2UM6Qp73g7DRN+/IvnPOJNPiIm5ZMw10kTFRFV6USrx18XlwykzERJIvFtMqY4UuZLZF2fi9h6WBDfpmN8xZzRTJYxvKf8fK5l3CbMIpIOEz5j2Bg/j8ZspFZfItzNJ82SY8yRoPz4nk0p3+VIKc/II/74HudNRO7brTF/wqR1q4hQ/ZiThLhX4gXnAjceaWsMzRjsx4uoFiij8owhdDSHMiacUIbQLTFlDHjiXT21QOM/cIk527B9/cAwSiElpHzL+AVTy3jU7AiPBSPabFeecaVDuPMc5ZfBe7139Xob9vau8Df+pWtbf7XH4fJat1+p/EaPe72/K3FdrZ0r2b1Wnmvdfq3+u1r/Xi3Xtf69WX9eiff1znOt8flm6x3bb9d6vjca32+0/tcaP6y4eqP9JPbfW93+V3veN9v/Y/n3q+Uf/IvF8VbF+Zv9Y9WX1b++2vrTlfN21Z+s813tcddLe75V+TA21xv961o+7IpfrnS+rnO+2b+3ehz2en/Xm9/0r/N/l++/9J94/Jldr3z6xf6pT37u6Ke2fFv/1I+98OBLT3yxf+qnLu/Un3r60y8+s+vf+6f6oXzqxGfrvz/pH95er37lM/1TyUtPfOGF9/ZPbX1w8J/h8r3u8l//8W8fmH+m//gvDBa7+9s+teWj9Zn6h94R7GTbjg7W9E/+bTj/WBK2n/hi2H7kT0P55CfHLn7i5U39/XL+k6df3jR28Wf70zeH5Umxdzhwj3/lRwd/H+/P/nJ91Ng398f+amBmS3/2gYGZsf6R5zcNDPZP/H0oj/2bnPcfg73jwj0r9d+3L/AdlPMf+5VQv9nvD/ZPCF/5stj911A+8YOy392y/ucH1T3Wn/qe4I8Ttz43+Ovnwn/yd4M/pu+X8/+N1OPPw3lmvyPw7vvO0B4nTgbu2V8L9me+LnD6/6xb4cGX+iceFQ6xNyV+nZF6T8v2me8K9d6+K3C5tcHSn/mtsL8XnsPip1MfCOefORaOOyoc0+LfmT1yPrEz/U+hvjPSbtPCMy31m26O/8NgLxGeafHj9M+F46elfae/V46X8+Wy/oEvhDi+Tcr+D4LfpyUupzfL+e4J2yf/WbZLO94azjuMo+PCY/4obD8k7XtI7Ox8MfSj438Z7PebOPpEWB7dK9s/Etrl+DcGfxw/FY4f/Viwd/ym0P7HfiL4+5jE/7HfD/U+JvF87N7QzsckDo4tBvvN+qPi56M/E/rp0Y/L+hA/469+LpznqMT3uOzffyH0372H5Djx/9E0nPewxP2RrwS/vEPa9eFLwc4Rab/XLH9Ytku9st8IPEeknzXLPZInjjwXeI6E//TdTwuvxNkRabcjGwJnU576b4lzqc/Ub4f8NPV7oV5TvxT8dOAXQ3wc/IFBczzZPyh+nBLOHZKnppZDfXdJ+0xK/5w6IOdpllvDcZOvhOXUu8N5pqTfT0p/m/zNsP+k5NdJaR8zFfgmpR9OfpOc79mwfVLqPdnsJ/12UvrR5CYpN3nwrwPHYYnXYVna4/BnwnGHpN8cfiz44/CPSFn62f0PBv8dkn7x8NeE7X0v+0n8H/qfUL+7nwj+PCR5YudfSFna/ZDU786PhvY/JPz928N+E98X/D4h6yek32+V/ScOy3rRowmp18QOWd/Ykbw88cehXhPihwnpnxMSB33hnBBdmNgp/eDzwe/DpfT//APBH32J/4kxOU7av/8f4h/J732Jn77Ec1/y9b3i1760/7jE3xbJTwelvsN+KX4e2xJ0bFz6T7M8KPl+vDle8s9B0fdx8de46O3Yn4X1B4+GvNecr+kHB78c7Dwi/X3sh8J5x5r+InE2Ju19QOJin7T32EuB56Dkhwea8wjP/ZJn9v9L8NOo5I/9Pxn8sr/ZfjZsH5P4PCD5eL/k9wMSpwe+NqyvngqczX4HpH33bxR70h77/ivUd5+s3ydx0+h8Je1ViF+bciV8lRxfzQV/ltJOlfi3vBjaq5LxQin+K6X/lpLPKomn8sOhPs1+qfjfC28hcbZfxkel6Pl+iddC9i+E6yFpx8ZPpfjR/05YX0jezCUOmuP2/Wpoh0r8uUN0v5D4KH48nLeQPOGlPl7iIBfeUvbPZf9c8mku9csl/guJy1L67waJl30SX4W0z5BX/F1IPBUSj0b0LJf2LuT4ptzo/27Rs0ziOpN2aMrus+G4B4TfSXtmwuXEr070JHtbsNuUrYwzMxlPZsE/41+WfumkvZ3EZ2PXynYjxz8q/cnK/lbiyArPyJdCfNnvDuc3omdG+kkq7ZJKXBpZNsc39kdFb42sN6Kje8QPjb2HZDxwh/TLVM6XyngmlTxkm+Nku5Xjrdht6tHU00j9Hpb2H9oVf26VuErF74nwptJfU/F/Iv5MJF7lyfJw2fDtlTzTLBPh3Sv+b8r3SfuPit2hv2R7KnlmVNbfL/1sj5y/GcfsEbvNcYmMI0Zlv1HJK81+e8TeY7L+MSk/KsfvluO3CtcdUr9HZLyxW5ZN+RE5bpf4d0Ts7pbyLjm+2d4sHxGeXXKenX8X+vHDsnyoWX5s7bhghxy/U867TeJ0h/h7h6xvuB4WPzXx1WzfKfbuEr6HhHsL2N0uHNvAD9uEe5vwbJPzbxfe7bL/iOw/XEq9H5Q4H5Hjt8j5HxC7zX73ic49IHG6UbbfLfnoHlneLfvdJXnvLqlHs997hOdu0fem/B6JK9zvXuG7R87X+Kk5X3OercJ5v/A346jNcnzTn2+X/d4ty00yju0F3Rn/vOjPxmeCv++Q/Pt2Oe8tYTnc745wvvFXZL9UdDVt8uI/BL5M8oOTvDDMp8E/469I/bdL+zT9rPH7fVLfpnyv1PMeqec9Up9meVfjB/Fb4487pD1uF3ubm3KzXfSrKW8W/94q13cb5bq/ud5slnId2d8Q9hv/9bC+17tloHQ3ydyajQtzF+aX6/9sHhRk5W3Lcxcunp//4LkzsuLO02fnluZOr8wvnVteOXd6+YOnzxrZtPX/2ZRY2Xjr6fmF5cXl5lwrK6frwlqA25YWn08aiHfW/zaEfDuYobOW9PT5ueWGtFm56czcylzy3FJ9fF16FQ552+LFlXOLC/VBG+68XL21B9+0BCtuv7QwIDkzevrspYUPj5q0GJzi8g7h753h/5dnD8n/B1YHJ93wv+DEW+cXPnRuYb6hPz/37Px5KbyrrvPlKicXl84trDR1qdcuJyuLK3PNfptOL55v1lyuXe/V/wNodOmLgkwCAA=="} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["sample_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1"],"name":[2],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.2"],"name":[3],"type":["chr"],"align":["left"]},{"label":["censos"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["ttcos"],"name":[5],"type":["dbl"],"align":["right"]}],"data":[{"1":"GSM50986","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=69.24 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"69.24"},{"1":"GSM50987","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=66.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"66.67"},{"1":"GSM50988","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=66.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"66.43"},{"1":"GSM50989","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=66.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"66.50"},{"1":"GSM50990","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"42.67"},{"1":"GSM50991","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=65 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"65.00"},{"1":"GSM50992","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=65.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"65.20"},{"1":"GSM50993","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=38.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"38.27"},{"1":"GSM50994","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=64.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"64.73"},{"1":"GSM50995","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=64.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"64.33"},{"1":"GSM50996","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=64.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"64.33"},{"1":"GSM50997","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"7.80"},{"1":"GSM50998","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=62.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"62.97"},{"1":"GSM50999","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=63.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"63.32"},{"1":"GSM51000","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.84 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"8.84"},{"1":"GSM51001","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=36.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"36.10"},{"1":"GSM51002","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"20.13"},{"1":"GSM51003","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=61.71 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"61.71"},{"1":"GSM51004","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"29.18"},{"1":"GSM51005","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"57.85"},{"1":"GSM51006","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"45.61"},{"1":"GSM51007","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=61.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"61.33"},{"1":"GSM51008","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"27.30"},{"1":"GSM51009","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=60.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"60.78"},{"1":"GSM51010","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"52.03"},{"1":"GSM51011","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=60.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"60.10"},{"1":"GSM51012","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"39.25"},{"1":"GSM51013","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"1.60"},{"1":"GSM51014","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"59.38"},{"1":"GSM51015","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"29.83"},{"1":"GSM51016","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=58.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"58.23"},{"1":"GSM51017","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"44.93"},{"1":"GSM51018","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"57.73"},{"1":"GSM51019","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"29.93"},{"1":"GSM51020","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"57.78"},{"1":"GSM51021","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=50.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"50.97"},{"1":"GSM51022","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=58.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"58.67"},{"1":"GSM51023","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"26.23"},{"1":"GSM51024","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"30.30"},{"1":"GSM51025","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"49.40"},{"1":"GSM51026","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"59.13"},{"1":"GSM51027","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"57.33"},{"1":"GSM51028","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.84 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"24.84"},{"1":"GSM51029","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"57.83"},{"1":"GSM51030","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"57.15"},{"1":"GSM51031","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=58.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"58.18"},{"1":"GSM51032","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.31 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"57.31"},{"1":"GSM51033","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.07"},{"1":"GSM51034","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=56.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"56.05"},{"1":"GSM51035","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"21.05"},{"1":"GSM51036","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=61.51 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"61.51"},{"1":"GSM51037","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.22 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"52.22"},{"1":"GSM51038","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"59.70"},{"1":"GSM51039","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"59.63"},{"1":"GSM51040","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=58.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"58.98"},{"1":"GSM51041","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"26.50"},{"1":"GSM51042","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=56.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"56.61"},{"1":"GSM51043","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"59.43"},{"1":"GSM51044","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=54.71 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"54.71"},{"1":"GSM51045","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"23.97"},{"1":"GSM51046","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=56.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"56.33"},{"1":"GSM51047","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=56.22 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"56.22"},{"1":"GSM51048","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"43.85"},{"1":"GSM51049","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=55.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"55.73"},{"1":"GSM51050","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"52.33"},{"1":"GSM51051","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=55.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"55.03"},{"1":"GSM51052","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"9.08"},{"1":"GSM51053","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"19.00"},{"1":"GSM51054","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=0 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"0.00"},{"1":"GSM51055","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=55.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"55.48"},{"1":"GSM51056","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"23.85"},{"1":"GSM51057","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"39.78"},{"1":"GSM51058","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=65.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"65.47"},{"1":"GSM51059","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=54.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"54.57"},{"1":"GSM51060","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=47.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"47.43"},{"1":"GSM51061","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"52.93"},{"1":"GSM51062","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=54.35 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"54.35"},{"1":"GSM51063","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=54 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"54.00"},{"1":"GSM51064","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.80"},{"1":"GSM51065","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=54.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"54.03"},{"1":"GSM51066","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.85"},{"1":"GSM51067","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.63"},{"1":"GSM51068","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.43"},{"1":"GSM51069","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.57"},{"1":"GSM51070","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"15.08"},{"1":"GSM51071","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.15"},{"1":"GSM51072","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.30"},{"1":"GSM51073","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.20"},{"1":"GSM51074","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.10"},{"1":"GSM51075","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"52.93"},{"1":"GSM51076","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"21.60"},{"1":"GSM51077","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"7.48"},{"1":"GSM51078","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"3.20"},{"1":"GSM51079","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"23.78"},{"1":"GSM51080","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"52.40"},{"1":"GSM51081","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"52.13"},{"1":"GSM51082","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=52.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"52.20"},{"1":"GSM51083","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.81 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"41.81"},{"1":"GSM51084","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=53.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"53.33"},{"1":"GSM51085","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"2.77"},{"1":"GSM51086","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"1.60"},{"1":"GSM51087","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=51.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"51.57"},{"1":"GSM51088","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.79 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"17.79"},{"1":"GSM51089","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=37.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"37.83"},{"1":"GSM51090","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=36.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"36.13"},{"1":"GSM51091","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"11.28"},{"1":"GSM51092","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=51.65 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"51.65"},{"1":"GSM51093","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.78"},{"1":"GSM51094","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=51.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"51.28"},{"1":"GSM51095","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=46.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"46.37"},{"1":"GSM51096","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=50.94 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"50.94"},{"1":"GSM51097","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=50.75 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"50.75"},{"1":"GSM51098","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=50.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"50.63"},{"1":"GSM51099","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"14.77"},{"1":"GSM51100","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=50.01 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"50.01"},{"1":"GSM51101","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"49.23"},{"1":"GSM51102","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"49.61"},{"1":"GSM51103","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.55 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"49.55"},{"1":"GSM51104","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"49.38"},{"1":"GSM51105","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=48.21 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"48.21"},{"1":"GSM51106","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"49.00"},{"1":"GSM51107","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=48.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"48.87"},{"1":"GSM51108","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=48.21 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"48.21"},{"1":"GSM51109","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=47.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"47.80"},{"1":"GSM51110","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=47.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"47.27"},{"1":"GSM51111","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=47.21 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"47.21"},{"1":"GSM51112","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=46.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"46.98"},{"1":"GSM51113","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"1.93"},{"1":"GSM51114","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=46.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"46.67"},{"1":"GSM51115","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"31.90"},{"1":"GSM51116","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.04 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"33.04"},{"1":"GSM51117","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"15.63"},{"1":"GSM51118","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=46.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"46.32"},{"1":"GSM51119","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=46.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"46.38"},{"1":"GSM51120","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"39.40"},{"1":"GSM51121","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"45.95"},{"1":"GSM51122","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"3.50"},{"1":"GSM51123","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"10.73"},{"1":"GSM51124","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"45.43"},{"1":"GSM51125","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"45.43"},{"1":"GSM51126","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"45.43"},{"1":"GSM51127","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"45.17"},{"1":"GSM51128","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=45.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"45.23"},{"1":"GSM51129","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"20.73"},{"1":"GSM51130","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.97"},{"1":"GSM51131","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.97"},{"1":"GSM51132","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"14.33"},{"1":"GSM51133","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.80"},{"1":"GSM51134","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.55 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.55"},{"1":"GSM51135","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"19.63"},{"1":"GSM51136","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=46.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"46.57"},{"1":"GSM51137","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.20"},{"1":"GSM51138","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.02"},{"1":"GSM51139","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=44.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"44.20"},{"1":"GSM51140","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.97"},{"1":"GSM51141","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.80"},{"1":"GSM51142","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.49 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.49"},{"1":"GSM51143","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.54 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.54"},{"1":"GSM51144","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.37"},{"1":"GSM51145","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"28.67"},{"1":"GSM51146","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"30.57"},{"1":"GSM51147","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.50"},{"1":"GSM51148","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=43.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"43.17"},{"1":"GSM51149","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.84 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"9.84"},{"1":"GSM51150","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"42.90"},{"1":"GSM51151","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"12.27"},{"1":"GSM51152","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.51 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.51"},{"1":"GSM51153","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"42.47"},{"1":"GSM51154","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"42.47"},{"1":"GSM51155","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"42.17"},{"1":"GSM51156","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.92 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.92"},{"1":"GSM51157","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.12 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"42.12"},{"1":"GSM51158","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"42.18"},{"1":"GSM51159","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.73"},{"1":"GSM51160","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.47"},{"1":"GSM51161","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.25"},{"1":"GSM51162","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.27"},{"1":"GSM51163","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"17.27"},{"1":"GSM51164","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=41.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"41.03"},{"1":"GSM51165","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.83"},{"1":"GSM51166","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.77"},{"1":"GSM51167","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.57"},{"1":"GSM51168","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.54 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.54"},{"1":"GSM51169","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.33"},{"1":"GSM51170","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.03"},{"1":"GSM51171","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.08"},{"1":"GSM51172","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=40.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"40.10"},{"1":"GSM51173","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.67"},{"1":"GSM51174","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.58"},{"1":"GSM51175","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.67"},{"1":"GSM51176","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.43"},{"1":"GSM51177","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.53"},{"1":"GSM51178","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=36.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"36.93"},{"1":"GSM51179","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=38.34 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"38.34"},{"1":"GSM51180","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.18"},{"1":"GSM51181","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=39.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"39.30"},{"1":"GSM51182","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"7.03"},{"1":"GSM51183","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=37.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"37.33"},{"1":"GSM51184","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"10.67"},{"1":"GSM51185","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=32.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"32.43"},{"1":"GSM51186","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=38.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"38.13"},{"1":"GSM51187","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=37.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"37.98"},{"1":"GSM51188","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.83"},{"1":"GSM51189","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=37.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"37.70"},{"1":"GSM51190","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"11.41"},{"1":"GSM51191","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=37.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"37.23"},{"1":"GSM51192","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=37.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"37.03"},{"1":"GSM51193","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"4.87"},{"1":"GSM51194","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=36.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"36.03"},{"1":"GSM51195","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=32.14 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"32.14"},{"1":"GSM51196","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.11 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.11"},{"1":"GSM51197","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.03"},{"1":"GSM51198","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.15"},{"1":"GSM51199","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.37"},{"1":"GSM51200","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.53"},{"1":"GSM51201","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.50"},{"1":"GSM51202","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.67"},{"1":"GSM51203","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.28"},{"1":"GSM51204","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.14 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.14"},{"1":"GSM51205","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.13"},{"1":"GSM51206","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.59 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.59"},{"1":"GSM51207","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.58"},{"1":"GSM51208","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.65 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.65"},{"1":"GSM51209","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"35.37"},{"1":"GSM51210","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.70"},{"1":"GSM51211","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.23"},{"1":"GSM51212","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.30"},{"1":"GSM51213","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.77"},{"1":"GSM51214","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.77"},{"1":"GSM51215","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.57"},{"1":"GSM51216","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"21.37"},{"1":"GSM51217","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.95"},{"1":"GSM51218","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.48"},{"1":"GSM51219","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=34.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"34.17"},{"1":"GSM51220","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.93"},{"1":"GSM51221","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.07"},{"1":"GSM51222","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=32.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"32.90"},{"1":"GSM51223","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=32.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"32.80"},{"1":"GSM51224","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=32.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"32.61"},{"1":"GSM51225","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"6.53"},{"1":"GSM51226","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=33.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"33.27"},{"1":"GSM51227","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.50"},{"1":"GSM51228","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.05"},{"1":"GSM51229","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.48"},{"1":"GSM51230","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.90"},{"1":"GSM51231","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=32.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"32.13"},{"1":"GSM51232","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.08 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.08"},{"1":"GSM51233","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.73"},{"1":"GSM51234","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.73"},{"1":"GSM51235","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.97"},{"1":"GSM51236","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.20"},{"1":"GSM51237","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.89 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.89"},{"1":"GSM51238","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.31 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.31"},{"1":"GSM51239","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.25"},{"1":"GSM51240","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=31.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"31.13"},{"1":"GSM51241","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.81 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.81"},{"1":"GSM51242","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.28"},{"1":"GSM51243","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.48"},{"1":"GSM51244","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.50"},{"1":"GSM51245","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.95"},{"1":"GSM51246","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"11.85"},{"1":"GSM51247","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.58"},{"1":"GSM51248","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.57"},{"1":"GSM51249","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.05"},{"1":"GSM51250","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.32"},{"1":"GSM51251","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.34 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"28.34"},{"1":"GSM51252","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.82 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.82"},{"1":"GSM51253","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.72 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.72"},{"1":"GSM51254","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.00"},{"1":"GSM51255","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"7.32"},{"1":"GSM51256","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=30.31 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"30.31"},{"1":"GSM51257","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"7.13"},{"1":"GSM51258","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.91 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.91"},{"1":"GSM51259","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"14.73"},{"1":"GSM51260","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.62 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.62"},{"1":"GSM51261","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.52 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.52"},{"1":"GSM51262","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.41"},{"1":"GSM51263","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=29.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"29.17"},{"1":"GSM51264","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"28.60"},{"1":"GSM51265","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.92 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.92"},{"1":"GSM51266","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.65 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"28.65"},{"1":"GSM51267","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.35 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"28.35"},{"1":"GSM51268","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"25.33"},{"1":"GSM51269","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"28.60"},{"1":"GSM51270","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"28.85"},{"1":"GSM51271","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.02"},{"1":"GSM51272","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.45 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.45"},{"1":"GSM51273","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.98"},{"1":"GSM51274","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.02"},{"1":"GSM51275","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.07"},{"1":"GSM51276","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.23"},{"1":"GSM51277","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.40"},{"1":"GSM51278","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"22.97"},{"1":"GSM51279","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.40"},{"1":"GSM51280","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.62 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.62"},{"1":"GSM51281","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.98"},{"1":"GSM51282","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.38"},{"1":"GSM51283","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.90"},{"1":"GSM51284","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.13"},{"1":"GSM51285","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.44 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.44"},{"1":"GSM51286","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.30"},{"1":"GSM51287","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.58"},{"1":"GSM51288","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.27"},{"1":"GSM51289","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.63"},{"1":"GSM51290","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.37"},{"1":"GSM51291","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.42 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.42"},{"1":"GSM51292","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.58"},{"1":"GSM51293","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"16.95"},{"1":"GSM51294","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.45 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"23.45"},{"1":"GSM51295","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.24 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.24"},{"1":"GSM51296","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.18 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.18"},{"1":"GSM51297","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.11 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.11"},{"1":"GSM51298","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.15"},{"1":"GSM51299","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.95 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.95"},{"1":"GSM51300","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.98"},{"1":"GSM51301","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"10.25"},{"1":"GSM51302","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=27.92 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"27.92"},{"1":"GSM51303","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.41"},{"1":"GSM51304","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.75 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"23.75"},{"1":"GSM51305","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.01 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.01"},{"1":"GSM51306","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.81 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.81"},{"1":"GSM51307","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.98 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.98"},{"1":"GSM51308","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.71 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.71"},{"1":"GSM51309","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=25.35 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"25.35"},{"1":"GSM51310","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"9.87"},{"1":"GSM51311","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.48"},{"1":"GSM51312","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.61"},{"1":"GSM51313","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.59 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.59"},{"1":"GSM51314","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"23.27"},{"1":"GSM51315","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.32 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"23.32"},{"1":"GSM51316","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.45 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.45"},{"1":"GSM51317","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.48 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.48"},{"1":"GSM51318","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.61 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.61"},{"1":"GSM51319","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.68 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.68"},{"1":"GSM51320","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.58"},{"1":"GSM51321","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.12 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.12"},{"1":"GSM51322","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.25"},{"1":"GSM51323","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.14 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"24.14"},{"1":"GSM51324","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.25 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"2.25"},{"1":"GSM51325","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=26.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"26.05"},{"1":"GSM51326","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.02 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.02"},{"1":"GSM51327","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.01 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.01"},{"1":"GSM51328","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.38"},{"1":"GSM51329","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.28 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.28"},{"1":"GSM51330","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.57"},{"1":"GSM51331","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.88 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"17.88"},{"1":"GSM51332","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.85"},{"1":"GSM51333","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=22.05 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"22.05"},{"1":"GSM51334","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"21.85"},{"1":"GSM51335","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=23.78 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"23.78"},{"1":"GSM51336","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.58 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"12.58"},{"1":"GSM95646","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.70"},{"1":"GSM95647","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.63"},{"1":"GSM95648","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.70"},{"1":"GSM95649","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.80"},{"1":"GSM95650","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"7.37"},{"1":"GSM95651","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.13"},{"1":"GSM95652","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.00"},{"1":"GSM95653","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.50"},{"1":"GSM95654","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.77"},{"1":"GSM95655","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.03"},{"1":"GSM95656","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.77"},{"1":"GSM95657","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.83"},{"1":"GSM95658","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.93"},{"1":"GSM95659","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.27"},{"1":"GSM95660","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"1.20"},{"1":"GSM95661","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.37"},{"1":"GSM95662","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.60"},{"1":"GSM95663","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.00"},{"1":"GSM95664","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.20"},{"1":"GSM95665","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.83"},{"1":"GSM95666","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=13.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"13.17"},{"1":"GSM95667","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.37"},{"1":"GSM95668","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.30"},{"1":"GSM95669","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.13"},{"1":"GSM95670","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"8.47"},{"1":"GSM95671","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.53"},{"1":"GSM95672","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.67"},{"1":"GSM95673","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.17"},{"1":"GSM95674","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.27"},{"1":"GSM95675","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.90"},{"1":"GSM95676","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.90"},{"1":"GSM95677","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.13"},{"1":"GSM95678","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=13.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"13.17"},{"1":"GSM95679","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"14.83"},{"1":"GSM95680","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.13"},{"1":"GSM95681","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.10"},{"1":"GSM95682","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.40"},{"1":"GSM95683","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.17"},{"1":"GSM95684","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.13"},{"1":"GSM95685","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"4.63"},{"1":"GSM95686","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.67"},{"1":"GSM95687","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.47"},{"1":"GSM95688","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.73"},{"1":"GSM95689","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.80"},{"1":"GSM95690","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.67"},{"1":"GSM95691","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.17"},{"1":"GSM95692","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.10"},{"1":"GSM95693","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"18.30"},{"1":"GSM95694","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.83"},{"1":"GSM95695","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=17.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"17.37"},{"1":"GSM95696","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"10.57"},{"1":"GSM95697","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.67"},{"1":"GSM95698","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.77"},{"1":"GSM95699","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.33"},{"1":"GSM95700","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.50"},{"1":"GSM95701","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.33"},{"1":"GSM95702","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.07"},{"1":"GSM95703","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.03"},{"1":"GSM95704","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.30"},{"1":"GSM95705","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.37"},{"1":"GSM95706","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.50"},{"1":"GSM95707","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.50"},{"1":"GSM95708","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.73"},{"1":"GSM95709","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.73"},{"1":"GSM95710","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.73"},{"1":"GSM95711","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.40"},{"1":"GSM95712","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.60"},{"1":"GSM95713","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.40"},{"1":"GSM95714","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"6.87"},{"1":"GSM95715","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.80"},{"1":"GSM95716","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=13.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"13.17"},{"1":"GSM95717","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.90"},{"1":"GSM95718","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.33"},{"1":"GSM95719","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.67"},{"1":"GSM95720","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"7.23"},{"1":"GSM95721","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.37"},{"1":"GSM95722","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.33"},{"1":"GSM95723","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.10"},{"1":"GSM95724","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.90"},{"1":"GSM95725","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=15.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"15.27"},{"1":"GSM95726","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.87"},{"1":"GSM95727","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.70"},{"1":"GSM95728","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.10"},{"1":"GSM95729","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=14.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"14.17"},{"1":"GSM95730","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=13.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"13.70"},{"1":"GSM95731","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=13.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"13.67"},{"1":"GSM95732","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=13.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"13.40"},{"1":"GSM95733","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.77"},{"1":"GSM95734","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.40"},{"1":"GSM95735","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"4.50"},{"1":"GSM95736","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.53"},{"1":"GSM95737","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.53"},{"1":"GSM95738","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.53"},{"1":"GSM95739","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.90"},{"1":"GSM95740","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.07"},{"1":"GSM95741","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"8.20"},{"1":"GSM95742","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.57"},{"1":"GSM95743","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.00"},{"1":"GSM95744","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.07"},{"1":"GSM95745","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.07"},{"1":"GSM95746","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.60"},{"1":"GSM95747","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=12.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"12.30"},{"1":"GSM95748","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.43"},{"1":"GSM95749","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.93"},{"1":"GSM95750","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.43"},{"1":"GSM95751","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.27"},{"1":"GSM95752","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.67"},{"1":"GSM95753","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.57"},{"1":"GSM95754","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.40"},{"1":"GSM95755","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.97"},{"1":"GSM95756","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.73"},{"1":"GSM95757","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.90"},{"1":"GSM95758","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.90"},{"1":"GSM95759","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.83"},{"1":"GSM95760","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.13"},{"1":"GSM95761","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.90"},{"1":"GSM95762","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.17"},{"1":"GSM95763","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.50"},{"1":"GSM95764","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=10.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"10.20"},{"1":"GSM95765","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.20"},{"1":"GSM95766","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.97"},{"1":"GSM95767","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.43 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.43"},{"1":"GSM95768","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.50"},{"1":"GSM95769","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"11.53"},{"1":"GSM95770","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.80"},{"1":"GSM95771","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.57"},{"1":"GSM95772","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.73"},{"1":"GSM95773","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.27 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.27"},{"1":"GSM95774","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.00"},{"1":"GSM95775","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.03"},{"1":"GSM95776","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.03"},{"1":"GSM95777","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.10"},{"1":"GSM95778","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"7.63"},{"1":"GSM95779","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.07 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.07"},{"1":"GSM95780","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"1","5":"5.10"},{"1":"GSM95781","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"7.40"},{"1":"GSM95782","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=8.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"8.10"},{"1":"GSM95783","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.93"},{"1":"GSM95784","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"7.33"},{"1":"GSM95785","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.70"},{"1":"GSM95786","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.97"},{"1":"GSM95787","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.47"},{"1":"GSM95788","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.93"},{"1":"GSM95789","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.53"},{"1":"GSM95790","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.70"},{"1":"GSM95791","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.97"},{"1":"GSM95792","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.00"},{"1":"GSM95793","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.77"},{"1":"GSM95794","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.00"},{"1":"GSM95795","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.23"},{"1":"GSM95796","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.97"},{"1":"GSM95797","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.00"},{"1":"GSM95798","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.63"},{"1":"GSM95799","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.40"},{"1":"GSM95800","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.50"},{"1":"GSM95801","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.47"},{"1":"GSM95802","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.53"},{"1":"GSM95803","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.30"},{"1":"GSM95804","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"7.10"},{"1":"GSM95805","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.37"},{"1":"GSM95806","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.13 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.13"},{"1":"GSM95807","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.63 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.63"},{"1":"GSM95808","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.30"},{"1":"GSM95809","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"3.90"},{"1":"GSM95810","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"3.37"},{"1":"GSM95811","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.03"},{"1":"GSM95812","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=0.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"0.57"},{"1":"GSM95813","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.67"},{"1":"GSM95814","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.57"},{"1":"GSM95815","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"3.00"},{"1":"GSM95816","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.5 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.50"},{"1":"GSM95817","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=0.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"0.57"},{"1":"GSM95818","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.60"},{"1":"GSM95819","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"1.33"},{"1":"GSM95820","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.23"},{"1":"GSM95821","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=16.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"16.93"},{"1":"GSM95822","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.87 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.87"},{"1":"GSM95823","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.17"},{"1":"GSM95824","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.30"},{"1":"GSM95825","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"20.03"},{"1":"GSM95826","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=19.8 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"19.80"},{"1":"GSM102606","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"1.37"},{"1":"GSM102607","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"9.03"},{"1":"GSM102609","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=7.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"7.23"},{"1":"GSM102610","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.93"},{"1":"GSM102611","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.97 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.97"},{"1":"GSM102612","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.93 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.93"},{"1":"GSM102613","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.60"},{"1":"GSM102614","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.37"},{"1":"GSM102615","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.30"},{"1":"GSM102616","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=6.3 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"6.30"},{"1":"GSM102617","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.60"},{"1":"GSM102618","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.4 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.40"},{"1":"GSM102620","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=5.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"5.37"},{"1":"GSM102621","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.70"},{"1":"GSM102622","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.47 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.47"},{"1":"GSM102623","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.20"},{"1":"GSM102624","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.37"},{"1":"GSM102625","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.67"},{"1":"GSM102626","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.37 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.37"},{"1":"GSM102627","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.03 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"4.03"},{"1":"GSM102628","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.83 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.83"},{"1":"GSM102629","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.73"},{"1":"GSM102630","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"3.20"},{"1":"GSM102631","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=3.2 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"3.20"},{"1":"GSM102632","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.77 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.77"},{"1":"GSM102633","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=2.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"2.33"},{"1":"GSM102634","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=0.1 (Follow-up time in months from Pre-Treatment baseline; integer)]","4":"0","5":"0.10"}],"options":{"columns":{"min":{},"max":[10],"total":[5]},"rows":{"min":[10],"max":[10],"total":[559]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuc2V0LnNlZWQoNDgzMSlcbmdzZTI2NThfc3VydmRfdGVzdCA8LSBnc2UyNjU4X3N1cnZkICU+JSBcbiAgc2xpY2Vfc2FtcGxlKG49MjApICU+JSBcbiAgc2VsZWN0KHNhbXBsZV9pZCwgY2Vuc29zLCB0dGNvcylcbmdzZTI2NThfc3VydmRfdGVzdCAlPiUgYXJyYW5nZShzYW1wbGVfaWQpXG5gYGAifQ== -->
<pre class="r"><code>set.seed(4831)
gse2658_survd_test &lt;- gse2658_survd %&gt;% 
  slice_sample(n=20) %&gt;% 
  select(sample_id, censos, ttcos)
gse2658_survd_test %&gt;% arrange(sample_id)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["sample_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["censos"],"name":[2],"type":["dbl"],"align":["right"]},{"label":["ttcos"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"GSM50996","2":"0","3":"64.33"},{"1":"GSM51007","2":"0","3":"61.33"},{"1":"GSM51014","2":"0","3":"59.38"},{"1":"GSM51030","2":"0","3":"57.15"},{"1":"GSM51038","2":"0","3":"59.70"},{"1":"GSM51059","2":"0","3":"54.57"},{"1":"GSM51101","2":"0","3":"49.23"},{"1":"GSM51103","2":"0","3":"49.55"},{"1":"GSM51155","2":"0","3":"42.17"},{"1":"GSM51190","2":"1","3":"11.41"},{"1":"GSM51202","2":"0","3":"35.67"},{"1":"GSM51264","2":"0","3":"28.60"},{"1":"GSM51291","2":"0","3":"24.42"},{"1":"GSM51332","2":"0","3":"21.85"},{"1":"GSM95671","2":"0","3":"18.53"},{"1":"GSM95756","2":"0","3":"9.73"},{"1":"GSM95757","2":"0","3":"9.90"},{"1":"GSM95814","2":"0","3":"4.57"},{"1":"GSM95819","2":"0","3":"1.33"},{"1":"GSM95823","2":"0","3":"20.17"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[20]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9wZGF0YSAlPiUgXG4gIGZpbHRlcihnZW9fYWNjZXNzaW9uICVpbiUgZ3NlMjY1OF9zdXJ2ZF90ZXN0JHNhbXBsZV9pZCkgJT4lIFxuICBzZWxlY3QoZ2VvX2FjY2Vzc2lvbiwgY2hhcmFjdGVyaXN0aWNzX2NoMSwgY2hhcmFjdGVyaXN0aWNzX2NoMS4yKSAlPiUgXG4gIGFycmFuZ2UoZ2VvX2FjY2Vzc2lvbilcbmBgYCJ9 -->
<pre class="r"><code>gse2658_pdata %&gt;% 
  filter(geo_accession %in% gse2658_survd_test$sample_id) %&gt;% 
  select(geo_accession, characteristics_ch1, characteristics_ch1.2) %&gt;% 
  arrange(geo_accession)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":[""],"name":["_rn_"],"type":[""],"align":["left"]},{"label":["geo_accession"],"name":[1],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1"],"name":[2],"type":["chr"],"align":["left"]},{"label":["characteristics_ch1.2"],"name":[3],"type":["chr"],"align":["left"]}],"data":[{"1":"GSM50996","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=64.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM50996"},{"1":"GSM51007","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=61.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51007"},{"1":"GSM51014","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.38 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51014"},{"1":"GSM51030","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=57.15 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51030"},{"1":"GSM51038","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=59.7 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51038"},{"1":"GSM51059","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=54.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51059"},{"1":"GSM51101","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.23 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51101"},{"1":"GSM51103","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=49.55 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51103"},{"1":"GSM51155","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=42.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51155"},{"1":"GSM51190","2":"[SURIND=1 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=11.41 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51190"},{"1":"GSM51202","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=35.67 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51202"},{"1":"GSM51264","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=28.6 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51264"},{"1":"GSM51291","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=24.42 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51291"},{"1":"GSM51332","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=21.85 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM51332"},{"1":"GSM95671","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=18.53 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM95671"},{"1":"GSM95756","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.73 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM95756"},{"1":"GSM95757","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=9.9 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM95757"},{"1":"GSM95814","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=4.57 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM95814"},{"1":"GSM95819","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=1.33 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM95819"},{"1":"GSM95823","2":"[SURIND=0 (Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)]","3":"[SURTIM=20.17 (Follow-up time in months from Pre-Treatment baseline; integer)]","_rn_":"GSM95823"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[20]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>seems legit.</p>
<p>join survival data with expression data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19zdXJ2ZCA8LSBsZWZ0X2pvaW4oZ3NlMjY1OF9leHByc19hZGpfY21wbHQsIFxuICAgICAgICAgIGdzZTI2NThfc3VydmQgJT4lIHNlbGVjdChzYW1wbGVfaWQsIGNlbnNvcywgdHRjb3MpLCBcbiAgICAgICAgICBieT1cInNhbXBsZV9pZFwiKVxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_survd &lt;- left_join(gse2658_exprs_adj_cmplt, 
          gse2658_survd %&gt;% select(sample_id, censos, ttcos), 
          by=&quot;sample_id&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>write out version with CoMMpass means in for missing genes</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuIyB3cml0ZV9jc3YoZ3NlMjY1OF9leHByc19zdXJ2ZCwgXCJnc2UyNjU4X2Fkal9leHByZXNzaW9uX3N1cnZpdmFsX2RhdGFfMjAyMjA1MDUuY3N2XCIpXG5gYGAifQ== -->
<pre class="r"><code># write_csv(gse2658_exprs_survd, &quot;gse2658_adj_expression_survival_data_20220505.csv&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
</div>
</div>
<div id="version-with-zeros" class="section level2">
<h2>version with zeros</h2>
<p>also need a version with zeros for expression values<br />
will use it to center on GSE2658 data (instead of CoMMpass data)</p>
<p><code>gse2658_exprs_adj</code> is the adjusted expression but before adding in mean values from CoMMpass</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["gene_expr"],"name":[3],"type":["dbl"],"align":["right"]},{"label":["length"],"name":[4],"type":["dbl"],"align":["right"]},{"label":["cpk"],"name":[5],"type":["dbl"],"align":["right"]},{"label":["szfctr"],"name":[6],"type":["dbl"],"align":["right"]},{"label":["adjlogcpkmed"],"name":[7],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000000419","2":"GSM102606","3":"7510.6","4":"6823","5":"1.1007768","6":"0.1298867","7":"3.083196"},{"1":"ENSG00000000419","2":"GSM102607","3":"5238.3","4":"6823","5":"0.7677414","6":"0.1295350","7":"2.567279"},{"1":"ENSG00000000419","2":"GSM102609","3":"5572.0","4":"6823","5":"0.8166496","6":"0.1282204","7":"2.671092"},{"1":"ENSG00000000419","2":"GSM102610","3":"3834.4","4":"6823","5":"0.5619815","6":"0.1296156","7":"2.116283"},{"1":"ENSG00000000419","2":"GSM102611","3":"4012.9","4":"6823","5":"0.5881430","6":"0.1312720","7":"2.163607"},{"1":"ENSG00000000419","2":"GSM102612","3":"3970.1","4":"6823","5":"0.5818702","6":"0.1273731","7":"2.191636"},{"1":"ENSG00000000419","2":"GSM102613","3":"4203.8","4":"6823","5":"0.6161219","6":"0.1315984","7":"2.227074"},{"1":"ENSG00000000419","2":"GSM102614","3":"3476.8","4":"6823","5":"0.5095706","6":"0.1268223","7":"2.006474"},{"1":"ENSG00000000419","2":"GSM102615","3":"4353.5","4":"6823","5":"0.6380624","6":"0.1379798","7":"2.209241"},{"1":"ENSG00000000419","2":"GSM102616","3":"3341.4","4":"6823","5":"0.4897259","6":"0.1296920","7":"1.916885"}],"options":{"columns":{"min":{},"max":[10],"total":[7]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>genes:</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGogJT4lIGRpc3RpbmN0KGdlbmVfaWQpICU+JSBkaW0oKVxuXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_adj %&gt;% distinct(gene_id) %&gt;% dim()
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDczNjcgICAgMVxuIn0= -->
<pre><code>[1] 7367    1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>makes sense 7449-82=7367</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGogJT4lIHVuZ3JvdXAoKSAlPiUgZGlzdGluY3Qoc2FtcGxlX2lkKSAlPiUgZGltKClcblxuYGBgIn0= -->
<pre class="r"><code>gse2658_exprs_adj %&gt;% ungroup() %&gt;% distinct(sample_id) %&gt;% dim()
</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiWzFdIDU1OSAgIDFcbiJ9 -->
<pre><code>[1] 559   1</code></pre>
<!-- rnb-output-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>OK</p>
<p>put in zero for genes that are missing from the microarray data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>put it all back together</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGpfd3plcm9zIDwtIFxuICBiaW5kX3Jvd3MoZ3NlMjY1OF9leHByc19hZGogJT4lIHNlbGVjdChnZW5lX2lkLCBzYW1wbGVfaWQsIGFkamxvZ2Nwa21lZCksIFxuICAgICAgICAgICAgcmVzdWx0c193eilcbmhlYWQoZ3NlMjY1OF9leHByc19hZGpfd3plcm9zLCAxMClcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_adj_wzeros &lt;- 
  bind_rows(gse2658_exprs_adj %&gt;% select(gene_id, sample_id, adjlogcpkmed), 
            results_wz)
head(gse2658_exprs_adj_wzeros, 10)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["adjlogcpkmed"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000000419","2":"GSM102606","3":"3.083196"},{"1":"ENSG00000000419","2":"GSM102607","3":"2.567279"},{"1":"ENSG00000000419","2":"GSM102609","3":"2.671092"},{"1":"ENSG00000000419","2":"GSM102610","3":"2.116283"},{"1":"ENSG00000000419","2":"GSM102611","3":"2.163607"},{"1":"ENSG00000000419","2":"GSM102612","3":"2.191636"},{"1":"ENSG00000000419","2":"GSM102613","3":"2.227074"},{"1":"ENSG00000000419","2":"GSM102614","3":"2.006474"},{"1":"ENSG00000000419","2":"GSM102615","3":"2.209241"},{"1":"ENSG00000000419","2":"GSM102616","3":"1.916885"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[10]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>still need to deal with NAs</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-frame-begin 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 -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["adjlogcpkmed"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000073060","2":"GSM95646","3":"NA"},{"1":"ENSG00000073060","2":"GSM95647","3":"NA"},{"1":"ENSG00000073060","2":"GSM95648","3":"NA"},{"1":"ENSG00000073060","2":"GSM95649","3":"NA"},{"1":"ENSG00000073060","2":"GSM95650","3":"NA"},{"1":"ENSG00000073060","2":"GSM95651","3":"NA"},{"1":"ENSG00000073060","2":"GSM95652","3":"NA"},{"1":"ENSG00000073060","2":"GSM95653","3":"NA"},{"1":"ENSG00000073060","2":"GSM95654","3":"NA"},{"1":"ENSG00000073060","2":"GSM95655","3":"NA"},{"1":"ENSG00000073060","2":"GSM95656","3":"NA"},{"1":"ENSG00000073060","2":"GSM95657","3":"NA"},{"1":"ENSG00000073060","2":"GSM95658","3":"NA"},{"1":"ENSG00000073060","2":"GSM95659","3":"NA"},{"1":"ENSG00000073060","2":"GSM95660","3":"NA"},{"1":"ENSG00000073060","2":"GSM95661","3":"NA"},{"1":"ENSG00000073060","2":"GSM95662","3":"NA"},{"1":"ENSG00000073060","2":"GSM95663","3":"NA"},{"1":"ENSG00000073060","2":"GSM95664","3":"NA"},{"1":"ENSG00000073060","2":"GSM95665","3":"NA"},{"1":"ENSG00000073060","2":"GSM95666","3":"NA"},{"1":"ENSG00000073060","2":"GSM95667","3":"NA"},{"1":"ENSG00000073060","2":"GSM95668","3":"NA"},{"1":"ENSG00000073060","2":"GSM95669","3":"NA"},{"1":"ENSG00000073060","2":"GSM95670","3":"NA"},{"1":"ENSG00000073060","2":"GSM95671","3":"NA"},{"1":"ENSG00000073060","2":"GSM95672","3":"NA"},{"1":"ENSG00000073060","2":"GSM95673","3":"NA"},{"1":"ENSG00000073060","2":"GSM95674","3":"NA"},{"1":"ENSG00000073060","2":"GSM95675","3":"NA"},{"1":"ENSG00000073060","2":"GSM95676","3":"NA"},{"1":"ENSG00000073060","2":"GSM95677","3":"NA"},{"1":"ENSG00000073060","2":"GSM95678","3":"NA"},{"1":"ENSG00000073060","2":"GSM95679","3":"NA"},{"1":"ENSG00000073060","2":"GSM95680","3":"NA"},{"1":"ENSG00000073060","2":"GSM95681","3":"NA"},{"1":"ENSG00000073060","2":"GSM95682","3":"NA"},{"1":"ENSG00000073060","2":"GSM95683","3":"NA"},{"1":"ENSG00000073060","2":"GSM95684","3":"NA"},{"1":"ENSG00000073060","2":"GSM95685","3":"NA"},{"1":"ENSG00000073060","2":"GSM95686","3":"NA"},{"1":"ENSG00000073060","2":"GSM95687","3":"NA"},{"1":"ENSG00000073060","2":"GSM95688","3":"NA"},{"1":"ENSG00000073060","2":"GSM95689","3":"NA"},{"1":"ENSG00000073060","2":"GSM95690","3":"NA"},{"1":"ENSG00000073060","2":"GSM95691","3":"NA"},{"1":"ENSG00000073060","2":"GSM95692","3":"NA"},{"1":"ENSG00000073060","2":"GSM95693","3":"NA"},{"1":"ENSG00000073060","2":"GSM95694","3":"NA"},{"1":"ENSG00000073060","2":"GSM95695","3":"NA"},{"1":"ENSG00000073060","2":"GSM95696","3":"NA"},{"1":"ENSG00000073060","2":"GSM95697","3":"NA"},{"1":"ENSG00000073060","2":"GSM95698","3":"NA"},{"1":"ENSG00000073060","2":"GSM95699","3":"NA"},{"1":"ENSG00000073060","2":"GSM95700","3":"NA"},{"1":"ENSG00000073060","2":"GSM95701","3":"NA"},{"1":"ENSG00000073060","2":"GSM95702","3":"NA"},{"1":"ENSG00000073060","2":"GSM95703","3":"NA"},{"1":"ENSG00000073060","2":"GSM95704","3":"NA"},{"1":"ENSG00000073060","2":"GSM95705","3":"NA"},{"1":"ENSG00000073060","2":"GSM95706","3":"NA"},{"1":"ENSG00000073060","2":"GSM95707","3":"NA"},{"1":"ENSG00000073060","2":"GSM95708","3":"NA"},{"1":"ENSG00000073060","2":"GSM95709","3":"NA"},{"1":"ENSG00000073060","2":"GSM95710","3":"NA"},{"1":"ENSG00000073060","2":"GSM95711","3":"NA"},{"1":"ENSG00000073060","2":"GSM95712","3":"NA"},{"1":"ENSG00000073060","2":"GSM95713","3":"NA"},{"1":"ENSG00000073060","2":"GSM95714","3":"NA"},{"1":"ENSG00000073060","2":"GSM95715","3":"NA"},{"1":"ENSG00000073060","2":"GSM95716","3":"NA"},{"1":"ENSG00000073060","2":"GSM95717","3":"NA"},{"1":"ENSG00000073060","2":"GSM95718","3":"NA"},{"1":"ENSG00000073060","2":"GSM95719","3":"NA"},{"1":"ENSG00000073060","2":"GSM95720","3":"NA"},{"1":"ENSG00000073060","2":"GSM95721","3":"NA"},{"1":"ENSG00000073060","2":"GSM95722","3":"NA"},{"1":"ENSG00000073060","2":"GSM95723","3":"NA"},{"1":"ENSG00000073060","2":"GSM95724","3":"NA"},{"1":"ENSG00000073060","2":"GSM95725","3":"NA"},{"1":"ENSG00000073060","2":"GSM95726","3":"NA"},{"1":"ENSG00000073060","2":"GSM95727","3":"NA"},{"1":"ENSG00000073060","2":"GSM95728","3":"NA"},{"1":"ENSG00000073060","2":"GSM95729","3":"NA"},{"1":"ENSG00000073060","2":"GSM95730","3":"NA"},{"1":"ENSG00000073060","2":"GSM95731","3":"NA"},{"1":"ENSG00000073060","2":"GSM95732","3":"NA"},{"1":"ENSG00000073060","2":"GSM95733","3":"NA"},{"1":"ENSG00000073060","2":"GSM95734","3":"NA"},{"1":"ENSG00000073060","2":"GSM95735","3":"NA"},{"1":"ENSG00000073060","2":"GSM95736","3":"NA"},{"1":"ENSG00000073060","2":"GSM95737","3":"NA"},{"1":"ENSG00000073060","2":"GSM95738","3":"NA"},{"1":"ENSG00000073060","2":"GSM95739","3":"NA"},{"1":"ENSG00000073060","2":"GSM95740","3":"NA"},{"1":"ENSG00000073060","2":"GSM95741","3":"NA"},{"1":"ENSG00000073060","2":"GSM95742","3":"NA"},{"1":"ENSG00000073060","2":"GSM95743","3":"NA"},{"1":"ENSG00000073060","2":"GSM95744","3":"NA"},{"1":"ENSG00000073060","2":"GSM95745","3":"NA"},{"1":"ENSG00000073060","2":"GSM95746","3":"NA"},{"1":"ENSG00000073060","2":"GSM95747","3":"NA"},{"1":"ENSG00000073060","2":"GSM95748","3":"NA"},{"1":"ENSG00000073060","2":"GSM95749","3":"NA"},{"1":"ENSG00000073060","2":"GSM95750","3":"NA"},{"1":"ENSG00000073060","2":"GSM95751","3":"NA"},{"1":"ENSG00000073060","2":"GSM95752","3":"NA"},{"1":"ENSG00000073060","2":"GSM95753","3":"NA"},{"1":"ENSG00000073060","2":"GSM95754","3":"NA"},{"1":"ENSG00000073060","2":"GSM95755","3":"NA"},{"1":"ENSG00000073060","2":"GSM95756","3":"NA"},{"1":"ENSG00000073060","2":"GSM95757","3":"NA"},{"1":"ENSG00000073060","2":"GSM95758","3":"NA"},{"1":"ENSG00000073060","2":"GSM95759","3":"NA"},{"1":"ENSG00000073060","2":"GSM95760","3":"NA"},{"1":"ENSG00000073060","2":"GSM95761","3":"NA"},{"1":"ENSG00000073060","2":"GSM95762","3":"NA"},{"1":"ENSG00000073060","2":"GSM95763","3":"NA"},{"1":"ENSG00000073060","2":"GSM95764","3":"NA"},{"1":"ENSG00000073060","2":"GSM95765","3":"NA"},{"1":"ENSG00000073060","2":"GSM95766","3":"NA"},{"1":"ENSG00000073060","2":"GSM95767","3":"NA"},{"1":"ENSG00000073060","2":"GSM95768","3":"NA"},{"1":"ENSG00000073060","2":"GSM95769","3":"NA"},{"1":"ENSG00000073060","2":"GSM95770","3":"NA"},{"1":"ENSG00000073060","2":"GSM95771","3":"NA"},{"1":"ENSG00000073060","2":"GSM95772","3":"NA"},{"1":"ENSG00000073060","2":"GSM95773","3":"NA"},{"1":"ENSG00000073060","2":"GSM95774","3":"NA"},{"1":"ENSG00000073060","2":"GSM95775","3":"NA"},{"1":"ENSG00000073060","2":"GSM95776","3":"NA"},{"1":"ENSG00000073060","2":"GSM95777","3":"NA"},{"1":"ENSG00000073060","2":"GSM95778","3":"NA"},{"1":"ENSG00000073060","2":"GSM95779","3":"NA"},{"1":"ENSG00000073060","2":"GSM95780","3":"NA"},{"1":"ENSG00000073060","2":"GSM95781","3":"NA"},{"1":"ENSG00000073060","2":"GSM95782","3":"NA"},{"1":"ENSG00000073060","2":"GSM95783","3":"NA"},{"1":"ENSG00000073060","2":"GSM95784","3":"NA"},{"1":"ENSG00000073060","2":"GSM95785","3":"NA"},{"1":"ENSG00000073060","2":"GSM95786","3":"NA"},{"1":"ENSG00000073060","2":"GSM95787","3":"NA"},{"1":"ENSG00000073060","2":"GSM95788","3":"NA"},{"1":"ENSG00000073060","2":"GSM95789","3":"NA"},{"1":"ENSG00000073060","2":"GSM95790","3":"NA"},{"1":"ENSG00000073060","2":"GSM95791","3":"NA"},{"1":"ENSG00000073060","2":"GSM95792","3":"NA"},{"1":"ENSG00000073060","2":"GSM95793","3":"NA"},{"1":"ENSG00000073060","2":"GSM95794","3":"NA"},{"1":"ENSG00000073060","2":"GSM95795","3":"NA"},{"1":"ENSG00000073060","2":"GSM95796","3":"NA"},{"1":"ENSG00000073060","2":"GSM95797","3":"NA"},{"1":"ENSG00000073060","2":"GSM95798","3":"NA"},{"1":"ENSG00000073060","2":"GSM95799","3":"NA"},{"1":"ENSG00000073060","2":"GSM95800","3":"NA"},{"1":"ENSG00000073060","2":"GSM95801","3":"NA"},{"1":"ENSG00000073060","2":"GSM95802","3":"NA"},{"1":"ENSG00000073060","2":"GSM95803","3":"NA"},{"1":"ENSG00000073060","2":"GSM95804","3":"NA"},{"1":"ENSG00000073060","2":"GSM95805","3":"NA"},{"1":"ENSG00000073060","2":"GSM95806","3":"NA"},{"1":"ENSG00000073060","2":"GSM95807","3":"NA"},{"1":"ENSG00000073060","2":"GSM95808","3":"NA"},{"1":"ENSG00000073060","2":"GSM95809","3":"NA"},{"1":"ENSG00000073060","2":"GSM95810","3":"NA"},{"1":"ENSG00000073060","2":"GSM95811","3":"NA"},{"1":"ENSG00000073060","2":"GSM95812","3":"NA"},{"1":"ENSG00000073060","2":"GSM95813","3":"NA"},{"1":"ENSG00000073060","2":"GSM95814","3":"NA"},{"1":"ENSG00000073060","2":"GSM95815","3":"NA"},{"1":"ENSG00000073060","2":"GSM95816","3":"NA"},{"1":"ENSG00000073060","2":"GSM95817","3":"NA"},{"1":"ENSG00000073060","2":"GSM95818","3":"NA"},{"1":"ENSG00000073060","2":"GSM95819","3":"NA"},{"1":"ENSG00000073060","2":"GSM95820","3":"NA"},{"1":"ENSG00000073060","2":"GSM95821","3":"NA"},{"1":"ENSG00000073060","2":"GSM95822","3":"NA"},{"1":"ENSG00000073060","2":"GSM95823","3":"NA"},{"1":"ENSG00000073060","2":"GSM95824","3":"NA"},{"1":"ENSG00000073060","2":"GSM95825","3":"NA"},{"1":"ENSG00000073060","2":"GSM95826","3":"NA"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[181]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>replace NAs in <code>SCARB1</code> gene (<code>ENSG00000073060</code>) with zero</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc19hZGpfd3plcm9zIDwtIGdzZTI2NThfZXhwcnNfYWRqX3d6ZXJvcyAlPiUgcmVwbGFjZV9uYShyZXBsYWNlPWxpc3QoYWRqbG9nY3BrbWVkPTApKVxuZ3NlMjY1OF9leHByc19hZGpfd3plcm9zICU+JSBmaWx0ZXIoZ2VuZV9pZD09XCJFTlNHMDAwMDAwNzMwNjBcIilcbmBgYCJ9 -->
<pre class="r"><code>gse2658_exprs_adj_wzeros &lt;- gse2658_exprs_adj_wzeros %&gt;% replace_na(replace=list(adjlogcpkmed=0))
gse2658_exprs_adj_wzeros %&gt;% filter(gene_id==&quot;ENSG00000073060&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-frame-begin {"metadata":{"classes":["grouped_df","tbl_df","tbl","data.frame"],"nrow":559,"ncol":3,"summary":{"A tibble":["559 × 3"],"Groups":["gene_id [1]"]}},"rdf":"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"} -->
<div data-pagedtable="false">
<script data-pagedtable-source type="application/json">
{"columns":[{"label":["gene_id"],"name":[1],"type":["chr"],"align":["left"]},{"label":["sample_id"],"name":[2],"type":["chr"],"align":["left"]},{"label":["adjlogcpkmed"],"name":[3],"type":["dbl"],"align":["right"]}],"data":[{"1":"ENSG00000073060","2":"GSM102606","3":"-0.987007909"},{"1":"ENSG00000073060","2":"GSM102607","3":"-1.259564289"},{"1":"ENSG00000073060","2":"GSM102609","3":"-1.920778143"},{"1":"ENSG00000073060","2":"GSM102610","3":"-2.750313297"},{"1":"ENSG00000073060","2":"GSM102611","3":"-1.794780472"},{"1":"ENSG00000073060","2":"GSM102612","3":"-2.569471477"},{"1":"ENSG00000073060","2":"GSM102613","3":"-1.774573134"},{"1":"ENSG00000073060","2":"GSM102614","3":"-1.250720197"},{"1":"ENSG00000073060","2":"GSM102615","3":"-2.683223483"},{"1":"ENSG00000073060","2":"GSM102616","3":"-2.437424118"},{"1":"ENSG00000073060","2":"GSM102617","3":"-0.516815624"},{"1":"ENSG00000073060","2":"GSM102618","3":"-1.983319948"},{"1":"ENSG00000073060","2":"GSM102620","3":"-2.411644632"},{"1":"ENSG00000073060","2":"GSM102621","3":"-1.253710065"},{"1":"ENSG00000073060","2":"GSM102622","3":"-1.783704974"},{"1":"ENSG00000073060","2":"GSM102623","3":"-3.005693760"},{"1":"ENSG00000073060","2":"GSM102624","3":"-1.047511258"},{"1":"ENSG00000073060","2":"GSM102625","3":"-2.356536689"},{"1":"ENSG00000073060","2":"GSM102626","3":"-2.711919979"},{"1":"ENSG00000073060","2":"GSM102627","3":"-0.436927553"},{"1":"ENSG00000073060","2":"GSM102628","3":"-1.430072330"},{"1":"ENSG00000073060","2":"GSM102629","3":"-1.846446544"},{"1":"ENSG00000073060","2":"GSM102630","3":"-3.382071459"},{"1":"ENSG00000073060","2":"GSM102631","3":"-2.138904428"},{"1":"ENSG00000073060","2":"GSM102632","3":"-1.647180894"},{"1":"ENSG00000073060","2":"GSM102633","3":"-2.150400764"},{"1":"ENSG00000073060","2":"GSM102634","3":"-0.969494818"},{"1":"ENSG00000073060","2":"GSM50986","3":"-1.169302717"},{"1":"ENSG00000073060","2":"GSM50987","3":"-1.119778199"},{"1":"ENSG00000073060","2":"GSM50988","3":"-2.343778193"},{"1":"ENSG00000073060","2":"GSM50989","3":"-1.695452648"},{"1":"ENSG00000073060","2":"GSM50990","3":"-2.213982277"},{"1":"ENSG00000073060","2":"GSM50991","3":"0.383076089"},{"1":"ENSG00000073060","2":"GSM50992","3":"-2.913757644"},{"1":"ENSG00000073060","2":"GSM50993","3":"-1.405868796"},{"1":"ENSG00000073060","2":"GSM50994","3":"-0.266429214"},{"1":"ENSG00000073060","2":"GSM50995","3":"-1.469290203"},{"1":"ENSG00000073060","2":"GSM50996","3":"-3.081902848"},{"1":"ENSG00000073060","2":"GSM50997","3":"-2.326112863"},{"1":"ENSG00000073060","2":"GSM50998","3":"-2.127697843"},{"1":"ENSG00000073060","2":"GSM50999","3":"-1.622499010"},{"1":"ENSG00000073060","2":"GSM51000","3":"-2.347031020"},{"1":"ENSG00000073060","2":"GSM51001","3":"-1.517958611"},{"1":"ENSG00000073060","2":"GSM51002","3":"-2.681561411"},{"1":"ENSG00000073060","2":"GSM51003","3":"-2.681681406"},{"1":"ENSG00000073060","2":"GSM51004","3":"-2.384628876"},{"1":"ENSG00000073060","2":"GSM51005","3":"-2.576005333"},{"1":"ENSG00000073060","2":"GSM51006","3":"-2.344896207"},{"1":"ENSG00000073060","2":"GSM51007","3":"-1.370701872"},{"1":"ENSG00000073060","2":"GSM51008","3":"-1.658462324"},{"1":"ENSG00000073060","2":"GSM51009","3":"-1.730072676"},{"1":"ENSG00000073060","2":"GSM51010","3":"-1.598996911"},{"1":"ENSG00000073060","2":"GSM51011","3":"-1.061863144"},{"1":"ENSG00000073060","2":"GSM51012","3":"-1.914809537"},{"1":"ENSG00000073060","2":"GSM51013","3":"-2.019931504"},{"1":"ENSG00000073060","2":"GSM51014","3":"-2.090514655"},{"1":"ENSG00000073060","2":"GSM51015","3":"-0.730681315"},{"1":"ENSG00000073060","2":"GSM51016","3":"-1.058652172"},{"1":"ENSG00000073060","2":"GSM51017","3":"-1.770364844"},{"1":"ENSG00000073060","2":"GSM51018","3":"-2.587475030"},{"1":"ENSG00000073060","2":"GSM51019","3":"-1.945779822"},{"1":"ENSG00000073060","2":"GSM51020","3":"-2.005506453"},{"1":"ENSG00000073060","2":"GSM51021","3":"-1.779983179"},{"1":"ENSG00000073060","2":"GSM51022","3":"-1.081802087"},{"1":"ENSG00000073060","2":"GSM51023","3":"-2.198291893"},{"1":"ENSG00000073060","2":"GSM51024","3":"-1.392294493"},{"1":"ENSG00000073060","2":"GSM51025","3":"-1.432911493"},{"1":"ENSG00000073060","2":"GSM51026","3":"-1.101146493"},{"1":"ENSG00000073060","2":"GSM51027","3":"-0.440341705"},{"1":"ENSG00000073060","2":"GSM51028","3":"-1.898124596"},{"1":"ENSG00000073060","2":"GSM51029","3":"-2.647877254"},{"1":"ENSG00000073060","2":"GSM51030","3":"-2.022952707"},{"1":"ENSG00000073060","2":"GSM51031","3":"-1.729785184"},{"1":"ENSG00000073060","2":"GSM51032","3":"-1.781723525"},{"1":"ENSG00000073060","2":"GSM51033","3":"-1.584561932"},{"1":"ENSG00000073060","2":"GSM51034","3":"-1.071056019"},{"1":"ENSG00000073060","2":"GSM51035","3":"-1.849405263"},{"1":"ENSG00000073060","2":"GSM51036","3":"-1.329420024"},{"1":"ENSG00000073060","2":"GSM51037","3":"-2.847746326"},{"1":"ENSG00000073060","2":"GSM51038","3":"-1.662189621"},{"1":"ENSG00000073060","2":"GSM51039","3":"-0.854691324"},{"1":"ENSG00000073060","2":"GSM51040","3":"-2.274664789"},{"1":"ENSG00000073060","2":"GSM51041","3":"-2.520044058"},{"1":"ENSG00000073060","2":"GSM51042","3":"-2.173872197"},{"1":"ENSG00000073060","2":"GSM51043","3":"-1.753351745"},{"1":"ENSG00000073060","2":"GSM51044","3":"-1.749746892"},{"1":"ENSG00000073060","2":"GSM51045","3":"0.593436857"},{"1":"ENSG00000073060","2":"GSM51046","3":"-2.513120478"},{"1":"ENSG00000073060","2":"GSM51047","3":"-1.872822469"},{"1":"ENSG00000073060","2":"GSM51048","3":"-2.909343626"},{"1":"ENSG00000073060","2":"GSM51049","3":"-1.808559269"},{"1":"ENSG00000073060","2":"GSM51050","3":"-1.982465757"},{"1":"ENSG00000073060","2":"GSM51051","3":"-1.390987359"},{"1":"ENSG00000073060","2":"GSM51052","3":"-0.938250278"},{"1":"ENSG00000073060","2":"GSM51053","3":"-2.257200586"},{"1":"ENSG00000073060","2":"GSM51054","3":"-2.836956910"},{"1":"ENSG00000073060","2":"GSM51055","3":"-2.465149896"},{"1":"ENSG00000073060","2":"GSM51056","3":"-1.616613515"},{"1":"ENSG00000073060","2":"GSM51057","3":"-1.009287051"},{"1":"ENSG00000073060","2":"GSM51058","3":"-2.339008159"},{"1":"ENSG00000073060","2":"GSM51059","3":"-1.165014107"},{"1":"ENSG00000073060","2":"GSM51060","3":"-2.221016152"},{"1":"ENSG00000073060","2":"GSM51061","3":"-1.979184160"},{"1":"ENSG00000073060","2":"GSM51062","3":"-1.266816987"},{"1":"ENSG00000073060","2":"GSM51063","3":"-2.030585844"},{"1":"ENSG00000073060","2":"GSM51064","3":"-2.821550013"},{"1":"ENSG00000073060","2":"GSM51065","3":"-1.724254741"},{"1":"ENSG00000073060","2":"GSM51066","3":"-1.901161836"},{"1":"ENSG00000073060","2":"GSM51067","3":"-2.113710672"},{"1":"ENSG00000073060","2":"GSM51068","3":"-2.107029037"},{"1":"ENSG00000073060","2":"GSM51069","3":"-3.138013780"},{"1":"ENSG00000073060","2":"GSM51070","3":"-1.913050178"},{"1":"ENSG00000073060","2":"GSM51071","3":"-2.364425279"},{"1":"ENSG00000073060","2":"GSM51072","3":"-1.502442780"},{"1":"ENSG00000073060","2":"GSM51073","3":"-0.716219864"},{"1":"ENSG00000073060","2":"GSM51074","3":"-1.017289330"},{"1":"ENSG00000073060","2":"GSM51075","3":"-0.743628025"},{"1":"ENSG00000073060","2":"GSM51076","3":"-2.001452747"},{"1":"ENSG00000073060","2":"GSM51077","3":"-2.904603937"},{"1":"ENSG00000073060","2":"GSM51078","3":"-2.568132034"},{"1":"ENSG00000073060","2":"GSM51079","3":"-1.012875596"},{"1":"ENSG00000073060","2":"GSM51080","3":"-1.379087418"},{"1":"ENSG00000073060","2":"GSM51081","3":"-2.352775473"},{"1":"ENSG00000073060","2":"GSM51082","3":"-2.859864883"},{"1":"ENSG00000073060","2":"GSM51083","3":"-0.692272438"},{"1":"ENSG00000073060","2":"GSM51084","3":"-1.731973398"},{"1":"ENSG00000073060","2":"GSM51085","3":"-1.724375566"},{"1":"ENSG00000073060","2":"GSM51086","3":"-2.818999643"},{"1":"ENSG00000073060","2":"GSM51087","3":"-2.101471526"},{"1":"ENSG00000073060","2":"GSM51088","3":"-2.266087327"},{"1":"ENSG00000073060","2":"GSM51089","3":"-1.979573889"},{"1":"ENSG00000073060","2":"GSM51090","3":"-2.358737443"},{"1":"ENSG00000073060","2":"GSM51091","3":"-2.123189940"},{"1":"ENSG00000073060","2":"GSM51092","3":"-1.655729597"},{"1":"ENSG00000073060","2":"GSM51093","3":"-1.626605180"},{"1":"ENSG00000073060","2":"GSM51094","3":"-1.265440995"},{"1":"ENSG00000073060","2":"GSM51095","3":"-1.666009209"},{"1":"ENSG00000073060","2":"GSM51096","3":"-1.338722566"},{"1":"ENSG00000073060","2":"GSM51097","3":"-1.254348174"},{"1":"ENSG00000073060","2":"GSM51098","3":"-1.519229380"},{"1":"ENSG00000073060","2":"GSM51099","3":"-1.848801345"},{"1":"ENSG00000073060","2":"GSM51100","3":"-2.022024855"},{"1":"ENSG00000073060","2":"GSM51101","3":"-1.359134891"},{"1":"ENSG00000073060","2":"GSM51102","3":"-1.837544926"},{"1":"ENSG00000073060","2":"GSM51103","3":"-1.619055734"},{"1":"ENSG00000073060","2":"GSM51104","3":"0.049279175"},{"1":"ENSG00000073060","2":"GSM51105","3":"-1.228656821"},{"1":"ENSG00000073060","2":"GSM51106","3":"-1.706046371"},{"1":"ENSG00000073060","2":"GSM51107","3":"-4.168418878"},{"1":"ENSG00000073060","2":"GSM51108","3":"-1.462819945"},{"1":"ENSG00000073060","2":"GSM51109","3":"-3.997280645"},{"1":"ENSG00000073060","2":"GSM51110","3":"-1.791637061"},{"1":"ENSG00000073060","2":"GSM51111","3":"-1.981208993"},{"1":"ENSG00000073060","2":"GSM51112","3":"-1.600485276"},{"1":"ENSG00000073060","2":"GSM51113","3":"-1.737094751"},{"1":"ENSG00000073060","2":"GSM51114","3":"-1.715639566"},{"1":"ENSG00000073060","2":"GSM51115","3":"-1.115756588"},{"1":"ENSG00000073060","2":"GSM51116","3":"-1.759011370"},{"1":"ENSG00000073060","2":"GSM51117","3":"-1.569711450"},{"1":"ENSG00000073060","2":"GSM51118","3":"-2.041814298"},{"1":"ENSG00000073060","2":"GSM51119","3":"-2.430043174"},{"1":"ENSG00000073060","2":"GSM51120","3":"-2.242002025"},{"1":"ENSG00000073060","2":"GSM51121","3":"-2.169074130"},{"1":"ENSG00000073060","2":"GSM51122","3":"-2.327538940"},{"1":"ENSG00000073060","2":"GSM51123","3":"-2.139356298"},{"1":"ENSG00000073060","2":"GSM51124","3":"-2.144410761"},{"1":"ENSG00000073060","2":"GSM51125","3":"-1.867176934"},{"1":"ENSG00000073060","2":"GSM51126","3":"-1.450162088"},{"1":"ENSG00000073060","2":"GSM51127","3":"-1.330955925"},{"1":"ENSG00000073060","2":"GSM51128","3":"-1.167341037"},{"1":"ENSG00000073060","2":"GSM51129","3":"-0.009471971"},{"1":"ENSG00000073060","2":"GSM51130","3":"-1.034575432"},{"1":"ENSG00000073060","2":"GSM51131","3":"-0.933856784"},{"1":"ENSG00000073060","2":"GSM51132","3":"-2.963991590"},{"1":"ENSG00000073060","2":"GSM51133","3":"-1.337141695"},{"1":"ENSG00000073060","2":"GSM51134","3":"-0.804212120"},{"1":"ENSG00000073060","2":"GSM51135","3":"-1.629637913"},{"1":"ENSG00000073060","2":"GSM51136","3":"-1.784756844"},{"1":"ENSG00000073060","2":"GSM51137","3":"-3.302387381"},{"1":"ENSG00000073060","2":"GSM51138","3":"-1.534110818"},{"1":"ENSG00000073060","2":"GSM51139","3":"-1.408265323"},{"1":"ENSG00000073060","2":"GSM51140","3":"-3.009445276"},{"1":"ENSG00000073060","2":"GSM51141","3":"-1.602289547"},{"1":"ENSG00000073060","2":"GSM51142","3":"-1.904632130"},{"1":"ENSG00000073060","2":"GSM51143","3":"-2.719273164"},{"1":"ENSG00000073060","2":"GSM51144","3":"-3.471853443"},{"1":"ENSG00000073060","2":"GSM51145","3":"-2.654534833"},{"1":"ENSG00000073060","2":"GSM51146","3":"-1.627071429"},{"1":"ENSG00000073060","2":"GSM51147","3":"-1.306689823"},{"1":"ENSG00000073060","2":"GSM51148","3":"-0.513586895"},{"1":"ENSG00000073060","2":"GSM51149","3":"-1.229756684"},{"1":"ENSG00000073060","2":"GSM51150","3":"-1.505463729"},{"1":"ENSG00000073060","2":"GSM51151","3":"-1.208701265"},{"1":"ENSG00000073060","2":"GSM51152","3":"-1.419706031"},{"1":"ENSG00000073060","2":"GSM51153","3":"-2.529402559"},{"1":"ENSG00000073060","2":"GSM51154","3":"-1.964067324"},{"1":"ENSG00000073060","2":"GSM51155","3":"-2.253537475"},{"1":"ENSG00000073060","2":"GSM51156","3":"-1.288669085"},{"1":"ENSG00000073060","2":"GSM51157","3":"-1.945080017"},{"1":"ENSG00000073060","2":"GSM51158","3":"-1.507724156"},{"1":"ENSG00000073060","2":"GSM51159","3":"-2.543055749"},{"1":"ENSG00000073060","2":"GSM51160","3":"-0.659745750"},{"1":"ENSG00000073060","2":"GSM51161","3":"-1.391116355"},{"1":"ENSG00000073060","2":"GSM51162","3":"-1.772131157"},{"1":"ENSG00000073060","2":"GSM51163","3":"-1.993831344"},{"1":"ENSG00000073060","2":"GSM51164","3":"-2.420972454"},{"1":"ENSG00000073060","2":"GSM51165","3":"-2.148771286"},{"1":"ENSG00000073060","2":"GSM51166","3":"-1.733716271"},{"1":"ENSG00000073060","2":"GSM51167","3":"-4.441381567"},{"1":"ENSG00000073060","2":"GSM51168","3":"-1.294102729"},{"1":"ENSG00000073060","2":"GSM51169","3":"-1.532519457"},{"1":"ENSG00000073060","2":"GSM51170","3":"-1.599421472"},{"1":"ENSG00000073060","2":"GSM51171","3":"-1.503357421"},{"1":"ENSG00000073060","2":"GSM51172","3":"-1.691408164"},{"1":"ENSG00000073060","2":"GSM51173","3":"-2.039579816"},{"1":"ENSG00000073060","2":"GSM51174","3":"-1.869369126"},{"1":"ENSG00000073060","2":"GSM51175","3":"-1.821673077"},{"1":"ENSG00000073060","2":"GSM51176","3":"-1.399571135"},{"1":"ENSG00000073060","2":"GSM51177","3":"-1.370001901"},{"1":"ENSG00000073060","2":"GSM51178","3":"-2.117504187"},{"1":"ENSG00000073060","2":"GSM51179","3":"-1.515144672"},{"1":"ENSG00000073060","2":"GSM51180","3":"-1.545722332"},{"1":"ENSG00000073060","2":"GSM51181","3":"-1.559892581"},{"1":"ENSG00000073060","2":"GSM51182","3":"-2.030418215"},{"1":"ENSG00000073060","2":"GSM51183","3":"-1.439111526"},{"1":"ENSG00000073060","2":"GSM51184","3":"-1.400783287"},{"1":"ENSG00000073060","2":"GSM51185","3":"-2.529870674"},{"1":"ENSG00000073060","2":"GSM51186","3":"-1.862429134"},{"1":"ENSG00000073060","2":"GSM51187","3":"-1.543902261"},{"1":"ENSG00000073060","2":"GSM51188","3":"-2.433815415"},{"1":"ENSG00000073060","2":"GSM51189","3":"-1.956325619"},{"1":"ENSG00000073060","2":"GSM51190","3":"-1.213963764"},{"1":"ENSG00000073060","2":"GSM51191","3":"-3.158739013"},{"1":"ENSG00000073060","2":"GSM51192","3":"-1.250133984"},{"1":"ENSG00000073060","2":"GSM51193","3":"-1.660710873"},{"1":"ENSG00000073060","2":"GSM51194","3":"-1.715419807"},{"1":"ENSG00000073060","2":"GSM51195","3":"-2.790854967"},{"1":"ENSG00000073060","2":"GSM51196","3":"-1.290496626"},{"1":"ENSG00000073060","2":"GSM51197","3":"-2.774519169"},{"1":"ENSG00000073060","2":"GSM51198","3":"-1.685059403"},{"1":"ENSG00000073060","2":"GSM51199","3":"0.628306775"},{"1":"ENSG00000073060","2":"GSM51200","3":"-2.451601599"},{"1":"ENSG00000073060","2":"GSM51201","3":"-2.422129668"},{"1":"ENSG00000073060","2":"GSM51202","3":"-2.236131770"},{"1":"ENSG00000073060","2":"GSM51203","3":"-1.627408576"},{"1":"ENSG00000073060","2":"GSM51204","3":"-1.754130340"},{"1":"ENSG00000073060","2":"GSM51205","3":"-1.495369223"},{"1":"ENSG00000073060","2":"GSM51206","3":"-2.113629020"},{"1":"ENSG00000073060","2":"GSM51207","3":"-1.076207687"},{"1":"ENSG00000073060","2":"GSM51208","3":"-2.071372239"},{"1":"ENSG00000073060","2":"GSM51209","3":"-0.957171295"},{"1":"ENSG00000073060","2":"GSM51210","3":"-2.353672105"},{"1":"ENSG00000073060","2":"GSM51211","3":"-1.419742656"},{"1":"ENSG00000073060","2":"GSM51212","3":"-1.650407376"},{"1":"ENSG00000073060","2":"GSM51213","3":"-2.652577030"},{"1":"ENSG00000073060","2":"GSM51214","3":"-1.960729440"},{"1":"ENSG00000073060","2":"GSM51215","3":"-1.263795897"},{"1":"ENSG00000073060","2":"GSM51216","3":"-0.781926989"},{"1":"ENSG00000073060","2":"GSM51217","3":"-2.038430888"},{"1":"ENSG00000073060","2":"GSM51218","3":"-1.714821614"},{"1":"ENSG00000073060","2":"GSM51219","3":"-2.494763451"},{"1":"ENSG00000073060","2":"GSM51220","3":"-1.410006930"},{"1":"ENSG00000073060","2":"GSM51221","3":"-2.738159021"},{"1":"ENSG00000073060","2":"GSM51222","3":"-2.296210793"},{"1":"ENSG00000073060","2":"GSM51223","3":"-1.031284459"},{"1":"ENSG00000073060","2":"GSM51224","3":"-1.694676654"},{"1":"ENSG00000073060","2":"GSM51225","3":"-1.157267143"},{"1":"ENSG00000073060","2":"GSM51226","3":"-2.296422174"},{"1":"ENSG00000073060","2":"GSM51227","3":"-0.911292718"},{"1":"ENSG00000073060","2":"GSM51228","3":"-1.446630306"},{"1":"ENSG00000073060","2":"GSM51229","3":"-1.751981858"},{"1":"ENSG00000073060","2":"GSM51230","3":"-2.912086508"},{"1":"ENSG00000073060","2":"GSM51231","3":"-1.901376909"},{"1":"ENSG00000073060","2":"GSM51232","3":"-1.455317957"},{"1":"ENSG00000073060","2":"GSM51233","3":"-0.825683100"},{"1":"ENSG00000073060","2":"GSM51234","3":"-1.298899741"},{"1":"ENSG00000073060","2":"GSM51235","3":"-3.154690813"},{"1":"ENSG00000073060","2":"GSM51236","3":"-2.700911645"},{"1":"ENSG00000073060","2":"GSM51237","3":"-2.000544044"},{"1":"ENSG00000073060","2":"GSM51238","3":"-1.016413946"},{"1":"ENSG00000073060","2":"GSM51239","3":"-1.353821769"},{"1":"ENSG00000073060","2":"GSM51240","3":"-0.977532162"},{"1":"ENSG00000073060","2":"GSM51241","3":"-2.572265825"},{"1":"ENSG00000073060","2":"GSM51242","3":"-2.115878752"},{"1":"ENSG00000073060","2":"GSM51243","3":"-2.204044133"},{"1":"ENSG00000073060","2":"GSM51244","3":"-1.755943327"},{"1":"ENSG00000073060","2":"GSM51245","3":"-1.592074835"},{"1":"ENSG00000073060","2":"GSM51246","3":"-1.204673176"},{"1":"ENSG00000073060","2":"GSM51247","3":"-1.500545251"},{"1":"ENSG00000073060","2":"GSM51248","3":"-1.568612782"},{"1":"ENSG00000073060","2":"GSM51249","3":"-1.804957430"},{"1":"ENSG00000073060","2":"GSM51250","3":"-1.965210019"},{"1":"ENSG00000073060","2":"GSM51251","3":"-1.470234840"},{"1":"ENSG00000073060","2":"GSM51252","3":"-1.661335590"},{"1":"ENSG00000073060","2":"GSM51253","3":"-2.460365195"},{"1":"ENSG00000073060","2":"GSM51254","3":"-2.516201510"},{"1":"ENSG00000073060","2":"GSM51255","3":"-0.912705602"},{"1":"ENSG00000073060","2":"GSM51256","3":"-1.146319820"},{"1":"ENSG00000073060","2":"GSM51257","3":"-2.440744065"},{"1":"ENSG00000073060","2":"GSM51258","3":"-1.558465952"},{"1":"ENSG00000073060","2":"GSM51259","3":"-0.559961530"},{"1":"ENSG00000073060","2":"GSM51260","3":"-2.043931801"},{"1":"ENSG00000073060","2":"GSM51261","3":"-2.631353599"},{"1":"ENSG00000073060","2":"GSM51262","3":"-1.294520511"},{"1":"ENSG00000073060","2":"GSM51263","3":"-2.013412625"},{"1":"ENSG00000073060","2":"GSM51264","3":"-1.960071511"},{"1":"ENSG00000073060","2":"GSM51265","3":"-1.546516387"},{"1":"ENSG00000073060","2":"GSM51266","3":"-1.836969192"},{"1":"ENSG00000073060","2":"GSM51267","3":"-1.798322049"},{"1":"ENSG00000073060","2":"GSM51268","3":"-0.984731938"},{"1":"ENSG00000073060","2":"GSM51269","3":"-1.938441152"},{"1":"ENSG00000073060","2":"GSM51270","3":"-0.533720393"},{"1":"ENSG00000073060","2":"GSM51271","3":"-1.624776638"},{"1":"ENSG00000073060","2":"GSM51272","3":"0.646946038"},{"1":"ENSG00000073060","2":"GSM51273","3":"-1.246832129"},{"1":"ENSG00000073060","2":"GSM51274","3":"-2.869971023"},{"1":"ENSG00000073060","2":"GSM51275","3":"-2.756992135"},{"1":"ENSG00000073060","2":"GSM51276","3":"-2.320160100"},{"1":"ENSG00000073060","2":"GSM51277","3":"-0.445220641"},{"1":"ENSG00000073060","2":"GSM51278","3":"-1.430900845"},{"1":"ENSG00000073060","2":"GSM51279","3":"-1.368795782"},{"1":"ENSG00000073060","2":"GSM51280","3":"-2.276362697"},{"1":"ENSG00000073060","2":"GSM51281","3":"-1.439248916"},{"1":"ENSG00000073060","2":"GSM51282","3":"-2.226471776"},{"1":"ENSG00000073060","2":"GSM51283","3":"-1.663753029"},{"1":"ENSG00000073060","2":"GSM51284","3":"-1.694814976"},{"1":"ENSG00000073060","2":"GSM51285","3":"-2.830746287"},{"1":"ENSG00000073060","2":"GSM51286","3":"-1.073487302"},{"1":"ENSG00000073060","2":"GSM51287","3":"-2.856427569"},{"1":"ENSG00000073060","2":"GSM51288","3":"-1.189756276"},{"1":"ENSG00000073060","2":"GSM51289","3":"-2.572242081"},{"1":"ENSG00000073060","2":"GSM51290","3":"-1.626410361"},{"1":"ENSG00000073060","2":"GSM51291","3":"-0.112092908"},{"1":"ENSG00000073060","2":"GSM51292","3":"-1.660691907"},{"1":"ENSG00000073060","2":"GSM51293","3":"-0.697849733"},{"1":"ENSG00000073060","2":"GSM51294","3":"-1.379215131"},{"1":"ENSG00000073060","2":"GSM51295","3":"-0.970798814"},{"1":"ENSG00000073060","2":"GSM51296","3":"-2.268167946"},{"1":"ENSG00000073060","2":"GSM51297","3":"-1.677587412"},{"1":"ENSG00000073060","2":"GSM51298","3":"-2.695951885"},{"1":"ENSG00000073060","2":"GSM51299","3":"-1.475312125"},{"1":"ENSG00000073060","2":"GSM51300","3":"-1.053136928"},{"1":"ENSG00000073060","2":"GSM51301","3":"-0.763024257"},{"1":"ENSG00000073060","2":"GSM51302","3":"-1.530076377"},{"1":"ENSG00000073060","2":"GSM51303","3":"-1.535949590"},{"1":"ENSG00000073060","2":"GSM51304","3":"-1.168650037"},{"1":"ENSG00000073060","2":"GSM51305","3":"-1.709326326"},{"1":"ENSG00000073060","2":"GSM51306","3":"-1.750416192"},{"1":"ENSG00000073060","2":"GSM51307","3":"-1.818251644"},{"1":"ENSG00000073060","2":"GSM51308","3":"-1.908020994"},{"1":"ENSG00000073060","2":"GSM51309","3":"-1.172840508"},{"1":"ENSG00000073060","2":"GSM51310","3":"-1.651626208"},{"1":"ENSG00000073060","2":"GSM51311","3":"-2.262900520"},{"1":"ENSG00000073060","2":"GSM51312","3":"-1.201578170"},{"1":"ENSG00000073060","2":"GSM51313","3":"-0.810994251"},{"1":"ENSG00000073060","2":"GSM51314","3":"-4.532928832"},{"1":"ENSG00000073060","2":"GSM51315","3":"-2.042086880"},{"1":"ENSG00000073060","2":"GSM51316","3":"-1.207978198"},{"1":"ENSG00000073060","2":"GSM51317","3":"-1.931679267"},{"1":"ENSG00000073060","2":"GSM51318","3":"-0.818252174"},{"1":"ENSG00000073060","2":"GSM51319","3":"-1.654436571"},{"1":"ENSG00000073060","2":"GSM51320","3":"-1.428266504"},{"1":"ENSG00000073060","2":"GSM51321","3":"-2.472446108"},{"1":"ENSG00000073060","2":"GSM51322","3":"-1.621661220"},{"1":"ENSG00000073060","2":"GSM51323","3":"-0.892964410"},{"1":"ENSG00000073060","2":"GSM51324","3":"-0.169056029"},{"1":"ENSG00000073060","2":"GSM51325","3":"-1.454191806"},{"1":"ENSG00000073060","2":"GSM51326","3":"-1.928970951"},{"1":"ENSG00000073060","2":"GSM51327","3":"-0.823915377"},{"1":"ENSG00000073060","2":"GSM51328","3":"-1.526648628"},{"1":"ENSG00000073060","2":"GSM51329","3":"-2.428311963"},{"1":"ENSG00000073060","2":"GSM51330","3":"-1.360985537"},{"1":"ENSG00000073060","2":"GSM51331","3":"-1.883266853"},{"1":"ENSG00000073060","2":"GSM51332","3":"-2.634420255"},{"1":"ENSG00000073060","2":"GSM51333","3":"-1.979880608"},{"1":"ENSG00000073060","2":"GSM51334","3":"-1.688028228"},{"1":"ENSG00000073060","2":"GSM51335","3":"-0.477765750"},{"1":"ENSG00000073060","2":"GSM51336","3":"-2.446839373"},{"1":"ENSG00000073060","2":"GSM95646","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95647","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95648","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95649","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95650","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95651","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95652","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95653","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95654","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95655","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95656","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95657","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95658","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95659","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95660","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95661","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95662","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95663","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95664","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95665","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95666","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95667","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95668","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95669","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95670","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95671","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95672","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95673","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95674","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95675","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95676","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95677","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95678","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95679","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95680","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95681","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95682","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95683","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95684","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95685","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95686","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95687","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95688","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95689","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95690","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95691","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95692","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95693","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95694","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95695","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95696","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95697","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95698","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95699","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95700","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95701","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95702","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95703","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95704","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95705","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95706","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95707","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95708","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95709","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95710","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95711","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95712","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95713","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95714","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95715","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95716","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95717","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95718","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95719","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95720","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95721","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95722","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95723","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95724","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95725","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95726","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95727","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95728","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95729","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95730","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95731","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95732","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95733","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95734","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95735","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95736","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95737","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95738","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95739","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95740","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95741","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95742","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95743","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95744","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95745","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95746","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95747","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95748","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95749","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95750","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95751","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95752","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95753","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95754","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95755","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95756","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95757","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95758","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95759","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95760","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95761","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95762","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95763","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95764","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95765","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95766","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95767","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95768","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95769","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95770","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95771","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95772","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95773","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95774","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95775","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95776","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95777","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95778","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95779","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95780","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95781","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95782","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95783","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95784","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95785","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95786","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95787","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95788","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95789","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95790","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95791","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95792","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95793","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95794","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95795","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95796","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95797","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95798","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95799","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95800","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95801","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95802","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95803","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95804","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95805","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95806","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95807","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95808","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95809","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95810","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95811","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95812","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95813","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95814","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95815","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95816","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95817","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95818","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95819","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95820","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95821","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95822","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95823","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95824","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95825","3":"0.000000000"},{"1":"ENSG00000073060","2":"GSM95826","3":"0.000000000"}],"options":{"columns":{"min":{},"max":[10],"total":[3]},"rows":{"min":[10],"max":[10],"total":[559]},"pages":{}}}
  </script>
</div>
<!-- rnb-frame-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>plot histogram of adjlogcpkmed from final version (with missing genes and NAs corrected)</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ2dwbG90KGdzZTI2NThfZXhwcnNfYWRqX3d6ZXJvcykgKyBcbiAgZ2VvbV9oaXN0b2dyYW0oYWVzKGFkamxvZ2Nwa21lZCkpICsgdGhlbWVfbWluaW1hbCgpICsgXG4gIGxhYnMoeD0oXCJleHByZXNzaW9uIHZhbHVlXCIpLCBcbiAgICAgICB0aXRsZT1cIkdTRTI2NTggYWRqbG9nY3BrbWVkIG1pY3JvYXJyYXkgZXhwcmVzc2lvbiB2YWx1ZXMgd2l0aCBtaXNzaW5nIGdlbmVzIGFuZCBOQXMgY29ycmVjdGVkIHRvIHplcm9cIilcbmBgYCJ9 -->
<pre class="r"><code>ggplot(gse2658_exprs_adj_wzeros) + 
  geom_histogram(aes(adjlogcpkmed)) + theme_minimal() + 
  labs(x=(&quot;expression value&quot;), 
       title=&quot;GSE2658 adjlogcpkmed microarray expression values with missing genes and NAs corrected to zero&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-output-begin eyJkYXRhIjoiYHN0YXRfYmluKClgIHVzaW5nIGBiaW5zID0gMzBgLiBQaWNrIGJldHRlciB2YWx1ZSB3aXRoIGBiaW53aWR0aGAuXG4ifQ== -->
<pre><code>`stat_bin()` using `bins = 30`. Pick better value with `binwidth`.</code></pre>
<!-- rnb-output-end -->
<!-- rnb-plot-begin eyJoZWlnaHQiOjYsIndpZHRoIjo5LCJzaXplX2JlaGF2aW9yIjoxLCJjb25kaXRpb25zIjpbXX0= -->
<p><img src="data:image/png;base64,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" /></p>
<!-- rnb-plot-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>final version (with missing genes and NAs corrected) with gene_ids</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>join survival data with expression data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-source-begin eyJkYXRhIjoiYGBgclxuZ3NlMjY1OF9leHByc193emVyb3Nfc3VydmQgPC0gbGVmdF9qb2luKGdzZTI2NThfZXhwcnNfYWRqX3d6ZXJvcywgXG4gICAgICAgICAgZ3NlMjY1OF9zdXJ2ZCAlPiUgc2VsZWN0KHNhbXBsZV9pZCwgY2Vuc29zLCB0dGNvcyksIFxuICAgICAgICAgIGJ5PVwic2FtcGxlX2lkXCIpXG5gYGAifQ== -->
<pre class="r"><code>gse2658_exprs_wzeros_survd &lt;- left_join(gse2658_exprs_adj_wzeros, 
          gse2658_survd %&gt;% select(sample_id, censos, ttcos), 
          by=&quot;sample_id&quot;)</code></pre>
<!-- rnb-source-end -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<p>final version (with missing genes and NAs corrected) with gene_ids and survival data</p>
<!-- rnb-text-end -->
<!-- rnb-chunk-begin -->
<!-- rnb-chunk-end -->
<!-- rnb-text-begin -->
<!-- rnb-text-end -->
</div>

<div id="rmd-source-code">---
title: "MM microarray data processing 20220414"
output:
      html_notebook:
        toc: yes
        toc_float: yes
        toc_depth: 4
---

```{r}
library(GEOquery)
library(readr)
library(tidyr)
library(dplyr)
library(ggplot2)
library(stringr)
```

not using
```{r}
# gse2658 <- getGEO('GSE2658', GSEMatrix=TRUE)
# show(gse2658)
```

## bring in data 

geo data from GSE2658 (Shaughnessy data from GEO)  
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2658  

```{r}
gse2658_lc <- getGEO(
  filename="~/Documents/stats/survival/commpass_proj/mm_microarray_datasets/GSE2658_series_matrix.txt.gz", 
  GSEMatrix=TRUE)
show(gse2658_lc)
```

get out phenotype data 
```{r}
gse2658_pdata <- pData(phenoData(gse2658_lc))
gse2658_pdata
```

get out expression matrix
```{r}
gse2658_exprs <- exprs(gse2658_lc)
dim(gse2658_exprs)
```

```{r}
gse2658_exprs[1:10,1:10]
```

```{r}
gse2658_exprs <- data.frame(gse2658_exprs) %>% tibble::rownames_to_column(var="probe")
```

there is one row with many NAs 
```{r}
gse2658_exprs[which(rowSums(is.na(gse2658_exprs))>0),] 
```

get out feature (gene) data 

```{r}
gse2658_features <- fData(gse2658_lc)
```

```{r}
dim(gse2658_features)
```

```{r}
gse2658_features[1:10,]
```

there are several gene identifiers for each probe, unfortunately none are ensembl ID  
and none other than the probe ID (col==`ID`) are unique...  
```{r}
length(unique(gse2658_features$ID))
```

these are gene ID/names below...  

genbank accession
```{r}
length(unique(gse2658_features$GB_ACC))
```

```{r}
length(unique(gse2658_features$`Representative Public ID`))
```

this one is the most name like... 
```{r}
length(unique(gse2658_features$`Gene Symbol`))
```

```{r}
gse2658_features %>% group_by(`Gene Symbol`) %>% summarise(n=n()) %>% arrange(desc(n))
```

```{r}
gse2658_features %>% group_by(`Gene Symbol`) %>% summarise(n=n()) %>% summarise(sum(n>1))
```

```{r}
length(unique(gse2658_features$ENTREZ_GENE_ID))
```


```{r}
length(unique(gse2658_features$`RefSeq Transcript ID`))
```

for reference, this is the gene metadata from the commpass spectra derivation 
```{r}
#"commpass_gene_metadata_20210601.csv"
```



CoMMpass rotation matrix

```{r}
cmps_spec_rm <- 
  read_csv("~/Documents/stats/survival/commpass_proj/spectra_commpass_product/CoMMpass_inclfollowup_final_SpectraData_20210601/spectra_rotation_matrix-gene_centers-2021-06-01.csv.gz")
```

bring in gene annotation to get gene names
```{r}
gencode_annot <- 
  read_csv("~/Documents/stats/survival/commpass_proj/commpass_spectra/Homo_sapiens.GRCh37.74.gtf.flat.csv")
```

```{r}
gid_names <- gencode_annot %>% distinct(gene_id, .keep_all = T) %>% select(gene_id, gene_name)
```

```{r}
cmps_spec_rm_wn <- left_join(cmps_spec_rm, gid_names, by="gene_id") %>% 
  select(-mean) %>% 
  relocate(gene_name)
```

are there any duplicate gene_names? 
```{r}
cmps_spec_rm_wn %>% 
    add_count(gene_name) %>% 
    filter(n>1) %>% 
  select(gene_name, gene_id, n)
```

crap, yes there is one, these were apparently combined later. just going to leave them and see how it goes... (note from future Brian, poorly)  


```{r}
dim(cmps_spec_rm_wn)
```

## combining datasets by gene name 

```{r}
cmps_spec_genenames <- cmps_spec_rm_wn %>% distinct(gene_name) %>% pull(gene_name)
```

```{r}
gse2658_features %>% filter(`Gene Symbol` %in% cmps_spec_genenames) %>% distinct(`Gene Symbol`) %>% dim()
```

7193 of 7449 genes in list with simple search (actually there are only 7448 unique gene names)

how many have multiple probe sets? 
```{r}
gse2658_features %>% 
  filter(`Gene Symbol` %in% cmps_spec_genenames) %>% 
  group_by(`Gene Symbol`) %>% 
  summarise(n=n()) %>% 
  arrange(desc(n))
```

```{r}
gse2658_features %>% 
  filter(`Gene Symbol` %in% cmps_spec_genenames) %>% 
  group_by(`Gene Symbol`) %>% 
  summarise(n=n()) %>% 
  summarise(sum(n>1))
```
4966 out of 7193 have multiple probesets   

which genes that are in the spectra rotation matrix are not in the expression set?
```{r}
cmps_spec_rm_wn %>% distinct(gene_name) %>% filter(!gene_name %in% unique(gse2658_features$`Gene Symbol`))
```
255 genes that are in the spectra rotation matrix are not in the microarray expression data  

although there are some genes with double names like `"DDR1 /// MIR4640"`  

need to sort out genes that are buried in there with weird names... 

## fishing through multiple names 

test runs 
```{r}
MAP2K3_sm <- gse2658_features %>% 
  filter(grepl("MAP2K3", `Gene Symbol`)) %>% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
MAP2K3_sm
```

```{r}
MAP2K3_sm %>% filter(grepl("(\\sMAP2K3)|(MAP2K3\\s)",`Gene Symbol`))
```

```{r}
ZNF263_sm <- gse2658_features %>% 
  filter(grepl("ZNF263", `Gene Symbol`)) %>% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
ZNF263_sm
```

```{r}
ZNF263_sm %>% filter(grepl("(\\sZNF263)|(ZNF263\\s)",`Gene Symbol`))
```

```{r}
JHDM1D_sm <- gse2658_features %>% 
  filter(grepl("JHDM1D", `Gene Symbol`)) %>% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
JHDM1D_sm
```

```{r}
JHDM1D_sm %>% filter(grepl("(\\sJHDM1D)|(JHDM1D\\s)",`Gene Symbol`))
```

```{r}
RTEL1_TNFRSF6B_sm <- gse2658_features %>% 
  filter(grepl("RTEL1-TNFRSF6B", `Gene Symbol`)) %>% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
RTEL1_TNFRSF6B_sm
```

```{r}
RTEL1_TNFRSF6B_sm %>% filter(grepl("(\\sRTEL1-TNFRSF6B)|(RTEL1-TNFRSF6B\\s)",`Gene Symbol`))
```

```{r}
ST7_sm <- gse2658_features %>% 
  filter(grepl("ST7", `Gene Symbol`)) %>% 
  select(`Gene Symbol`:`RefSeq Transcript ID`, GB_ACC, `Representative Public ID`)
ST7_sm
```

```{r}
ST7_sm %>% filter(grepl("(\\sST7)|(ST7\\s)",`Gene Symbol`))
```

will need to extract the "simple" (or RNAseq matching) name out of the multiples  
example with a complicated one...  
just looking for space before or after as above with `grepl` seems to work. 
```{r}
str_match(ST7_sm %>% filter(grepl("(\\sST7)|(ST7\\s)",`Gene Symbol`)) %>% pull(`Gene Symbol`), 
          pattern="(\\sST7)|(ST7\\s)")[,2] %>% str_trim()
```

fix all names... 
need list of genes that are in the spectra rotation matrix but not in the expression set 
```{r}
miss_genes <- cmps_spec_rm_wn %>% 
  distinct(gene_name) %>% 
  filter(!gene_name %in% unique(gse2658_features$`Gene Symbol`)) %>% 
  pull(gene_name)
```

subset of `gse2658_features` that have multiple names
```{r}
genes2fix <- gse2658_features %>% 
  filter(grepl("///", `Gene Symbol`)) %>% 
  select(ID, `Gene Symbol`) 
genes2fix
```

grabbing genes missing from microarray set so far that have names hidden in the multiple name structure 
```{r}
probe_name <- list() #vector(mode="character")
for(i in seq(1, length(miss_genes))){
  tname <- miss_genes[i]
  probe_name[[tname]] <- genes2fix %>% 
    filter(grepl(pattern = paste0("(\\s",tname,")|(",tname,"\\s)"), `Gene Symbol`)) %>% pull(ID)
    # str_match(genes2fix$`Gene Symbol`, pattern=paste0("(\\s",i,")|(",i,"\\s)"))[,2] %>% str_trim()
  # names(probe_name[[]]) <- i
}
```


making dataframe out of list 
```{r}
probe_names_df <- stack(probe_name) %>% 
  select(gene_name=ind, probe_ID=values)
```

number of unique genes recovered 
```{r}
probe_names_df %>% distinct(gene_name) %>% dim()
```

```{r}
255-171
```

now there are only 84 genes with no probes in the microarray gene expression data 
```{r}
notin_microa <- names(probe_name[lapply(probe_name,length)==0])
notin_microa
```


checked many of the genes (esp those with "real" looking names) and only these looked like I need to deal with them:

this one is the same gene (listed as alias, same entrez gene id)   
MTERF==MTERF1  
https://www.genecards.org/cgi-bin/carddisp.pl?gene=MTERF1&keywords=MTERF
```{r}
gse2658_features %>% 
  filter(grepl("MTERF", `Gene Symbol`)) %>% 
  select(ID, `Gene Symbol`, ENTREZ_GENE_ID)
```

this one is the same gene (listed as alias, same entrez gene id)  
PIDD==PIDD1  
https://www.genecards.org/cgi-bin/carddisp.pl?gene=PIDD1&keywords=PIDD  
```{r}
gse2658_features %>% 
  filter(grepl("PIDD", `Gene Symbol`)) %>% 
  select(ID, `Gene Symbol`, ENTREZ_GENE_ID) 
```






need to join all the names back to the microarray expression  
then deal with the missing 84 genes

spectra info from: `cmps_spec_rm_wn`  
names of genes in spectra rotation matrux: `cmps_spec_genenames`  
microarray probe to gene name from: `gse2658_features`  
`probe_names_df` has the names of genes recovered from multiple name structure and their probes  

easy ones with same gene names  
```{r}
gse2658_fin_cmps_spec <- gse2658_features %>% 
  filter(`Gene Symbol` %in% cmps_spec_genenames) %>% 
  select(gene_name=`Gene Symbol`, probe_ID=ID) %>% 
  tibble::remove_rownames()
```

adding on ones recovered from multiple name structure  
```{r}
gse2658_fin_cmps_spec <- 
  bind_rows(gse2658_fin_cmps_spec, probe_names_df)
```

now the last few stragglers from above (gene name changes)
```{r}
gse2658_fin_cmps_spec <- bind_rows(gse2658_fin_cmps_spec, 
                                   gse2658_features %>% 
                                     filter(`Gene Symbol` %in% c("MTERF1","PIDD1")) %>% 
                                     select(gene_name=`Gene Symbol`, probe_ID=ID) %>% 
                                     tibble::remove_rownames())
gse2658_fin_cmps_spec$gene_name <- gsub("MTERF1", "MTERF", gse2658_fin_cmps_spec$gene_name)
gse2658_fin_cmps_spec$gene_name <- gsub("PIDD1", "PIDD", gse2658_fin_cmps_spec$gene_name)
```

check it
```{r}
gse2658_fin_cmps_spec %>% distinct(gene_name) %>% dim()
```

```{r}
cmps_spec_rm_wn %>% distinct(gene_name) %>% dim()
```

```{r}
7448-7366
```

back to the expression matrix...
```{r}
colnames(gse2658_exprs)[1] <- "probe_ID"
# gse2658_exprs %>% filter(probe_ID %in% gse2658_fin_cmps_spec$probe_ID)
gse2658_exprs_sm_wgn <- left_join(gse2658_fin_cmps_spec, gse2658_exprs, by="probe_ID") 
dim(gse2658_exprs_sm_wgn)
```

```{r}
gse2658_exprs_sm_wgn %>% distinct(gene_name) %>% dim()
```


treat multiple probesets like transcripts going into the expectra pipeline? 

unclear how to get length... not sure the transcript idea works since these probes do not uniquely match a transcript

how consistent are the probes for the same gene?
```{r}
gse2658_exprs_sm_wgn %>% group_by(gene_name) %>% summarise(n=n()) %>% arrange(desc(n))
```

```{r}
gse2658_exprs_sm_wgn %>% group_by(gene_name) %>% summarise(n=n()) %>% summarise(sum(n>1)) 
```

5075 of 7366 have multiple probes. 

problem row (has NAs):
```{r}
gse2658_exprs_sm_wgn %>% filter(probe_ID=="1552256_a_at")
```

gene names with multiple probes
```{r}
gse2658_exprs_sm_genes_mpo <- gse2658_exprs_sm_wgn %>% 
  group_by(gene_name) %>% 
  summarise(n=n()) %>% 
  filter(n>10) %>% 
  pull(gene_name)
```

```{r}
gse2658_exprs_sm_wgn %>% 
  filter(gene_name %in% gse2658_exprs_sm_genes_mpo) %>% 
  group_by(gene_name, probe_ID) %>% 
  rowwise() %>%
  summarise(row_mean=mean(c_across(contains("GSM"))),
            row_sd=sd(c_across(contains("GSM")))) %>% 
  arrange(gene_name)
```


```{r}
gse2658_exprs_sm_wgn %>% 
  filter(gene_name %in% gse2658_exprs_sm_genes_mpo) %>% 
  pivot_longer(-c(gene_name, probe_ID), names_to = "sample_id", values_to = "expr") %>% 
  group_by(gene_name, sample_id) %>% 
  summarise(mean_expr=mean(expr), median_expr=median(expr), sd_expr=sd(expr))
```

```{r}
gse2658_exprs_sm_wgn_long <- gse2658_exprs_sm_wgn %>% 
  pivot_longer(-c(gene_name, probe_ID), names_to = "sample_id", values_to = "expr")
head(gse2658_exprs_sm_wgn_long, 10)
```

plot histogram of raw expr values
```{r fig.width=9, fig.height=6}
ggplot(gse2658_exprs_sm_wgn_long) + 
  geom_histogram(aes(expr)) + theme_minimal() + 
  labs(x=("expression value"), 
       title="GSE2658 microarray expression values as downloaded")
```

plot histogram of log2(raw expr values)
```{r fig.width=9, fig.height=6}
ggplot(gse2658_exprs_sm_wgn_long) + 
  geom_histogram(aes(log2(expr))) + theme_minimal() + 
  labs(x=("expression value"), 
       title="GSE2658 log2 microarray expression values as downloaded")
```

get gene length by gene_id
```{r}
gencode_gene_len <- gencode_annot %>% filter(feature=="exon") %>% 
  mutate(ex_size=(end-start)+1) %>% group_by(gene_id) %>% 
  dplyr::summarise(length = sum(ex_size))
```


***have to convert to gene_id*** since the commpass loadings use gene_id and there is one gene name that has 2 IDs everything will get messed up unless I convert to gene_id now.

gene name `PAGR1` has 2 ensembl IDs: `ENSG00000185928` and `ENSG00000263136` in the CoMMpass data, but those 2 have been merged in newest ensembl.    
I need to try to map these probes to one, the other, or both... 
```{r}
gse2658_features %>% filter(grepl("PAGR1", `Gene Symbol`)) %>% select(ID, GB_ACC, `Gene Symbol`)
```
`1559125_at` actually misses the gene in the newest ensembl and the GB_ACC is unhelpful  

how different are the probes in expression? 
```{r fig.height=6, fig.width=5}
gse2658_exprs_sm_wgn_long %>% 
  filter(gene_name=="PAGR1") %>%  
  ggplot() + geom_histogram(aes(expr)) + facet_wrap("probe_ID", ncol=1) + theme_minimal()
```

PAGR1 gene id garbage 

In the CoMMpass expression data, the PAGR1 gene has 2 ENSG IDs, which is annoying and creates problems since the microarray data only has one row for PAGR1.  
Later, these two ENSG IDs were merged into one (ENSG00000280789).  
It gets worse since there are 3 probesets assigned to that gene name in the microarray data and the probeset 1559125_at doesn’t really match any of the ENSG IDs old or new.  

Probeset: 218300_at			Chromosome 16: 29,819,557-29,819,872  
in ENSE00003711437 of ENST00000320330.8 from gene ENSG00000185928  
in ENSE00001241136 of ENST00000609618.2 from gene ENSG00000263136  

Probeset: 231878_at			Chromosome 16: 29,822,107-29,822,455  
in ENSE00003711437 of ENST00000320330.8 from gene ENSG00000185928  

Gene: ENSG00000185928  
ENST00000320330.8 PAGR1-201 	Chromosome 16: 29,816,152-29,822,489 forward strand.  
ENST00000562285.1 		Chromosome 16: 29,817,239-29,830,627 forward strand.  

Gene: ENSG00000263136  
ENST00000609618.2			Chromosome 16: 29,812,261-29,820,092 forward strand.  

**Plan:**  
1559125_at: remove  
218300_at: ENSG00000263136  
231878_at: ENSG00000185928   

```{r}
gse2658_exprs_sm_long_gid <- 
  left_join(gse2658_exprs_sm_wgn_long %>% filter(probe_ID!="1559125_at"), # remove 1559125_at
            gid_names %>% filter(gene_id %in% cmps_spec_rm$gene_id & gene_name!="PAGR1"), # join back in gene_ids except PAGR1 
            by="gene_name") %>% 
  mutate(gene_id=case_when(gene_name=="PAGR1" & probe_ID=="218300_at" ~ "ENSG00000263136",
                           gene_name=="PAGR1" & probe_ID=="231878_at" ~ "ENSG00000185928", 
                           TRUE ~ gene_id)) %>% 
  relocate(gene_id)
```


***now back to our regularly scheduled program*** of normalizing the expression values, now by gene_id  

```{r}
gse2658_exprs_sm_gid_sum <- gse2658_exprs_sm_long_gid %>% 
  group_by(gene_id, sample_id) %>% 
  summarise(gene_expr=sum(expr))
head(gse2658_exprs_sm_gid_sum, 10)
```

2nd way to do the sum, just in case I messed up (though I think it's ok the way I did it)
```{r}
gse2658_exprs_sm_gid_sum2 <- 
  left_join(gse2658_exprs_sm_long_gid, gencode_gene_len, by="gene_id") %>% 
  group_by(gene_id, sample_id) %>% 
  mutate(cpk=expr/(length/1000)) %>% 
  summarise(gene_expr=sum(cpk)) 
head(gse2658_exprs_sm_gid_sum2, 10)
```

```{r}
gse2658_exprs_sm_wgn_sum_wgl <- left_join(gse2658_exprs_sm_gid_sum, gencode_gene_len, by="gene_id")
head(gse2658_exprs_sm_wgn_sum_wgl, 10)
```

```{r}
gse2658_exprs_sm_wgn_sum_wgl <- gse2658_exprs_sm_wgn_sum_wgl %>% mutate(cpk=gene_expr/length)
head(gse2658_exprs_sm_wgn_sum_wgl,10)
```

plot histogram of log2(cpk)
```{r fig.width=9, fig.height=6}
ggplot(gse2658_exprs_sm_wgn_sum_wgl) + 
  geom_histogram(aes(log2(cpk))) + theme_minimal() + 
  labs(x=("expression value"), 
       title="GSE2658 log2(cpk) microarray expression values")
```

```{r}
gse2658_exprs_szfctrs <- gse2658_exprs_sm_wgn_sum_wgl %>% ungroup() %>% group_by(sample_id) %>% summarise(szfctr=median(cpk, na.rm = T))
```

write out size factors for later use (like for normalizaing genes for UAMS or SBUK)
```{r}
# write_csv(gse2658_exprs_szfctrs, "gse2658_sample_size_factors.csv")
```

```{r}
gse2658_exprs_sm_wgn_sum_wgl_sz <- left_join(gse2658_exprs_sm_wgn_sum_wgl, gse2658_exprs_szfctrs, by="sample_id")
```

```{r}
gse2658_exprs_adj <- gse2658_exprs_sm_wgn_sum_wgl_sz %>% 
  mutate(adjlogcpkmed=log2(cpk/szfctr))
```

plot histogram of adjlogcpkmed
```{r fig.width=9, fig.height=6}
ggplot(gse2658_exprs_adj) + 
  geom_histogram(aes(adjlogcpkmed)) + theme_minimal() + 
  labs(x=("expression value"), 
       title="GSE2658 adjlogcpkmed microarray expression values")
```

2nd way continued... 
```{r}
gse2658_exprs_szfctrs2 <- gse2658_exprs_sm_gid_sum2 %>% ungroup() %>% 
  group_by(sample_id) %>% 
  summarise(szfctr=median(gene_expr, na.rm = T))
```

```{r}
gse2658_exprs_sm_wgn_sum2_sz <- left_join(gse2658_exprs_sm_gid_sum2, gse2658_exprs_szfctrs2, 
                                          by="sample_id")
```

```{r}
gse2658_exprs_adj2 <- gse2658_exprs_sm_wgn_sum2_sz %>% 
  mutate(adjlogcpkmed=log2(gene_expr/szfctr))
```

both ways to do sum for CPK are the same, but this plot takes a long time to render... 
```{r}
# plot(gse2658_exprs_adj$adjlogcpkmed, gse2658_exprs_adj2$adjlogcpkmed)
```

using original way 
```{r}
dim(gse2658_exprs_adj)
```


## NAs and missing genes 

deal with NA values for SCARB1 here,  
as well as putting in the TCGA gene_center values for the missing genes  

```{r}
genes_still_mis <- cmps_spec_rm %>%  
  filter(!gene_id %in% gse2658_exprs_adj$gene_id) %>% 
  pull(gene_id)
```

```{r}
# write_csv(data.frame(gene_id=genes_still_mis), "genes_missing_GSE2658_from_commpass_20220414.csv")
```

gene means for values to fill in
```{r}
gene_means <- left_join(cmps_spec_rm, gid_names, by="gene_id") %>% 
    select(gene_id, mean)
```

get things in order just to be sure
```{r}
gse2658_exprs_adj <- gse2658_exprs_adj %>% arrange(gene_id, sample_id)
```

```{r}
gse2658_sids <- unique(gse2658_exprs_adj$sample_id)
```

put in genes that are missing from the microarray data  
use mean value for that gene from the CoMMpass loadings matrix  
```{r}
# makes empty DF for adding the genes  
results <- data.frame()
for(g in genes_still_mis){
  results <- bind_rows(results, data.frame(gene_id=rep(g,559), sample_id=gse2658_sids))
}
# joins on the mean values and makes them the adjlogcpkmed
results <- left_join(results, gene_means, by = "gene_id") %>% 
  rename(adjlogcpkmed=mean)
```

put it all back together 
```{r}
gse2658_exprs_adj_cmplt <- 
  bind_rows(gse2658_exprs_adj %>% select(gene_id, sample_id, adjlogcpkmed), 
            results)
head(gse2658_exprs_adj_cmplt, 10)
```

```{r}
tail(gse2658_exprs_adj_cmplt, 10)
```

still need to deal with NAs
```{r}
gse2658_exprs_adj_cmplt %>% filter(if_any(everything(), is.na))
```

replace NAs in `SCARB1` gene (`ENSG00000073060`) with mean value from loadings matrix
```{r}
gse2658_exprs_adj_cmplt <- left_join(gse2658_exprs_adj_cmplt, gene_means, by = "gene_id") %>% 
  mutate(adjlogcpkmed=coalesce(adjlogcpkmed, mean)) %>% 
  select(-mean)
gse2658_exprs_adj_cmplt %>% filter(gene_id=="ENSG00000073060")
```

plot histogram of adjlogcpkmed from final version (with missing genes and NAs corrected)
```{r fig.width=9, fig.height=6}
ggplot(gse2658_exprs_adj_cmplt) + 
  geom_histogram(aes(adjlogcpkmed)) + theme_minimal() + 
  labs(x=("expression value"), 
       title="GSE2658 adjlogcpkmed microarray expression values with missing genes and NAs corrected")
```

final version (with missing genes and NAs corrected) with gene_ids
```{r}
# write_csv(gse2658_exprs_adj_cmplt, "gse2658_exprs_adj_20220503.csv")
```



## normalization equation  

$$e_g=log_2 \left (\frac{cpk}{size factor}\right)$$



$$cpk=\frac{ \sum_{s=1}^{m}c_s }{gene \, length_{kb}}$$

$$size \, factor= median(sample \, cpk)$$

## phenotype data

column structure is weird
```{r}
colnames(gse2658_pdata)
```

### important variables for me now: 

ID that matches expression data: `geo_accession`
```{r}
head(gse2658_pdata$geo_accession)
```

treatment info: `source_name_ch1`  
looks like all samples are pre-treatment? doesn't really jive with what's in the paper, but... 
```{r}
table(gse2658_pdata$source_name_ch1, useNA="a")
```


survival indicator: `characteristics_ch1`  
info `(Indicator of disease-related death; integer, 0=alive or death by other cause, 1=disease related death, na=death cause undetermined)`  
will need to extract the 1/0 version  
```{r}
head(gse2658_pdata$characteristics_ch1)
```

survival indicator: `characteristics_ch1.2`  
info: `(Follow-up time in months from Pre-Treatment baseline; integer)`  
will have to extract `SURTIM` to get the value in months  
```{r}
head(gse2658_pdata$characteristics_ch1.2)
```

making survival dataframe: 

```{r}
gse2658_survd <- gse2658_pdata %>% 
  select(sample_id=geo_accession, characteristics_ch1, characteristics_ch1.2)
gse2658_survd$censos <- str_match(gse2658_survd$characteristics_ch1, pattern="\\[SURIND=(.?)\\s")[,2]
gse2658_survd$ttcos <- str_match(gse2658_survd$characteristics_ch1.2, pattern="\\[SURTIM=(.?)\\s")[,2]
```

```{r}
gse2658_survd <- gse2658_pdata %>% 
  select(sample_id=geo_accession, characteristics_ch1, characteristics_ch1.2) %>% 
  mutate(censos=as.numeric(str_match(characteristics_ch1, pattern="\\[SURIND=(.?)\\s")[,2])) %>% 
  mutate(ttcos=gsub("\\[SURTIM=","", characteristics_ch1.2)) %>% 
  mutate(ttcos=as.numeric(gsub("\\s*\\(Follow-up time in months from Pre-Treatment baseline; integer)]\\s*","", ttcos))) %>% 
  tibble::remove_rownames()
gse2658_survd
```

```{r}
set.seed(4831)
gse2658_survd_test <- gse2658_survd %>% 
  slice_sample(n=20) %>% 
  select(sample_id, censos, ttcos)
gse2658_survd_test %>% arrange(sample_id)
```

```{r}
gse2658_pdata %>% 
  filter(geo_accession %in% gse2658_survd_test$sample_id) %>% 
  select(geo_accession, characteristics_ch1, characteristics_ch1.2) %>% 
  arrange(geo_accession)
```

seems legit.  

join survival data with expression data
```{r}
gse2658_exprs_survd <- left_join(gse2658_exprs_adj_cmplt, 
          gse2658_survd %>% select(sample_id, censos, ttcos), 
          by="sample_id")
```

write out version with CoMMpass means in for missing genes
```{r}
# write_csv(gse2658_exprs_survd, "gse2658_adj_expression_survival_data_20220505.csv")
```

## version with zeros 

also need a version with zeros for expression values   
will use it to center on GSE2658 data (instead of CoMMpass data)

`gse2658_exprs_adj` is the adjusted expression but before adding in mean values from CoMMpass
```{r}
head(gse2658_exprs_adj,10)
```

genes:
```{r}
gse2658_exprs_adj %>% distinct(gene_id) %>% dim()
```
makes sense 7449-82=7367

```{r}
gse2658_exprs_adj %>% ungroup() %>% distinct(sample_id) %>% dim()
```
OK


put in zero for genes that are missing from the microarray data  
```{r}
# makes empty DF for adding the genes  
results_wz <- data.frame()
for(g in genes_still_mis){
  results_wz <- bind_rows(results_wz, data.frame(gene_id=rep(g,559), sample_id=gse2658_sids))
}
# puts in zero for adjlogcpkmed
results_wz$adjlogcpkmed <- 0
```

put it all back together 
```{r}
gse2658_exprs_adj_wzeros <- 
  bind_rows(gse2658_exprs_adj %>% select(gene_id, sample_id, adjlogcpkmed), 
            results_wz)
head(gse2658_exprs_adj_wzeros, 10)
```


still need to deal with NAs
```{r}
gse2658_exprs_adj_wzeros %>% filter(if_any(everything(), is.na))
```

replace NAs in `SCARB1` gene (`ENSG00000073060`) with zero
```{r}
gse2658_exprs_adj_wzeros <- gse2658_exprs_adj_wzeros %>% replace_na(replace=list(adjlogcpkmed=0))
gse2658_exprs_adj_wzeros %>% filter(gene_id=="ENSG00000073060")
```

plot histogram of adjlogcpkmed from final version (with missing genes and NAs corrected)
```{r fig.width=9, fig.height=6}
ggplot(gse2658_exprs_adj_wzeros) + 
  geom_histogram(aes(adjlogcpkmed)) + theme_minimal() + 
  labs(x=("expression value"), 
       title="GSE2658 adjlogcpkmed microarray expression values with missing genes and NAs corrected to zero")
```

final version (with missing genes and NAs corrected) with gene_ids
```{r}
# write_csv(gse2658_exprs_adj_wzeros, "gse2658_exprs_adj_withzeros_20220518.csv")
```

join survival data with expression data
```{r}
gse2658_exprs_wzeros_survd <- left_join(gse2658_exprs_adj_wzeros, 
          gse2658_survd %>% select(sample_id, censos, ttcos), 
          by="sample_id")
```

final version (with missing genes and NAs corrected) with gene_ids and survival data
```{r}
# write_csv(gse2658_exprs_wzeros_survd, "gse2658_exprs_adj_withzeros_survd_20220518.csv")
```

</div>


</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});

$(document).ready(function () {
  $('.knitsql-table').addClass('kable-table');
  var container = $('.kable-table');
  container.each(function() {

    // move the caption out of the table
    var table = $(this).children('table');
    var caption = table.children('caption').detach();
    caption.insertBefore($(this)).css('display', 'inherit');
  });
});

</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->
<script>
$(document).ready(function () {
  window.initializeSourceEmbed("MM_microarray_data_processing_20220414.Rmd");
  window.initializeCodeFolding("show" === "show");
});
</script>

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3,h4",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
